<SEC-DOCUMENT>0001640334-17-002570.txt : 20180830
<SEC-HEADER>0001640334-17-002570.hdr.sgml : 20180830
<ACCEPTANCE-DATETIME>20171130214105
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001640334-17-002570
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20171201
<PUBLIC-REL-DATE>20180830
DATE AS OF CHANGE:		20180102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01812
		FILM NUMBER:		171232585

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head><title>inmune_s1.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><b>
<p style="MARGIN: 0px" align="center">Marc Ross, Esq. </p></b>
<p style="MARGIN: 0px" align="center"><b>As confidentially submitted to the Securities and Exchange Commission on November 30, 2017. This draft </b></p>
<p style="MARGIN: 0px" align="center"><b>registration statement has not been publicly filed with the Securities and Exchange Commission and all</b></p>
<p style="MARGIN: 0px" align="center"><b>information herein remains strictly confidential.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="right"><b>Registration No. 333- </b></p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES</font></b></p>
<p style="MARGIN: 0px" align="center"><b><font size="3">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>Washington, D.C. 20549</b></font></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font style="MARGIN: 0px" size="5"><b>FORM S-1</b> </font></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>REGISTRATION STATEMENT</b></p>
<p style="MARGIN: 0px" align="center"><b>UNDER</b></p>
<p style="MARGIN: 0px" align="center"><b>THE SECURITIES ACT OF 1933</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="50%" align="center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>(Exact name of registrant as specified in its charter)</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width="30%">
<p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td>
<td valign="bottom" width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width="30%">
<p style="MARGIN: 0px" align="center"><b>2836</b></p></td>
<td valign="bottom" width="5%"></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width="30%">
<p style="MARGIN: 0px" align="center">47-5205835</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>(State or other jurisdiction of</b></p>
<p style="MARGIN: 0px" align="center"><b>incorporation or organization)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>(Primary Standard Industrial</b></p>
<p style="MARGIN: 0px" align="center"><b>Classification Code Number)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>(I.R.S. Employer</b></p>
<p style="MARGIN: 0px" align="center"><b>Identification No.)</b></p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p>
<p style="MARGIN: 0px" align="center">David Moss</p>
<p style="MARGIN: 0px" align="center">1224 Prospect Street, Suite 150</p>
<p style="MARGIN: 0px" align="center">La Jolla, CA 92037</p>
<p style="MARGIN: 0px" align="center">Phone: (858) 964 3720 </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>(Address, including zip code, and telephone number, including area code, of the registrant&#8217;s principal executive offices)</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">David Moss</p>
<p style="MARGIN: 0px" align="center">1224 Prospect Street, Suite 150</p>
<p style="MARGIN: 0px" align="center">La Jolla, CA 92037</p>
<p style="MARGIN: 0px" align="center">Phone: (858) 964 3720</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Copies to:</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Marc Ross, Esq. </p>
<p style="MARGIN: 0px" align="center">Sichenzia Ross Ference Kesner LLP 1185 Avenue of the Americas, 37<sup>th</sup> Floor</p>
<p style="MARGIN: 0px" align="center">New York, NY 10036</p>
<p style="MARGIN: 0px" align="center">(212) 930-9700</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>Approximate date of commencement of proposed sale to the public:</b> From time to time after this Registration Statement becomes effective.<font size="3"></font></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: <font face="Wingdings">x</font></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, emerging growth company, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;emerging growth company&#8221;, and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr height="15">
<td valign="bottom" width="40%">
<p style="MARGIN: 0px">Large accelerated filer</p></td>
<td valign="bottom" width="10%">
<p style="MARGIN: 0px">&#9744;</p></td>
<td valign="bottom" width="40%">
<p style="MARGIN: 0px">Accelerated filer</p></td>
<td valign="bottom" width="10%">
<p style="MARGIN: 0px">&#9744;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="bottom">
<p style="MARGIN: 0px">Non-accelerated filer</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&#9744;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">Smaller reporting company</p></td>
<td valign="bottom">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">x</font></p></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="bottom">
<p style="MARGIN: 0px">Emerging growth company</p></td>
<td valign="bottom">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">x</font></p></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="left"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. <font style="FONT-FAMILY: Wingdings">&#168;</font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">
<table id="pagebreak0f4e2ec9-d4c6-498f-bdf8-44f50c1aa74a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>CALCULATION OF REGISTRATION FEE</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="center"><b>Title of each class of securities</b><font size="3"></font></p>
<p style="MARGIN: 0px" align="center"><b>to be registered</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount to be Registered(1)</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="center">
<p style="MARGIN: 0px" align="center"><b>Proposed Maximum Offering Price Per Share </b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="center">
<p style="MARGIN: 0px" align="center"><b>Proposed Maximum Aggregate Offering</b></p>
<p style="MARGIN: 0px" align="center"><b>Price(2)</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount of Registration</b></p>
<p style="MARGIN: 0px" align="center"><b>Fee</b><font size="3"></font></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Common Stock, $.001 par value being offered by the Company </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Placement Agent&#8217;s Common Stock Purchase Warrants (3) </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Common Stock, $.001 par value being offered by selling stockholders <font size="3"></font></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$<font size="3"></font></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>Total</b><font size="3"></font></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px"><b>$</b><font size="3"></font></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(4</td>
<td valign="bottom" width="1%">)</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(1) Pursuant to Rule 416 under the Securities Act, the shares of Common Stock registered hereby also include an indeterminate number of additional shares of Common Stock as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions.<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">(3) We have agreed to issue warrants exercisable within five years after the effective date of this registration statement representing an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;% of the shares issued in the offering (the &#8220;Placement Agent Warrants&#8221;) to the Placement Agent. Resales of the Placement Agent&#8217;s Warrants on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, are registered hereby. Resales of shares issuable upon exercise of the Placement </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">(4) to be paid upon the first non-confidential filing of this Registration Statement with the Securities and Exchange Commission. <font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="left">
<table id="pagebreakdb7ded86-3b3c-4891-96e2-d1e0030375a6" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">EXPLANATORY NOTE</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">This Registration Statement (the &#8220;Registration Statement&#8221;) contains one prospectus (the &#8220;Prospectus&#8221;) in connection with ta public offering of up to&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;shares of our Common Stock at a price of $&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share and one prospectus to be used in connection with the potential resale by certain selling stockholders (the &#8220;Selling Stockholders&#8221;) of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common Stock (the &#8220;Selling Stockholder Prospectus&#8221;). The Prospectus and the Selling Stockholder Prospectus are identical in all respects except for the alternative pages for the Selling Stockholder Prospectus included herein which are labeled &#8220;Alternate Page for Selling Stockholder Prospectus&#8221;.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The Selling Stockholder prospectus is substantially identical to the Prospectus, except for the following principal points:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">They contain different outside and inside front covers;</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">They contain different Offering sections in the Prospectus Summary section on;</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">They contain different Use of Proceeds sections;</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">The Capitalization and Dilution sections are deleted from the Selling Stockholder Prospectus;</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">A Selling Stockholder section is included in the Selling Stockholder Prospectus; and</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">The Plan of Distribution Sections are different.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has included in this Registration Statement, after the financial statements, a set of alternate pages to reflect the foregoing differences of the Selling Stockholder Prospectus as compared to the Prospectus.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak3e67f64b-ae3c-4b5b-a72d-c27dc0017d9c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><font color="red">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted</font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-TOP: 1px solid" valign="top" width="33%"></td>
<td style="BORDER-TOP: 1px solid" valign="top" width="34%"></td>
<td style="BORDER-TOP: 1px solid" valign="top" width="33%">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top" width="33%">
<p style="MARGIN: 0px"><font color="red">PRELIMINARY PROSPECTUS<font size="3"></font></font></p></td>
<td valign="top" width="34%">
<p style="MARGIN: 0px" align="center"><font color="red">SUBJECT TO COMPLETION <font size="3"></font></font></p></td>
<td valign="top" width="33%">
<p style="MARGIN: 0px"><font color="red">DATED __, 2017<font size="3"></font></font></p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="33%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="34%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="33%"></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Up to [*] Shares of Common Stock</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">INmune Bio Inc. is offering a minimum of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock (the &#8220;Minimum Shares Offering&#8221;) for gross proceeds of $5,000,000 (the &#8220;Minimum Offering Amount&#8221;) before deduction of commissions and offering expenses and a maximum of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (&#8220;Maximum Shares Offering&#8221;) of our common stock for gross proceeds of $15,000,000 before deduction of commissions and offering expenses (&#8220;Maximum Offering Amount&#8221;). Our Common Stock is not currently traded in a public marketplace. We intend to apply to list our Common Stock on a national exchange or marketplace. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All funds sent to the Company by investors to purchase the common stock will be deposited in a non-interest bearing escrow account, maintained at and by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#8220;Escrow Agent&#8221;). Within three business days of receipt of the Minimum Offering Amount in escrow the Company will close on the subscription amounts in escrow as of such date subject to the Maximum Offering Amount and thereafter from time to time the Company will have additional closings until the Maximum Offering Amount has been sold or&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;, if we do not sell and receive payments for the Minimum Offering Amount prior to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , investor subscriptions will be returned without interest or deduction.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our Common Stock is not traded on any national securities exchange and is not quoted on any over-the-counter market. We intend to list our common stock on a national stock market, however, there no assurance that our application will be approved. We have retained&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;to act as our placement agent in connection with this offering and to use their &#8220;best efforts&#8221; to solicit offers to purchase all or nothing with respect to the Minimum Shares Offering and &#8220;best efforts&#8221; with respect to the Maximum Shares Offering. The Placement Agent is not purchasing or selling any securities pursuant to this offering. The closing of the offering will only occur if at least the Minimum Share Offering amount of common stock are being sold. See &#8220;Plan of Distribution beginning on page 13 of this prospectus for more information regarding these arrangements. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Our business and an investment in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page _ of this prospectus for a discussion of information that you should consider before investing in our securities.</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak0c15db0b-41c1-439c-8bbc-58a6c130d2ee" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">4</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Public Offering</b></p>
<p style="MARGIN: 0px" align="center"><b>Price</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Placement Agent</b></p>
<p style="MARGIN: 0px" align="center"><b>Fees (1)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Proceeds, before</b></p>
<p style="MARGIN: 0px" align="center"><b>expenses</b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Per share</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Per Share</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b>Per Share</b></p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Minimum Share Offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Maximum Share Offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Total</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">___________</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(1)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">In addition, we will reimburse the expenses of the Placement Agents as described in the Plan of Distribution.</p></td></tr></table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">The date of this prospectus is ________, 2017.<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak035131f7-ddec-498d-953d-e8d483c0a256" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">5</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="TOC_1">TABLE OF CONTENTS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">
<p style="MARGIN: 0px" align="center"><b>Page</b><font size="3"></font></p></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#PROSPECTUS SUMMARY">Prospectus Summary<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">8</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#RISK FACTORS">Risk Factors<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">13</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#USE OF PROCEEDS">Use of Proceeds<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">36</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#FORWARD-LOOKING STATEMENTS">Forward-Looking Statements<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">7</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#PLAN OF DISTRIBUTION">Plan of Distribution<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">77</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS">Market for Common Equity and Related Stockholder Matters<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">37</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Description of Business<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">59</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Description of Property<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Legal Proceedings<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Directors and Executive Officers<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#EXECUTIVE COMPENSATION">Executive Compensation<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">71</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Certain Relationships and Related Transactions<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT">Security Ownership of Certain Beneficial Owners and Management<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">74</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#DESCRIPTION OF SECURITIES">Description of Securities<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">75</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Indemnification for Securities Act Liabilities<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#LEGAL MATTERS">Legal Matters<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">76</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#EXPERTS">Experts<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">77</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Changes in Accountants<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Additional Information<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#Consolidated Financial Statements(fin)">Financial Statements<font size="3"></font></a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="right">80</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">You should rely only on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We have not, and the Placement Agent has not, authorized anyone to provide you with any information other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not, and the Placement Agent is not making an offer of these securities in any jurisdiction where the offer is not permitted.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">For investors outside the United States: We have not and the Placement Agent has not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of securities and the distribution of this prospectus outside the United States.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak73807e34-37b2-41e3-9044-5156f5d74e9c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">6</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="FORWARD-LOOKING STATEMENTS">FORWARD-LOOKING STATEMENTS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">This prospectus contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements reflect our current view about future events. When used in this prospectus, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward&#8211;looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize new and improved products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors (including the risks contained in the section of this prospectus entitled &#8220;Risk Factors&#8221;) relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p><b style="MARGIN: 0px">
<table id="pagebreake41f1b41-459d-4e09-aa70-60ee2c71121b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">7</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="BORDER-TOP: black 1px solid; BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; BORDER-LEFT: black 1px solid" cellspacing="0" cols="2" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center"><b><a name="PROSPECTUS SUMMARY">PROSPECTUS SUMMARY</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information you should consider in making your investment decision. You should read the following summary together with the more detailed information regarding us and our common stock being sold in the offering, including the risks of investing in our common stock discussed under &#8220;Risk Factors,&#8221; beginning on page&nbsp;13 and our historical and pro forma condensed combined financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. For convenience, in this prospectus, unless the context suggests otherwise, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;Company&#8221; and &#8220;us&#8221; and &#8220;INmune Bio&#8221; refer to Inmune Bio Inc., a Nevada corporation. </i></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">We are pharmaceutical clinical stage immunotherpay company focused on developing pioneering strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient&#8217;s cancer. INMB targets cells of the innate immune system that include natural killer cells (&#8220;NK cells&#8221;) and myeloid derived suppressor cells, (&#8220;MDSC cells&#8221;) that we believe offer unique therapeutic opportunities and may be safer, easier to execute and more effective than currently available treatments. We plan to develop our two existing drug platforms, INKmune (&#8220;INKmune&#8221;) and INB03 (&#8220;INB03&#8221;) that harness the innate immune system to provide a unique set of therapies for patients with cancer. We plan to be the Innate Immune System company with an initial focus on cancer. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The immune system has two parts &#8211; the adaptive immune system and the innate immune system. Oncology research has focused on leveraging the adaptive immune system (T-cells) to attack the cancer. The innate immune system has been less intensively studied. We believe that the innate immune system must be part of the fight along with the adaptive immune system to properly treat cancer and our product platforms may help address these issues. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A primary role of the innate immune system is attacking the cancer to both kill the cancer cells, especially residual disease, and to expand the immune response by recruiting cytotoxic T cells of the adaptive immune system. The cancer causes dysfunction of the innate immune system that allows it to evade the immune system, grow and kill the patient. There are two types of innate immune system dysfunction &#8211; &#8220;effector dysfunction&#8221; and &#8220;protector dysfunction&#8221;. The ability of the cancer cell to evade NK cell killing is &#8220;effector dysfunction&#8221;. Without effective NK cell killing the patient&#8217;s immune system cannot help the patient eradicate their cancer. The second element of the dysregulated innate immune response to the cancer involves the myeloid derived suppressor cells (MDSC). In patients with advanced cancer, especially with chronic inflammation associated with the cancer, part of the dysregulated immune response to that cancer is proliferation of the MDSC cell population that secrete cytokines that provide an &#8220;immunosuppressive shield&#8221; around the cancer that prevents the patient&#8217;s immune system from attacking the tumor. We term this, &#8220;protector dysfunction.&#8221; This complicated two-part dysfunction of the innate immune system results in an immune system that both ignores the tumor and cannot attack the tumor because of the localized immunosuppressive shield that surrounds the cancer. We believe successful immunotherapy for cancer must accomplish two equally important goals. First, the innate immune system must be stimulated to attack the cancer &#8211; eliminate &#8220;effector dysfunction&#8221; by improving NK cell ability to kill tumors and, the XX eliminate &#8220;protector dysfunction&#8221;, by eliminating the MDSC population so the newly energized immune system can better target the tumor cells`. In many patients with cancer, effector and protector function occur simultaneously. Without addressing these immunologic defects, the probability of success is limited and the patient may suffer relapse and progression of their cancer.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We believe our products, INKmune and INB03 address the dysfunction of innate immune system&#8217;s response to cancer and can be used alone or in combination with each other or in combination with other cancer therapies. INKmune is focused on improving effector function. INKmune is designed to convert inert NK cells that ignore the patient&#8217;s cancer into NK cells that will attack the patient&#8217;s cancer. INB03 is focused on the protector function. INB03 prevents proliferation and function of the patient&#8217;s MDSC population to limit the immunosuppressive shield around the cancer and promote NK/DC crosstalk, a critical step in recruiting the immune system to the fight the cancer. Each product has a unique mechanism that allows them to be used alone, in combination with each other or in combination with other cancer therapies. Furthermore, because each product targets the patient&#8217;s immune system, they can be used to treat a wide variety of cancers; both hematologic malignancies and solid tumors. That is, INmune Bio focused on re-engineering the patient&#8217;s immune system to attack their cancer; we are not focused on what type of cancer the patient has.</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p></b>&nbsp;
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak6ed8d055-b652-41cb-ae81-71902f3c378c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">8</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To our knowledge, INB03 is the only innate immune system check-point inhibitor in development. INB03 combats tumor based immunosuppression by preventing the proliferation of the MDSC population and decreasing the immunosuppressive cytokines in the tumor microenvironment that protect the tumor from attack by the patient&#8217;s immune system. By inhibiting the immunosuppressive factors, there is an increase in immune regulatory cytokines that promotes NK/DC cross-talk to recruit the cytotoxic T cells of the adaptive immune system to fight the cancer. Finally, because MDSC may cause a patient&#8217;s tumor to be resistant or refractory to immunotherapy, combination therapy with INB03 may eliminate MDSC based resistance and improve the response to many immunotherapy drugs. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We will start the clinical development program of each product platform separately. Once we have established safety and efficacy individually, we may choose to combine the product platforms in a single patient or combine the products with other cancer therapies. The first four trials we plan to perform are listed below. The initiation of first two trials are funded by our initial financing. Completion of the trials and completion of the second two trials is dependent on a successful public financing. As data becomes available and with interaction with future partners, we may decide to alter the order or focus of the development program. </p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="2" width="100%" border="0">
<tr height="15">
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top" width="10%">
<p style="MARGIN: 0px" align="center">Product</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">Disease. Phase and design</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="left">INKmune</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">Phase I/II biomarker directed trail of intraperitoneal INKmune in women with relapse/refractory ovarian cancer (PII is randomized with active control)</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">INB03</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">Phase I open label dose escalation trial in patients with advanced solid tumors and elevated numbers MDSC measurable in their circulation</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">INKmune</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Phase I/II biomarker directed trial of intravenous INKmune is patients with high risk MDS not eligible for stem cell transplant (PII is randomized with active control)</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">INB03</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">Phase II biomarker directed combination therapy trial, INB03+checkpoint inhibitor, cancer patients proven to be refractory/resistant first line therapy who have elevated MDSC measurable in their blood</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We lease office space at 1224 Prospect Street, Suite 150, La Jolla, CA 92037. Our phone number is 1-858-964-3720 and our website address is www.inmunebio.com. The references to our website in this prospectus are inactive textual references only. The information on our website is neither incorporated by reference into this prospectus nor intended to be used in connection with this Offering.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Risks Associated With Our Business</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Our business is subject to numerous risks described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. You should carefully consider these risks before making an investment. Some of these risks include: </p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><font face="Symbol">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>We have no approved products on the market and have generated no product revenues to date.</i></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>We will need additional capital. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations. </i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>We have a limited operating history, and expect to incur significant additional operating losses.</i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>We are currently focused on the development of a two product candidates.</i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><i>We are dependent on obtaining certain patents and protecting our proprietary rights.</i><i></i></p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></font>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakc3c92d20-ead2-435b-889f-85b248f6202e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">9</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p><font face="Symbol">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidate.</i><i></i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>We face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.</i><i></i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>There is no public market for securities and you may have to hold your shares of our common stock for an indefinite period of time.</i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top"><i>The Company&#8217;s common stock is controlled by insiders.</i></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></font>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify"><b>JOBS Act</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (or the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">An emerging growth company may also take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">we may present only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"></td>
<td valign="top" width="4%"><font face="Symbol">
<p style="MARGIN: 0px"><font face="Symbol">&#183;</font></p></font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"></td>
<td valign="top" width="4%"><font face="Symbol">
<p style="MARGIN: 0px"><font face="Symbol">&#183;</font></p></font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"></td>
<td valign="top" width="4%"><font face="Symbol">
<p style="MARGIN: 0px"><font face="Symbol">&#183;</font></p></font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2021. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have elected to take advantage of certain of the reduced disclosure obligations regarding executive compensation in this prospectus and, as long as we continue to qualify as an emerging growth company, we may elect to take advantage of this and other reduced burdens in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are also a &#8220;smaller reporting company,&#8221; as defined under SEC Regulation S-K. As such, we also are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and also are subject to less extensive disclosure requirements regarding executive compensation in our periodic reports and proxy statements. We will continue to be deemed a smaller reporting company until our public float exceeds $75 million on the last day of our second fiscal quarter in the preceding fiscal year.</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak990c4250-16ff-4f46-b444-df736c85f245" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">10</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: black 1px solid" width="1%"></td>
<td style="BORDER-TOP: #000000 1px solid" width="20%"></td>
<td style="BORDER-TOP: #000000 1px solid" width="2%"></td>
<td style="BORDER-TOP: #000000 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid"></td>
<td colspan="3">
<p style="MARGIN: 0px" align="center"><b>Summary of the Offering</b></p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid"></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Amount of this Offering</p>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The Company will not sell any securities pursuant to this offering unless it sells at least shares common stock. The Company will not sell more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Common stock. </p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Minimum Offering Amount</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$5,000,000</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Maximum Offering Amount</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$15,000,000</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Common Stock to be outstanding after this offering</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Use of proceeds</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">After deducting the commission payable to the Placement Agent and the estimated offering expenses that are payable by us, we estimate that the net proceeds from the sale of the common stock offered by us pursuant to this prospectus will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if the Minimum Offering Amount is sold and $ if the Maximum Offering Amount is sold. We expect to use the net proceeds from this offering for the following purposes:</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="26%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our Phase I/II clinical trial for our INKmune product candidate for Ovarian Cancer;</td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our planned Phase I/II clinical trial for INKmune in high-risk MDS;</td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our planned Phase I/II clinical trials for INB03 for MDSC;</td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our Phase I/II clinical trials for INB03 combined with an approved checkpoint inhibitor for melanoma; and</td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the remaining amounts for manufacturing, research and development activities, working capital and general corporate purposes.</td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="20%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD>&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD>&#13;&#10;<P style="MARGIN: 0px" align=justify>For additional information on the use of proceeds, please see &#8220;Use of Proceeds&#8221;. </P></TD></TR>'>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify">For additional information on the use of proceeds, please see &#8220;Use of Proceeds&#8221;. </p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="27%">&#13;&#10;<P style="MARGIN: 0px">Placement Agents Warrants</P></TD>&#13;&#10;<TD vAlign=top width="63%">&#13;&#10;<P style="MARGIN: 0px" align=justify>We have agreed to issue the Placement Agent warrants to purchase up to the number of shares of our common stock equal to 8 % of the aggregate number of shares sold in the offering. The warrants are exercisable at a per share price equal to $ [100% of the public offering price per share], at any time, and from time to time, in whole or in part, during the five-year period commencing at the effective date of the offering. </P></TD></TR>'>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Placement Agents Warrants</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">We have agreed to issue the Placement Agent warrants to purchase up to the number of shares of our common stock equal to&nbsp;&nbsp;&nbsp;&nbsp; % of the aggregate number of shares sold in the offering. The warrants are exercisable at a per share price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;[100% of the public offering price per share], at any time, and from time to time, in whole or in part, during the five-year period commencing at the effective date of the offering. </p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="27%">&#13;&#10;<P style="MARGIN: 0px">Escrow</P></TD>&#13;&#10;<TD vAlign=top width="63%">&#13;&#10;<P style="MARGIN: 0px" align=justify>All funds sent to the Company by investors to purchase the common stock and Warrants after the effectiveness of the registration statement of which this prospectus forms a part will be deposited in a non-interest bearing account, maintained at and by (the &#8220;Escrow Agent&#8221;). If we do not sell and receive payments for the Minimum Offering Amount prior to , investor subscriptions will be returned without interest or deduction.</P></TD></TR>'>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Escrow</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">All funds sent to the Company by investors to purchase the common stock and Warrants after the effectiveness of the registration statement of which this prospectus forms a part will be deposited in a non-interest bearing account, maintained at and by&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;(the &#8220;Escrow Agent&#8221;). If we do not sell and receive payments for the Minimum Offering Amount prior to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;, investor subscriptions will be returned without interest or deduction.</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>&nbsp;
<table id="pagebreak41342172-1e8c-4478-ad04-0782b1af28b5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">11</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid" width="20%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid" width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-TOP: #000000 1px solid; BORDER-RIGHT: black 1px solid" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top width="27%">&#13;&#10;<P style="MARGIN: 0px">Subscription Procedures</P></TD>&#13;&#10;<TD vAlign=top width="63%">&#13;&#10;<P style="MARGIN: 0px" align=justify>Investors interested in subscribing for the common stock and warrants in this offering must complete and deliver to the Placement Agent a completed subscription agreement to the address provided in the subscription agreement and deliver the purchase price in the amount of $ per share of common stock being purchased by wire transfer in immediately available funds using the wire transfer instructions provided in the subscription agreement. Funds and subscription documents will be held in escrow until the closing of this offering at which time the escrowed funds and subscription documents will be released by the Escrow Agent. Promptly following the closing the common stock and warrants purchased by the investor in the offering will issued to the investor. If this offering is not completed for any reason all proceeds deposited into escrow will be returned to the investor without interest or deduction.</P></TD></TR>'>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Subscription Procedures</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Investors interested in subscribing for the common stock and warrants in this offering must complete and deliver to the Placement Agent a completed subscription agreement to the address provided in the subscription agreement and deliver the purchase price in the amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share of common stock being purchased by wire transfer in immediately available funds using the wire transfer instructions provided in the subscription agreement. Funds and subscription documents will be held in escrow until the closing of this offering at which time the escrowed funds and subscription documents will be released by the Escrow Agent. Promptly following the closing the common stock and warrants purchased by the investor in the offering will issued to the investor. If this offering is not completed for any reason all proceeds deposited into escrow will be returned to the investor without interest or deduction.</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top width="27%">&#13;&#10;<P style="MARGIN: 0px">Risk factors</P></TD>&#13;&#10;<TD vAlign=top width="63%">&#13;&#10;<P style="MARGIN: 0px" align=justify>See &#8220;Risk Factors&#8221; beginning on page __ and the other information included in this prospectus for a discussion of factors you should carefully consider before investing in our securities</P></TD></TR>'>
<td style="BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Risk factors</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">See &#8220;Risk Factors&#8221; beginning on page 13 and the other information included in this prospectus for a discussion of factors you should carefully consider before investing in our securities</p></td>
<td style="BORDER-RIGHT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid; BORDER-LEFT: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p><b style="MARGIN: 0px">&nbsp;
<table id="pagebreakba082ad9-de97-4f89-8a28-4cfac8a450f4" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">12</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></b>
<p style="MARGIN: 0px" align="center"><b><a name="RISK FACTORS">RISK FACTORS</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>You should carefully consider the risks described below as well as other information provided to you in this document, including information in the section of this document entitled &#8220;Information Regarding Forward Looking Statements.&#8221; If any of the following risks actually occur, the Company&#8217;s business, financial condition or results of operations could be materially adversely affected, the value of the Company&#8217;s Common Stock could decline, and you may lose all or part of your investment.</i><i><font size="3"></font></i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>RISKS RELATED TO OUR BUSINESS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We have no approved products on the market and have generated no product revenues to date.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To date, we have no approved products on the market and have generated no product revenues. Until, and unless, we receive approval from the FDA and other regulatory authorities for our product candidates, we cannot sell our products and will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from the net proceeds of the Offering, cash on hand, licensing fees and grants and additional financings, to the extent such financings can be obtained. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We will need additional capital. If additional capital is not available or is available at unattractive terms, we may be forced to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations. </i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In order to develop and bring our product candidates to market, we must commit substantial resources to costly and time-consuming research, preclinical and clinical trials and marketing activities. We anticipate that our existing cash and cash equivalents will enable us to maintain our current operations for at least the next six months. We anticipate that we will need approximately an additional $5 million to continue our operations for the next 12 months, not including any funds raised in this Offering. We anticipate using our cash and cash equivalents to fund further research and development with respect to our lead product candidates. We may, however, need to raise additional funding sooner if our business or operations change in a manner that consumes available resources more rapidly than we anticipate. Our requirements for additional capital will depend on many factors, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">successful commercialization of our product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the time and costs involved in obtaining regulatory approval for our product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">costs associated with protecting our intellectual property rights;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">development of marketing and sales capabilities;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">payments received under future collaborative agreements, if any; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">market acceptance of our products.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To the extent we raise additional capital through the sale of equity securities, the issuance of those securities could result in dilution to our shareholders. In addition, if we obtain debt financing, a substantial portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, thus limiting funds available for our business activities. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations. In addition, we may be required to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves or license rights to technologies, product candidates or products on terms that are less favorable to us than might otherwise be available. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company will require substantial additional funds to support its research and development activities, and the anticipated costs of preclinical studies and clinical trials, regulatory approvals and eventual commercialization. Such additional sources of financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to initiate clinical trials or obtain approval of any product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development, forego sales and marketing efforts and forego attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak0d545823-641c-4b5e-aa08-f4d55226ea70" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">13</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There is no assurance that we will be successful in raising the additional funds needed to fund our business plan. If we are not able to raise sufficient capital in the near future, our continued operations will be in jeopardy and we may be forced to cease operations and sell or otherwise transfer all or substantially all of our remaining assets.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We face intense competition in the markets targeted by our lead product candidates. Many of our competitors have substantially greater resources than we do, and we expect that all of our product candidates under development will face intense competition from existing or future drugs. </i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We expect that all of our product candidates under development, if approved, will face intense competition from existing and future drugs marketed by large companies. These competitors may successfully market products that compete with our products, successfully identify drug candidates or develop products earlier than we do, or develop products that are more effective, have fewer side effects or cost less than our products.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Additionally, if a competitor receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product candidate may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current product candidates can extend up to three and one-half years. See &#8220;Business &#8212; Government Regulation.&#8221; </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">These competitive factors could require us to conduct substantial new research and development activities to establish new product targets, which would be costly and time consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Competition and technological change may make our product candidates and technologies less attractive or obsolete.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We compete with established pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same indications we are pursuing and that have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others may render our technology or product candidates obsolete or noncompetitive, or result in treatments or cures superior to any therapy we develop. We face competition from companies that internally develop competing technology or acquire competing technology from universities and other research institutions. As these companies develop their technologies, they may develop competitive positions that may prevent, make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would be able to derive from the sale of any products.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There can be no assurance that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments. Furthermore, if our competitors&#8217; products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if our products are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians and patients will accept our product(s) as a treatment of choice.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Furthermore, the pharmaceutical research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant. The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting revenues or income with certainty or even confidence.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak657482db-bac3-42d1-820f-e33775bb541d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">14</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>The clinical and commercial utility of our INKmune therapy is uncertain and may never be realized.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our INKmune therapy is in an early stage of development. We anticipate initiating clinical trials in the second half of 2018 for INKmune in ovarian cancer and follow with a clinical trial in high risk MDS in 2019. Success in early clinical trials, if achieved, does not ensure that large-scale trials will be successful nor does it predict final results. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may not ultimately be able to provide the FDA with satisfactory data to support a claim of clinical safety and efficacy sufficient to enable the FDA to approve INKmune for commercialization. This may be because clinical trials may fail to produce favorable data, because the FDA may disagree with how we interpret the data from these clinical trials, or because the FDA may not accept these therapeutic effects as valid endpoints in pivotal trials necessary for market approval. We will also need to demonstrate that INKmune therapy is safe. We do not have data on possible harmful long-term effects of INKmune therapy and will not have any data on long-tens effects in the near future. For these and other reasons, the clinical effectiveness and commercialization of INKmune therapy is uncertain and may never be realized.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected. </i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our success will depend in part on our ability to obtain patents and maintain adequate protection of our technologies and products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies to produce and market drugs in direct competition with us and erode our competitive advantage. Some foreign countries lack rules and methods for defending intellectual property rights and do not protect proprietary rights to the same extent as the United States. Many companies have had difficulty protecting their proprietary rights in these foreign countries. We may not be able to prevent misappropriation of our proprietary rights. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have received, and are currently seeking, patent protection for numerous compounds and methods of treating diseases. However, the patent process is subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining and defending patents. These risks and uncertainties include the following: patents that may be issued or licensed may be challenged, invalidated, or circumvented, or otherwise may not provide any competitive advantage; our competitors, many of which have substantially greater resources than us and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products either in the United States or in international markets; there may be significant pressure on the United States government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as a matter of public policy regarding worldwide health concerns; countries other than the United States may have less restrictive patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Moreover, any patents issued to us may not provide us with meaningful protection, or others may challenge, circumvent or narrow our patents. Third parties may also independently develop products similar to our products, duplicate our unpatented products or design around any patents on products we develop. Additionally, extensive time is required for development, testing and regulatory review of a potential product. While extensions of patent term due to regulatory delays may be available, it is possible that, before any of our product candidates can be commercialized, any related patent, even with an extension, may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, the United States Patent and Trademark Office (the &#8220;PTO&#8221;) and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our licensors are able to obtain patents, the patents may be substantially narrower than anticipated.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak48e356e3-9513-4317-a554-207340604a78" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">15</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our success depends on patent applications that are licensed exclusively to us and other patents to which we may obtain assignment or licenses. We may not be aware, however, of all patents, published applications or published literature that may affect our business either by blocking our ability to commercialize our product candidates, by preventing the patentability of our product candidates to us or our licensors, or by covering the same or similar technologies that may invalidate our patents, limit the scope of our future patent claims or adversely affect our ability to market our product candidates.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition to patents, we rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions, and security measures to protect our confidential and proprietary information. These measures may not adequately protect our trade secrets or other proprietary information. If they do not adequately protect our rights, third parties could use our technology, and we could lose any competitive advantage we may have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access to our trade secrets, which could impair any competitive advantage we may have.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Patent protection and other intellectual property protection is crucial to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We have a limited operating history, and expect to incur significant additional operating losses.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are an early stage company formed in September 2015 and have only a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation of our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We expect to incur substantial additional operating expenses over the next several years as our research, development, and commercial activities increase. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the preclinical and clinical development of our product candidate; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; implementing successful manufacturing, sales, and marketing arrangements; and raising sufficient funds to finance our activities. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.<b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We are currently focused on the development of a single product candidate.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Although we intend to be opportunistic in pursuing additional products which support the Company&#8217;s objectives, our product development efforts are currently focused on a single product, INKmune, for which we are researching multiple indications and delivery strategies. If INKmune fails to achieve clinical endpoints or exhibits unanticipated toxicity or if a superior product is developed by a competitor, our prospects for obtaining regulatory approval and commercialization may be negatively affected. </p><b><i></i></b>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak43586722-f46e-46fd-acff-1c500055feec" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">16</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>INKmune represents a novel approach to cancer treatment that creates significant challenges for us.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We believe INKmune represents a novel approach to cancer treatment. Advancing this novel therapy creates significant challenges for us, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Educating medical personnel regarding the potential side effect profile of INKmune;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with commercial development of immunotherapies for cancer; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Even if we are able to commercialize any product candidate that we develop, the product may become subject to unfavorable pricing regulations, third party payor reimbursement practices or healthcare reform initiatives that could harm our business.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The commercial success of our product candidate will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidate will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities (such as Medicare and Medicaid), private health coverage insurers and other third party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidate. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish and maintain pricing sufficient to realize a meaningful return on our investment.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There is significant uncertainty related to third party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidate obtains marketing approval.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We are dependent on obtaining certain patents and protecting our proprietary rights.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing on the proprietary rights of third parties or having third parties circumvent our rights. We have filed and are actively pursuing a patent application for our product candidate. The patent positions of biotechnology, biopharmaceutical and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. Thus, there can be no assurance that our patent application will result in the issuance of a patent, that we will develop additional proprietary products that are patentable, that any patents issued to us will provide us with any competitive advantages or will not be challenged by any third parties, that the patents of others will not impede our ability to do business or that third parties will not be able to circumvent our patents. Furthermore, there can be no assurance that others will not independently develop similar products, duplicate any of our products not under patent protection, or, if patents are issued to us, design around the patented products we developed or will develop.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may be required to obtain licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can be given that any licenses required under any such patents or proprietary rights would be made available, if at all, on terms we find acceptable. If we do not obtain such licenses, we could encounter delays in the introduction of products or could find that the development, manufacture or sale of products requiring such licenses could be prohibited.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakadb3ffef-9aa7-4cee-969e-0753cc5ea19b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">17</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A number of pharmaceutical, biopharmaceutical and biotechnology companies and research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to or affect our business. Some of these technologies, applications or patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents, if any, that we may be able to obtain or result in the denial of our patent applications. In addition, if patents that cover our activities are issued to other companies, there can be no assurance that we would be able to obtain licenses to these patents at a reasonable cost or be able to develop or obtain alternative technology. If we do not obtain such licenses, we could encounter delays in the introduction of products, or could find that the development, manufacture or sale of products requiring such licenses could be prohibited. In addition, we could incur substantial costs in defending ourselves in suits brought against us on patents it might infringe or in filing suits against others to have such patents declared invalid.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Much of our know-how and technology may not be patentable. To protect our rights, we plan to require employees, consultants, advisors and collaborators to enter into confidentiality agreements. There can be no assurance, however, that these agreements will provide meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure. Further, our business may be adversely affected by competitors who independently develop competing technologies, especially if we obtain no, or only narrow, patent protection.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We are subject to various government regulations.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The manufacture and sale of human therapeutic products in the U.S. and foreign jurisdictions are governed by a variety of statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products and government review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain marketing approval based on establishing the safety and efficacy of the product for each use sought, including adherence to current cGMP during production and storage, and control of marketing activities, including advertising and labeling.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The product we are currently developing will require significant development, preclinical and clinical testing and investment of substantial funds prior to its commercialization. The process of obtaining required approvals can be costly and time-consuming, and there can be no assurance that we develop successfully this product or any future products, or that this product or any future products we develop will prove to be safe and effective in clinical trials or receive applicable regulatory approvals. Potential investors and shareholders should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory environment which controls our business.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are engaged in a rapidly changing field. Other products and therapies that will compete directly with the product that we are seeking to develop and market currently exist or are being developed. Competition from fully integrated pharmaceutical companies and more established biotechnology companies is intense and is expected to increase. Most of these companies have significantly greater financial resources and expertise in discovery and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing than us. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biopharmaceutical or biotechnology companies. Many of these competitors have significant products that have been approved or are in development and operate large, well-funded discovery and development programs. Academic institutions, governmental agencies and other public and private research organizations also conduct research, seek patent protection and establish collaborative arrangements for therapeutic products and clinical development and marketing. These companies and institutions compete with us in recruiting and retaining highly qualified scientific and management personnel. In addition to the above factors, we will face competition based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capability, reimbursement coverage, price and patent position. There is no assurance that our competitors will not develop more effective or more affordable products, or achieve earlier patent protection or product commercialization, than our own.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak9015c2b3-b502-49e1-9fd2-c3799f5238b1" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">18</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Other companies may succeed in developing products earlier than ourselves, obtaining FDA and European Medicines Agency (&#8220;EMA&#8221;) approvals for such products more rapidly than we will, or in developing products that are more effective than products we propose to develop. While we will seek to expand our technological capabilities in order to remain competitive, there can be no assurance that research and development by others will not render our technology or products obsolete or non-competitive or result in treatments or cures superior to any therapy we develop, or that any therapy we develop will be preferred to any existing or newly developed technologies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We may request priority review for our product candidate in the future. The FDA may not grant priority review for our product candidate. Moreover, even if the FDA designates such product for priority review, that designation may not lead to a faster regulatory review or approval process and, in any event, would not assure FDA approval.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may be eligible for priority review designation for our product candidate if the FDA determines such product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists. A priority review designation means that the goal for the FDA to review an application in six months, rather than the standard review period of ten months. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Thus, while the FDA has granted priority review to other oncology disease products, our product candidate, should we determine to seek priority review, may not receive similar designation. Moreover, even if our product candidate is designated for priority review, such a designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within an accelerated timeline or thereafter.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We believe we may in some instances be able to secure approval from the FDA or comparable non-U.S. regulatory authorities to use accelerated development pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We anticipate that we may seek an accelerated approval pathway for our product candidate. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak59672d34-a623-41fc-afac-9598f9698f2e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">19</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Prior to seeking such accelerated approval, we will seek feedback from the FDA and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a New Drug Application, or NDA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation (e.g., breakthrough therapy designation), there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other non-U.S. authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidate.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our product candidates are in clinical development and the risk of failure of our product candidates is high. It is impossible to predict when or if our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable non-U.S. regulatory authority that a drug product is not safe or effective for its intended uses. It is possible that even if our product candidate has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face additional setbacks.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The design of a clinical trial can determine whether its results will support approval of a product; however, flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of clinical trials for our product candidate warrant marketing approval, the FDA or comparable non-U.S. regulatory authorities may disagree and may not grant marketing approval of our product candidate.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Any clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidate.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If clinical trials of our product candidate fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable non-U.S. regulators, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidate.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are not permitted to commercialize market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S. regulatory authorities, such as the EMA, impose similar restrictions. We may never receive such approvals. We must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidate in humans before we will be able to obtain these approvals.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak42c7f3da-211c-421d-8be2-33318b144d14" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">20</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted a NDA to the FDA or similar drug approval filings to comparable non-U.S. regulatory authorities for any product candidate.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Any inability to successfully complete preclinical and clinical development could result in additional costs to us and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we are required to conduct additional clinical trials or other testing of our product candidate beyond the trials and testing that we contemplate, (2) we are unable to successfully complete clinical trials of our product candidate or other testing, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable safety concerns associated with our product candidate, we, in addition to incurring additional costs, may:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">be delayed in obtaining marketing approval for our product candidate;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">not obtain marketing approval at all;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">obtain approval for indications or patient populations that are not as broad as we intended or desired;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">be subject to additional post-marketing testing or other requirements; or</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">be required to remove the product from the market after obtaining marketing approval.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we experience any of a number of possible unforeseen events in connection with clinical trials of our product candidate, potential marketing approval or commercialization of our product candidate could be delayed or prevented.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval of our product candidate, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">clinical trials of our product candidate may produce unfavorable or inconclusive results;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the number of patients required for clinical trials of our product candidate may be larger than we anticipate, patient enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">data safety monitoring committees may recommend suspension, termination or a clinical hold for various reasons, including concerns about patient safety;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">regulators or institutional review boards, or IRBs, may suspend or terminate the trial or impose a clinical hold for various reasons, including noncompliance with regulatory requirements or concerns about patient safety;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">patients with serious, life-threatening diseases included in our clinical trials may die or suffer other adverse medical events for reasons that may not be related to our product candidate;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak5d8787cc-c1ea-414a-8443-980ee2fe628f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">21</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">participating patients may be subject to unacceptable health risks;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">patients may not complete clinical trials due to safety issues, side effects, or other reasons;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">changes in regulatory requirements and guidance may occur, which require us to amend clinical trial protocols to reflect these changes;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our third party contractors, including those manufacturing our product candidate or components or ingredients thereof or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may experience delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">patients who enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial&#8217;s duration;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may have to suspend or terminate clinical trials of our product candidate for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of a product candidate;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the FDA or comparable non-U.S. regulatory authorities may disagree with our clinical trial design or our interpretation of data from preclinical studies and clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the FDA or comparable non-U.S. regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third party manufacturers with which we enter into agreements for clinical and commercial supplies;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the supply or quality of raw materials or manufactured product candidate or other materials necessary to conduct clinical trials of our product candidate may be insufficient, inadequate, delayed, or not available at an acceptable cost, or we may experience interruptions in supply; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the approval policies or regulations of the FDA or comparable non-U.S. regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Product development costs for us will increase if we experience delays in testing or pursuing marketing approvals and we may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidate. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidate or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidate and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of marketing approval of our product candidate.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak501de8aa-5e11-4421-b701-cc41094632d9" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">22</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we experience delays or difficulties in the enrollment of patients in clinical trials, we may not achieve our clinical development on our anticipated timeline, or at all, and our receipt of necessary regulatory approvals could be delayed or prevented.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may not be able to initiate or continue clinical trials for INKmune or any other product candidate if we are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the size and nature of the patient population;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the severity of the disease under investigation;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the proximity of patients to clinical sites;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the eligibility criteria for the trial;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the design of the clinical trial;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">efforts to facilitate timely enrollment;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">competing clinical trials; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidate, delay or halt the development of and approval processes for our product candidate and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. Enrollment delays may also delay or jeopardize our ability to commence sales and generate revenues from our product candidate. Any of the foregoing could cause the value of the Company to decline and limit our ability to obtain additional financing, if needed.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A pharmaceutical product cannot be marketed in the U.S. or other countries until we have completed rigorous and extensive regulatory review processes, including approval of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office, or the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We expect to rely on orphan drug status to develop and commercialize our product candidate, but our orphan drug designation, if obtained, may not confer marketing exclusivity or other expected commercial benefits as anticipated.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Market exclusivity afforded by orphan drug designation is generally offered as an incentive to drug developers to invest in developing and commercializing products for unique diseases that impact a limited number of patients. The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Qualification to maintain orphan drug status is generally monitored by the regulatory authorities during the orphan drug exclusivity period, currently seven years from the date of approval in the United States.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak3b9c3eeb-c32e-4922-b64b-dd3eab9bb892" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">23</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We intend to seek orphan drug designation in the United States for our product candidate for the treatment of AML and ovarian cancer and we expect to rely on orphan drug exclusivity for our product candidate. Even if granted, orphan drug designation, and related market exclusivity, in the United States could be lost. Further, even if we are granted orphan drug status, the FDA can still approve different drugs for use in treating the same indication or disease, which would create a more competitive market for us and our revenues will be diminished.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Further, for our product candidate, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#8217;s period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to the orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If the market opportunities for our product candidate are smaller than we believe they are, our revenues may be adversely affected and our business may suffer. Because the target patient populations of our product candidate are small, we must be able to successfully identify patients and capture a significant market share to achieve and maintain profitability.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We focus our research and product development on treatments for certain cancer indications. Our projections of both the number of people who have failed other therapies or have limited medical options for such indications, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence. The number of patients with such diseases in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Additionally, because our target patient populations are small, we will be required to capture a significant market share to achieve and maintain profitability.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We may fail to comply with regulatory requirements</i></b><i>.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our success will be dependent upon our ability, and our collaborative partners&#8217; abilities, to maintain compliance with regulatory requirements, including cGMP, and safety reporting obligations. The failure to comply with applicable regulatory requirements can result in, among other things, fines, injunctions, civil penalties, total or partial suspension of regulatory approvals, refusal to approve pending applications, recalls or seizures of products, operating and production restrictions and criminal prosecutions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Even if our product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have never commercialized a product. Even if INKmune, INB03 or any other product candidate we develop is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third party payors and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak7704bbed-39c3-4556-86e9-e3e95bad50e6" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">24</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Efforts to educate the medical community and third party payors on the benefits of our product candidate may require significant resources and may not be successful. If our product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of INmune or any other product candidate we develop, if approved for commercial sale, will depend on a number of factors, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the efficacy and safety of the product;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the potential advantages of the product compared to alternative treatments;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the prevalence and severity of any side effects;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the clinical indications for which the product is approved;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">limitations or warnings, including distribution or use restrictions, contained in the product&#8217;s approved labeling;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our ability to offer the product for sale at competitive prices;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our ability to establish and maintain pricing sufficient to realize a meaningful return on our investment;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the product&#8217;s convenience and ease of administration compared to alternative treatments;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the willingness of the target patient population to try, and of physicians to prescribe, the product;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the strength of sales, marketing and distribution support;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the approval of other new products for the same indications;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">changes in the standard of care for the targeted indications for the product;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the timing of market introduction of our approved products as well as competitive products and other therapies;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">availability and amount of reimbursement from government payors, managed care plans and other third party payors;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">adverse publicity about the product or favorable publicity about competitive products; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">potential product liability claims.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The potential market opportunities for our product candidate are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidate could be smaller than our estimates of the potential market opportunities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak7fd28bcb-f774-4c1b-b611-91c9a44781f9" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">25</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Even if we obtain regulatory approvals for INKmune and/or INB03, those approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could prevent us from realizing the full benefit of our efforts.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If we obtain regulatory approvals, INKmune and/or INB03 therapy, and the manufacturing facilities used for its production will be subject to continual review, including periodic inspections, by the FDA and other United States and foreign regulatory authorities. In addition, regulatory authorities may impose significant restrictions on the indicated uses or marketing of INKmune or other products that we may develop. These and other factors may significantly restrict our ability to successfully commercialize INKmune.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We and many of our vendors and suppliers will be required to comply with current Good Manufacturing Practices, or GMP, which include requirements relating to quality control and quality assurance as well as to the corresponding maintenance of records and documentation. Furthermore, any manufacturing facilities will need to be approved by regulatory agencies before these facilities can be used to manufacture INKmune, and they will also be subject to additional regulatory inspections. Any material changes we may make to our manufacturing process may require approval by the FDA and state or foreign regulatory authorities. Failure to comply with FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We must also report adverse events that occur when our products are used. The discovery of previously unknown problems with INKMune, INB03 or manufacturing facilities used to manufacture INKmune or INB03 may result in restrictions or sanctions on our products or manufacturing facilities, including withdrawal of our products from the market. Regulatory agencies may also require us to reformulate our products, conduct additional clinical trials, make changes in the labeling of our product or obtain re-approvals. This may cause our reputation in the market place to suffer or subject us to lawsuits, including class action suits.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If our product candidate receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Clinical trials of our product candidate will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of our product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">regulatory authorities may withdraw their approval of the drug or seize the drug;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may be required to recall the drug or change the way the drug is administered;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">we could be sued and held liable for harm caused to patients;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the drug may become less competitive; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our reputation may suffer.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak70f21cf5-61f9-420f-9dc5-d10f52127907" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">26</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Any of these events could have a material and adverse effect on our operations and business. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Any product candidate for which we obtain marketing approval, along with the manufacturing processes, qualification testing, post-approval clinical data, labeling and promotional activities for such product, will be subject to continual and additional requirements of the FDA and other regulatory authorities.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">These requirements include submissions of safety and other post-marketing information, reports, registration and listing requirements, good manufacturing practices, or GMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping. Even if marketing approval of our product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical products to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved labeling.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, later discovery of previously unknown problems with our products, manufacturing processes, or failure to comply with regulatory requirements, may lead to various adverse results, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">restrictions on such products, manufacturers or manufacturing processes;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">restrictions on the labeling or marketing of a product;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">restrictions on product distribution or use;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">requirements to conduct post-marketing clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">requirements to institute a risk evaluation mitigation strategy, or REMS, to monitor safety of the product post-approval;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">warning letters issued by the FDA or other regulatory authorities;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">withdrawal of the products from the market;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">refusal to approve pending applications or supplements to approved applications that we submit;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">recall of products, fines, restitution or disgorgement of profits or revenue;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">suspension, revocation or withdrawal of marketing approvals;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">refusal to permit the import or export of our products; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">injunctions or the imposition of civil or criminal penalties.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We currently have no sales, marketing or distribution capabilities and have no experience as a company in marketing products. If we develop internal sales, marketing and distribution organization, this would require significant capital expenditures, management resources and time, and we would have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakf3272ab7-3776-4f20-9cf5-7d9123ae904e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">27</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we expect to pursue collaborative arrangements regarding the sales, marketing and distribution of our products. However, we may not be able to establish or maintain such collaborative arrangements, or if we are able to do so, their sales forces may not be successful in marketing our products. Any revenue we receive would depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the sales, marketing and distribution efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales, marketing and distribution efforts of our product candidates. There can be no assurance that we will be able to develop internal sales, marketing distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The development and commercialization of new drug products is highly competitive. We expect that we will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to INKmune and any other of our product candidates that we may seek to develop or commercialize in the future. Specifically, due to the large unmet medical need, global demographics and relatively attractive reimbursement dynamics, the oncology market is fiercely competitive and there are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of cancer. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We rely on key personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow effectively.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are dependent on certain members of our management, the loss of services of one or more of whom could materially adversely affect us. In particular, our success depends to a significant extent upon the continued services of Dr. Raymond J. Tesi, our President and CEO. Dr. Tesi has overseen INmune Bio since inception and provides leadership for our growth and operations strategy as well as being an inventor of our patents. Loss of the services of Dr. Tesi would have a material adverse effect on our growth, revenues, and prospective business. We are also highly dependent on the other principal members of our management and scientific team. We are not aware of any present intention of any of our key personnel to leave our company or to retire. However, we have no employment agreement with our President or other executives. The loss of any of our key personnel, or the inability to attract and retain qualified personnel, may significantly delay or prevent the achievement of our research, development or business objectives and could materially adversely affect our business, financial condition and results of operations.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our ability to manage growth effectively will require us to continue to implement and improve our management systems and to recruit and train new employees. There can be no assurance that we will be able to successfully attract and retain skilled and experienced personnel.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We face an inherent risk of product liability claims as a result of the clinical testing of our product candidate despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we commercially sell any product that we may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability claims may result in:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">decreased demand for our product candidate or products that we may develop;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakf87fc418-c002-464e-9c7c-bbd51087a39f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">28</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">injury to our reputation and significant negative media attention;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">withdrawal of clinical trial participants;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">significant costs to defend resulting litigation;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">substantial monetary awards to trial participants or patients;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">loss of revenue;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">reduced resources of our management to pursue our business strategy; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the inability to commercialize any products that we may develop.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Although we plan to maintain general liability insurance, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate, which could adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To execute our business plan, we will need to rapidly add other management, accounting, regulatory, manufacturing and scientific staff. We currently have only 2 full time employees consisting of our executive officers and retain the services of additional personnel on an independent contractor basis. We will need to attract, retain and motivate a significant number of new additional managerial, operational, sales, marketing, financial, and other personnel, as well as highly skilled scientific and medical personnel, and to expand our capabilities to successfully pursue our research, development, manufacturing and commercialization efforts and secure collaborations to market and distribute our products. This growth may strain our existing managerial, operational, financial and other resources. We also intend to add personnel in our research and development and manufacturing departments as we expand our clinical trial and research capabilities. Any inability to attract and retain qualified employees to enable our planned growth and establish additional capabilities or our failure to manage our growth effectively could delay or curtail our product development and commercialization efforts and harm our business.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak9c409e0a-b1a3-4e9e-b6bc-da2aca45fc55" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">30</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we or any of our third party manufacturers do not maintain high standards of manufacturing, our ability to develop and commercialize our product candidate could be delayed or curtailed.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We and any third parties that we may use in the future to manufacture our products must continuously adhere to cGMP regulations rigorously enforced by the FDA through its facilities inspection program. If our facilities or the facilities of third parties who produce our products do not pass a pre-approval inspection, the FDA will not grant market approval for INKmune. In complying with cGMP, we and any third-party manufacturers will need to expend significant time, money and effort in production, record-keeping and quality control to assure that each component of INKmune meets applicable specifications and other requirements. We or any of these third-party manufacturers may also be subject to comparable or more stringent regulations of foreign regulatory authorities. If we or any of our third-party manufacturers fail to comply with these requirements, we may be subject to regulatory action, which could delay or curtail our ability to develop, obtain regulatory approval of, and commercialize INKmune. If our component part manufacturers and suppliers fail to provide components of sufficient quality, and that meet our required specifications, our clinical trials or commercialization of INKmune could be delayed or halted, and we could face product liability claims.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us and any third-party manufacturers. We and such manufacturers will be subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we will seek to ensure that our procedures for using, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We plan to rely on third parties to conduct clinical trials for our product candidate. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidate may delay or impair our ability to obtain regulatory approval for our product candidate.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We plan to rely on academic institutions and private oncology centers to conduct and sponsor clinical trials relating to INKmune. Our reliance on third parties to conduct clinical trials could, depending on the actions of such third parties, jeopardize the validity of the clinical data generated and adversely affect our ability to obtain marketing approval from the FDA or other applicable regulatory authorities.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Such clinical trial arrangements will provide us with information rights with respect to the clinical data, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the clinical trials. If investigators or institutions breach their obligations with respect to the clinical trials of our product candidate, or if the data proves to be inadequate, then our ability to design and conduct any future clinical trials may be adversely affected.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will design our clinical trials and will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak0ee3d045-4891-48cb-932a-f4771817f1d7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">31</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidate and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidate.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidate or commercialization of our products, producing additional losses and depriving us of potential product revenue.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Recent legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for our products, if approved, that could materially affect our opportunity to commercialize such products.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our products profitably, if approved. Among policy-makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the demand for any of our products, if approved;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our ability to set a price that we believe is fair for any of our products, if approved;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our ability to generate revenues and achieve or maintain profitability;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the level of taxes that we are required to pay; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the availability of capital.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In March 2010, the Affordable Care Act, or the ACA, became law in the United States (see &#8220;Business &#8212; Government Regulation&#8221;). The goal of ACA is to reduce the cost of healthcare, broaden access to health insurance, constrain healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry, impose additional health policy reforms, and substantially change the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of any of our products, if they are approved. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak989af303-5a45-4ce8-93d4-5f1916be617b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">32</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In September 2011, the Leahy-Smith America Invents Act, or the American Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent application, which could have a material adverse effect on our business and financial condition.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our patents or patent applications.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Risks Related to our Common Stock and this Offering</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>There is no public market for securities and you may have to hold your shares of our common stock for an indefinite period of time.</i></b><i></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There is currently no established public trading market for our securities and an active trading market in our securities may not develop or, if developed, may not be sustained. We intend to submit an application with a national market for listing of our Common Stock after the registration statement relating to this prospectus is declared effective by the SEC. If for any reason our Common Stock is not listed on a national market or a public trading market does not otherwise develop, purchasers of the shares may have difficulty selling their Common Stock should they desire to do so. No market makers have committed to becoming market makers for our Common Stock and none may do so. There is no assurance that if we file an application with a nation al market for quotation of our stock our application will be approved. Even if our application is approved, a market for our Common Stock may not develop or be sustained. If an active market for our securities does not develop, it may be difficult for you to sell shares of our common stock without depressing the market price for the shares or at all. As a result of these and other factors, you may not be able to sell your shares of our common stock above the price you paid for such shares or at all. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies by using our shares of common stock as consideration.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak14464a08-887a-4b2f-83db-bdc7e9262fb7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">33</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>The Company&#8217;s common stock is controlled by insiders.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company&#8217;s officers and directors will beneficially own approximately 71.1% of our outstanding common stock. Accordingly, shareholders may have no effective voice in the management of the Company. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>We do not intend to pay dividends for the foreseeable future.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have paid no dividends on our common stock to date and we do not anticipate paying any dividends to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of the business, we anticipate that we will retain any earnings to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our common stock, and could significantly affect the value of any investment in our Company.<b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Our articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board of Directors will have the authority to issue up to 10,000,000 shares of our preferred stock without further stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.<b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If our shares are quoted on an exchange, we will be required to remain current in our filings with the SEC and our securities will not be eligible for quotation if we are not current in our filings with the SEC.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">In the event that our shares are quoted an exchange, we will be required to remain current in our filings with the SEC in order for shares of our Common Stock to continue to be eligible for such quotation. If our shares are not eligible for quotation on the OTCQB or an exchange, investors in our Common Stock may find it difficult to sell their shares.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If we take advantage of specified reduced disclosure requirements applicable to an &#8220;emerging growth company&#8221; under the JOBS Act, the information that we provide to stockholders may be different than they might receive from other public companies.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">As a company with less than $1 billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; under the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td>
<p style="MARGIN: 0px" align="justify">only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</p></td></tr>
<tr>
<td></td>
<td valign="top"></td>
<td></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td>
<p style="MARGIN: 0px" align="justify">reduced disclosure about our executive compensation arrangements;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakd0bd5d2d-ebc7-4a56-bb79-ddd6a6c4cc67" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">34</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr outerhtml='&#13;&#10;<TR height=15><TD>&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%">&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD width="74%">&#13;&#10;<P style="MARGIN: 0px" align=justify>no non-binding advisory votes on executive compensation or golden parachute arrangements; and</P></TD></TR>'>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify">no non-binding advisory votes on executive compensation or golden parachute arrangements; and</p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD></TD>&#13;&#10;<TD vAlign=top width="3%"></TD>&#13;&#10;<TD width="74%"></TD></TR>'>
<td></td>
<td valign="top"></td>
<td></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD>&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%">&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD width="74%">&#13;&#10;<P style="MARGIN: 0px" align=justify>exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</P></TD></TR>'>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1 billion in annual revenues, we have more than $700 million in market value of our stock held by non-affiliates, or we issue more than $1 billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced burdens. We have not taken advantage of any of these reduced reporting burdens in this prospectus, although we may choose to do so in future filings. If we do, the information that we provide stockholders may be different than you might get from other public companies in which you hold stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Our management will have broad discretion over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree.</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We currently intend to use the net proceeds from this offering to for our clinical trials of INKmune and INB03. We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us or our stockholders. The failure of our management to use such funds effectively could have a material adverse effect on our business, prospects, financial condition, and results of operation.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>If the Company only raises the Minimum Offering Amount, we may not have sufficient capital to execute our business strategy.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If we close on the Minimum Offering Amount, we may not have sufficient capital to execute on our business strategy the way have intended. Our ability to obtain additional financing thereafter may have a materially adverse effect on our ability to execute its overall plan and your investment may be lost.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Investor funds will not accrue interest while in escrow prior to closing.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">All funds delivered in connection with subscriptions for the common stock will be held in a non-interest bearing escrow account with the Escrow Agent until the closing of the offering, if any. If we are unable to sell and receive payments for the Minimum Offering Amount prior to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;investor subscriptions will be returned without interest or deduction. Investors in the common stock offered hereby may not have the use of such funds or receive interest thereon pending the completion of the offering.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Additional stock offerings in the future may dilute your percentage ownership of our company.</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Given our plans and expectations that we may need additional capital and personnel, we may need to issue additional shares of common stock or securities convertible or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. The issuance of additional securities in the future will dilute the percentage ownership of then current stockholders.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">You will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , shares at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; per share and after deducting the Placement Agent&#8217;s commission and estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share in the case of the Minimum Shares Offering and after giving effect to the sale by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares offered in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share and after deducting the Placement Agents&#8217; commission and estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share in the case of the Maximum Shares Offering. In addition, in the past, we issued options and warrants to acquire shares of common stock. To the extent these options or warrants are ultimately exercised, you will sustain future dilution.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak467d535d-71a0-4cfc-b4cd-193d7ade28ee" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">35</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="USE OF PROCEEDS">USE OF PROCEEDS</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">After deducting the commissions payable to the Placement Agent and sub-agent the estimated offering expenses that are payable by us, we estimate that the net proceeds from the sale of the common stock offered pursuant to this prospectus will be approximately $4,600,000 million if only the Minimum Offering Amount is sold and $13,800,000 million if the Maximum Offering Amount is sold. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We currently intend to use the net proceeds from this offering to fund our research and drug development activities, including the following: </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our Phase I/II clinical trial for our INKmune product candidate for Ovarian Cancer;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our planned Phase I/II clinical trial for INKmune in high-risk MDS;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our planned Phase Iclinical trial with INB03 in patients with advanced cancer and elevated MDSC in their blood;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">our Phase II clinical trials for INB03 combined with an approved checkpoint inhibitor for treatment fo patients with cancer who have failed first line therapy and have increased MDSC in their blood; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the remaining amounts for manufacturing, research and development activities, working capital and general corporate purposes.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may also use a portion of the net proceeds from this offering and our existing cash to in-license, acquire or invest in complementary business, technologies, products or assets. However, we have no current plans, commitments or obligations to do so. We have acquired high quality MSC cells secondary to our relationship with the Anthony Nolan Cord Blood Bank. We plan to sell these cells for research and clinical uses to third parties. We expect this business to be self-funding for the fore-seeable future. We may decide to develop an MSC related product if the opportunity fits the focus of our company. If we enter in to a development program with MSC, we cannot predict if it will be self-funding or require other support from the company.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds from this offering. Pending any use as described above, we intend to invest the net proceeds in high-quality, short-term, interest-bearing securities.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak22d71173-137e-4d18-a9d4-9b1c1c0e23cf" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">36</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We believe that the net proceeds from this offering and our existing cash will be sufficient to fund our operations through at least the next 12 months. This expected use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions. We cannot specify with certainty all of the particular uses of the net proceeds that we will receive from this offering, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures will depend on numerous factors, including the ongoing status of and results from clinical trials and other studies, the product approval process with the FDA, and the scope of our commercialization efforts, as well as any strategic collaborations that we may enter into with third parties for our product candidates, any unforeseen cash needs, and our investments and acquisitions. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in using these proceeds. Investors will be relying on our judgment regarding the use of the net proceeds from this offering. Pending the use of proceeds as described above, we plan to invest the net proceeds that we receive in short-term and intermediate-term interest-bearing obligations, investment-grade investments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We cannot predict whether the invested proceeds will yield a favorable return.&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There is no market for our Common Stock. We intend to list our common stock on a national stock market however, there no assurance that our application will be approved.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">As of October 30, 2017, there were 8,363,345 shares of Common Stock issued and outstanding. As of October 30, 2017 there were approximately 45 holders of record of our Common Stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>DIVIDEND POLICY</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have not declared any cash dividends on our common stock since inception and do not anticipate paying such dividends in the foreseeable future. We plan to retain any future earnings for use in our business operations. Any decisions as to future payment of cash dividends will depend on our earnings and financial position and such other factors as the Board of Directors deems relevant.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak93656738-45bf-431f-892b-890935171765" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">37</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>CAPITALIZATION </b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The following table sets forth or capitalization, as of September 30, 2017:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">on an actual basis; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">On a pro forma basis to give effect to the sale of the shares in this offering at the assumed public of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , after deducting commissions payable to the Placement Agent and other estimated offering expenses payable to us.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="5" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30, 2017</b></p></td>
<td><b>&nbsp;</b></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="5" align="center">
<p style="MARGIN: 0px" align="center"><b>(Pro forma)</b></p></td>
<td><b>&nbsp;</b></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>(Actual) </b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Maximum </b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="center">
<p style="MARGIN: 0px" align="center"><b>Minimum</b> </p></td>
<td>&nbsp;</td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Preferred Stock, $.001 par value, 10,000,000 shares authorized none outstanding; </b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Common stock; $0.001 par value; 200,000,000 shares authorized, 8,363,345 shares issued and outstanding actual, maximum, and minimum shares issued and outstanding </b><b>pro forma</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Additional paid-in capital</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Retained Earnings</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>Other comprehensive income</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Total stockholder&#8217;s equity</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" colspan="2">$</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">&nbsp;</td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>DILUTION</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If you invest in our securities, your interest will be immediately and substantially diluted to the extent of the difference between the public offering price per share of our common stock and the pro forma net tangible book value per share of our common stock after giving effect to this offering.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our net tangible book value as of September 30, 2017 was $1,328,080 or approximately $0.20 per share of common stock, based upon 6,693,333 shares outstanding as of September 30, 2017 (and on an-exchanged basis with respect to Exchangeable Shares).</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">If the minimum amount is raised, after giving effect to the sale of the shares and warrants in this offering at the assumed public offering price of $1.50 per share and after deducting commissions paid to the Placement Agents and other estimated offering expenses payable by us, our pro forma net tangible book value at September 30, 2017 would have been approximately $XX or $XX per share. This represents an immediate increase in pro forma net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share to our existing stockholders, and an immediate dilution of $XX per share to investors purchasing securities in this offering.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">If the maximum amount is raised, after giving effect to the sale of the shares and warrants in this offering at the assumed public offering price of $XX per share and after deducting commissions paid to the Placement Agent and other estimated offering expenses payable by us, our pro forma net tangible book value at September 30, 2017 would have been approximately $XX or $XX per share. This represents an immediate increase in pro forma net tangible book value of approximately $XX per share to our existing stockholders, and an immediate dilution of $XX per share to investors purchasing securities in this offering.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Dilution in pro forma net tangible book value per share represents the difference between the amount per share paid by purchasers of our common stock in this offering and the pro forma net tangible book value per share of our common stock immediately after this offering.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak936dbcd6-6707-439f-914d-d33c6b377b21" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">38</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table illustrates the per share dilution to investors purchasing shares in the offering if the minimum number of shares are sold:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top">
<p style="MARGIN: 0px">Assumed public offering price per share</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Net tangible book value per share as of September 30, 2017</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Increase in net tangible book value per share attributable to this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Pro forma net tangible book value per share after this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Amount of dilution in net tangible book value per share to new investors in this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The following table illustrates the per share dilution to investors purchasing shares in the offering if the maximum number of shares are sold:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top">
<p style="MARGIN: 0px">Assumed public offering price per share</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Net tangible book value per share as of&nbsp; September 30, 2017</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Increase in net tangible book value per share attributable to this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Pro forma net tangible book value per share after this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Amount of dilution in net tangible book value per share to new investors in this offering</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right"></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If any shares are issued upon exercise of outstanding options or warrants, new investors will experience further dilution.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>BUSINESS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Our Strategy</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our objective is to develop and commercialize our product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient&#8217;s disease. This can be in cancer where NK cells are inactive and contribute to a tumor&#8217;s evasion of the immune system and/or disease progression while MDSC proliferate to protect the tumor from attack by the patient&#8217;s immune system or this can be in chronic infection where similar dysfunction exists or other neurologic and metabolic diseases where chronic inflammation results in innate immune system dysfunction and disease progression. Our initial focus will be the treatment of cancer &#8211; both hematologic malignancies and solid tumors. We plan to pursue two parallel development programs. With INKmune, we will initially focus on treating women with relapse refractory ovarian carcinoma. With INB03, we will treat patient with advanced cancers with elevated levels of MDSC in their blood. Once resources are available, we will expand our development programs with INKmune and INB03 into high risk MDS and a combination trial with approved checkpoint inhibitors in patients with melanoma respectively. Both programs will expand into the study and treatment of other cancers based on pre-clinical data and resource availability. The principal components of our strategy to achieve this objective are to:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">pursue development strategies and regulatory approval pathways that allow the treatment of oncology patients with our lead product candidates, INKmune and INB03;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">adopt a product development strategy that solidifies our existing IP to prevent competition and expand our IP suite into related immunotherapeutic areas;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">provide clear value propositions to third-party payers, such as managed care companies or government programs like Medicare, to merit reimbursement for our product candidates; and</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">enter into collaborations with other pharmaceutical companies with respect to, among other things, our INKmune and INB03 product candidates and other products that will benefit from development or marketing resources beyond those in our Company.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak1f8162ba-461f-4f35-9624-0d447b4b6129" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">39</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Pursue development and regulatory approval pathways</i>. We believe INKmune and INB03 may be approvable under pathways that are potentially shorter than those typically available for drug products based on novel active ingredients, including as an orphan drug under the Orphan Drug Act and approval under the FDA Accelerated Approval Program (see &#8220;Government Regulation&#8221;). The Company has not yet had a discussion with the Medicines and Healthcare Products Regulatory Agency (MHRA) and/or FDA regarding such designations, but plans to do so in 2019. We believe both our high risk MDS and ovarian carcinoma treatment programs fit the criteria used by the FDA to grant these regulatory designations. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Adopt a two-pronged patent strategy.</i> We are pursuing a two-pronged product development strategy that will seek to solidify our existing IP to prevent competition and expand our IP suite into related immunotherapeutic areas. We are confident that our core in-licensed IP (see &#8220;Intellectual Property&#8221;) will allow us both freedom-to-operate and provide robust protection from outside competition. The Company will continue to invest in expanding the patent suite. The Company will also seek to further to strengthen its IP position by looking to in-license IP related to immunotherapeutic strategies focused on the innate immune system. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Provide clear value propositions to third-party payors to merit reimbursement for our product candidates</i>. We are designing our clinical development programs to demonstrate compelling competitive advantages to patients and prescribers and also to demonstrate value propositions to third-party payors. We believe the use of INKmune and or INB03 in patients with a high risk of tumor progression and death from tumor will both prolong survival, improve the patent&#8217;s quality of life and decrease the total cost of care for patients with these lethal malignancies. For example, ovarian cancer patients relapse frequently. Each relapse requires an expensive, hospital-based treatment regimen that has decreasing benefits. Treatment with INKmune as an out-patient may provide a more durable remission and limit the need for treatment-associated hospitalizations. At the patient level, we believe INKmune and INB03 therapy, once approved, should improve survival and quality of life. At the payer level, we believe INKmune, once approved, should provide more predictable costs and outcomes.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Enter into collaborations to maximize the value of our technology</i>. We believe there are two reasons for us to enter into collaborations with other companies. The first is the further development of INKmune and INB03 by either providing additional innovations to the product, including combination therapy strategies, and/or providing resources to improve the speed and breadth of the development process. The second is to optimize the commercialization of our products either globally or regionally. The ideal partner will benefit us in both ways.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are also developing a service business based on our unique capabilities to manufacture cell therapies. We have developed a way to provide large quantities of high quality human mesenchymal stem cells to the medical research and biotech community. We plan to act as a contract manufacturer of research grade and clinical grade (cGMP) MSC for third parties that need MSC for their research and clinical development.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Overview of Immunotherapy</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The immune system has two parts, innate and adaptive. The innate immune system is the body&#8217;s first line of defense against an infection, providing immediate, non-specific responses to eliminate harmful cells in the body. Components of the innate immune system include cytokines, chemokines, macrophages, neutrophils and NK cells, among others.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The adaptive immune system is often initially triggered by the innate immune system, mounts a delayed response against diseased cells and plays a role protecting against re-infection. An adaptive immune response is highly specific to a particular pathogen or antigen and is developed or learned from prior exposure. Key components of the adaptive immune system include antibodies which bind to antigens and mark them for destruction by other immune cells, B-cells which produce these antibodies upon exposure to antigens, and T-cells which attack and eliminate the diseased cells.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak6eb3bbd8-d508-4062-8dc0-1b379e769048" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">40</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The biopharmaceutical industry has made significant advances in harnessing specific components of innate and adaptive immune systems for therapeutic use. Some of these approaches are summarized below.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Cytokines.</i></b> One of the early applications of immunotherapy is the use of cytokines, including interferons and IL-2. Interferons are molecules that inhibit the growth and replication of diseased cells and stimulate innate immune cells to attack them. They have been used as standard of care for hepatitis B and C and multiple sclerosis, and to a lesser extent, as treatment for certain cancers, including chronic myeloid leukemia, cutaneous T-cell lymphoma, myeloma and non-Hodgkin&#8217;s lymphoma. However, the use of interferons has generally decreased over the years due to serious adverse events (<i>e.g.</i>, flu-like symptoms and dramatic weight loss) and introduction of new therapies with higher efficacy, better safety profiles and more convenient administration. IL-2 activates T-cells and NK cells to attack diseased cells. IL-2 is used to treat select cancers, but due to its relatively poor safety profile, physicians often only resort to this therapy for the most advanced settings.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Antibody therapy.</i></b> Antibodies exist in three formats; monoclonal, polyspecific and antibody0drug conjugates. mAbs represent an effective therapeutic modality and are important to the treatment paradigm of various diseases. Recent insights into the detailed mechanism of mAbs link their strong disease fighting potential to the immune system. Drug manufacturers have leveraged mAbs&#8217; ability to induce an antibody-dependent cell-mediated cytotoxicity, or ADCC effect to develop better treatments that prolong survival and quality of life of patients. In addition, mAbs designed to inhibit specific checkpoints in the immune system have demonstrated strong immune responses and therapeutic benefit in patients. However, the degree of efficacy of these therapies is heavily reliant on the immune system of patients, many of whom are severely immuno-compromised. For example, despite over $1.0 billion of sales generated by recently launched PD-1 and PDL1 checkpoint inhibitors, they are reported to be generally only effective in approximately 10% to 25% of the addressable patient population. In addition, mAbs are manufactured through a complex process that requires purification of cell products created from a cell line. Polyspecfic antibodies, for example bi-specific antibodies, are able to target more than one antigen. These are often used to bring and effector T cell in contact with a target cell. Antibody drug conjugates are mAbs attached to a toxin, chemotherapy or radio therapy that delivers the cancer killing payload directly to the cancer.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Dendritic Cell Therapies.</i></b> This approach is designed to indirectly stimulate a patient&#8217;s T-cells by leveraging the role of dendritic cells in presenting antigens to T-cells. Cancer vaccines are the most common application of dendritic cells. The only FDA-approved dendritic cell therapy is PROVENGE, which entails collecting monocytes from the patient, maturing them into dendritic cells, &#8220;loading&#8221; <i>ex vivo</i> with the patient&#8217;s cancer antigens, and then re-infusing in the patient. Currently, this process is cumbersome and expensive, and again, relies on an intact and effective immune system of the patient. There are additional ongoing preclinical studies and clinical trials being conducted by our competitors aimed at addressing certain of the limitations associated with this approach. To date, current clinical results of dendritic cell therapies have been mixed.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>CAR-T and TCR Therapies.</i></b> T-cells recognize diseased cells by receptors engaging with antigens that are present on or inside the diseased cells. CAR-T therapy entails genetically engineering T-cells to express synthetic CARs that direct T-cells to antigens on the surface of cancer cells. TCR therapy modifies T-cells to express high-affinity tumor specific TCRs that recognize intra-cellular antigens that must be presented on the surface of target cells. In early clinical trials, CAR-T and TCR therapies have demonstrated impressive anti-tumor activity in a narrow spectrum of hematologic cancers and garnered significant attention by research institutions and biopharmaceutical companies. We believe a key limitation of adaptive autologous immunotherapy is the need to retrieve non-compromised immune cells from a cancer patient and require a complex and costly manufacturing process to develop the therapy. As a consequence of this need to harvest active T-cells, current Phase I clinical trials for autologous CAR-T cell therapy in large part enroll patients from highly selected, often relatively early-stage disease in a narrow spectrum of cancers, including bulky hematological cancers. In addition, Phase I clinical trials of CAR-T cell immunotherapy have reported severe adverse toxicities of cytokine release syndrome and neurotoxicity, requiring hospitalization, pre-conditioning and, in some instances, intensive care unit admission following side effects associated with cytokine release syndrome. As a result, though our competitors continue to develop their CAR-T and TCR product candidates with the goal of addressing certain of the limitations associated with these approaches, we believe these serious challenges may limit their potential and use in a variety of indications, including solid tumors.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>NK Cells</i></b>. NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for co-stimulation, which is why they are called &#8220;natural killers.&#8221;</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak390c4320-ce06-42eb-a6bb-2c46a206e7f6" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">41</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">NK cells bind to stress ligands expressed by the diseased cells and directly eliminate them. This binding induces NK cells to release cytokines, including IL-12, IL-15, IL-18, interferons and GM-CSF, which are integral in recruiting additional innate and adaptive immune responses by the host. NK cells also represent a critical effector cell for ADCC, whereby target cells bound with human antibodies, whether made by the patient&#8217;s body or administered, are selectively destroyed by the NK cells.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>MDSC Cells:</i></b> MDSC are present in low quantities in healthy patients. MDSC develop and proliferate in patients with chronic infection and with cancer. In cancer, MDSC are a unique and well defined cell population that home to the cancer and secrete immunosuppressive cytokines that provide a protective, immunosuppressive shield to the tumor. This protective immunosuppressive shield prevents the patient&#8217;s immune system from attacking the tumor. The presence of MDSC in the tumor microenvironment and/or circulating in the patient&#8217;s blood predict for more advanced disease, resistance to immunotherapy and a worse patient survival.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>INKmune: Our NK cell Directed Product Candidate</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">INKmune is our lead product candidate that converts resting NK cells into primed NK cells, an essential step in them becoming activated cancer-killing NK cells. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Cancers grow and relapse because they evade the immune system. NK cells are the most important cell elimination of residual disease that causes cancer relapse. NK cells target cells based on a series of complex antigens on the cancer cell surface that signal the NK cells to see and kill the cancer cell. We call these cancer antigens Signal 1 (S1) and Signal 2 (S2) or priming and triggering signals respectively. An NK cell must see both S1 and S2 on the cancer cell surface to kill the cancer cell. If either signal is missing, the NK cell ignores the cancer cell so the cancer cell survives and grows.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">The main &#8220;job&#8221; of a cancer cell is to survive. The first priority for survival is to evade NK cell killing. The vast majority, &gt;98%, of cancer cells do this by downregulating Signal 1- the priming signal. When an NK cell interrogates a cancer cell expressing only Signal 2 that has no Signal 1, it ignores it. This allows the cancer to evade NK cell killing to grow, and is one of the causes of cancer relapse.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">We have described the functional biology underlying Signal 1 and Signal 2 interaction of NK cells and cancer cells. We have learned counteract the loss of the priming signal by artificially providing Signal 1 to the resting NK cell. We call this product INKmune. When we deliver INKmune to a resting NK cell, it provides Signal 1 to convert the resting NK cell in to a tumor primed NK cell (TpNK). TpNK are poised to kill any cancer cell that expresses Signal 2. Since most cancer cells still express Signal 2, The TpNK binds to the cancer cell, becomes an activated NK cell that will kill the cancer cell that was previously untargeted by the NK cell.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">There are two advantages of TpNK compared to cytokine primed NK cells (LAK) or monocloncal antibody primed NK cells (MabNK). Both LAK and MabNK require the priming agent to be present at all times for the NK cell to be a cancer killing cell. As soon as the cytokine or Mab are removed, the NK cell becomes a resting NK cell that cannot kill the cancer cell. INKmune provides a permanent &#8220;on&#8221; switch. Once INKmne cause the resting NK cell to become a TpNK, the NK cell remains primed and ready to kill even if INKmune is removed. The second advantage is that TpNK do not require a specific target compared to MabNK. Herceptin, a Mab targeting HER2 on breast cancer is an illustrative example. The women with HER2 positive breast cancer, 20% of all women with breast cancer, can be treated with and benefit from Herceptin immunotherapy. Unfortunately, the other 80% who are HER2 negative, have a worse survival because they can not avail themselves to immunotherapy. INKmune may benefit the women with HER2 negative breast cancer.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">Because INKmune primes NK cells to target naturally occurring antigens, INKmune can be used in to treat a wide variety of cancers including hematologic malignancy (AML, MM, CML, high risk MDS) and solid tumors (renal, prostate, breast, ovarian, pancreas and lung). We expect the list of INKmune sensitive tumors to continue to expand.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakc349a401-779f-47d5-805b-3a672b4253d2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">42</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">The primary role for INKmune will be an immunotherapy targeting residual disease in patients after debulking cancer therapies such as cytotoxic chemotherapy and surgery. We do not expect to need to modify INKmune to treat these additional types of cancer, because it is a universal cancer therapy where &#8220;one size fits all&#8221;. We believe for INKmune to receive regulatory approval for each cancer indication, clinical trials will be need to be performed which demonstrate its safety and effectiveness as a treatment for each such cancer. We believe the difficulty and cost of achieving these labels extensions will decline, with each successive approval, if and when achieved. That is, even though INKmune may be effective therapy in patients with breast or lung cancer. We will need to do separate pivotal trials for approval in each indication.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Three step process to preparation for INKmune human clinical trials:</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune GMP scale-up for Phase I/II clinical material</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Once the dose and delivery of INKmune has been determined, we anticipate that good manufacturing practice, or GMP clinical material will be produced by a contract manufacturing organization. We anticipate completing production of INKmune for the clinical trials in 1H18.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune Biomarker Development Program</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company has discovered two biomarker strategies that can be used to demonstrate: i) who should receive INKmune therapy; ii) if the INKmune therapy is working; and iii) when INKmune therapy should be repeated. For the initial Phase I/II trials in patients ovarian cancer or high risk MDS, we expect the biomarker testing will be performed in a single laboratory under the direction of the company. In the near future, we will develop assay systems with standard operating procedures to ensure uniform testing of the biomarker across clinical sites. This will facilitate expansion of the clinical programs to multiple sites. We anticipate that, in the future, the biomarker program will be a surrogate marker for both clinical effectiveness and marketing purposes. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Interaction with Regulatory Authorities Regarding INKmune Development</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We met with the MHRA as part of a Scientific Advice Meeting in September 2017. The purpose of the meeting was to explain to the MHRA our manufacturing process and clinical plan for the development of INKmune in a Phase I/II trial in relapse/refractory ovarian cancer. The MHRA provided positive feedback on our manufacturing and clinical plans. We will be submitting a CTA in 1Q18 to support the ovarina cancer Phase I/II trial in the UK. We expect to meet with the FDA in 2H18 in preparation for expanding the Phase II component of the clinical trial in to the US. We plan a similar two step regulatory process for the high risk MDS trial.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune Product Development Path</i><i> Proposed Phase I/II Study in patients with cancer</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In the second half of 2018, we plan to perform an open label Phase I/II cancer study in patients with ovarian carcinoma. Patients will be enrolled who have a low burden of relapse refractory disease and have no evidence of NK cell tumor killing because their NK cells are resting NK cells (resting NK cells can be differentiated from activated NK cells using flow cytometry). The study design agreed upon after discussion with the MHRA on September 12, 2017 will be a two-step Phase I/II study. In the Phase I, patients will be treated with INKmune in a traditional open label study to demonstrate safety and determine the dose of INKmune to be carried into the larger Phase II portion of the study. Once safety and INKmune dose has been defined, a randomized study of women treated with INKmune will be compared to a group of control patients who receive only standard of care treatment with letrozole. We expect to treat 6 patients in the Phase I portion of the trial, but this number can increase by to as many as 18. The Phase II portion of the protocol will enroll 30 patients in a 2:1 randomization (20 active: 10 control). In both trials, in addition to immunologic monitoring of NK activation status and ability to kill tumors, CA125, a serologic biomarker of tumor burden will be used to determine the effect of INKmune therapy on the patient&#8217;s ovarian cancer. The Phase II proof-of-concept study should allow us to accurately design future studies for regulatory approval. The dose and frequency of intraperitoneal INKmune therapy will be finalized during the Phase I portion of the trial. We are planning 3 cycles of INKmune therapy IP. Each cycle involves three IP infusions of INKmune. Overall, patients will receive at least 9 doses of INKmune IP. If patients are responding, the attending physician may decide to extend the therapy beyond the 3 cycles of therapy. The company is prepared to support these patients with INKmune therapy as dictated by their response to therapy. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak598d5e89-a118-4bb1-bde0-368732925626" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">43</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If resources permit, the company plans to initiate a Phase I/II clinical trial treating patients with high-risk MDS with INKmune delivered intravenously. MDS is a disease of the elderly with few effective therapies. Patients with high risk MDS have measurable leukemic blasts (&gt;5%) in their bone marrow and will most likely die of their disease due to progression to AML or bone marrow failure. Current therapies do not effectively treat a majority of these patients. The only known cure for patients with high risk MDS is allogenic bone marrow transplant, a therapy that is often contraindicated in older patients. INKmune may be an effective immunotherapy for this disease by priming the patient&#8217;s NK cells to eradicate the blasts in their marrow. We expect the Phase I/II trial will occur in the UK and US. Although we have not presented the trial design to the regulatory authorities, we expect the design of the trial will be similar to the ovarian cancer trial with the primary efficacy end-point tailored to the disease (a decrease in the number of leukemic blasts in the bone marrow). </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i><u>INKmune Registration Studies and/or Partnering</u></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">After completion of proof-of-concept Phase II studies with INKmune, the Company will decide whether to continue to develop INKmune as a treatment for high risk MDS and ovarian carcinoma indication and/or expand into other tumor types. We expect to have biopharma partners participate in this decision. We may also seek to be acquired at this stage or partner INKmune. Although our development strategy is focused on North America and Europe, we believe INKmune will also be attractive for markets on the Pacific Rim, South Asia and South America, but will wait for partners to help with the development in those regions. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune Regulatory Strategy</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company&#8217;s regulatory strategy is very simple. INKmune is a new therapy for the treatment of cancer that will need to be proven safe and effective by well-designed clinical trials that show a meaningful clinical benefit to patients. We believe that registration trials will need to be designed as randomized trials in patients with cancer where one group of patients received INKmune and another receive best available care. We received advice from the MHRA ion September 12, 2017 on the design clinical trial for ovarian cancer. We will meet with the FDA once we have data from the Phase I trial. Because there are no therapies similar to INKmune approved in any market, we plan to take advantage of the regulatory opportunities afforded to therapies that treat small markets with a high unmet need. In the U.S., this includes Orphan Drug Designation and expedited programs for approval including Accelerated Approval, Breakthrough Therapy Designation, Fast Track Designation, and priority review (see &#8220;Government Regulation&#8221;). We cannot predict which of these programs we will benefit from without further discussions with the FDA. Similar programs exist in the EU with the EMA.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Emerging Market Opportunity</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The cancer therapy market is very large, diverse and competitive. Although the concept of immunotherapy with monoclonal antibodies has been around for more than 20 years, the concept that patient derived immunosuppressive factors was a barrier to effective cancer treatment was recently recognized and had its first therapy approved just 4 years ago (Yervoy, BMS, March 2011). Since then, two additional &#8220;check point&#8221; inhibitors have been approved, but the market is in its infancy. Most of the focus on strategies for modulating tumor-based immunosuppression focus is on the adaptive immune system (&#8220;T-cells&#8221;). The role of, and the importance of manipulating the innate immune system has more recently become a target of therapeutic development. NK cells are part of the innate immune system and are critical in both tumor surveillance (prevention) and treatment (killing). Myeloid Derived Suppressor Cells (&#8220;MDSC&#8221;) are part of the innate immune system that only appear once the patient has chronic inflammation, a common occurrence in patients with cancer. The main role of the MDSC is to protect the tumor from attack by the patient&#8217;s immune system. Because T-cell focused strategies have do not have an effect on the innate immune system, patient&#8217;s receiving such treatments may fail to recruit half of the patient&#8217;s immune system, the innate immune system, to attack the patient&#8217;s cancer. Clinicians increasingly recognize that durable responses to cancer requires a coordinated attack by the patient&#8217;s adaptive and innate immune system. Normalizing the response of the innate immune system requires eliminating the dysregulated innate immune response that decreases the patient&#8217;s ability to see and attack the cancer as well as mechanisms the protect the cancer from immunologic attack (effector and protector function respectively). INKmune primes NK cells to enable them to attack the tumor. INB03, by decreasing the proliferation and function of MDSC, will lessen the immunosuppressive shield that protects the tumor from immunologic attack and, through NK/DC crosstalk, recruit the adaptive immune system to the fight. In summary, INmune Bio has two product platforms aimed at re-engineering the patients&#8217; innate immune system&#8217;s response to their cancer. INKmune and INB03 target the different parts of the innate immune response. INKmune targets the effector function &#8211; promotes NK cell killing of cancer cells. INB03 targets the protector function &#8211; decreases the MDSC protecting the tumor from immune attack. These therapies supplement the immunotherapies focused on the adaptive immune response that are being developed by other companies. We expect the combination of immunotherapies that leverage both sides of the immune system, adaptive and innate, will improve the ability of the patient to fight their cancer. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak419fcd27-7ddb-4b0e-b65b-e77c51e258db" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">44</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Challenges in the Market for Innate Immune System targeted immunotherapies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The market for new oncology therapies is busy, complicated and rapidly evolving. We will be competing with companies that are older, larger, better financed and have greater experience. There are two types of drug companies &#8211; development companies and commercial companies. Development companies take the risk of developing new products to proof-of-concept. Once proof-of-concept has been achieved, if the drug provides clinical benefit, the product is usually acquired by a commercial company, which completes the drug&#8217;s clinical development and markets the product. We are a development company which will seek to develop products such as INKmune from the bench to the bedside to demonstrate proof-of-concept. The goal for the Company is to successfully develop such products to the point where they are attractive targets for potential partners/acquirers. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The immunotherapy market is growing rapidly at an annual rate of over 20%. Recently, the market is biased towards T cell-based immunotherapies including bi-specific antibody therapies, checkpoint inhibitors and CAR-T cell-based therapies. The difference in the number of clinical trials that are focused on the adaptive immune system verses innate immune system for the treatment of cancer is great. Therefore, our challenge will be to educate partners on the value of NK cell-based therapeutic strategies. The need to educate people of the importance of INB03 is equally challenging. At the academic level, there is a recognition that therapies targeting MDSC are needed to improve the results of immunotherapies. Investors and potential partners are only learning about MDSC. We will be responsible for educating them on the importance of MDSC and why INB03 is may be an important addition the oncologist&#8217;s armamentarium. We believe educating investors and partners about new therapeutic opportunities is an easier task than trying to differentiate the Company from the many other cancer immunotherapy companies. We plan to use a combination of publication, presentation and investor relations to promote INKmune and INB03 and to educate the clinical, biopharma and investor community on the value of these novel therapeutic approaches.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>INKmune Competition</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. We believe that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, price and reimbursement level. Many of our potential competitors, including many of the organizations named below, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than us in obtaining FDA approval for and achieving widespread market acceptance of their drugs. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Further, the development of new treatment methods for the conditions we are targeting could render our drugs non-competitive or obsolete.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakfc8b1ca7-ec3a-4868-ba93-80a4df0cb566" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">45</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">INKmune is an immunotherapy that harnesses the biology of NK cells for the treatment of cancer. There is a long list of immunotherapy strategies for the treatment of cancer and the immunotherapy for cancer market is growing rapidly. There are at least three ways to classify immunotherapy for cancer. The list below classifies immunotherapy strategies beginning with those that are most closely related to INKmune:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">1.</td>
<td valign="top">Companies in the NK cell therapy business;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">2.</td>
<td valign="top">Companies in the personalized immune-oncology business; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">3.</td>
<td valign="top">Companies in the precision immuno-oncology business.</td></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are not aware of any approved treatments that are classified as NK cell therapies. We are aware of three public companies in the NK cell therapy business: NantKwest, Fate Therapeutics and Fortress Biotech. These companies have products that involve replacing or supplementing NK cells of the patient for the treatment cancer. Their product requires extensive ex-vivo cell manipulations which, with respect to NantKwest and Fate Therapeutics, may include gene therapy. The next larger group of companies are in the personalized immuno-oncology business with products focused on T cell activation strategies. The most popular are the CAR-T cell therapies which are a patient specific ex-vivo gene therapy approach to a single disease (for example: pediatric ALL). CAR-T therapy has become wildly popular of late and includes many private companies, newer public companies such as Bluebird, Juno Therapeutics and Mustang Bio as well as established companies such as Novartis and Gilead. For many of the companies, CAR-T cell therapies is their only business. For the latter two, CAR-T cell therapies is a newly in-licensed programs with marketing authorization in the US. Finally, the precision immune-oncology category also includes companies with anti-cancer antibody products and the newer &#8220;check-point&#8221; inhibitors. Antibody therapies are all about &#8220;illuminating&#8221; the cancer to the innate immune system (NKcells). Monoclonal antibodies were the original immunotherapy that drove the growth of well-known biopharma companies including Genentech/Roche, Amgen, Merck and others. Each of these products is disease specific (ie: treat only HER2+ breast cancer). Modern therapeutic antibodies are much more complicated bi-specific and tri-specific antibodies that attempt to connect the cancer with activated T-cells of the adaptive immune system. Check-point inhibitors are currently the most rapidly expanding product category in immuno-oncology. These CTLA-4(ipilimumab) and PD-1 inhibitors (pembrolizumab and nivolumab) specifically block a mechanism that shields cancers from T-cell killing. The two companies in this business are Merck (pembrolizumab) and GSK (ipilimumab and nivolumab). There are many others trying to join this promising therapeutic area including large companies such as BMS and Roche.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">There are a number of FDA approved drugs that improve the ability of the innate immune system (NK-cells) to treat cancer including mono-clonal antibody therapies (for example: Rituximab&#174;; Avastin&#174; and Herceptin&#174; marketed by Roche/Genentech); and &#8220;check-point&#8221; inhibitors (Yervoy&#174; and Opdiv&#174;, BMS, Keytruda&#174;, Merck ). There is a large amount of development activity in the immune checkpoint inhibitor field from both pharmaceutical giants including AstraZeneca, Merck &amp; Co, Pfizer, Merck KGaA, Roche, GSK, Novartis and Amgen and many start-ups, small companies and university spin-offs which have emerged in the past two years. Examples (in alphabetical order) include Agenus, Alligator Bioscience, Ambrx, AnaptysBio, arGEN-X, Bioceros, BioNovion, Cellerant Therapeutics, Checkpoint Therapeutics, Compugen, CureTech, Enumeral, Five Prime Therapeutics, Genmab, GITR, ImmuNext, IOmet Pharma, iTeos Therapeutics, Jounce Therapeutics, KAHR Medical, Multimeric Biotherapeutics, Nativis, Orega Biotech, Pelican Therapeutics, Pieris Pharmaceuticals, Prima BioMed, Redx Pharma, Sorrento Therapeutics, Tesaro, TG Therapeutics, Theravectys and ToleroTech active in the field. The list of companies with poly-specific antibodies that attempt to link the cancer with a cytotoxic T cell is long, includes both private and public companies (Amgen, Xencor, F-Star, Merus and many others). Finally, two CAR-T cell therapies were just approved for the treatment of ALL &#8211; Kymriah&#8482; (Novartis) and Yescarta&#8482; (Gilead). We expect additional drugs to gain marketing authorization in the immune-oncology space. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakad4c9447-e5e2-40e7-9f86-11da86887741" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">46</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">According to the BioProcess Technology Consultants, Inc. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/pdf/kmab-07-01-989042.pdf), World Preview 2017, Outlook to 2022, the monoclonal antibody total market size in 2013 was nearly $75B USD and is expected to grow to $125B by 2020. According to Evaluate Pharma, the check-point inhibitor market is in its infancy, but is expect to be valued at more than $7B USD by 2023. To our knowledge, there are two companies with NK cell immunotherapies in development. The first is Fortress Biotech (NASDAQ:FBIO) which is developing CNDO109 for the treatment of AML. CNDO109 is an allogeneic ex-vivo NK cell activation program that utilizes live cancer cells to prime the related donor&#8217;s NK cells. The primed NK cells are then given to the patient with AML. This program has entered a Phase I clinical trial in the US; the results of the trial are not known. Prof. Mark Lowdell, a founder of this Company, performed a single center trial in the UK using almost identical technology as CNDO109. The results of the trial were very promising with several patients having a prolonged remission after a single treatment (Kottaridis et al. (2015). PLoS ONE 10(6):1-19). NantKwest, (NASDAQ: NK)is an early stage biotech company that is using a genetically engineering strategy of a NK cell line to produce a live, off-the-shelf NK cell product to treat a variety of cancers. The clinical data data for this product is sparse at this time. Fate-NK 100 and Engineered hnCD16iNK from Fate Therapeutics are products designed to replace or supplement NK cells in patients with cancer. The company reports that they are enrolling a trial with Fate-NK 100 in women with relapsed/refractory ovarian cancer. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Intellectual Property</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Proprietary protection for our product candidates, technology and processes is important to our business and we seek patent protection in the U.S. and internationally when we deem appropriate. We also rely on trade secrets, know-how and continuing technological advances to protect various aspects of our core technology. We require our employees, consultants and scientific collaborators to execute confidentiality and invention assignment agreements with us. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have in-licensed a critical patent application in the United States on which the INKmune technology is based. Our rights under this license will expand to international jurisdictions in the next 12 months. We continue to seek additional patents to protect and expand our rights relating to INKmune. We own the following patent application:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="BORDER-RIGHT: black 1px solid; BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="2" width="100%" border="0">
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="bottom" width="15%">
<p style="MARGIN: 0px" align="justify"><b>Patent/<br>Application</b></p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="bottom" width="22%">
<p style="MARGIN: 0px" align="center"><b>Number</b></p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="bottom" width="43%">
<p style="MARGIN: 0px" align="justify"><b>Name</b></p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="bottom" width="20%">
<p style="MARGIN: 0px" align="justify"><b>Jurisdiction</b></p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">62219652</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">&#8220;IN VIVO ACTIVATION OF NATURAL KILLER CELLS&#8221;</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">U.S.A.</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">7101974B2</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">TNF-&#945; VARIANTS</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">USA</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">7446174B2</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Protein based TNF-&#945; variants for the treatment of TNF-&#945; related disorders</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">U.S.A</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">62104026</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">&#8220;CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR&#8221;</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">U.S.A.</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">62269839</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">&#8220;CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR&#8221;</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">U.S.A.</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">PCT/US2016/066552</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">&#8220;CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR&#8221;</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">PCT</p></td></tr>
<tr height="15">
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">Patent</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">PCT/US2013/059071</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">METHODS OF TREATING NEUROLOGICAL Related U.S. Application Data DISEASES</p></td>
<td style="BORDER-TOP: black 1px solid; BORDER-LEFT: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="justify">PCT</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot assure you that our pending patent applications will result in issued patents.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On August 2, 2016, the Company filed for a trademark on INKmune and INmune. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak33f80fd0-e348-4f07-8b76-06ed52f25439" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">47</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune License Agreement</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On October 29, 2015, we entered into an exclusive license agreement with INmune Ventures, LLC, owner of all of the rights related to our principal patent (the &#8220;License Agreement&#8221;). Pursuant to the License Agreement, we were granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, we agreed to the following milestone payments:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase I initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase II initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">250,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase III initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA filing </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA awarded </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">9,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, we agreed to pay the licensor a royalty of 1% of net sales during the life of each patent granted to the Company. The Licensor is owned by RJ Tesi, our President and a member of our Board of Directors, David Moss, our Chief Financial Officer, Treasurer and a member of our Board of Directors and Mark Lowdell, our Head of Scientific Advisory Board.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt" align="justify">On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures LLC. Pursuant to the Assignment and Assumption Agreement, Immune Ventures assigned all of its rights, obligations and liabilities under the Exclusive License Agreement between the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education and Immune Ventures. Pursuant to the Assignment and Assumption Agreement, the Company agreed to convert the amount Immune Ventures paid of $31,640 into INmune common stock at $1.50 per share for 21,094 shares for the reimbursement of amounts paid by the Assignor to the University of Pittsburg.</p>
<p style="MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">On October 3, 2017, the Company entered into a license agreement with Xencor, Inc., which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencors&#8217;s proprietary protein known as &#8220;XPRO1595&#8221; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation.&nbsp; In connection with the license agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and agreed to issue Xencor shares (&#8220;Initial Shares&#8221;) of the Company&#8217;s common stock equal to 19% of our fully diluted company shares the value of which are discussed below.&nbsp;The Company also issued warrants to Xencor which is discussed below.</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">The Company also agreed to pay Xencor a royalty of 5% on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country. </p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">Under the license agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives equal to (i) 60% of sublicensing revenue received in respect of any sublicense granted prior to initiation of a Phase 1 Clinical Trial of a Licensed Product in the applications for the treatment of disease in humans (the &#8220;Field&#8221;); (ii) 30% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 1 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field; (iii) 15% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field; (iv) 10% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field and prior filing of the first NDA application for any Licensed Product in the Field; and (v) 5% of Sublicensing Revenue received in respect of any sublicense granted on or after the approval of the first NDA application for any Licensed Product in the Field.&nbsp; For clarity, initiation of a clinical trial shall mean dosing of a first patient in said clinical trial.&nbsp;&nbsp; </p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px" align="justify">In connection with the License Agreement, the Company entered into a stock issuance agreement with Xencor pursuant to which it agreed to issue Xencor 1,585,000 shares of its common stock with a fair value of $XX based on XX, and fully vested warrants to purchase an additional number of shares of common stock equal to 10% our the fully diluted company shares immediately following such purchase with a fair value of $XX based on XX. The warrants have an exercise price of $XX and expire on October 3, 2023. The aggregate purchase price for the full exercise of the option to Acquire Additional Shares is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the Option for less than 10% of the fully diluted company shares immediately following such purchase. The purchase price for the additional shares may be paid by cash or by way of a cashless exercise. In connection with the stock issuance agreement, the Company, Xencor and more than 90% of shareholders as of September 30, 2017 (&#8220;Key Holders&#8221;) entered into a voting agreement. Pursuant to the voting agreement, Xencor and the Key Holders agreed to vote their respective shares to vote one individual designated by the holder of a majority of Xencor&#8217;s shares of the Company&#8217;s common stock to the Company&#8217;s board of directors. The voting agreement shall continue in full force and effect from the date hereof through the earliest of the following dates, on which date it shall terminate in its entirety: (a) the date of a qualified offering, as defined in the issuance agreement; (b) ten (10) years from the date of this Agreement; (c) the date of the closing of a qualified sale, as defined in the issuance agreement; or (d) the date as of which the parties hereto terminate this agreement by written consent of the holders of a majority of the Investor Shares.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;
<table id="pagebreakea076a13-8482-43d6-a892-487ed37f241f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">48</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>INKmune Research and Development </b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We expect to use third parties to conduct our preclinical and clinical trials under the direct supervision of management. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Joint Development Agreement</i></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">On September 3, 2016, the Company entered into a joint development agreement with Novamune, Inc. (&#8220;Novamune&#8221;)(the &#8220;Development Agreement&#8221;).&nbsp; Novamune had previously developed and licensed technology relating to ex-vivo activation of NK cells for the treatment of cancer and other diseases.&nbsp; The parties agreed to exclusively collaborate on the further development of technologies related to NK cells for therapeutic applications.&nbsp; The Company and Novamune will share equally in the costs related to such joint development projects and will jointly own any intellectual property developed by the joint projects, provided that Novamune shall have an exclusive royalty free license to use any such intellectual property relating to ex-vivo applications and the Company shall have an exclusive royalty free license to use any such intellectual property relating to in-vivo applications.&nbsp; The Development Agreement is subject to Novamune investing a total of $1,250,000 in the Company, of which $350,000 has previously been advanced through a convertible note payable (see further discussion in Note 5).&nbsp; The balance of $900,000 shall be invested in the Company on the earlier of (i) December 31, 2017, or (ii) 60 days after the Company becomes publicly traded. As of December 31, 2016 and 2015, the Company had a joint development receivable outstanding related to Novamune&#8217;s portion of R&amp;D costs incurred through year-end of $156,381 and $0, respectively.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>INKmune Manufacturing </b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We intend to contract with third parties for the manufacture of our compounds for investigational purposes, for preclinical and clinical testing and for any FDA approved products for commercial sale. Pre-clinical and clinical material for the early clinical trials will be manufactured under the direction of Mark Lowdell and Advent Bioservices International, our strategic partner, at a licensed GMP facility. Material produced at this facility can be used for clinical trials world-wide. We expect to transfer the manufacturing to a commercial contract manufacturing organization after completion of Phase II studies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak981661ec-5a73-4b85-922d-6a475664a175" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">49</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Our Innate Immune System Check-point inhibitor product candidate</b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We renamed XPRO1595 that we obtained from Xencor INB03. INB03 is a novel innate immune system check-point inhibitor that prevents proliferation of MDSC and decreases the secretion of immunosuppressive immune regulatory cytokines that protect the tumor from the patient&#8217;s immunologic attack. The changing cytokine environment, decreased immunosuppressive cytokines and increased pro-inflmmatory immunoregulatory cytokines, changes the patient&#8217;s immune response to their tumor with improved NK/DC crosstalk that causes expansion of the immune response including recruitment of the adaptive immune system with an increase in effector and cytotoxic T cells that attack the cancer. After treatment with INB03, we expect the patient&#8217;s dysregulated immune response that is the hallmark of cancer progression is converted to a coordinated immune response that can attack the cancer. In animal models of an inflammatory cancer, this resulted in smaller and fewer cancers with increased survival. INB03 is an engineered PEGylated protein that closely mimics a portion of human inflammatory cytokine that is increased in patients with advanced cancer. By specifically neutralizing the cytokine, there is no phosphorylation of STAT3, an essential step required for the proliferation of the MDSC population, and secretion of the immunosuppressive cytokines. The combination of decreased MDSC proliferation and decreased immunosuppressive cytokines allows the immune system to function normally. These data are published in a peer reviewed journal in 2016. In summary, INB03 functions as an innate immune system checkpoint inhibitor by eliminating the population of MDSC that provides an immunosuppressive shield protecting the tumor, the patient&#8217;s immune system is able to function normally to the benefit of the patient &#8211; it can attack the tumor.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Because INB03 targets the patient&#8217;s immune system and not the tumor, INB03 is an immunotherapy that can be used to treat many types of hematologic malignancies and solid tumors. The decision to use INB03 in a patient will be based on biomarkers that should predict that a patient will benefit from the drug. MDSC, cells rarely exist in patients without cancer or chronic inflammation, can be measured in the tumor and/or blood. If MDSC are present in significant numbers, the patient should benefit from INB03 therapy. The corollary is also true, we do not expect cancer patients with normal levels of MDSC in their blood and/or tumor microenvironment to benefit from INB03. Basing treatment decisions on the presence of MDSC is a precision medicine, biomarker directed immunotherapy strategy that should improve the probability of benefiting a patient and improve the efficiency and decrease the risk of the clinical development process. INB03 can be used as part of combination of anti-cancer therapy including, but not limited to, cytotoxic, immunotherapy, radiation and/or surgery. Our initial clinical development will focus on using INB03 as monotherapy, we expect to use INB03 as part of combination therapy as part of Phase II development with or without partners. We do not expect to modify INB03 to treat each different type of cancer, because it is a therapy that targets the immune system, not the cancer. We expect to develop the drug beyond Phase II to target a specific type of cancer based on the current system of regulatory approval. For instance, INB03 may be approved to treat patients with elevated MDSC who have lung cancer. To get subsequent approval for the treatment of patients with breast cancer who have increased MDSC, we will need to perform a second pivotal trial. After the first regulatory approval, if and when achieved, we believe the difficulty and cost of achieving these labels extensions will decline, with each successive approval.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">INB03 as a subcutaneous injection, similar to an insulin treatment, given one to three times per week. Because this is a simple subcutaneous injection similar to an insulin injection (the therapy patients give themselves for treatment of Type 1 diabetes mellitus), we expect patients to administer the therapy to themselves and not require expensive or logisitically challenging clinic visits to receive the therapy. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Three step process to preparation for INB03 human clinical trials:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Release of INB03 drug supply</i></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">GMP INB03 is available for clinical development after completion of release testing. The process for releaser testing will take 3 months. The process started in November 2017. The supply of INB03 is limited, but enough to complete the planned Phase I and Phase II studies in oncology. For additional trials, new batches INB03 will need to be produced. We plan a two pronged approach to production of the new drug supply. We will produce INB03 using the existing <i>E.coli</i> based system until the newer process is validated and functional. When resources are available, a more efficient manufacturing system will be developed that may include moving to a different production platform such as fungi or yeast. In summary, we do not expect the drug supply to limit the clinical development program in oncology. We expect to start the process of manufacturing improvements and scale-up after results of the Phase I trial are known and have a validated and more efficient manufacturing process in place before the initiation of pivotal trials. We have begun discussion with contract manufacturers to make new batches of INB03. We expect this process to begin in within 12 months of completing the financing. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Interaction with Regulatory Authorities Regarding INB03 Development</i></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We plan to perform the Phase I and Phase II trials with INB03 in Australia under the regulatory authority of the TGA using the CTX scheme (Clinical Trials Exemption). We expect our first interaction with the regulatory body to occur in 1H18.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak2d629bb8-ec21-47cb-acf2-e150279c7baf" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">50</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INB03 Product Development Path</i><i>: Proposed Phase I and Phase II Studies in patients with cancer</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Phase I study: We plan an open label, biomarker directed, dose escalation study in patients with metastatic epithelial cancer and elevated biomarkers of systemic inflammation and MDSC in their blood. A minimum of 9 patients will be treated in three dosing cohorts for 3 months. Patients will receive INB03 by subcutaneous injection once a week during the duration of the study. We cannot rule out longer treatment of the patients at the discretion of the treating physician. The goal of the Phase I trial is to assess safety, determine a dose to carry in to the Phase II trial, and verify the utility of our biomarker strategy. The most probable tumor types with be patients with breast, lung, GI cancer and melanoma. The dosing cohorts are expected to be 0.3mg/kg, 1.0 mg/kg and 3.0mg/kg once a week. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Phase II study: We believe the best Phase II trial is a combination therapy study. Elevated levels of MDSC in the blood is a predictor of treatment failure in patients with melanoma treated with checkpoint inhibitors. MDSC are recognized as a barrier to the function of CPI. We believe combination therapy where INB03 decreases the levels of MDSC and the combination of INB03 and CPI stimulate the immune response against the tumor will be an effective treatment of patients who have been resistant to CPI because of elevated levels of MDSC. The design of the Phase II trial is tentative. At this time, we plan to treat patients with advanced advanced cancer who have failed first line therapy and have increased circulating levels of MDSC in their blood. The patients will be treated with both INB03 and a check-point inhibitor. The most probably tumor types in the trial will be melanoma or lung cancer. We expect to perform the Phase II trial in AUS under the regulatory authority of the TGA. The exact design of the Phase II development program may be changed by results obtained in the Phase I trial and/or by a development partner. If resources permit, we may open Phase II clinical trials sites in the US under the regulatory authority of the FDA.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i><u>INB03 Registration Studies and/or Partnering</u></i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We plan to aggressively pursue an efficient registration strategy using INB03 to improve the lives of patients with cancer and biomarkers of inflammation and elevated MDSC. This is not the only cancer indication INB03 can be used for. We plan to pursue those other indications as resources become available. We have an active partnering position as it relates to INB03 development in cancer. There are two partnering opportunities with this novel innate immune system check-point inhibitor. The first is a traditional partnership focused on the developing the drug for all oncology applications. The second is a more focused partnership developing INB03 as part of a combination therapy for a company&#8217;s existing therapy, most probably an approved CPI. For example, CTLA4 targeted checkpoint inhibitors do not work well when given to melanoma patients with increased MDSC in their blood. A company with a CPI may want to combine INB03 with their product in a clinical development program. After completion of proof-of-concept Phase II studies, the Company will decide what the most efficient registration strategy is available to the company with INB03. We may to have biopharma partners participate in this decision making. We may also seek to be acquired at this stage. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our INB03 platform can be used in cancer patients in many ways. It can be used alone or in combination with, but not limited to, other cancer therapies including cytotoxic chemotherapy, immunotherapy, radiation and surgery. We expect INB03 will be used most commonly as part of combination therapy. INB03 can also be used treat many types of hematologic and epithelial cancers. Patients with increased MDSC can be identified by examining the tumor specimen and/or blood. Patients with increased MDSC in the tumor or blood have more advanced disease, more resistance to immunotherapy and worse survival. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak292ed5b4-e014-4591-b256-a6c209692325" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">51</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INB03 Regulatory Strategy</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company&#8217;s regulatory strategy is very simple. INB03 is a new therapy for the treatment of cancer that will need to be proven safe and effective by well-designed clinical trials that show a meaningful clinical benefit to patients. This means that registration trials will need to be randomized trials in patients with cancer. Our first first-in-man clinical trial will be an open label trail. We expect the initial Phase I trials to be open label trials until we understand the best type of patient to treat with INB03 and if INB03 is best used alone or in combination with other therapy(s). Once we understand these important issues, we plan to seek advice from the competent regulatory authorities to allow the Company to design clinical trials that meet the needs for registration. We will meet with the FDA after completion of the Phase I trial. Because there are no therapies similar to INB03 approved in any market, we plan to take advantage of the regulatory opportunities afforded to therapies that treat small markets with a high unmet need. In the U.S., this includes Orphan Drug Designation and expedited programs for approval including Accelerated Approval, Breakthrough Therapy Designation, Fast Track Designation, and priority review (see &#8220;Government Regulation&#8221;). We cannot predict which, if any, of these programs we will benefit from without further discussions with the FDA. Similar programs exist in the EU with the EMA. We will engage the EMA once we have initiated Phase II trials in the US and AUS.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Challenges in the Market for Innate Immune System Check-Point inhibitor</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The market for new oncology therapies is busy, complicated and rapidly evolving. We will be competing with companies that are older, larger, better financed and have greater experience. There are two types of drug companies &#8211; development companies and commercial companies. Development companies take the risk of developing new products to proof-of-concept. Once proof-of-concept has been achieved, if the drug provides clinical benefit, the product is usually acquired by a commercial company, which completes the drug&#8217;s clinical development and markets the product. We are a development company which will seek to develop products such as INB03 from the bench to the bedside to demonstrate proof-of-concept. The goal for the Company is to successfully develop such products to the point where they are attractive targets for potential partners/acquirers. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To our knowledge, there are no innate immune check-point inhibitors in development that have the unique characteristics on INB03: i) decreases the proliferation of MDSC; ii) decreasing local and systemic immunosuppression caused by MDSC by stopping production of immunosuppressive cytokines and; iii) improving NK/DC cross-talk to recruit the adaptive immune system to fight the cancer. Because this will a first-in-class therapy, we will need to educate clinicians, patients, partners and investors about the drug and the therapeutic opportunity. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>INB03 Competition</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">To our knowledge, there are no other innate immune system check-point inhibitors in development that combine the characteristics of decreasing the population and function of MDSC while promoting NK/DC crosstalk that expands and recruits the adaptive immune response to attack the patient&#8217;s tumor. Lilly is developing LY3022855, a human IgG1 monoclonal antibody designed to target the CSF1R that should inhibit MDSC from receiving CSF1 signals, decreasing their survival and relieving the effect of MDSC in the tumor. Daiichi Sankyo Inc, in collaboration with Bristol Myers Squibb, is testing DS-8273a, a TRAIL-R2 agonistic antibody in combination with a PDL1 inhibitor to decrease the number of MDSC in patients with colorectal cancer. Rgenix Inc, is developing RGX-104, an orally bioavailable small molecule immunotherapy that targets LXR (liver X Receptor). RGX-104 reportedly depletes MDSC. Syntrix Biosystems is developing SX-682. SX-682 is a small-molecule dual-inhibitor of CXCR1 and CXCR2, the chemokine receptors pivotal to tumor metastasis, therapy-resistance, and myeloid cell suppression of cancer surveillance by the adaptive immune system. By blocking the CXCR1/2 pathway, SX-682 may prevent recruitment of MDSC to the tumor microenvironment. The University of Minnesota has a trivalent antibody program aimed at treating patients with advanced hematologic malignancies. This CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) product may target CD33+ MDSC. Siamab Therapeutics is developing a anti-Salhlil-TN monoclonal antibody that targets MDSC in some tumor types. Clathera Biosciences, in collaboration with Incyte, a US based biotech, is developing CB-1158 (INCB01158), an arginase inhibitor to decreases MDSC. A Phase II clinical trial is open that combines CB-1158 with novulomib, a anti-PD1 CPI marketed by Bristol Myers Squib.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Government Regulation</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products. These agencies regulate, among other things, research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising and promotion of our product candidates. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive result. Moreover, failure to comply with applicable FDA or other requirements may result in civil or criminal penalties, recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from the market. </p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak03b42c12-bf22-488d-8c0a-6d021ed468a8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">52</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Various regulatory authorities regulate, among other things, the research, manufacture, promotion and distribution of drugs in the United States under the FFDCA and other statutes and implementing regulations. The process required by the FDA before prescription drug product candidates may be marketed in the United States generally involves the following: </p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">completion of extensive nonclinical laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA&#8217;s Good Laboratory Practice regulations;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">for some products, performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s regulations, including Good Clinical Practices, to establish the safety and efficacy of the product candidate for each proposed indication;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">submission to the FDA of a new drug application or NDA;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">satisfactory completion of an FDA preapproval inspection of the manufacturing facilities at which the product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, regulations; and</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.<b> </b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Nonclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and other animal studies. The results of nonclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA. Some nonclinical testing may continue even after an IND is submitted. The IND also includes one or more protocols for the initial clinical trial or trials and an investigator&#8217;s brochure. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before or during studies due to safety concerns or non-compliance with regulatory requirements. An independent institutional review board, or IRB, at each of the clinical centers proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the consent form signed by the trial participants and must monitor the study until completed. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The FDA offers a number of regulatory mechanisms that provide expedited or accelerated approval procedures for selected drugs in the indications on which we are focusing our efforts. These include accelerated approval under Subpart H of the agency&#8217;s NDA approval regulations, fast track drug development procedures and priority review. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We plan to seek orphan drug designation for INKmune for the treatment of ovarian carcinoma. The U.S., E.U. and other jurisdictions may grant orphan drug designation to drugs intended to treat a &#8220;rare disease or condition,&#8221; which, in the U.S., is generally a disease or condition that affects no more than 200,000 individuals. In the E.U., orphan drug designation can be granted if: the disease is life threatening or chronically debilitating and affects no more than 50 in 100,000 persons in the E.U.; without incentive it is unlikely that the drug would generate sufficient return to justify the necessary investment; and no satisfactory method of treatment for the condition exists or, if it does, the new drug will provide a significant benefit to those affected by the condition. If a product that has an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for a period of seven years in the U.S. and 10 years in the E.U. Orphan drug designation does not prevent competitors from developing or marketing different drugs for the same indication or the same drug for different indications. Orphan drug designation must be requested before submitting an NDA. After orphan drug designation is granted, the identity of the therapeutic agent and its potential orphan use are publicly disclosed. Orphan drug designation does not convey an advantage in, or shorten the duration of, the review and approval process. However, this designation provides an exemption from marketing and authorization (NDA) fees. We plan to follow a similar path with INB03, although the precise indication cannot be determined until we are farther along in the development process. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak346ef71a-22be-4329-b676-bc174b04cb9d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">53</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Clinical Trials</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified medical investigators according to approved protocols that detail the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor participant safety. Each protocol is submitted, in the US, to the FDA as part of the IND. To the extent we conduct trials in the United Kingdom, we would make our submission to the MHRA for a CTA (clinical trials authorization). </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap, or be combined. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Phase 1 clinical trials typically involve the initial introduction of the product candidate into healthy human volunteers. In Phase 1 clinical trials, the product candidate is typically tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Phase 2 clinical trials are conducted in a limited patient population to gather evidence about the efficacy of the product candidate for specific, targeted indications; to determine dosage tolerance and optimal dosage; and to identify possible adverse effects and safety risks.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Phase 3 clinical trials are undertaken to evaluate clinical efficacy and to test for safety in an expanded patient population at geographically dispersed clinical trial sites. The size of Phase 3 clinical trials depends upon clinical and statistical considerations for the product candidate and disease, but sometimes can include several thousand patients. Phase 3 clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide an adequate basis for product labeling.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Clinical testing must satisfy extensive FDA regulations. Reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted for serious and unexpected adverse events. Success in early stage clinical trials does not assure success in later stage clinical trials. The FDA, an IRB or we may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>New Drug Applications</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Assuming successful completion of the required clinical trials, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA. An NDA also must contain extensive manufacturing information, as well as proposed labeling for the finished product. An NDA applicant must develop information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP. The manufacturing process must be capable of consistently producing quality product within specifications approved by the FDA. The manufacturer must develop methods for testing the quality, purity and potency of the final product. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life. Prior to approval, the FDA will conduct an inspection of the manufacturing facilities to assess compliance with cGMP. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak6a5a0af4-00c8-4d90-88c7-c4fc509d403f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">54</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The FDA reviews all NDAs submitted before it accepts them for filing. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information and is subject to review before the FDA accepts it for filing. After an application is filed, the FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers them carefully when making decisions. The FDA may deny approval of an NDA if the applicable regulatory criteria are not satisfied. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA. If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require us to conduct Phase 4 testing which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness after NDA approval, and may require surveillance programs to monitor the safety of approved products which have been commercialized. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not met or if safety or efficacy questions are raised after the product reaches the market. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Post-Approval Requirements</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. Pharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. If our future suppliers are not able to comply with these requirements, the FDA may, among other things, halt our clinical trials, require us to recall a product from distribution, or withdraw approval of the product.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The FDA closely regulates the marketing, labeling, advertising and promotion of pharmaceutical products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak8950d816-9564-4f99-98a8-3507d1394b38" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">55</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Other Healthcare Laws and Compliance Requirements</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our sales, promotion, medical education, clinical research and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services and state and local governments. Our promotional and scientific/educational programs must comply with the federal Anti-Kickback Statute, the civil False Claims Act, physician payment transparency laws, privacy laws, security laws, and additional federal and state laws similar to the foregoing.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The federal Anti-Kickback Statute prohibits, among other things, the knowing and willing, direct or indirect offer, receipt, solicitation or payment of remuneration in exchange for or to induce the referral of patients, including the purchase, order or lease of any good, facility, item or service that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. The government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham research or consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payors.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Federal false claims and false statement laws, including the federal civil False Claims Act, or FCA, imposes liability on persons or entities that, among other things, knowingly present or cause to be presented claims that are false or fraudulent or not provided as claimed for payment or approval by a federal health care program. The FCA has been used to prosecute persons or entities that &#8220;cause&#8221; the submission of claims for payment that are inaccurate or fraudulent, by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, submitting claims for services not provided as claimed, or submitting claims for services that were provided but not medically necessary. Actions under the FCA may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the FCA can result in significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other illegal sales and marketing practices. The government has obtained multi-million and multibillion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, certain companies that were found to be in violation of the FCA have been forced to implement extensive corrective action plans, and have often become subject to consent decrees or corporate integrity agreements, restricting the manner in which they conduct their business.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors; knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; and willfully obstructing a criminal investigation of a healthcare offense. Like the federal Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak1dd6a680-84b9-4379-b791-d58e2acf5149" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">56</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Given the significant size of actual and potential settlements, we expect that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that our products, once commercialized, are sold in a foreign country, we may be subject to similar foreign laws.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposed new reporting requirements on certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, for payments or other transfers of value made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Covered manufacturers are required to collect and report detailed payment data and submit legal attestation to the accuracy of such data to the government each year. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Additionally, entities that do not comply with mandatory reporting requirements may be subject to a corporate integrity agreement. Certain states also mandate implementation of commercial compliance programs, impose restrictions on covered manufacturers&#8217; marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and other healthcare professionals.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified requirements on certain health care providers, plans and clearinghouses (collectively, &#8220;covered entities&#8221;) and their &#8220;business associates,&#8221; relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain states have their own laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other and/or HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Coverage and Reimbursement</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Sales of pharmaceutical products depend significantly on the extent to which coverage and adequate reimbursement are provided by third-party payors. Third-party payors include state and federal government health care programs, managed care providers, private health insurers and other organizations. Although we currently believe that third-party payors will provide coverage and reimbursement for our product candidates, if approved, we cannot be certain of this. Third-party payors are increasingly challenging the price, examining the cost-effectiveness, and reducing reimbursement for medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. We may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of our products. The product candidates that we develop may not be considered cost-effective and thus may not be covered or sufficiently reimbursed. It is time consuming and expensive for us to seek coverage and reimbursement from third-party payors, as each payor will make its own determination as to whether to cover a product and at what level of reimbursement. Thus, one payor&#8217;s decision to provide coverage and adequate reimbursement for a product does not assure that another payor will provide coverage or that the reimbursement levels will be adequate. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak0032e852-8132-424a-80b0-0cbdda4a2f0d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">57</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>Healthcare Reform</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">By way of example, in March 2010, the Affordable Care Act was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the Affordable Care Act of importance to our potential drug candidates are:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakc3c3203d-2248-43df-a795-b0e12542e14e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">58</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include, among others, the Budget Control Act of 2011, which mandates aggregate reductions to Medicare payments to providers of up to 2% per fiscal year effective April 1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Foreign Regulation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Employees</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have two full-time employees, consisting of our executive officers, and retain the services of additional personnel on an independent contractor basis.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Facilities</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We currently lease office space at 1024 Prospect Street, Suite 150, La Jolla, CA 92037. Our rent is $675 per month and is a 12 month term ending on September 1, 2018. Thereafter it goes month-to-month. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Legal Proceedings</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 35.65pt" align="justify">We are not a party to any legal proceedings. In November 2016, an individual filed an action in Cook County, Illinois, against the Company, David J. Moss, its Chief Financial Officer, Treasurer, Secretary and a member of its board of directors, Raymond J. Tesi, its president and Chief Executive Officer (the Company, Mr. Moss and Mr. Tesi are referred to collectively as the &#8220;Company Parties&#8221;). The action alleged claims against the Company Parties concerning payment of monies and/or securities allegedly owed. In April 2017, the Company Parties and the Claimant entered into a Settlement Agreement and Mutual General Release agreement with that individual (the &#8220;Settlement Agreement&#8221;). Pursuant to the settlement agreement, the Company issued 33,335 shares of the Company&#8217;s common stock valued at $50,000, based on the value of the stock of the last round of financing of $1.50 per share. These shares are held by the Company subject to a restriction on transfer for a period of two years from the date the Company completes an initial public offering or otherwise becomes a public company after which the Company will deliver the shares to the Claimant. The agreement to issue the shares was a full and complete settlement of all claims that the Claimant may have had against the Company Parties and the Cook County action was dismissed with prejudice. The obligation was recorded as accrued settlement liability as of December 31, 2016, pending delivery of the shares to the Claimant after the restriction period expires.</p>
<p style="MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 35.3pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.7pt; TEXT-INDENT: 35.3pt" align="justify">During 2017, the Company received notice that another company had filed trademark application with the United States Patent and Trademark Office to register a certain trademark. The Company filed an opposition in the United States Trademark Trial and Appeal Board. Subsequently, INmune and this company entered into a settlement agreement pursuant to which the Company agreed not to oppose the company&#8217;s trademark and the company paid INmune cash proceeds of $150,000 in full consideration for the settlement agreement. </p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a style="MARGIN: 0px" name="MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><i>Certain information contained in this </i><i>Registration Statement includes forward-looking statements. The statements herein which are not historical reflect our current expectations and projections about </i><i>the Company&#8217;s future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to </i><i>the Company and their management and their interpretation of what is believed to be significant factors affecting the businesses, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things, (i) our projected sales and profitability; (ii) our growth strategies; (iii) anticipated trends in our industry; (iv) our future financing plans; and (v) our anticipated needs for working capital. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; or &#8220;project&#8221; or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition, prospects and opportunities could differ materially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors, including the ability to raise sufficient capital to continue the Company&#8217;s operations. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under &#8220;Risk Factors&#8221; and matters described </i>in this Registration Statement. In li<i>ght of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this Registration Statement will in fact occur.</i></p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakf1ceb3d0-d4c9-4293-b46f-9010c65d3791" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">59</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><i>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and notes thereto appearing elsewhere in this prospectus. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements as a result of many factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth under &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements.&#8221;</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Overview</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We are a pioneering clinical-stage immunotherapy company focused on re-engineering the patient&#8217;s innate immune system to treat cancer. We do this by targeting two key cells of the innate immune system, natural killer, or NK cells, and myeloid derived suppressor cells, or MDSC. NK cells are the body&#8217;s first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules required to activate adaptive immune cells such as T-cells. NK cells play a key role in the immune-surveillance that prevents people from getting cancer and in eliminating residual disease which may cause people to relapse after cytotoxic therapy. MDSC are myeloid cells that develop secondary to the chronic inflammatory environment found in many cancers. MDSC, produced in the bone marrow, take up residence in the tumor microenvironment, the tissue associated with the cancerous cells, to protect to the tumor from immunological attack by the patient&#8217;s immune system. MDSC play a critical role in making the cancer resistant to immunotherapy such as currently approved checkpoint inhibitors. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We believe INKmune, our NK cell directed therapy, and INB03, our MDSC directed therapy offer unique strategies to improve the response of patient&#8217;s the innate immune system to their cancer. Both therapies will use a precision medicine approach to select patients who will benefit from the therapy and monitor the response to the therapy. Neither therapy is cancer specific. The decision to use either INKmune or INB03 alone or in combination other cancer therapies or with each other depends on immunologic parameters that can be tested in patients before treatment. The type of cancer is not important. This means that both therapies can be used to treat patients wide varied to hematologic malignancies and solid tumors that have the immunologic profile needed to respond. Put simply, we are treating the immune system to attack the patients the cancer, not targeting the patient&#8217;s cancer directly. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">INKmune improves the ability of the patient&#8217;s own NK cells to attack their tumor. INKmune itself will not kill cancer cells. INKmune interacts with the patient&#8217;s NK cells to convert them from an inert resting NK cells that ignores the cancer into a primed NK cells that kills the cancer cell. INKmune is a replication incompetent proprietary cell line that is given to the patient after determining that i) the patient has adequate NK cells in their circulation and those NK cells are functional when exposed to INKmune in vitro. INKmune is designed to be given to patients after their immune system has recovered after cytotoxic chemotherapy to target the residual disease the remains after treatment with cytotoxic therapy. INB03 is an engineered protein therapeutic that targets the ligand of CD120a &#8211; a ligand essential for MDSC proliferation. Without the ligation of CD120a, the proliferation of the MDSC stops and the MDSC population collapses. Without the immunosuppressive shield provided by the MDSC population, the patient&#8217;s immune system can attack the tumor. A secondary effect of INB03 is to improve NK cells-dendritic cell cross-talk to help expand patient&#8217;s anti-tumor immune response by recruiting cytotoxic T cells of the adaptive immune system.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We believe our innate immune system re-engineering platform provides unique strategies to repair the immunologic dysfunction that characterizes the innate immune system of patients with cancer. The products can be used alone, in combination with other anti-tumor or immunotherapy treatments or with each other. In the near term, we are developing the products separately. After completion of proof-of-concept Phase II trials, we will consider developing them as a combination therapy. Until we complete clinical trials, we cannot predict if either product will be successful when use alone, in combination with other therapies or in combination with each other.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak4f2fdafc-a261-4f23-982e-9ff8050dd719" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">60</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Mesenchymal Stem Cells (&#8220;MSC&#8221;) are a pluripotent stem cell that has potent immunologic effects, can be used alone as an anti-inflammatory strategy, as a vector to deliver gene therapy or can differentiate into separate different cell types. INmune Bio has acquired a large quantity of MSC that can be repurposed for use in medical research or clinical trials. We plan to sell these cells to third parties. We may expand this activity in the future to include positioning the company as a contract manufacturer for companies developing MSC products or developing our own MSC based products. At this time, the program will be self-sustaining and growing on reinvestment of revenues from the sale of the MSC products.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify"><i>Our Integrated Discovery and Development Process</i>. Our focus on re-engineering the patient&#8217;s immune system to better attack their cancer allows for synergies between the development and discovery process. A majority of your effort is focused on the development process that includes improving the manufacturing systems for INKmune and INB03 and optimizing bioassays to be used during the clinical trials. These manufacturing and monitoring programs may produce discoveries that the company can capitalize on as product improvements or new products. INB03 has uses beyond oncology including the treatment of neurodegenerative and neuropsychiatric diseases, cardiovascular diseases including congestive heart failure and metabolic diseases including nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;) and nonalcoholic steatohepatitis (&#8220;NASH&#8221;). Although the Company will focus on the immune-oncology uses of INB03 in the near term, the Company plans to expand the development into these other indications as resources become available. All attempts will be made to fund new research and development with non-dilutive resources that come from grants or revenue from sales of the MSC products. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;&nbsp; </p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Since our inception in 2015, we have devoted substantially all of our resources to the discovery and development of our product candidates, including preparing for clinical trials, drug manufacturing and funding general and administrative support for these operations. To date, we have generated no revenue. We have incurred net losses in each year since our inception and, as of September 30, 2017, we had an accumulated deficit of $729,610. Our net losses were $277,491 and $48,868 for the years ended December 31, 2016 and 2015, respectively, and $403,257 and $142,814 for the nine months ended September 30, 2017 and 2016, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We classify our operating expenses into three categories: royalties and cost of licensing, research and development, and selling, general and administrative expenses. Personnel costs including salaries, benefits, bonuses and stock-based compensation expense comprise a significant component of our research and development and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two categories based on the nature of each cost.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>Royalties and Cost of Licensing</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Royalties and cost of licensing primarily consists of our expenses related to the generation of revenue from our license agreements. These expenses primarily consist of royalty payments made pursuant to our in-licensing agreements and patent amortization expense. We have in-licensing agreements with various parties for the right to use their products and / or intellectual property. We expect our royalty payments to be small until we advance our products through the clinic and generate sales.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>Research and Development</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">clinical trial and regulatory-related costs;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">manufacturing and testing costs and related supplies and materials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">employee-related expenses, including salaries, benefits, travel and stock-based compensation; and</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakbeb279d6-9d82-4a39-9156-c36a90e715dd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">61</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">facility expenses dedicated to research and development.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Substantially all of our research and development expenses to date have been incurred in connection with our product candidates. We expect our research and development expenses to increase significantly for the foreseeable future as we advance an increased number of our product candidates through clinical development, including the conduct of our planned clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">per patient trial costs;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the number of sites included in the clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the countries in which the clinical trials are conducted;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the length of time required to enroll eligible patients;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the number of patients that participate in the clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the number of doses that patients receive;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the cost of comparative agents used in clinical trials;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the drop-out or discontinuation rates of patients;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">potential additional safety monitoring or other studies requested by regulatory agencies;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the duration of patient follow-up; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">the efficacy and safety profile of the product candidate.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We do not expect any of our product candidates to be commercially available for at least the next several years, if ever. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will increase substantially as we:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">continue research and development, including preclinical and clinical development of our existing product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">potentially seek regulatory approval for our product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">seek to discover and develop additional product candidates;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakfc08eb90-4df5-4b27-aa49-4c46ca7e9df3" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">62</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">seek to comply with regulatory standards and laws;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">maintain, leverage and expand our intellectual property portfolio;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">add operational, financial and management information systems and personnel; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">incur additional legal, accounting and other expenses in operating as a public company.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We may generate a small amount of revenue from MSC product sales in the near future. We do not plan to put a significant commercial infrastructure in place to support the sale of the MSC products. We may partner with specialty groups to help with distribution and sales. We will be opportunistic in sales of the MSC for clinical trials. We do not expect to generate revenue from product sales of INKmune or INB03 until we successfully complete development and obtain marketing approval for one or more of our product candidates. We do not expect to happen for at least the next several years, if ever. Until such time that we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our research and development programs or commercialization efforts. Failure to receive additional funding could cause the company to fail.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Intangible Assets</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We capitalize costs incurred in connection with patent applications (principally legal fees), patent purchases, and trademarks related to our cell line currently generating our revenue from licensing agreements, as intangible assets. We amortize these assets using the straight-line method over the estimated useful lives of the patents, generally five to 15 years. Other intangibles, consisting of trademarks and copyrights, are considered to have indefinite lives and are not amortized but reviewed for impairment annually, or sooner under certain circumstances.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Fair Value of Financial Instruments</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We have common stock warrants that meet the definition of derivative financial instruments and are accounted for as a derivative liability. The fair value of this warrant derivative liability is based on a Black Scholes simulation model at each reporting period. Estimating the fair value of the underlying shares is highly complex and subjective because our stock is not publicly traded.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak35d332ad-f7f6-434a-8ec1-f0a4bf80280c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">63</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The derivative warrant liability for the common stock warrants was $0.0 and XXX million at December 31, 2016 and September 30, 2017, respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Stock-Based Compensation</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We record the fair value of stock options issued to our employees as of the grant date as compensation expense. We recognize compensation expense, net of forfeitures, on a straight-line basis over the requisite service period, which is equal to the applicable vesting period.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We account for equity instruments issued to non-employees using a fair value approach under ASC Subtopic 505-50, <i>Equity-Based Payments to Non-Employees</i>. We value equity instruments and stock options granted using the Black-Scholes option-pricing model. The value of non-employee stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.35pt; TEXT-INDENT: 33.75pt" align="justify">During 2017, the Company issued fully vested warrants to purchase 31,667 shares of the Company&#8217;s common stock to a third party in conjunction with the common stock sold for cash, with an exercise price of $1.50, maturity date of June 30, 2022, and fair value of $36,922 using the Black-Scholes option-pricing model which were recorded as stock-based compensation.</p>
<p style="MARGIN: 0px"><b>&nbsp; </b></p>
<p style="MARGIN: 0px"><b>Off-Balance Sheet Arrangements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">During the periods presented, we did not have any off-balance sheet arrangements as defined under SEC rules.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Licensing and Collaboration Agreements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We anticipate that in-licensing, out-licensing and strategic collaborations will become an integral part of our operations, providing the company with opportunities to leverage our partners&#8217; expertise and capabilities to further expand the potential of our technologies, product candidates and revenue streams. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Xencor</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">In October 2017, we licensed INB03, also known as XPro1595, from Xencor. This exclusive, global, unrestricted license came with considerable know-how, intellectual property, pre-clinical data, regulatory documentation and product stocks. Currently, we are focused on the immune-oncology uses of this unique asset. In the future, we may develop the asset in a wide variety of therapeutic areas, with a variety of delivery techniques by ourselves or in conjunction with partners.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Anthony Nolan Cord Blood Bank </i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In November 2017, we entered into a global/exclusive licensing agreement with the ANCBB, the oldest and largest cord blood bank in the United Kingdom. ANCBB, in collaboration with the Mark Lowdell, developed a methodology for producing large volumes of high quality pooled human umbilical cord MSC. We have made and agreement with the ANCBB to sell these cells for medical research. The agreement provides the ANCBB a low single digit royalty. We believe we are well positioned to become a preferred manufacturing partner for companies who need MSC for clinical programs. The company may decide to expand this agreement in the future if the commercial and/or development opportunities warrant such expansion. At the current time, we expect this program to be funded on revenues from commercial sales.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak76c2b627-e7b7-4540-8638-f0515627fff7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">64</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Unit Offering </b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">In a private placement pursuant to, we sold 1,693,335 of units to accredited investors at a per unit price of $10,000 with each unit consisting of 6,667 shares of our common stock and received net proceeds of approximately $2,540,000. Pursuant to the subscription agreement between the Company and the investors of the offering for a period of two years from June 30, 2017, if the Company sells shares of common stock or the right to receive common stock at a price per share which values the Company at less than $10,000,000, the Company will issue additional shares of Common Stock to each investor in the offering such that the investor will receive the same effective price per share as the investors in any such future offering. Pursuant to the Subscription Agreements between the Company and the investors, the Company agreed to file the registration statement that this prospectus forms a part of to register the shares of common stock issued in the offering. Pursuant to the Subscriptions, the Company is to file a registration statement to register the share of common stock sold in the offering within five months after the final closing and seek to have the registration statement declared effective by the Securities and Exchange Commission within six months of the filing. If the Company fails to meet either of the Registration Deadlines, each investor will be entitled to receive a cash payment in the amount of 1% of the amount of the investment for each month that a Registration Deadline is not met, up to a maximum of 12%. The offer and sale of the units were made in reliance on the exemption from registration afforded under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act. The unit offering was not conducted in connection with a public offering, and no public solicitation or advertisement was made or relied upon by the investors in connection with the Unit Offering.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">In connection with the offering we paid a registered broker dealer a commission of $47,500, and we issued 31,667 of warrants with a strike price of $1.50 for 5 years from June 30, 2017 with a fair value of $36,922. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Comparison of the nine months ended September 30, 2017 and September 30, 2016</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="14" align="center">
<p style="MARGIN: 0px" align="center"><b>Nine Months Ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30, </b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30, </b></p>
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Change</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Change</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">%</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Operating Expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">386,245</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">69,485</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">316,760</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">456</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Research and Development</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">167,006</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">73,329</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">93,677</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">100</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Tax Expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Other Income</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(150,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(150,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(100</td>
<td valign="bottom" width="1%">)%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net and comprehensive loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">403,251</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">142,814</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">260,437</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>Operating Expenses</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Operating expenses were $386,245 for the nine months ended September 30, 2017 compared to $69,485 for the nine months ended September 30. 2016.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Research and Development</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Research and development expenses increased to $167,006 for the nine months ended September 30, 2017 from $73,329 for the nine months ended September 30 2016. This increase was due to the start of our research program.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Other Income</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Other Income increased to $150,000 for the nine months ended September 30. 2017 from $0 for the nine months ended September 30, 2016. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak64772004-f19f-4352-95ed-2cff57106add" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">65</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Comparison of the twelve months ended December 31, 2016 and December 31, 2015</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="14" align="center">
<p style="MARGIN: 0px" align="center"><b>Twelve Months Ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>December 30, </b></p>
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>December 31, </b></p>
<p style="MARGIN: 0px" align="center"><b>2015</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Change</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Change</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">$</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center">%</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Operating Expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">125,996</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">48,868</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">77,128</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">158</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Research and Development</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">101,495</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">101,495</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">100</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Other Loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">100</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net and comprehensive loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">277,491</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">48,868</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">228,623</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Operating Expenses</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Operating Expenses were $125,996 for the twelve months ended December 31, 2016 compared to $48,868 for the twelve months ended December 31. 2015. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Research and Development</i>&nbsp;</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Research and development expenses increased to $101,495 for the twelve months ended December 31, 2016 from $0 for the twelve months ended December 31, 2015. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>MANAGEMENT</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table sets forth our executive officers and directors, their ages and position(s) with the Company. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="25%">
<p style="MARGIN: 0px" align="center"><b>Name</b></p></td>
<td valign="top" width="2%">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="10%">
<p style="MARGIN: 0px" align="center"><b>Age</b></p></td>
<td valign="top" width="2%">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px" align="center"><b>Position</b></p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Raymond J. Tesi, MD</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">61</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">President and CEO, and Director</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">David J. Moss</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">47</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Chief Financial Officer, Treasurer and Secretary, and Director</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Mark Lowdell, PhD</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">54</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Chief Scientific Officer and Director</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">J. Kelly Ganjei</p></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">44</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Director</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">Tim Schroeder </p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center">60</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">Director</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Edguardo Baracchini </p></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">58</p></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px">Director</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Directors are elected annually and hold office until the next annual meeting of the stockholders of the Company and until their successors are elected. Officers are elected annually and serve at the discretion of the Board of Directors. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Raymond J. Tesi, M.D. </i></b>has been our President, Chief Executive Officer and a member of the board of directors of the Company since the formation of the Company in September 2015. From November 2011 until May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development stage biotech formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was founder, CEO and President of Coronado Biosciences. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991. Dr. Tesi&#8217;s significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the board of directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakff7beaac-0fd3-4665-8644-ba4271a161ca" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">66</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>David J. Moss</i></b>, M.B.A. has been a member of the board of directors of the Company since its formation in September 2015. Mr. Moss has founded, funded and taken public various companies in a variety of industries since 1995, most recently Tonix Pharmaceuticals (NASDAQ: TNXP). Mr. Moss served as a director of Pegasi Energy Resources Corporation from May 2007 to January 2014 and was a founding investor in Reliant Service Group LLC which recently sold in 2015 to leading private equity firm. Mr. Moss previously served as Managing Director, Corporate Finance for a New York based securities firm where he advised companies on corporate strategy, financings and business development. He also served as Managing Partner at a Seattle based venture capital firm. Mr. Moss also serves on the board of directors of CareSpan International, Inc. Mr. Moss holds an MBA from Rice University and a BA in Economics from the University of California, San Diego. Mr. Moss was selected as a Director due to his extensive entrepreneurial background and his substantial financial and accounting experience.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Mark Lowdell</i></b><b>, <i>Ph.D.</i> </b>has been a member of the board of directors of the Company since its formation in September 2015 and has been our Chief Scientific Officer since October 2015. Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London where he has led a translational immunotherapy group since 1994. Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist. Prof. Lowdell&#8217;s education and significant academic and clinical experience with cellular therapies were instrumental in his selection as Chair of the SAB.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Timothy Schroeder </i></b>Timothy Schroeder, CEO and Founder of CTI Clinical Trial &amp; Consulting Services (CTI), has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm has supported more than 100 drug and device approvals, and currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Mr. Schroeder held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Mr. Schroederis currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Mr. Schroeder was named as an EY Entrepreneur of the Year in 2015 and was recognized as Top Leader by the Enquirer Media in 2016.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b><i>Edguardo Baracchini, Ph.D., M.B.A. </i></b>Dr. Baracchini joined Xencor, Inc. as its Chief Business Officer in January 2010. Xencor whose common stock is listed on NASDAQ is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for treatment of autoimmune diseases, asthma and allergic diseases and cancer. Dr. Baracchini has over 20 years of experience in structuring and negotiating research and development partnerships, mergers and acquisitions, and in-licensing agreements. To date, he has negotiated more than 80 business transactions with multinational and Asian pharmaceutical firms, biotechnology companies, and prominent universities, leading to transactions valued in excess of $5.3 billion. Additionally, Dr. Baracchini has been a key member of executive teams that have risen over $600 million in private and public financing, and have successfully completed two IPOs.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Dr. Baracchini served as Senior Vice President of Business Development at Metabasis Therapeutics form 2002 and until its merger with Ligand Pharmaceuticals in 2009. Prior to joining Metabasis, Dr. Baracchini held the position of Vice President of Business Development at Elitra Pharmaceuticals from 1999 to 2002. He served as the Director of Business Development at Agouron Pharmaceuticals from 1996 through it&#8217;s acquisition by Warner-Lambert in 1999. Dr. Baracchini was the Assistant Director of Business Development at Isis Pharmaceuticals from 1992 to 1996. From 1988 to 1992 Dr. Baracchini performed postdoctoral research at UCSD and The Scripps Research Institute. Dr. Baracchini holds a Ph.D. in molecular and cell biology from the University of Texas at Dallas, an M.B.A. from the University of California, Irvine, and a B.S. in microbiology from the University of Notre Dame.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak5c124daa-d322-407b-ae43-98d9c9c0e856" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">67</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>J. Kelly Ganjei</b>, Mr. Ganjei joined Cognate BioServices, Inc. in 2011 as the Chief Executive Officer. Mr. Ganjei has over 20 years of experience within the life science, venture capital and IT sectors and has lead companies through various stages of development, ranging from the virtual start-up, to the mid-cap restart, through the exponential growth phase, and into a public exit. Prior to joining Cognate, Mr. Ganjei was the principal at an SBA venture capital firm where he was brought on to support deal flow into and out of the fund, with a specific focus on regenerative medicine, immunotherapy and cell therapy investment opportunities. While in this role, he helped the venture capital firm exit the SBA program and was the key driver of several other strategic deals for various portfolio companies. Previously, Mr. Ganjei was the CEO and Co-founder of Remegenix, Inc.. Prior to Remegenix, Inc., was a Vice President of Business Development at TissueGene, Inc., Mr. Ganjei helped close several tranches of TissueGene&#8217;s Series A and B funding and was responsible for developing the global informatics infrastructure for the company and its affiliates. Prior to TissueGene, Inc., Mr. Ganjeiserved as a Product Marketing Manager for LabVantage where he was the key technical sales and marketing lead for LabVantage&#8217;s life science software product offering globally and was responsible for the design of all life science product initiatives. Mr. Ganjei has published numerous scientific, peer-reviewed papers in a number of journals and has been an invited guest speaker and presenter at various business forums. Mr. Ganjei received his B.S. in Microbiology from the University of Maryland College Park in 1995 and began his career at NIH in May of the same year.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Family Relationships</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">None.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Corporate Governance</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are committed to maintaining strong corporate governance practices that benefit the long-term interests of our Shareholders by providing for effective oversight and management of the Company. Our governance policies, including our Corporate Communications Policy, Insider Trading Policy, Code of Conduct, and Committee Charters can be found on our website at http://www.inmunebio.com/. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Nominating and Corporate Governance Committee regularly reviews our corporate governance policies, Code of Conduct, and Committee Charters to ensure that they take into account developments at the Company, changes in regulations and listing requirements, and the continuing evolution of best practices in the area of corporate governance.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">The Board conducts an annual self-evaluation in order to assess whether the directors, the committees, and the Board are functioning effectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Code of Ethics</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have recently adopted a Code of Ethics that applies to our principal executive officers and principal financial officer, principal accounting officer or controller, or persons performing similar functions and also to other employees. Our Code of Ethics can be found on our website at www.inmunebio.com.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Involvement in Certain Legal Proceedings</b> </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Except as disclosed in the bios above, our Directors and Executive Officers have not been involved in any of the following events during the past ten years:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">1. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; </p></td></tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">2. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); </p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakcfae81ce-ba3b-480b-a7df-1575c77405ed" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">68</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top>&#13;&#10;<P style="MARGIN: 0px" align=justify>&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="5%">&#13;&#10;<P style="MARGIN: 0px" align=justify>3. </P></TD>&#13;&#10;<TD vAlign=top width="73%">&#13;&#10;<P style="MARGIN: 0px" align=justify>being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities; </P></TD></TR>'>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">3. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities; </p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top></TD>&#13;&#10;<TD vAlign=top width="5%"></TD>&#13;&#10;<TD vAlign=top width="73%"></TD></TR>'>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top>&#13;&#10;<P style="MARGIN: 0px" align=justify>&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="5%">&#13;&#10;<P style="MARGIN: 0px" align=justify>4. </P></TD>&#13;&#10;<TD vAlign=top width="73%">&#13;&#10;<P style="MARGIN: 0px" align=justify>being found by a court of competent jurisdiction in a civil action, the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; </P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">4. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">being found by a court of competent jurisdiction in a civil action, the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; </p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top></TD>&#13;&#10;<TD vAlign=top width="5%"></TD>&#13;&#10;<TD vAlign=top width="73%"></TD></TR>'>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top>&#13;&#10;<P style="MARGIN: 0px" align=justify>&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="5%">&#13;&#10;<P style="MARGIN: 0px" align=justify>5. </P></TD>&#13;&#10;<TD vAlign=top width="73%">&#13;&#10;<P style="MARGIN: 0px" align=justify>being subject of, or a party to, any federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or </P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">5. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">being subject of, or a party to, any federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or </p></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top></TD>&#13;&#10;<TD vAlign=top width="5%"></TD>&#13;&#10;<TD vAlign=top width="73%"></TD></TR>'>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr outerhtml='&#13;&#10;<TR height=15><TD vAlign=top>&#13;&#10;<P style="MARGIN: 0px" align=justify>&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="5%">&#13;&#10;<P style="MARGIN: 0px" align=justify>6. </P></TD>&#13;&#10;<TD vAlign=top width="73%">&#13;&#10;<P style="MARGIN: 0px" align=justify>being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. </P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">6. </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. </p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Board Committees</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our Board of Directors has established three standing committees: an audit committee, a nominating and corporate governance committee and a compensation committee, which are described below. Members of these committees are elected annually at the regular board meeting held in conjunction with the annual stockholders&#8217; meeting. The charter of each committee is available on our website at www.inmunebio.com.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Audit Committee</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Audit Committee, among other things, is responsible for:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr outerhtml='&#13;&#10;<TR><TD>&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD colSpan=2>&#13;&#10;<P style="MARGIN: 0px"><FONT style="FONT-FAMILY: Symbol">&#183;</FONT></P></TD>&#13;&#10;<TD>&#13;&#10;<P style="MARGIN: 0px">Appointing, approving the compensation of, overseeing the work of, and assessing the independence, qualifications, and performance of the independent auditor;</P></TD></TR>'>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="4%" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px">Appointing, approving the compensation of, overseeing the work of, and assessing the independence, qualifications, and performance of the independent auditor;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">reviewing the internal audit function, including its independence, plans, and budget;</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">reviewing the internal audit function, including its independence, plans, and budget;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">approving, in advance, audit and any permissible non-audit services performed by our independent auditor;</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">approving, in advance, audit and any permissible non-audit services performed by our independent auditor;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">reviewing our internal controls with the independent auditor, the internal auditor, and management;</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">reviewing our internal controls with the independent auditor, the internal auditor, and management;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">reviewing the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">reviewing the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">overseeing our financial compliance system; and</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">overseeing our financial compliance system; and</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top width="7%">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top width="3%" colSpan=2>&#13;&#10;<P style="MARGIN: 0px">&#9679;</P></TD>&#13;&#10;<TD vAlign=top width="89%">&#13;&#10;<P style="MARGIN: 0px">overseeing our major risk exposures regarding the Company&#8217;s accounting and financial reporting policies, the activities of our internal audit function, and information technology.</P></TD></TR>'>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px">overseeing our major risk exposures regarding the Company&#8217;s accounting and financial reporting policies, the activities of our internal audit function, and information technology.</p></td></tr></table>The Board has affirmatively determined that each member of the Audit Committee meets the additional independence criteria applicable to audit committee members under SEC rules and the NASDAQ Stock Market. The Board of Directors has adopted a written charter setting forth the authority and responsibilities of the Audit Committee. The Board has affirmatively determined that each member of the Audit Committee is financially literate, and that all members meet the qualifications of an Audit Committee financial expert. The Audit Committee consists of Tim Schroeder and Kelly Ganji.
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak2b753d11-e16a-4e24-8224-8665720fe0d2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">69</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Compensation Committee</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Compensation Committee is responsible for establishing and administering our executive compensation policies. The role of the Compensation Committee is to (i) formulate, evaluate and approve compensation of the Company&#8217;s directors, executive officers and key employees, (ii) oversee all compensation programs involving the use of the Company&#8217;s stock, and (iii) produce, if required under the securities laws, a report on executive compensation for inclusion in the Company&#8217;s proxy statement for its annual meeting of shareholders. The duties and responsibilities of the Compensation Committee under its charter include:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Annually reviewing and setting compensation of executive officers;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Periodically reviewing and making recommendations to the Board with respect to compensation of non-employee directors;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Reviewing and approving corporate goals and objectives relevant to Chief Executive Officer compensation, evaluating the Chief Executive Officer&#8217;s performance in light of those goals and objectives, and setting the Chief Executive Officer&#8217;s compensation levels based on this evaluation;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Reviewing competitive practices and trends to determine the adequacy of the executive compensation program;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Approving and overseeing incentive compensation and equity-based plans for executive officers that are subject to Board approval;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Making recommendations to the Board as to the Company&#8217;s compensation philosophy and overseeing the development and implementation of compensation programs;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Periodically reviewing and making recommendations to the Board with respect to compensation of non-employee directors;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Reviewing and approving corporate goals and objectives relevant to Chief Executive Officer compensation, evaluating the Chief Executive Officer&#8217;s performance in light of those goals and objectives, and setting the Chief Executive Officer&#8217;s compensation levels based on this evaluation;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">When appropriate, the Compensation Committee may, in carrying out its responsibilities, form and delegate authority to subcommittees. The Chief Executive Officer plays a role in determining the compensation of our other executive officers by evaluating the performance of those executive officers. The Chief Executive Officer&#8217;s evaluations are then reviewed by the Compensation Committee. This process leads to a recommendation for any changes in salary, bonus terms and equity awards, if any, based on performance, which recommendations are then reviewed and approved by the Compensation Committee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Compensation Committee has the authority, at the Company&#8217;s expense, to select, retain, terminate and set the fees and other terms of the Company&#8217;s relationship with any outside advisors who assist it in carrying out its responsibilities, including compensation consultants or independent legal counsel.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Board has adopted a written charter setting forth the authority and responsibilities of the Compensation Committee. The Compensation Committee consists of Tim Schroeder and Kelly Ganji.. The Board has affirmatively determined that each member of the Compensation Committee meets the additional independence criteria applicable to compensation committee members under SEC rules and the NASDAQ Stock Market.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Nominating and Corporate Governance Committee</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Nominating and Corporate Governance Committee, among other things, is responsible for:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">reviewing and assessing the development of the executive officers, and considering and making recommendations to the Board regarding promotion and succession issues;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">evaluating and reporting to the Board on the performance and effectiveness of the directors, committees, and the Board as a whole;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">working with the Board to determine the appropriate and desirable mix of characteristics, skills, expertise, and experience, including diversity considerations, for the full Board and each committee;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">annually presenting to the Board a list of individuals recommended to be nominated for election to the Board;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">reviewing, evaluating, and recommending changes to the Company&#8217;s Corporate Governance Policies and Committee Charters;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">recommending to the Board individuals to be elected to fill vacancies and newly created directorships;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">overseeing the Company&#8217;s compliance program, including the Code of Conduct; and</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">overseeing and evaluating how the Company&#8217;s corporate governance and legal and regulatory compliance policies and practices, including leadership, structure, and succession planning, may affect the Company&#8217;s major risk exposures.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak146e939c-5992-4c6a-83bd-e215a2525ba2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">70</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Board of Directors has adopted a written charter setting forth the authority and responsibilities of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee consists of Tim Schroeder and Kelly Ganji.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="EXECUTIVE COMPENSATION">EXECUTIVE COMPENSATION</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table sets forth the compensation for our fiscal years ended December 31, 2016 and 2015 earned by or awarded to, as applicable, our principal executive officer, principal financial officer and our other most highly compensated executive officers as of December 31, 2016. In this prospectus, we refer to such officers as our &#8220;Named Executive Officers.&#8221;</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="left"><b>Name and Principal Position</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Year</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Salary ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Bonus ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Stock<br>Awards ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Option<br>Awards ($)<sup>(4)</sup></b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Non-Equity</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Incentive Plan</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Compensation</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Nonqualified</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Deferred</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Compensation</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Earnings ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>All Other Compensation ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Total ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Raymond J. Tesi</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="7%">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2016</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">__</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2015</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">David J. Moss</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2016</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom"><b>
<p style="MARGIN: 0px">&nbsp;</p></b></td>
<td id="ffcell" valign="bottom" align="right"><b>&#8212;</b></td>
<td valign="bottom"><b>
<p style="MARGIN: 0px">&nbsp;</p></b></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2015</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom"><b>
<p style="MARGIN: 0px">&nbsp;</p></b></td>
<td id="ffcell" valign="bottom" align="right"><b>&#8212;</b></td>
<td valign="bottom"><b>
<p style="MARGIN: 0px">&nbsp;</p></b></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Mark Lowdell</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2016</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="center">2015</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Employment Agreements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have not entered into any employment agreements with our executive officers. </p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak7d2c809f-198a-4f9f-badb-9dc89ab30197" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">71</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Outstanding Equity Awards at Fiscal Year End</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table summarizes the total outstanding equity awards as of December 31, 2016, for each Named Executive Officer:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Outstanding Equity Awards at Fiscal Year End</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="18" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Option awards</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="14" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Stock awards</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="left"><b>Name</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Number of securities underlying unexercised options (#) exercisable</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Number of securities</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>underlying</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>unexercised</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>options</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(#) unexercisable</b> </p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Equity</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>incentive</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>plan awards: Number of</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>securities</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>underlying</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>unexercised</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>unearned</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>options</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(#)</b> </p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Option</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>exercise price</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>($)</b> </p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Option expiration date</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Number of shares or units of stock that have not vested (#)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Market value of shares of units of stock that have not vested ($)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Equity</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>incentive</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>plan awards: Number of</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>unearned</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>shares, units or other rights that have not vested</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(#)</b> </p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Equity</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>incentive</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>plan awards: Market or payout value of</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>unearned</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>shares, units or other rights that have not vested</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>($)</b> </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Raymond J. Tesi</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="6%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">David Moss</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Mark Lowdell</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">&#8212;</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Director Compensation</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table shows the compensation earned by persons who served on our Board of Directors during the fiscal year ended December 31, 2016, who are not one of our Named Executive Officers.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Name</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Fees</b></p><b>
<p style="MARGIN: 0px">Earned</p>
<p style="MARGIN: 0px">or Paid</p>
<p style="MARGIN: 0px">in Cash</p>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Stock<br>Awards</b> <b>($)</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Option<br>Awards</b> <b>($)</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Non-Equity</b></p><b>
<p style="MARGIN: 0px">Incentive Plan</p>
<p style="MARGIN: 0px">Compensation</p>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Nonqualified</b></p><b>
<p style="MARGIN: 0px">Deferred</p>
<p style="MARGIN: 0px">Compensation</p>Earnings ($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>All Other</b></p><b>
<p style="MARGIN: 0px">Compensation</p>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Total<br></b><b>($)</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Tim Schroeder </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">J. Kelly Ganjei</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Edguardo Baracchini</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="7%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p><b>
<p style="MARGIN: 0px" align="justify"><b>Equity Compensation Plan Information</b></p></b>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Adoption of INmune Bio, Inc. 2017 Stock Incentive Plan</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On November 15, 2017, the Board approved the INmune Bio, Inc. 2017 Stock Incentive Plan (the &#8220;2017 Plan&#8221;). The purpose of the 2017 Plan is to promote the interests of the Company and its stockholders by providing (i) officers and employees, (ii) advisors, and (iii) non-employee directors with appropriate incentives and rewards.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The 2017 Plan provides for the granting of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash-based awards. The 2017 Plan also provides for the granting of performance stock awards so that the Board may use performance criteria in establishing specific targets to be attained as a condition to the grant or vesting of awards under the 2017 Plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak77e1493f-d5f7-4355-92a0-97db868c3f08" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">72</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The 2017 Plan provides for the grant of stock awards to employees, directors and consultants of the Company and its affiliates covering an aggregate of 1,700,000 shares of common stock, subject to adjustments in the event of certain changes to the Company&#8217;s capitalization.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The common stock subject to the 2017 Plan may be unissued shares or reacquired shares, including shares purchased on the open market. If a stock award granted under the 2017 Plan is forfeited, expires or is canceled or settled without issuance of common stock it shall not count against the maximum number of shares that may be issued under the 2017 Plan.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Board has broad discretion in making grants under the 2017 Plan and may make grants subject to such terms and conditions as determined by the Board or a duly appointed committee thereof. Grants under the 2017 Plan will be subject to the terms and conditions set forth in the document making the award, including, without limitation any applicable purchase price and provisions pursuant to which the grant may be forfeited. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Board may terminate or amend the 2017 Plan at any time, except for certain actions that may not be taken without stockholder approval. The 2017 Plan is scheduled to terminate on November 15, 2027.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreaka4335962-c430-4740-8eaf-e2d04081fb72" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">73</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of November 28, 2017, and as adjusted to reflect the sale of common stock in this offering, for: </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">each of our current directors and executive officers;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">all of our current directors and executive officers as a group; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of common stock that they beneficially owned, subject to applicable community property laws.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Applicable percentage ownership is based on 8,363,345 shares of common stock outstanding at October 30, 2017. Under Rule 13d-3 of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o INmune Bio Inc. 1224 Prospect Street, Suite 150, La Jolla, CA 92037. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Name and Address(1) </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Common Stock</b></p>
<p style="MARGIN: 0px" align="center"><b>Owned</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Percentage of Common Stock</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>Executive Officers and Directors</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Raymond J. Tesi</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,503,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">18</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">David J. Moss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,186,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">14.1</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Mark Lowdell</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,503,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">18</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Tim Schroeder</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">166,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">(2)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">2</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">J. Kelly Ganjei</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">&#8212;</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Edguardo Baracchini </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,585,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">(3)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">19</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Officers and Directors </b><b>as a group (5 individuals)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,945,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">71.1</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Beneficial owners of more than 5% </b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Novamune, Inc.</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">300,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">3.59</td>
<td valign="bottom" width="1%">%</td></tr></table>
<p style="MARGIN: 0px">_____________</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">*</p></td>
<td valign="top">
<p style="MARGIN: 0px">Less than 1%.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">1</p></td>
<td>
<p style="MARGIN: 0px">Except as otherwise indicated, the address of each beneficial owner is Immune Bio Inc., 1224 Prospect Street, Suite 150, La Jolla, CA 92037.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">2</p></td>
<td>
<p style="MARGIN: 0px">the shares of the Company&#8217;s common stock are held by CTI Holdings, a company that Mr. Schroeder is the sole shareholder of XX.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">3</p></td>
<td>
<p style="MARGIN: 0px">the shares of the Company&#8217;s common stock are held by Xencor, Inc.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak1dcd4d31-8320-46a4-ae84-c37aee88a14b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">74</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Other than as disclosed below, since the formation of the Company, there have been no transactions or proposed transactions, which have materially affected or will materially affect us in which any director, executive officer or beneficial holder of more than 5% of our outstanding common or preferred stock, or any of their respective relatives, spouses, associates or affiliates, has had or will have any direct or material indirect interest. We have no policy regarding entering into transactions with affiliated parties.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>License Agreement</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">On October 29, 2015, we entered into an exclusive license agreement with Inmune Ventures, LLC, owner of all of the rights related to our principal patent (the &#8220;License Agreement&#8221;). Pursuant to the License Agreement, we were granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, we agreed to the following milestone payments:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase I initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase II initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">250,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase III initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA filing </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA awarded </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">9,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">In addition, we agreed to pay the licensor a royalty of 1% of net sales during the life of each patent granted to the Company. The Licensor is owned by RJ Tesi, our President and a member of our Board of Directors, David Moss, our Chief Financial Officer, Treasurer and a member of our Board of Directors, and Mark Lowdell our Chief Scientific Officer.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="DESCRIPTION OF SECURITIES">DESCRIPTION OF SECURITIES</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following is a summary of the material provisions of our Common Stock, and our certificate of incorporation, and bylaws, all as in effect upon the date of this prospectus. You should also refer to our certificate of incorporation, and bylaws, which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Common Stock</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are authorized to issue up to 200,000,000 shares of Common Stock, par value $0.001 per share. As of the date of this prospectus, there are 8,363,345 shares of Common Stock issued and outstanding. The outstanding shares of Common Stock are validly issued, fully paid and nonassessable. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Holders of Common Stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of Common Stock do not have cumulative voting rights. Therefore, holders of a majority of the shares of Common Stock voting for the election of directors can elect all of the directors. Holders of Common Stock representing a majority of the voting power of the Company&#8217;s capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of the Company&#8217;s outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to the Company&#8217;s certificate of incorporation.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Holders of Common Stock are entitled to share in all dividends that our Board of Directors, in its discretion, declares from legally available funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the Common Stock. The Common Stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions applicable to the Common Stock. </p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreaka30ef1fd-3b79-4f54-a3c5-830666d845d5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">75</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Preferred Stock</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Company is authorized to issue up to 10,000,000 shares of preferred stock, par value $.001 per share, with such rights and preferences as may be determined from time to time by our board of directors, of which no shares of preferred stock are issued and outstanding as of the date of this prospectus. Our board of directors may, without stockholder approval, issue preferred stock with dividends, liquidation, conversion, voting or other rights or preferences as they may determine. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Options and Warrants</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">None.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Listing</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our common stock is not quoted or listed on a quotation or over the counter marketer, stock market or exchange. We intend to apply to list our Common Stock on national exchange or marketplace. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Transfer Agent and Registrar</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">VStock Transfer, LLC will serve as our transfer agent and registrar. They are located at 18 Lafayette Place, Woodmere, NY 11598, phone number (212) 828-8436.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Disclosure of Commission Position on Indemnification for Securities Act Liabilities </b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Chapter 78 of the Nevada General Corporation Law (&#8220;NGCL&#8221;) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he is not liable pursuant to NGCL Section 78.138 or acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. NGCL Chapter 78 further provides that a corporation similarly may indemnify any such person serving in any such capacity who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection with the defense or settlement of such action or suit if he is not liable pursuant to NGCL Section 78.138 or acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the court or other court of competent jurisdiction in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court or other court of competent jurisdiction shall deem proper. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our Articles of Incorporation provide that we may indemnify our officers, directors, employees, agents and any other persons to the maximum extent permitted by the NGCL.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="LEGAL MATTERS">LEGAL MATTERS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The validity of our common stock offered by this prospectus will be passed upon by Sichenzia Ross Ference Kesner LLP. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakb6df2ed7-a1aa-48e4-ac2b-c52f315d055f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">76</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="EXPERTS">EXPERTS</a></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The consolidated financial statements of INmune Bio Inc. as of December 31, 2016 have been included herein and in the registration statement have been so included in reliance on the report of GBH CPAs, PC, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have filed with the SEC a registration statement on Form S-1 (including the exhibits, schedules and amendments thereto) under the Securities Act, with respect to the shares of our common stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further information with respect to us and the common stock offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus as to the contents of any contract, agreement or other documents are summaries of the material terms of that contract, agreement or other document. With respect to each of these contracts, agreements or other documents filed as an exhibit to the registration statement, reference is made to the exhibits for a more complete description of the matter involved. A copy of the registration statement, and the exhibits and schedules thereto, may be inspected without charge at the public reference room facilities maintained by the SEC at 100 F Street, N.E., Washington D.C. 20549. Copies of these materials can be obtained from the Public Reference Room of the SEC at prescribed rates, or accessed at the SEC&#8217;s website at www.sec.gov. Please call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC&#8217;s website is http://www.sec.gov.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">As a result of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, we will file periodic reports, proxy statements, and other information with the SEC. These periodic reports, proxy statements, and other information will be available for inspection and copying at the SEC&#8217;s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.inmunebio.com. After the closing of this offering, you may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website (www.inmunebio.com) as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a style="MARGIN: 0px" name="PLAN OF DISTRIBUTION">PLAN OF DISTRIBUTION</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Placement Agent is not purchasing or selling any securities offered by this prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to use its best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we will enter into a subscription agreement directly with investors in connection with this offering and we may not sell the entire amount of securities offered pursuant to this prospectus. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the offering. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have agreed to pay the Placement Agents a fee of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;( &nbsp; &nbsp;%) of the aggregate purchase price of the shares of common stock and warrants sold in this offering. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreakc1471dbd-42a8-4161-a8b0-08d19e01beb2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">77</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Escrow Arrangements</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">All funds sent to the Company by investors in the United States to purchase the common stock after the effectiveness of the registration statement of which this prospectus forms a part will be deposited in a non-interest bearing account, maintained by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;(the &#8220;Escrow Agent&#8221;). Effectiveness of this registration statement will not be requested and no investor funds will be accepted until indications of interest have been received for at least the Minimum Offering Amount. Confirmations and final prospectuses will be distributed to all investors at the time of pricing, informing investors of the closing date, which will be scheduled for three business days after pricing. No investor funds will be accepted prior to effectiveness of the Registration Statement. After the Registration Statement is declared effective and prior to the closing date, all investor funds will be placed promptly, and in any event no later than noon Eastern Standard Time of the next business day following receipt, in escrow with the Escrow Agent in an escrow account established for the benefit of the investors. Prior to the closing date, the Escrow Agent will advise the Company whether the investors have deposited the requisite funds in the escrow account with the Escrow Agent. If the requisite funds have been deposited, the Company&#8217;s transfer agent will deposit with The Depository Trust Company the securities to be credited to the respective accounts of the investors. Investor funds will be collected by the Company through the facilities of the Escrow Agent on the scheduled closing date. In the event that requisite investor funds are not received by the closing date, all funds deposited in the escrow account will promptly be returned in full.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We have paid the Placement Agent an engagement fee of $&nbsp;&nbsp;&nbsp; . We will reimburse the Placement Agent for its e reasonable out-of-pocket expenses in connection with the performance of tis services under the placement agent agreement. The Placement Agent agreement provides that the Placement Agent may provide us with other services including advising us on mergers and acquisitions. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table shows the per share and total placement agent&#8217;s fees that we will pay to the Placement Agent in connection with the sale of the common stock and warrants offered pursuant to this prospectus assuming the sale of the Minimum Offering Amount and the Maximum Offering Amount.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Per share of common stock and warrant placement agents&#8217; fees</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="1%">
<p style="MARGIN: 0px">$</p></td>
<td width="9%">
<p style="MARGIN: 0px" align="right">[&#9679;]</p></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Minimum Offer Amount Total</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">[&#9679;]</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Maximum Offering Amount Total</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">[&#9679;]</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Because there cannot be any assurance that Maximum Offering Amount will be sold in this offering, the actual total offering commissions, if any, are not presently determinable and may be substantially less than the maximum amount set forth above.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If we do not sell and receive payments for the Minimum Offering Amount prior to&nbsp;&nbsp;&nbsp;&nbsp; , investor subscriptions will be returned without interest or deduction.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our obligations to issue and sell the shares of common stock and warrants to the purchasers is subject to the conditions set forth in the subscription agreement, which may be waived by us at our discretion. A purchaser&#8217;s obligation to purchase the shares of common stock and warrants is subject to the conditions set forth in the subscription agreement as well, which may also be waived.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We estimate the total offering expenses in this offering that will be payable by us, excluding the placement agents&#8217; fees, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; which include legal, accounting and printing costs, various other fees and reimbursement of the placement agent&#8217;s expenses.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The foregoing does not purport to be a complete statement of the terms and conditions of the placement agent agreement and the subscription agreement. A copy of the placement agent agreement and the form of subscription agreement with investors are included as exhibits to the Registration Statement of which this prospectus forms a part.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Placement Agent may be deemed to be underwriters within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by them and any profit realized on the resale of the securities sold by them while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As underwriters, the Placement Agent would be required to comply with the Securities Act and the Securities Exchange Act of 1934, as amended, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">may not engage in any stabilization activity in connection with our securities; and</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreaka31c8731-60d9-4659-a23a-be3dfe9e9c14" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">78</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Placement Agent&#8217;s Warrants</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">We have agreed to issue to the Placement Agent warrants, or the Placement Agents&#8217; warrants, to purchase up to a total of up to&nbsp;&nbsp;&nbsp; % of the shares of common stock sold in this offering (shares assuming the sale of the Minimum Offering Amount, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares assuming the sale of the Maximum Offering Amount). The warrants are exercisable at a per share price equal to $&nbsp;&nbsp;&nbsp;&nbsp; , at any time, and from time to time, in whole or in part, during the five-year period commencing six months from the effective date of the offering, which period shall not extend further than five years from the effective date of the offering in compliance with FINRA Rule 5110(f)(2)(G). The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The Placement Agent (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the offering. We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. </p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>STATE SUITABILITY STANDARDS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>California</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">No securities shall be sold pursuant to this prospectus to residents of the State of California unless such residents have either of (i) a minimum of $65,000 gross income and net worth of $250,000, or (ii) a minimum net worth of $500,000. In either instance, an investor who is resident of the State of California shall not invest more than ten (10%) of their net worth in this offering. Net worth shall be determined exclusive of home, home furnishings and automobiles. Assets included in the computation of net worth may be valued at fair market value. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Offer restrictions outside the United States</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Other than in the United States, no action has been taken by us or the Placement Agent that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak88af9bf3-3aaa-4ea3-8375-631de7bc1cc8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">79</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="100%">
<p style="MARGIN: 0px" align="center"><a name="Consolidated Financial Statements(fin)">Consolidated Financial Statements</a></p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>For The Year Ended December 31, 2016 and for the Period from September 25, 2015 (Inception) </b></p>
<p style="MARGIN: 0px" align="center"><b>to December 31, 2015 and</b></p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>For The Three and Nine Months Ended September 30, 2017 and 2016</b></p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak6a6938d6-4439-4b25-8f89-6bb85d111df5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">80</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="INDEX TO 2">INDEX TO </a>CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Page</b></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">82</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED BALANCE SHEETS">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2016 AND 2015</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">83</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEAR ENDED DECEMBER 31, 2016 AND FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">84</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT FOR THE YEAR ENDED DECEMBER 31, 2016 AND FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">85</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED STATEMENTS OF CASH FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2016 AND FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">86</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#NOTES TO CONSOLIDATED FINANCIAL STATEMENTS">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">87</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED BALANCE SHEETS1">CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2017 AND DECEMBER 31, 2016 (UNAUDITED)</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">94</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 1">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">95</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#CONSOLIDATED STATEMENTS OF CASH FLOWS 1">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2017 AND 2016 (UNAUDITED)</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">96</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><a href="#NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</a></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">97</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak33971b35-450b-4e28-b281-cc4e25be29bd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">81</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="center">&nbsp;</p>
<p style="MARGIN: 0px">To the Board of Directors and Stockholders of</p>
<p style="MARGIN: 0px" align="justify">INmune Bio, Inc.</p>
<p style="MARGIN: 0px" align="justify">La Jolla, CA</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have audited the accompanying consolidated balance sheets of INmune Bio, Inc. as of December 31, 2016 and 2015 and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; deficit, and cash flows the year ended December 31, 2016 and for the period from September 25, 2015 (Inception) to December 31, 2015. The Company&#8217;s management is responsible for these financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of INmune Bio, Inc. as of December 31, 2016 and 2015 and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0.5in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying consolidated financial statements have been prepared assuming that INmune Bio, Inc. will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, INmune Bio, Inc. has suffered recurring losses from operations and has not yet generated any revenue from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="50%">
<p style="MARGIN: 0px" align="justify">/s/ GBH CPAs, PC</p></td>
<td valign="top" width="50%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">GBH CPAs, PC</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>www.gbhcpas.com</u></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Houston, Texas</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">November 30, 2017</p></td>
<td valign="top"></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak7ad924b9-8fc7-4657-b084-d73ae6cbfd2b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">82</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE<font color="#f52887"> </font>BIO, INC. </b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED BALANCE SHEETS">CONSOLIDATED BALANCE SHEETS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>December 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>December 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2015</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top" colspan="8">
<p style="MARGIN: 0px; TEXT-INDENT: -0.1in" align="center"><b>ASSETS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>CURRENT ASSETS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Cash</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">141,659</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">11,882</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Research and development tax credit receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">68,866</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">VAT receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">35,239</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Joint development cost receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">156,381</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Prepaid expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">3,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Prepaid expenses &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">46,462</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL ASSETS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">451,607</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">11,882</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top" colspan="8">
<p style="MARGIN: 0px" align="center"><b>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">207,709</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Accounts payable and accrued liabilities &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">13,101</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Short-term debt &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Stock payable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">600,810</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,750</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>NON-CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Accrued settlement liability</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">650,810</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,750</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>COMMITMENTS AND CONTINGENCIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>STOCKHOLDERS&#8217; DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock, $0.001 par value, 210,000,000 shares authorized, 5,066,667 and 5,000,000 shares issued and outstanding, respectively</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,067</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Additional paid-in capital</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">124,933</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated other comprehensive loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(2,844</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(326,359</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL STOCKHOLDERS' DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(199,203</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(18,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">451,607</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">11,882</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak4d9ddc7d-564d-4488-9d2a-7b2d91abaa82" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">83</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC. </b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</a></b></p>
<p style="MARGIN: 0px" align="center"><b>FOR THE YEAR ENDED DECEMBER 31, 2016 AND FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2015</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>REVENUE</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>OPERATING EXPENSES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">General and administrative</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">125,996</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">48,868</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Research and development</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">101,495</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Total operating expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">227,491</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>LOSS FROM OPERATIONS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(227,491</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px; TEXT-INDENT: 0in"><b>OTHER INCOME (EXPENSE)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px; TEXT-INDENT: 0in">Loss on settlement of lawsuit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0in">Total other expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>NET LOSS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(277,491</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px; TEXT-INDENT: 0in">Net loss per common share &#8211; basic and diluted</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.06</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.01</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Weighted average number of common shares outstanding &#8211; basic and diluted</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000,182</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">4,489,796</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>COMPREHENSIVE INCOME (LOSS)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(277,491</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(48,868</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Other comprehensive loss &#8211; loss on foreign currency translation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(2,844</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Total comprehensive loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(280,335</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak176e1d7e-bce3-4037-a6e7-fa49d238a683" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">84</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC. </b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT</a></b></p>
<p style="MARGIN: 0px" align="center"><b>FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015 AND THE YEAR ENDED DECEMBER 31, 2016</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Common Stock</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Additional</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Accumulated Other</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Shares</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Par<br>Value</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Paid-in<br>Capital</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Comprehensive<br>Loss</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Accumulated<br>Deficit</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b><b>Total</b> Stockholders&#8217; Deficit</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Balance, September 25, 2015 (inception)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Proceeds from issuance of common stock for cash</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">30,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Balance, December&nbsp;31, 2015</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">5,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">5,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">25,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(48,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(18,868</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Proceeds from issuance of common stock for cash</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">67</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">99,933</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">100,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Loss on foreign currency translation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(2,844</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(2,844</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(277,491</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(277,491</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Balance, December&nbsp;31, 2016</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">5,066,667</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">5,067</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">124,933</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(2,844</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(326,359</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(199,203</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak7fd96e43-9865-4a7a-81c3-7872e112ede0" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">85</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC. </b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF CASH FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></b></p>
<p style="MARGIN: 0px" align="center"><b style="MARGIN: 0px">FOR THE YEAR ENDED DECEMBER 31, 2016 AND FOR THE PERIOD FROM SEPTEMBER 25, 2015 (INCEPTION) TO DECEMBER 31, 2015</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2015</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(277,491</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(48,868</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0in">Stock-based compensation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">30,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Loss on settlement of lawsuit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">50,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">Research and development tax credit receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(68,866</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">VAT receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(35,239</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">Joint development cost receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(156,381</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Prepaid expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(3,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Prepaid expenses &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(46,462</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">206,959</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Accounts payable and accrued liabilities &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">13,101</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net cash used in operating activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(317,379</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(18,118</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from issuance of short-term debt &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">350,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from sale of common stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">100,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Net cash provided by financing activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">450,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Impact on cash from foreign currency translation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(2,844</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">NET INCREASE IN CASH</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">132,621</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">11,882</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">CASH AT BEGINNING OF YEAR</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">11,882</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">CASH AT END OF YEAR</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">141,659</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">11,882</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash paid for income taxes</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash paid for interest expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak7a4c6213-8500-4118-972f-ceead866cdb5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">86</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC.</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="NOTES TO CONSOLIDATED FINANCIAL STATEMENTS">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 1</u></b><b> &#8211; ORGANIZATION AND BASIS OF PRESENTATION</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Organization</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">INmune Bio, Inc. (the &#8220;Company&#8221; and/or &#8220;INmune&#8221;) was originally organized in the State of Nevada on September 25, 2015 and is an early stage specialty pharmaceutical company focused on developing pioneering strategies for oncology that focus on engineering and harnessing the innate immune system to treat the patient&#8217;s cancer. INmune&#8217;s proprietary is to focus on the innate immune system that include natural killer cells (&#8220;NK cells&#8221;), myeloid derived suppressor cells (&#8220;MDSC cells&#8221;) and dendritic cells (&#8220;DC cells&#8221;), which are believed to offer unique therapeutic opportunities and may be safer, easier to execute, and more effective than currently available treatments. INmune plans to develop their two existing drug platforms: INKmune (&#8220;INKmune&#8221;) which primes NK cells and INB03 (&#8220;INB03&#8221;) which down regulates MDSC cells. Together or individually, the Company expects that these therapies will harness the innate immune system to provide a unique set of therapies for patients with cancer. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">INmune Bio International Ltd (England) (&#8220;INmune UK&#8221;) is a wholly owned subsidiary of INmune that was formed on April 6, 2016 in the United Kingdom (&#8220;UK&#8221;). Inmune UK was duly organized under the laws of England and has </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">1,000 shares owned by INmune. The Company will perform its drug manufacturing and currently performs its drug research and development in the UK and will continue to perform research and development activities in this region. The UK has an R&amp;D rebate program that allows the Company to recover some of its R&amp;D expenses (see further discussion in Note 4).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Basis of Presentation and Principles of Consolidation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying consolidated financial statements of the Company have been prepared in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) in the United States of America and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The consolidated financial statements herein have been prepared in accordance with GAAP and include the accounts of the Company and those of its wholly-owned subsidiary, INmune UK. All significant intercompany accounts and transactions have been eliminated.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 2</u></b><b> &#8211; GOING CONCERN</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of December 31, 2016, the Company had an accumulated deficit of $326,359. Losses have principally occurred as a result of the substantial resources required for research and development of the Company&#8217;s products which included the general and administrative expenses associated with its organization and product development as well as the lack of sources of revenues until such time as the Company&#8217;s products are commercialized. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern from the issuance date of these financial statements. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management plans to obtain additional funding through the issuance of common stock for cash and by implementing its strategic plan to allow the opportunity for the Company to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 3</u></b><b> &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Use of Estimates</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak7a97b25e-4a57-41c0-abe2-ff244557a72e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">87</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Receivables, Net</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Receivables currently consist of an R&amp;D tax credit receivable, VAT receivable and joint development cost receivable. The R&amp;D tax credit receivable is recorded when R&amp;D is incurred. At that time, the Company records a receivable for the amount of the credit it expects to receive based on the expenses incurred. The VAT receivable is recorded when the Company receives an invoice with VAT related to it. The receivable is recorded for the amount expected to be returned when the VAT tax return is filed. The joint development cost receivable is recorded when the Company incurs R&amp;D expenses based on the amount it expects to receive as a reimbursement per the Novamune agreement (see Note 4 for detailed explanation of the agreement). The collectability of these receivables are evaluated periodically based on the actual R&amp;D credit returns submitted, the VAT returns submitted and the amounts received from Novamune. As of December 31, 2016 and 2015, there were no trade receivables. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Intangible Assets</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company capitalizes costs incurred in connection with in process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. The Company amortizes these assets using the straight-line method over the estimated useful lives of the patents, generally five to 15 years. Other intangibles, consisting of trademarks and copyrights, if any, are considered to have indefinite lives and are not amortized but reviewed for impairment annually, or sooner under certain circumstances.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Basic and Diluted Loss per Share </i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. There were no potentially dilutive shares at December 31, 2016 and 2015.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stock-Based Compensation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Company records the fair value of stock options issued to its employees as of the grant date as compensation expense. The Company recognizes compensation expense, net of forfeitures, on a straight-line basis over the requisite service period, which is equal to the applicable vesting period.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Company accounts for equity instruments issued to non-employees using a fair value approach under ASC Subtopic 505-50, <i>Equity-Based Payments to Non-Employees</i>. The Company values equity instruments and stock options granted using the Black-Scholes option-pricing model. The value of non-employee stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Research and Development</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Research and development costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakbd9c5478-7449-418f-8570-ac30a4c5de5a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">88</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Income Taxes</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Foreign Currency</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company accounts for its foreign currency transaction gains and losses as other comprehensive income (loss) included in equity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>New and Recently Issued Accounting Pronouncements</i></b><b><i></i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard&#8217;s core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating its adoption method and the impact of the standard on its consolidated financial statements and has not yet determined the method by which the Company will adopt the standard in 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">In April 2016, the FASB issued ASU No. 2016-10, &#8220;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&#8221; (Topic 606). In March 2016, the FASB issued ASU No. 2016-08, &#8220;Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)&#8221; (Topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, &#8220;Revenue from Contracts with Customers&#8221;. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company does not expect the new standard to have a material effect on its consolidated financial statements. </p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In April 2016, the FASB issued ASU No. 2016-09, &#8220;Compensation &#8211; Stock Compensation&#8221; (Topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company has adopted this standard effective January 1, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221; (&#8220;ASU 2016-15&#8221;). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak9bcd4106-4012-44d5-b4a6-5ee62f6691fa" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">89</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its financial position, results of operations, or cash flows.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Subsequent Events</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has evaluated all transactions from December 31, 2016 through November 30, 2017, the financial statement issuance date for subsequent disclosure consideration.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>NOTE 4</u></b><b> &#8211; </b><b>RESEARCH AND DEVELOPMENT ACTIVITY</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Company incurred $101,495 and $0 of research and development costs for the years ended December 31, 2016 and 2015, respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">According to UK tax law, the Company is allowed an R&amp;D tax credit that reduces a company&#8217;s tax bill in the UK for expenses incurred in R&amp;D. According to the UK Government, R&amp;D takes place when a project seeks to achieve an advance in overall knowledge or capability in a field of science or technology. A company has to have staff headcount of less than 500 and either revenue of less than &#8364;100m or a balance sheet total of less than &#8364;86m. INmune UK submitted R&amp;D tax credit requests for research and development expenses incurred in 2016, and recorded a related receivable in the amount of $68,866 as of December 31, 2016. In 2017, the Company received the funds owed under the tax credit.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company is also eligible to recover all VAT for all R&amp;D expenses paid. INmune UK recorded a VAT receivable in the amount of $35,239 as of December 31, 2016 for VAT paid during 2016 that was due to be reimbursed. In 2017, the Company received the funds due to be reimbursed.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 3, 2016, the Company entered into a joint development agreement with Novamune, Inc. (&#8220;Novamune&#8221;) (the &#8220;Development Agreement&#8221;). Novamune had previously developed and licensed technology relating to ex-vivo activation of NK cells for the treatment of cancer and other diseases. The parties agreed to exclusively collaborate on the further development of technologies related to NK cells for therapeutic applications. The Company and Novamune will share equally in the costs related to such joint development projects and will jointly own any intellectual property developed by the joint projects, provided that Novamune shall have an exclusive royalty free license to use any such intellectual property relating to ex-vivo applications and the Company shall have an exclusive royalty free license to use any such intellectual property relating to in-vivo applications. The Development Agreement is subject to Novamune investing a total of $1,250,000 in the Company, of which $350,000 has previously been advanced through a convertible note payable (see further discussion in Note 5). The balance of $900,000 shall be invested in the Company on the earlier of (i) December 31, 2017, or (ii) 60 days after the Company becomes publicly traded. As of December 31, 2016 and 2015, the Company had a joint development receivable outstanding related to Novamune&#8217;s portion of R&amp;D costs incurred through year-end of $156,381 and $0, respectively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>INKmune License Agreement</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">On October 29, 2015, the Company entered into an exclusive license agreement with Inmune Ventures, LLC, owner of all of the rights related to our principal patent (the &#8220;License Agreement&#8221;). Pursuant to the License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate any improvements or additions to the patents that may be developed in the future. In consideration for the patent rights, the Company agreed to the following milestone payments:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="70%" align="center" border="0">
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase I initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">25,000</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase II initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">250,000</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each Phase III initiation </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">350,000</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA filing </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">1,000,000</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Each NDA/EMA MA awarded </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">9,000,000</p></td>
<td valign="bottom" width="1%"></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">In addition, the Company agreed to pay the licensor a royalty of 1% of net sales during the life of each patent granted to the Company. The Licensor is owned by RJ Tesi, our President and a member of our Board of Directors, David Moss, our Chief Financial Officer, Treasurer and a member of our Board of Directors and Mark Lowdell, our Head of Scientific Advisory Board. As of December 31, 2016 and 2015, no sales had occurred under this license.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 5</u></b><b> &#8211; LOANS PAYABLE</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">On May 9, 2016, the Company received cash proceeds of $350,000 from the issuance of a convertible note to Novamune that matured on August 1, 2016, with a conversion rate of $1.50 per share, and an annual interest rate of 8%. On September 3, 2016, the maturity date was extended to March 3, 2017. As of December 31, 2016, the Company had an outstanding balance of convertible debt of $350,000 and did not accrue interest on such note since, under the agreement, the note converted at no interest when the Company closed its financing in 2017.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i></i></b><b><i>Accounts payable</i></b><b><i> &#8211; Related Party</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of December 31, 2016, the Company had outstanding amounts due to a related party for travel expenses incurred of $3,849. In addition, as of December 31, 2016, the Company had outstanding amounts due to a related party for travel expenses incurred of $9,252 from INmune UK. There were no related party payables incurred during 2015<font color="#f52887"> . </font></p>
<p style="MARGIN: 0px" align="justify"><font color="#f52887"> &nbsp; </font></p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreake4f7bee8-8281-4acb-80d7-6bde69c3b3bc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">90</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 6</u></b><b> &#8211; STOCKHOLDERS&#8217; EQUITY</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The Company is authorized to issue up to 210,000,000 shares of common stock at par value $0.001 per share. As of December 31, 2016 and 2015, the Company had 5,066,667 and 5,000,000, respectively, of the Company&#8217;s common stock issued and outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During 2015, the Company issued a total of 5,000,000 shares to the 3 company founders, Mark Lowdell (Chief Scientific Officer), David Moss (CFO), RJ Tesi (President and CEO), and related individuals designated by the founders for total cash proceeds of $30,000.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">During 2016, the Company received $100,000 to issue 66,667 shares of the Company&#8217;s common stock. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">As of December 31, 2016 and 2015, the Company had $30,000 and $30,000, respectively, of outstanding stock payable due to its law firm for 20,000 shares of the Company&#8217;s common stock valued at $1.50 per share based on the value of the services provided.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">As of December 31, 2016, the Company recorded an accrued settlement liability of $50,000 for 33,335 common shares related to a legal settlement (see Note 8). </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 7</u></b><b> &#8211; INCOME TAXES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of December 31, 2016, the Company had a cumulative US tax net operating loss of $177,605 that can be carried forward to reduce future years&#8217; taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The Company&#8217;s net operating loss carrying forwards, if not utilized, will begin to expire, beginning in 2028.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Company filed its UK tax return for the period from April 6, 2016 to December 31, 2016 and it had no tax liability.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 8</u></b><b> &#8211; COMMITMENTS AND CONTINGENCIES</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">In November 2016, an individual filed an action in Cook County, Illinois, against the Company, David J. Moss, its Chief Financial Officer, Treasurer, Secretary and a member of its board of directors, Raymond J. Tesi, its president and Chief Executive Officer (the Company, Mr. Moss and Mr. Tesi are referred to collectively as the &#8220;Company Parties&#8221;). The action alleged claims against the Company Parties concerning payment of monies and/or securities allegedly owed. In April 2017, the Company Parties and the Claimant entered into a Settlement Agreement and Mutual General Release agreement with that individual (the &#8220;Settlement Agreement&#8221;). Pursuant to the settlement agreement, the Company issued 33,335 shares of the Company&#8217;s common stock valued at $50,000, based on the value of the stock of the last round of financing of $1.50 per share. These shares are held by the Company subject to a restriction on transfer for a period of two years from the date the Company completes an initial public offering or otherwise becomes a public company after which the Company will deliver the shares to the Claimant. The agreement to issue the shares was a full and complete settlement of all claims that the Claimant may have had against the Company Parties and the Cook County action was dismissed with prejudice. The obligation was recorded as accrued settlement liability as of December 31, 2016, pending delivery of the shares to the Claimant after the restriction period expires.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During 2017, the Company received notice that another company had filed trademark application with the United States Patent and Trademark Office to register a certain trademark. The Company filed an opposition in the United States Trademark Trial and Appeal Board. Subsequently, INmune and this company entered into a settlement agreement pursuant to which the Company agreed not to oppose the company&#8217;s trademark and the company paid INmune cash proceeds of $150,000 in full consideration for the settlement agreement. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp; </p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak4cdfffc3-f0d2-4f61-a1db-feca86428c08" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">91</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>NOTE 9</b><b> &#8211; SUBSEQUENT EVENTS</b></p>
<p style="MARGIN: 0px"><em></em>&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Share Issuances</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In 2017, the Company issued 1,393,335 shares of the Company&#8217;s common stock for total cash proceeds of $2,056,000. In addition, the Company issued 233,345 shares of the Company&#8217;s stock for the conversion of the full value of the Company&#8217;s outstanding convertible debt (converted at no interest) of $350,000, and 20,000 shares of the Company&#8217;s common stock for the settlement of the outstanding common stock payable of $30,000 outstanding at December 31, 2016.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">In connection with the private placement offering, the Company agreed to file a registration statement under the Securities Act of 1933 within five months after the final closing of the offering and will seek to have such registration statement declared effective within six months of filing registering the shares of common stock in the offering. Upon the effectiveness of the registration statement, each investor in the offering agreed not to sell shares of common stock purchased in the offering for a period of at least six months from the effective date of such registration statement. If the Company fails to meet either of the registration deadlines, each investor will be entitled to receive a cash payment in the amount of 1% of the amount of the investment for each month that a registration deadline is not met, up to a maximum of 12%. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 30, 2017, the Company issued fully vested warrants for investment banking services to purchase 31,667 shares of the Company&#8217;s common stock with an exercise price of $1.50, a maturity date of June 30, 2022 and a fair value of $36,922 based on the Black-Scholes Option Pricing model.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>License Agreements</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 3, 2017, the Company entered into a license agreement with Xencor, Inc., which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor&#8217;s proprietary protein known as &#8220;XPRO1595&#8221; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation. The Company believes the protein has numerous medical applications. In connection with the license agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and agreed to issue Xencor shares (&#8220;Initial Shares&#8221;) of the Company&#8217;s common stock equal to 19% of our fully diluted company shares the value of which are discussed below.&nbsp;The Company also issued warrants to Xencor which is discussed below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company also agreed to pay Xencor a royalty of 5% on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Under the license agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives equal to (i) 60% of sublicensing revenue received in respect of any sublicense granted prior to initiation of a Phase 1 Clinical Trial of a Licensed Product in the applications for the treatment of disease in humans (the &#8220;Field&#8221;); (ii) 30% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 1 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field; (iii) 15% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field; (iv) 10% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field and prior filing of the first NDA application for any Licensed Product in the Field; and (v) 5% of Sublicensing Revenue received in respect of any sublicense granted on or after the approval of the first NDA application for any Licensed Product in the Field. For clarity, initiation of a clinical trial shall mean dosing of a first patient in said clinical trial. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;&nbsp; </p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak86d74e90-4166-44ec-87d9-7e87e46ffe84" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">92</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In connection with the License Agreement, the Company entered into a stock issuance agreement with Xencor pursuant to which it agreed to issue Xencor 1,585,000 shares of its common stock with a fair value of $12,221,000 based on the discounted cash flow method of the income approach as set forth in an independent valuation report from HSSK LLC dated October 3, 2017, and fully vested warrants to purchase an additional number of shares of common stock equal to 10% our the fully diluted company shares immediately following such purchase with a fair value of $4,193,000 based on Black-Scholes Option Pricing Model. The warrants have an exercise price based on a valuation of the Company at $100,000,000 and expire on October 3, 2023. The aggregate purchase price for the full exercise of the option to Acquire Additional Shares is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the Option for less than 10% of the fully diluted company shares immediately following such purchase. The purchase price for the additional shares may be paid by cash or by way of a cashless exercise. In connection with the stock issuance agreement, the Company, Xencor and more than 90% of shareholders as of September 30, 2017 (&#8220;Key Holders&#8221;) entered into a voting agreement. Pursuant to the voting agreement, Xencor and the Key Holders agreed to vote their respective shares to vote one individual designated by the holder of a majority of Xencor&#8217;s shares of the Company&#8217;s common stock to the Company&#8217;s board of directors. The voting agreement shall continue in full force and effect from the date hereof through the earliest of the following dates, on which date it shall terminate in its entirety: (a) the date of a qualified offering, as defined in the issuance agreement; (b) ten (10) years from the date of this Agreement; (c) the date of the closing of a qualified sale, as defined in the issuance agreement; or (d) the date as of which the parties hereto terminate this agreement by written consent of the holders of a majority of the Investor Shares.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recorded $16,514,000 for the acquisition of intangible assets in the fourth quarter of 2017 as the fair value of the cash, stock and warrants on the date of acquisition in accordance with Accounting Standards Codification 730 &#8211; <i>Research and Development</i>.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures LLC. Pursuant to the Assignment and Assumption Agreement, Immune Ventures assigned all of its rights, obligations and liabilities under the Exclusive License Agreement between the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education and Immune Ventures. Pursuant to the Assignment and Assumption Agreement, the Company agreed to convert the amount Immune Ventures paid of $31,640 into INmune common stock at $1.50 per share for 21,094 shares for the reimbursement of amounts paid by the Assignor to the University of Pittsburg.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;&nbsp; </p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak19370760-417c-4037-a1bf-acd3d6ce3edb" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">93</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC.</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED BALANCE SHEETS1">CONSOLIDATED BALANCE SHEETS</a></b></p>
<p style="MARGIN: 0px" align="center"><b>(UNAUDITED)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>December 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top" colspan="8">
<p style="MARGIN: 0px" align="center"><b><u>ASSETS</u></b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>CURRENT ASSETS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Cash</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,843,499</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">141,659</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Research and development tax credit receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">40,487</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">68,866</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">VAT receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">131,821</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">35,239</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Joint development cost receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">84,733</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">156,381</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Prepaid expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">13,779</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">3,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Prepaid expenses &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">46,462</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL ASSETS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">2,114,319</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">451,607</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top" colspan="8">
<p style="MARGIN: 0px" align="center"><b><u>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</u></b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">100,895</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">207,709</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable and accrued liabilities &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">60,642</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">13,101</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Short-term debt &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Stock payable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">30,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px"><b>TOTAL CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">191,537</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">600,810</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>NON-CURRENT LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accrued settlement liability</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">50,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL LIABILITIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">241,537</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">650,810</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>COMMITMENTS AND CONTINGENCIES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>STOCKHOLDERS&#8217; DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock, $0.001 par value, 210,000,000 shares authorized 6,693,347 and 5,066,667 shares issued and outstanding, respectively</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,694</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,067</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Additional paid-in capital</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,566,228</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">124,933</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated other comprehensive income (loss)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">29,470</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(2,844</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(729,610</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(326,359</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL STOCKHOLDERS' DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">1,872,782</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(199,203</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">2,114,319</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">451,607</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak63d577bd-929f-4998-8515-4e12d4828629" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">94</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC.</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 1">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</a></b></p>
<p style="MARGIN: 0px" align="center"><b>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016</b></p>
<p style="MARGIN: 0px" align="center"><b>(UNAUDITED)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>For the Three Months Ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>For the Nine Months Ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30,<br>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30,<br>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30,<br>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>September 30,<br>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>REVENUE</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>OPERATING EXPENSES</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">General and administrative</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">261,207</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">26,632</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">386,245</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">69,485</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Research and development</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">46,320</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">27,565</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">167,006</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">73,329</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total operating expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">307,527</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">54,197</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">553,251</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">142,814</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>LOSS FROM OPERATIONS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(307,527</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(54,197</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(553,251</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(142,814</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px; TEXT-INDENT: 0in"><b>OTHER INCOME (EXPENSE</b>)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on settlement of lawsuit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">150,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">Total other income</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">150,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>NET LOSS</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(307,527</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(54,197</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(403,251</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(142,814</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Net loss per common share &#8211; basic and diluted</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.05</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.01</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.07</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(0.03</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Weighted average number of common shares outstanding &#8211; basic and diluted</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,625,883</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,813,698</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>COMPREHENSIVE INCOME (LOSS)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(307,527</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(54,197</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(403,251</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(142,814</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Other comprehensive income &#8211; gain on foreign currency translation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">15,496</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">113</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">32,314</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">3,389</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total comprehensive loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(292,031</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(54,084</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(370,937</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(139,425</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr></table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to these consolidated financial statements.</p>
<p style="MARGIN: 0px" align="center">
<table id="pagebreak6e27dd49-a84b-44e7-8e3f-4999f19d2b5f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">95</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC. </b></p>
<p style="MARGIN: 0px" align="center"><b><a name="CONSOLIDATED STATEMENTS OF CASH FLOWS 1">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></b></p>
<p style="MARGIN: 0px" align="center"><b style="MARGIN: 0px">FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2016</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(403,251</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(142,814</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Stock-based compensation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">36,922</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on settlement of lawsuit</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(150,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">Research and development tax credit receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">28,379</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(51,892</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">VAT receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(96,582</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(36,717</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px; TEXT-INDENT: 0in">Joint development cost receivable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">71,648</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(119,042</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Prepaid expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(10,779</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(3,000</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Prepaid expenses &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">46,462</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">43,186</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">126,540</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Accounts payable and accrued liabilities &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">47,541</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">157,088</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Net cash used in operating activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(386,474</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(69,837</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from issuance of short-term debt &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from sale of common stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">2,056,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Net cash provided by financing activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">2,056,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">350,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Impact on cash from foreign currency translation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">32,314</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">3,389</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">NET INCREASE IN CASH</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,669,526</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">280,163</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">CASH AT BEGINNING OF PERIOD</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">141,659</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">11,882</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">CASH AT END OF PERIOD</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">1,843,499</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">295,434</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash paid for income taxes</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash paid for interest expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px; TEXT-INDENT: 0in">NONCASH INVESTING AND FINANCING ACTIVITIES:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0in">Issuance of common stock for conversion of short-term debt &#8211; related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak47f70494-d9e3-4901-870d-c107896b526c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">96</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO, INC.</b></p>
<p style="MARGIN: 0px" align="center"><b><a name="NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></b></p>
<p style="MARGIN: 0px" align="center"><b>(UNAUDITED)</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 1</u></b><b> &#8211; ORGANIZATION AND BASIS OF PRESENTATION</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Organization</i></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">INmune Bio, Inc. (the &#8220;Company&#8221; and/or &#8220;INmune&#8221;) was originally organized in the State of Nevada on September&nbsp;25, 2015 and is an early stage specialty pharmaceutical company focused on developing pioneering strategies for oncology that focus on engineering and harnessing the innate immune system to treat the patient&#8217;s cancer. INmune&#8217;s proprietary is to focus on the innate immune system that include natural killer cells (&#8220;NK cells&#8221;), myeloid derived suppressor cells (&#8220;MDSC cells&#8221;) and dendritic cells (&#8220;DC cells&#8221;), which are believed to offer unique therapeutic opportunities and may be safer, easier to execute, and more effective than currently available treatments. INmune plans to develop their two existing drug platforms: INKmune (&#8220;INKmune&#8221;) which primes NK cells and INB03 (&#8220;INB03&#8221;) which down regulates MDSC cells. Together or individually, the Company expects that these therapies will harness the innate immune system to provide a unique set of therapies for patients with cancer. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">INmune Bio International Ltd (England) (&#8220;INmune UK&#8221;) is a wholly owned subsidiary of INmune that was formed on April 6, 2016 in the United Kingdom (&#8220;UK&#8221;). Inmune UK was duly organized under the laws of England and has 1,000 shares owned by INmune. The Company will perform its drug manufacturing and currently performs its drug research and development and will continue to perform research and development activities in this region. The UK has an R&amp;D rebate program that allows the Company to recover some of its R&amp;D expenses (see further discussion in Note 4).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Basis of Presentation and Principles of Consolidation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying consolidated financial statements of the Company have been prepared in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) in the United States of America and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The consolidated financial statements herein have been prepared in accordance with GAAP and include the accounts of the Company and those of its wholly-owned subsidiary, INmune UK. All significant intercompany accounts and transactions have been eliminated.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Interim Financial Statements</i></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information under Regulation S-K. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2017 may not necessarily be indicative of the results that may be expected for the year ending December 31, 2017. These unaudited interim financial statements should be read in conjunction with the audited financial statements of the Company for the years ended December 31, 2016 and 2015, and notes thereto contained in this prospectus.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 2</u></b><b> &#8211; GOING CONCERN</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of September 30, 2017, the Company had an accumulated deficit of $729,610. Losses have principally occurred as a result of the substantial resources required for research and development of the Company&#8217;s products which included the general and administrative expenses associated with its organization and product development as well as the lack of sources of revenues until such time as the Company&#8217;s products are commercialized. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern from the issuance date of these financial statements. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management plans to obtain additional funding and implement its strategic plan to allow the opportunity for the Company to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak4b2b2dda-d599-4ba8-9b2f-b20466396c76" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">97</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 3</u></b><b> &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Use of Estimates</i></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">Preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management&#8217;s estimates and assumptions.</p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Account Receivable, Net</i></b></p>
<p style="MARGIN: 0px; TEXT-INDENT: -1.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Receivables currently consist of R&amp;D tax credit receivable, VAT receivable and Joint development cost receivable. The R&amp;D tax credit receivable is recorded when R&amp;D is incurred. At that time, the Company sets up a receivable for the credit it expects to receive based on the expenses it has incurred. The VAT receivable is recorded when the Company receives an invoice with VAT related to it. The receivable is set up for the amount expected to be returned when the VAT tax return is filed. The Joint development cost receivable is set up when the Company incurs R&amp;D expenses based on the amount is expects to receive as a reimbursement per the Novamune agreement (see Note 4 for detailed explanation of the agreement.) The collectability of these receivables are evaluated periodically based on the actual R&amp;D credit returns submitted, the VAT returns submitted and the amounts received from Novamune. As of September 30, 2017 and 2016, there were no trade receivables.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Intangible Assets</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company capitalizes costs incurred in connection with in process research and development purchased from others if the asset has alternative uses and such uses are not restricted under applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line as intangible assets. The Company amortizes these assets using the straight-line method over the estimated useful lives of the patents, generally five to 15 years. Other intangibles, consisting of trademarks and copyrights, if any, are considered to have indefinite lives and are not amortized but reviewed for impairment annually, or sooner under certain circumstances.</p><i></i>&nbsp;
<p style="MARGIN: 0px"><b><i>Basic and Diluted Loss per Share </i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of September 30, 2017 and 2016, the Company excluded 31,667 and 0, respectively, of potentially issuable shares related to warrants due to their anti-dilutive effect. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stock-Based Compensation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company records the fair value of stock options issued to its employees as of the grant date as compensation expense. The Company recognizes compensation expense, net of forfeitures, on a straight-line basis over the requisite service period, which is equal to the applicable vesting period.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company accounts for equity instruments issued to non-employees using a fair value approach under ASC Subtopic 505-50, <i>Equity-Based Payments to Non-Employees</i>. The Company values equity instruments and stock options granted using the Black-Scholes option-pricing model. The value of non-employee stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the term of the related financing or the period over which services are received.</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak2bd3202f-cd78-4f30-a810-ba59571deaca" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">98</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Research and Development</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Research and development costs are expensed as incurred. Research and development credits are recorded by the Company as a reduction of research and development costs. Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Income Taxes</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Foreign Currency</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company accounts for its foreign currency transaction gains and losses as other comprehensive income (loss) included in equity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>New and Recently Issued Accounting Pronouncements </i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard&#8217;s core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating its adoption method and the impact of the standard on its consolidated financial statements and has not yet determined the method by which the Company will adopt the standard in 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">In April 2016, the FASB issued ASU No. 2016-10, &#8220;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&#8221; (Topic 606). In March 2016, the FASB issued ASU No. 2016-08, &#8220;Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)&#8221; (Topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, &#8220;Revenue from Contracts with Customers&#8221;. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company does not expect the new standard to have a material effect on its consolidated financial statements.</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 2pt" align="justify">
<table id="pagebreakaa746c25-aae5-48b3-b00e-8471f07a5336" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">99</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In April 2016, the FASB issued ASU No. 2016-09, &#8220;Compensation &#8211; Stock Compensation&#8221; (Topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company has adopted this standard effective January 1, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221; (&#8220;ASU 2016-15&#8221;). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its financial position, results of operations, or cash flows.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Subsequent Events</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has evaluated all transactions from September 30, 2017 through November 30, 2017, the financial statement issuance date for subsequent disclosure consideration.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>NOTE 4</u></b><b> &#8211; </b><b>RESEARCH AND DEVELOPMENT ACTIVITY</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company incurred $167,006 and $73,329 research and development costs during the nine months ended September 30, 2017 and 2016, respectively. During the three months ended September 30, 2017 and 2016, the Company incurred $46,320 and $27,565, respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In addition, the Company is allowed a R&amp;D tax credit which is a corporation tax relief that reduces a company&#8217;s tax bill in the UK for expenses incurred in R&amp;D. According to the UK Government, R&amp;D takes place when a project seeks to achieve an advance in overall knowledge or capability in a field of science or technology. A company has to have staff headcount of less than 500 and either revenue of less than &#8364;100m or a balance sheet total of less than &#8364;86m. INmune UK will receive a R&amp;D Credit for research and development expenses incurred in 2017, a receivable has been accrued in the amount of $40,487 as of September 30, 2017 and $68,866 as of December 31, 2016. During the nine months ended September 30, 2017 and 2016, the Company received $106,096 and $0, respectively, related to R&amp;D expenses submitted for the UK R&amp;D tax credit.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company is also eligible to recover all VAT for all R&amp;D expenses paid. INmune UK recorded a VAT Receivable for in the amount of $131,821 as of September 30, 2017 for VAT paid to date during 2017 that will be reimbursed and $35,239 as of December 31, 2016. During the nine months ended September 30, 2017 and 2016, the Company received $36,890 and $0, respectively, related to VAT submitted for reimbursement. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 3, 2016, the Company entered into a joint development agreement with Novamune, Inc. (&#8220;Novamune&#8221;) (the &#8220;Development Agreement&#8221;). Novamune has previously developed and licensed technology relating to ex-vivo activation of NK cells for the treatment of cancer and other diseases. The parties have agreed to exclusively collaborate on the further development of technologies related to NK cells for therapeutic applications. The parties will designate specific development projects which will be undertaken by the party with appropriate expertise. The Company and Novamune will share equally in the costs related to such joint development projects and will jointly own any intellectual property developed by the joint projects, provided that Novamune shall have an exclusive royalty free license to use any such intellectual property relating to ex-vivo applications and the Company shall have an exclusive royalty free license to use any such intellectual property relating to in-vivo applications. The Development Agreement is subject to Novamune investing a total of $1,250,000 in the Company, of which $350,000 has previously been advanced. The balance of $900,000 shall be invested in the Company on the earlier of (i) December 31, 2017, or (ii) 60 days after the Company becomes publicly traded. As of September 30, 2017 and December 31, 2016, the Company had a Joint Development Receivable of $84,733 and $156,381, respectively. During the nine months ended September 30, 2017 and 2016, the Company received $150,000 and $0, respectively, related to R&amp;D expenses submitted for reimbursement under the Development Agreement.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three and nine months ended September 30, 2017 and 2016, no sales had occurred under the INKmune license agreement.</p>
<p style="MARGIN: 0px" align="justify"><font color="#f52887"> &nbsp; </font></p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakfb0bba8f-f801-48ed-8933-f77820f0d799" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">100</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 5 &#8211; LOANS PAYABLE</u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">During the nine months ended September 30, 2017, the Company issued 233,345 shares of the Company&#8217;s common stock for the conversion of the full value of the Company&#8217;s outstanding convertible debt of $350,000. As of September&nbsp;30, 2017 and December 30, 2016, the Company had outstanding short-term debt &#8211; related party of $0 and $350,000, respectively.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Accounts Payable &#8211; Related Party</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of September 30, 2017, the Company had outstanding amounts due to a related party for travel expenses incurred of $10,609 in Inmune UK. In addition, the Company had $50,033 of outstanding amounts due to University College London for research and development expenses. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>NOTE 6</u></b><b> &#8211; STOCKHOLDERS&#8217; EQUITY</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company is authorized to issue up to 210,000,000 shares of common stock at par value $0.001 per share. As of September 30, 2017 and December 31, 2016, the Company had 6,963,347 and 5,066,667, respectively of the Company&#8217;s common stock issued and outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During 2016, the Company received $100,000 to issue 66,667 shares of the Company&#8217;s common stock. This amount was held in escrow until the issuance of the related shares in early 2017 and recorded as restricted cash as of December&nbsp;31, 2016. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of September 30, 2017 and December 31, 2016, the Company recorded an accrued settlement liability of $50,000 for 33,335 common shares related to a legal settlement (see further discussion in Note 7). </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In 2017, the Company issued 1,393,335 shares of its common stock for total cash proceeds of $2,056,000 and warrants to purchase 31,667 shares of the Company&#8217;s common stock were issued to a third party as compensation for investment banking services related to the sales of common stock. In addition, the Company issued 233,345 shares of the Company&#8217;s stock for the conversion of the full value of the Company&#8217;s outstanding convertible debt (converted at no interest) of $350,000. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the private placement offering, the Company agreed to file a registration statement under the Securities Act of 1933 within five months after the final closing of the offering and will seek to have such registration statement declared effective within six months of filing registering the shares of common stock in the offering. Upon the effectiveness of the registration statement, each investor in the offering agreed not to sell shares of common stock purchased in the offering for a period of at least six months from the effective date of such registration statement. If the Company fails to meet either of the registration deadlines, each investor will be entitled to receive a cash payment in the amount of 1% of the amount of the investment for each month that a registration deadline is not met, up to a maximum of 12%. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of September 30, 2017 and December 31, 2016, the Company had $30,000 and $30,000, respectively, of outstanding stock payable due to its law firm for 20,000 shares of the Company&#8217;s common stock valued at $1.50 per share based on the value of the services provided.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Warrants</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">During 2017, the Company issued fully vested warrants to purchase 31,667 shares of the Company&#8217;s common stock to a third party in conjunction with the common stock sold for cash (see discussion of common stock issuances above), with an exercise price of $1.50, maturity date of June 30, 2022, and fair value of $36,922 using the Black-Scholes option-pricing model which were recorded as stock-based compensation and additional paid in capital.</p>
<p style="MARGIN: 0px">
<table id="pagebreak2d012551-a744-46a8-9107-073d78536217" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">101</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The assumptions used for the warrants granted during the nine months ended September 30, 2017 are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Nine Months Ended September</b>&nbsp;<b>30,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b> </p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Exercise price</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.50</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Expected dividends</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Expected volatility</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">106.55</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Risk free interest rate</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.89</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Expected life of warrant</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">5 years</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The following is a summary of the Company&#8217;s warrant activity:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of</b></p>
<p style="MARGIN: 0px" align="center"><b>Warrants</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Weighted</b></p>
<p style="MARGIN: 0px" align="center"><b>Average</b></p>
<p style="MARGIN: 0px" align="center"><b>Exercise Price</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Weighted</b></p>
<p style="MARGIN: 0px" align="center"><b>Average Life</b></p>
<p style="MARGIN: 0px" align="center"><b>Remaining</b></p>
<p style="MARGIN: 0px" align="center"><b>(years)</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px"><b>Outstanding and exercisable &#8211; December 31, 2016</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Forfeited</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Granted</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">31,667</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1.50</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">4.9</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px"><b>Outstanding and exercisable &#8211; September 30, 2017</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">31,667</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">1.50</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">4.9</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The aggregate intrinsic value of the outstanding warrants was $0.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>NOTE 7</u></b><b> &#8211; COMMITMENTS AND CONTINGENCIES</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In November 2016, an individual filed an action in Cook County, Illinois, against the Company, David J. Moss, its Chief Financial Officer, Treasurer, Secretary and a member of its board of directors, Raymond J. Tesi, its president and Chief Executive Officer (the Company, Mr. Moss and Mr. Tesi are referred to collectively as the &#8220;Company Parties&#8221;). The action alleged claims against the Company Parties concerning payment of monies and/or securities allegedly owed. In April 2017, the Company Parties and the Claimant entered into a Settlement Agreement and Mutual General Release agreement with that individual (the &#8220;Settlement Agreement&#8221;). Pursuant to the settlement agreement, the Company issued 33,335 shares of the Company&#8217;s common stock valued at $50,000, based on the value of the stock of the last round of financing of $1.50 per share. These shares are held by the Company subject to a restriction on transfer for a period of two years from the date the Company completes an initial public offering or otherwise becomes a public company after which the Company will deliver the shares to the Claimant. The agreement to issue the shares was a full and complete settlement of all claims that the Claimant may have had against the Company Parties and the Cook County action was dismissed with prejudice. The obligation was recorded as accrued settlement liability as of December 31, 2016, pending delivery of the shares to the Claimant after the restriction period expires.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During the nine months ended September 30, 2017, the Company received notice that another company had filed trademark application with the United States Patent and Trademark Office to register a certain trademark. The Company filed an opposition in the United States Trademark Trial and Appeal Board. Subsequently, INmune and this company entered into a settlement agreement pursuant to which the Company agreed not to oppose the company&#8217;s trademark and the company paid INmune cash proceeds of $150,000 in full consideration for the settlement agreement that were accounted for as income from a lawsuit settlement on the income statement.<font color="#f52887"> </font></p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak7c1a673f-a119-418c-8200-7ae1faf96b83" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">102</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>NOTE 8</u></b><b> &#8211; SUBSEQUENT EVENTS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 3, 2017, the Company entered into a license agreement with Xencor, Inc., which has discovered and developed a proprietary biological molecule that inhibits soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license in licensed patent rights, licensed know-how and licensed materials (as defined in the license agreement) to make, develop, use, sell and import any pharmaceutical product that comprises, contains, or incorporates Xencor&#8217;s proprietary protein known as &#8220;XPRO1595&#8221; that inhibits soluble tumor necrosis factor (or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or in combination with one or more active ingredients, in any dosage or formulation. The Company believes the protein has numerous medical applications. In connection with the license agreement, the Company paid Xencor a one-time non-creditable and non-refundable fee of $100,000 and agreed to issue Xencor shares (&#8220;Initial Shares&#8221;) of the Company&#8217;s common stock equal to 19% of our fully diluted company shares the value of which are discussed below.&nbsp;The Company also issued warrants to Xencor which is discussed below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company also agreed to pay Xencor a royalty of 5% on Net Sales of all Licensed Products in a given calendar year, which are payable on a country-by- country and licensed product by licensed product basis until the date that is the later of (a) the expiration of the last to expire valid claim covering such Licensed Product in such country or (b) ten years following the first sale to a third party of the licensed product in such country. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Under the license agreement, the Company also agreed to pay Xencor a percentage of any sublicensing revenue that it receives equal to (i) 60% of sublicensing revenue received in respect of any sublicense granted prior to initiation of a Phase 1 Clinical Trial of a Licensed Product in the applications for the treatment of disease in humans (the &#8220;Field&#8221;); (ii) 30% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 1 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field; (iii) 15% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 2 Clinical Trial of a Licensed Product in the Field and prior to initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field; (iv) 10% of Sublicensing Revenue received in respect of any sublicense granted on or after initiation of a Phase 3 Clinical Trial of a Licensed Product in the Field and prior filing of the first NDA application for any Licensed Product in the Field; and (v) 5% of Sublicensing Revenue received in respect of any sublicense granted on or after the approval of the first NDA application for any Licensed Product in the Field. For clarity, initiation of a clinical trial shall mean dosing of a first patient in said clinical trial. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the License Agreement, the Company entered into a stock issuance agreement with Xencor pursuant to which it agreed to issue Xencor 1,585,000 shares of its common stock with a fair value of $12,221,000 based on the discounted cash flow method of the income approach as set forth in an independent valuation report from HSSK LLC dated October 3, 2017, and fully vested warrants to purchase an additional number of shares of common stock equal to 10% our the fully diluted company shares immediately following such purchase with a fair value of $4,193,000 based on Black-Scholes Option Pricing Model. The warrants have an exercise price based on a valuation of the Company at $100,000,000 and expire on October 3, 2023. The aggregate purchase price for the full exercise of the option to Acquire Additional Shares is $10,000,000 which purchase price shall be pro-rated for any partial exercise of the Option for less than 10% of the fully diluted company shares immediately following such purchase. The purchase price for the additional shares may be paid by cash or by way of a cashless exercise. In connection with the stock issuance agreement, the Company, Xencor and more than 90% of shareholders as of September 30, 2017 (&#8220;Key Holders&#8221;) entered into a voting agreement. Pursuant to the voting agreement, Xencor and the Key Holders agreed to vote their respective shares to vote one individual designated by the holder of a majority of Xencor&#8217;s shares of the Company&#8217;s common stock to the Company&#8217;s board of directors. The voting agreement shall continue in full force and effect from the date hereof through the earliest of the following dates, on which date it shall terminate in its entirety: (a) the date of a qualified offering, as defined in the issuance agreement; (b) ten (10) years from the date of this Agreement; (c) the date of the closing of a qualified sale, as defined in the issuance agreement; or (d) the date as of which the parties hereto terminate this agreement by written consent of the holders of a majority of the Investor Shares.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recorded $16,514,000 for the acquisition of intangible assets in the fourth quarter of 2017 as the fair value of the cash, stock and warrants on the date of acquisition in accordance with Accounting Standards Codification 730 &#8211; <i>Research and Development</i>.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures LLC. Pursuant to the Assignment and Assumption Agreement, Immune Ventures assigned all of its rights, obligations and liabilities under the Exclusive License Agreement between the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education and Immune Ventures. Pursuant to the Assignment and Assumption Agreement, the Company agreed to convert the amount Immune Ventures paid of $31,640 into INmune common stock at $1.50 per share for 21,094 shares for the reimbursement of amounts paid by the Assignor to the University of Pittsburg. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakaf1716ec-62e2-468c-8b66-2f4416496e29" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">103</p></td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#INDEX TO 2">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Up to SHARES OF COMMON STOCK</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PROSPECTUS</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">_______________, 2017</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak876d3ab7-04f4-4d02-8863-7d3851fe1848" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">104</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Alternate Prospectus</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font color="red">The information in this prospectus is not complete and may be changed. The Selling Stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted</font></p>
<p style="MARGIN: 0px"><font color="red"></font>&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-TOP: 1px solid" valign="top" width="33%"><font color="red"></font></td>
<td style="BORDER-TOP: 1px solid" valign="top" width="34%"><font color="red"></font></td>
<td style="BORDER-TOP: 1px solid" valign="top" width="33%">
<p style="MARGIN: 0px" align="right"><font color="red"></font>&nbsp;</p></td></tr>
<tr height="15">
<td valign="top" width="33%">
<p style="MARGIN: 0px"><font color="red">PRELIMINARY PROSPECTUS<font size="3"></font></font></p></td>
<td valign="top" width="34%">
<p style="MARGIN: 0px" align="center"><font color="red">SUBJECT TO COMPLETION <font size="3"></font></font></p></td>
<td valign="top" width="33%">
<p style="MARGIN: 0px"><font color="red">DATED __, 2017</font><font size="3"></font></p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="33%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="34%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="33%"></td></tr></table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>1,693,334&nbsp;Shares</b></p>
<p style="MARGIN: 0px" align="center"><b>Common Stock<font size="3"></font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">This prospectus relates to the public offering of up to&nbsp;1,693,334 shares of common stock, par value $.001 per share (&#8220;Common Stock&#8221;), of INmune Bio, Inc. being offered by Selling Stockholders named in this prospectus for their own account. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">This is the initial registration of shares of our Common Stock. Selling stockholders will offer their respective shares at a fixed price of per share until our common shares are quoted on the Over-the-Counter Bulletin Board or national securities exchange, and thereafter, at prevailing market prices or privately negotiated prices. We will not receive any of the proceeds from the sale of those shares being sold by the selling stockholders. We will pay the expenses of registering these shares.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Our Common Stock is not traded on any national securities exchange and is not quoted on any over-the-counter market. Our Common Stock is not traded on any national securities exchange and is not quoted on any over-the-counter market. We intend to list our common stock on a national stock market however, there no assurance that our application will be approved. If our shares become listed on a national securities exchange, sales will be made at prevailing market prices or privately negotiated prices.<font size="3"></font></p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The selling stockholders are offering these shares of Common Stock. The selling stockholders will receive all proceeds from the sale of the Common Stock. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution.&#8221;<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, and we have elected to comply with certain reduced public company reporting requirements. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.<font size="3"></font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak7de6adde-0cbf-4916-9756-894252d907a2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">105</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font size="3"></font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2017.<font size="3"></font></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">You should rely only on the information contained in this prospectus. We have not authorized any dealer, salesperson or other person to provide you with information concerning us, except for the information contained in this prospectus. The information contained in this prospectus is complete and accurate only as of the date on the front cover page of this prospectus, regardless when the time of delivery of this prospectus or the sale of any common stock. We may not sell the securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, our common stock in any jurisdiction in which the offer or sale is not permitted.<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak92bc4c61-9d10-4cfc-98b8-51de2ca77e61" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">106</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Table of Contents</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Prospectus Summary<font size="3"></font></p></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="center">108</p></td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Risk Factors<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">13</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Use of Proceeds<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">36</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Forward-Looking Statements<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">7</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Selling Stockholders<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">109</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Plan of Distribution<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">110</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Market for Common Equity and Related Stockholder Matters<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Description of Business<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">59</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Description of Property<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Legal Proceedings<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Directors and Executive Officers<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">71</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Executive Compensation<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Certain Relationships and Related Transactions<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">74</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Security Ownership of Certain Beneficial Owners and Management<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">75</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Description of Securities<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Indemnification for Securities Act Liabilities<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">76</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Legal Matters<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">77</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Experts<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Changes in Accountants<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Additional Information<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">80</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Financial Statements<font size="3"></font></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="left">&nbsp;
<table id="pagebreakb803d8e8-ace5-4f24-aec9-98ea3c1aec8c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">107</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the common stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any common stock in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.<font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="20%">
<p style="MARGIN: 0px" align="left">Shares of Common Stock offered by the selling stockholders:</p></td>
<td valign="top" width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">2,2226,444 Shares of Common Stock </p></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Risk factors:</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">An investment in our Ordinary Shares involves a high degree of risk. You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the &#8220;Risk Factors&#8221; section beginning on page __ of this prospectus before deciding whether or not to invest in our Common Stock.</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Market for our Ordinary Shares:</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Our Common Stock is not currently traded in a public marketplace. We intend to apply to list our Common Stock on national exchange or marketplace. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Use of Proceeds</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">This prospectus relates to shares of our Common Stock that may be offered and sold from time to time by the selling stockholders. We will not receive any of the proceeds resulting from the sale of the shares held by the selling stockholders.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>FORWARD-LOOKING STATEMENTS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">This prospectus contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements reflect our current view about future events. When used in this prospectus, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward&#8211;looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize new and improved products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors (including the risks contained in the section of this prospectus entitled &#8220;Risk Factors&#8221;) relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;
<table id="pagebreak86a7352f-1e54-49ec-acfd-6875d88781e1" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">108</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SELLING STOCKHOLDERS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The table below sets forth information concerning the resale of the shares of common stock by the selling stockholders. The selling stockholders obtained their share in a private placement (the &#8220;Private Placement&#8221;) of units (&#8220;Units&#8221;) conducted by the Company. Each Unit consisted of 6,667 shares of Common Stock. The offering terminated on June 30, 2017. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table also sets forth the name of each person who is offering the resale of shares of Common Stock by this prospectus, the number of shares of common stock beneficially owned by each person, the number of shares of common stock that may be sold in this offering and the number of shares of common stock each person will own after the offering, assuming they sell all of the shares offered. Except as indicated below, the selling stockholders have not held any position or office or had any other material relationship with us or any of our predecessors or affiliates within the past three years.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="FONT-SIZE: 10pt; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-ALIGN: justify" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Name of Selling Stockholder</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of Share of Common Stock Beneficially Owned Prior to Offering</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of Shares of Common Stock Being Offered</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of Shares of Common Stock Beneficially Owned After the Offering</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Percentage of Ownership After the Offering (1)(2)</b><font size="3"></font></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Andre H. Forrester</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">William Strawbridge</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Brett Maas</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Brett Nesland</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">50,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">50,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">BWL Investments Ltd.</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">CTI Holdings, Inc.</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">166,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">166,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Daniel Melrod</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">David Peretz</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">13,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">13,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Don Stangle</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">150,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">150,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Donald Weaver</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">10,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">10,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Francis A. Nardella </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Galakatos Living Trust</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">20,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="left">George Todd, Trustee of the George Todd Revocable Trust dated February 10, 2017</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">James G. Athas</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Jason Paul</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Joseph M. Lobacki</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Kenneth M. Sutin, M.D. Revoc Trust</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Kinsale SCT Holdings Limited</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Lawrence A. Pabst</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Lawrence A Pabst</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Lincoln Park Capital Fund, LLC</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">333,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">333,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Linda Powers</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">300,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">300,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Malibu Investments Limited</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">6,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,678</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Nicholas Carosi III Revocable Living Trust dated October 3, 1984</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Peter E. Lengyel</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">RNE Partners LLC</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Robert B. Prag</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">33,333</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">Ronald Rech</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">Timothy J. Alpers</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">66,667</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td></tr></table>
<p style="MARGIN: 0px" align="justify">____________</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">(1)</td>
<td valign="top">
<p style="MARGIN: 0px">Applicable percentage ownership is based on 8,363,345 shares of common stock outstanding as of October 30, 2017, together with securities exercisable or convertible into shares of common stock within 60 days of October 30, 2017 for each stockholder. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock that are currently exercisable or exercisable within 60 days of October 30, 2017 are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.</p></td></tr>
<tr>
<td valign="top">(2)</td>
<td valign="top">Assumes all shares offered hereby are sold.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak005ad680-cf4e-449c-beef-a399e0861a92" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">109</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PLAN OF DISTRIBUTION</b> </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">No market currently exists for our shares. The price reflected in this prospectus of $&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share is the initial offering price of the shares of Common Stock upon the effectiveness of the registration statement of which this prospectus forms a part. We intend to list our common stock on a national stock market however, there no assurance that our application will be approved. The selling stockholders may, from time to time, sell any or all of their shares of common stock covered by this prospectus in private transactions at a price or on any stock exchange, market or trading facility on which the shares may then be traded. The term &#8220;selling stockholders&#8221; includes donees, pledgees, transferees or other successors-in-interest selling shares received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other non-sale related transfer. We will pay the expense incurred to register the shares being offered by the selling stockholders for resale, but the selling stockholders will pay any underwriting discounts and brokerage commissions associated with these sales. The selling stockholders may use any one or more of the following methods when selling shares:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%"><font style="FONT-FAMILY: Symbol">&#183;</font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font face="Symbol">&#183;</font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font face="Symbol">&#183;</font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">privately negotiated transactions; and</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top"><font face="Symbol">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></font></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">a combination of any such methods of sale.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The selling stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), if available, rather than under this prospectus. The selling stockholder shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if they deem the purchase price to be unsatisfactory at any particular time.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The selling stockholders or their pledgees, donees, transferees or other successors in interest, may also sell the shares directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling stockholder and/or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. It is possible that a selling stockholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at a price per share which may be below the then market price. The selling stockholders cannot assure that all or any of the shares offered in this prospectus will be sold by the selling stockholders. The selling stockholders and any brokers, dealers or agents, upon effecting the sale of any of the shares offered in this prospectus, may be deemed to be &#8220;underwriters&#8221; as that term is defined under the Securities Act, or the Securities Exchange Act of 1934, as amended, or the rules and regulations under such acts. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakb517fdbf-594d-47fa-8381-be62f1fd869f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">110</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share offering price of the shares of Common Stock being sold under this prospectus has been arbitrarily set. The price does not bear any relationship to our assets, book value, earnings or net worth and it is not an indication of actual value. Additionally, the offering price of our shares is higher than the price paid by our founders, and exceeds the per share value of our net tangible assets. Therefore, if you purchase shares in this offering, you will experience immediate and substantial dilution. You may also suffer additional dilution in the future from the sale of additional shares of common stock or other securities, if the need for additional financing forces us to make such sales. Investors should be aware of the risk of judging the real or potential future market value, if any, of our common stock by comparison to the offering price. </p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are required to pay all fees and expenses incident to the registration of the shares but excluding brokerage commissions or underwriter discounts.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The selling stockholders, alternatively, may sell all or any part of the shares offered in this prospectus through an underwriter. No selling stockholder has entered into any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered into.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The selling stockholders may pledge their shares to their brokers under the margin provisions of customer agreements. If a selling stockholder defaults on a margin loan, the broker may, from time to time, offer and sell the pledged shares. The selling stockholders and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations under such act, including, without limitation, Regulation M. We have informed the selling stockholders that, during such time as they may be engaged in a distribution of any of the shares we are registering with the U.S. Securities Exchange Commission, they are required to comply with Regulation M. In general, Regulation M precludes the selling stockholders, any affiliated purchasers, and any broker-dealer or other person who participates in a distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase, any security which is the subject of the distribution until the entire distribution is complete. Regulation M defines a &#8220;distribution&#8221; as an offering of securities that is distinguished from ordinary trading activities by the magnitude of the offering and the presence of special selling efforts and selling methods. Regulation M also defines a &#8220;distribution participant&#8221; as an underwriter, prospective underwriter, broker, dealer, or other person who has agreed to participate or who is participating in a distribution.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If the selling stockholder notifies us that it has a material arrangement with a broker-dealer for the resale of the common stock, then we would be required to amend the registration statement of which this prospectus is a part, and file a prospectus supplement to describe the agreements between the selling stockholder and the broker-dealer.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak6e893c49-e468-45e4-b344-5ac780bfc430" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">111</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">INMUNE BIO INC.</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">SHARES OF COMMON STOCK</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Prospectus</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">, 2017</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak1a294dc2-9631-457e-aeb5-935cb2bc5821" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">112</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PART II</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table sets forth the costs and expenses payable in connection with the sale of the shares of common stock being registered. The registrant will pay all expenses of the registration and sale of the shares of common stock, other than selling commissions and fees, stock transfer taxes and fees and expenses, if any, of counsel or other advisors to the selling stockholders. All of the amounts shown are estimates except the SEC registration fee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The following table sets forth an itemization of all estimated expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="87%">
<p style="MARGIN: 0px"><b>Nature of Expense:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="10%" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Amount</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">SEC Registration Fee </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">$</p></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">FINRA filing fee</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">Accounting fees and expenses </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">*</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">Legal fees and expenses </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">*</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">Transfer agent&#8217;s fees and expenses</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">Printing and related fees</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">Miscellaneous</p></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">
<p style="MARGIN: 0px" align="right">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">*</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="bottom" width="87%">
<p style="MARGIN: 0px">Total </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">$</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td></tr></table>
<p style="MARGIN: 0px">___________</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">*</td>
<td valign="top">Estimated</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">We are a Nevada corporation, and accordingly, we are subject to the corporate laws under the Nevada Revised Statutes. Our Articles of Incorporation provide that we may indemnify our officers, directors, employees, agents and any other persons to the maximum extent permitted by the NGCL.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Such indemnification provision may be sufficiently broad to permit indemnification of our executive officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act. We do not currently carry directors&#8217; and officers&#8217; liability insurance covering our directors and officers, but we have plans to do so. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. No pending material litigation or proceeding involving our directors, executive officers, employees or other agents as to which indemnification is being sought exists, and we are not aware of any pending or threatened material litigation that may result in claims for indemnification by any of our directors or executive officers. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">From March 2017 through June 30, 2017, we sold an aggregate 1,693,333 to accredited investors at a per unit price of $10,000 with each unit consisting of 6,667 shares of our common stock and received gross proceeds 2,540,000. Investors participating in the unit offering met the accredited investor definition of Rule 501 of the Securities Act. The offer and sale of the units were made in reliance on the exemption from registration afforded under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act. The unit offering was not conducted in connection with a public offering, and no public solicitation or advertisement was made or relied upon by the investors in connection with the Unit Offering. In April 2017, the Company issued 33,335 shares of its restricted common stock pursuant to a Settlement Agreement and Mutual Release Agreement. The Shares were issued in reliance on the exemption from registration afforded under Section 4(a)(2) of the Securities Act. </p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakc6bb897a-6df7-43ac-a06c-115c8dd90a41" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">113</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(a) Exhibits</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">A list of exhibits filed herewith is contained in the exhibit index that immediately precedes such exhibits and is incorporated herein by reference.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(b) Financial Statement Schedules</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">See page F-1 for an index of the financial statements and financial statement schedules included in this Registration Statement.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>ITEM 17. UNDERTAKINGS.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(a) The undersigned registrant hereby undertakes:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(1)</td>
<td valign="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">To include any prospectus required by Section 10(a)(3) of the Securities Act;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(ii)</td>
<td valign="top">To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price, set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iii)</td>
<td valign="top">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</td></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>provided</i>,<i> however</i>, that the information required to be included in a post-effective amendment by paragraphs (a)(1)(i), (a)(1) (ii) and (a)(1) (iii) above may be contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(2)</td>
<td valign="top">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(3)</td>
<td valign="top">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(4)</td>
<td valign="top">That, for the purpose of determining liability under the Securities Act to any purchaser:</td></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak92616425-4a00-4fbf-b011-58c60f90be08" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">114</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(ii)</td>
<td valign="top">each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) (&#167;230.415(a)(1)(i), (vii), or (x)) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in this registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of this registration statement relating to the securities in this registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of this registration statement or made in a document incorporated or deemed incorporated by reference into this registration statement or prospectus that is part of this registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in this registration statement or prospectus that was part of this registration statement or made in any such document immediately prior to such effective date;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described above, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak1dc8bc8d-8c36-4965-99e7-7d64912d0b19" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">115</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of La Jolla, State of California, on this _____ day of ______, 2017.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="50%"></td>
<td valign="top" width="35%">
<p style="MARGIN: 0px">INMUNE BIO INC.</p></td>
<td width="15%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td></td>
<td>&nbsp;</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">&nbsp;</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">David Moss</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">Chief Financial Officer</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates stated. Each person whose signature appears below hereby constitutes and appoints Raymond J. Tesi and David Moss, or any of them, as such person&#8217;s true and lawful attorney-in-fact and agent with full power and substitution for such person and in such person&#8217;s name, place and stead, in any and all capacities, to sign and to file with the Securities and Exchange Commission, any and all amendments and post-effective amendments to this Registration Statement, with exhibits thereto and other documents in connection therewith, including any registration statements or amendments thereto filed pursuant to Rule 462(b) under the Securities Act, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any substitute therefor, may lawfully do or cause to be done by virtue thereof.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="35%">
<p style="MARGIN: 0px" align="center"><b>Signature</b></p></td>
<td valign="bottom" width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="center"><b>Title</b></p></td>
<td valign="bottom" width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="20%">
<p style="MARGIN: 0px" align="center"><b>Date</b></p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">Raymond J. Tesi, M.D.</p></td>
<td valign="bottom"></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">President, Chief Executive Officer and Director</p>
<p style="MARGIN: 0px" align="center"><i>(Principal Executive Officer)</i></p></td>
<td valign="bottom"></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid"></td>
<td></td>
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">David J. Moss</p></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="center">Chief Financial Officer, Treasurer, Secretary and Director</p>
<p style="MARGIN: 0px" align="center"><i>(Principal Financial and Accounting Officer)</i></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid"></td>
<td></td>
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">Mark Lowdell, Ph.D.</p></td>
<td></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="center">Chief Scientific Officer</p></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td></td>
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="top"></td>
<td></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">Timothy Schroder</p></td>
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">Director</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">Edguardo Baracchini</p></td>
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">Director</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top"></td>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">J. Kelly Ganjei</p></td>
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">Director</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">, 2017</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak80fb5e48-3843-47d1-9979-947911559e5c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">116</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#TOC_1">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>EXHIBIT INDEX</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="6%">
<p style="MARGIN: 0px" align="left"><b>Exhibit No.</b></p></td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Description of Exhibit</b></p></td></tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">3.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Certificate of Incorporation</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">3.2</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Bylaws</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">5.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Opinion of Sichenzia Ross Ference Kesner , LLP as to the legality of the securities being offered*</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">10.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Form of Subscription Agreement*</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">10.2</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Form of Selling Stockholders Subscription Agreement</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">10.3</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">INmune Bio, Inc. 2017 Stock Incentive Plan</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">21.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Subsidiaries</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">23.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Consent of Sichenzia Ross Ference Kesner LLP (contained in Exhibit 5.1)*</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">23.2</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">Consent of Auditor </p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>&nbsp;</td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px">24.1</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px">Power of Attorney (included in signature pages)</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">&nbsp;*To be filed by amendment. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">117</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<html><head><title>inmune_ex31.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 3.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img19.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd08917cc-4e81-4fb2-9e2e-a7d4c60c7753" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img20.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak002fc71a-3397-42a3-9d73-ae77764f4420" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img21.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak20247122-df74-42b0-997c-094c00381bf4" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img22.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak1bbb6b98-faf0-460d-a2cb-1705318a11bd" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img23.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakbdecbef7-44cd-429a-b77c-5667f78e35b3" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img24.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak485ddf53-4032-4e91-9297-b2f6ff3ab788" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img25.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak8f2ed0ab-0ce3-4d40-b93d-873745d707ee" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img26.jpg">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreake0b39d61-ad76-4302-9d86-7b64c016f730" class="pagebreak" style="WIDTH: 100%; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div></td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex31img27.jpg">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<html><head><title>inmune_ex32.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 3.2</b></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center">BY-LAWS</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">OF</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">INmune Bio Inc.</p>
<p style="MARGIN: 0px" align="center">(hereinafter called the &#8220;Corporation&#8221;)</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE I</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>OFFICES</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Registered Office.</u> The registered office of the Corporation shall be 701 S. Carson Street, Suite 200, Carson City, NV 89701.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Other Offices.</u> The Corporation may also have offices at such other places both within and without the State of Nevada as the Board of Directors may from time to time determine.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE II</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>MEETING OF STOCKHOLDERS</u></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Place of Meetings.</u> Meetings of the stockholders for the election of directors or for any other purpose shall be held at such time and place, either within or without the State of Nevada as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting or in a duly executed waiver of notice thereof.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Annual Meetings.</u> The Annual Meetings of Stockholders shall be held on such date and at such time as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting, at which meetings the stockholders shall elect by a plurality vote a Board of Directors, and transact such other business as may properly be brought before the meeting. Written notice of the Annual Meeting stating the place, date and hour of the meeting shall be given to each stockholder entitled to vote at such meeting not less than ten nor more than sixty days before the date of the meeting.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak7af3a036-c4fd-49bd-a030-bf264927384c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 3</u>. <u>Special Meetings.</u> Unless otherwise prescribed by law or by the Articles of Incorporation, Special Meetings of Stockholders, for any purpose or purposes, may be called by either (i) the Chairman, if there be one, or (ii) the President, (iii) any Vice President, if there be one, (iv) the Secretary, or (v) any Assistant Secretary, if there be one, and shall be called by any such officer at the request in writing of a majority of the Board of Directors or at the request in writing of stockholders owning a majority of the capital stock of the Corporation issued and outstanding and entitled to vote. Such request shall state the purpose or purposes of the proposed meeting. Written notice of a Special Meeting stating the place, date and hour of the meeting and the purpose or purposes for which the meeting is called shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 4</u>. <u>Quorum.</u> Except as otherwise provided by law or by the Articles of Incorporation, the holders of 33.3 percent of the capital stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business. If, however, such quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, of the time and place of the adjourned meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder entitled to vote at the meeting.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak8d45a815-bb4e-4bec-b93f-4714cc68ebbc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-2-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 5</u>. <u>Voting.</u> Unless otherwise required by law, the Articles of Incorporation or these By-Laws, any question brought before any meeting of stockholders shall be decided by the vote of the holders of a majority of the stock represented and entitled to vote thereat. Each stockholder represented at a meeting of shareholders shall be entitled to cast one vote for each share of the capital stock entitled to vote thereat held by such stockholder. Such votes may be cast in person or by proxy but no proxy shall be voted on or after three years from its date, unless such proxy provides for a longer period. The Board of Directors, in its discretion, or the officer of the Corporation presiding at a meeting of stockholders, in his discretion, may require that any votes cast at such meeting shall be cast by written ballot.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 6</u>. <u>Consent of Stockholders in Lieu of Meeting.</u> Unless otherwise provided in the Articles of Incorpo-ration, any action required or permitted to be taken at any Annual or Special Meeting of Stockholders of the Corporation, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. The written consents shall be delivered to the Corporation by delivery to its registered office in Nevada, its principal place of business, or an officer or agent of the Corporation having custody of the book in which the proceedings are recorded. Delivery to the registered officer shall be by hand or certified or registered mail, return receipt requested. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shill be given to those stockholders who have not consented in writing.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakda060dfe-0524-4c68-ae52-cd5b9b0c88d0" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-3-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 7</u>. <u>List of Stockholders Entitled to Vote.</u> The officer of the Corporation who has charge of the stock ledger of the Corporation shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder of the Corporation who is present.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 8</u>. <u>Stock Ledger.</u> The stock ledger of the Corporation shall be the only evidence as to who are the stock-holders entitled to examine the stock ledger, the list required by Section 7 of this Article II or the books of the Corporation, or to vote in person or by proxy at any meeting of stockholders.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE III</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>DIRECTORS</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Number and Election of Directors.</u> The Board of Directors shall consist of one or more members, the exact number of which shall initially be fixed by the Incorporator and thereafter from time to time by the Board of Directors. Except as provided in Section 2 of this Article, directors shall be elected by a plurality of the votes cast at Annual Meetings of Stockholders. Any director may resign at any time upon written notice to the Corporation. Directors need not be stockholders.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakd547acb8-0e0b-46e4-958b-c27258d9acd8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-4-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Vacancies.</u> Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and qualified, or until their earlier resignation or removal.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 3</u>. <u>Duties and Powers.</u> The business of the Corporation shall be managed by or under the direction of the Board of Directors which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Articles of Incorporation or by these By-Laws directed or required to be exercised or done by the stockholders.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 4</u>. <u>Meetings.</u> The Board of Directors of the Corporation may hold meetings, both regular and special, either within or without the State of Nevada. Regular meetings of the Board of Directors may be held without notice at such time and at such place as may from time to time be determined by the Board of Directors. Special meetings of the Board of Directors may be called by the Chairman, if there be one, the President, or any one (1) director. Notice thereof stating the place, date and hour of the meetings shall be given to each director either by mail not less than forty-eight (48) hours before the date of the meeting, by telephone or telegram on twenty-four (24) hours&#8217; notice, or on such shorter notice as the person or persons calling such meeting may deem necessary or appropriate in the circumstances.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak60b5a6bc-e4bc-45f7-a0b5-1c018a0d62cd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-5-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 5</u>. <u>Quorum.</u> Except as may be otherwise specifically provided by law, the Articles of Incorporation or these By-Laws, at all meetings of the Board of Directors, a majority of the entire Board of Directors shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors. If a quorum shall not be present at any meeting of the Board of Directors, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 6</u>. <u>Actions of Board.</u> Unless otherwise provided by the Articles of Incorporation or these By-Laws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all the members of the Board of Directors or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 7</u>. <u>Meetings by Means of Conference Telephone</u>. Unless otherwise provided by the Articles of Incorporation or these By-Laws, members of the Board of Directors of the Corporation, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors or such committee by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section 7 shall constitute presence in person at such meeting.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakbabaf8bd-0ad5-404a-b842-b2ee215f66dd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-6-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 8</u>. <u>Committees.</u> The Board of Directors may, by resolution passed by a majority of the entire Board of Directors, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of any such committee. In the absence or disqualification of a member of a committee, and in the absence of a designation by the Board of Directors of an alternate member to replace the absent or disqualified member, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any absent or disqualified member. Any committee, to the extent allowed by law and provided in the resolution establishing such committee, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation. Each committee shall keep regular minutes and report to the Board of Directors when required.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 9</u>. <u>Compensation.</u> The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid for attendance at each meeting of the Board of Directors or a stated annual salary as director. Compensation may also consist of such options, warrants rights, shares of capital stock or any other form of remuneration approved by the Board of Directors. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like reimbursement of expenses for attending committee meetings.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak28359663-74c0-4289-b67a-44cdb67e7379" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-7-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 10</u>. <u>Interested Directors.</u> No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose if (i) the material facts as to his or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or their committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or (ii) the material facts as to his or their relationship or interest and as to the contract or transaction are disclosed or are known to the shareholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the shareholders; or (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof or the shareholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE IV</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>OFFICERS</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>General.</u> The officers of the Corporation shall be chosen by the Board of Directors and shall be a President, a Secretary and a Treasurer. The Board of Directors, in its discretion, may also choose a Chairman of the Board of Directors (who must be a director) and one or more Vice Presidents, Assistant Secretaries, Assistant Treasurers and other officers. Any number of offices may be held by the same person, unless otherwise prohibited by law, the Articles of Incorporation or these By-Laws. The officers of the Corporation need not be stockholders of the Corporation nor, except in the case of the Chairman of the Board of Directors, need such officers be directors of the Corporation.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak05b87607-c94b-4f3e-8978-382eda10a3d8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-8-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Election.</u> The Board of Directors shall elect the officers of the Corporation who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors; and all officers of the Corporation shall hold office until their successors are chosen and qualified, or until their earlier resignation or removal. Any officer elected by the Board of Directors may be removed at any time by the affirmative vote of a majority of the Board of Directors. Any vacancy occurring in any office of the Corporation shall be filled by the Board of Directors. The salaries of all officers of the Corporation shall be fixed by the Board of Directors.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 3</u>. <u>Voting Securities Owned by the Corporation.</u> Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the President or any Vice President and any such officer may, in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any corporation in which the Corporation may own securities and at any such meeting shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof, the Corporation might have exercised and possessed if present. The Board of Directors may, by resolution, from time to time confer like powers upon an-other person or persons.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreaka93d481b-6af1-4718-8c08-ae1d98972012" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-9-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 4</u>. <u>Chairman of the Board of Directors.</u> The Chairman of the Board of Directors, if there be one, shall preside at all meetings of the stockholders and of the Board of Directors. Except where by law the signature of the President is required, the Chairman of the Board of Directors shall possess the same power as the President to sign all contracts, certificates and other instruments of the Corporation which may be authorized by the Board of Directors. During the absence or disability of the President, the Chairman of the Board of Directors shall exercise all the powers and discharge all the duties of the President. The Chairman of the Board of Directors shall also perform such other duties and may exercise such other powers as from time to time may be assigned to him by these By-Laws or by the Board of Directors.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 5</u>. <u>President.</u> The President shall, subject to the control of the Board of Directors have general supervision of the business of the Corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. He shall execute all bonds, mortgages, contracts and other instruments of the Corporation requiring a seal, under the seal of the Corporation, except where required or permitted by law to be otherwise signed and executed and except that the other officers of the Corporation may sign and execute documents when so authorized by these By-Laws, the Board of Directors or the President. In the absence or disability of the Chairman of the Board of Directors, or if there be none, the President shall preside at all meetings of the stockholders and the Board of Directors. The President shall be the Chief Executive Officer of the Corporation. The President shall also perform such other duties and may exercise such other powers as from time to time may be assigned to him by these By-Laws or by the Board of Directors.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakd85d4c1f-2b21-46bb-975a-af1df137f3bc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-10-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 6</u>. <u>Vice-Presidents.</u> At the request of the President or in his absence or in the event of his inability or refusal to act (and if there be no Chairman of the Board of Directors), the Vice-President or the Vice-Presidents if there is more than one (in the order designated by the Board of Directors) shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. Each Vice-President shall perform such other-duties and have such other powers as the Board of Directors from time to time may prescribe. If there be no Chairman of the Board of Directors and no Vice-President, the Board of Directors shall designate the officer of the Corporation who, in the absence of the President or in the event of the inability or refusal of the President to act, shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 7</u>. <u>Secretary.</u> The Secretary shall attend all meetings of the Board of Directors and all meetings of stockholders and record all the proceedings thereat in a book or books to be kept for that purpose; the Secretary shall also perform like duties for the standing committees when required. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board of Directors or President, under whose supervision he shall be. If the Secretary shall be unable or shall refuse to cause to be given notice of all meetings of the stockholders and special meetings of the Board of Directors, and if there be no Assistant Secretary, then either the Board of Directors or the President may choose another officer to cause such notice to be given. The Secretary shall have custody of the seal of the Corporation and the Secretary or any Assistant Secretary, if there be one, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by the signature of the Secretary or by the signature of any such Assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Corporation and to attest the affixing by his signature. The Secretary shall see that all books, reports, statements, certificates and other documents and records required by Law to be kept or filed are properly kept or filed, as the case may be.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak00e77c7e-ac80-4858-afbe-bf44ca165e1b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-11-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 8</u>. <u>Treasurer.</u> The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render unto the President and the Board of Directors, at its regular meetings, or when the Board of Directors so requires, an account of all his transactions as Treasurer and of the financial condition of the Corporation. If required by the Board of Directors, the Treasurer shall give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors for the faithful performance of the duties of his office and for the restoration to the Corporation, in case of his death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession or under his control belonging to the Corporation.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 9</u>. <u>Assistant Secretaries.</u> Except as may be otherwise provided in these By-Laws, Assistant Secretaries, if there be any, shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors, the President, any Vice-President, if there be one, or the Secretary, and in the absence of the Secretary or in the event of his disability or refusal to act, shall perform the duties of the Secretary, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Secretary.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreakb79eb260-6777-4b18-b8d9-583ef9b05c34" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-12-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 10</u>. <u>Assistant Treasurers.</u> Assistant Treasurers, if there be any, shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors, the President, any Vice-President, if there be one, or the Treasurer, and in the absence of the Treasurer or in the event of his disability or refusal to act, shall perform the duties of the Treasurer, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Treasurer. If required by the Board of Directors, an Assistant Treasurer shall give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors for the faithful performance of the duties of his office and for the restoration to the Corporation, in case of his death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession or under his control belonging to the Corporation.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 11</u>. <u>Other Officers.</u> Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the power to choose such other officers and to prescribe their respective duties and powers.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE V</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>STOCK</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Form of Certificates.</u> Every holder of stock in the Corporation shall be entitled to have a certificate signed, in the name of the Corporation (i) by the Chairman of the Board of Directors, the President or a Vice-President and (ii) by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Corporation, certifying the number of shares owned by him in the Corporation.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak605d85a7-460b-4124-894a-a2491a12c472" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-13-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Signatures.</u> Any or all of the signatures on the certificate may be by facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 3</u>. <u>Lost Certificates.</u> The Board of Directors may direct a new certificate to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issue of a new certificate, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate, or his legal representative, to advertise the same in such manner as the Board of Directors shall require and/or to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen or destroyed.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 4</u>. <u>Transfers.</u> Stock of the Corporation shall be transferable in the manner prescribed by law and in these By-Laws. Transfers of stock shall be made on the books of the Corporation only by the person named in the certificate or by his attorney lawfully constituted in writing and upon the surrender of the certificate therefor, which shall be canceled before a new certificate shall be issued.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak060476ec-ffe5-4e8b-89b2-c8ca0faebe6a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-14-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 5</u>. <u>Record Date.</u> In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty days nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 6</u>. <u>Beneficial Owners.</u> The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares of the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by law.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE VI</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>NOTICES</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Notices.</u> Whenever written notice is required by law, the Articles of Incorporation or these By-Laws, to be given to any director, member of a committee or stockholder, such notice may be given by mail, addressed to such director, member of a committee or stockholder, at his address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail. Written notice may also be given personally or by telegram, e-mail, fax, telex or cable.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak236e0718-7a66-49d0-8a28-70f83eb989b4" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-15-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Waivers of Notice.</u> Whenever any notice is required by law, the Articles of Incorporation or these By-Laws, to be given to any director, member of a committee or stockholder, a waiver thereof in writing, signed, by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE VII</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>GENERAL PROVISIONS</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Dividends.</u> Dividends upon the capital stock of the Corporation, subject to the provisions of the Articles of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting, and may be paid in cash, in property, or in shares of the capital stock. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for any proper purpose, and the Board of Directors may modify or abolish any such reserve.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Disbursements.</u> All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 3</u>. <u>Fiscal Year.</u> The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak66b0bb70-bed0-49d2-a77c-7fc36dd36638" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">-16-</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 4</u>. <u>Corporate Seal.</u> The corporate seal shall have inscribed thereon the name of the Corporation, the year of its organization and the words &#8220;Corporate Seal, Nevada&#8221;. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE VIII</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>INDEMNIFICATION AND DIRECTORS&#8217; LIABILITY</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1</u>. <u>Indemnification of Directors and Officers.</u> The Corporation shall be required, to the fullest extent authorized by the Nevada Revised Statutes, as the same may be amended and supplemented, to indemnify any and all directors and officers of the Corporation.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">ARTICLE IX</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u>AMENDMENTS</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 1.</u> These By-Laws may be altered, amended or repealed, in whole or in part, or new By-Laws may be adopted by the stockholders or by the Board of Directors, provided, however, that notice of such alteration, amendment, repeal or adoption of new By-Laws be contained in the notice of such meeting of stockholders or Board of Directors, as the case may be. All such amendments must be approved by either the holders of a majority of the outstanding capital stock entitled to vote thereon or by a majority of the entire Board of Directors then in office.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><u>Section 2</u>. <u>Entire Board of Directors.</u> As used in this Article IX and in these By-Laws generally, the term &#8220;entire Board of Directors&#8221; means the total number of directors which the Corporation would have if there were no vacancies.</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="left">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">-17-</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<html><head><title>inmune_ex102.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 10.2</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Subscriber: ________________________________________</p>
<p style="MARGIN: 0px 0px 0px 83.45pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 83.45pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 83.45pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 83.45pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 83.45pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.1pt" align="center"><b><font size="3">INMUNE BIO INC.</font></b><font size="3"></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0.1pt" align="center"><b><font size="3">SUBSCRIPTION AGREEMENT</font></b></p>
<p style="MARGIN: 0px 0px 0px 0.1pt" align="center"><b><font size="3"></font></b><font size="3"></font>&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><img src="inmune_ex106img1.jpg">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table id="pagebreak1122a6ee-7748-4f47-a4ae-920d9a108952" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>SUBSCRIPTION AGREEMENT</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">This Subscription Agreement (the &#8220;<u>Subscription Agreement</u>&#8221;) is entered into by and between INmune Bio Inc., a Nevada corporation (the &#8220;<u>Company</u>&#8221; and/or &#8220;<u>INmune</u>&#8221;), and the Subscriber(s) whose name appears on the signature page to this Subscription Agreement (the &#8220;<u>Subscriber</u>&#8221; and, together with other subscribers to the Offering (as hereinafter defined), &#8220;<u>Investors</u>&#8221;).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">This Subscription Agreement is executed and delivered in connection with the offering of up to 500 units (the &#8220;<u>Offering</u>&#8221; and the &#8220;<u>Units</u>,&#8221; respectively) at $10,000 per Unit for gross Offering proceeds of up to $5,000,000, each Unit consisting of 6,666 shares of the Company&#8217;s common stock, par value $.001 per share (the &#8220;<u>Common Stock</u>&#8221;). The Units and the Common Stock are referred to herein as the &#8220;<u>Securities</u>&#8221;. The Offering has a minimum of $500,000 (the &#8220;<u>Minimum Offering</u>&#8221;) and a maximum of $5,000,000 (the &#8220;<u>Maximum Offering</u>&#8221;). The Company is offering the Units on a &#8220;best efforts-all or none&#8221; basis as to the Minimum Offering and on a &#8220;best efforts&#8221; basis thereafter up to the Maximum Offering. The Company may hold one or more closings at any time after the Minimum Offering is subscribed for (each a &#8220;<u>Closing</u>&#8221;), in its sole discretion.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">The Units are being offered to Investors by the Company and may be offered through selected selling agents as may be engaged by the Company. The terms of the Offering are more fully described in the Confidential Private Placement Memorandum dated November 15, 2016 (the &#8220;<u>Memorandum</u>&#8221;).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 19.9pt" align="justify">The Offering will commence on the date of the Memorandum and will continue until January 15, 2017 or the earlier sale of all of the Units or the Company&#8217;s termination or withdrawal of the Offering (the &#8220;<u>Offering Period</u>&#8221;). The Company may extend the Offering Period in its sole discretion, without notice to or consent of Investors, for an additional period of 60 days.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 19.9pt" align="justify">The Company will appoint an escrow agent to hold all subscription funds in a non-interest bearing escrow account. In the event a prospective Investor&#8217;s subscription is not accepted for any reason, in the sole discretion of the Company, the escrow agent will return the purchase price to the prospective Investor without interest or deduction.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">This Subscription Agreement and the Form of Purchaser Questionnaire provided herewith are collectively referred to as the &#8220;<u>Transaction Documents</u>&#8221;).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber hereby subscribes for and agrees to purchase from the Company, and the Company agrees to sell to Subscriber, the dollar amount of Units set forth on the signature page hereof.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber herewith tenders to the Company the entire amount of the purchase price by check made payable to the order of &#8220;INmune Bio Inc. Escrow,&#8221; or Subscriber has paid the entire amount of the purchase price by wire transfer of immediately available funds to:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>Ba</b><b>nk Name</b>:&nbsp;&nbsp; CitiBank, N.A</p>
<p style="MARGIN: 0px 0px 0px 135px" align="left">530 Central Avenue</p>
<p style="MARGIN: 0px 0px 0px 135px" align="left">Cedarhurst, NY 11516</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>ABA Number: </b>021000089</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>Swift code: </b>CitiUS33</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>Account Number: </b>4996945212</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>Account Name: </b>INmune Bio Inc. Escrow</p>
<p style="MARGIN: 0px 0px 0px 60px"><b>Re: </b>Private Placement - (Subscriber&#8217;s Name)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber herewith delivers to the Company a completed and signed Subscription Agreement and completed and signed Purchaser Questionnaire (&#8220;<u>Qualified Purchaser Questionnaire</u>&#8221;) for the purchase of the Units.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak40721588-4424-4e39-8890-44e88f932c6d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px" align="justify">Such funds will be held for the Subscriber&#8217;s benefit. Subscriber will not be a stockholder until such time as Subscriber&#8217;s subscription is accepted by the Company and a Closing of the purchase and sale of the Units being subscribed for by Subscriber takes place. Until such time as Subscribers subscription is accepted or rejected, as the case may be, this subscription shall be irrevocable and Subscriber will not have access to its subscription funds.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For a period of two years from the final closing date of this Offering, in the event the Company sells shares of Common Stock or the right to receive Common Stock at a price per share which values the Company at less than $10,000,000, then the Company will issue additional shares of Common Stock to each Investor in this Offering such that the Investor will receive the same effective price per share as the investors in any such future offering.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 0in"><b>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Securities offered have not been registered under the Securities Act of 1933, as amended; registration rights</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">Subscriber acknowledges that (i) the Securities have not been registered under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the &#8220;<u>Securities Act</u>&#8221;), or the securities laws of any state; (ii) absent registration, any resale or other transfer of the Securities must be made in compliance with the Securities Act; (iii) the Securities are being offered for sale in reliance upon exemptions from registration contained in the Securities Act and applicable state securities laws; and (iv) the Company's reliance upon such exemption is based in part upon Subscriber's representations, warranties and agreements contained in this Subscription Agreement and in the Qualified Purchaser Questionnaire that Subscriber is also delivering to the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">The Company agrees to file a registration statement under the Securities Act of 1933 (the &#8220;Registration Statement&#8221;), within five months after the final closing of this Offering and will seek to have such Registration Statement declared effective within six months of filing (the &#8220;Registration Deadlines&#8221;). The Registration Statement will register the resale of the shares of Common Stock offered herby. The Registration Statement will also seek to register additional shares of Common Stock for sale directly by the Company, with an intent to apply for inclusion on the Nasdaq stock market or lesser market if we do not meet Nasdaq requirements. If such listing is achieved, each investor in this Offering agrees not to sell shares of Common Stock purchased in this Offering for a period of at least six months from the effective date of such Registration Statement. If company does not file Registration Statement within five months after the final closing of this Offering, If the Company fails to meet either of the Registration Deadlines, each investor will be entitled to receive a cash payment in the amount of 1% of the amount of the investment for each month that a Registration Deadline is not met, up to a maximum of 12%.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Representations, Warranties, Acknowledgements and Agreements</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 27px; TEXT-INDENT: -20.05pt" align="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In order to induce the Company to accept this Subscription Agreement, Subscriber represents and warrants to, and acknowledges and covenants with, the Company as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber understands that (i) this Subscription Agreement may be accepted or rejected in whole or in part by the Company in its sole and absolute discretion, and (ii) this Subscription Agreement shall survive Subscriber's death, disability or insolvency, except that Subscriber shall have no obligation in the event that this Subscription Agreement is rejected by the Company. In the event that the Company does not accept Subscriber's subscription, or if the Offering is terminated for any reason, Subscriber's subscription payment (or portion thereof, as the case may be) will be returned to Subscriber without interest or deduction.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -15.05pt" align="justify">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber has carefully read this Subscription Agreement, the Qualified Purchaser Questionnaire, and the Memorandum (including, without limitation, the risks set forth under the heading &#8220;Risk Factors&#8221;). In making the decision to invest in the Units, Subscriber has relied upon the information provided by the Company herein and in the Memorandum (the &#8220;<u>Offering Materials</u>&#8221;).</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -15.05pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak67258ec7-4e16-4bd8-a7b2-26df4b9118ed" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page3</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px" align="justify">Subscriber has been advised to discuss with his, her, or its counsel the representations, warranties and agreements which Subscriber is making by signing this Subscription Agreement, the applicable limitations upon Subscriber's resale of the Securities, and the investment, tax and legal consequences of this Subscription Agreement. No oral or written representations have been made and no oral or written information has been furnished to the Subscriber or his advisor(s) in connection herewith that were in any way inconsistent with the information set forth in the Offering Materials and Subscriber disclaims reliance on any statements made or information provided by the Company, the Selling Agent(s) or any of their respective employees, counsel or agents or any other person or entity in the course of Subscriber&#8217;s consideration of an investment in the Units other than those set forth in the Offering Materials. <b>AN INVESTMENT IN THE UNITS INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE UNDERTAKEN ONLY BY PERSONS WHOSE FINANCIAL RESOURCES ARE SUFFICIENT TO ENABLE THEM TO ASSUME SUCH RISK AND TO BEAR THE TOTAL LOSS OF THEIR INVESTMENT.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber understands that no federal or state agency has made any finding or determination regarding the fairness of the Offering, or any recommendation or endorsement of the Securities.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber is purchasing the Units for Subscriber's own account, with the intention of holding the Units for investment purposes, with no present intention of dividing or allowing others to participate in this investment or of reselling or otherwise participating, directly or indirectly, in a distribution of the Securities; and Subscriber agrees not to make any sale, transfer or other disposition of the Securities without registration under the Securities Act and applicable state securities laws unless counsel acceptable to the Company is of the opinion that such registration is not required. Subscriber is not acquiring the Securities, or any interest therein, on behalf of another person and Subscriber, if an entity, was not formed for the purpose of purchasing the Units.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber's overall commitment to investments which are not readily marketable is not disproportionate to Subscriber's net worth, and Subscriber's investment in the Units will not cause such overall commitment to become excessive.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber, if an individual, has adequate means of providing for his or her current needs and personal and family contingencies and has no need for liquidity in his or her investment in the Units.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber is an &#8220;Accredited Investor&#8221; as that term is defined in Rule 501(a) under Regulation D promulgated by the SEC under the Securities Act. Subscriber is financially able to bear the economic risk of this investment, including the ability to afford holding the Securities for an indefinite period or to afford a complete loss of this investment.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The address shown on the signature page to this Subscription Agreement is Subscriber's principal residence if he or she is an individual, or its principal business address if a corporation or other entity.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber, together with any offeree representatives of Subscriber (as identified in the Qualified Purchaser Questionnaire) has such knowledge and experience in financial business matters as to be capable of evaluating the merits and risks of an investment in the Securities. Subscriber acknowledges that the Offering Materials may not contain all information that is necessary to make an investment decision with respect to the Company and the Units and that Subscriber must rely on his, her or its own examination of the Company and the terms and conditions of the Offering prior to making any investment decision with respect to the Units.</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd86450e9-9553-46b5-a319-48541a07bf36" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page4</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber has been given the opportunity to ask questions of and receive answers from the Company and its executive officers concerning the business and operations of the Company and the terms, provisions, and conditions of the Offering and to obtain any such additional information that Subscriber deems necessary or advisable to verify the accuracy of the information contained in the Offering Materials, or such other information as Subscriber desired in order to evaluate an investment in the Company; and Subscriber availed himself, herself or itself of such opportunity to the extent considered appropriate in order to evaluate the merits and risks of the proposed investment. To the extent that any such information has not been publicly disclosed, Subscriber agrees to keep all such information confidential unless required to be disclosed by a court or administrative body of competent jurisdiction or until such information is publicly disclosed by the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber has made an independent evaluation of the merits of the investment and acknowledges the highly speculative nature of an investment in the Units including, without limitation, the information under &#8220;Risk Factors&#8221; in the Memorandum.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The information provided by Subscriber in the Qualified Purchaser Questionnaire is true, complete and accurate and Subscriber has duly executed and delivered such Qualified Purchaser Questionnaire and any applicable exhibits thereto.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber has taken no action that would give rise to any claim by any person for brokerage commissions, finders' fees or the like relating to this Subscription Agreement or the transactions contemplated hereby (other than commissions to be paid by the Company to the Selling Agent(s) or as otherwise described in the Offering Materials and, in turn, to be paid to its selected dealers).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -17.1pt" align="justify">n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber understands that the certificate(s) representing the Securities will bear a legend substantially similar to the legend set forth immediately below until (i) such Securities shall have been registered under the Securities Act and effectively disposed of in accordance with a registration statement, or (ii) in the opinion of counsel reasonably satisfactory to the Company such securities may be sold without registration under the Securities Act:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 78px; TEXT-INDENT: 0.25in" align="justify">&#8220;These securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the "blue sky" or securities laws of any state and may not be offered, sold, pledged, hypothecated, assigned or transferred except (i) pursuant to a registration statement under the Securities Act which has become effective and is current with respect to these securities, or (ii) pursuant to a specific exemption from registration under the Securities Act but only upon a holder thereof first having obtained the written opinion of counsel reasonably satisfactory to the Company, that the proposed disposition is consistent with all applicable provisions of the Securities Act as well as any applicable "blue sky" or similar securities laws."</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If at any time prior to issuance of the Securities to Subscriber, any representation or warranty of Subscriber shall no longer be true, Subscriber promptly shall give written notice thereof to the Company specifying which representations and warranties are not true and the reason therefore, whereupon Subscriber's subscription may be rejected by the Company in whole or in part.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">p.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Subscriber represents that the amounts invested by it in the Company in the Offering were not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations, including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at &lt;http://www.treas.gov/ofac&gt;. In addition, the programs administered by OFAC (the &#8220;OFAC Programs&#8221;) prohibit dealing with individuals or entities in certain countries regardless of whether such individuals or entities appear on the OFAC lists.</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreake05bd079-428e-4502-9f90-7cf1cf56e347" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page5</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">q.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding the place where this Subscription Agreement may be executed by any of the parties hereto, all of the terms, provisions, and conditions hereof shall be construed in accordance with and governed by the laws of the State of New York, without giving effect to its conflict of laws principles. Any dispute arising out of or in connection with this Subscription Agreement or the Offering Materials shall be exclusively adjudicated before a court located in the City and County of New York and the parties hereto exclusively submit to the exclusive jurisdiction and venue of the state and local courts of the State of New York located in the City and County of New York and the U.S. District Court for the Southern District of New York with respect to any action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum and Subscriber consents to the service of process in any such action or legal proceeding by means of registered or certified mail, return receipt requested, in care of the address set forth below or such other address as Subscriber shall furnish in writing to the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber hereby irrevocably waives trial by jury in any action or proceeding involving, directly or indirectly, any matter (whether sounding in tort, contract, fraud or otherwise) in any way arising out of or in connection with this Subscription Agreement or Subscriber's purchase of the Units.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber acknowledges that he, she or it understands the meaning and legal consequences of the representations, warranties and acknowledgments contained in this Subscription Agreement and in the Qualified Purchaser Questionnaire, and hereby agrees to indemnify and hold harmless the Company, and each of its stockholders, officers, directors, affiliates, controlling persons, agents and representatives, from and against any and all loss, damage, expense, claim, action, suit or proceeding (including the reasonable fees and expenses of legal counsel) as incurred arising out of or in any manner whatsoever connected with (i) a breach of any representation or warranty of Subscriber contained in this Subscription Agreement or in the Qualified Purchaser Questionnaire (ii) any sale or distribution by Subscriber in violation of the Securities Act or any applicable state securities laws or (iii) any untrue statement of a material fact made by Subscriber and contained herein or in the Qualified Purchaser Questionnaire, or omission to state herein or in the Qualified Purchaser Questionnaire, a material fact necessary in order to make the statements contained herein or in the Qualified Purchaser Questionnaire, in light of the circumstances under which they were made, not misleading. Subscriber acknowledges that such damage could be substantial since (a) the Securities are being offered without registration under the Securities Act in reliance upon the exemption pursuant to Section 4(2) and/or Regulation D of the Securities Act for transactions by an issuer not involving a public offering and, in various states, pursuant to exemptions from registration, (b) the availability of such exemptions is, in part, dependent upon the truthfulness and accuracy of the representations made by Subscriber herein and in its Qualified Purchaser Questionnaire, and (c) the Company will rely on such representations in accepting Subscriber's Subscription Agreement.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">t.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber is not subscribing for the Units as a result of or subsequent to any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, any seminar or meeting, or any solicitation of a subscription by a person not previously known to Subscriber in connection with investments in securities generally.</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakb69f1518-2634-4fc6-a34f-ee5ab54f0e8f" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page6</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">u.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unless otherwise indicated on a separate sheet of paper that details any such affiliation submitted by Subscriber to the Company along with this completed Subscription Agreement, Subscriber is not affiliated directly or indirectly with a member broker- dealer firm of the Financial Industry Regulatory Authority (&#8220; <u>FIN R A&#8221;) </u>as an employee, officer, director, partner or shareholder or as a relative or member of the same household of an employee, director, partner or shareholder of a FINRA member broker-dealer firm.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 62px; TEXT-INDENT: -20.1pt" align="justify">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber represents that he, she or it has full power and authority (corporate, statutory or otherwise) to execute and deliver this Subscription Agreement and to purchase the Units. The execution, delivery and performance of this Subscription Agreement and the Qualified Purchaser Questionnaire will not: (i) violate, conflict with or result in a default under any provision of the Certificate or By-Laws (or analogous organizational documents), if any, of Subscriber; or (ii) violate or result in a violation of, or constitute a default (whether after the giving of notice, lapse of time or both) under, any provision of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable to Subscriber. This Subscription Agreement constitutes the legal, valid and binding obligation of Subscriber, enforceable against Subscriber in accordance with its terms except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors&#8217; rights generally and subject to general principles of equity (regardless of whether such enforcement is considered in a proceeding at law or at equity). This Subscription Agreement supersedes all prior arrangements or understandings with respect thereto, whether oral or written. The terms and conditions of this Subscription Agreement shall inure to the benefit of and be binding upon the parties and their respective successors, heirs and assigns.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 27px; TEXT-INDENT: -20.05pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In order to induce Subscriber to execute and deliver this Subscription Agreement, the Company represents and warrants to, and covenants with, Subscriber as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each of the Company and its Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;Material Adverse Effect&#8221;) and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. </p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: -22.6pt" align="justify">
<table id="pagebreakb2008106-0fd5-4bfa-a9c0-8dea7aead31c" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page7</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22px" align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party do not and will not: (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, charge, pledge, security interest or encumbrance upon any of the properties or assets of the Company or any Subsidiary (a &#8220;Lien&#8221;), or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px" align="justify">(ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -18.05pt" align="justify">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The execution, delivery and performance by the Company of this Subscription Agreement and the Offering and sale of the Units to accredited investors contemplated hereby shall, assuming the representations and warranties of Subscriber are true and correct, be in compliance with the exemptions from registration set forth in Regulation D and/or Section 4(a)(2) of the Securities Act and applicable state securities &#8220;blue sky&#8221; laws.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and, if and as applicable, nonassessable, free and clear of all Liens imposed by the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capitalization of the Company is as set forth in the Offering Materials. The Company has not issued any capital stock and/or common stock equivalents not set forth in the Offering Materials. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind (&#8220;Person&#8221;), any right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents.</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: -22.6pt" align="justify">
<table id="pagebreak382202c1-f5f5-4f83-bac5-92be058b3c3d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page8</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
<p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Subscribers) and will not result in a right of any holder of securities of the Company to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock and other securities of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except for the Company&#8217;s certificate of incorporation, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Offering Materials, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>&nbsp;</b>Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakdf42d7d8-76cf-4ee8-868a-1637e8dd9782" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page9</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 64px; TEXT-INDENT: -22.6pt">k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Intellectual Property</u>.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -14.35pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The term &#8220;<u>Intellectual Property Rights</u>&#8221; includes:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 96px; TEXT-INDENT: -0.25in" align="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the name of the Company, all fictional business names, trading names, registered and unregistered trademarks, service marks, and applications (collectively, &#8220;<u>Marks''</u>);</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 96px; TEXT-INDENT: -0.25in" align="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all patents, patent applications, and inventions and discoveries that may be patentable (collectively, &#8220;<u>Patents''</u>);</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 96px; TEXT-INDENT: -0.25in" align="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all copyrights in both published works and published works (collectively, &#8220;<u>Copyrights</u>&#8221;);</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 96px; TEXT-INDENT: -0.25in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all rights in mask works (collectively, &#8220;<u>Rights in Mask Works''</u>); and</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 96px; TEXT-INDENT: -0.25in" align="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all know-how, trade secrets, confidential information, customer lists, software, technical information, data, process technology, plans, drawings, and blue prints (collectively, &#8220;<u>Trade Secrets'</u>') owned, used, or licensed by the Company as licensee or licensor.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -17.1pt" align="justify">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Offering Materials contain a complete and accurate description of all contracts relating to the Intellectual Property Rights to which the Company is a party or by which the Company is bound, except for any license implied by the sale of a product and perpetual, paid-up licenses for commonly available software programs with a value of less than $10,000 under which the Company is the licensee. There are no outstanding and, to the Company&#8217;s knowledge, no threatened disputes or disagreements with respect to any such agreement.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -19.85pt" align="justify">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Intellectual Property Rights are all those necessary for the operation of the Company&#8217;s businesses as it is currently conducted or as represented, in writing, to the Subscribers to be conducted. The Company is the owner of all right, title, and interest in and to each of the Intellectual Property Rights, free and clear of all liens, security interests, charges, encumbrances, equities, and other adverse claims, and has the right to use all of the Intellectual Property Rights. To the Company&#8217;s knowledge, no employee of the Company has entered into any contract that restricts or limits in any way the scope or type of work in which the employee may be engaged or requires the employee to transfer, assign, or disclose information concerning his work to anyone other than of the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -19.35pt" align="justify">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Offering Materials contain a complete and accurate list of all Patents. Except as set forth in the Offering Materials, the Company is the owner of all right, title and interest in and to each of the Patents, free and clear of all Liens and other adverse claims. All of the issued Patents are currently in compliance with formal legal requirements (including payment of filing, examination, and maintenance fees and proofs of working or use), are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days after the initial Closing Date. No Patent has been or is now involved in any interference, reissue, reexamination, or opposition proceeding. To the Company&#8217;s knowledge: (1) there is no potentially interfering patent or patent application of any third party, and (2) no Patent is infringed or has been challenged or threatened in any way. To the Company&#8217;s knowledge, none of the products manufactured and sold, nor any process or know-how used, by the Company infringes or is alleged to infringe any patent or other proprietary right of any other Person.</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -19.35pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreaka9c3cc3b-55e0-4a76-91bc-d37dc6646d1e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page10</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -16.5pt" align="justify">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Offering Materials contain a complete and accurate list and summary description of all trademarks. The Company is the owner of all right, title, and interest in and to each of the Marks, free and clear of all Liens and other adverse claims. All trademarks that have been registered with the United States Patent and Trademark Office are currently in compliance with all formal legal requirements (including the timely post-registration filing of affidavits of use and incontestability and renewal applications), are valid and enforceable, and are not subject to any maintenance fees or taxes or actions falling due within ninety days after the Initial Closing Date. No trademark has been or is now involved in any opposition, invalidation, or cancellation and, to the Company&#8217;s knowledge, no such action is threatened with respect to any of the trademarks. To the Company&#8217;s knowledge: (1) there is no potentially interfering trademark or trademark application of any third party, and (2) no trademark is infringed or has been challenged or threatened in any way. To the Company&#8217;s knowledge, none of the trademarks used by the Company infringes or is alleged to infringe any trade name, trademark, or service mark of any third party.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -19.35pt" align="justify">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With respect to each trade secret, the documentation relating to such trade secret is current, accurate, and sufficient in detail and content to identify and explain it and to allow its full and proper use without reliance on the knowledge or memory of any individual. The Company has taken all reasonable precautions to protect the secrecy, confidentiality, and value of its trade secrets. The Company has good title and an absolute (but not necessarily exclusive) right to use the trade secrets. The trade secrets are not part of the public knowledge or literature, and, to the Company&#8217;s knowledge, have not been used, divulged, or appropriated either for the benefit of any Person (other than the Company) or to the detriment of the Company. No trade secret is subject to any adverse claim or has been challenged or threatened in any way.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within six months following the initial Closing Date, the Company and the Subsidiaries will be insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. In addition, within six months following the initial Closing Date, the Company shall obtain directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to obtain the foregoing insurance coverage.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Subscribers and certain other &#8220;accredited investors&#8221; within the meaning of Rule 501 under the Securities Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No Person other than the Subscribers has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assuming the accuracy of the Subscribers&#8217; representations and warranties set forth in Section C.1., no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Subscribers as contemplated hereby.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">p.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Subscribers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which will not be publicly disclosed in the Registration Statement or within 210 days of the initial Closing Date, whichever occurs first. The Company understands and confirms that the Subscribers will rely on the foregoing representation in effecting transactions in securities of the Company. </p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 6px; TEXT-INDENT: 0px" align="justify">
<table id="pagebreakde843171-1bb7-496f-9097-a603d051a3a1" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page11</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All of the disclosure furnished by or on behalf of the Company to the Subscribers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, when taken together as a whole, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Subscriber makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section C.1. hereof.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">q.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assuming the accuracy of the Subscribers&#8217; representations and warranties set forth in Section C.1., neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the Securities Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company acknowledges and agrees that each of the Subscribers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Subscriber is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Subscriber or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Subscribers&#8217; purchase of the Securities. The Company further represents to each Subscriber that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">t.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;Money Laundering Laws&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any subsidiary, threatened.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">u.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With respect to Units to be offered and sold hereunder in reliance on Rule 506(b) under the Securities Act (&#8220;Regulation D Securities&#8221;), none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &#8220;Issuer Covered Person&#8221; and, together, &#8220;Issuer Covered Persons&#8221;) is subject to any of the &#8220;Bad Actor&#8221; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &#8220;Disqualification Event&#8221;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e).</p>
<p style="MARGIN: 0px 0px 0px 51px; TEXT-INDENT: -27pt" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak48e62ae3-8a83-4cd1-8e1a-ed3836cb92e5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page12</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notice Provisions</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">Any and all notices, demands or requests required or permitted to be given under this Subscription Agreement shall be given in writing and sent, by registered or certified U.S. mail, return receipt requested, by facsimile transmission with proof of electronic transmission, by hand, or by overnight courier, addressed to the parties hereto at their addresses set forth above or such other addresses as they may from time-to-time designate by written notice, given in accordance with the terms of this Section D, together with copies thereof as follows:</p>
<p style="MARGIN: 0px 0px 0px 37px">In the case of the Company to: INmune Bio Inc.</p>
<p style="MARGIN: 0px 0px 0px 37px">1224 Prospect Street</p>
<p style="MARGIN: 0px 0px 0px 37px">Suite 150</p>
<p style="MARGIN: 0px 0px 0px 37px">La Jolla, CA 92037</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 37px">In the case of Subscriber, to the address of Subscriber on the signature page to this Agreement.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">Notice given as provided in this Section shall be deemed effective: (i) on the business day hand delivered (or, if it is not a business day, then the next succeeding business day thereafter), (ii) on the first business day following the sending thereof by overnight courier, and (iii) on the seventh calendar day (or, if it is not a business day, then the next succeeding business day thereafter) after the depositing thereof into the exclusive custody of the U.S. Postal Service. As used herein, the term business day (other than Saturday or Sunday) shall mean any day when commercial banks are open in the State of New York.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Miscellaneous.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 30px" align="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Subscription Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal representatives, successors and assigns.</p>
<p style="MARGIN: 0px 0px 0px 30px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 30px" align="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Offering Documents, together with the Transaction Documents, constitute the entire agreement between the Subscriber and the Company with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed by the party to be bound thereby.</p>
<p style="MARGIN: 0px 0px 0px 30px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 30px" align="justify">3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No term or provision contained herein may be modified, amended or waived except by written agreement or consent signed by the party or parties to be bound thereby. A waiver by either party of a breach of any provision of this Subscription Agreement shall not operate, or be construed, as a waiver of any subsequent breach by that same party.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 30px" align="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscriber acknowledges that the subscription made hereby is not binding upon the Company until the Company accepts it. The Company has the right to accept or reject this subscription in whole or in part in its sole and absolute discretion. If this subscription is rejected in whole, the Company shall return the purchase price to Subscriber, without interest or deduction, and the Company and Subscriber shall have no further obligation to each other by reason of this Subscription Agreement or the subscription made hereby.</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak1ccd9a3e-7de1-48c7-8e6e-9e2123755e09" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page13</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The representations and warranties of the Company and the Subscriber made in this Subscription Agreement shall survive the Closing and the execution and delivery hereof and delivery of the Securities.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are consummated.</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 60px; TEXT-INDENT: -0.25in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>[Offering Information, Legends, and Notices Follow]</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table id="pagebreak35cc794f-2d8b-4b2b-bb13-95ef91dae508" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page14</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>OFFERING INFORMATION, LEGENDS, AND NOTICES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">THE SECURITIES OFFERED HEREBY HAVE NOT BEEN APPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE &#8220;SEC&#8221;), OR ANY STATE REGULATORY AUTHORITY. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">IT IS INTENDED THAT THE SECURITIES OFFERED HEREBY WILL BE OFFERED TO ACCREDITED INVESTORS, AS DEFINED IN RULE 501 OF REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT AND ARE BEING OFFERED PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS FOR NONPUBLIC OFFERINGS. SUCH EXEMPTIONS LIMIT THE NUMBER AND TYPES OF INVESTORS TO WHICH THE OFFERING WILL BE MADE AND RESTRICT SUBSEQUENT TRANSFERS OF THE SECURITIES SUCH SECURITIES MAY ONLY BE RESOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IF, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">THE SECURITIES OFFERED HEREBY SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN AFFORD TO SUSTAIN A LOSS OF THEIR ENTIRE INVESTMENT. INVESTORS WILL BE REQUIRED TO REPRESENT THAT THEY ARE FAMILIAR WITH AND UNDERSTAND THE TERMS OF THIS OFFERING.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">THE OFFEREE, BY ACCEPTING DELIVERY OF THE OFFERING MATERIALS, AGREES TO RETURN THE OFFERING MATERIALS AND ALL ACCOMPANYING OR RELATED DOCUMENTS TO THE COMPANY UPON REQUEST IF THE OFFEREE DOES NOT AGREE TO PURCHASE ANY OF THE SECURITIES OFFERED HEREBY.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">ANY OFFERING MATERIALS SUBMITTED IN CONNECTION WITH THE PRIVATE PLACEMENT OF THE SECURITIES DO NOT CONSTITUTE AN OFFER OR SOLICITATION BY ANYONE IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION IS NOT AUTHORIZED. ANY REPRODUCTION OR DISTRIBUTION OF ANY OFFERING MATERIALS IN WHOLE OR IN PART, OR THE DIVULGENCE OF ANY OF THEIR CONTENTS, WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY, IS PROHIBITED. ANY PERSON ACTING CONTRARY TO THE FOREGOING RESTRICTIONS MAY PLACE HIM/HERSELF AND THE COMPANY IN VIOLATION OF FEDERAL OR STATE SECURITIES LAWS.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>NASAA UNIFORM LEGEND</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak693dbc3b-2488-4dad-b0b3-27765e349ba7" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page15</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>FOR RESIDENTS OF FLORIDA</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">EACH FLORIDA RESIDENT WHO SUBSCRIBES FOR THE PURCHASE OF SECURITIES HEREIN MAY HAVE THE RIGHT, TO THE EXTENT PROVIDED IN SECTION 517.061(11)(A)(5) OF THE FLORIDA SECURITIES ACT, TO WITHDRAW HIS SUBSCRIPTION FOR THE PURCHASE AND RECEIVE A FULL REFUND OF ALL MONIES PAID. SUCH RIGHT OF WITHDRAWAL MAY BE EXERCISED PRIOR TO THE EXPIRATION OF THREE (3) BUSINESS DAYS AFTER THE LATER TO OCCUR OF (A) PAYMENT OF THE PURCHASE HAS BEEN MADE TO THE COMPANY, ITS AGENT, OR AN ESCROW AGENT OR (B) COMMUNICATION OF THE RIGHT OF WITHDRAWAL TO THE FLORIDA RESIDENT. WITHDRAWAL WILL BE WITHOUT ANY FURTHER LIABILITY TO ANY PERSON. TO ACCOMPLISH THIS WITHDRAWAL, A SUBSCRIBER NEED ONLY SEND A LETTER OR TELEGRAM TO THE COMPANY AT THE ADDRESS OF THE COMPANY SET FORTH HEREIN INDICATING HIS INTENTION TO WITHDRAW.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 0.25in" align="justify">SUCH LETTER OR TELEGRAM SHOULD BE SET AND POSTMARKED PRIOR TO THE END OF THE AFOREMENTIONED THIRD BUSINESS DAY. IT IS ADVISABLE TO SEND SUCH LETTER BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO ENSURE THAT IT IS RECEIVED AND ALSO TO EVIDENCE THE TIME IT WAS MAILED. IF THE REQUEST IS MADE ORALLY, IN PERSON OR BY TELEPHONE TO AN OFFICER OF THE COMPANY, A WRITTEN CONFIRMATION THAT THE REQUEST HAS BEEN RECEIVED SHOULD BE REQUESTED.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak45642190-94cf-47fd-8bd5-80649578acfa" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page16</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE PAGE FOR:</b></p>
<p style="MARGIN: 0px 0px 0px 127px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>INDIVIDUAL INVESTOR</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.5in"><b>I</b><b>N WITNESS WHEREOF</b>, this Subscription Agreement has been executed by Subscriber and by the Company on the respective dates set forth below.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signature (If Purchased Jointly)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 90px">_______________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _______________________________</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Print Name ______________________________ Print Name _______________________________<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Date: __________________________________ Date: ____________________________________&nbsp;<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Social Security # _________________________ Social Security # ____________________________<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Residential Address ______________________&nbsp; Residential Address _________________________&nbsp;<u></u></p>
<p style="MARGIN: 0px 0px 0px 90px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 90px">_______________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; __________________________</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Telephone # ____________________________ Telephone # _______________________________<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Fax #&nbsp; _________________________________&nbsp; Fax # ____________________________________</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Email: _________________________________ Email: ____________________________________<u>&nbsp;</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in"><b>EXACT </b>Name in which Securities are to be issued: _________________________________________</p>
<p style="MARGIN: 0px 0px 0px 1in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">________________________________________________________________________________</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Purchase Price: $ ______________________________<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">Form of Joint Ownership (<i>if applicable</i>): <font face="Wingdings">o </font>Tenants-in-Common <font face="Wingdings">o </font>Joint Tenants with Right of Survivorship</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: -0.5in"><font face="Wingdings">o </font>Other: ___________________________________<u></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table id="pagebreak74117246-9dcf-436b-b994-5ae7c652cb7a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page17</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE PAGE FOR:</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY OR TRUST</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>I</b><b>N WITNESS WHEREOF</b>, the undersigned has executed this Subscription Agreement on the date set forth below:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Name of Partnership, Corporation, and Limited Liability Company or Trust</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">By: _________________________________&nbsp; Federal Tax ID Number ____________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Name: _______________________________ State of Organization&nbsp; _____________________________&nbsp;<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Title: ________________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Date: ________________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Principal Business Address: ____________________________________________________________</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Attn; ________________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Telephone: ____________________________</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Fax: _________________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Email: ________________________________<u></u></p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px"><b>E</b><b>XACT </b>Name in which Securities are to be issued: _____________________________________________</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">____________________________________________________________________________________</p>
<p style="MARGIN: 0px 0px 0px 120px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 120px">Purchase Price: $ ________________________</p>
<p style="MARGIN: 0px 0px 0px 1in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1in"><u></u>&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakdf18921b-4b8f-4bcc-8501-668d009825d6" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page18</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center"><b>INMUNE BIO INC.</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE PAGE FOR: </b></p>
<p style="MARGIN: 0px; TEXT-INDENT: 49.2pt" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SUBSCRIPTION AGREEMENT ACCEPTANCE</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>I</b><b>NMUNE BIO INC.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="2" cellpadding="0" width="45%" align="left" border="0">
<tr>
<td width="30%">
<p style="MARGIN: 0px"><b>By</b><b>:</b></p></td>
<td style="BORDER-BOTTOM: black 1px solid" width="70%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>Printed Name: </b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>T</b><b>itle:</b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>Dated:</b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>Subscription Agreement No: </b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>Subscriber: </b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px"><b>A</b><b>m</b><b>o</b><b>unt of Purchase Price: $ </b></p></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 1.75in">&nbsp;</p><b style="MARGIN: 0px">
<table id="pagebreak26535a9c-6e07-4f43-bbda-dca7d0829011" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">Page19</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p><u></u></b>&nbsp;</BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<html><head><title>inmune_ex103.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px 0px 0px 0in" align="right"><b>EXHIBIT 10.3</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>INMUNE BIO, INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2017 STOCK INCENTIVE PLAN</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(e</b><b>ff</b><b>ect</b><b>ive November 15, 2017, subject to stockholder approval)</b></p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px"><b>1&nbsp;General</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">1.1&nbsp;<b>P</b><b>urpose</b>. The purposes of the INmune Bio, Inc. 2017 Stock Incentive Plan (the &#8220;Plan&#8221;) is to promote the interests of INmune Bio, Inc. (the &#8220;Company&#8221;) and the stockholders of the Company by providing (i) executive officers and other employees of the Company and its Subsidiaries (as defined below), (ii) certain advisors who perform services for the Company and its Subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the &#8220;Board&#8221;) with appropriate incentives and rewards to encourage them to enter into and continue in the employ and service of the Company and to acquire a proprietary interest in the long-term success of the Company, as well as to reward the performance of these individuals in fulfilling their personal responsibilities for long-range and annual achievements. The Plan is intended to be a written compensatory plan within the meaning of Rule 701 promulgated under the Securities Act.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">1.2 <b>Effective Date and Term</b>. The Plan will become effective upon the date it is approved by the stockholders of the Company (the &#8220;Effective Date&#8221;). Unless terminated earlier by the Committee, the Plan will expire on the tenth (10th) anniversary of the Effective Date.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">1.3 <b>De</b><b>f</b><b>initions</b>. Capitalized terms in the Plan, unless defined elsewhere in the Plan, shall be defined as set forth below:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>162(m) Term. </b>The term &#8220;162(m) Term&#8221; means the period starting on the date when the Company&#8217;s stockholders first approve this Plan and ending on the date of the first meeting of the Company&#8217;s stockholders that occurs in the fifth year following the year in which the Company&#8217;s stockholders first approve this Plan.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Exchange Act</b>. The term &#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder and any successor thereto.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>A</b><b>ff</b><b>i</b><b>liated Company</b>. The term &#8220;Affiliated Company&#8221; means any company, partnership, association, organization or other entity controlled by, controlling or under common control with the Company.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>A</b><b>w</b><b>ard</b>. The term &#8220;Award&#8221; means any award or benefit granted under the Plan, including, without limitation, Options, SARs, Restricted Stock, Restricted Stock Units, Other Stock-Based Awards and Cash-Based Awards.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>A</b><b>w</b><b>ard Agreement</b>. The term &#8220;Award Agreement&#8221; means a written Award grant agreement under the Plan.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd5c3933e-60d7-4dd5-a59e-a64c7e231acf" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center"></td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>C</b><b>ash-Based Award</b>. The term &#8220;Cash-Based Award&#8221; means a right or other interest granted to an Eligible Grantee under Section 4.2(vi) of the Plan that may be denominated or payable in cash, other than an Award pursuant to which the amount of cash is determined by reference to the value of a specific number of shares of Stock. For the avoidance of doubt, dividend equivalents constitute Cash-Based Awards.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>C</b><b>hange of Control</b>. The term &#8220;Change of Control&#8221; shall be deemed to occur if and when:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">any person, including a &#8220;person&#8221; as such term is used in Section 14(d)(2) of the Exchange Act (a &#8220;Person&#8221;), is or becomes a beneficial owner (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(ii)</td>
<td valign="top">individuals who, as of the Effective Date, constitute the Board (the &#8220;Incumbent Board&#8221;) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company&#8217;s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding for this purpose any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iii)</td>
<td valign="top">all or substantially all of the assets of the Company are sold, transferred or distributed, or the Company is dissolved or liquidated; or</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iv)</td>
<td valign="top">a reorganization, merger, consolidation or other corporate transaction involving the Company (a &#8220;Transaction&#8221;) is consummated, in each case, with respect to which the stockholders of the Company immediately prior to such Transaction do not, immediately after the Transaction, own more than 50% of the combined voting power of the Company or other corporation resulting from such Transaction in substantially the same respective proportions as such stockholders&#8217; ownership of the voting power of the Company immediately before such Transaction.</td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Notwithstanding the foregoing or any other provision of this Plan, the term Change of Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd76b937c-7775-45fa-93f5-2635ba995536" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>C</b><b>ode</b>. The term &#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended. A reference to any provision of the Code shall include reference to any successor provision of the Code.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>C</b><b>o</b><b>m</b><b>m</b><b>ittee</b>. The term &#8220;Committee&#8221; means the committee of the Board described in Section 2 hereof and any sub-committee established by such Committee pursuant to Section 2.4.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>C</b><b>overed Employee</b>. The term &#8220;Covered Employee&#8221; means an Employee who is, or who is anticipated to become, between the time of grant and payment of the Award, a &#8220;covered employee,&#8221; as such term is defined in Section 162(m)(3) of the Code (or any successor section thereof).</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>D</b><b>isability</b>. The term &#8220;Disability&#8221; means &#8220;Disability&#8221; as defined in any Award Agreement to which the Grantee is a party.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Eligible Grantee</b>. The term &#8220;Eligible Grantee&#8221; shall mean any Employee, Non- Employee Director or Key Advisor, as determined by the Committee in its sole discretion.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Employee</b>. The term &#8220;Employee&#8221; means an active employee of the Company or a Subsidiary, but excluding any person who is classified by the Company or a Subsidiary as a &#8220;contractor&#8221; or &#8220;consultant,&#8221; no matter how characterized by the Internal Revenue Service, other governmental agency or a court, or any employee who is not actively employed, as determined by the Committee. Any change of characterization of an individual by the Internal Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan, unless the Committee determines otherwise.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>F</b><b>air Market Value. </b>For purposes of determining the &#8220;Fair Market Value&#8221; of a share of Stock as of any date, the &#8220;Fair Market Value&#8221; as of that date shall be, unless otherwise determined by the Committee, the closing sale price during regular trading hours of the Stock on the immediately preceding date on the principal securities market in which shares of Stock is then traded; or, if there were no trades on that date, the closing sale price during regular trading hours of the Stock on the first trading day prior to that date. If the Stock is not publicly traded at the time a determination of Fair Market Value is required to be made hereunder, the determination of such amount shall be made by the Committee in such manner as it deems appropriate.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>G</b><b>r</b><b>antee</b>. The term &#8220;Grantee&#8221; means an Employee, Non-Employee Director or Key Advisor of the Company or a Subsidiary who has been granted an Award under the Plan.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>ISO</b>. The term &#8220;ISO&#8221; means any Option intended to be and designated as an incentive stock option within the meaning of Section 422 of the Code.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>K</b><b>e</b><b>y Advisor</b>. The term &#8220;Key Advisor&#8221; means a consultant or other key advisor who performs services for the Company or a Subsidiary.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd5603047-6632-4465-824c-d4e4a93bc2c9" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>N</b><b>on-Employee Director</b>. The term &#8220;Non-Employee Director&#8221; means a member of the Board who is not an Employee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>N</b><b>QSO</b>. The term &#8220;NQSO&#8221; means any Option that is not designated as an ISO, or which is designated by the Committee as an ISO but which subsequently fails or ceases to qualify as an ISO.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Option</b>. The term &#8220;Option&#8221; means a right, granted to an Eligible Grantee under Section 4.2(i), to purchase shares of Stock. An Option may be either an ISO or an NQSO.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Other Stock-Based Award</b>. The term &#8220;Other Stock-Based Award&#8221; means a right or other interest granted to an Eligible Grantee under Section 4.2(v) of the Plan that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Stock, including but not limited to (i) unrestricted Stock awarded as a bonus or upon the attainment of Performance Goals or otherwise as permitted under the Plan, and (ii) a right granted to an Eligible Grantee to acquire Stock from the Company containing terms and conditions prescribed by the Committee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>P</b><b>e</b><b>r</b><b>f</b><b>ormance Goals</b>. The term &#8220;Performance Goals&#8221; means performance goals based on the attainment by the Company or any Subsidiary of the Company or any Affiliated Company (or any division or business unit of any such entity), or any two or more of the foregoing, of performance goals pre-established by the Committee in its sole discretion, based on one or more of the following criteria (if applicable, such criteria shall be determined in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) or based upon the Company&#8217;s GAAP financial statements): (i) the attainment of certain target levels of, or a specified percentage increase in, revenues, earnings, income before taxes and extraordinary items, net income, operating income, earnings before income tax, earnings before interest, taxes, depreciation and amortization or a combination of any or all of the foregoing; (ii) the attainment of certain target levels of, or a percentage increase in, after-tax or pre-tax profits including, without limitation, that attributable to continuing and/or other operations; (iii) the attainment of certain target levels of, or a specified increase in, operational cash flow; (iv) the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or a portion of, the Company&#8217;s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the Company, which may be calculated net of such cash balances and/or other offsets and adjustments as may be established by the Committee; (v) earnings per share or the attainment of a specified percentage increase in earnings per share or earnings per share from continuing operations; (vi) the attainment of certain target levels of, or a specified increase in return on capital employed or return on invested capital; (vii) the attainment of certain target levels of, or a percentage increase in, after-tax or pre-tax return on stockholders&#8217; equity; (viii) the attainment of certain target levels of, or a specified increase in, economic value added targets based on a cash flow return on investment formula; (ix) the attainment of certain target levels in, or specified increases in, the fair market value of the shares of the Company&#8217;s common stock; (x) the growth in the value of an investment in the Company&#8217;s common stock; (xi) the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level in or increase in, all or a portion of controllable expenses or costs or other expenses or costs; (xii) gross or net sales, revenue and growth of sales revenue (either before or after cost of goods, selling and general administrative expenses, research and development expenses and any other expenses or interest); (xiii) total stockholder return; (xiv) return on assets or net assets; (xv) return on sales; (xvi) operating profit or net operating profit; (xvii) operating margin; (xviii) gross or net profit margin; (xix) cost reductions or savings; (xx) productivity; (xxi) operating efficiency; (xxii) working capital; or (xxiii) market share; (xxiv) customer satisfaction; (xxv) workforce diversity; (xxvi) results of clinical trials; (xxvii) acceptance of a new drug application by a regulatory body; (xxviii) regulatory body approval for commercialization of a product; (xxix) launch of a new drug; (xxx) completion of out-licensing, in-licensing or disposition of product candidates or other acquisition or disposition projects; and (xxxi) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Board. Subject to the limitations in Section 4.2, the Committee in its sole discretion may designate additional business criteria on which the Performance Goals may be based or adjust, or modify or amend the aforementioned business criteria. The relative weights of the criteria that comprise the Performance Goals shall be determined by the Committee in its sole discretion. In establishing the Performance Goals for a performance period, the Committee may establish different Performance Goals for individual Grantees or groups of Grantees. Subject to the limitations in Section 4.2(ix)(d), the Committee in its sole discretion shall have the authority to make equitable adjustments to the Performance Goals in recognition of unusual or non-recurring events affecting the Company or any Subsidiary of the Company or any Affiliated Company or the financial statements of the Company or any Subsidiary of the Company or any Affiliated Company, in response to changes in applicable laws or regulations, including changes in generally accepted accounting principles or practices, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment of a business, as applicable. Performance Goals may include a threshold level of performance below which no Award will be earned, a level of performance at which the target amount of an Award will be earned and a level of performance at which the maximum amount of the Award will be earned.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">
<table id="pagebreak933b7019-e0b3-45a3-9e1b-50cdf0ad5887" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">4</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Re</b><b>stricted Stock</b>. The term &#8220;Restricted Stock&#8221; means an Award of shares of Stock to an Eligible Grantee under Section 4.2(iii) that may be subject to certain restrictions and to a risk of forfeiture. Stock issued upon the exercise of Options or SARs is not &#8220;Restricted Stock&#8221; for purposes of the plan, even if subject to post-issuance transfer restrictions or forfeiture conditions. When Restricted Stock vests, it ceases to be &#8220;Restricted Stock&#8221; for purposes of the Plan.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Re</b><b>stricted Stock Unit</b>. The term &#8220;Restricted Stock Unit&#8221; means a right granted to an Eligible Grantee under Section 4.2(iv) to receive Stock or cash at the end of a specified deferral period, which right may be conditioned on the satisfaction of specified performance or other criteria.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Ret</b><b>irement</b>. The term &#8220;Retirement&#8221; means any termination of employment or service as an Employee, Non-Employee Director or Key Advisor as a result of retirement in good standing under the rules of the Company or a Subsidiary, as applicable, then in effect.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>R</b><b>ule 16b-3</b>. The term &#8220;Rule 16b-3&#8221; means Rule 16b-3, as from time to time in effect promulgated by the Securities and Exchange Commission under Section 16 of the Exchange Act, including any successor to such Rule.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>Securities Act</b>. The term &#8220;Securities Act&#8221; means the Securities Act of 1933, as amended.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Stock</b>. The term &#8220;Stock&#8221; means shares of the common stock, par value $0.001 per share, of the Company.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Stock Appreciation Right or SAR</b>. The term &#8220;Stock Appreciation Right&#8221; or &#8220;SAR&#8221; means the right, granted to an Eligible Grantee under Section 4.2(ii), to be paid an amount measured by the appreciation in the Fair Market Value of Stock from the date of grant to the date of exercise of the right.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>Subsidiary</b>. The term &#8220;Subsidiary&#8221; means any present or future subsidiary corporation of the Company within the meaning of Section 424(f) of the Code, and any present or future business venture designated by the Committee in which the Company has a significant interest, including, without limitation, any subsidiary corporation in which the Company has at least a 50% ownership interest, as determined in the discretion of the Committee.</p>
<p style="MARGIN: 0px">
<table id="pagebreak12527981-181b-414c-9902-dc997d30083d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">5</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>2 </b><b>A</b><b>dministration</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>2.1 </b><b>C</b><b>o</b><b>m</b><b>m</b><b>ittee</b>. The authority to manage the operation of and administer the Plan shall be vested in a committee (the &#8220;Committee&#8221;) in accordance with this Section 2. The Committee shall be selected by the Board, and shall consist solely of two or more members of the Board who are non-employee directors within the meaning of Rule 16b-3 and are outside directors within the meaning of Code Section 162(m). Unless otherwise determined by the Board, the Company&#8217;s Compensation Committee shall be designated as the &#8220;Committee&#8221; hereunder. If the Board, at any time, consists of only one member, such sole member may take all actions granted to the Committee hereunder.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>2.2 </b><b>P</b><b>owers of the Committee</b>. The Committee&#8217;s administration of the Plan shall be subject to the following:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">Subject to the provisions of the Plan, the Committee will have the authority and discretion to select from among the Eligible Grantees those persons who shall receive Awards, to determine the time or times of receipt, to determine the types of Awards and the number of shares covered by the Awards, and to establish the terms, conditions, performance criteria, restrictions, and other provisions of such Awards;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(ii)</td>
<td valign="top">The Committee will have the authority and discretion to interpret the Plan, to establish, amend, and rescind any rules and regulations relating to the Plan, to determine the terms and provisions of any Award Agreement made pursuant to the Plan, and to make all other determinations that may be necessary or advisable for the administration of the Plan;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iii)</td>
<td valign="top">Any interpretation of the Plan by the Committee and any decision made by it under the Plan is final and binding on all persons; and</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iv)</td>
<td valign="top">In managing the operation of and administering the Plan, the Committee shall take action in a manner that conforms to the articles of incorporation and by-laws of the Company, and applicable state corporate law.</td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreaka51d2eb1-74de-4f4d-8288-742172db391a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">6</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>2.3 </b><b>P</b><b>r</b><b>ohibition Against Repricing</b>. Notwithstanding any provision of the Plan to the contrary, in no event shall any action be taken under the Plan that constitutes a Repricing of any Option or SAR granted under the Plan, or of any option or stock appreciation right granted under the any other plan of the Company or of an acquired company, except with approval of the stockholders of the Company.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>2.4 </b><b>De</b><b>legation of Authority</b>. To the extent not inconsistent with applicable law, the rules of the NASDAQ Stock Market or other provisions of the Plan, the Committee may, at any time, allocate all or any portion of its responsibilities and powers to any one or more of its members or, with respect to Awards made to Employees other than executive officers, the Chief Executive Officer, including without limitation, the power to designate Grantees hereunder and determine the amount, timing and terms of Awards hereunder. Any such allocation or delegation may be revoked by the Committee at any time.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>2.5 </b><b>Indemnification</b>. Each person who is or shall have been a member of the Committee, or the Board, shall be indemnified and held harmless by the Company against and from any loss, cost, liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken in good faith or failure to act in good faith under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company&#8217;s approval, or paid by him or her in satisfaction of any judgment in any such action, suit or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall be in addition to any other rights of indemnification or elimination of liability to which such persons may be entitled under the Company&#8217;s articles of incorporation or by-laws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>3 </b><b>A</b><b>vailable Shares of Stock Under the Plan</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>3.1 </b><b>Shares Available for Awards</b>. Subject to the adjustments described below, the maximum number of shares of Stock reserved for the grant of Awards under the Plan shall be 1,700,000. Of the maximum number of shares of Stock reserved for the grant of Awards under the Plan, no more than 700,000 of such shares may be issued pursuant to stock-settled Awards other than Options (that is, Restricted Stock, Restricted Stock Units, SARs, Performance Awards, Other Stock-Based Awards and dividend equivalent Awards, in each case to the extent settled in shares of Common Stock).</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>3.2 </b><b>F</b><b>orfeited, Cancelled and Expired Awards</b>. Awards granted under the Plan that are forfeited, expire or are canceled or settled without issuance of Stock shall not count against the maximum number of shares that may be issued under the Plan as set forth in Section 3.1 and shall be available for future Awards under the Plan. Notwithstanding the foregoing, any and all Stock that is (i) withheld or tendered in payment of an Option exercise price; (ii) withheld by the Company to satisfy any tax withholding obligation; (iii) covered by a SAR (to the extent that it is settled in Stock, without regard to the number of shares of Stock that are actually issued to the Grantee upon exercise); (iv) withheld by the Company to satisfy any debt or other obligation owed to the Company or any Subsidiary, and (v) any fractional shares of Common Stock that are cancelled pursuant to the Plan, shall be considered issued pursuant to the Plan and shall not be added to the maximum number of shares of Stock that may be issued under the Plan as set forth in Section 3.1.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak56132e9a-7f72-4519-b322-0704d2f06899" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">7</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>3.3 </b><b>A</b><b>djustments</b>. In the event of any change in the Company&#8217;s capital structure, including but not limited to a change in the number of shares of Stock outstanding, on account of (i) any stock dividend, stock split, reverse stock split or any similar equity restructuring, or (ii) any combination or exchange of equity securities, merger, consolidation, recapitalization, reorganization, or divesture or any other similar event affecting the Company&#8217;s capital structure, to reflect such change in the Company&#8217;s capital structure, the Committee shall make appropriate equitable adjustments to the maximum number of shares of Stock that may be issued under the Plan as set forth in Section 3.1. In the event of any extraordinary dividend, divestiture or other distribution (other than ordinary cash dividends) of assets to stockholders, or any transaction or event described above, to the extent necessary to prevent the enlargement or diminution of the rights of Grantees, the Committee shall make appropriate equitable adjustments to the number or kind of shares subject to an outstanding Award, the exercise price applicable to an outstanding Award, and/or a Performance Goals. Any adjustments under this Section 3.3 shall be consistent with Section 409A or 424 of the Code, to the extent applicable, and made in a manner that does not adversely affect the exemption provided pursuant to Rule 16b-3 or qualification under Section 162(m) of the Code, to the extent each may be applicable. The Company shall give each Grantee notice of an adjustment to an Award hereunder and, upon notice, such adjustment shall be final, binding and conclusive for all purposes. Notwithstanding the foregoing, the Committee shall decline to adjust any Award made to a Participant if such adjustment would violate applicable law.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>3.4 </b><b>F</b><b>r</b><b>a</b><b>ct</b><b>ional Shares</b>. The Company shall not be obligated to issue any fractional shares of Stock in settlement of Awards granted under the Plan. Except as otherwise provided in an Award Agreement or determined by the Committee, (i) the total number of shares issuable pursuant to the exercise, vesting or earning of an Award shall be rounded down to the nearest whole share, and (ii) no fractional shares shall be issued. The Committee may, in its discretion, determine that a fractional share shall be settled in cash.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>4 </b><b>A</b><b>w</b><b>ards</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>4.1 </b><b>G</b><b>e</b><b>neral</b>. The term of each Award shall be for such period as may be determined by the Committee, subject to the limitations set forth below. Subject to the terms of the Plan and any applicable Award Agreement, payments to be made by the Company or any Subsidiary of the Company upon the grant, maturation, or exercise of an Award may be made in such forms as the Committee shall determine at the date of grant or thereafter, including, without limitation, cash, Stock, or other property. In addition to the foregoing, the Committee may impose on any Award or the exercise thereof, at the date of grant, such additional terms and conditions not inconsistent with the provisions of the Plan, including, but not limited to forfeiture and clawback provisions, as the Committee shall determine; provided, however, that any such terms and conditions shall not be inconsistent with Section 409A of the Code.</p>
<p style="MARGIN: 0px">&nbsp;
<table id="pagebreak95738af5-b1e4-4ac4-b3f9-97a5657c8f77" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">8</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>4.2 </b><b>Types of Awards</b>. The Committee is authorized to grant the Awards described in this Section 4.2, under such terms and conditions as deemed by the Committee to be consistent with the purposes of the Plan. Such Awards may be granted with value and payment contingent upon Performance Goals. Each Award shall be evidenced by an Award Agreement containing such terms and conditions applicable to such Award as the Committee shall determine.</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top"><i>O</i><i>ptions</i>. The Committee is authorized to grant Options to Grantees on the following terms and conditions:</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top"><u>T</u><u>y</u><u>pe of Award</u>. The Award Agreement evidencing an Option shall designate the Option as either an ISO or an NQSO, as determined in the discretion of the Committee. At the time of the grant of Options, the Committee may place restrictions on the exercisability or vesting of Options that shall lapse, in whole or in part, upon the attainment of Performance Goals; provided that such Performance Goals shall relate to periods of performance of at least one fiscal year.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">b.</td>
<td valign="top"><u>E</u><u>x</u><u>erc</u><u>ise Price</u>. The exercise price of each Option granted under this Section 4.2 shall be established by the Committee or shall be determined by a method established by the Committee at the time the Option is granted; provided, however, that the exercise price shall not be less than 100% of the Fair Market Value of a share of Stock on the date of grant of the Award. No dividends or dividend equivalents will be paid on shares of Stock subject to an Option.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">c.</td>
<td valign="top"><u>E</u><u>x</u><u>erc</u><u>ise</u>. Upon satisfaction of the applicable conditions relating to vesting and exercisability, as determined by the Committee and set forth in the Award Agreement, and upon provision for the payment in full of the exercise price and applicable taxes due, the Grantee shall be entitled to exercise the Option and receive the number of shares of Stock issuable in connection with the Option exercise provided, however, that no Option may be exercised more than ten years after its grant date. Except as set forth in Section 4.3, no NQSO granted hereunder may be exercised after the earlier of (A) the expiration of the NQSO or (B) unless otherwise provided by the Committee in an Award Agreement, ninety days after the severance of an NQSO holder&#8217;s employment or service with the Company or any Subsidiary. The shares issued in connection with the Option exercise may be subject to such conditions and restrictions as the Committee may determine, from time to time. An Option may be exercised by any method as may be permitted by the Committee from time to time, including but not limited to any &#8220;net exercise&#8221; or other &#8220;cashless&#8221; exercise method.</td></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak0ab53bd4-4f83-4f70-80d3-579c4ede5146" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">9</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">d.</td>
<td valign="top"><u>Restrictions Relating to ISOs</u>. In addition to being subject to the terms and conditions of this Section 4.2(i), ISOs shall comply with all other requirements under Section 422 of the Code. Accordingly, ISOs may be granted only to Eligible Grantees who are employees (as described in Treasury Regulation Section 1.421-7(h)) of the Company or of any &#8220;Parent Corporation&#8221; (as defined in Code Section 424(e)) or of any &#8220;Subsidiary Corporation&#8221; (as defined in Code Section 424(f)) on the date of grant. The aggregate Fair Market Value (determined as of the time the ISO is granted) of the Stock with respect to which ISOs (under all option plans of the Company and of any Parent Corporation and of any Subsidiary Corporation) are exercisable for the first time by an Eligible Grantee during any calendar year shall not exceed $100,000. ISOs shall not be transferable by the Eligible Grantee otherwise than by will or the laws of descent and distribution and shall be exercisable, during the Eligible Grantee&#8217;s lifetime, only by such Eligible Grantee. The Committee shall not grant ISOs to any Employee who, at the time the ISO is granted, owns stock possessing (after the application of the attribution rules of Section 424(d) of the Code) more than ten percent (10%) of the total combined voting stock of the Company or of any Parent Corporation or of any Subsidiary Corporation, unless the exercise price of the ISO is fixed at not less than one hundred and ten percent (110%) of the Fair Market Value of a share of Common Stock on the date of grant and the exercise of such ISO is prohibited by its terms after the fifth (5th) anniversary of the ISO&#8217;s date of grant. In addition, no ISO shall be issued to an Eligible Grantee in tandem with a NQSO issued to such Eligible Grantee in accordance with Treasury Regulation Section 14a.422A-1, Q/A-39.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p><i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(ii)</td>
<td valign="top"><i>SARs</i>. The Committee is authorized to grant SARs to Grantees on the following terms and conditions:</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top"><u>I</u><u>n General</u>. SARs may be granted independently or in tandem with an Option at the time of grant of the related Option. An SAR granted in tandem with an Option shall be exercisable only to the extent the underlying Option is exercisable. Payment of an SAR may be made in cash, Stock, or a combination of the foregoing, as specified in the Award Agreement or determined in the sole discretion of the Committee. At the time of the grant of SARs, the Committee may place restrictions on the exercisability or vesting of SARs that shall lapse, in whole or in part, upon the attainment of Performance Goals; provided that such Performance Goals shall relate to periods of performance of at least one fiscal year.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">b.</td>
<td valign="top"><u>Ter</u><u>m and Exercisability of SARs</u>. SARs shall be exercisable over the exercise period at such times and upon such conditions as the Committee may determine, as reflected in the Award Agreement; provided, however, that no SAR may be exercised more than ten years after its grant date. Except as set forth in Section 4.3, no SAR granted hereunder may be exercised after the earlier of (A) the expiration of the SAR or (B) unless otherwise provided by the Committee in an Award Agreement, ninety days after the severance of an SAR holder&#8217;s employment or service with the Company or any Subsidiary.</td></tr></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak56b0ca24-1872-43bc-b64b-4f370bdd6de8" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">10</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">c.</td>
<td valign="top"><u>Payment</u>. An SAR shall confer on the Grantee a right to receive an amount with respect to each share of Stock subject thereto, upon exercise thereof, equal to the excess of (A) the Fair Market Value of one share of Stock on the date of exercise over (B) the grant price of the SAR (which in the case of an SAR granted in tandem with an Option shall be equal to the exercise price of the underlying Option, and which in the case of any other SAR shall be such price as the Committee may determine but in no event shall be less than the Fair Market Value of a share of Stock on the date of grant of such SAR). An SAR may be exercised by giving written notice of such exercise to the Committee or its designated agent. No dividends or dividend equivalents will be paid on shares of Stock subject to an SAR.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p><i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(iii)</td>
<td valign="top"><i>Re</i><i>stricted Stock</i>. The Committee is authorized to grant Restricted Stock to Grantees on the following terms and conditions:</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top"><u>I</u><u>ssuance and Restrictions</u>. Restricted Stock shall be subject to such restrictions on transferability and other restrictions, if any, as the Committee may impose at the date of grant, which restrictions may lapse separately or in combination at such times, under such circumstances, in such installments, or otherwise, as the Committee may determine. The Committee may place restrictions on Restricted Stock that shall lapse, in whole or in part, upon the attainment of Performance Goals; provided that such Performance Goals shall relate to periods of performance of at least one fiscal year. Except to the extent restricted under the Award Agreement relating to the Restricted Stock, a Grantee granted Restricted Stock shall have all of the rights of a stockholder including, without limitation, the right to vote Restricted Stock and the right to receive dividends thereon.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">b.</td>
<td valign="top"><u>Certificates for Stock</u>. Restricted Stock granted under the Plan may be evidenced in such manner as the Committee shall determine. If certificates representing Restricted Stock are registered in the name of the Grantee, such certificates shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock, and the Company may retain physical possession of the certificate.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">c.</td>
<td valign="top"><u>D</u><u>ividends</u>. Except to the extent restricted under the applicable Award Agreement, cash dividends paid on Restricted Stock shall be paid at the dividend payment date subject to no restriction. Unless otherwise determined by the Committee, Stock distributed in connection with a stock split or stock dividend shall be subject to the transfer restrictions, forfeiture risks and vesting conditions to the same extent as the Restricted Stock with respect to which such Stock or other property has been distributed. Notwithstanding the foregoing, the Committee may not provide for the current payment of dividends for Restricted Stock subject to Performance Goals; for such Awards, dividends may accrue but shall not be payable unless and until the Award vests upon satisfaction of the applicable Performance Goals and all other applicable conditions to vesting.</td></tr></tr></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak7f297272-8c21-478e-a017-fed1d4dab757" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">11</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p><i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(iv)</td>
<td valign="top"><i>Re</i><i>stricted Stock Units</i>. The Committee is authorized to grant Restricted Stock Units to Grantees, subject to the following terms and conditions:</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top"><u>Conditions to Vesting</u>. At the time of the grant of Restricted Stock Units, the Committee may place restrictions on Restricted Stock Units that shall lapse, in whole or in part, upon the attainment of Performance Goals; provided that such Performance Goals shall relate to periods of performance of at least one fiscal year.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">b.</td>
<td valign="top"><u>B</u><u>e</u><u>nefit Upon Vesting</u>. Unless otherwise provided in an Award Agreement, upon the vesting of a Restricted Stock Unit, there shall be delivered to the Grantee, within 30 days of the date on which such Award (or any portion thereof) vests, the number of shares of Stock equal to the number of Restricted Stock Units becoming so vested.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">c.</td>
<td valign="top"><u>D</u><u>ividend Equivalents</u>. To the extent provided in an Award Agreement, subject to the requirements of Section 409A of the Code, an Award of Restricted Stock Units may provide the Grantee with the right to receive dividend equivalent payments with respect to Stock subject to the Award (both before and after the Stock subject to the Award is earned, vested, or acquired), which payments may be either made currently or credited to an account for the Grantee, and may be settled in cash or Stock, as determined by the Committee. Any such settlements and any such crediting of dividend equivalents may, at the time of grant of the Restricted Stock Unit, be made subject to the transfer restrictions, forfeiture risks, vesting and conditions of the Restricted Stock Units and subject to such other conditions, restrictions and contingencies as the Committee shall establish at the time of grant of the Restricted Stock Unit, including the reinvestment of such credited amounts in Stock equivalents, provided that all such conditions, restrictions and contingencies shall comply with the requirements of Section 409A of the Code. Notwithstanding the foregoing in this Section 4.2(iv)(c), dividend equivalents may accrue on unearned Restricted Stock Units subject to Performance Goals but shall not be payable unless and until the applicable Performance Goals are met and certified.</td></tr></tr></tr></table>
<p style="MARGIN: 0px">&nbsp;</p><i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(v)</td>
<td valign="top"><i>O</i><i>ther Stock-Based Awards</i>. The Committee is authorized to grant Awards to Grantees in the form of Other Stock-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan. At the time of the grant of Other Stock-Based Awards, the Committee may place restrictions on the payout or vesting of Other Stock-Based Awards that shall lapse, in whole or in part, upon the attainment of Performance Goals; provided that such Performance Goals shall relate to periods of performance of at least one fiscal year. The Committee shall determine the terms and conditions of such Awards at the date of grant. Other Stock-Based Awards may not be granted with the right to receive dividend equivalent payments.</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak52c0381e-4746-44cb-99ca-440f47749bdc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">12</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></i><i>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(vi)</td>
<td valign="top"><i>Cash-Based Awards</i>. The Committee is authorized to grant Awards to Grantees in the form of Cash-Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan. At the time of the grant of Cash-Based Awards, the Committee may place restrictions on the payout or vesting of Cash-Based Awards that shall lapse, in whole or in part, upon the attainment of Performance Goals. The Committee shall determine the terms and conditions of such Awards at the date of grant.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(vii)</td>
<td valign="top"><i>Settlement of Options and SARs</i>. Shares of Stock delivered pursuant to the exercise of an Option or SAR shall be subject to such conditions, restrictions and contingencies as the Committee may establish in the applicable Award Agreement. Settlement of SARs may be made in shares of Stock (valued at their Fair Market Value at the time of exercise), in cash, or in a combination thereof, as determined in the discretion of the Committee and set forth in the Award Agreement. The Committee, in its discretion, may impose such conditions, restrictions and contingencies with respect to shares of Stock acquired pursuant to the exercise of an Option or an SAR as the Committee determines to be desirable.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(viii)</td>
<td valign="top"><i>Ve</i><i>sting; Additional Terms</i>. Except as set forth in Section 4.3, other than Options, SARs, Restricted Stock, Restricted Stock Units or Other Stock-Based Awards conditioned upon the attainment of Performance Goals that relate to performance periods of at least one fiscal year, Options, SARs, Restricted Stock, Restricted Stock Units or Other Stock-Based Awards granted hereunder shall vest as determined by the Committee and set forth in the Award Agreement. The term of any Award granted under the Plan will not exceed ten years from the date of grant.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(ix)</td>
<td valign="top"><i>Q</i><i>ualified Performance-Based Compensation</i>.</td></tr></tr></tr></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></i>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top">The Committee may determine that Restricted Stock, Restricted Stock Units, Other Stock-Based Awards or Cash-Based Awards granted to a Covered Employee shall be considered &#8220;qualified performance-based compensation&#8221; under section 162(m) of the Code, in which case the provisions of this Section 4.2(ix) shall apply. As required pursuant to Section 162(m) of the Code and the regulations promulgated thereunder, the Committee&#8217;s authority to grant new awards that are intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Code (other than qualifying Options and qualifying SARs) shall terminate upon the first meeting of the Company&#8217;s stockholders that occurs in the fifth year following the year in which the Company&#8217;s stockholders first approve this Plan.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak430d97d6-0acc-483c-ad66-dc3c033e0f46" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">13</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">b.</td>
<td valign="top">When Awards are made under this Section 4.2(ix), the Committee shall establish in writing (i) the objective Performance Goals that must be met, (ii) the period during which performance will be measured, (iii) the maximum amounts that may be paid if the Performance Goals are met, and (iv) any other conditions that the Committee deems appropriate and consistent with the requirements of Section 162(m) of the Code for &#8220;qualified performance-based compensation.&#8221; The Performance Goals shall satisfy the requirements for &#8220;qualified performance-based compensation,&#8221; including the requirement that the achievement of the goals be substantially uncertain at the time they are established and that the Performance Goals be established in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the Performance Goals have been met. The Committee shall not have discretion to increase the amount of compensation that is payable, but may reduce the amount of compensation that is payable, pursuant to Awards identified by the Committee as &#8220;qualified performance-based compensation.&#8221;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">c.</td>
<td valign="top">Performance Goals must be pre-established by the Committee. A Performance Goal is considered pre-established if it is established in writing not later than 90 days after the commencement of the period of service to which the Performance Goal relates, provided that the outcome is substantially uncertain at the time the Committee actually established the goal. However, in no event will a Performance Goal be considered pre-established if it is established after 25% of the period of service (as scheduled in good faith at the time the goal is established) has elapsed.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">d.</td>
<td valign="top">The Committee in its sole discretion shall have the authority to make equitable adjustments to the Performance Goals in recognition of unusual or non- recurring events affecting the Company or any Subsidiary of the Company or any Affiliated Company or the financial statements of the Company or any Subsidiary of the Company or any Affiliated Company, in response to changes in applicable laws or regulations, including changes in generally accepted accounting principles or practices, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment of a business, as applicable, provided such adjustment occurs in writing not later than 90 days after the commencement of the period of service to which the Performance Goal relates (and in no event later than the date that 25% of the period of service has elapsed). In addition, the Committee may specify that certain equitable adjustments to the Performance Goals will be made during the applicable Performance Period, provided such specification occurs in writing not later than 90 days after the commencement of the period of service to which the Performance Goal relates (and in no event later than the date that 25% of the period of service has elapsed).</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">e.</td>
<td valign="top">The Committee shall certify the performance results for the performance period specified in the Award Agreement after the performance period ends. The Committee shall determine the amount, if any, to be paid pursuant to each Award based on the achievement of the Performance Goals and the satisfaction of all other terms of the Award Agreement. Subject to the provisions of Section 3.3 relating to capitalization adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, a maximum of 50,000 shares of Stock subject to qualified performance-based compensation may be granted to any Eligible Grantee during any calendar year during the 162(m) Term.</td></tr></table></p>
<table id="pagebreak84818bec-ad66-4b5a-ba0b-c9e7b94e7a70" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">14</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr outerhtml='&#13;&#10;<TR><TD vAlign=top rowspan="0">&#13;&#10;<P style="MARGIN: 0px">&amp;nbsp;</P></TD>&#13;&#10;<TD vAlign=top rowspan="0">f.</TD>&#13;&#10;<TD vAlign=top rowspan="0">The Committee may provide in the Award Agreement that Awards under this Section 4.2(ix) shall be payable, in whole or in part, in the event of the Grantee&#8217;s death or Disability, or under other circumstances consistent with the Treasury regulations and rulings under Section 162(m) of the Code.</TD></TR>'>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">f.</td>
<td valign="top">The Committee may provide in the Award Agreement that Awards under this Section 4.2(ix) shall be payable, in whole or in part, in the event of the Grantee&#8217;s death or Disability, or under other circumstances consistent with the Treasury regulations and rulings under Section 162(m) of the Code.</td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>4.3 </b><b>C</b><b>hange of Control of the Company.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">The Committee may, at the time an Award is made or at any time prior to, coincident with or after the time of a Change of Control:</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="8%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">a.</td>
<td valign="top">provide for the adjustment of any Performance Goals as the Committee deems necessary or appropriate to reflect the Change of Control;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">b.</td>
<td valign="top">provide for the cancellation of any Awards then outstanding if the surviving entity or acquiring entity (or the surviving or acquiring entity&#8217;s parent company) in the Change of Control replaces the Awards with new rights of substantially equivalent value, as determined by the Committee;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">c.</td>
<td valign="top">provide that upon an involuntary termination of a Participant&#8217;s employment as a result of a Change of Control, any time periods shall accelerate, and any other conditions relating to the vesting, exercise, payment or distribution of an Award shall be waived; or</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">d.</td>
<td valign="top">provide that Awards shall be purchased for an amount of cash equal to the amount that could have been obtained for the shares covered by a Restricted Stock Award if it had been vested and or by an Option or SAR if it had been exercised at the time of the Change of Control.</td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(ii)</td>
<td valign="top">Notwithstanding any other provisions of the Plan or an Award Agreement to the contrary, the vesting, payment, purchase or distribution of an Award may not be accelerated by reason of a Change of Control for any Grantee unless the Grantee&#8217;s employment is involuntarily terminated as a result of the Change of Control as provided in the Award Agreement or in any other written agreement, including an employment agreement, between us and the Grantee.</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak454f83d3-bbe5-4cd8-8982-3e28c04f107d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">15</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>5 </b><b>Operation</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.1 </b><b>D</b><b>uration</b>. Grants may be made under the Plan through November , 2027. In the event of Plan termination while Awards remain outstanding, the Plan shall remain in effect as long as any Awards under it are outstanding, although no further grants may be made following Plan termination.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.2 </b><b>U</b><b>ncertificated Stock</b>. Nothing contained in the Plan shall prohibit the issuance of Stock on an uncertificated basis, to the extent allowed by the Company&#8217;s Articles of Incorporation and Bylaws, by applicable law and by the applicable rules of any stock exchange.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.3 </b><b>Tax Withholding</b>. All distributions under the Plan are subject to withholding of all applicable taxes, and the Committee may condition the delivery of any shares or other benefits under the Plan on satisfaction of the applicable withholding obligations. The Committee, in its discretion, and subject to such requirements as the Committee may impose prior to the occurrence of such withholding, may permit such withholding obligations to be satisfied through cash payment by the Grantee, through the surrender of shares of Stock which the Grantee already owns, through withholding from other compensation payable to the Grantee or through the surrender of unrestricted shares of Stock to which the Grantee is otherwise entitled under the Plan, but only to the extent of the minimum amount required to be withheld under applicable law.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.4 </b><b>U</b><b>se of Shares. </b>Subject to the limitations on the number of shares of Stock that may be delivered under the Plan, the Committee may use available shares of Stock as the form of payment for compensation, grants or rights earned or due under any other compensation plans or arrangements of the Company or a Subsidiary, including the plans and arrangements of the Company or a Subsidiary assumed in business combinations.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.5 </b><b>N</b><b>ontransferability</b>. Awards granted under the Plan, and during any period of restriction on transferability, shares of Common Stock issued in connection with the exercise of an Option or a SAR, or vesting of a Restricted Stock Award may not be sold, pledged, hypothecated, assigned, margined or otherwise transferred by a Grantee in any manner other than by will or the laws of descent and distribution, unless and until the shares underlying such Award have been issued, and all restrictions applicable to such shares have lapsed or have been waived by the Committee. No Award or interest or right therein shall be subject to the debts, contracts or engagements of a Grantee or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law, by judgment, lien, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy and divorce), and any attempted disposition thereof shall be null and void, of no effect, and not binding on the Company in any way. Notwithstanding the foregoing, the Committee may permit Options and/or shares issued in connection with an Option or a SAR exercise that are subject to restrictions on transferability, to be transferred one time and without payment or consideration to a member of a Grantee&#8217;s immediate family or to a trust or similar vehicle for the benefit of a Grantee&#8217;s immediate family members. During the lifetime of a Grantee, all rights with respect to Awards shall be exercisable only by such Grantee or, if applicable pursuant to the preceding sentence, a permitted transferee.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak2ca511e1-9126-4196-97cf-5ce4b8b85cf5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">16</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.6 </b><b>F</b><b>orm and Time of Elections</b>. Unless otherwise specified herein, each election required or permitted to be made by any Grantee or other person entitled to benefits under the Plan, and any permitted modification, or revocation thereof, shall be in writing filed with the Committee at such times, in such form, and subject to such restrictions and limitations, not inconsistent with the terms of the Plan, as the Committee shall require.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.7 </b><b>A</b><b>greement with Company</b>. An Award under the Plan shall be subject to such terms and conditions, not inconsistent with the Plan, as the Committee shall, in its sole discretion, prescribe. The terms and conditions of any Award to any Grantee shall be reflected in such form of written document as is determined by the Committee. A copy of such document shall be provided to the Grantee, and the Committee may, but need not, require that the Grantee shall sign a copy of such document. Such document is referred to in the Plan as an &#8220;Award Agreement&#8221; regardless of whether any Grantee signature is required.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.8 </b><b>G</b><b>e</b><b>nder and Number</b>. Where the context admits, words in any gender shall include any other gender, words in the singular shall include the plural and the plural shall include the singular.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>5.9 </b><b>Limitation of Implied Rights.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(iii)</td>
<td valign="top">The Plan shall at all times be unfunded and neither a Grantee nor any other person shall, by reason of participation in the Plan, acquire any right in or title to any assets, funds or property of the Company or any Subsidiary whatsoever, including, without limitation, any specific funds, assets, or other property which the Company or any Subsidiary, in its sole discretion, may set aside in anticipation of a liability under the Plan. Nothing contained in the Plan and no action taken pursuant hereto shall create or be construed to create a fiduciary relationship between the Company and any Grantee or any other person. A Grantee shall have only a contractual right to the Stock or amounts, if any, payable under the Plan, unsecured by any assets of the Company or any Subsidiary, and nothing contained in the Plan shall constitute a guarantee that the assets of the Company or any Subsidiary shall be sufficient to pay any benefits to any person.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iv)</td>
<td valign="top">The Plan does not constitute a contract of employment or service, and selection as a Grantee will not give any participating Employee, Non-Employee Director or Key Advisor the right to be retained in the employ or service of the Company or any Subsidiary, nor any right or claim to any benefit under the Plan, unless such right or claim has specifically accrued under the terms of the Plan. Except as otherwise provided in the Plan or the Award Agreement, no Award under the Plan shall confer upon the holder thereof any rights as a stockholder of the Company prior to the date on which the individual fulfills all conditions for receipt of such rights.</td></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak90432b41-baa4-4d99-a762-1faee6849859" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">17</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.10 </b><b>Section 409A</b>. It is intended that all Options and SARs granted under the Plan shall be exempt from the provisions of Section 409A of the Code and that all other Awards under the Plan, to the extent that they constitute &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Code, will comply with Section 409A of the Code (and any regulations and guidelines issued thereunder). The Plan and any Award Agreements issued hereunder may be amended in any respect deemed by the Board or the Committee to be necessary in order to preserve compliance with Section 409A of the Code. Notwithstanding anything in this Plan to the contrary, if required by Section 409A of the Code, if a Grantee is considered a &#8220;specified employee&#8221; for purposes of Section 409A of the Code and if payment of any Award under this Plan is required to be delayed for a period of six months after &#8220;separation from service&#8221; within the meaning of Section 409A of the Code, payment of such Award shall be delayed as required by Section 409A of the Code, and the accumulated amounts with respect to such Award shall be paid in a lump sum payment within ten days after the end of the six month period. If the Grantee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section 409A of the Code shall be paid to the Grantee&#8217;s beneficiary within sixty (60) days after the date of the Grantee&#8217;s death. For purposes of Section 409A of the Code, each payment under the Plan shall be treated as a separate payment. In no event shall a Grantee, directly or indirectly, designate the calendar year of payment. To the extent that any provision of the Plan would cause a conflict with the requirements of section 409A of the Code, or would cause the administration of the Plan to fail to satisfy the requirements of Section 409A of the Code, such provision shall be deemed null and void to the extent permitted by applicable law. Notwithstanding anything in the Plan or any Award Agreement to the contrary, each Grantee shall be solely responsible for the tax consequences of Awards under the Plan, and in no event shall the Company have any responsibility or liability if an Award does not meet any applicable requirements of Section 409A of the Code. Although the Company intends to administer the Plan to prevent taxation under Section 409A of the Code, the Company does not represent or warrant that the Plan or any Award complies with any provision of federal, state, local or other tax law.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px"><b>5.11 </b><b>Re</b><b>gulations and Other Approvals</b>.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">The obligation of the Company to sell or deliver Stock with respect to any Award granted under the Plan shall be subject to all applicable laws, rules and regulations, including all applicable federal and state securities laws, and the obtaining of all such approvals by governmental agencies as may be deemed necessary or appropriate by the Committee.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(ii)</td>
<td valign="top">Each Award is subject to the requirement that, if at any time the Committee determines, in its absolute discretion, that the listing, registration or qualification of Stock issuable pursuant to the Plan is required by any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the grant of an Award or the issuance of Stock, no such Award shall be granted or payment made or Stock issued, in whole or in part, unless listing, registration, qualification, consent or approval has been effected or obtained free of any conditions not acceptable to the Committee.</td></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreaka21aaa41-d39f-4a2d-9f59-187bb5c45473" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">18</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(iii)</td>
<td valign="top">In the event that the disposition of Stock acquired pursuant to the Plan is not covered by a then current registration statement under the Securities Act and is not otherwise exempt from such registration, such Stock shall be restricted against transfer to the extent required by the Securities Act of 1933, as amended, or regulations thereunder, and applicable state securities laws, and the Committee may require a Grantee receiving Stock pursuant to the Plan, as a condition precedent to receipt of such Stock, to represent to the Company in writing that the Stock acquired by such Grantee is acquired for investment only and not with a view to distribution.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iv)</td>
<td valign="top">With respect to persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3.</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(v)</td>
<td valign="top">All Awards under the Plan will be subject to any compensation, clawback and recoupment policies that may be applicable to the employees of the Company, as in effect from time to time and as approved by the Board or Committee, whether or not approved before or after the Effective Date. Subject to the requirements of applicable law, any such compensation, clawback and recoupment policies shall apply to Awards made after the effective date of the policy.</td></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify"><b>5.12 </b><b>N</b><b>on-Employee Director Award Deferrals</b>. The Committee may permit a Non- Employee Director to defer receipt of the payment of cash or the delivery of shares that would otherwise be due to such Non-Employee Director in connection with any Restricted Stock, Restricted Stock Units, Other Stock-Based Awards or Cash-Based Awards. If any such deferral election is permitted, the Committee shall establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such deferrals, which rules and procedures shall be consistent with applicable requirements of Section 409A of the Code. Unless otherwise specified in a Non-Employee Director&#8217;s valid election, any deferred amount will be deferred until the earliest to occur of the Non-Employee Director&#8217;s death, separation from service, or Change of Control; provided that any such deferral election is made by the Non- Employee Director on or prior to December 31 of the calendar year preceding the calendar year in which any such amounts are earned, or, if such Non-Employee Director is newly eligible for purposes of Section 409A of the Code, then within 30 days following the date he or she is first eligible, and then only with respect to amounts earned after the date of the election.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>6 </b><b>A</b><b>m</b><b>e</b><b>ndment and Termination</b></p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Plan may be terminated or amended by the Board at any time, except that the following actions may not be taken without stockholder approval:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(i)</td>
<td valign="top">any increase in the number of shares that may be issued under the Plan (except by certain adjustments provided for under the Plan);</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd9aeaf18-d9c1-49ec-98a7-49d2eab99331" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">19</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top" width="4%">(ii)</td>
<td valign="top">any change in the class of persons eligible to receive ISOs under the Plan;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iii)</td>
<td valign="top">any change in the requirements of Sections 4.2(i)(b) and 4.2(ii)(c) hereof regarding the exercise price of Options and the grant price of SARs;</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(iv)</td>
<td valign="top">any repricing or cancellation and regrant of any Option or, if applicable, other Award at a lower exercise, base or purchase price, whether in the form of an amendment, cancellation or replacement grant, or a cash-out of underwater options or any action that provides for Awards that contain a so-called &#8220;reload&#8221; feature under which additional Options or other Awards are granted automatically to the Grantee upon exercise of the original Option or Award; or</td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">(v)</td>
<td valign="top">any other amendment to the Plan that would require approval of the Company&#8217;s stockholders under applicable law, regulation or rule or stock exchange listing requirement.</td></tr></tr></tr></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">Notwithstanding any of the foregoing, adjustments pursuant to Section 3 shall not be subject to the foregoing limitations of this Section 6.</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px"><b>7 </b><b>G</b><b>overning Law</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">The Plan and all Award Agreements entered into under the Plan shall be construed in accordance with and governed by the laws of the State of New York, except that any principles or provisions of New York law that would apply the law of another jurisdiction (other than applicable provisions of U.S. Federal law) shall be disregarded. Notwithstanding the foregoing, matters with respect to indemnification, delegation of authority under the Plan, and the legality of shares of Stock issued under the Plan, shall be governed by the Nevada Revised Statutes.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>8 </b><b>Severability</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">If any of the provision of this Plan is finally held to be invalid, illegal or unenforceable (whether in whole or in part), such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby; provided that, if any such provision is finally held to be invalid, illegal or unecnforceable because it exceeds the maximum scope determined to be acceptable to permit such provision to be enforceable, such provision shall be deemed modified to the minimum extent necessary in order to make such provision enforceable.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center">* * * * *</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak9f21500b-571a-4173-b275-6fed757a0374" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">20</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<html><head><title>inmune_ex211.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 21.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td width="21%">
<p style="MARGIN: 0px 0px 0px 0in">Subsidiaries</p></td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">Name of Subsidiary</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px 0px 0px 0in">Jurisdiction of Formation </p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">INmune Bio International Ltd.</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">England </p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<html><head><title>inmune_ex232.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 23.2</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>CONSENT</b><b> </b><b>OF</b><b> </b><b>INDEPENDENT</b><b> </b><b>REGISTERED</b><b> </b><b>PUBLIC</b><b> </b><b>ACCOUNTING</b><b> </b><b>FIRM</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated November 30, 2017 relating to INmune Bio, Inc.&#8217;s consolidated financial statements as of December 31, 2016 and 2015 and for the year ended December 31, 2016 and for the period from September 25, 2015 (Inception) to December 31, 2015. We also consent to the reference to our firm under the heading <i>"Experts" </i>appearing therein.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">/s/GBH CPAs, PC</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">GBH CPAs, PC</p>
<p style="MARGIN: 0px">www.gbhcpas.com</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Houston, Texas</p>
<p style="MARGIN: 0px">November 30, 2017</p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>inmune_ex31img19.jpg
<TEXT>
begin 644 inmune_ex31img19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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MU9HH K?8;7_GWC_[YH^PVO\ S[Q_]\U9HH K?8;7_GWC_P"^:/L-K_S[Q_\
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MTGV&U_Y]X_\ OFK-% %;[#:_\^\?_?-'V&U_Y]X_^^:LT4 5OL-K_P ^\?\
MWS1]AM?^?>/_ +YJS10!6^PVO_/O'_WS1]AM?^?>/_OFK-% %;[#:_\ /O'_
M -\U!>V-K]AN/]'C_P!4W\/M6A5:\_X\;C_KDW\C0 6/_'A!_N"K-5K'_CP@
M_P!P59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/^/&X_P"N3?R- !8_
M\>$'^X*LU6L?^/"#_<%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0\;\_'>\R<?N'Y_[=VJO\,GA72[(MM!&OP;LC_IC-5CQL"?CK>D#.('S_P"
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M9P,X/09Z'UK>^'WCZ?Q1K&J65X(UV8GM=N.8R6&/J-OZT >CT5Y!J'Q#U?\
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MYQ/+)SO";,CZ8% &[1110 4S:N[=@;L8SCG%/HH *09QS2T4 %%%% !1110
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M\GC'7Z5JT4 9<>CZ9$P*64(VLK#CH5&T'\  *6;1=,N'F>:R@D:9@TA9<[B
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MNH,&(#I)@\<<X*BO:J* /,M#\%Z[H?A#^Q4:UEDN%D2ZE9CDK@A,<=N*J_\
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M]RY_[]4?\)/8?W+G_OU0!N45A_\ "3V']RY_[]4?\)/8?W+G_OU0!N45A_\
M"3V']RY_[]4?\)/8?W+G_OU0!N45A_\ "3V']RY_[]4O_"36/_/.Y_[]4 ;=
M%8$?B6S1,,+EVR3GR?\ Z]/_ .$GL/[ES_WZH W**PG\5:=&C.Z7*JHR28N@
MK8@GCN8$FB.4<94T 2U6O/\ CQN/^N3?R-6:K7G_ !XW'_7)OY&@"2#B!/\
M='08J6D!R,BEH **** "BBB@ HHHH ***CDD2)=TCJBCNQP* )**K?;[3_GZ
M@_[^"C[?:?\ /U!_W\% %FD&<G..O%5_M]I_S]0?]_!1]OM/^?J#_OX* +-%
M5OM]I_S]0?\ ?P4?;[3_ )^H/^_@H LT56^WVG_/U!_W\%'V^T_Y^H/^_@H
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M@#RC_A1.B#&W5-1&.F)6_P :BD^ VDR-SK>H[1_"7)_]FKURB@#R,? 71UC
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MMUG_ +^M_P#%4H^"J!@3XMUHC/(\YN?_ !ZO5:* /*3\%5)./%VM#T_>M_\
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M !1110 4444 %%%% !1110 4444 >1?$()_PM_P7G.[:_P"7S5Z[7DWCXO\
M\+@\%@ ;=LASCV:O6: "BBB@ HHHH **** "L+Q#_P ?.E_]?/\ 2MVL+Q#_
M ,?.E_\ 7S_2@#0?4;*.8Q/=P+(#@H9 #GZ5=KROQ'Y\FK>*DMI+, 6H+>:Q
M#@;1G9C^+'3WK5M==NVN],6"[86[)#"T+  J3@9;/)/TXH [EIHT=$9U5G^Z
MI/)^E35YU9R:E?3:?=W6J[M\SQ(0%Q'@CD<=3D=?2B?Q'JD=O"WVT%[=B),
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M\7^'IM8O==O$M[0R*D",?F&UL\YXYI/ >E1P^ O%VKPW5PMQ;,T 0-@#W^M
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M9V.K8Z[3FI*\*\$K>>'/C3?>&EU*YN+$Q,P65R<D)G/US7NM !1110 4444
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MTV#2M&OY;2=5U,;E3(S$@QEF]AD?G6L_C#3X_%LOAR0,MTEO]H5B1M<>@]Z
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M/L-M_P \5JQ10!7^PVW_ #Q6C[#;?\\5JQ10!E:K96PTB\(A7_4O_(U+HO\
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M^$(%Q_$91C^=>O44 >1+XB^+?S*?"]OUX8R#_&F_V[\7O^A>M_\ OM:]?HH
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M^*P&#\/83[_:!_\ %4?\)M\5O^B>0_\ @0/_ (JO6Z* /)/^$V^*W_1/(?\
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M/Q;K2^"-6U^XALFEM9C%%'"6P=L@1LY]:PW^+-^-3EC&FJL 1-JOD.&,._\
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M);O+;PRPJNXB1U^4J.GR]ZNW!^('VI;U_"^A2W(&!()R7 ^NREMY?'J+YO\
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MZF@#TJBBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T
M3H-J*/04ZHH#N@0Y)RHY/6I: "BBB@ HHHH **** "H+F;[/:S38SY:,^/7
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ML<7VNYA$C2RC*QH!UQWYX_&N%U>_T_2_#6M:)::_87FFR-"UC&MRCR(?.0E
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MPR:5:Z>=0D,4<+))D??;)*D>F":FT;X;6VFSV\TUVT[JLZRC& WF*J\>F M
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MD]: 'T4QF5<;F SP,FF//#$<22QH?1F H FHIH((R#D'N*1F5%+,0JCJ2<4
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M %;[%:YS]FAY_P"F8H%G:CI;0C/7""K-% $!M;<XS!$<=/D'%'V2W_Y]XO\
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M(7RQC/KBK=% &=?:/I^I6C6UU:QO"QR5 QG\JO*H10J@!0, #M3Z* "BBB@
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M6T^W8LDE\21CYKR0_P VH'A/30^_S;_/_7[+_P#%4 7;W2--U!UDO;*"=T&
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M8P;(-PF/^^:U/%5I;PZ!*\-I"'WKTC [UE^#/^1K\3?]=H__ $$4 =S1110
M4444 %%%% !1110 56O/^/&X_P"N3?R-6:K7G_'C<?\ 7)OY&@"P.G Q2T44
M %%,)VJ3R<#/%$;B1 X##/9A@T /HHHH **** "BBB@ HHHH **** "BBB@
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M*@#F_'5K<PZ]H^L#2GU6TMTECDMDQE6;;AL'KT-<-:^!->FBC+6[6A%I+(B
M*V-Q4B,YSZ'I7L/_  DFF?\ /9^/^F3?X4T^)M,RN)7(+;<B)O\ "@"70,?V
M!8A;9[8"%0(9#EDXZ&O-?$_A;7)=9UG4=,B+>?<6Z2PD\2Q!@V1[@J/PS7HP
M\2Z8W*S.5)V@^4W7\J>WB"R5E7]X6+[,!#UH \AMM%\2W&L:KYUM=I#=2E9
M)#M8?:0>.>/D]*9+X3\36UG.EK%=J)2ZR;9\DQ"X. ,G_GF![U[+)K-E$2KN
MP(XQL;_"H4U^T?\ @F (SDH?7% '$VFDZLGPS%J\%[(RW"N8)91YCP!\LN1Z
MKD>O-1^"?"-[9^)5U?4+)HP+39;AY-YA4LWR'GGC^==D_BJ!68"SNF ; (3K
M4D&OP2WMO:R03PO< [#(!C([?6@#EKKPW?\ ]HZS+'9C;<7L4D>T@;E&<_2N
M,MO FMPV-ZC:?<) S6H>*&=0\FSS-Q!)Z?,.*]4B\5P7#R_9[&ZECC8KYB@8
M)'IS3T\4-)RFCWY7UPO^- '*WV@ZH/ .B64ME/=R6K)Y]J9P'8!".6!&<$CO
M3/#7@N_M;'65NH_)NKNRMXHY"^X@B/YUZ_W@*ZS_ (2AN/\ B3W^>XPO'ZT[
M_A(92V!H]\1G&<)_C0!P>H>']=U[1['3;C0_LW]EQ1H3YJ[;E@0O&#D#&6Y]
M*S8O VO:=*)DTD36J1L)K9+@*9OWY8*#NXXP?PKTZ/Q#-(>-&O@H8 L=G&?Q
MJQ)K-Q'<-'_8]ZRCI(-F#_X]0!YKI?@WQ!'XHL;Z:"XMX582(L=PI2!=V2C
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MD.H>(M[@:5!A2,'S#\WKB@#HZ*YX:AXBZG2[?&>F\YQ33J'B4_<TJV'IND-
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MFX<\CCK0 M8&N@G6=#P ?W['GZ"MP31GHZ_G7/:U<Q/KFBK&ZNPG8$ YQP*
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M$NE+N_TI#M<(P!Z9S_A0!LT5C-XDTD-*HNE<Q+N?;S@9Q_6H_P#A+=$S@WJ
M^A.* -VBL4^*M(!P;G!^E,;Q5I"@$W!Y&1QU^E $OB8;M!G7GG XKG?!G'BW
MQ./^FT?_ *"*MZWXBL]0TN:ULQ-)<,!L41GDU3\&9_X2WQ.&!#"6//\ WR*
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M^M(?#VE-))(;;YI"I8^8W.,8[^PJR^IV$9(>\MP0,D&04]+ZUD&4N86 ..)
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M7AK3FM(?M<@),K2/$<L2?0#WK5_X2W3]RADN%SGDQ-QC\* -O[-!_P \(_\
MO@4GV:'_ )XQ\=/D%9$/B6VG"[;>Y!;D QGD9QFI!XCM-ZJT<Z[FP"8SZXH
MU!!$#D1(#ZA17'^$_P#D=?%?_7PO\JUY_%5E;,WFQ3K&O#2%. ?2L;PBP?QE
MXJ<=&G0C_OF@#MZ*** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_ (\;
MC_KDW\C0!9HIJDLH)&"1TIU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4C?=/TI:1ONGZ4 >0Z0N^%HSDI)XLV2*.A7#<'VKTP
M:%I@#!;.(!TV, HY%>;Z#MV'=_T-G'&><-7K= &0/#6B@@_V;;9!S_JQUIW_
M  CNCX/_ !+K;D8)\L9-:M% &4GAW1T0(NF6NT= 8AQ33X9T-E56TJS95.0#
M"IQ^E:]% &4OA_2$5532[155MR@0J,'UZ4Y= TA""FEV:D'(Q"O!_*M.B@#,
M_L'2 S,-,M,L,$^2O/Z4CZ!I$ADWZ79MYIS)F%?F/OQS6I10!E?\(]HOD"'^
MR;+R@VX)Y"XSZXQ4BZ)I:0M"NGVHC;[R"(8/X5HT4 98T32U#@:;:@28WXB7
MYL=,_D*7^P]+P1_9MI@@@_N5[]:TZ* ,IM T=T5&TNS95&U085P!Z=*&\.Z*
MZ*CZ39,JYV@P+@9_"M6B@#,31=+CB:---M51EV,HB7!'I]*;_P ([HN%']DV
M7RYV_N%XSU[5JT4 947AW1895EBTFR21?NLL"@C]*'\/:+(^]]*LF;.<F%<Y
M_*M6B@#+?P[HLC%GTFR9B,$F!>?THBT/28%*PZ;:(&(8A8E&2.AK4IC+N7&2
M/<'F@"@VAZ4\WFMIMH9/[QA7-)%H.DV\ZSP:9:1S*<K(D*AA^.*TAP,4M &9
M_8.DA0HTRTV@D@>2O?KVIK>'=&:-(VTJS*1_<4PKA?IQ6K10!D?\(SH07:-'
ML=N<X\A>OY4X>'=$"%!I-EM)W$>0N,^O2M6B@#,CT#1XMOEZ79KMSC;"HQGK
MVIQT;32NTV%L1N#8\H=1WK1HH SFT+2G.7TVT;ZPK_A6)K.G6MKJ^A&UM(H0
M+DY\M OIZ5UE<YXC_P"0SH/)'^DGI^% %7P;96DNDW$KVT3.UT^6*#)Z5T(T
MRR4L19P L,,1&.:Q/ ^[^Q)PQZ74GX=*Z>@"LMI;(X=;>)6' (49IS6ELYRT
M$9/J5%3T4 5_LEK_ ,^\7_?(IQMX#G,*'/7Y14U% %?[';$@FWCR.AVBE6V@
M0DK"@SUPHJ>B@"(P1,FQHU*^A'%.6-%.551QC@4^B@!@1%Z*!^%+M7.=HSZX
MIU% #%1%7:J@+Z 4*JKG:H&>N!3Z* "F!%#%@H#'J<=:?10 F #G'6N;\<<>
M&I#C.)%/3-=+7,>.B1X;<@@8E7)- %Z37].MM:M='FG"7MQ$7C0_Q 8_7FK%
MEJ]E?_:?)F'^C3M;R;CC#J<$5P?BW1+C6/&%N;1"EW;V1GMKC'"2+C S[Y->
M:74FMWDDMWJ<$UC97-W=3&-HBZK,7!&>G/7!H ^E3(@!)=0!U.::)HB6 D0E
M>H##BO$8X/$-S;V.CSQ7DJZG%%<33%"I"QQ]#Z$MMK TY-5_M"]>SMKZ/SXY
M$N,*2[8DRP+=SM![4 >_P:Q9W%W=6R2@-;$"1B1MY /!_&JM^T<FOZ&ZN&^:
M;:0<@_NZ\0N;:W:PNO[-TR__ ++>\B^62(E1B-<ED_B&_/<<UW'@"&>*RT"&
MYCD@\JYN=L;1F,8*$C"GH.: /5**** "BBB@ HHHH **** ,3Q:H;PW=Y .%
MSS7/^"?^1J\2_P#76/\ ]!%=!XL_Y%N[P,_+7.^"B?\ A+?$PY_UD?;_ &10
M!WM%%% !1110 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@"S111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW3
M]*6D;[I^E 'EOA?2IM4M=1-O.D4MGXA>Z4R E3MR,''UKN/^)X9%*WNF&-A@
M?NVR3[?-7-> L_V9XHVYS_:-QC'TKS;PY+XHM5\*PSB[>&U?[1*^&)/FQ,R
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M.B@#);1[AF)&LWXSV!3_ .)J"?PY'=H8KN_NYX"<F)RNTG\JW:* &!%&#@9
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M$]IJ\/VC0KJYT998YGMXHBY9S;88X]?,)S[T =@?A]=;@H\;:H&;E1YAR?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M EAW&%-XPV.14E-7.P9&#BG4 %%%% !1110 4444 %(<8YI:@F4M!(@&2RD
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MO_A'-8 W[=YC3'U^]TKH:* .<NO%3V5E+=W&A:HD,2%W)1. /^!5O12"6))
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ME 'VI<Y4C.X+W]*]L_X2#0HU+C5; 9 )VSID_D:A'B7PTI9EU&R!8Y)##DT
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MAG\/DKM** .0B\,H7;S?#'AH+GY=L )_'Y*;_P (TWGX_P"$6\,>5Z^2,_\
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MQ]P9SC;C/% 'T?16-X9^UGPSI_VZ4RW7DCS'*XW'Z5LT <5X$S_:WBSYL_\
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M5T-% '.?\)A9;MO]GZOT)_X\)/\ "HCXSL1Y7_$MUG]X"1C3I.,'OQQ7444
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MM^]D_P *K2ZGK-A/:B_MK+R[BX6',$C$C) SR!725@^)6P^E Y(-]%P/]X4
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MOL>* /3K;Q5H-W?164&J6DES,F](UE!9A]*HZCX]\-:=#?L^J6LDEDA>2%)
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MI4 4_*'8?EG%5=3\;V<*6+VFD02Q2/$+FY"*4C+8W*.Y.#UH AE\.:#N6_\
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MK 'H1NKTVO-O!P<?%SQMG.TK!C_QZ@#TFBBB@ HHHH **** "BBB@ JM>?\
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M\!>'UC;$MU$&5>8[HJ<*#P/KGGUP*70/#FAPWZZGIJ1BU51Y)#YP0,=.V.E
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M;_"H-8U&PT;1KC47CC>.)-P5,9;V%5-0\0V^D^%EUM+1WMV579(UY ;O^HH
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M V"ZA<EA@]Z02(>C@\XZ]ZH_V#IF3_HW7K\[?XU$?#6D';FS'RMN'[QN#^=
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M9IWVI+J*:7<GG%Q]U<[LG./0?6N_K@/#O@V\TOQE?ZQ=+;LLT\CQNIRP5E4
M=/4&N_H X[PJRV^L>)GF*1I]N)W,P [UU"WMJWW;F$Y])!7GMTGF)XBBDC^1
M]352I&=Z_-6I-K'AW3M<CTP:$_F--Y*S1VJ>7O()(SGV/:@#K/M]E_S^0?\
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M[<:MKT=U"R"U>Q*3QL?OS*N(V_ A3^%=7X3TJ?1?#EI97;(]TBGS77^(Y/\
M3%2G1V(4-J5X<*5SN7GCZ41Z"(XU1-0NQALYW#)_2@#9HK-_LOYP_P!LN=P
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M_DI/B,#I]@LSC_ONO1#:V[#!@B.1CE!7!^%P!\7?%P P!;6W_H4E 'H=%%%
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MRK;+%;@-U())Q]>/RK:'PVU 'GQIJY_X$?\ XJC_ (5KJ/\ T.NK_P#?1_\
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M:2?$.O* .O\ :,O_ ,534^&-KE6_X2'76QW_ +0EY_\ 'J -/P\"=;\18[W
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ME<I)&-S*+Z3@?G4C> O JWD%L;Z\$\P!B3^T),L.W>@#T/[=:_\ /S!_W\%
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M.W3;09.3B%>?TIW]BZ6>NG6O_?E?\* .;_X6IX._Z"Y_\!9?_B:/^%J>#O\
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MO1(M2\+6D/EQW6FQ16\@&!(@".<X[]>M32S^']4F8/+8WDT,9<J'5V51UX%
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MVG([_P"12G6K$-M,I!P#C;Z]* -*BLJ37;&/.YWX'.$)[XIXUNR;HSGW"'%
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M<.HZ8[5N:AJ%KI5A->WDHBMX5W.YZ 4 <7_PBWCC"C_A-'X&"?(3G_QRI?\
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MUUJPO;R[M8+E&EM&"S#/W20"/T- '%GX?^),?+XYU'/O''_\13O^%?\ B/\
MZ'G4O^_<?_Q%>@>=$2%$B$GH-PYH$T1) D0D=0&'% 'G_P#PK_Q'_P!#SJ7_
M '[C_P#B*3_A7_B/_H>=2_[]Q_\ Q%>A)+')G8ZMCKM.:DH \<TGP7KFH:OK
M=JWBZ]7R90'/E1GS,YY(*^U:$?P[OI8W:+QI<-Y3E)"((<*P[?<ZBNG\,?\
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M1J<AQ_X_6:_PN,D*A[J(R; ,[!A#YI<A>.!@XP*S[WX1M<6GV6TU"!7 195
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MJLX+8E5 ^:/=EOJ=WZ56\-_#K_A'O$=_J+:GO%Y;M#Y04+UQS^']: +3>&_
M4<<DY6WVJ^QF%XYPWI]ZHWT3P!%($<VP8@$#[8_.1D?Q>E8W_"L)Y+ 6<>LP
M9M[HR1XA0\%&0[^.6PW>K<?PKTNUAM#->*\=K,DKO*@RP6$QX)/N<_A0!>_L
MKX?)'YN;?:'\OBZ<_-Z?>HM;/P-<65]<K:QBVL7V2NS/P<!O7GK7.VWPHL+/
M=/!X@C69KEI8RR)(H20;=NT\9YX/K72S> 8Y?#^K:4-29$O9DD61(U!C*JHQ
M[Y*Y_&@!L$/P_O)((XQ9NTXW1@NW/..YXJ+1!X,U;4-1BLM,A,=@BL\Y&5;)
M/3Z8K-L/A'I.FPVMI/JTDDH>-U+1J&81N7(!]\\UJ:-X L?#ND:I;-J[O%J$
M0@\PHJ>6,MC&.I^8T 21W/@22"!X8K219W9(P(SDLO4'TZCK56TUCP3<6*W%
MU96]M)N"-&T>XJQR0.._!_*J6D_"C2K6V@,&N3RK%+(\CA0/,#8R.OR].HJ6
MZ^'N@Z1BZNM5DAA>=9RK\AI K#('_ C0!J/>^!(W96%D-JAR?+.,'&.?QJK<
MZUX&AO+&WBMK6X%U.\)DC4;8MB,Q)]OD(X]:QSX&\)6I,-SKX:#[,-L3 <$@
M#S,]\YZ>]6M/^$^@"SMQ;:A*\:.)0P_B_=-&>_&=V[ZT 6-3U_P/9:3#?6UI
M:W?FNJI'''R07"DGTQ[U8_MGX?K!+*_V-%A56DW1'C)QZ<\\<5GQ_"'2H8;?
M_B:3;(PHE;8H$JJ^\ \\8('(]*P]-^&$%[K6JZ9JNJ6VYHP;6*W8N\:>87!8
M$ =Z /4;+1?#]S;1W-K86DD,H#(XC!!':N4\(6T-K\5O%L5O$D48MK;"HN!]
MZ2NXTK3HM)TJWL("3' FQ2>]<7X8_P"2N^+_ /KVMO\ T*2@#T.BBB@ HHHH
M **** "BBB@ JM>?\>-Q_P!<F_D:LU6O/^/&X_ZY-_(T 6:*** "BBB@ HHH
MH **** "BBB@#S<:;IMW\6KJ8VD*)I-IYQV*,M*^#N/OAC5[Q=JEOKOPPU2]
ML=[PO&ZC<N#E6VG]0:['=;K.R[HQ,PRPXW$41RVT@\J-XF&"=JD=/I0!X#9:
M??\ AG7M,LVM[BXL$TNXO+21&.Y=UL<H#V^;<<^]9-KKE_<V>HPPWU]%#.+7
M8$F+E&,I#?-QSCK7T -?TZ3Q'#HB 23O;&97494*"5(S^!K!UKQ_X=\.:LVF
M3V\C>5M-Q+%!E(<GC<0,"@#ST#4]/UVX-O?Z@T=IK%O!#&9F(VL%W<>]/\.:
MQJL'C-&OKN[:ZAGFDO802Q\H;< KV'7'XUZSI_B+3=0U>_L4B:/[&D<KS2)M
M1]V<$$]>E:<ATZ=9$D-NP?Y'Y'/L: .-\8^*A<?#3^TM(64R:HJPVF1M8%P2
M"?P!KSBPTSQ-X,TK5-#^QBU>ZT])D^RRERQC95<C@88[B:]TA_LO3M,MX8FM
MH;) %A&1L [ 5$VMZ5_;)TM[B/[8L/FE6QPF1W_$4 >$R22%]2U#0I-0.GFU
MMA<2%CN*93?@_G2S*;RYNETJ34(["ZU6VCW[CYC1&-1U],5[\9[!58&2W50H
M+#( P>F?TIJW6G;HU6:WS(?D (^8CCCZ8H \&UNUUW3_ (B'3+>ZOXA]JA6T
M\LEF,.%W$'T^]G\:BT?^UHM<U.S\_5+F=H+D.R@I)#\K8)7/S>W(KZ&NI;2U
M3[1=/#$J\>9(0,?B:YOQ!XRT[P_>:9 MM]KN-2DV1"''3USCI0!QOPBEO/[0
MU&&5IIXQ#'F9AM ;+9!7^]TR<^E>OU%$J! RHJ;AD@#%2T <GX9)/B?Q,!VG
M3'_CU>;:EXQ\4:?K]Y.E^'6RNKE'MR3M9!*JCCV!X_&O2/#''BGQ.>?]>G_L
MU8-U\1]$M-:D@NM)E2'[1-!-/Y1;#(X7)&.A)_"@#F]1^)^JZAJ]W802"SAM
M[P*9@,;55]I!/N:Z'Q1X_O\ 2O$BZ=9FVE4HC*A^_(&3.1[<Y_"N@T[Q)X<U
MJ_U&QT]%FNK16:5/*QOVGG![\X%<QI?CW2$NM1U36K!+22-_+7;\\O'R@;.O
M2@#/'Q0UF[U&UL;'[-)+),8Y/DX7"Y.?3%4[7XM:W]BEENDA4PW4L3OY>%VA
M?EP?7-=Q_P )UX3@5YHT<QQ)YK2QVQ*KE=V,C^+!Z5EW_P 3O"L&GW7V:SFF
MN$C,XMGMBA8XW<Y''&#].: .<N?BWK$%Y<0*(':.SEFVB/@,J;ASWS6SX;\5
MZ]J'C:WLM2OXHT1)(VC5,+,P52"/^^JTV^(OA6 S"\M)H98HD,H-L23O'0<<
MULZ/XKT+5]06*V@ECN55F;S8"ACP!G.>G&* /-].^(7B*RNFM+C4;>61+EAM
MDCRTY)'R+Z8_K5KQYJ?B6P\3:U<:?<3'3UBM+=XE8CRVDR?,'TV$'ZUN:C\1
MM': 2:3IS371N8TC\R C<'S\Z\<CY:M:YXXN-)\6?V7+8(8"$R\@P),JQX8\
M9&.GO0!PL]_K=IX@U.::_P!0M[6ZGO([>2.0OO*R8"[>-N%R0<]!6YX*U*0?
M#C7);J^O)(82-EU'*79\CG;Z'/!]\U:3XPZ7]AA:XTJX2ZF1FCC9,<X)';T[
MUJ>&_B7HVMZE9:*8/(O+J!) F/E+%-Y&,>F: .%M+^]^PZ!]DU35FU"42E(V
M<D>678>OS,H_05M^$];N+?0M<M]8N=0D@GN98[62(EI"%C!<J>W\7XYKUT0Q
M#!$:#;T^4<4>5&!CRTQ_NB@#Q#^T]06P\-C3[W5I-1+8C5F)2>/S#G//) Z^
MU=+\.=>N DUOJ%Q<RQW%RT=N\Y+'S!C<H)[#*X_&O2A%&,8C0;>GRCBHC:V[
M21R&%-\9)0X^Z3U_E0!Y=X;U#51X\>.[O[A+:7[2([9E.QB-G(Y]ZH>%_&/B
M=/&6EZ$R[]/E56E$D7[P _Q;O2O9_+3=NV+D=#BFB*,-N"(&'?;S0!YKH7B_
M7;SXFZSI%P VGP),(%\K!#(P"\^XS6!JGCWQ1::1//!.TMP;WRV3[+A81ACM
MW9YZ8Z5[2(XPQ8(H8]2!S1Y,7(\I.3D_** /#?\ A*O&5G??N+GS&NIX7E$R
M8"!H@VT>@R<4^'X@>+GO9(O,!D93YT0M^+<>859@<\X4;NU>W^5'_P \T_[Y
M%4;30-*L+R:[M;"&*XG_ -9(HY;ZT >6Q^*?&4[&X%P([2RT\WDK-;X-R%D?
MIS\N0H'>MB^OM9O?A[I6H:H;@>=<QR7JVH*ND&[D?EUKT*\T^TO[5[6ZMXY8
M'&&1AP1Z5,L,:1+$J*(U& N. * /-+Z&^NOAE%'IKZC:M)<KL,Y+R^7_ (5S
M3>)/&MUA3"I^RZC!M"9!7Y9,JWMP*]SVKC&T8';%)Y:#.$7DY/% 'C4/BOQ?
M=V"_9KEFC5\I=&VQYH[C&>W'.:V_#NO^)M4U'5-/O6VFTLY)"ZQXR[\Q@>X6
MO21%&!@(H [ 57MM/L[%YGMK=(FG??*5'WCZF@#QW0/$7B.S;2K-+N661WQ(
M);?)G;S,."<\;1G_ +YJ[XCU;Q3I?Q U(::LWV*90J-LWJ)/*&/PS7KGE1@@
MB-<CH=O2GE%)R5!/TH \7'B3QU'=FWN#,RQS!(I$M_\ 7.8U8*>>!DXSS5;6
M-4^(4DEQ8&VG: *8960'G WL0?<-M_X#7N&Q/[J]<]*7:O\ ='Y4 >*:QJOC
M/2]-N;RU>XBAB65#&4)5%"J01[\FLM-:\0-<'Q!%<7DUO8_;%1[@$=/*VJW)
MP3D_E7O<UO#<0O#+&KQN,,I'!%5_[)L!9FS%I%]G)W&/'!- '"W%SXD;X>:9
M=2279N[F99+DVV3+'&RL<+]#MKBE\)>*=3F.I7T5Z^H;X#\^0&'DN3D>H8*/
MK7O850H4 !1T%.H \@\$V_C6\O;$ZS<ZM#;I)ND$V06.T[E//W=W3VQ6;++\
M1IO$NI010ZM%923;5D^8JJ^9@%#V^7FO<:* /*/#UQXH/BG2].O;VX\MXI)K
MI)6.]-K,J@CT(53^-8VL:;XMT_Q+JMWHUOJKM+J1(EB)*O&(T*@CN-VX5[2+
M6!;EKD1*)F&TOCDBJ\VI6-L\2S74,9F.$W.!N/3 H \?A3Q_9ZK;+:6>HB)G
M+,FTK%SC)8^O%:FA?\)T/ NK_;!J7VWS?W E4^?MYSMY^F*];HH \N\+6OBR
MYUJS_M*;5HM/A$[+YY*M(,KY8DYY.-U<[:Z+XOTG5+N6SCU57N[R9U9<E21(
M-ID]5*%L?A7N=% '@VN:KXIT:X,EYJ.I1W%S/(UO;[V &+@(F1_<,9/XXITA
M^(,XO5NAK#6TD\HF2)#D*<^6(^?N_=S^->X36EO<.CS0H[(<J6&<5'>7MK86
MS7%Y/'!"O)>1@ /SH \IETKQ/'X;\+"VM[U+VV%P)6"G?'N5P"?3J*S]GQ#A
MU/3;<OJS6YNU1R2W,?!9F;TY/Y5Z]I6KV>LV[7%C(9(0VT/CAO<'N*TZ /#M
M*M/%]CIUT\1UN-;*W!$+[L22F1]VWGD!=GYU)!:>/M0AAEEGUFV9I(%*[V7"
ML6WDCVPOTS7MM5WF59XXRKEG!((7@8]3VZT >)6D?Q)^W6*SOJ@'V10X^;:?
M[V?]OI^M:.C:1XE@\:Z//JQUBXMHG=5=Y&(4MS\W^SQ7LE% 'AEYX?\ %.G^
M(+ZXLHM8-M=7LCEK:1@=^_Y&/^QMS^8K<@\->(KWX?:Y;:K/?3:A>79*0M(?
MEC$O&WV*C->G7-U;V4#3W4\<,2]7D8*!^)K'T[Q?I.K:A]BT^26X89S+'$6C
M&/\ :'% 'D1\!^(HKN;R=/E\M88%B;<005F5CSCJ ,U'X@B\5>&=#:XU+4;U
M(I9V+;KE@6;^'#=@.*^@J8\:2+B1%8>C#- 'CNH:+XHUWPYX8NK-[@W4=K.)
M9?-(<%A@'/KTK5U7PIK%Q\/WTS9<3W$5^LL:M*2S( ._US7IP  P  !V%.H
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ME02-I(Y'I3Z** "HDC*,YWEMQS@]JEIA8 @$C)Z#/6@!QZ<5'&7,2F0!7(Y
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M[2!N'&3C'&.?RH U:*I>?>[7/V$9'W1YP^;].*:USJ *[=/5@5R3YX&#Z=*
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M:-=7.BVT\KZPUP)%$<P*QQ#/7CCJ..])#I_CRW\16R0.[2&&22YN9#\K \@
M>OXT =)X>&JZ-;9N-%O)[IG9W(^X&8Y)4=NI&:HW\OC:\UYKLPWME:1./LZ6
MZ>9N&WD.N0#SGFH4L/B-Y=JSW$Q<KDH+D#;\X/S''/RY':HX-/\ B2LFQ[QG
M5VF+,9@=BEFV >^,?A0!J,^O/$QU&VU.^8[?DB3R%X;.-H)S[GOTINE:/9Z;
M<"ZA\&2&YDD+F21=Q0^QQQ3?$VA>*+JZT\Z:7EVV+1S22S#!<@YX]<GK7.61
M\?:CJ.H:=97UXCV<8PSML1FQP!GWZT >CMKNL1VTC1^'9LKPB;NI_+I7/R0:
M]J6VZUW2I;IE;*V4;$1*#V/'S].X%4;S2?B+=:A/)!=F&WC*"%#< DG'+?3V
MJ75-%^(%SI\KV6I-!>&93&@N!M"?Q GUZ4 =:-1U:UMU2VT$"-<!45\8'TQ4
M)\0:[SCP[*><#+G_  K<TR.[ATVWCOI5ENEC E=1@,W<U=H \Z%G.M_=7G_"
M*32/=X,_FRDACZ8QT%6&MY39?9%\&6PAC82)%T7<#UQMZXKO:* /*K#PZ(+J
MXN;CP=Y\LC$_OI-ZXZX *\<]JZ:UU35K.,0V_A<PQ XVQM@?EBNOHH YLZYK
M.]530I.3C+,0!^E5H]>\0.Q!\-NH)PI,A_7CI76T4 <M_;7B4'YO#T?"YXN"
M>?3[M UOQ%N;=X>7;@;2)SD_^.UU-% '+1ZYXA:0!_#P5#W\XYS_ -\T[^U/
M$YBW+H5MNY^4W1'?C^'TKIZ* .2_M+QD7P- TX+M)!-^W7' ^Y5K3[WQ1)/"
M+_1[""$D^:T=X7*CV&P9KHZ* $W#U%8U_8S7'B#2KV)P(;59EE7?C.\+CCOT
M-0W'A6WN+AYFO]14N<E4F  _2HQX.M0,?VEJ9^LX_P#B: .CW+ZC\Z3<O]X?
MG7.GP=:D8.H:G_W_ !_A2-X-LFZWVH\XSB<<_I0!TFX>H_.C<OJ/SKG?^$/M
MO^@CJ?\ W_'^%(?!UJ1@ZAJ?_?\ '^% '1;E_O#\Z-Z?WE_.N;/@NR(4'4-2
M.WI^_'^%1'P#I1;)N+\DG)S,/\* .IWJ>C#\Z\\\,KGXP^+&]+:W_P#0I*Z&
MV\':;:74-Q'+=;XF##,N02/7BN>\,@_\+?\ %IR>+:WX]?FDH ]%HHHH ***
M* "BBB@ HHHH *K7G_'C<?\ 7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH **
M** "BBB@ HHHH X1O!GAV\U:ZQ>-)<3NTAB6124;=DD=^&]:M0?#W2X!(RSW
M)EF;,TI8;I1Z'CIGFN,MO".J/XFU"8V-Y&%EFE259MNXF0LN,'ICL:6VTSQ5
M/?7#366IQO*1'*%N/W>W(^8?-D''I0!VC^ =&D(($@4LC,H(P^QMP!_$5+8^
M"M,L;O[2))I'5U,6\C]VJMN"CVR2?QK&MM(UBQT'Q!9Q)=M&+A#:!IB9'B\M
M"X5B<@[MXZUSP\/>(+FUO9XX=4ABBMY9=/@>Z;>'V?*&.[D[@3R2.: .Q;X?
M:0=52_5YEE5TD(!!!922IY'')/2G/X8LK[3M-L+&\DBMM,D:/<I^?<,<5C>'
M=*U^+QM]KO/[2$1#>8SNI@(VK@ 9SG.>U4M4\,^()M2URZMH[J-EF>:Q\N8J
MK,<8. <'IWH Z*7X>:&)5EA788579&Q!564$*3W_ (CWK+T?X9I'%*=:NH)I
MCY8@:W! 144KCYL]C63>Z-KLOGM)IFJ,PN2]ZT=T0+E.<"(;OEY^E5;K1-;L
M]*DN;V#4=JQHD$*W3;U4D?(<-]X 8SG\: /2+KPMH]Y8Z?:2)^ZLQB !O5"O
MX\$U)<>'=(N(K:&9 1;V_P!ECR_(7&,?7%><OX<\3&*!!:ZAL;S#:K]IYM"9
M0R^8=WS?)D=^M-O/"'B%+2TCBAU%[EIGEEF6Z) ?S21D%ON[>F/:@#M&\)^'
M=1+3QL V[RF=9,$@((RGY#%+<^%/#;W"69 CN)93-%M;D,$5#C_@*BN,A\-:
MS:Q3P?V/J#L[D12)<X5)2,^:?F^Z,XQ[=*MP:%?V.H:%%+YW]J2WWFR.TC,/
M+4+N]@" : /3[&R@TZSBM+9-D,0PJYZ59HHH YC02O\ PE'B( DD-$3D8_OU
MP-Q>ZQ8:V@)N9+*;79YXF0$^5M60%#[$D$?2NYM+V+3M;\27DP/EQ"(MCJ?O
M5=.I;2BKH=R=SDX"IP?7KWH \WTWQ3XEU&W$?VR\CRZMYNQ2P'D.Y7IC[P I
M7\1^*X;6T6;4)T2=$F:?RAE,P[]O3IFO2H[D1E4CT*9 V2VU(P%^O--FO7+"
M%O#]S)'M'.V,J/;D]J +.@7,]YH=G<7+!IGB!9@I7)]<&M6L/^V;J--JZ#?9
M X1?+Z?]]4U=9O7MC*="U!6#%?+)CW$8Z_>QB@#>HK$;6+M7*_V#?G&,$&/G
M_P >[5#+X@U",@+X9U.3(SE3%Q[??H Z&BL*77;Z.1E7P]J,@ R&4QX/_CU.
MMM8NYU4OHE_"68@AS'QCOPU &W16(FKWC*Q.AWZX4$ F/G/;[W:D&M7GFLG]
M@:A@-@-F/!YZ_>H W**PVUF]4MC0=0;:<#!CYXZ_>I8=5NI&C#:)?1AE+$L4
M^4C/!^;J?ZT ;=%8T6K7<A7=HE\FXX.XIQ[_ 'J/[6N_*W_V)?9W8VY3/U^]
M0!LT5E+JMTP3.CWB[NN2GR_7YJ;)J=RC*!I5V^7*D@IP!_%UZ&@#7HK(35KM
M@I.C7JY R"4X_P#'J=)J=V@4II-TV1TRO'ZT :M%9#ZI=@1XT>[.\?-RGR_7
MFFOJ>H1HC?V3.^XG*HRY'IU- &S16/%JM_)G=H]Q&,X&YE_QIC:IJ7GR(NCS
M;%4E7++ACZ=: -NBLK^T+U<[M+G/!(VE?RZU&=6U "(C1+HAA\PW)E?_ !Z@
M#9HK(BU.^ECE9M)N(RHRBL5^;VZTR74M32.-TTF1RPRRAAE3^= &U16.^IWZ
MI&RZ1.Q9?F7<N5/Y]*6&_P!0DE9'TR2,#H[,,'CZT :]9LEA.\P9=0N(UW[M
MBA<8_N].G^-(]UJ*N +(,",Y#=#5>[U.\LY;;S+1?*EN$A+;N1N( - %I+"=
M;.6!M0N7=^DK!=R_3C%96N0ZC%8SM%JEQ"\T@CC,<6_RP>^ "<_I3K76=2U&
M^OXK.T@$-I<O;%Y6(RRA3GCM\U68KK7VEQ)96BIZ[VH AL?"T.GP,D%[<>8Y
M)DF(4NY/J<5=;297N'E.IW6&(.SY<#'X4D\FMJ[>3!9,F?ER[9Q^51/+XA\T
MK';:?LYPS._^% %L:>P.3=SG)SSC_"FQ:?)%<^=]NN&&T@H=N"?7IUJBS>+-
MWR1:-M]Y)?\ "IM^NK9JQAT\W&X[E5WVX]N.M %Z6%Y8@@GDC8 C>N,].O(J
M.*P\N=Y?M$C%\9! '([]*J^;K^4_T>PP<;OG?C]*<C:\3\\6G 8/1WZ]NU %
MUK,-$8S+)MSD<]*@@T_R+>&$7$S")PX+$9/L?:HIFUW(\B/3RO&=[O\ CT%,
M#>(L29CTSI^[P\GZ\4 :@@4;N3\Q)//K2>2OFL^3N.,\UF,WB/;\D6E[L]Y)
M,8_*FJWB;REW1:3YF><228_E0!L*NWN3R33ZR WB#C,6F].<._\ A1(WB#)\
MJ+32.VYW_P * +!T^-I-YED+9!Z^ASBK$<2QO(RYS(VXY/?&/Z505M>_=;H]
M.Z_O,._ ]N*8S:_\VV+3>IVY=^G;/% &S16!!_PDZ;0\6D[03G$LI/ZBH;[4
MM;TFSN-0OH-/:SMT+N(7<R$#TR,9H Z6BL"74=3GU::ST^&S*P1QN[7#,"=^
M>F![4]7\49.^'2<=L22?X4 ;E%9"MX@_>;HM-_V,._Z\57+>*_+7$6C[_P"+
M,DN/Y4 ;]%8"-XKQAXM'Z]1))_A6?%XBU%_"5OJ!A@^VRW:VQ )V#,OEY]>G
M- '7T5E!-;\A09+3S-WS'G&/RJ/9KY"?O;+K\Q!;I^5 &S16+Y&NM(NZ[ME4
M'G:.3^E2O;:QM8)?1@]B4'^% &K16/\ 9]:"D"[@.<8)7D?I2/:ZV5<)?0@G
M[IV=/TH V:*Q8[76\$27\.<#!5._?M4J6VJ(RLU^K\$,I0 9[8XH U:\\\,$
M?\+>\7#/_+M;?^A25T&K2:MI>AZC??;4>2"%Y478,?*,XZ5R_@UVG^*GB:=B
M-S65JQ^I+T >ET444 %%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]
M<F_D: +-%%% !1110 4444 %%112B5-VUUYQAUP:EH **** "BBB@ HHHH *
M*** "F/&DJ[74,OH13Z* "BBB@ J/8I<.5&X< XYJ2B@ HHHH \_OF9;CQ27
M7Y0T/Y9:KNNZYXATS7K6.WLK1].N)TMT9Y2)'8J2>-O;:>]5M0C65_%BN,C9
M"1CKU:MW4K 7>OV%[)=1K;6D;NL1_P">IQM;\!N_.@#FF\>70?6&$$&+6<6T
M$!<[RQ<*&88X!&3WI;SQGK5K83.;2S6:RG$5UOF(!);"A?E[@@U/J7A&74YK
MJ\OM0MH[R2,1P/''M "NK9(SR?EQ^--G\-7,UE>6LU_82O?L9+MGBZ=@5&[C
M Q0!L^)M:N],\)'5;98UGVQD(_3+$#&?QIL'B_2U,=O=W2K="/,F!\H;8'*@
M^N"#576K$7GA^STBUU2UCMX1&ER\HW,R*!C'(P3@<UF2^%(TN9 VLVJV;2BX
MC#KEE;8J#G/3*Y]^E &Y!XYT"YBGDAO0PA"D@#EMQ(7'KD@C\*DA\9Z-<WMK
M:07!DEN0I3:.!N) S^(/Y5QC^ ;:<*'UNPD9(8H]K0Y4F.5Y,L-W(._&/:KF
MG^&;?3M<M=437=.C2W54D6"/9N ).W[Q^7GI]: -SQAXM'AR2QCBB\V263?,
MO]V%<;F_5:TKSQ/IUA>SVD[.)881,P"]5) XY]Q6'JNBZ/JVH:E=:GJ5C,MS
M L5LK@?N ,Y/7G.1^54W\-V$\FB/J'B"":[TU#%/("%-Q&<$AAGU4'\* .DM
M/%FF7VN2:/#*PNE#$;E^5MIPP!SU!KFV\:7L-[JVE7;+!=*6.GW!0;90#RN/
M4<_E3M)M])T?7KC4'\0:<;:X=Y8X@0K_ #G=RV>1Z<"DU#3?#VK:?<07VN6#
M^9<?:;:5& ,7.>N>>"1^- %#4_&^L:4M\ES=PK)!%;W$1\D?O(GV!S^!9ORK
MK?#>J7VKS7US+*K6(=%M<1@%U**Q;/U)&/:L;4M+\+:KJNFW5QJMH9+2V-KY
M?F#$BLI X_'-;&B7&@>'M$M].@U*T\F+<$)E'.6/]>* .GHK,'B#1RY0:G:[
MAU'FC-)_PD.C[6;^T[3:HW,?-' ]: -2BLR+7])G<I%J5J[#J%E!--D\1:-"
MQ634[1&'4&4#% &K16.WBC0D.&U:R!QGF84T>*O#Y8*-9L<D9 \Y: -JBL;_
M (2C0=P7^V++<3@#SEZTU_%7AZ/[^LV*Y..9EZT ;=%93>(]%4$MJEH .3F4
M41^(M&FG$$>IVCRMG"+*"3CK0!JT5E'Q%HP;:=3M >>/-%-_X2/1>?\ B:6G
M )/[T< =: ->BLQ-?TF2.21-2M62(9=A*,+]:/[?T?<Z_P!I6NY%WL/-' ]:
M -!U#+M)(^AQ3ZQSXFT01K(=5L]C9VMYPP<=:8/%GA\IO&M6.WU\]<4 ;=8G
MB(E;>PPA;.H6XX[?..:F7Q+HK*6&J6F!U_>BLO6=3LM12QBL[E+AEO[=SY1W
M8&_OB@#!EU'4M.TS7KFT5RJ:ZXF,2[W6'8FX@>OXTMIX_AT_3K5[NX.J273R
M/');1@8C&WJ.S<]*L((0VLQSW<ME,NL/-&5_B!5,9'<'!_*J'_"/^'X61(M1
MOH+B*21II(/E\S?C<.G^R* )]:^)D=FNIV]K:,;VUR8UDX# ,%)/_?0I(_%>
MLW-]'+/;K;6L&IO ZJ<EXUCD)STYRHJE<^#O#TGG-+J&HE9%DVJOH[*W'')R
MHJVFDZ-'=$/J&JRC[09RA&06965B>.^XT =%X;\4Q>)?-\JVDC5462-S]UU8
M C\>>173UQ6AC2] <QQ7&I7 ($48E4LL2#HHXX' K<_X22P#A")P2Q7_ %9Z
MT ;-%8Q\1V'FF/$Y(](C@TYO$-DJ%B)^&VX$9S0!KT5B_P#"26 FEBVW&Z,9
M;]T<?A2GQ+9+$LABNMK=#Y)H V:*QO\ A);+*CR;O<W0>0<T/XAM$*CR+MF9
M0P"P$G!H V:*Q/\ A)K('!@O!CK^X/'UI#XGLAG%O>E1U86[8'XT ;E%8X\0
MVC$?N;H9SC,)[#-(?$5F" 8[G)4MCR30!LU@^-/^1+U?_KV:GKXFL7( AN\D
M@ >0>]97B;5X]1\/:EIUI:WDES)"R*! <9H L&*:?4==B@D:*5K.WV.O!!P]
M>>Z7XWOUG2&\NKEIO[/\B=<\)= JIQSUY8_A7H:7+:?XCO9);:Y>.:"!5,4)
M<9 ;/(^M9,ND^'([N2>33[]Y4OS>G; 3F0[ACIR/F/% %#Q5XGU'PU+HVGQW
MBRS6L:SWSOUE7(0CZY<-^%>BQ2I/"DT;!D=0RD=P>17)SC3;QM4\^RUEAJ"J
MDN;9OE"_+\O'%6=.OK30=-M=.@L]9FCACVHSVS.P4= 3B@#JJ\[APG@RV'4?
MVQ'C(_Z>:Z5/$\$L2R#3-7 9MN&LG!'N1Z5@+:W2>#XFFLKIG744N#"D9,FT
M3;L[>O2@#G=3US5+#6[]/MMY;7<D=RTGGDF")%C!1E&>,')Z5%8ZEJMQ\-=8
M:>]O+:^MI\A6F8R*, @[NN#Z5UA&C7$VH7=SHVKW$EY'Y4OGV;$^61C8O'3K
MQ[U5^QZ(^D7&GOI>ORPW#AI6DMFWL.PSCH/2@#4U.2=/&'A]5N9E2>WE\Q Y
MVL1LP<>O)JCHFF7-IX^O FK:A=06]K_I"3SLT?F2$%2JDX& K?G5V2:SN+JS
MO?[*U5I;$;82\+*<'&>,>PJ9-3BL)KBXAT74FDN&#2D0,22.G;IR: .JHK!'
MB1L<Z1J(.>@@8_TH?Q Z;<:3?MD#.(3Q^E &]16&NNNRR'^RK\;<8!A(S^E-
M;7Y@@8:1>G+;<>6<].O2@"7Q9QX/UC_KSE_]!-<;X(Y^)OB4Y_Y<;3_V>M_7
MM0O-0T34=/MM*NFDFMWC5BI RR\=O>N<\'AH/BOXBA88(L;8'V(WT >GT444
M %%%% !1110 4444 %5KS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H LT444 %%
M%% !1110 4444 %%%032"&%Y2"0BEB!U.* )Z*XN+XBV4QQ'I>HG_MEBB7X@
MQQ@D:'J;X('"+_C0!VE%<0/B-"1G^PM4QZ^6/7'K1)\0T15*:!JLF?[J+Q^9
MH [>BN&3XD1NZJOA[5B",D^6N!^M-_X65'YFQ?#VK,V,G$:\?K0!W=%< ?BC
M$K[3X;UC(&?]6O\ C3E^)(89'AK6,?[B?XT =[17"_\ "R/^I9UC_OE/_BJ/
M^%D?]2SK'_?*?_%4 =U17"_\+(_ZEG6/^^4_^*I?^%C,#C_A&=7S_NI_\50!
MW-%<,GQ$D<9_X1?6!DX&53_XJE'Q"DVJW_"+ZN W X3_ .*H OZ;#%<^)?$4
M$RAXV$(93Z?-6=/K.@GQ7>:=>V6UK> RK<%SA]I 90 >H)'%8^E^-)4\1:TZ
M^'=4+S"/Y0$RN-W7YO>N=NX+.[Q*^B:\NIM.TLMP-IW[N2-N[ &<'@=J .K_
M .$T\+XO?]$N=D6TQJ()=[Y7<25ZJ,\9/%.'C/P>MA')-%*'=4WJL4A + .0
M#WQ_2N/CM[V2>>[:TUPWDT0@D=880#&!C&,^PI9;"-M(L[--'UQ&A?<LFR(E
MAM*8//O0!WK^(?"%Q<SP&,R>1;^>SA'V[=F[&?7;VK7T*XT7Q'I$=W8VY-LP
MVJ)$93@'WKS5-,ECNOM(T?7,>0T84)" <Q[,D;L'UYK?\,ZG>>%=(-D/#VMW
M0+&0%C%P/0?-[4 =Y_8FG>8)/LB;AT.32#1=. 8"TCPV,]><5SR^-]08*W_"
M':R$.?F+0\?^/U"_CK4P<Q^"=;D3) 8-#SCZO0!U8T?3@5(M(_EZ<4]=.LU)
M(MH\D8)Q7(CQMKI!8>!-9VYPO[R#K_W\I?\ A,O$G./ 6K]?^>L'_P <H ZU
M=.LUSBUAY]4!I_V*UQC[-#C_ '!7&_\ "9^)LD?\(%JW_?V#_P".5+'XL\2R
M$9\$:C'Q_'+#_1Z .L^QVHQ_HT/'3Y!3OLEMC'V>+ _V!7(_\)/XL[>#[C\9
M4_\ BJ3_ (2?Q8!_R)UP?I*G_P 50!U_V2WSG[/%GUV"D^R6V"/L\7/!^05Q
MY\5^*D.T^";UCCJDL6/U>I?^$J\2X4CP7?Y)P1YL7'_C] '6+:VZG*P1 ^H0
M4&TMF.6MXB?=!7(_\);XER?^*'U+@X_UL//_ (_1_P );XER!_P@^I<CKYL/
M'_C] '6&RM3UM83_ -LQ1]AM<Y^S0?\ ?L5Q_P#PF'B?(_XH35.>O[V'C_R)
M5D>)O$?.[PA>^V)(_P#XN@#J/L-KG/V:#/\ US%(;&T/6U@/_;,5R[^)O$G&
MSPA>=>=TL?\ \743^)O%8/R^#K@CWFC_ /BJ .O^R6QZV\/_ 'P*06ELK;EM
MX@P[A!FN1_X2?Q;_ -"?/_W]3_XJC_A)_%O_ $)\_P#W]3_XJ@#KOLEN22;>
M'V^04OV.V_Y]HO\ O@5R'_"3^+?^A/G_ ._J?_%4?\)/XM_Z$^?_ +^I_P#%
M4 =<+6W (%O$ W4!!S2?9+;)/V>+)&#\@Y%<E_PD_BW_ *$^?_OZG_Q5'_"3
M^+?^A/G_ ._J?_%4 =;]BM< ?9H<#H/+%'V&TQC[+!CT\L5R7_"3^+?^A/G_
M ._J?_%4?\)/XM_Z$^?_ +^I_P#%4 ==]DML<6\/_? IZ00Q_<AC7Z*!7*0:
M_P"*90=_AAXL?WY%Y_)JE76/%+M@:#&@SU>3_ T /UR[OCK%GI>FI:I+.CRR
M33KD +C  ')ZUSUUXUU'3;]89]+MKHK%"\QMR",MNSM.3G[M6M8L?$NMM"TF
MFVUO/"&\N>.9@5!QD<'O@533PYK,/E_9]&LD:((J,TSD80';GG_:- '5:#KE
MEXC6::RA_P!'A8*LV 0YYR!Z8K=\J/.?+3_OD5Y]X4TKQ5X6T&/38+#37*L7
M9M[\DULB^\;=],TK\)'H ZGRT_N+^5)Y4?\ <3_OFN5^W>./^@;I/_?R2C[=
MXX_Z!ND_]_)* .K\J/\ N+^5'EQ_W%_*N4^W>./^@;I/_?R2C[=XX_Z!ND_]
M_)* .J\J/.=BY/\ LTOEIC&U<#MBN4^W>./^@;I/_?R2C[=XX_Z!ND_]_)*
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M-1O&TR;S2+#=A%:12K'(Y/7/)ZUC7WPM6P\.7\%A<2WMQ+$(8$9$0QIDG (
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MUVWT#3Q=7 9B[K'%$I&Z1V. HSWR10!LT56MI6GMHY'B:)G7)C<C*^QQ5F@
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MDN+.RCAFE^\Z@Y/^%:M%% !1110 445C:G>1V,\$DT$IB0,_F*W"G!X(S_\
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MC>-M8L]#LX=+LXYI)S=2L;JX8[5CP>N">_2HY?B#X@:_.MQ) +--$^V"T,A
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M^B23F\DU-FOFO'NFN/,&26!&W&<8^8U.OPF\)IDBTEW'&6\SDX_"I!\*_"P
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MW$VH)&UM"8$:&Y*'RR"I4X/(P34Y^%_@H[/^*=L/E&/]4.?K4B?#7P6B!?\
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M7TO_ ,!EI?\ A7/@S9M_X1G3 N<X^SKUH QYO"W@E[R&YDNSF(Q%46[8*6C
M"D@'DX ZU-J&F^!M3NM0N+Z:TFN+L;7DD;+1X&/D)^[T[5K+X \(HVY?#FFA
MO46ZTZ3P%X3E_P!9X>TYL>L H \U?PQI]SXO:6\URQ?1 Q*QBX;>08U3&W&!
MTZYS72V/A_P%I\4:QWT;;)FF#/.2=Q 'Y<"NB7X?^$$.5\-Z:"?2W6D7X>^#
MD)*^&M,!/7%NM '(W/A#P*SK<V.LR6$ZQB)9;:Z9> 2>0" ?O=ZY*X\&?V80
M=&\7V-W&J&,1WAV[5R#A2 2.G:O71\/_  @%91X;TW#_ 'A]G7FF#X=^#5
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M'9?E'3IW&.OUKG]6\/>%[_6+"X@U^.&SMU"M%L+,V,8^;&3TKTK_ (1K1/\
MH%VO_?L5(-$TM5VK86X7TV"@#BWC^'C7T#O/;^=&[NB_-@EB6)(Q@\DTJ0>
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MZZ2**$AN$.?,;D ^H^7:,>U0S^%]6AOY-4A@M;F=[V68PR#Y75HU1<^N"N:
M.QDUK2XBHEU"U0LF]=TRC*^O7I2PZQIEPZQ0:A:RR/\ =1)5)/T&:\]L_AK?
MK9O%>7232.\,18]H59F8#_OLC\*U],\&SVNLV]ZYB0"\EN9-@[$+L4>W#?G0
M!UEQJVGVL_DW-];0R8SLDE"G\C2QZC8SQ^9#=P.F"=RR C X)_"N3U/P9=:I
MK<]]-)$5DO(6"D<K#&KC ^I9?RK,N/!>O1LZV,EJBW*S^<22-GF2HY"@>P-
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M !1110 4444 %%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D:
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C&_S"21LQP,<U)10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5KS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H LT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-+!<9[G IU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: .&_X75X(_Z"J_]\-_
MA1_PNKP1_P!!5?\ OAO\*^0J* /L!/C/X'=L'6$7W*-_A4R?%[P&ZY/B&W4^
MA1__ (FOCFB@#[(_X6[X"_Z&2V_[XD_^)H_X6[X"_P"ADMO^^)/_ (FOC>B@
M#[(_X6[X"_Z&2V_[XD_^)H_X6[X"_P"ADMO^^)/_ (FOC>B@#[(_X6[X"_Z&
M2V_[XD_^)H_X6[X"_P"ADMO^^)/_ (FOC>B@#[(_X6[X"_Z&2V_[XD_^)I?^
M%M^ \9_X22V_[X?_ .)KXVHH ^SH_BCX)E&4\0VQ'^Z_^%2_\++\&?\ 0?M?
MR;_"OBRB@#[3_P"%E^#/^@_:_DW^%'_"R_!G_0?M?R;_  KXLHH ^T_^%E^#
M/^@_:_DW^%'_  LOP9_T'[7\F_PKXLHH ^T_^%E^#/\ H/VOY-_A1_PLOP9_
MT'[7\F_PKXLHH ^T_P#A9?@S_H/VOY-_A1_PLOP9_P!!^U_)O\*^+** /M/_
M (67X,_Z#]K^3?X4?\++\&?]!^U_)O\ "OBRB@#[3_X67X,/77[7\F_PH_X6
M7X,_Z#]K^3?X5\644 ?:G_"RO!O'_$_M>>G#?X4]/B'X1D4E-=M2!UZ_X5\4
M44 ?;?\ PGOA7G_B=VO'N?\ "A?'GA9E##6[4@^Y_P *^)** /MW_A.O#'_0
M:M?^^C_A1_PG7AC_ *#5K_WT?\*^(J* /MW_ (3KPQ_T&K7_ +Z/^%'_  G7
MAC_H-6O_ 'T?\*^(J* /MW_A.O#'_0:M?^^C_A1_PG7AC_H-6O\ WT?\*^(J
M* /MW_A.O#'_ $&K7_OH_P"%'_"=>&/^@U:_]]'_  KXBHH ^W?^$Z\,?]!J
MU_[Z/^%'_"=>&/\ H-6O_?1_PKXBHH ^W?\ A.O#'_0:M?\ OH_X4^/QKX;E
M.$UFU./]JOA^B@#[D'B[P^9#&-7M-P&2-]2?\)3H/_06M/\ OX*^%Z* /NC_
M (2G0?\ H+6G_?P4?\)3H/\ T%K3_OX*^%Z* /NC_A*=!_Z"UI_W\%'_  E.
M@_\ 06M/^_@KX7HH ^Z/^$IT'_H+6G_?P4?\)3H/_06M/^_@KX7HH ^Z/^$I
MT'_H+6G_ '\%'_"4Z#_T%K3_ +^"OA>B@#[H_P"$IT'_ *"UI_W\%'_"4Z#_
M -!:T_[^"OA>B@#[H_X2G0?^@M:?]_!1_P )3H/_ $%K3_OX*^%Z* /NC_A*
M=!_Z"UI_W\%'_"4Z#_T%K3_OX*^%Z* /NC_A*=!_Z"UI_P!_!1_PE.@_]!:T
M_P"_@KX7HH ^Z/\ A*=!_P"@M:?]_!1_PE.@_P#06M/^_@KX7HH ^Z/^$IT'
M_H+6G_?P4?\ "4Z#_P!!:T_[^"OA>B@#[H_X2G0?^@M:?]_!1_PE.@_]!:T_
M[^"OA>B@#[H_X2G0?^@M:?\ ?P4?\)3H/_06M/\ OX*^%Z* /NC_ (2G0?\
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M6O\ WT?\*^(J* /MW_A.O#'_ $&K7_OH_P"%'_"=>&/^@U:_]]'_  KXBHH
M^W?^$Z\,?]!JU_[Z/^%'_"=>&/\ H-6O_?1_PKXBHH ^W?\ A.O#'_0:M?\
MOH_X4?\ "=>&/^@U:_\ ?1_PKXBHH ^W?^$Z\,?]!JU_[Z/^%07?CGPPUG.J
0ZU:DF-@!N/I]*^*:* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>inmune_ex31img20.jpg
<TEXT>
begin 644 inmune_ex31img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M]"C_ (1/P_\ ] >S_P"_0K9HH QO^$3\/_\ 0'L_^_0H_P"$3\/_ /0'L_\
MOT*V:* ,;_A$_#__ $![/_OT*/\ A$_#_P#T![/_ +]"MFB@#&_X1/P__P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T %C_QX0?[@JS5:Q_X
M\(/]P59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *K7G_'C<?\ 7)OY&K-5KS_CQN/^N3?R- !8
M_P#'A!_N"K-5K'_CP@_W!5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\
M_P"/&X_ZY-_(T %C_P >$'^X*LU6L?\ CP@_W!5F@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &L,J
M0"1GN*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H +'_CP@_W!5FJUC_QX0?[@
MJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BB@!B@A0&.3C
MDXQFGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %5KS_CQN/\ KDW\C5FJUY_QXW'_
M %R;^1H 2P_X\+?G/[L<U:JM8_\ 'A!_N"K- !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\
M;C_KDW\C5FJUY_QXW'_7)OY&@ L#FP@(_N"K-5K'_CP@_P!P59H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D!!Z'-+10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^50 <8X'%9.O:GJ)\0Z3>K!=SSW.AM--;K,RC>-P\S&1R, \<T ?1A8+C)
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M%% !13"HW!NXX'-/H **** "BBB@ HHHH **** "BBB@ HHIB,67+*5.>AH
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MZQ6Z%U<7>HFXB\EC=S-)A..!DGT%=;10!QEC\/=*L;J.<3WEP8%*VJSSLZP
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M\JOUGZ'_ ,@*Q_ZX+_*M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D "J !@#I2T4 %%%% !1110 4444 %%%% !111
M0 457NIS;6[2B-I,8^5>IJ5&WHK8(R,X/:@!](0&4@C(/6EJLA4SR$HRL.,D
M\$>O\Z '&UB81 KGRCE.>E2.P1"Q!('H,FGTS)R1C@=_6@!]%-5@V<=CBG4
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M /HIJC"@9SCO3J "BBB@ HHHH :P#*5(R",&N 7X9Q0I=:?;:I-%H5U(99K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5KS_CQN/\ KDW\C5FJUY_Q
MXW'_ %R;^1H K:",:!8#T@7^5:59VA\Z#8_]<%_E6C0 4444 %%%% !1110
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MOJB3J488=-J*2.<XPO2G6?A#Q-:VUK9-HHV0:U]J$\97=Y>5;/7IU_*O=J*
M/ X? 'B3RKBTDTV3=;)=;;D%?]*\P+M7KV*GKZUJ?#GPWX@TKQ?I]Q>Z$]E:
MQZ5]FED^09E4]3M/.<_I7M%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: *?AW_D7-.Y)_T=.2
M/:M6LSP^H3P]IZ#H+= /RK3H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BHXW$L8<9P>F1@U)0 4444 %%%% !16%9^(K._O=7L[4-)<Z8^R6,
M'ECM##'YXKFK7XKZ/<PK<M;74=I]H^RO.R':DN?NGCW% 'H5%>>W'Q5TJ#4(
MK065V[3RF&V8*<3.,9 X]QS4EM\3]-N]5L].CLKC[1=1B5 W "=R?I0!WU%<
M$WQ+LR+BYM],O)],@D\LWJ+\C-G' QDCWZ5;\/>.[;Q%XBO-&AL)XIK12TCN
MPQC.!^>: .RHK@M3^(L6F:Q=:5-I%P;BW0R/^]4#R^S9]\CCKS6S=^*8;;PF
MOB"*UEGMM@D= =K(O?KZ4 =)16/X?UE?$&BP:G';O!%.-R*Y!)&>M;% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2E78'& <<F@#O:*P- \6:5XF-RNFO.6MF"RI- \3*3[, :WZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^
M1JS5:\_X\;C_ *Y-_(T 9_A7_D4]+_Z]4_E6S6-X5_Y%/2_^O5/Y5LT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112,P498X%
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6&IHS6-Y!<A#AO)D#;3Z''2BVU73[N[FM;:]@FGAQYD<<@8I]0.E %^BBB@
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M0!/17(0_$+PW<"%H[N0I+DAC"V  =IR>W)QS75*RR('1@RL,@@Y!% $M%%%
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M6>T1KR+&U^Q(Z$CN:ETWP]IND75Q<V-LL4MQCS2#][&?\: /&X+:\DO])?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QX
MW'_7)OY&@#/\*_\ (IZ7_P!>J?RK9K&\*_\ (IZ7_P!>J?RK9H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O.[.>,=,4ZBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M86CF0XR6[=/QKJ_%WA^Z\1VMI:0W"16JSB2Y5L_O%':N<M/AE]GUK6'-XO\
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M5FJUY_QXW'_7)OY&@#-\)%3X2TDJ<J;6/!_"MNL3PE_R*6DXQ_QZQ]/I6W0
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M2ZG;C9%<-$A"Q]UVXQSQSC/%,G^&SSW5I*=<G!M54)*(4\PD CDXY!STZ<4
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MKG9?A[K-O;Z7(=-M]2D2VDMI4FDQY;M(["0>H^89'IGF@#T&/QUX9E\QEU:
MB.18GY^ZS' 'XY%.M?'/AJ]CNI+?58'6UC\V4@_=7GG]#^5<U/\ #ZX?Q5!>
MQ+ EDUNDEQ%CAKE!A2!Z#"UR47P\\4M*TILHH\0E</<A@[*S, !@;0=V.^*
M.VT3XBV-R-4N=4O+>&R@N_(MI ?]8,?3WKN+>YAN[6.XMY%EAD7<CKT85X[J
M/@[Q=?O+<)IEO;&XNQ*R)=#< 0!@-CCISQ76>"K_ %BPNK7POJ.G)&+2Q0M-
M')O ;T/'?^E %75/%OB?2-;@%YI]G%ILUU)%$/-)F9 K$-MV\#@=^]-T/QOK
M=[)!]KLX%34;)[NQVM]W&,*W'H>OM6OJ'AV[USQC=75XFVRMK)H+7G[SR8RW
MX;?UK!T+PIXBA:S.H6\"IH]F]K:JDF3<9& V?X>/K0!UW@[6[O6_"\>HWD:"
MY+R*R1]/E8C _*N4T'QUJVL:TD"FU?\ TN2&>S7_ %D"*2 QXYS@?G71>!M-
MU32_"?V+4+=;>Y625E"R;OO,2/YURT/AGQ%<:_9WESI=O;WMI-)(VHQ3C-PG
M.U"N/3 ZT =_XAU9="T"\U-D+_9XF=4'\38X'YUS,.I^*[2WL=4U*2V>RF8/
M<QQQC_1HSSG=WP.M:UUI5_XC\&W%AJRQV][.CC]WRJ')VG^1K#,'CB_T>31I
M;2QM D#1&[\S>)?EPN$XV_F: -*/XD>%7MY+AM26..-E5BXQC=G!^AP?RJ:/
MXB>&II52/4 RE=V_'R_G7G&F_#GQ58WS7!LK5U=K=W4W(.XQLY.>.^X5IZQ\
M/=9U77]2>*&"SM;D./-CD!$BG&T%.NX8/.>_2@#KE^(OAHV,MV]X8XXG5&WK
M@_-DJ<>AP:U+#Q'8:OI%Y?Z4WG& ."N,'>H/!_*N!U/P3XBU=%O)K6UBO(UB
MA$2R@JRK]Y_T&![FNE\.Z+K5@GB1)UBMY+VX>6UDCD#8W9[=L9% ',Z/\1=7
MN+3^T9'BNX8XI'O+1(@LEJP!PI]1G S6[9_%3P[):VYOYS:7,D F>)APN5SU
M_E63#X&UJ[O(;N]AMX+N&RD@EN(I 3=LT94%QVY.:9;^"/$%_87-EJL5G&CZ
M?%;(\; G='M(S[':,T =,/B/X>:S>Y6>0E&"F(*-YR 0<9Z8(-,T;Q]9:WXH
M72K&VF>![43K<D<9W,"/I\O7US7'CX9ZM]BMYOL>C+-!("+-8?DD& "6.[KC
M)K0?0/$7A2-M7T^.TDG&G?9S!'"2 X=V4* >AW 4 =+X^UV\\.Z"E[:NT:FX
M1)IEB$ABC)Y8*<9Q]:SO#_C.998DU6Y-[;WUQY6GW4$ 4.,?Q 'C]:V-7MM>
MU/1-/FLS'%>H5DG@D^Y(.Z&N3M/AWK-L'U&VFM;:]:^%TEKMW11CN!S0!J3?
M$*TN+BWNK(WWDBVN'-J;92960H.N[C&[]:AL_BQIBZ=I<FI6UY#=W<*/(B1
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M HHHH **** *V9OM038OD>7G?GG=GICTQ5FBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/^/&X
M_P"N3?R- &1X'_Y$;0_^O*+_ -!%=!7/^!_^1&T/_KRB_P#01704 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5KS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H R/ __(C:'_UY1?\
MH(KH*Y_P/_R(VA_]>47_ *"*Z"@ HHHH **** "BBB@ HHHH **** "BBB@
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M,'(!]?6@!:*** "BBB@ HHHH **** (HC(8P9557[A3D5+110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H R/ _\ R(VA
M_P#7E%_Z"*Z"N?\  _\ R(VA_P#7E%_Z"*Z"@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ J+RHP"!&N"<D;1S4M% $0BC'2-1SG[
MHIWEI@C:O/7BGT4 -V*1@J,>F*:8T*[2BE1T!'%244 ,\M./D7CIQ2>5'C&Q
M<?[M244 ,5%3[J@9]!2[5SG:/RIU% "8'H*6BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_P!<F_D:LU6O/^/&X_ZY
M-_(T 8_@4Y\":$<$?Z%%P?\ =%=#7/\ @?\ Y$;0_P#KRB_]!%=!0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <I<?$#PS:
M7LUI<:FD<\#;9593\GH3QTJ=?&_A^34GTZ*_22]09:%0=P&,Y^E>9W6G6_BS
MXI^(])AU:&WAGMXDF7R]S3 $DJIR,$#O5O?:^%OC/+)>S):68TL+"[':&QN'
MXF@#M_\ A8OAL>1NO@OVD?Z/E3^]/HM3MX\\-C3AJ"ZE&]IO\MI5!PK>AXKR
M#Q!//;VOPVM;::&#4[=I) DW.S)&TL/0X/Y5';:II<7PSU&VENDM-=DOPUW%
M(,;7YZ+Z=: /:(O&6@3:?=7RZE%Y-J0)R<@QD]B/6DL_&FA7TKPK>K%.D1F,
M4H*ML'\7TKS7Q5X2FM?#AUQ=0&I"]U*&\O;B&/8AB&[! R?E^85!XYNK+Q!\
M0M'U#3!]MTZRLY3?30'*A&&!S^(H ]%B^(7AV5"RW3;2"R'8<.HZL/;O4^F^
M//#VK75M!9WPD:Z)$)P</C.<?D:\?TB[.D2M8QZO%JVAMIT[P2N?GLLHP"GK
MCD[?J:L_#&^L;9=(^W7=OJ$AA\JTMU^_ YE.>/IDYH ]_HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6
MO/\ CQN/^N3?R- &1X&X\":$/^G*+_T$5T%<_P"!O^1$T+_KRB_]!%=!0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4TTVR
MCN?M*6T2S9SO"\T^XL;6[*FXMXY2O0LN<59HH J2:?:2R+));1,ZC"L5Y IK
M:78,S,UG"69MQ)0<FKM% $ @B$ A$:^4!MV8XQ45MI]I9QM';V\4:,26"KUS
M5RB@"M'86D1<I;1+O^]A!S21V%I%()$MHE8="$ Q5JB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6
MO/\ CQN/^N3?R- &1X'_ .1&T/\ Z\HO_01705S_ (&X\":%_P!>47_H(KH*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JHVH6
M2$JUU I7J#(.*MUY5=^#?#X^(=AITFFQ30W%G/)*TH#,S?+@D]S0!Z=#<0W
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M<?98(_L:3J"%0JNXJ#[DUFR74EG>W6A>$M6CM;2RM);YF\O>#)N?]V.1@9%
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M'\7W%[;:DX2+3O-C@9?D4DL">O.,9K:\*:EJP\37VC7MZ+^!;2&[2?;@H7+
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M]X&.? FA$?\ /E%_Z"*Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0]2  WMTH ](U?PIHFNSK<:A8I+,HVB3D-CTJM=>$?#9LHUN-.MTM[2,@$G
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M[F#X?G5)(KF31_MTDH\Q'G4.SYXR,]<XKF? _B_5]5\;R65]?F:SF29H5=D
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M"M^8H ]GHKPSX@RV=O\ $2RO&MKNYM9])DNI((9F 9@&P^ >V!^573X?6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#>(QIFJ:C?6=_>7+&&_A(DMYHR&*JI (Z8[]J /?:*\4BT?4Y/B==>'HM<O
MMK8Q3*Y8<R?*23QW)/YTW19M4\2Z=XOU?4-3NH[G1WEBM40@*AC3.[&.<D?K
M0![;17AND>*=9\83^#]'O[F6VM[^UDGNI(^#,49P!]#M'2KWQ!T34/#ND37M
MOJ]Q+$UQ;PVL.[YHP6PPSZ$4 >R45Y9\/Y8/%6L7&LR74L,MEMMTT[<1L YW
M.#U))/Y5ZG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(C+*BJ47!& % '_ZJR]/^'*65_I_F:Q<W%C8.)(+62-<!\$9W8SCD\9KOZ*
M.(MO OV?QO)XI.LW3W4A(:(QJ%,>,!.G0<<^U-U#X=6EUJ%Y<6>HW5A!??\
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M>9.TCPQ1J6)A4_ZPX' QCKZU:?XA:4TELMK#=723)&[R0Q,PB#@%=V!UY'%
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M%X[T&?RQ'<,QE#;!MY8J,D?7!'YUSVM_$Q9[>ZA\/ -<)9&[CFD7Y,#.1^E
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M<]Q#<O!Y;J\?[S:<G@GTIL&AZ];7TU[%X8D)34Q<Q0,\>-I5!QSQ@J:]EHH
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M^@BNHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH *Y+X@75U;>&'^Q7JVMP\BJK,P7=R,KD\#(SUKK:QM>ET>.P"ZYY!M78
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ME65W#F0KG)R<@YKLPRDD @D=>:Q;_P 2Z?I]W=6\K.6M8//F*+D(N1P?<YH
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MHW>N* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H Y[X;Y_P"%;^'<X_X\
M(L?]\BNJKE?AMC_A6_AW!S_H$7_H(KJJ "BBB@ HHHH **** "BBB@ HHHH
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M%"*H<!N>>?>O37\$>'G2&,Z9$%A<N@'&"<9_#@<43>"O#D^I_;Y-,A-QO#Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5:\_X\;C_ *Y-_(U9JM>?\>-Q_P!<F_D: .9^&'_)-M!Z_P#'I'U'^R*Z
M^N0^&(9?AMH.XYS9QD<]MHKKZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!CNL:%G("CJ33Z:RJZE6 (/4&G4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4KW4;/3E
MC-Y<)")'"(7/WF/:KM<-\3M@\.VC,45A?1 ,PZ#GI0!W-%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_
M *Y-_(U9JM>?\>-Q_P!<F_D: .6^%G_)-="_Z]4_D*[*N-^%G_)-="_Z]4_D
M*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_P"/&X_ZY-_(T <M\+/^
M2:Z%_P!>J?R%=E7&_"S_ ))KH7_7JG\A794 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KS_CQN
M/^N3?R-6:K7G_'C<?]<F_D: .6^%G_)--"Y_Y=4_D*[*N-^%F/\ A6NA8_Y]
M4_D*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI,C./6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_P"/&X_ZY-_(
MT <M\+/^2:Z%_P!>J?R%=E7'?"TD_#70L_\ /JG\A78T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %)@9SCD4M% !1110 4444 %
M%%% !2$9(.3Q2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@#E_A:,?#70O^O5/
MY"NQKCOA:2?AKH6?^?5!^@KL: "BBB@ HHHH **** "BBB@ HHHH **** "B
MDQSGFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^
M1JS5:\_X\;C_ *Y-_(T <S\,0!\-]!P0?]$CS@?[(KKZXWX6?\DUT+_KU3^0
MKLJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "JUY_P >-Q_UR;^1JS5:\_X\;C_KDW\C0!QWPQO[
M2/X<:(CW4*LML@(:0 C@5U_]IV/_ #^VW_?U?\:^%8;B=?W:3R*OHK8IOV^[
M_P"?F7_OHT ?=G]IV/\ S^VW_?U?\:/[3L?^?VV_[^K_ (U\)_;[O_GYE_[Z
M-'V^[_Y^9?\ OHT ?=G]IV/_ #^VW_?U?\:/[3L?^?VV_P"_J_XU\)_;[O\
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M/[3L?^?VV_[^K_C1_:=C_P _MM_W]7_&OA/[?=_\_,O_ 'T:/M]W_P _,O\
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M.[-]345 'WE_:^F?]!&T_P"_Z_XT?VOIG_01M/\ O^O^-?!M% 'WE_:^F?\
M01M/^_Z_XT?VOIG_ $$;3_O^O^-?!M% 'WE_:^F?]!&T_P"_Z_XT?VOIG_01
MM/\ O^O^-?!M% 'WE_:^F?\ 01M/^_Z_XT?VOIG_ $$;3_O^O^-?!M% 'WE_
M:^F?]!&T_P"_Z_XT?VOIG_01M/\ O^O^-?!M% 'W@-9TPYQJ-IP<?ZY?\:4:
MQI;#(U*T_P"_Z_XU\'44 ?=_]MZ5YGE_VE:;L9QYR]/SJ ^)]"5B#JMID'!_
M>"OA>B@#[H_X2G0?^@M:?]_!1_PE.@_]!:T_[^"OA>B@#[H_X2G0?^@M:?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>inmune_ex31img21.jpg
<TEXT>
begin 644 inmune_ex31img21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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MPB?A_P#Z ]G_ -^A1_PB?A__ * ]G_WZ%;-% &-_PB?A_P#Z ]G_ -^A5?\
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MG\JV: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5:\_X\;C_ *Y-_(U9JM>?\>-Q_P!<F_D: *?AP8\-
MZ:,D_P"CIR>O2M6LKPXQ?PYIS'O;H?TK5H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_ !XW
M'_7)OY&K-5KS_CQN/^N3?R- %7P^"/#VG@XSY"=.G2M.LSP_@>']/"C \A,#
M\*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *8V=IV@$]@:?10!%&7,:F0 /CD Y J6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&
MK-5KS_CQN/\ KDW\C0!6T#/]@:?G_G@G\JTJS]#_ .0%8_\ 7!?Y5H4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: *V@G.@6!!SF!>?PK
M2K/T/_D!6/\ UP7^5:% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\
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M.7T<?B37;%;N'[*Q33K16(7"Q*-^/J#Q[4 >I7NI6FGV,]Y<3HD,"%Y#N'
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M^7&,<USR_#GPZNF2Z?Y-R897#L3<-OXQ@;LYP,# JIX?\3:_K7BJXLQ9VO\
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M91=;6W1PC!R<XZ9QS7(:?XIU'3]:O]<M+"WN+.>.TEO/*GR$:13G;QSR?TH
M]%U;POIVM:K8:E>&Y^T6!W0&.=D4'U(!P3U'XU)=>&=.N_$,6M3>>UU%&8E7
MSF\LJ1@@IT/6N)/Q,U%;[5(ETV&5+=)&AV2\'9*$()QUP2:<GC_Q+]IA@;PY
MYCE$N)1!)OVQ.1CMP0&!H W#\-O#A@NX3%<B&Y^\HNG 09R0O/RC/IZU(W@;
MPY+<6TS^:TMNBQKFY)WA3E=XS\Q'O71W$9U#2Y8U=H3<0%0PZIN7K]1FO.-,
M\(VL_BS4M-%W=)]C2*1) _).?FS]: .CM/ &D6RV/DW5\4L[DW$0^TL1DXXZ
M]..E/G^'WA^>\O)Y8YO+N0WF0^<PC!;[S!>@)P.?:N0\.>/;K0?#-M:W^G-+
MB"1K219MS7#!V^4C'!Z>M=EHVK7?B+0[Y-4TFZTUU!0A\C>N.&4XH E\.^#[
M#P_/=7-O<W=Q+=JJR//.SY"YQU)]35.W\ :?!=*S7%S+:1RM/%:NY*I(01NZ
M^A/'O7+^%?'LNC^$].M]5LIWFDM3);2F3=]HVD YXX^\/6M75?B3)I N(;G2
M%2\MI5CEC-QA!N!((;;SD*>U %F/X8:; 8O(O[V((&1@)6P\98-LZ],@5/=_
M#G1KJ>>5))XO,0((XY"$0A=NX+G&=N1^-5#\19C$+I=%<V7V:&=IO-Z>:!M&
M,>K ?C3O!VIWD?\ PE-YJD#0&"43- )?,"#R]Q .!0!L>'_!]KX:N9Y;6ZG9
M)8T1HW8[<J -W7K@5TJLK#*D$>QKS'5_'VH7&@7L2:9]DNYK07-J3/\ ?A9M
MN[./E..<5U?@W3WL/#\)=I?,N%65D>;S A*CH<#@]?QH Z6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_ %R;^1JS5:\_X\;C
M_KDW\C0!!HX!T2SVY4>2N.?:M"J&BC&B60SG$*_RJ_0 4444 %%%% !1110
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MN4A8Q,FY,@_+R>I]1Z5G:)XY&D:2UA/IVJ3W-O<&U7[0\9=Y1_!D'&>#S[4
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MC[=NZ)3CTXJ[56P_X\+?C'[L5:H **** "BBB@ HHHH **** "BBB@ HHHH
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MG_:40N%N;<2R(ORR@RJIQS[YK#L_$.M1Z^L[Z]YEN=62U$#CY61D0^O^T<4
M>JC2M/!!%C;#&<?NE[_A2+IEA&K+'96Z!UV,%B497T/'2N-\6:KJ7_"12:;:
M:NNF)#8?:D=ER)7)88ZC@;1^=<N?&7B:5)M1.HQ0PV\,$K6QB^\69P1G/'W1
M^= 'KEQIMC=P+#<V=O-&GW4DC# ?0&GSV=K/;>1/;12P_P#/-T!7\CQ7FGA_
MQ3XEU#Q@DES=Z<FDSSM"MJ9?WH(QC ]>:M^(_$>MVVH:U=V6H0PV^CB+-FT.
MXS;R0><^W'% '9GPUH9!_P")18\R>;G[.N=WKTZU8@TO3[.YDN;6PMH)Y?\
M621Q*K/]2!DUS/A6^U[4]8U![R]@:QMYI(E@$.UQ\WRY.>P%<W/XF\7MJH2&
M_L%@?4Y+)$,'. '().>VWIWH ]#/A[1S=M=-I=DUP[;C(8%+9QC.<5 /"V@
MR%='LE:1&1F6!02&SGG'?)K@8/&WB34B+&WN+2WN;>&YFFN&AW+-Y4CK@+GY
M<[?4XJ*+Q]XEE-]=YM19VEE]I9#%ABV, 9]-PS]#0!WC^!?#3PR1?V3;*D@
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MI-)NC?-<?9V@49(<J6&/7(6M:+QKI[>$9/$$L<L<,3F*2(K\ZR!]FW'^]Q0
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M1P*RY-'T W$=G+:VOGL1,D1.&)'\0&<\8_2LC1=7U"_\-:PEQ<DW5D98ENE
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M.E '12?#SPU)/;2?92H@B$/EJ^%< 8&X=R,5<T/P;IF@:A/>VAF:66/ROWC
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M;PWHUP\[RV$+M.RM*2OWBI!!/T(%27&@Z7=7D%W/:1O-  $)'ITX[X[5KT4
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M+Z?92M<VBD882'! ;CID57C^&^JRVMC9W5[;BWM[&6R9HR=Q#D'/3KQ7J=%
M'GMIX*U&_P#MW_"0R6LA>U%K!Y!/W?[S<#!R!TJII?PUGTR1+O[6+B\-DR2F
M5V8-<$ ;\GG@;OSKTVB@#R>/P%XGBT,6 N-.9ET\V2-O8?QJ^2=N?X:YR5-1
MT_Q\D3PI//;M:(+4/(H=EB1&<8&U@!D\^E>]T4 9>D1ZG'!+_:;P,[2$QB(8
MPG8'@<UJ444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCC$S#Y(&<<+0!KZ-\.-*TFXTB<222S::CA6/'F,V/F/N,?K45_\ #^2_>_\
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M3-R1*"V!&,H P4EN>!E@/QKG9O&>H1WVLQ2:Q$L=OJ$,=NRVX.489*=>O;-
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MPMK%UXB?4=*6"5;RS^Q3+.QVQ@9PP&/<T>"?"FH:!K^KO=V]NUO($6WGZO\
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M;PKXJ;7Y=:DDDMVL[*<+#-$V59-N<GBK \;^'XS)+/KEBL'F!(V\SVY!]\T
M<7K7@/4XM0N;73K6&ZL=1MHH&DD8@VY4C+#\L_4U3?P/XBL[V\@M[.*6U&I6
MUW%+O(9@@3=_Z#7HT_C'P[!.]L^K6WVA(C,8@_S;0N[/Y<U1@^(WAFXT^.?^
MU[2*2524CD?!ZD#^5 ' GPIK=C:_:KW2[=474)KN=XSR(RJ#&>O\)J/X522V
M_B*!+NW6>2:SV031HH\F-2?E;'<[N_I7H6G>+]/70K&?7-4T]9;S<$:*3,<F
M#V.*Q_\ A)] LY[F'PS%IT5Y%>107)8"-65L]" <GB@#)U7PWJ4S^+2GAP2R
MW\B_9)=J9X)).<\9KF=0FD;Q=.][9/);0W%N9+=$1G,JHPQECG@GMQ7MR^(]
M'-[-9?VC;_:H%W2Q;N4'O60)?!E[?2:L/[,ENH5$KW.T%U'8Y_&@#S<>#?$4
M]S;M)H>W?=WDTSL5W;9!)L#'//++4=OX9\2POH\TF@BVDL44/*""A1!D[QV)
M(SD"O:;35M/OK!KZUNXI;5<YE5OE&.M4X_$F@W=FTRZE:R6[,8RV[@G'3\J
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M',]NA#<"3) R>N.?QK!M[&_FUV& Z1>6VK-JD5Q'=[OD%N FX<'IP>*]JHH
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MI--COY+B19BZDLK1+Y8'R_PD'''?->]44 ?/5II5I.]@)FUX6%Q.N]I"R#/
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M5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@"=1M0#C@=J=2#@8I: "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H LT444 %%%% !1110
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M14OH79MEC.MO,GDG"L<X &.1Q5>_\3^&M,U9=.GC!N"P7,5J74,>@+ 8!]J
M/+;[7+/6;*&35=9F62.UM_L(67"SD%-Y_P!HYW9_&NT\>W3K8>&88->FTO[7
M*D1:&79O#* /KUKT 65HVUOLL/ PN8QP*;=063B)KJ.(B-AY9D PK=!CWH \
M)BUB^.IZF=0U^5;F*.:&2R=MVY!'@$KG@8YS[FH_^$MFMM3TPQ:^]M:6Z6Y9
M/.\M A=MYQ_&"!STQBO;+5=&U:>\E@MX99$8V\[F/KQG'OUJ;^PM*P!_9]N0
MJ[!E.WI^IH \6\/7$-O<V-E#XANHKB;59%N(A<]B%PV.Q///M5MM0\46]AJ$
M#7VH-/H8F^U7#S',FXKY9S_=PK\=J]A?1-,DF21[& NC^8K;>0WK^@IFH3Z7
MIL$ES>^3%'.1&[/CYSS@>_>@#C?A_P"([7RY-/O/$2:A+-<%;-WG\PN.3M#?
MQ8K.\::IJMMXSN((?$;Z?;1V(N$AS@,X9!MZ]\FNJ70= U74[-[)E3^Q;@Y@
MAP%63D?-WSUJ*[\*?:?%LFOZE-;2V<=N46%HSE0"#N)SU^6@#RN]\?ZR=;BE
M37GB#1NLL+2;51A S#Y/]X 9SUJS<W.HM+H&LZKXIE=9K.::$J^Q8Y/)8!1R
M<DG@_6O8TT?0=21;M;*UF%P@D#@?>4C@_E3I-$T2.Q2UEL[=;:/=L1N@SG./
MS- 'D]KXMN7MM&2Z\12V*K8_:$=6S]JD\YP5(R,\ #%"ZQJ3SWWD>)'AC;64
MADG7Y<HZ1C/7C&37J6G:=X=U"SMI;&UM9H+=B(2@R$(/./QK.UOP-::G+:+!
M';06BW2W%U'L.9\$'&<\=* /)]7\;:[;:7"%\03--;22;&#^7YZ#&UF.3NYS
MQ[5KVMU%;W>JW">))%GEU=$9))<YCP<']3S7K4OAO1IHHXI-.@9(EVH"O0>E
M$OAS1YV)ETZ!LD$_+W'3^9H \MB\0:U;:Q+>MXC::.+69;$6K-A#'M<ACS_L
M#'U-2>!?%.H76JR:GJ^O.FE):B6X^TR8C68E1A,_P<G]*]"N?!VB36DT45E'
M [@D2)G*L?XOK7(V?PF;[%]DU#4EDB6!8$\A"I(!4Y;.<GY?UH W/&NL2Q6.
MCI9ZE]BM=1N0DE]&W^KC\MG# ^Y 'XUPJ>(M?OK*(R>(6LXTCNO+G_Y[B)W"
MMG/?:*]:ET33KC2(=+N+5)K.)%18W[!1@?RK%N_"*7/B*QNF%I_9=I"8EM/+
M.><\YSCJ: /+Y;^[5]6U2YUN1-1:S@Q%(^05X. /0]?QK:D\5:H^IM,FKB":
M"\M[./32V/-C=4R^,]?F/..U>C7ND>'=2O397=I:S7/DC,9^]Y8/' [9%6&\
M/:,;F.Y;3X/.C01HY'('84 >2Z7XNUN&W@U*^\0[_-6ZB,.W(C*!2IQGD_-6
M9#XKN]3L+JQU;4EF,5Y:R0^9+N/S&3//X#CM7L%AH7A>ZB,VGV=I+&'8%HSN
M ;OWZU9'A+01C&E6_&,<>G2@#F_'.KWUMJND:7;ZE_9EO<Q2RO==/F3;M3.>
M^3^58GA37/$?B77=+2;6$AA%N;B2)(O]<%PN<YZ-NS^%>EZCI%AJT*PW]K'<
M1H=RAQT-4IK+0=+NHK^9+6VG4"".5FVX'9>OM0!Q7B[Q#JUMKVI+9ZH+4:9'
M#+';%.+C>5!!.>?O5QLC7=[?M,+\QWUSK$;()1N\K,?IGG'2O;KWP]I.HWL=
MY=V,4UQ']V1LY%5[CPGH=U>F\GTV%[@L&,ASG(& >M 'E=SXV\5,MM:6E_8B
M:W2:26:YD\H2[)77WS@+G%=/X$UKQ%KWB+4Y;O4K>33K601F%(^I,:MD-GIE
MO2NK;P;X=9%1M)@*K(9 .>&/4]:<(- \-227+-9Z>;@@.\D@0.1]3]* /,]5
M\=>)[5]9EM[Z +$)7M1Y&^-U1<D!L]1WIU]XT\6Z;J,>B/>V,UQ.(Y!>>7L1
M0V<IU/S<>M=1XL\'Z5<>&M2ETI;"QGO$Q+>2M\FP]3G.!Q5VWT#PM!IMKIU_
M'IOF3A6">;CS6'=<MD_A0!R5MXV\37T4KC4=)MVT^*)KC>0T<V_.2&SQC;[]
M:H3>+]6T>2ZL+$V,%[_:%T9FAMN)1&^,E<]\\FO39?!?AZ>2WDDTF!FMUV1=
M?E'Y\_C4!\ ^%'E$C:+;EPS-G+=6ZGKWH S/!-T=2U_6M190'N+>RD?:>,M#
MD\5W=9&E:#I6A^:=-LTMO-"A]A/(48'7T%:] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^
M1H LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-
MS\V,'IG-.H **** ,S6_)_L:]\\.8O);=LSNZ=L<_E7B7AJU-C:^$[DR:FES
M+O-UYHE(4JA!SG@#)KWUF"J68@ =234,IMYH'C=T:-U(;YAT- 'SM97-M/!J
M;375R9'MMJP[9F,[>:F9!Q@C&>GK5J^L=/\ [7CBCM[^;28;JWE^99SMS$ Q
MYY^^>@KTGP]I'AS1-1N;B#[8DMN[6\/VN=F4#D[8@20!\O;%='H/B&S\2V#W
M5JCJB3/$4E !RC%3QGU% 'E7@S4DT'Q+JFH7T]R^GK'(QF9)OW:^80H8,/3'
M0=,5UGQ#O$ETWP_?6MQ<A#J%O*# K'=&74L2 .F/6NSU#3;/5;*2RNQF&4C>
MJMM+8.<'';VJQ%';0VT<48C$,8"J.,#'2@#A_ $.E)K7B22S6?S9+W>AD$@S
M&47'WN/O;J\TO;VX35=:>2XU*..YBN%7Y9MRN -G3Y1R3C%?12J@)=5&3U('
M6HVBA<E6CC8YR00#^- 'A<-FU[9:];6NI7X:""WO+9I9)$WR#?O&3Z_+Q7=>
M$=<LH;6WNM3DEMKSQ%</<6T$FY_E/('<+P?:MSQ)H.CZK:1)J$K6T*R@GRI#
M'O/]TXZU8N-#T@ZCI]U-&JR68*6J;L(N<=%Z9XZ_6@#S+XEW=U#XLE,$MRK0
MQ12)_K-H^90=@3@G!.=W%41JDD%\FJ6^J7[3G4I8TC96V;2DA4 $=,[>M>X/
M;P2-NDBC=L;<LH)QZ4PZ?9%@3:P;@=P_=CKZT >1>$)+>?Q_I=SYUU->/:2K
M=&57PLNYB1SP!CCBL3Q3:VEMXH\8B:6[29Y;<Q ;B&4A,^V,YKWM+2WBD\Q(
M(E<_Q*@!J*73[*Y=FFM()&; 8O&"3CD9H \&.K:K+:'1[;6)(;!+]D-S.K_*
MGE1E02HR!N+5W]_J>I6GPLLYOMLC7$FR&:\BC.50D@O@C/ ]J[.>QTJUM9WE
MLK58-N^4>2N"!W(QS3M.O+'6=(BN;4))9S+\H*\$=.E 'D&EZC-;%+Q-8NY-
M/M=:\CS'R<PX'7C-8M_XFU,6MJ+75+S,$<CKD?>.Y,=LDX)]J]@T/P=%I%QJ
MKSW2WEOJ$_GFW>W54C;O@#\/RK9.CZ8TBL=.M"5!"DPKP#UQQ["@#Q?5-9 7
M7KNWU%(9I=5MLY53N4!P1@CWZTR5DAE\3ZK;:^_G1:G$J1%482?O #U'89Y%
M>T-X<T1]S2:18.6.YBULAR?7I2?\(WH8W8T;3_F;<?\ 1DY/KTZT >2?\)+J
MF;W4)?$3V]UYEQ"; P9^1=PC(PO' 4Y)Q63;ZUJ>KVZVNHZO<B.SU*V??E1A
M6$9Y/0C<2:]V;2-,:1I&T^T+NFQF,*Y*^A..E9^H6/AS3K1OMUC806TLB(0;
M=<,V0%! 'KC% 'FMEK^IR[=.7Q"+>&?4YE.H(D8VJL:LJGC&2>Y%5[KQ5XDE
MTU;M/$IM7CTV6X:(I'\[H6QP1G!P*]9;PQH,MFUM_9%B+=VWE%@4 GUZ=:2?
MPGH%S(9)=)M&8Q^5DPK]WTZ4 >=Z9XLU3_A.%?4=<VZ:<XC0(8L #(/&X$9Z
M].:ZKXBSVDO@F25I(VC>1#$^X8SV(K0O/!NAW%K=1PV%M;RW$;1F585)&>IQ
M5I/#>EG1+329[9;BUM541K*-W3H>: /,I]?URRN+Q+35[97DUMK8LJ)DKB0Y
M.!_L]326/B[7Y4B:\UFWDBNK>XC6/"\-'G#'CN%/MS7IG_"*:")Y)AIEL'DD
M\QB(Q][D9^O)J%/!7AR-%5=+M\+NVY0<9ZXH \QEUO4[*XBU6/7#"QT2!H;8
M>6$);8&"C'4$D^V/2L^Q\3:WKTVG0ZCKKP"'4&A+N8LL/)W@L0-O7BO8F\'^
M'Y%@632K9Q ACCW1@[5/:FGP7X<-NT']C68C8[L"%1SC&>G6@#S*R\6:PVF6
M%E:7]OIX\JYN7N0BA9"CR87ICG:/?FID\>:[/>M-_:$$,,%O!.\#;1OW.RE>
M>>BY_&O2$\': EC%9_V9 8(F+HK(#@GK^=,G\%>';BY>>72X&=PH;Y1C Z#%
M '%Z%XRU+_A.9+35]1C6R=))%4E/+V@#;M(Y'?.[VKK/%NJ3VHTRVL[P6@O;
M@(UV,$(N/?CG^E1ZO\/M$U/3KVVA@CM);N,QM.D89E!ZXSTK8N- T^\TF+3+
MJ 36\:@*'ZC'?/K0!YG;>*?%&H:UI>C0:I DIEN();@J"LWEL@##CN">G%;7
MB[7M;L/%L6GZ?J,<<2V+W3QE068K@8Z=\Y_"NNA\*Z+;3V<\-A$DEF,0,%Y6
MI;G0-+N]5CU.>T1[N-2BR$<X(QB@#R6'QUXMDTII_M,#>?")H]CQF1<D$C'0
M8&>O-5Y_%&N_:[C6H=<99/[/C$<3A0N3,JD8(Z]3G^E>HKX#\-);W,,>EPHM
MP^^0HN#G.>#VJ:Y\&^'[N...?3876.,1+E1PH.?YT >>ZIXBUS0+E)KJZMKF
M\DTI'>9$&8]\C -TYP"/RI3J6IW6KZ3;W/BI71+LLLZ!0&78C .<;>I/%>D2
M>&=&FN1/+8Q2.(/L_P ZY&STQ^-0#P9X>6R2R&EVXMTE\X)L'W^.?T% 'G6B
M^(]4GT^UTRTU""QEF:YD:Z54",R!=J],<]^_-5CX\\3S6TVH+J$$"P6$=VUL
MRCYSE@0.,\X%>E'P/X>-@ME_9Z"!)3*J@]&.,_G@4ZY\%^'[N1GFL$):,1$=
M!M'0?K0!RVA^*M5O/B1<:;<7T9L2)?)A&TA@I7!!'.1GG)[U@>*$NCXE\313
M:FKL#:M;PRXPNXY! ]AQ^->F:;X3T72;]KVSL42X.?GZD9ZX].@INI>#]#U?
M4&O[RS#W3!09 <$@=* /.;_QKXDMYVTB*YADNDN9 ;E&1<J-V%^; [#\!3?^
M$[\7)!J5T\E@PL(XO,A3)),@500>G5@>N*[\_#_PT\<B2:>)!)+YS&1BQ+<\
MY/U-68O!VA0FZ\NPC5;J$0RJ/NLHQCC\!0!PFC>*O%E]<V^C7-Q:074SLPN6
M=6PH3<%^7(SG]*C2YE\7:_H#:F86MY(;A9H)1\AVEE9A]0.M=M_P@?A]=.CL
MH[(QI')YBR1N5D!Z??'/3CZ<47?@G29O)DAA>.:VMV@MR'(50V2<CODL<T 4
MOB#=0V7P[OY[2&VNK>*+B-F)1D'49!K(TS26U7XBW27PMY;2TT^TGAC7/[LD
MR;=I[=#GUXKI+'P98Q>#8O#=\\EU; '>=Q4MDD]NW-6=-\*:7I.JR:E:BY%S
M(@C8O.S*5'08)QQSCTR: .'OOB/JUOXNN],@M;.2WCDEAC+%N&3&">?Y46OC
MKQ9=Z0U\+'3R_P!GAO D9;B)NJG)Z\C\JZJ[^'GAR^OI+R6VF$TDAE)2=E^8
M]2 #QFJNH>"3I]J&\,!8;IXEM'^TSN8Q!C'"\C<.,<4 :'A;Q#)KT-Q<RR0B
M!IV2TP<,ZJ2"<'K74UPT/@4V>I>&9+:Z\NWT6'RV"\&;Y<<C]?PKN: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR
M;^1JS5:\_P"/&X_ZY-_(T 6:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MK7G_ !XW'_7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH **** "BBB@ HHHH
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M444 %%%-!!) ()'6@!U%%% !12 @]"#]*"0.IQ0 M%)D'H>E (/0T +1110
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M%C7[C3Q#)+((X(/,SN+/LCYQQDD'IWKF]2\%WMC!=:-;P3:E#K-RL\\\K@+
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M8E@NHQ%D QW<BE@6+$,0>023P:EG^'WAZ>YDG:TE'F*%>)9W$;87:&V@XW
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M])KR9/ 7B?S+&'[;8+:0S6\\@RQ;,85<#Y>X7//K7K S@9ZT +1110 4444
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MS/K^L6U_JW]IV]PKS7]J###?,!$6\O&&QTY&1CUKMQ\+K&0VXN=0NI5AB:(
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MB\MO#,D%OY:@Y4R1%SSST._]* -[PAXHOK^QUV[U%C+%8W3I$1$$)4>HSUK
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M-WER##+[&KM96@?V@VAV9U;'V\Q@SX 'S?A6K0 4444 %%%% !1110 4444
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MEG\PCRRJLQXQ_LU:?Q7;-K=M'#/9OISV[R/.9"'!7=T&.G'7->8:QX/\17T
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MP-3T;4/B LD&G27%];8@:Z63B+/7Y?ZUNVFG:#I^M7^HPR6Z7]R1]H8S#/?
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MSJ3P<K@CTKK_ !WH6HWF@^'[&TTYYQ#\DRP\M%^[P,-V&>,T =R=:TQ0N;Z
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M "BBB@ K/UMVCT2]=3AA"V/RK0K/UH@:)>EAQY+?RH T**** "BBB@ HHHH
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MH **** "BBB@ HHHH *SM=_Y %__ -<&_E6C6=KO_( O_P#K@W\J -&BBB@
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MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN_\
M( O_ /K@W\JT:SM=_P"0!?\ _7!OY4 :-%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 03"/RF:1 RJ-V",]*YW3/%FC
M:O<6,5M!,6NXW:,O;D;0A (/''45D?$*[\B[TB&\DGCTB5G%RT0/WL#:"1R!
MUK@?"$$.H7NEV$=U<".YMKV,DY5A\\>T^H- 'M6JWEKI.F3W]Q"7BC"[Q''N
M8Y('0=>M4M3\2:1H2Z?+=K)'_:$BQ0E("3EAD!L=/QKRN234'\,:M<W=S=1-
MIC)I\6\_Z]EE4%O?A35/6M2^WW45S?W%PNIPWT8A@"';Y>WY".,<_*?QH ]\
M,$)8L8D)/4[131#$%VB- N<XVC&:^>TU;4FL[UCKTRW$XF6:(1N&C(=B"21@
M= !CVK3_ +3OK.Z329-;NFTZ26!KFY)!,8*H<9 X!.10!ZYH^H:9KB75S:0'
M*2F"8RP[6+#J.>W-:9L[8Q&(V\6P]5V#!KY^O+Y[;1KY=(U63RX9IY6C+[6?
MY%^=6/!(QT_2N[\;7ES-9^$PFK3Z?!>7"QW$@*J2I"\DD<4 >C-8VC@AK:(Y
M7;]P=/2FK86B,&6VB#   [!T%?/>HZ_K$5B\46LW#BR1WMYY&4>8@*X( 'S$
M\UU@O-6E\0RZ7!>W#Q7P34TN%88BA56WJ!]73\J /3-3OM,\/64VHW2B&($>
M8Z)D\G':JNJZYHNBV-K?7JJL-[*B1,(MQ9GZ9_.O#X-?O[NQUJ"ZU5KBVN=/
M\U%.,[_-CPW(ZX).*OW%Y<Q6BZ;-JQU#3XKJR:&:4IPQ"LR@@ <<_E0![P]G
M:R(J/;QLJG*@J, UA>*/",'BA;%)KJ>!+2=9@D1 #$$$9X]JX?POJVJ7/CB*
M2?Q!%-'/<W,36*H2P5=^PDXP!@#FF>(M8U%_$/B!VUB:RFTR:$65F-H$ZX1C
MQC+;B2O% 'J_V"U,4:/!&XC&%W**R++PI:67B"YUD2SRW$O$:.P*0+W"#'&:
M\OT36=375K+49_$4TAFU86K6SLFS850D=,Y&XU:^)/B;4K+Q9);6FIO:QVEJ
MDP 95&26['EB<=J /6UTRQ1BRVD())8G8.IZTW^Q]-%O]G^Q0^5NW;-O&?6O
M'M(U/6)]>6:;Q-,\;:M]C6$F/9L(&2,#/ZUL>#'\07OBY]/O+^Y:'1#)%<LP
M7$[,1L/3IA6H ]%N]$T^\AGCDMD4SIL=U4!B/K6?+)H.B6NG^'YC&L4^(((&
MYW;1GG_OFN!\1:SJG]K:UJ$>M2VDVGW<4%O8#;B5"2I.",G/7\*Y4K<ZA=6-
MK_;<J71U^Z"RLR%X BS8QD<9QWXYH ]V&@:2  +"  ,&'R]QWJS;Z996D\D]
MO:Q1RR??=5P37AL7BOQ%JLL=JOB1+%;%6/G2;<W.V7:>W)P","NQ^',^NZGJ
M&H7]]X@>]LXI#%' 54=1NSP,CKW]* -+2_!]GX?O]9UO6+R&Y6Y<SN\JX$7&
M.I/H!716VBZ)+I@B@L;<V<Q\P*!\K$]Z\K_MN\OK'4K^]\1)-!=0WD+Z4Z@[
M-JL%Q@9'8Y)[U4_X2S5K/Q)IL,.K,+*V-K#)$A01@.QW!LC<3C'W>G>@#V0>
M'M)%S]I&GP>=MV;]O.WTIB>&=$C1$33+<*C[U 7HWK7C*>)/%-M-?V[:_.UP
M[1LL:F(G82V6B;&WL.#GI790^(]17X46NI+J!GOKC;%]L*@%"?XB,8R,>E '
M;2^'-&GFFFDTZ!I)O]8Q7EJC'AC10DB#3H-LB"-QCJHQ@?H*\OEUOQ5-KL6@
M6>O()HKXVYN)(P?-7D@\#&0%Q^-=%XXU_5['4]*T2QU&&PFN87GDNV7ABG\
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MA'6+^0:K87\EO-)IRH4>'/S!@QY_[YH L2^%_!MOJ,?G:?I\=YN:9 QPV>[
M9I8_!?A*]MS-%I%E-%/E]ZKD/DY)S[UYY=7]UK'B+1M7FN[0R3V]PZ0AO]6,
M<*1G.<=:T'\9:GX>L=$988OL.H:?$MM'$C';.=HQ]/O'Z"@#KH_!?@Z:[?R]
M*L7N+<IN"\F,J!MSSQP!4UAX2\*F[2^L+&U,T,S.)(CG:YZ_C7(QZ_?Z5JNJ
M6'E64.ISW<$+S$ML&Z%69CSUZ@>^*QM-\1ZYH=I#INAVUM=W%S<7$LKO,$&5
M9^A8@?PY- 'K/_"/Z28[^(V,6R_8M<C'^L. O/X 5'IFD:+X?M1IEG%#!',2
M?*)Y<G^=< ?'OB>.>X,T&F+#:W5O#,BEBQ$A4'#!L<9JAJ6L:KJ>H>&?$,AM
M=DLTQ@B5BNS;C ?)QUH [S_A7GACR9H?[.4K-@-D\@#. /;DUK:KHVEZCI<6
MG:@H-J'7:K-C)'2N<\%>*K[6],U)KWROM-HY&TJ4(],Y_G7#WOBK6/$EG:1W
M<=K!?6NH6X"[9$*.RR$A@3\R_+U% 'I,O@'P[*[R?8MDKRF5I%.&+'.>??)J
M.3P?X7PZF*- (5M" X&U1@A?_'1^5<3)\4=96"R*VEFTFU_M(".PRKJO!!^4
M'<>M4KF!6U+7B5:,KKD#K^\)P2&SWH ])3P'X<2[%U_9R&;;MW'O\NW/UQ58
M?#;PPK!EL,.!@/NY^]N'ZU0\>^-+_P ,7MC!91P-YJF1_,1F) .,#;T^IXJJ
MGCG5[F*\U*VM[+^S+)?WZ2,5E)\H/D9..IQC% &\W@706D:0PR%VG6X+;^2Z
M@ 'IVVC\J!\//#:S-,EEMD8."P//S#!KGT\7>)HK>UO+FUTQK:[EMS'Y;G=L
MDD"$8W9R!SGIFH)O'?B074EE;V>GM<"]N+=#(&"XCC1P>O\ MX_"@#?'PW\+
M[D=K$L414&6[*21^(R:L1^!?#UC>0W<4!@DCG\Y"'P-_:N(D^)OB2/2FOI+3
M3P);(WD"@-P%)#!N>^.*T-?UF^U6^O--NHXA'9WEI);20[@3O$G#'..-OZT
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MQ_#?1HKB.X6XOQ-%*LR2><-P8)L'\/I7:T4 <B/ 6C'0Y]'<W,UI-<BZ822
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M3>!M!N+J^N9K1WFOB#.S3.<D8P1S\IX'2H'^'GAI[);4V+"))/-!69PP;O\
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M /"KO#^54BX:);5K7RS,V-C9SW]Z6/X9:#$25>]+,Z.Q:ZD.XIG'5O<UV]%
M'&?\*YT'^T)+PQW!DD=WV^>^T;_O#&<>GY5'#\-="MI[6:$72R01B,_Z0^)
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MI6(?#&E-K_\ ;AAE_M#;M\SSGQCTVYQ^E8?@CQ3?:SI&H7&JJJS6DK!D50&
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MV[K!/>*_*O@$\?B.]5]%UG5=7^(^F7EPK6MM=:9-+#;+.S*R@I@LO16Y[9H
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M+P%9Z#J5M?1ZA?SM:P-;PQRRY5$)' &/85@'Q1>:D;1]2M9[:%M;$4+Q3IP
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M2BBB@ HHHH **** "BBB@ ICND:%W8*HZDT^JUQ;Q74+0S('1L94]\'(_44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZDB@#R5? _B658[1[18IY8RK7*2'85//[T8^9@<<YZTV'P=K5OIDL5WX<#O
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MG)'2I[J]M;&/S+J>.%#P"[8H \8L_!6HVFFS13^$!YD<+13W"W.6N,G@H-^
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M2=B#P1CK6OXST6\N_%&HM-8W-VUQ:(FF2QQ[A;R CG/\/.37J^!G..:,#TH
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M=4F)BU$"V1I2=P,!SGU^<_G7O#11N,.BM]1FJJ?86N71!;F>/!90!N7TSZ4
M>*SZK9VGAK5%O+R]&J.DD=ZDQ.Q6+G:?8XV@?A75?#O4K:-M<M+;49[FWMHX
MY!O<N4S&N<?CFO0I!9F5895A\R3D(P&6QS^-2K## '9(E7=RVU>M '@^FZI=
M0J;I]9GGM+?4;>26Z$QVK&9#NW#L0!S[8J2'7U>[N8;[6]1L]'%U<BUGCF.X
M-B/:#Z]3@>YKV'0]1TK7+*:?3D5H1*T<@,>W+C&>*TS:V[  P1D [@-HZ^M
M'C-WK2PZK)J-CK-W#<)>6L,D3L5# B3(D7/)X%>VUF7Z:996L]Y>10K"G[R5
MV4=N_P"M6K6ZAO;2*Z@</#*H=&'<'I0!9HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N:^(/_(@:W_UZM72US7Q!_Y$#6_^
MO5J .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#RK_A#M3M?%U_>?V);WOFWANXK^24[@IS\FW<.>G;'6LV#P/XAC
MM-5A&G1JVHQI/DR+B!P03$,'.W_ 5ZI-K^DV]V]K+?PK/&NYHRW(%1IXCT=\
M;=1@.4$F=W&T]#0!YJWAC7[[6;*[N?#5O#;!WD:WBD3"-Y;+SEN22V>.*R1X
M)\2S6<?VC0G,\6##B>/";9@PSSG[HXQQ7L:ZWI+1^8-0M]FXIGS!U';]*>NK
MZ>]P(%O(3*4\P+O'*XSG\J /*O\ A']:MBMY)X:DB9;_ .T2RBXCW+%M^8Y!
M^O%8&@6<NHW)LIK0)=W5M<PV$J2HRLNZ1SO"G<"=VW)Q7M[:[H[VLLK7UNT"
M-Y<A+9&?2H+*T\/6-XKV<=C%<RC*% H8@^GUH YSP'HTNE_;)FT!-,5HUC*^
M:7>9USEOO%0#QCO7)VOA6]1-.:;P[*[0M<R3 2+^\W;=H//L?SKT2;Q2%\:V
M6@PQ1RQ7$4C-,KY*,HSC'Y5NR7MK#.D$ES$DS_=1G )_"@#PF#PAXF^S6AET
M>Y$MM;P@%)H_FVEMV23D8R,8QWKL]&TO[=\0[Q;9XVT>U9+QXE(8)=,#QD<'
MJU>C+<P2R-$DT3N.JAP2/PJE8II%BTT5E]DA9W+R+&R@D]R<4 <3XVTNXE\5
M1W;:(^IVL^G26BA& \N5F4J3STX-8.D>#=6TS4K6"[TAKZ[C,#I>-/A(PJ@,
M#A@3CD#^M>O?;[0(7-U!M!P3Y@QFG?:[?)'VB+(7<1O' ]?I0!YOXUT:XU+Q
M/?2KI4UPATEX89%; \[)(/Y5SVH:#J[6$D%IH,T<4L%FLN'&2RNI=ASUP._%
M>K6>L/<:A?PRP+%:6^TQ7)D4K(" <]>.3WJOH'BB'64U!Y(UM4M+HVX:1QB3
M@'(.?>@#S*VT36K>WMTNM$N[FV2WFMHXG="4=LD-P<8.X?E3XO#=^=4CN+SP
M]<W,TL$9M29@%@<%N&P1QT/'K7I?BGQ+'X<TG[8L:W+EU58E< G<<9Z]*3Q%
MXHM_#NCV]W*@>:Y=(XH=P&YF_I0 [1-7M_%>D7B-:-'''(UK(CL&#$ 9P1U'
M->60> ]>6^A)+K#YG]EE!T^S#G>?^^17J_A^[MI=*A9;2/3Y'7?):Y4%2>Y
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M&Z\X(KVQ-.L8K=[>*SMT@<?/&L2A6^HQ@U"NAZ1&RM'I=DC(05*VZ C'3'%
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M4 %%%% !7(?%+_DF/B'_ *\V_F*Z^N0^*7_),?$/_7FW\Q0!U]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7(?%+_DF/B'_KS;^8KKZY#XI?\DQ\0_\ 7FW\Q0!U]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M,DD2*-I)&"HHR2>U9ND^(=)UPRC3+^&Z,1PXC/W:M:A#;W&GSQ79 MW0B3)Q
M\O>N$\)MI%YXMGU#3!;V]NUOY5M&I >=5/+@?W1D<^] 'HU%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<A\4L
M?\*P\0Y/_+HW\Q77UR'Q2 /PR\09_P"?1OYB@#KZ*** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !51+J&67RXR7.,[E&5_/IFK744U45!A5"CT H ?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445&-_F'.W9CCUH DHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N'^+W_ "3'6?\ KE7<5P_Q>_Y)CK/_ %RH [BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I.<^
MU+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7#_%[_DF.L_]<J[BN'^+W_),=9_ZY4 =Q1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_0QVW_?#_P#Q-?&]% 'V1_PMWP%_T,EM_P!\2?\ Q- ^+G@/G_BH[;_OA_\
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MM/\ O^O^-']K:;_T$+3_ +_+_C7P;3@S#&">.E 'WC_:FG_\_P#:_P#?Y?\
M&C^T[ C(OK;'KYJ_XU\)>?-DGS7R?F//>E-U<!=@GDV^FXT ?=G]IV&0/MUM
MD]/WJ_XTO]I6'_/[;?\ ?U?\:^%?M-P<,9Y,KT^;I31?7?\ S\2_]]&@#[L_
MM.Q_Y_;;_OZO^-']IV/_ #^VW_?U?\:^$_M]W_S\R_\ ?1H^WW?_ #\R_P#?
M1H ^[/[2L?\ G\M_^_J_XT?VG8_\_MM_W]7_ !KX6^UW7_/S-_WV:/M=U_S\
MS?\ ?9H ^Z1J5B>EY;_]_5_QH_M*Q_Y_+?\ [^K_ (U\+B_O%^[=3#Z.:0WM
MV3S<S?\ ?9H ^ZQ?VA&1=0$?]=!1]OM,9^U08_ZZ"OA==4OU)5;R<+Z!S3O[
M1O\ (C^VW&T=!YAH ^YA?VC=+J _204AO[,=;J 8]9!7PTNI7\/^KO;A?I(:
M7^TK^4Y>]N&+#G,AYH ^XQJ-D>EY;G_MJO\ C3OMMKQ_I,//3]X*^$UU*^3[
MMW,/HYJS_;&I_P#00N?EZ?O#0!]R?;+7_GXA_P"^Q2&^M0<&Y@'_ &T%?#W]
MLZKG_D)77_?TTQM6U)SEK^Y)QMYD/2@#[E^V6W_/S#_W\%+]LMO^?B+_ +[%
M?#O]KZIG_D(W7'3]Z:/[9U7_ *"5U_W]- 'W#]LM?^?B'_OL4OVRV_Y^(O\
MOL5\.?VSJN?^0E=?]_32_P!LZK_T$KK_ +^F@#[B^V6W_/Q%_P!]BC[9;?\
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M\);XB_Z#=_\ ^!#?XT ?</G1?\]$_P"^A1YT7_/1/^^A7P]_PEOB+_H-W_\
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&?0F@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>inmune_ex31img22.jpg
<TEXT>
begin 644 inmune_ex31img22.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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MG_<_PKO*X/X/?\DRTG_<_P *[R@ HHHH **** "BBB@ HHHH **** "BBB@
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MFE^QVV,>1'@_[-6** *WV&U_Y]X_^^:/L-K_ ,^\?_?-6:* *WV&U_Y]X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>G%+10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@#
MEOA9_P DUT+_ *]4_D*[*N-^%G_)-="_Z]4_D*[*@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM
M>?\ 'C<?]<F_D:LU6O/^/&X_ZY-_(T <M\+/^2:Z%_UZI_(5V5<;\+/^2:Z%
M_P!>J?R%=E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 56O/^/&X_P"N3?R-6:K7G_'C<?\ 7)OY
M&@#EOA9_R370O^O5/Y"NRKC?A9_R370O^O5/Y"NRH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "DR,D9&1UI:A6)$D>0 [GQNY]* )J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIJKMSR3DYYIU !1110 44
M44 %%%% !1110 4444 %%%% !1110 56O/\ CQN/^N3?R-6:K7G_ !XW'_7)
MOY&@#EOA9_R370O^O5/Y"NRKC?A9_P DUT+_ *]4_D*[*@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T <O\ "T$?#70LC_EU3^0KL:Y+
MX9G/PW\/\G_CRC[?[(KK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD(R"#WH 6BHT01H$7.!TR<U)0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !15![Y8]4@LO+D+31M)Y@'RKM(&#[G/Z5?H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BF,NY"N<9&.*@M;9+6W6)"Q [LQ))_&@"U1110 4444 %5KS_
M (\;C_KDW\C5FJUY_P >-Q_UR;^1H YOX:?\DV\/_-N_T*+MT^4<5UM<O\.?
M^2;>'/\ L'P_^@BNHH **** "BBB@ HHHH **** "BBFL2!\HR?K0 ZBBB@
MHHHH **** "BBB@ HHHH .]%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O/^/&X_ZY-_(U
M9JM>?\>-Q_UR;^1H P/AS_R3;PY_V#X?_01745R_PY_Y)MX<_P"P?#_Z"*ZB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[M1110 4444 %%%% !14&V7S]Q8>7MQM'KZU/0 4444 %%%% !1110 4444
M%%(<XX&:6@ HHHH *K7G_'C<?]<F_D:LU6O/^/&X_P"N3?R- &!\.?\ DFWA
MS_L'P_\ H(KJ*Y?X<_\ )-O#G_8/A_\ 01744 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5GOJ^GQW)MWNX5F&<H7Y&*T
M*\:USPFFHZ]J5Y+X:N9$?5(FWK =SIM?>P]5)*YH ]5;6=.2&*5KR$1RMMC;
M=PQIRZG9.DCK=1%8R YW?=STKQ"^\*:F+>>R@T.\BMHKNY:!([4LH4R$H%'8
M8[UL+I;7_B33=%MHD6.[LH)-6B(P\31;<;A[E0/QH ])UG4=$\RVTC5)8B=0
MRL43\[\#/]*EA31]0EA6(V]Q)8G;&.&,9 Q7)^.=#>YUG0KVTL)9Y(%F@5HH
M=_E%HF$;-Z*'(.?:LCP3X>U&R\1:1<MIDUDUO;31ZC(T119W+.5(/\74&@#J
M]=\>Z=I$LT$(^T7%O/%%/&.-F\XS6\-9T_["MXUW$L+';N+<9]*\M\5^'KR?
M4]>3^P[FX6^N8766& N&C&,Y/KUXJK>>&9A<B#^P-3;1TO96:"WB*D!TC"N@
M]BK9H ]0\1^(H]!T4:D(C<1EU7Y#P >^:OG5; 6OVHW<(A!P7W<9]*XB[T&Y
M;X2+I"6%P&6$*+8G?)M';IUKG_\ A&F@U)+JW\.W1T!KL'^S_((9,*V7V>^1
M0!ZQ)JMA$D;R7<2K+]PEOO4O]IV.\I]KAW 9(WBO#M8\,:HUM$D&AWXC*3F"
M,6Q?8&E5D0_W"%'Z4Z'P;<W-AJ5ZF@7R7R30.1) 4:6/Y?,5?4GG]: /6]%\
M3V^N7^IVL$4BFQE$;,<8;*A@1SZ&M/\ M"S/FXN8B803( P^7'K7#>"].>TG
M\4+8Z-=:5;7+J]HDT)BY\I5./^!9KG;#0 -0L'AT.\CN$BN4U=GA.V=2'QG^
M\22,?A0!Z)H/BF#Q#)/]FM+A+>,92X<#8XR1P<]<BH'\;V(O]5LHK2ZN)-.C
MC=Q$%/F!RP&WGG[IKG]*T^>T^$MY::3ITUK>-%,#$D11V8YP0/7&*X:XT8+;
M>(I-+T+4((I;.U\E5@*[IU,A8_7D4 >R:WI.D^)+-+;4@P5,2(RR^6Z'V8'(
MJUI.GZ;H>F1VMFRI;@\.\FXL?4L>IKR:^\./J,.MW-K!J)O(Y=BJJ$CR6'S;
M5[G@5!#HWE2:=;WMEK%YX? G(B^SD!9LIY9"\X&-V* /9X]4L9+R:T2ZB,\
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MV=I$(X(5"HH'05:P,DXY/6EHH *:0",$ YIU% !1110 4444 %%%% !1110
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M/F* 0ZGFE&AZ4LT<HL81)&-J,%Z#I7CT7B+Q&^EVES:^(Q;1V^D6UU);K'&
MSG8"/N\ [CTKL_'/B*^LO#&ES6%^UK=7K##1!<O^[+84L"HZ9Y[4 =>N@Z4D
M'DK80"/?OV[>-WK4D6CZ=!>->16<27##!D"\XKQ<>+_%EX9IDUU;>.ULH[EU
M 1MQ#JC G'?D_C6A_;'BW_A)(M%.L7;2:CY%U:2B*/:L)VM(/N^F\#- 'K%U
MI%A?7,-S<VD4LT)W1NPY4T6NDV%E<R7-M:QQ32??=1RU<)XTU+7[/Q'8V6EZ
MQ]G4VC3NCHI\PQY)'3^+&*Y:'Q3XPCTJXE?5XY6NE4P[6CWQ')!"]AGC&[O0
M![%_8FF><\OV&'S';<S;>2?6@:'I81$%C!M1MZC;T/K7C=GXI\57*'R_$\;I
M%8?:"S1JI+ G@Y7O[>E6G\>^*)=3FO4>.*SMYC"\#%0#[[?OY_2@#UV]TJPO
MFCDO+:.4Q?<+_P -17NG:9)<QZE>00F:V!V3R<; >O->1W^J:U>:%:F;Q4)5
MN6MY_P!TJAH\@[ER!C;DCKSQ7KWEVFI63VS3)=1$>7(0P.2.N<=Z ,$OX&EA
MGB^TZ0T=P=TJB=?FYSZ^M:-IHWA^[AM[JUM+66-$*12)\PV\@@'\ZX@:5HL_
MB+QEIYLH2(+.(Q*  %"PKC!'OBN?T#Q)KWA_PS'#'<P/'+9E[>(8!B8S%,Y/
MY\T >JGPYX>L;3+6-O#;PR?:,L2%1A_%G/'2HK,>$[S499;&73)[R9=K^5*K
M,P^@-8?@C4]:U'2M4M_$$L,YB!VN'1CM*@X;;\O<UQ>DB6RTGPE=-%:);+J6
M&D@.)F#2D#('4?ATH ]?L?#^DZ9,TUE8Q02.NUF0<D<\?J:CB\,:)#J OH]-
MA6Z#;A( <Y]:\Z;QSK%O;VVLR:A UM?&93;,O%KMQ@G W=^:H:?XT\4W\C:?
M#J<:S?;K>)9IU7)64/V4=!L^O- 'I=_HGAH@PW]K:+]LG#;)#M,DG.,<]>O2
MKTN@Z3/);O+80LUNNR(E?N#TKRZ_O-7U#4=/.IZG RV6MI9>2NT995<&3GD9
MQQ73^,=9UA-?CTK3+^/3UBLI+UIG _>;"!LY]=WZ4 :\^F^%=(N(4GAL;6:6
M7S(P[A27]1D^M)>+X/GU&9[R?3&O'*B7?.NXXQ@$9]A7&:1'+XH\>:=J%[>D
MQ2:-'</:NBGNA('&1\W/KQ5RYCTJ7QUXD6^2WCMQI@.YL ]!R/>@#KQIGAV.
M^6%8+07-P!*JY^9P.XYYZ?I4,?A9H_$T6H?;&_L^!#Y%B!\B.<Y;^5>6:=JF
MNZ?H5I)'?^6T>GW<MN954N%4R%3DC/0"K5_KWC!+6PA'B%5FEM1?>=M15(Y^
M0Y'/W<\<\T >U30QW$+Q3(KQN,,K#@BJ4VEZ9J"QR2VL$ZJA5&(R-IZ@?E7F
M#:]K.J+=W?\ PDXM=SM:C3UC4O\ =7#+\N0<D\GCI6/H>MZY9>%+1+;Q"R_9
M+#[8$E"'S22?W1..@Q]?FH ]7U7PUY^G7$.C7']E74[ O<0CDCGC]:OZ/I$.
MD:-!IJ?.D:;69NKGN3]:\M_X27Q??1ZW>6^J10&*")X;-]@9&DR< GT"GJ>]
M;>CZ]J=W\,]2NVU5VU*U>1//D10Z$-P&XVDXZXXH [2/PQHL10IIL"E&WJ0O
M1O6K']CZ=]JDNOLD7GRKM=]O+"O&V\0^+;6U>YE\3;Q;0VEPR>6G[SS=@*_=
MZ?.?RJU;>,==U/Q?/86^MJ8+E98H=@0)%(JD@#<-Q.1@YX]* /4QH6DA446$
M.(P0HV] >3_.FP_V/J2S:?$+>=+5PKPC!\MNO3MU%<=\.]8U?7KAY+R\G9;"
M)K6Y1T #SAR<].FTCI7,SZWKD>L7UE:ZT+:2771:M(B1Y\MDCQVY(W&@#U]=
M'TU&5ELH0RG<#MZ'UJ6UTVSLFD:VMHXFD.7*KC->/6_BO7=6M!9+XF33Y[.%
MW^U.J$7# GAN#TP.F.M)>^)O%$<&HW5MKPGC2\2U4*B+L#CA@6'&,'K0!ZN=
M T@M*3I\!,I!?Y?O$=/YT_\ L/2][.;*$LS[V)7JW//ZFO'=3\9^*+&SC0:V
MLL]H)&D,7EYD *@%R1@]3]RKVM>.==L-5U*1+\&$02&WC4*R9#H 1@9! )SG
MUH ]8BT?3H&=H[.%"Z;&PO5?2L];+0+C4/L*06KW5JHD\M0,H#T)'XUS'AZ_
MUJ]\(ZU'J&J&6XB1C!<H49PI4L,[1MZ"N'LKS4+"VM=:T_Q"\LT=E;M<>8(]
MTV^2,%#QT7=CUXH ]OOM)L-3$8O;:.81-N3</NFDAT[3X+]IXK>)+IE^9E^]
MCI^5><>#/%FN:QXJS=WL9LYGFC%I@9386P1CD9P.OK7JFT;MV!NQC..: 'T5
M7,\8G6 D^8PR!@XQ]:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 56O/^/&X_P"N3?R-6:K7G_'C<?\ 7)OY&@#'\#'/@30B/^?*+_T$5T-<
MYX"!7P!H(;J+&+/_ 'R*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (W19%*NH93U!&0:< %    '  IU% &:^CZ7-,TTNG6DDKG+.\"ECVY
M.*S=8\+V]_I?V;33%IEPI'E7-O H:,9R0.. >?SK@-6\3>)++QEJ,<>I V-O
MJ=O:"+R>THC!YSVW_I3AXJU^%;<C5%8F&]W[DS@QJQ0GGZ4 >H:3IL6DZ5;V
M$1)2%<;CU)ZD_G573X= NWO%L+:Q8AC%<B.!1D]PW'->7W'B/Q5:V[W<^NH1
M;VD-Z\8M\!][NNW[W3Y/UIBZIK&AZ_J6HZ;<0_99=7$$EHL>2Y=1DY]L>G>@
M#UO^PM)VE?[+LMAQ\OV=,<=.U#Z)I,CN\FF63NXP[-;H2P]^.:\8L_%WC2?1
MEOI-9LD:[EC\L1-YC*#NSE>-HZ<9KN_$U]K6@^']'TYM4#7MY=K;27_EXV@J
M3G&>O'K0!U5W+I.BZ<WVG[-:V(X*; $Y_P!D"H[73-"O+*&6VT^PDMB?-B*V
MZ;0?[P&.#7DVM)JVLZSHNF7VIF40:PUNLA3Y779(<GGDX7'XUO\ C74=4T>[
MTZUT>Y%E80PEIXXD_>+\^T/MS]SGKGO0!V]G:^'=0:?[+9Z?,T,A27%NORMW
M!XJU_8ND_)_Q+++]W]S_ $=?E[\<<5Y!+K&I>'KN75+;5(DM[J_CC>/R^)-T
M2Y8G/OFJ,OC+Q1%8:FT>JR!O+CN(7D3)YG*$ 9X&%H ]TN;*TO8A%<VT,\8.
M0DL88#\#3$TRQCG6>.RMDF1=JR+$H91Z XZ5XXNL>,+;78X/[?MVCLC$9?M,
MI3S58Y)V\YZX'TKHO VO:M>>)[NUU+4&G1X!-"H&8W&6^9#GIQTQVH ] ETS
M3[F9;B>QMI9EZ2R0JS#'N1FLV.;PW=ZK/IZ1V$EZ<M-'Y*DM@\Y..>M<3+K.
MMB>/4AJK".XU4Z>]D!_JT(X(YX(QZ=ZO>"- 2'1M6NGNFENS/.B7##YX^>2#
MGOQ^5 '6'_A'X]6BL_)L1?21X11"NXH.V<=/:K3Z#H[H$;2K(QAMP7[.F ?7
MI7B]E;7WGZ0]EK!6Y73[N5KF1=S':ZGCGK_3-2V?C'QCK-Q%J-K?VEK;V<=M
M]HCN9=@<.BEFVXYR3Q]: /6M4O="LXX]/U5K58W4%()HP5('3 QCC%.BT70;
MJ&.2'3=/>(N)5*0)C<.AZ=>!^5<9\0HWO]4\)?9K>VN;J6=RL<S;48&)CUP>
M/PK($7BCPG>Z5H=GJ$,,7V6>\N%\O>,AW<JO(_A % 'ILF@Z%'%,9-)T]8W^
M:4FW0 ^YXJ"UL?#FK/'=V]K8W+V_[M9!$I*X[=*\@O\ 6?&.I>"]8N-0U*U%
ME=6LDD>PX?Y=V5 ]"  :+'4?$&BZI-%HTEE%!9)$UT3"$\W(R7<_3 []* /9
M/^$:T;S[B8:? 'G&)"$ SZU:MM)L+.P:PM[6..U;.8E4!>>O%>5/XA\>1:;#
MJ1U6Q,=Q?QVBH+<<9SD]?I26?C7QC!?O=W,EK+IT,[VLJ%-F&7H0>>3Z4 >A
M_P#"->&Y&DL196Q?R5C>, ;A&,8'TX%3W5IH<\4.GW:6<B0 ".*4*=F!@8ST
MXXK@?!:ZC/\ $8ZEJ5Q!--=Z2)<Q1A-NXH=I]<>M8^MZ?Y=[JM_):07^BW&H
M!3>I_P ?%I,L@!X[@-\O4=: /4&\(Z"Z2HNG0*LJ!'5%"@J"&QQ[BJ6B>&;Z
MRUZ?4]0O4N=D?V>RC6,*(8LYQP.O)%>?Z#XC\3-*MA!K<9EO[^Y2.2>#=Y21
M%^G/.=G3MFM6V\7^)/$36T&G7%I8S6]N]Q<-,N5FV2LA _N@[<]Z /1'LM)U
M2^6[,<%Q<6Q,8<8)3U'ZU3D\+^'+:TN-^GVL4+MYLC; ,$=\]L5YKX+O-0/B
MW4M'TVYMK(27WVNY<IN\Q=B91.F>0<GT-:WQ(U35-237=$LYH8+.QTHW5T9(
M@[3;MP"J,\?=Z^] &H/ 9?Q<M\;:P_L=81$D*D[L D@D8P<Y]:Z>YT?1/MR7
MUS96HF)V!W1?F)_F:\YD\9>*8===+&*%M(L[A;217BQ_"#G?^/3%5$\7:QJ5
MA$-86SGFAU*W46\L 1XRPDS\O/3'![\T >FCPGHGV:6W73;=8I6#,JH!TZ8]
M![5?T[3++2XY8[.%8EED:5P.[,<G^=>7I\0/$EQXAN+2U:SD5'G\RV*8>W6,
M@#<>^<U/%XZ\2?V?<)>16D=S):0W4!')4.5^4KW/S4 =NOA#1H[^^O5BE$]\
MI2=O.;YP>V,U'#X)T"$QE;($1Q&%0[%AM.<C!^IKS@^-/$L\NFZE<3>1% ;H
M20^5M\UHRZC<,\=.G8UIZ?XR\7W-N+:[LX+>>],9L[AD^4*V"<KWX)YS0!Z!
M8Z+H]KILUG8V\26\P*R>4<%L\')'-9VE>'/#-K>#[%%#)- 0RH9-_EG/4 ]#
MFL#P<;N+P#JQ@N42^CEG+2>7E0XST&>E<CX=36=$LXY=.2Q357M)+J>X> 9D
MB!;:I]\AN?0B@#U/_A#M"^TW$[6",UPI5U8Y7!ZX7H"?:F?\(1X?1(Q'8A&0
M@AU8AB1T)/4XKG?#_BKQ)KWBT6B+9KI\=M%<S?WPKEA@<=?D-0ZIXTU^/QI/
MIEJ(1:).( WE[@"0>6;L>.E '83>$M%GU1[^6R5IW8.Q)X+#H<>O)YJQJF@:
M;K#1F^MED:/[K=#CTSZ>U>9:3XU\;ZA!:;Q9+-?Z?+=6P5,X,90'(]]_Z5T7
M@?Q3J?B(W5[)+$]E;V<6]%CVL+@IEQGT!!&.U '5)H&F1:DM]%;+'=)&(E9.
M $ P%QTQQTJI=>$]!FU1K^ZME:XF8;C(Y*OCH"#P1[5P=AXS\;:Q'?7=M%:V
M]EF802RQ\(8V/&?XLA3Z4ZP\4ZOXCTNWU2X^QO:K=11B$Q#*, -S$]LL"1[$
M4 >B3^'])N)1+/90LRQF)<J,*I&" .PJ%M$T&_2*S:TM9Q8L L94-Y??'TYZ
M5Y+K7BKQ-?17EE=:J+*4W$*I&(-I4-.%!4Y^==N#GCN*T!JWB'2M2U*"UELC
M>M?VMJU[]F"^:'V#YN>O- 'JRZ!I"7C7BZ;:"X88,GDKG'Y54F\+:#/''&^F
M6P2-BRJL84<]>G;BN O/&>OV^B6/VG4;>VF:>X22Z$((;RU0J-N>,EB.O:MK
M4O$VNZ9\.;'4K@0IJ]V\<)8IA(V;/)'MB@#H;GP[H+7,OGVT0EO.&!."Y]OI
M5F/P[I<6DOI:VP%I(/G7/+^Y/4FN(NKC4!JNE-K%Q9W5_9W$ICFB^5=N/EW#
M^$GTYK"A\?\ BR;2KLPF*6<Q)/%(EN,*G\6WG]X.1@\<4 >G)X4T-$9/L$;*
MRJA#<Y"XP.?3 J&Y\(Z<B37&F65I;ZB?FBG:%3L?&,XQ7G[>.O$8O-&=[R!;
M:Y94:06XV2%NS'/R-CMS75>*]9U:/6)+/2KJ*V%C8M?S;TW&55."H]..] &[
MX9T/^P=(%M)/Y]S(YEGFVXWNQR3C]*>?#.B&X\\Z=;^;YOF[M@SO]?KP*X[P
MQK_B7Q%XM<QWULNDP*CRPF+#C?$K =?5JR]>\<^(=*\5:M$+NW6UB23[-"Z?
M*<1@@[^Y#9)&.E 'HJ^%-!7;_P 2FT.UBPW0J>3U[4V#0M"\N[MHK.V=96 N
M$*ALD=,C\:\TE\4>/8_[.LFO+!;J\N45#Y>2$? 4D>F<TESXA\1:=JMYIM@;
M!-4NKXQO=+ !NV@=NY.?6@#TEO".@/Y8.DVNV-"B@1#&#C.>.3P*;'X>\/1W
M\BK96AN)(B'B*@Y4D9.WW..:XBQ\8>)&\1:/!J-Q;Q6TOE13&*+=&\A!W@MD
M;6X&!@]Z;XSDU2Q^(G]HZ++:P74&EN\C3IGS$#)Q_P#7H ]*LM(T_3K0VMG9
MPPP,,,B( &^OK5/_ (1?0@DB#2[55< ,%B & <^GJ,UY_9^*O%ESK-CI[7%N
MDVH/#<1(L&1';F,LV3GL=JY]ZTO%GC#6=(\:6-C9/$;$F-9U:+=RQ ^]GY3S
M0!W%IH6E6-VUW:V%O%<,H4R)& Q'UK3HHH 3 SG'-+110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_
MD: ,CP/_ ,B-H?\ UY1?^@BN@KG_  /_ ,B-H?\ UY1?^@BN@H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBFE@O4@9]30 ZBBB@#GI?!_ARYN);B
M;2+=YII%ED<@Y9UQ@GGJ,#\JCD\!^%Y99)9-%MF>3.\D'G(P>_I7&ZYX_P#$
M6FZCK$5O;Z?)!9WD-G%P^YVD"8YSCC?^E5;GQYXOTS3T_M*ULK>5)65I-_F<
M8!7>$)VY)QSB@#MIO /A>2V\J;2+=HQ&(R6S]T$D#Z#)JW:>&M ^W_VM;64#
M3N!B53D?4>]<5IOC[4-4O[-[BWMCI%_=&P"IN\Q6"J=YYQ@E_P!*SO#/B36-
M+\((MJT#116$DZ&7).Y6/7VZ4 =[-X/\(VMO*)]*LHH9I S[^ SC.._7DUM7
M^D6&J:?]@O+9);;CY&[8Z5Y-=ZOK%U:ZO?7T]M/ [6Q2V.X",'?TQWK7O/'N
ML6NHS7,<-N^GC4GTX1<[P5#8;KWVT =6_@7PU)%;(^E0D6S;XCSE6[FK.I^%
M=$UFY@N-0L(IY8%V1LV?E7.<?G7'^#/&.OZQX@AM=66Q$%U!-)&( P*F.0(>
MI[YJ'Q5X]U;P]XHDBA@AFT^!E5QM;/,>\\^N: .I;PCX0^T+:OIMEYS2?:%B
M)^8M_>QFJUQX5\$1^;#<6.G*8\"17?!7)R,\\9)KAI?$6K)K5CXIO%MF,EC+
M);PQ[OE!W*H;GZ$TRYFOH#JUQ?BVNYY7LYG)W!2&=>.#VH ]6_X1S1'N+:[_
M +/@::!0(9,<J.V*-.\-:-I-[-=V-A#!<3</(HY(]/UKB;+Q/XC37$2>2R-C
M'J::>8D5MQ#*ASGIQOIWA3Q-K^L^)?*D>"2RD5WFC"G-M@X"@C@YY]: .P/A
M70VU*34#IT)NI#EI,'D^OUJUI6@Z9HMH]KI]I'!#(<LB]":\ZU37-:TCQ=XF
MN%O$>)$MX;:-P=J,^_!_#:<UT_AC6M1N9M:TS4?*ENM+90)D!"RA@Q&<]_EY
MH N#P3X95PPT>W##<,X/1N2.O>E7P1X<2>WF72+</;C$6 ?EQTKSR#Q]XA-U
M*LUQ;B1;E UOL.54G& >C+SU&:U%\9^(-0U3^QK3[)%=B>Y82RYVLD;L HYZ
M\#\,T =IJ'A_0]<U*&XNX(9[RQ(\LAOFBYR/I4T_AO2KG6H]7EM5:^B4JDIZ
M@$8Q7E::SKNF^+M9U6U>T$6;0741+,K,XC1@A![$G\J[[Q-K>J6UYI>G:.ML
MMW?AV#W&=@VH6QP>IQB@"1O!'A>1;NS_ +.M_P#22'FC!Y(SZ>F<T]O OAN2
M:VF;2XC);J$1N<X!R ?7&37#W>O:CIOB.[U;9 +PZ*DDB*Y:(.)95)&#ST'2
MF/\ %+6%\,QWHM;03K=R6\KNDFT!%1@2H.X9WGGVH [Q? 7A];..T%G^YCG\
M]5W=']:E_P"$,\/_ -J2:E_9L7VJ0EG?GDGOCUKEM"^(&L:KXN72;BSL8;=F
M(4_.&<#'S*Q.UAST'-3:OXXU>VN-:N+&SLWT_2)5BN!+N\UR202N#C''>@#I
MM*\':%HE\+VPL5BG$?E!@>B\<?H*JGP-H1OY;HV[?O9O.DBW?(SYSDCUSS4'
MA3Q!K.NW%])=6-M%8V\TL"21D[F=&QW/3K7*3?%+4[:YU..6RLCY#M'!$%=9
M WFA%W GD%23E: .PG\ ^'9Q,6L@KRS&?>IP5<]2/3//YT^X\%^'[V.S\RT4
MK:J4CV'&02<@^H))_.N0M?B#XGO)[.P71[);N?S ZN64?*QR0"V<;1GFJ\7C
MJ_TSP_IT.DZ;";F9KB>6-O,=0JS." <YR2IZGO0!V$/PZ\-VUS'=0V7ESQR^
M:LBMSG_]0%7-8\'Z)X@N5NK^TWR^5Y3'."Z>A]N3^=<WI7CO6M0\61:5-I<%
MM#(1@2;@Y78&+!L[3R2,#GBF^(/B#J.C^+H]'BLK=H9)8X59@S,2YQG*G"@>
MAYH Z"3P!X<ENY+EM/7?(!N /!(Z-]:A'P^T".'RDA;>&5PS-DY4$+GV&X_G
M7*WGQ#UNXT6RFAMK2#^TK2=XG 8F.2/&>_3YA69:Z]KND^)&U1XX+AO[,BFN
MR7;;@GD@9Z\T 7=.^&VM)K/^E3116OG,\UQ"?GN$/\.,\=C^%=;_ ,*[\.B1
MF=)6>2)81ND'"K@@#CV%8U]\0M3M9Y;M--MWT<7LEA')N/F&1 QR><;?E/:L
MU/%VJ:O=>&+V[T.$27DK&SV3$9/E.<D;NAQWH ["/X>^'8UC7[(6$;NX#-U+
MYW9^NXTY? /AV"SE@2UV*Y#&0-\R[2",'L!BN6E^(VNVT>H22Z/;21V82-G@
M+,/.;&4X/.,G./2JVJ>--5\0^%[JP@TD07;:?-<W/F[H_+12P!49!SP#^- '
M>:9X5TG3=)NK"T5_L]WN,I+9+;A@G-47\ Z*\$-IY4RPP@[7$@RP/5#QT_QK
M-F\07N@?#K1[NUBBFN)4AC!G)*C<0,D [FZ]!64_Q*UQM+@O;;2;656L7NWY
M(QL9@P SGHM ';V'A73-,UB;4[5'2XE01L-WR[1T&/Q/YU6N_ F@7NI2ZA-:
MG[1+()68-CYN>?UKBM>\4WOB>2&"VMEM[&WOH(I9=["02-V&#C'U%=5XF\1Z
MIHFIVEG:6]M*ES;2/&T@;(=-O7!Z<T 17'@B'2-/2?PY&/[2M(6BM/M#910Q
M&0>G' _*MKPUHC:+H4=I+Y9N9,R3LBX5I&Y;CTS7$-\2M:.EVM]%I-JT3V45
MY*2Q^4,0"!SZL,4V?Q?>:,OB&[MM/A25-26%FE:1UVX8[B >.F.,#F@#J#\/
M/#QFGD^S,CSG<XC;"AB<D@=LG/YFIG\":$SN1 ZAW1V56P"5  _0"N9O/B%K
M<>H06]O86&V2T$^9'/SGR]YVD-@@=,=:)/B)JJ:4ET-,MS)/:QS0J-Q&YI A
M!YSC)/2@#I%\!^'HX;A9+3?'(N#YC9V@-NX].>:='X'\.&4SI9(Q=TD)#9!9
M<;3^E<1JGB_7M=\,7FGRV%G:WJV4]S<AV=0(U#8* -N!^7O6[!KM]HOPKTJ_
MMXUEN&6-&+*S[59L%L+R<#F@"/Q%X&S+:Q>'XK$!&DDEM[@9!+@#>.1S\OZ5
MO:5X74>$(M&UXIJ&1F4,/ESZ#T KSEO%FK6VH3>*+:+3Y9!I0GN58R;2JL_W
M1G@G'>MRX^(VK_V^UG:VMHT3#;&'5SAB,C<P./PZT =;#X'\/6\=JB6"XM]Q
M3)ZD]2:@/P[\+[$6/34C,8 1D."H' Q7'_\ "RO$S:;I<T>B6;3ZC!Y\*#>0
MRKC=T.1]Y<9K4T_QYK%YXPL-)N-/MH(+J&.0Y+;QN7)PV=IP>,#GF@#I(_!6
M@1SP3"Q4O#M*YZ$@8!/O5C5M#T;5KV$W\,;W(3:@+89ESR/<5S?B#QCJ]AJN
MHII]M;26NE>2;H3;M[^9M^[@XXW?I5+1;>ZUGXB:E=ZHMO)%;Q126P1I%,89
M5([XZ'G/?- '9V.BZ1HVH37=K!'!<785'.<;]H  _  57?P=H$E]<7DNFQ22
MW&XR;N0<KM/YCBO++V\US4=3N[B::%Y(->CBM068*IPG!P?N^OXUM/\ $KQ)
M.GD:?I%C+>P1M)=!RP3 9E^7YO\ 9[T =J/!WA6S:!CIEK&T+^9$6)RK#N.:
M>?!7AR<3,]A%*)Y!*Y)SEAWKG/B/LNO"^DWL]M(TYOK<;(92#AF&Y00<<]*Q
M].O?%/AB2.VM=,B\G5+J5[:UNIB[01J%[AN^?6@#O(/!F@6MQ'/!IT<9B*LJ
MCH"N<'Z\FI+[P_HFOW8O+FWBN98U,18'/RY!*G\0/RKSQO'_ (GUG2-1FBTV
MTM[&6W=[:XW'=@$#!&>3SV%5_#^M:_H<,-AINF65T888&OI3(X+;U)5OF;&1
M@Y]<T =]IGA^^B\4W&K:A);,D49MK&.&,KY<1(//)R?E'I5[4_"FAZO?+=ZA
MI\4\ZXPSCH0<@_I7#KX\\87*VCP:=I0CNM1DL(V._DH')/WO]@U%:_$S7VM[
MFYN=,L5M0YMX)%8@M,)A$<@MTZGCTH ]4B>)@4B92(_E(4YQ[5/7#> +:Z@F
M\0->M$;B2^#.L)8HIV+TW$GWKN: "BBB@ HHHH **** "BBB@ HHHH ****
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M.!/)U%+.\(N"1&KA"K#Y>>'_ $K>M?& 7P;<^)-0MO*MXM[H(VW%T7OV]#0
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M%89GB*3%B[1EAC&!P=O7WH ZG6_#&FZ]9VMG<M*L-JX=$BE*X(Z$X/;%/O\
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M&".UG:"\2-DG9@O+@D *>3]T\C@57D^+NG);F3^RKW<9#'&K84.PSG#'CC%
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M=[](O(_*94BS@B5C((]N>@.[UK1^'=Y?WT6MRZ@TPD_M [8IF#-$NQ?ERO%
M'=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #"#N!!X'4>M/HHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(!&",BEHH 3H,"EHHH
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MY4JO?''8<T =;17$67C*[U&;P^EI8VT@U2(RR?OCF%03D].>GYUV] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_ *Y-
M_(U9JM>?\>-Q_P!<F_D: ,WPD,>$M)& ,6L? ^E;=8WA7_D4]+_Z]4_E6S0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%(V['RXS[T +1110 4444 %%%% !142S1O(R*X+)]X ]/K4M
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M&@#/\*_\BGI?_7JG\JV:QO"O_(IZ7_UZI_*MF@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BHI'$<;R$$A5)('M7GL/Q6
MMIYEB3P[K1=HS.H\I,F+(&[[WN/SH ]'HKG/#/BFW\2V<UQ'#);-%,\9BFP&
MX)&<9]JWDFBE!,<B/CKM8'% $M%0_:K?.//BSZ;Q2?:K?&?/BQC/WQ0!/15<
M75N2 L\1).  XY-9FAZ]#K,=R0HBD@N&@,;,-WR@'./QH VZ*K_:[8@D7$6
M<$[QQ3O.B\KS?-3R_P"_N&/SH FHKFO$_BNS\.:7'>,/M#32"*&.)@2[<GCG
MV-6[76XY]"&J2PO;_NV8Q2D!L@=.N* -JBN6TCQA#J[V82SFBCN(6E,DA4"/
M#%<'GKQ70?;+7&?M,/)P/G'6@"S159[NW0D//$I R07&0/6H;74["]LHKNVN
MXI+>7_5R!L!NW&: +]%1>=%G'F)D=MPIR2)(NY'5E]0<B@!]%0B>(J6$J%5Z
MG<,"@S1  F5 #R"6% $U%1>=%@GS$XZ_,.*/.BQGS4QZ[A0!+16)IWB&VU#4
M;^S2*:(V3A'DE ".2 ?E.?>I(-;AN-;NM,$4BM;Q)(96 V-N)& <]>* ->BH
MC+&%W%U"],D\4V6YA@A>>69$B0?,Q/ H GHK TSQ/9:MJ^H:;"LJ3617<T@
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M /.["^2P^"JW%CJLS2+&NZ<2%F1F89&>W7'M7!V>HKJ4^D/JVN7,BV^K!/\
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MRX5PQ(+<9^Z*]BA\+Z);F,Q:9;J8\[,+TSUI(O"^AP-&T6F6Z&-MR$+]T^M
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M6EH *K7G_'C<?]<F_D:LU6O/^/&X_P"N3?R- $&A_P#("L?^N"_RK0K/T/\
MY 5C_P!<%_E6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !115(ZA9!BK7EN&!P095R#^= %VBJT-Q#<*6AD215)4E3G!
M'459H **** "BBB@ HHHH *8H*C!8MSWJ.>>*V@:>>18XD&6=C@ 403Q7,"3
M0N'B=0RL.A!H GHJ*25(8FDE=411EF8X %0M?6L=L+E[B-8",B0L #0!;HIB
ML&4,IRI&0?6GT %%%% !115>ZN[>SA,US,D48."SG H L45 )HS!YPD3RL9W
M[N,>N:D5E=0RD,I&00>#0 ^BBB@ HJLMQ"UP]NLBF9 &9 >0#T_E3I9XH GF
MNJ;V"+N.,D]J )Z**KRW$,+(LLB(SG"!FQN/M0!8HJM-=VUN0LUQ%$2,@.X7
M^=,DOK2*%9WN8A&S!5<L,$DX S]: +E%%% !1110 4444 %%%% !115.[U*S
ML7B2ZN(X6F;;&'.-QH N454N[ZUL(1-=3)#&Q"AF/!)IT%Y;7#R)!,DC1':X
M4Y*GWH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% $3J6  8K@@\=_:I:** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^
M1JS5:\_X\;C_ *Y-_(T 0:'_ ,@*Q_ZX+_*M"L_0_P#D!6/_ %P7^5:% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,9=R
ME3GD8XKRE_ ^@2?$L64ML)(GT]Y'\PY=I-R?.6_O=>?>O6:PG\+Z?+XB&O,9
MOMP3RP0_RA?3&* /*-$\1ZGX0N;BWM8XY-+EU:\@6,C+Y7S&!S_P&NS\!>(]
M<UF:2+6&BS+;BZMP$"L%)';N 3C-:0^'GA_SA*T,KD3//M9P1O?.X].^X_G5
M[0O"&B^'3,VFVHB:4%2V<D*3G:/:@#SU_'/B6RU!)[N]L39-<7-N(_+ _P!6
MKLK%NWW0*KIX\\72V4X6XMQ.)[?RV:W !260)@<\@9SFN\;X>>''/[VU:4&5
MY2KMD;GSN[=\FHS\,_"^05L2K J=RMS\IROY&@#G;7Q/XFLM5WZCJ-K<6<-T
M;61(X ID(56W9SQ]_&/:L>#QKXXN;1KM5M_L]X-UL%C!D !(;:/XCC'I7H@\
M":$+F*<V[M)%<?:!N;J^ ,GC_9%1?\*X\+A9 FGK&7</E#@J1G&/3K0!F6GB
MK4?^%8W6N-<027T*-AV&T9&/O#L?:N7M_&GBRXBL[:"[B6XDO_LKO/:A6Y5B
M/ER<8V^M>G)X7TI/#TFA?9LV$BE70G[V>N:S(/AWX9M&5[>Q\ME<2 JW.X C
M/UP30!PVHZ_KWB?1+O1YKBT0P6LSW;M"")]C  !>W7/X5O7FL7OA_P"%&AS:
M8\4=Q);6T:EUW'YE7.U?XCUXXK8;X;>%WBCC>PW+&6VY;LQR1],UK7OA;1[_
M $2'1YK1?L4&/+C7C;CIB@#S8^(=?\3:&NDRW,,,SVMU+/)/;+F149T"[,X!
M^49YK.NFO/$GA2?3(KB""TT>V3=') ',LN V5)/ Y'/J*] ;X:>%C"(UT\)A
M]V5;!YX/X'FIYOAUX8FCCC.G*B)'Y0"'&5R3S^)H X@>*O&$5I>S6EQ9M;65
MS'81IY0W;GC3:?< M4>H>.?%MGI1C:>T2[MGD^T3"(-@!5*[U_@!).3D]*]"
MMO F@VEI>VL=H?)O0!,I;K@8!^M5W^'?AF2#R?L1"8(;#??SP<^O2@#A;[XA
M^(=,NKV>66V=!'(\$#1!0ZC;M9'_ (LY.>!T%3#QMXO2PDANG@BO(Y%<R+;A
MF$1!P63. ..N:[A?A[X:621C8AE=&0QL<J V,X'X"H1\./#BVRP):NFTD[U?
MYCGL3CI0!7UKQ+JD/A;0I[![=;W5I8H?.;E(]R,Q8#O]W]:XG7;_ %7Q6-#T
M^_N(0D>M2V4Q\D,LQ59,-CTPO3U/M7J5_P"&-)U'18-)GM\6EOM\E5.#'M&
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M^_U.QL;V>_BGBDM 654"L7XY/ZUU-96G:!INE/&]G;+&Z0B ,.NP8X_05JT
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M1110 4444 %%%% !1110 4444 %%%% #%977<C!E]0<T^F*JHNU%"KZ 8I]
M#'19$9'&588(I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH =1300>A!QQQ3J "BBJES,8$#B)Y,NJ[4QGDXS]!UH MT4S=^\V8/3.:?0
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MC7%S*D(=I" >,''I72>#_P"T7\,V,NJ7!GNI(]S,4V]2?Z8K/E\*7ESX*LM
MN+F%GC:-9W6/"O&&^8 9XR*ZR*,11)&OW44*/PH EHHHH 8J*F=J@9.3@=Z?
M133GC!QSS0 ZBBB@ HHHH **** &2Q++&4?[IZT^BB@ HHHH **** "BBB@
MHHHH **** &(&"X9MQ]<8I]%% !3'8JA8*6('0=Z?10 U22H)!!/8TZBB@ H
MHHH **** &'=Q@ \\Y]*?110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H
M @T0$:'8@_\ /%?Y5H53TS/]EVNX@GRER1T/%7* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBFLH92IZ$8- #J*S]/>V^R^1:%_+MV,)W[L@KU&6Y/UK0H
M **** "BBB@ HHHH **** "BBB@ HHHH *C=<_,H&\#Y2>U)'(LJ;D)(Z=,5
M+]* "BBF.2J$A2Q'8=Z 'T4Q264$@J2.A[4;CO VG&.M #Z*** "BBB@ HIF
MX^8%V'&,[NU/H **** "BBB@ HHHH **BCD66-9$.5;IQBI: "BBB@ HHHH
M**** "BBB@ HHHH **** "F$9(.2,>G>GTF1G&1GTH 6BBB@ HHHH **** "
MBBB@ HHHH **** "BD!!Z'-+0 45#+*L(4L"=Q X%34 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F
M_D: (])1H])LT;[RQ*#^57:IZ6K+I=JK$EA$N2?I5R@ HHHH **** "BBB@
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MKFFWE[J"7,-K9-;,"OS'+,PYSVW ?04 =_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4$88C?(BAR,';SQ]:GHH *
M*** "BD)P,TR*598PZ@X/J* )**** "BBB@ HHICNL:%W8*H&23VH ?2'.#C
MKVH!!&0<@TM $48(09558\L%Z9J.6#S987WNOE,6PIP&X(P?7K5FB@!DB&2-
ME#%<CJ.U"C:H&<X&,T^B@"O-"LR!2S@!@WRL0>*L444 %%%% !1110 4444
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MJS5:Q_X\(/\ <%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX*UR'[*FH>'KJ[9K>W2%A*56!HP =W'UK=:SUUA81/H6HXMM;>XD*Q$[HSO
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M_CQN/^N3?R-6:K7G_'C<?]<F_D: "Q_X\(/]P59JO9 BRA!&"$%6* "BBB@
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M.,8([UH:AXQM-.\*P^()+:Y>WE"D1H!O&3CGG%>>^"()-/\ #OB0K#.UK):
M*\D6',IB *]>@;( [8K:U:Y/_"FXXXK>=I&B"*A3G.[TH V/$'Q"L=!=5;3=
M0N_]'%S(UNBXC0C/))'IVKJM-OEU'3;>]2-XUG0.$?[PSZUQOB5Y=0\-Z'I,
M,1QJC103L1RL0QO'Y$UW$$*6]O'#&,)&H4#V% $]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-4EE!*E<]C3J
M* "BBB@ HHHH **** "BBB@ JM>?\>-Q_P!<F_D:LU6O/^/&X_ZY-_(T +9?
M\>4/^X*L56L?^/"#_<%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P >-Q_UR;^1JS5:\_X\;C_KDW\C0!+#_J4P,<=*DIB;O+7=]['-/H ****
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MFO!FI'1_@G']E9GU#4KB2"+8ID8$DGH.3A0: /9Y]4L+6R^VSWD,=J?^6K.
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MD#J:\DGUN;Q3>^&+V>V\F>WUK[+*0&0'@=LUL>,XVC^(FARPP>;(=.NRZ[B
MV#'C^9H ]'BECFB66)PZ,,JP/!%)%/%,7$4BN4.UL'H:\>M/'UUHF@Z/!8:8
MIM/LL4D@P7(#[1C@_+UZFGZ9KVI>'9M1FMM/B?3KO4FC8E\L'<G!QGIDT >K
MO>0M\D<\?F.&$>3U(SG\L5);RK- CK(L@(P67H2.#^M>/P['O/#=\+(1SB74
MHI$5CAMHFR.O0D9JUHNI>(&G\/1:,UM!:O;7$@M&!(9@TG!.?44 >N,2%)49
M..!FG#IS7"^$_%VH^(M2CM9((%6&W+7A12/+DWLH3KZ '\:KS^--634&NX[:
MW_L5-0%@Y/\ K03CY^O3GICM0!W"WUJUVUJMQ&;A1DQAOF'X5(US"DZ0-(HE
M<$JA/)Q7F?@;1I[R]U37[T6[W<=W,(Y55@V[ R#D]!Q^M8:7>N2Z_P"&=1,E
MM<ZC):7<BDY";0T>,\\XY_.@#V^F.ZQHSNP55&23VKS!?B;J-S=6WV+3%D@6
M*%[K.1CS!G(;H,>_6MKQGJMY+)-X?L(8)&ET^6ZG:8\+&O'&".<D4 =?'<P3
M/LCE1V"AL \X/0U9KR&UU>\T2"2_L["&2[BTRR4LQ.9 PC&.N.]3W?C_ ,1P
MW\=J--@$EML:^C"DX#$'A@<+A2.OO0!ZO4$PE(3RBH.\;LC.5[UYA<^,O$NH
M>&)M4LH[&V@N8)&MY3("\94L",9Y/RY!Z#-7(/'&K!GD>V@>TLIHK:[;G>S,
M 2R\],$4 >E45Y5)\1/$7]CSZBFE0+;K<^0LG+XQU)4'..16]J/BJ]M?!&GZ
MQ##;FZN]@*!MRC<"3MP?FZ=!0!V]5KBZ@M4#W$B1J2%!8XR3VKS&V^)6M7EM
M!/%I]L$>T^TONSD ,JL,9]7%4O$/B"Z\2ZAITWDQ)I-MJBPKR?,:0!LGKTX/
M:@#V2JUQ>6UIY8N)DB\QMB;CC<?05ROBSQ/J.E:K#I^EQ6[3?9)+R4S]/+3.
M0.1S7"ZP^J>+=?COMMLEBFB&]ACE5MT9&>>"/FWCKZ4 >O6^JV%W,\%O>0RR
MHQ5D1@2".U7Z\4T&4^%+.RUR[T^VEGEL9I!/%N4Y&\X;)/7UK7O_ !MXETZ.
MWLVMM.FU&]^>U:)LJ4P#\R!LCKC/?% 'JE%>8#QIXKF#"WTVQ>2*T6XE02 G
M.6! P?:M+POXTOKOPYJFIZRD&ZQ))6WC93CT*$D@T =YT'-5X+F"Y5F@E215
M8J2IS@CM7DM[XV\13Z,;>>.SB?4M/:\MI(E/[M 5!5N>3\XYJ2.SOO#GP@%_
M8FVM[^Y2!I)$#$%<J%ZG[W/)^M 'JT=W;S320QS(\L7WT!Y7ZU9KQFVU.^\-
M>-=:O(X[>6$"U6[VYY9HUW%>>/F.>]='X6\9:MKGB!HKBRB739FE6"10592C
M$<DGYLA<\=,T >@,ZKC<0,G S3Z\JT71[3QMXD\47&M-)-]DN?LMM"SD"%?+
M4[@!CN33KKQ9=^%+1K*PCBO;'1D4WDSMEW5F/"\]0._- 'J=%>3S?$;Q"-.N
MM2BTJV-I!>BTYD^;)"D=_P#:ZU?7QOK[ZF-!.GVR:QGS,ELQ^5Z]>OMF@#TF
MBO,;;XB:OJ,UO]CTR$1FW>6?S7"["F PR3CJPK"NOB#XBU71F$$<-M-YT!W"
M-@"C\X!)Y[<]Z /9DFCD9U1U8H<, >AJ6O)H_%%]9:S>Z5I]K:Q:K>ZB(O,)
M.PX1F).3_LX_&G0?$?7;IY88-,MVEM(YS>9. K1LW3GD$+^M 'J$TT4$?F2N
MJ)D#+' YJ8$$9'0UP/B[6XKOX>6>JRV23QW$UJS0LQX+2(.WH33=$\8:I=^-
M#HLUA';62H3'N!#,H0$$$G#<Y''I0!W27$,LLD22JTD?WU!Y7ZU/7CT>LWOA
M_P <ZU/:VD3:?+J<-K<,S$ME\#Y1GWJ<?$C7Y-/N=2BTZU:S*F2V+':< \@Y
M/)Z=* /6JKP7$-RA>"59%5BI*G.".HKS.7QKXG_M>:R-A9O#;;5NU&5.'!Y#
M$X&,?CFLSPOKNN:+IRZ?:6MNT%U+.+,ODD2*0?FY^[C- 'L]%<5X-\1ZCXDE
MD:<6P@AMX_-,0/$[ %E!ST'(KM: "BBB@ HHHH **** &!0O08R<T^BB@!N1
MNVYYQG%.HHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_X
M\;C_ *Y-_(T 6:*** "BBB@ HJ"&99HPZ9VDD<^QQ4] !1110 4444 %%%%
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M4T;5YX$EF4WJ+"DK*DL:!^6&,9!!_(4 =[;?#[2K?5TU#S;AS',9HXBY"*Q
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ML?@+0K/[*DCN\<,30)%/,=I5LY&,\]30/AOX>&E260@F.]]XG\YO,4]L-G(
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MGU7P)INJ:G)J$4]S93S "<VSE1+]1].,BFWOP[T2\GM79942%522-7.)U!R
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MX@#()(6P2C?>7\>*XL^,+O0?&&K7-]IUR8'@M7EA$P86I;=GD#!K<O/'MO\
M:)K46<J6CS2V4=]O&TS*&R,8_P!D\T 6'^'>D_;K:XAEN8(HHXTE@CDPDX0
M+O'?&!^52^*/ ]GXGO8[J>\NH&6W-NP@DVAU)S@_C@_A7#67B746^'3Z9!%<
MWE\;:6:6Y2X5&A4/@=1R>G'I6]IOC^*PCTG27LKBZD^R0^=.K@XD:(/C&,GK
MUH M1_#"PB>)UU._9TN(KAB\I;<T84#/X*!2#X8V!:21]2OEN))WD::*0HQ1
MAAH\_P!W&?SJB/BLCVGVAM N40RR1QEY@H?9G=@D=>#QWZ5U&L>)VT^TTY[6
MPDN[S4?^/>V#A"3@$Y)'& : ,@_#&R1F$.HW<<37,=P4W_Q)TQ0GPKT$3,9)
M;N2#;(JV[2_NT5\;@!^%<_XA\2ZAXFO-$TW3K"Y2&[\T7 CG5'610,C)'\/7
MWS4_C+7-9LI+CP_"KM;QZ49GNA(!(&]??'TH VT^&5A':(J:EJ'VN-P4N_./
MF*HSA0?3FK\'@?3[;P?=>&X[BZ-M<$L\DDFYP2020?J*P++XBBPT0+=:9<&Z
M@\F)4DE"M+Y@8JQR.,[#UKK/"OB&+Q+HJW\=M);'>4>*3DJPZ\]_K0!S\'PM
MTNVOENX]1U(N&+L'N"0S%2I8^_S&HT^%>E"SCM6U'41$I!D5)RHEPVY=WKC
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M\VO1O+>)"CL4ZB/.,\>]6(/A[=K>$W&IB:S^T/>K;E>!<,&!/3[OS']*M?\
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MOX8;FW.EW]ZMY)O!\Q",Y4'WXKH/"^A7>F:;?07Z6PEN)Y) 8%(^5NQKIZ*
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M5KS_ (\;C_KDW\C0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **9N&XKGY@,D4^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 3('4TM)@'J*6@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_X
M\;C_ *Y-_(T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBFJ=RYP1[&@!U%%% !1110 4444 %%%% !1110 4444 , "J%4
M= *?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M )@9SCD]Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/^/&X
M_P"N3?R- %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HI,\XI: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_ !XW'_7)OY&K-5KS_CQN
M/^N3?R- %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"((HD9P/F8 $^N*EHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1J
MS5:\_P"/&X_ZY-_(T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **9M^8-D\#IGBGT %%%% !1110 4444 ,(8L"
M&P!U&.M/HHH *85!(//!]:?10 44PALK@X ZC'6GT %)D9QGFFAE8D @E3@^
MU)L7S"X4;B,$]\4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C
M_KDW\C5FJUY_QXW'_7)OY&@"S1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!3&1696(Y7I3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &(6* LNUC
MU&<XI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: +-%%% !1110 44T@D<'!
M^E.H **** "DR-VWOC-+10 4444 %%%% !1110 4444 %%%% !1110 4444
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MD*3R!@5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6N#[-_A7Q;10!]I_\++\&?\ 0?M?R;_"C_A9?@S_ *#]K^3?X5\644 ?:?\
MPLOP9_T'[7\F_P */^%E^#/^@_:_DW^%?%E% 'VJ/B3X./37[7\F_P *6/XB
M>$9CB/7;5C_P(?TKXIHH ^W/^$[\,$?\AJU_[Z/^%+_PG7AC_H-6O_?1_P *
M^(J* /MW_A.O#'_0:M?^^C_A1_PG7AC_ *#5K_WT?\*^(J* /MW_ (3KPQ_T
M&K7_ +Z/^%'_  G7AC_H-6O_ 'T?\*^(J* /N*+QAX=F_P!7J]J>,_?Q4O\
MPE.@YQ_:UI_W\%?#%% 'W1_PE.@_]!:T_P"_@H_X2G0?^@M:?]_!7PO10!]T
M?\)3H/\ T%K3_OX*/^$IT'_H+6G_ '\%?"]% 'W1_P )3H/_ $%K3_OX*/\
MA*=!_P"@M:?]_!7PO10!]T?\)3H/_06M/^_@H_X2G0?^@M:?]_!7PO10!]T?
M\)3H/_06M/\ OX*/^$IT'_H+6G_?P5\+T4 ?='_"4:%_T%K3_OX*7_A)]#_Z
M"MI_W\%?"U% 'W0?%&A#KJUI_P!_!3CXET0==5M.F?\ 6BOA6B@#[H_X2C0L
M9_M:T_[^"C_A*=!_Z"UI_P!_!7PO10!]T?\ "4:$/^8M:?\ ?P4+XGT-C@:K
M:?\ ?P5\+T4 ?='_  E&A?\ 06M/^_@IR>(]%D.%U2T.!G_6BOA6B@#[R_M?
M3,9_M&T_[_K_ (T@UC2R,C4;3_O^O^-?!U% 'WE_:^F?]!&T_P"_Z_XT?VOI
MG_01M/\ O^O^-?!M% 'WE_:^F?\ 01M/^_Z_XT?VOIG_ $$;3_O^O^-?!M%
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4_P#/S+_WT:/MUW_S\R_]]&@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>inmune_ex31img23.jpg
<TEXT>
begin 644 inmune_ex31img23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M-'V&U_Y]X_\ OFK-% %5M.LW&&MHB/=:7[!:?\^\?_?-6:* *WV&U_Y]X_\
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MQS"*W:* .=_X07PK_P! #3_^_ H_X07PK_T -/\ ^_ KHJ* .=_X07PK_P!
M#3_^_ H_X07PK_T -/\ ^_ KHJ* .=_X07PK_P! #3_^_ H_X07PK_T -/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_
MUR;^1JS5:\_X\;C_ *Y-_(T >2_L[?\ (FWO_7Q_C7L=>._L[@_\(9>''!N.
M/UKV*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HJ*5F2)F5"[ <*#UJ6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQ
MN/\ KDW\C0!Y7^SX<^!)QN!Q<MQZ=:]=KR3]GY%'@"1@/F:Y;)_&O6Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI!D#DY]Z6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *K7G_ !XW'_7)OY&K-5KS_CQN/^N3?R- 'E_[/O\
MR3UO^OE_YUZS7DW[/O\ R3UO^OE_YUZS0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !111WH **** "BBB@ HHHH **** "BBDYS0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !5>-Y3+('10@/RL&R3]1VJQ10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $3E@OR*"V1P3BI:** "
MBBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- '
ME_[/O_)/6_Z^7_G7K->3?L^_\D];_KY?^=>LT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KS_C
MQN/^N3?R-6:K7G_'C<?]<F_D: /+_P!GW_DGK?\ 7R_\Z]9KR;]GW_DGK?\
M7R_\Z]9H **** "BBB@ HHHH **** "BBB@ HHHH 8H(4!CN/KC%/HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "CZT44 %%%% !1110 4444 %1/(D:AG( ) _$U+10 4444 %%%% !1110
M4444 %%%% #&=5*ACC<<#WI](5!()'3I2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 444G44 +13%4(H51A0, "GT %%%% !1110 56O
M/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H \S^ *;?AP'_ +US)W]#7JM>6? -%7X9
MQN/O-=2Y_ UZG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^
M1H \X^ G_)+[?_KZF_G7J%>7_ 3_ ))?;_\ 7U-_.O4* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@!WF(3@.OYU!)=1QW<5N<[Y 2,=!CUKP6Q.I7EAXFDAU?4HYHM2BLK5A.<Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV0N89!&TB-)M*!B 3T/3/Z5B:=\4GOO.C&EQFXCN5B\J*?<60JK;QQSPWZ4
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M*_#&SSCF>0\?6O2J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX5A9[B#^^DQQVS7I-><_! 8^&-C_ -='_G7HU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &-XAT"W\0V,=K<R21K',DRE#CYD8,OZ@5@
MQ_#RTAO%N8]1NPRW?VL@MD%\*.YZ?**M>-;\V6G6+9G6.6_MXF>"0H1ND4#I
MU!)P16=_PL&<W<EO%HTKE9WM4)?[T@4$#IWR* -6Y\%:3=0ZLDJ,6U-M\KC@
MJ0,#'ICK66WPZBECMC+J]VUQ%.L\D^T!I"OW ?3&3T]:H-\5XHM/2[ETMPHB
M+2@/GRVR0%/'<BE_X6O;G3[:Y73)2]Q)*D:$X#[ I^4]R=WZ4 =1-X1TFXU6
M_P!0FAWS7L"P29_NCT^O]*Q_^%>1F",G6KTWD,H>"Z8Y,:@$!0"<=#62OC#4
MKO594O89H+6WU=;2,VSD9X8D,>XXK3'Q,M#>-$NGW,D3"5HGC7)81D!B1VY8
M4 :-CX-73_"U]H<6I3L+QY':=D!92[9; Z=S62_PSD>QDM3XBNMKVL5KG[.F
M0D97;_Z"*H3_ !.O+N"P.F::?-FO$@E5N<;E9L?7 JSIOCI=.98[B*\FCN=0
MF@,T_2)@S';] !0!L>(/!<>N6&F6SZE+$UBNW?Y:L)!MVG*GC.._:L6S^&%U
M;Z?<6S>()CYUD]CL$*[5B+NP&>O5S3;KXNZ797$)N+6Y4R%E('(VB0IN [G(
MS]*]#W"]L-T,C()H\HXZC(X- '!:/X<N[CQNM_J%O+Y6DVJVD4\BJ/M+#)#;
M1QQD8J?Q)X(F\7I9SSWTUJPADBF22)6R&]%.0#[CFLSPO\1EM=)M[35;;4[F
M\8R[)1%N$P1CG!SR0,5T_A[QG8^(K\PV4%U_QZI.S.N%4$L .O7Y30!EV/@&
M[L954^(;E[-F$D\(C5?,D&1G(Y&<]!52'X;WD8L(I=9,EG:-(OEF( ^6V,#.
M,Y&!6HWQ+T>-;EY;34HTMYC SM;@ R?W!\W)J,_$[P_)913B*^:.0.6"PC,8
M4J&W<\8+"@#-?X97<U@T-QJXDEM[;['8NT8_=1;E//')^4<U'<>'_%>@W4,V
ME:@UP]W-;1S*L*$!8T"DL3T&U3TYSBMX?$C0OMLMN?M(2+.ZX,0\K([9SUIK
M?$K0X[>266&_C:,1L8W@ <J^-K 9Z'<.?>@!GC+PA>^*;BV,%W%!"L9CD#+\
MR\YW(<9![=JR$^'.JVVI>;;:X!:K/%,J21AB2JJ.21WVUV>D>)+#6[*XNK?S
M8UMF*S+,NUD(&>1GTYK('Q TV=;A+>WO#.L3RP(\0'V@+G)3GD#!_*@#/T[P
M5K6GRZ/,FH6WFV-Q,SG;]Z.3J!QUZU/XA\*:M<Z[<:EHUS;1_;[46MXMP3]T
M9PRX!Y^8\53T'Q)K47AC4/$VIM)=68A+PVP@".K G/<Y&,<_6H+7XD10^)+I
M=5N6BTY[."XA0Q;6A+,X8,<\CY1S0!L>$O"VI:!J>I?:I+62PFV_9S&S>8N,
M_>X]_6N9DT^_\5:WXBTVP>S%F+Q'F>4.).-_ ^7'?KFNY@\:Z'=:X-(BNMUT
MQ*KQ\K,,94'UY%<IXL\5ZA:>,1HVBW-O9.D!N)Y)H0RR$$8!/;@F@!+3P;XE
MMM*L9_\ B7G5+*]DN%3>WENCA@03C.>14%EX U_1+A+W2Y;![F\$JWJSKE$W
MOO\ EX.<$8YKJ(O&NCR6HU/^U$%L/W)BV#)D(R#U]%/%.T_QYI&H>(8-&MY_
M-EEMQ,LH'RL3@X'X&@#D8OA]K=M<W-CNTXV,HDD%VT8\W>ZG*_=X&YNW;BF6
M_@SQ+#:V=X;'3$N["5=D,8_UZK@98XZX&1^%:GBOXC6UG'J%OI\D/VC3YX5F
M\X9&UG4''TW?I72Q^.?#9TV&\DUJT$4AV!]_!8#)% '"Q^$_$K06+2Z?9H\$
MMRYV,=S"1< 'CL36'K'A[6-)T.>6\T^.WC73?LAEC_OEG(/O]X=:]2L_&>C:
MGXI.AV5\CW,</FE0,AP1G /J!S^-9NA^+[36M2U70M=^QQSI=M;Q6S-N\U=J
MGH1SUH X[PCXGNM+$T$&F-<7]Q?1FYE90OF!QCY-O'&WVZUV?CWPG=>(WTV?
M3ML5[!(5:5AP(F^\/KP*VM&D\..TEMHOV(-"262W &TGOQ]*N3WECH>GQF]O
M/+A3""6X?))]SW- 'EH\%ZOI>F)$=/?4GBU!(D!VD_9HE=4)R>^167;>#];,
ML<UQX9DF19;A5ADEV;/,EWJPVGH ,&O9/[?TI)HX7U&#S)L-&N[E@>F*EN-9
MTZSOHK*YO88KF;_5Q,WS-0!Y)+X=\0:?->V1\-&\MI[NVD\R,J5VJJ[AR02
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M^N3?R-6:K7G_ !XW'_7)OY&@#@_@A_R3"P_ZZ/\ SKT6O.O@A_R3"P_ZZ/\
MSKT6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\2>'X
MO$-E;V\LTD0AN8YU*?WD8,/U%8J>!XH+RUF^W7)D6^-X<G*EL*"#[845I^*_
M$\?A:SM[A[*:Z\^80JD1&=QZ?J:YR3XK6L>HR6?]C7;-&&#,KJ<,%#$8^AZT
M :T_P]T>>'5$!EC:_F$Q9& ,;+]W;QQ@Y/XUGWWPU.H6,=M<ZQ<3!MQG,@SN
M)Q@K_=QCWJJ?BY9)9?:9=&O4W*KQH2"9%)(R/I@U-!\5;*?5[*Q?3+R)YMHD
MR1^Z+9P&7KVH DNOA\8Y)WMM2DCB%X+Y4?E1)@C^M<9HWAC6;F_NH)=/>TCG
M\Q+J=HS\JNP)V-T/('2NKE^*6EW&FRS2Z?<>4[(D:[Q^\W!CU'W2-O(/K4<7
MQ7TH6,)@TR]DC6 2MQ]U00#GUP2* )+/X8S6:Q>7K+>9')%*#LX#(A3IGN":
MM_\ "OC/H.I:9>WB2M=W?VJ.58R#$2VXXYZ]1GWJ!/B+)'/J4MQI4WV.'R?L
M[*P^<.F[)/0 CGFJ-S\1I=6:-=-LIQ9M9S7#S1L"Z%&*$CUPWM0!N7W@:;[9
M:S:3JCV") L$X5,F0 ]1Z-[UH>%8=<B?41JTS20B?;:;_O; H&3^.:QM(\?V
MXMX[>>.YFDCT_P"V>?*54RJ!S@8'.012P?%'1Y=:M],=)(Y)G2+.X,5=@" 0
M.?XASTH HP>%)/#4[WES=G4;72UEN+2RMX")/WF<[CD[NG8"MKP#H2Z3HLT_
MV,VLEW,TJQ/]Z-#]U3]#D_C6EXOOO[+\+:G>K+)#)%;L1+$FYE.#@]#6'IOQ
M L?MNFZ01=7=Q.D8:YV<!G) W8''0T 5Y_ NJWN@:A9W6HVQNI=1.H6[I 0J
M/Z$;N1[9%9.J_#36=3BAMY=;M=XA?<ALV\M264Y3YOEQCOFNM\0>/-*\-WZV
M=RD\L@3S)3%&6$2]BV!Q_P#6HLOB!H5_K_\ 8UJ\\MT6"AD@<ISWW8P!QZT
M<G!\,-7;4)?MNH6K6\L!222&(J[L""N[+'(&*L2_#W7KF.6:?5+,WCI!;[EM
MR!Y4;(W3=U)0<UT-W\0=%LI;R.?SU:SNEM9?W3<,V<'IT..M1W?Q*T"SN6@D
M:X+*Y5ML+$ !MI;ITSQ0!-X=\-:AI_\ ;:ZG=03Q:E(6 BC*E05V^I[5AVG@
MSQ'#_KKVT<6<$L%B%CQQ)N&7YYP&]NE=!:>.]'OO$<6B6S2R32_=E"'83LWX
MSC'2GWGC;0[#Q#'HD]PPNV=4.(V*JS8V@G& 3D?G0!%#H>H-\/;G0[V6(W3V
MLD.^,8'S X/7WKCKSP7XJN].U6%HK)GOM/CLPP8 C:7YZ_[5=OXM\2VOAW3)
M-\K+=S1OY"I$TAR!U(4$X%<_8^.(9K3=J^H1Q0"P62X6.%]REBPW ^F!0!F^
M'OA]>6'BE+PQ::T<-SY[W*C,RG S'G/MUQ5_Q'X:\1W_ (LNK_3X84MY;'[*
MCF8;D)(.['X5JP_$?PH&MUBOB!<L<-Y+  \<L<<9]33KSXB>&[&6\MVO7EN+
M569UCB8AL<':0,'J.E '&VW@#Q5;L+I?L?VF">.XB1B"KD(RLK<_[?7VKHO#
M_A?7='\36^HR+:2Q3V[1W.SY?))(("C/.,8K5@^(&A/!IS7%R;>:^B658G0Y
M0,,C<?X?QK5L/$VCZEJ$EA9WT<MS&&+1KU&#@_K0!P_BCPGK]WJFOO865O-;
M:E):RH[2A2IB,>X$=\[#6/>>$_%$IN)UTB.*-I96 CNU5@&A\O.2.!GDC'2O
M3/\ A*-%_M233C?Q"ZC4LRDX' R>>F0*L:;K^DZVLWV"]AN5BXDV,"!0!P_@
M?P[KNAZZDU[81"WN+)5DE64$QNI; _VLC'YUC77@W7+G5)I_[+5)GUM;O[2)
M1N\H!!C_ ,=/YUZ!?>,M%MM%U"_@OK>464;%D#C.1T&/<\5Q8^)>N2SQV<&G
M:8]TR-.";M0C18XY+<'KUH I64>I>!XAK=YH.)(8Q;2L;M29LD[=@QQWXYSF
MNK\;Z1J&J7.B:E:VOVJWM68SVA."VX#!^HQ^M= -6L/LMI'JDME'=3J&$#RH
M<M[9//UJW_;&E[Y4_M&TW0_ZQ?/7*?7GB@#R[PGX&O=.\0Z:^KZ8+B%;,J'9
MLB%B5(7\,$9J7QCH&L7?C*[O+?3)9XR+=H98Y-H^4J&W<'/TXKU&._LYK5KF
M.ZA>W7.Z59 4&.N3TKGM=\96VC:$U\ES9WDTDFRW2*==KY/'.>PZT <S\2+.
M&Z\0Z 9].:[:194,,8)8DQOC..P./RK /@O5+;4M/BU#3+R\22)-AMYL)#M?
M=M;@] /;)KK;K4='232M>UW3(X-<D5UMD^T9.0K8QAMN"!P?>N@\*>*8/$>A
M0W[A+:9_,+V[2#<@5RN3STXZT >6V_A!K/PG/YF@7C:A->R!Y$1B=N[<A(QR
MO(_6IH_"FN):_8;C2F^W7,<1MKJ+.VVPS<9_AQU_&O9H+RUN8FDM[F*:-3AF
MC<,!^5<+)\1[D1W6H6^B376B6TACEO4<+R.I"L<X'TH P?#VA26.H6T[:)<Q
MWCZR6\\PM\L&$Y)[#(:K'C[2+^[\4W+MI<][!<V BLI(E+>1,#R3CIGCGVKT
MV'4+21EC6YA\TH',7F#<!CTZT\:A8MR+NW./25>/UH \Y\(:?/:?$C5)+O2[
MD.]M&OVQX6",Z\/ANAR2#GOBLWQ;X(U63Q#J3Z);*L,X6_#E2V9U.T@<]P['
M\*];:ZMT\O=<1+YGW,N!N^GK3&O;5&96N85*#+ R 8^M 'B^K^&!;N$;1;^X
MN(-+,C216[,IN9)5<A2.I&3]*B71-4:<)/I=V^H/+;S?:1$Q"PK&HDC)[$@,
M,=Z]AN]>T^T>&)KJ)IKA6,$:N/WF 3P?PI-+U>.]TZ&\N(A8O,S*(I9%R2"1
MU'7I0!Y'8^%;<VECY_AR\SY5X]P&@?+',AB!'J/DQ71W,=S+\'+>UFTR_DFX
MC>V$#&3&\_P]>F*]&^V6_P!H$ N(?,S@IO&[IZ5;H \$OO#TCS206VB:LFAP
M7"2S6T43(SY &5!!SC!R*ZS4](>V^#]SIL>EWQDV%;6W),TJG^$G 'OVKT87
M=LP8K/$0IPQ#C@^]4=9U8:5HTVH10M=^7T2)AEOQH \STS3KR3XC6.H1Z;J$
M:YVS-/ P  Z,&Z 'GY?UIOC_ $PKK^O.NBWMQ)?VD,<,]O;M(.'4MDCITKUY
M)XRXCWH),9*;AD?A3BZ;PA9=Q&0I/)% 'A6IZ&LEP;5=+U=] 2ZCEFA@@=7.
M8FR0,'/S$5UNIP&U^$CV:6>HH&PL<,X,LVWS 1G ';MCBO2LIS@K[TW?%( "
MR,#TY!S0!X=H\%W#K\T^H1ZTFH009AF7*PK!Y(Y)(QQSQGJ*R;;RSI&HRK97
M,=Y-;^6BJC9F.]BTON-I&0.PZU] W%O;WD$UO*J,D\;1N >64C!%<[I'@[3]
M"OXKC3D5H]K)()26(7' 7L.>N: /-O"27=OJOANRFM+TQVNHSD-);M&$1DCV
M]>V=U>[5"$C)R%0E3Z#@T]AN0@$C(ZCM0 ^BL^]O%TO3I;J59IE@3<P1"SM]
M !S5B"1;B!)D#!74, P(/X@T 6***3H.: %HJO;W$-S%YD,B2(21N0Y&0<']
M:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KS_CQN
M/^N3?R-6:K7G_'C<?]<F_D: .#^"'_),+#_KH_\ .O1:\Z^"'_),+#_KH_\
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MYY^E>DB\MB)")XR(SA_F^[]:?]HAPI\U,-T^8<T >01Z=<K/+%=:;=#5EO\
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MPQ8OJ?B.RTM]<U>2T\F4QL[.GF*,;3GZD]>:]P$,*AE5$&[[P ZT+#$KAE1
MRC ('(% 'BOEZS::/K<NHWM]"VDJUK"X=CY[,PPW'7&WK[T7FK2QZS-?QZI>
M@Q7T"QI\^SYU<MD>F0*]JDAAEC99$5D;D@C(-9VL-IMEIT]W?0@Q<;V5 6R>
M ?KS0!Y+X/UJ;4?B3-;7.IW*>5=W((D=O+N#O.P(.G"Y].E7/%&JW5M\2YH&
MOIX[5L0F%=^"&MB1C Q]_'/7-=;I/@'0K+4XKF*XGG:SE,T<<DA.QV!Y/KP3
M77M:P2/O>&-F)!R5YR.E '(_#-;:+P9#!;R.[1RR"4,6)5MY)^]7;U7A@AMD
MV0QI&N2<*,#)Y-6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!P?P0_Y)A8?]='_G7HM>=?
M!#_DF%A_UT?^=>BT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <[XGT.XUJ"S-G=1VUS:SK-&\D>]>",@C([5R-Q\+[^]MUANM9MR#+/)
M*8[4J6\U A_BXX%=;XE\6Z?X6BMY+Y+A_M#%(U@A:0E@,X^4'K6+_P +6\-I
M<S0223*T2%\")F)PNXC '&!0!H>%/#>H:()C>ZC%<EHEBC$<.P*JYP3R<GGK
M[5B+\/-3BTRSBBU:S^UVEQ+*DCVA*%7VY4KNY^[US5U?BEX=-H]PWVQ$0Q\-
M;.&8.2 0,9/(/2I+7XG^'+O4X; 2S1RS#CS8F0AO[I!&0: .2\:>%M1T32/,
MCO?M4%R8([B%+8L[.F[!4@_*.3Q@UKZC\/M1U76!?)JL4=B]XUY]G>W.\%@P
MY.[MN]*OI\4_#LVFR7DJSK"DB(GFQ$>9NS@C(_V33I?BGX9B-MB6Y=9XTE#)
M;N55&Z$G&!U _&@#&_X5SJ<>F+I[3V$Z(-B1FT.V2,<#>V[[W0Y]JVO#7A'5
M?#M_;R?VA%-:B I.K1$L><A5.> ./RJ#_A9NFV\NH13PWH$,_E0MY#'S#R2!
M@=@"?PI+SXD:;-=MIT"W!233S<"Z^S2.JG'\04=!W]^* &ZMX&O]0U.^BANX
MUTK4KJ&[N-RYD1H]IP.>^P?G6MX9TG4=%O=;N;]HF@O+@3QB,<KA%0#\D!_&
MH;?QIID,:VL]R6N+:TCN+AQ;2!&C91ADR.<Y'KZ5+'\0/#EUKL6BBY?[3*%*
M;XF56) (&2,9P1Q0!B/X.UE-?L;B/[-+:)J;WG(P0I5!Z]?E-8=M\+-8BNC>
M,]@]Q,#$PECWB%<DJZ\]?F/Y5VNK>)X='\3W,5UJ44=G;6 GEMS Y=>6^<$<
M$<=/:M70O%.D^(FF_LVY\TP@&0,A4@'H>>W!H Q_%&C7,UGHKV;DZI8SJ8)/
M+)0G'(;T!XYJIJ^E^*M?L2M[]DM6BE22WMT._>XS]YL\#\*WK+Q;H^IZW-H]
MM<EKR'.08R%..NUB,-C(Z>M03^,M TN];2[O4S]JB94;S%Y!.<9.,=J .5?P
MCK_]KVNJ-:VA=]1%[<Q>: J!4=,#UR'S^%9>FZ1/XKU'5+.Q^S+96VJ2&2X5
MP60[74 +^-=\OCKP^^HW5A]NQ-:[O-W(0ORG!PW0X/I6:OQ$\-0:M:V5BI9;
MHL\D\4)"  $Y)QS0!D'P3KDELL4D4&ZSM)[:W*R >=Y@9<MZ8#9^HJGXA^'^
MM:G9Z?;V]M:1B/3A;,@D VR*2<_[6>/I7<V_C7P]=>>8M2BQ!'YCECM&W.."
M>O/'%'_":^'?LL=R=3A6-RP7<<'(&2"#T.* ."E\%^)EL+Z"&SMIA/?VMY'(
MMP%(\L(&7I_L=?>K,/A#7E,>G264!AMK\7Z7GG#<_P!W]WC'!.WK].*W_$?Q
M LK#0[NZT:>WN[FW42%""5*]3@BKL_B^WGTNQN=-O;%Y)YXXG65^F<;L#.<C
M- ',^$O!^MZ/K.@SW.GP11V5K+!/(ER"69BO.,<]*JZUX4U^7QA)J$5A&T']
MH+-&?M019%VN,;<?>YZYKT"R\4Z)?WPLK;4K>2ZR1Y:N,DCK_.G>(+MK#3&N
M@D!:$AXS/(%4/T'.1V)H Y'X?>&M6T0ZF+RU2&*2)(H59][#:I&W=Q\HZ#BL
MWP=X<U[0_'/VN[T\_99HYHGD>Z&%+/O!1<>V,9[Y[5Z'_P )!ID=S#9SZA:I
M=R(&$?FKS^M4[#Q#')$\NIW.G6@6XDC0FZ0[E4D YSP>.10!P7B#PKKUSJ]V
MG]C1W22:A%=B[\T F-2/EQCKQ5>W\)W5U?Z*FI>'F>VBN[AI5*DA5<OL/X%@
M:]+'BG2&UR#2$O87N9HO.0)(""/\\UH'4[ -(K7ML&BQY@,JY3/3//% 'CMK
MX)U&W2[B@TB\6^MTG3SVN/W4R')"@;><@[>O%6XO#-Z\VF7<?AIK6%+LL(]V
M71B%&\\<#C]*]6_M;3=S+_:%KN098><N5'OS534?$FDZ;9_:I[Z Q>8(\K(#
M\QZ=* /)YO#%U-H\,<.A7=O<6]A/#>;8S_I#-C8 ?XNC<^]=I_PC[0?#-[+1
M[&2UGFC$CV^"K%CC<#[UV$>I64RH\=Y;LK_<(D4[L=<<T_[=:;-_VF';D#.\
M8YZ4 >,ZGX4_M'4S]FT&^M])FOH66 1,I10KB1L=LDK76>.="E6TT&""TGNM
M#L6V7-G"I=F01LJ_*.N#MKT,D $DX ZDUE:=K^G:K',]K=1LL4K0L2<#<I(.
M/7I0!Y+;>'S:OHS:UX>O;["3L"MHTC0QDMY:,1W *C'M5>P\/RV>BZ1]B\/7
MUOJ1O+KSI?LS(5#[_+)/H,K7MXN[9MNV>([@2,,.<=:KSZUIMOY/FWL'[Z3R
MX\.#EO2@#QP:!<R:+.+;PYJ=K<@Q+J)Y'VE5ERQ48^8E?3Z5-I'A>&37M!C.
MD:W%8+)*S"Y!(08&S/RC:-V>#7M+RQQ &214#' W$#)IQDC# %UW'H,T >8?
M$339[G6;?[1975Y8&S=+9+>,N8Y^Q./PQ]*J>"]&CM/',<FIV%TVJ?8T,URT
M)V--SN.[IGI7JID03A'>/)&44GYO>L63Q38+J5K;P+YXGN'MVG0C;&ZXX)[]
M: /,_$%MJ2?$.XU"/3M09%ND0O':LY:+8^=KCC!.WC'IZ5GVVF:K:V-N--L=
M7BGGT]X[K?$P^=98^.G'RAL5[TK*<9926Y&.]/\ EW8XS0!X;<>'H[MIKFWT
M6_&@Q2021VCPMN\W@,RK]2V:;8Z5J-E-=7>G:3JUO=2W%Q&F;=@%C,3!,>V[
M'/K7N68^4!7CJ/2JE[J5IIT22W4ZQH\BQJ2>K,0 /S- 'A"Z#*NDQ+;:7XA\
MZ:Y@-WF)L%A(OFD#']T'G\*]'\9V4UMX:TN*RM[F;38+B,W<$:EI'AR"1@=>
M^17<+Y2L^PKOZL >?_K4V9I?W8CB#AF ?)' H \6GTZY-OMETK6!9+;%=)C(
M+O'+DG<>/E/*X'M576K>_6V\2W&J2ZC%<V]C'Y3A2L;2#=OP>^?EKVK6=232
M-(NM0:WDN/LT9D\J)<NV/055U32K+Q7H7V2\1TAN%#LG1OH: /*IK>X_M!IH
M1J__  C#2P?:E="'9MK[B!CIG&?PJ6UMKNXU"RL[R;6%L&>X^QC!5C&&!0/Q
MZ 8KU^SL8+2PALT&^.)0HW<DX]:LF./@E%)7IQTH ^>9(=5U"SUQ9H-3DBGB
M\SRV@8D.)TW?-WPN[M6Q<WU^EU>"P?4$TA#:B4%2KK#L0-C\>OMFO5M&UFTU
MQ;P6\+1FVG:"173&2"0?P.*;X@UBQ\/:<+NYMMT4DJ0G9'G[S!1GCIS0!Y1;
MWM])JL,-SJFK1Z09IVM9 ^&,(B)&3CIO!'TKT#P3XGM[[3+&PGN99;]H6EW2
MCEU\QE'/<X6M'1M>TO7Y+Z&VM\-8/Y4BO%C&0#P"/0TGAV;1M:EDUS3[?9*N
M;4L5*\*Q[?4F@#SVYU/58_$,WVF\OH]4&H[7@5L1?8AMRWL!\W/UK:\#7MS)
MX"U#6)M0OKR^(='$DF\H5Z!1CWKT4P1&8NT"%MN-Y49/M2I!#$A2.)$4]550
M : /G^+Q%JK:%=12>(;NVRULT;2MW(DW)OZ#.!S[5W5SKMTGP<M-4:]N[>[:
M.(K+(_[QR2,Y..<C->AFQM&7:UK 5]#&,4YK>!XA$T,;1CHA48'X4 >%:S=R
M6LFM2V6OW5K))?J[!YM@F0HQ"[N@[8Z],5[#X5FEN/"^FSS&4R26Z,3*<MR!
MU/>M)K&U<8>U@;/7,8-3JH50J@!0,  =* 'T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D:
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M\5;U6QL;,6<<=_JP>ZTHRQ#[1,6:X(8*,9X^8#K@5[UE0<EAC'K7+M:Z?/\
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M 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H X/X(?\ ),+#_KH_\Z]%KSKX(?\
M),+#_KH_\Z]%H **** "BH)95B3<P8C('RJ2>:F'(S0 M%%% !1110 4444
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MN9(]=E,5SI-ON8R;E5C(ZL,_PCCD]J]4TG6=%UNQN+VRBW16KO$^ZW*D%>H
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M:@0Q8!(4$C)P/YU8B%O/!%.L:;"H="5'&>?ZT >4_%6]OHM?L1!<7$*PVGG
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M@^IZ<UZ]9:-I%OI+6=G96\=C,N6CCC 5P?852/@GPZ8[2/\ LJW"6C%HE"
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M>U &3X/UVTO;5=&"SQWUG;HTT<HY ;H0>XKRQ_[)TQ?$U_8W<D+#5H]FP_\
M++CGZ$[ORKVNST+3]/U*]U"V@5;J\(,S]S@8 ^E-GO--AU.#3)(1]HN5+J!#
ME2!UR<8H \4NM1;3=1:XT_5KPWZZPT:1/+E/(PO)7TJ*VGFC\/7C2>(+\3RH
ML5UYL12.*7GASG@G!Y]J^@/LMONR;>+/KL%(;6W*LI@C(;EAL'- 'FKWURGP
M/^T+)<+(85'F*^6QD<AO3WKSFRUNYDDTS3)?$=Y!%]JG+!+C:?+V2,#GTR%&
M?>OI+R8A%Y7EIY>,;-O'Y4S[%:Y!^S0Y'0^6* / KOQ$-4TG&K:Y.EO]E7[
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M **** "BBB@ HHHH **** "BBB@ HHHH \\^(8/]M:&ZQSLJ"X\[RE8_(8F
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MH6CB?2K&.*-I@7D@SDG/<BL^'P3X3DFECM[&'S(D\F18SC /8X^GZ4 <)?\
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M9:3_ +G^%=Y0 4444 %%%% !13,MOQM^7'7-/H **** "BBB@ HHHH ****
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MZ;X?U?Q!:WFF>)4L;B1!"%B=2C9)P%_VLD_I7::3X8TG2=+BL8K=941-I>4
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M-;Z7IB0IH3S?:KMICEQ('W_+ST)Z\5U&J:7:>(+!()I&:!9%D!B8<E2"/U%
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M9JM>?\>-Q_UR;^1H XSX/?\ ),M)_P!S_"N\K@_@]_R3+2?]S_"N\H ****
M"BBB@ HHHH **** "F*"JX+%N>II]1H&7.Y]V3QQC% $E%%% !1110 4444
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MA+=S:5JNM"ZMV:WNI>'4Q-&G\1 Y]OPK4_X6?;QP,]SH]W%(P1X8MRDR1L2
MPY]NGO3;'X8M;);6]QK#W%G#%-#Y+0*/W<G5<]:@D^&NI2Q#S-;#31A8H9#
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M6YHOAZPT'36L;4.\;DEVE;<SD^IH XG2/#%CJ/@#3M7-PRZI+!'=R7K'+NQ
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MQQ/JOB'1?["^W"S2\>*216*I<,J,2F!UY'Z5O>+_ (?'Q/JBW@U.2V7R?*9
M,]P1CTY K,L?A7<:==6;6VN2""UN1=1QLN<2$8?\#EOSH OVWQ)M+BS%S]@N
M"JK(950;FB*%EP1[E<?C45I\6=+NEC6/3[]YWF:$1QQ;CN"AO7T(JS/\/;<K
MX@^R71MFU4C9L'$7 R/<%@2?K6-IWPKU'3M2ANDUJ!Q'-YQ5H#RQ14/?T44
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M>"*8",RKC#8QU^4=^U '+V7C#7-/:.VTS0HKE[N]FCVR7C'YE"G^[P,$4?\
M"W;N*ZO)9]#*Z="C[)A)U=0.#QW)_2NLM_ 6GV=[:W45_J1>VN&N%#S AF;
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MT,,$ML^RV(8QR8S@[NO%=5H&@ZEIVEWEMJ.J1W4LZ[$:&'RU0 'MD\\\\]J
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MP)A8@RD#I_L"M*[\"7=U>377]N2QRR6$=GE8EP-I1B<8[E>GO0!1D^(LFI:
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/\
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MK3NT>?,=PPR.>  WZ4 =?H&L0Z[HUOJ4".B3 _*XY!!((_,&O._%?B#4-/\
M$%]!/?7%F=RC394)\@G ^63G@YSV/!%=AX6\.7OAV!+:74_M-ND3*L8CVC<7
M+;NOOBLS5_ =UJ5YJ874XTT[4YEENK=H2S'"JORMGCA1VH G@\;M&]K#=6,@
M+WR6$DBG($C*A!^AW5SGBKX@37WAG5&TZWO;01PF:UO5&%DVYR,YK=N_ =Q/
MJ4<D6J&*Q2[ANQ!Y>3O3:.N?11VK-N_A?=7&DSZ5'KSK8G<MO$T>?+5OO9YY
M/ITQ0!U'A[Q/!K@N;?[/<075FJ&:*9,-A@<'KWP:Y^]\=1WR1-%::I90I?K
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M[B*SMI[*UBMH(T<,MQL;.6],],5V&MV&L7GA>P2*TMY=1MKB"=K<R!4;8V2
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M1Z5;R"47"#-V$0^8RD,JXX^[SSWJ2XT5M$L;A?$EE!8V<FGPVJ2K<!LW"*"
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M !XW'_7)OY&K-5KS_CQN/^N3?R- '+?"S_DFNA?]>J?R%=E7&_"S_DFNA?\
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MZT >K7GBNV6]L8[.ZLI(9)&6X9YU#(%ZX&>M33^(?#-]:;YM2TZ>!64_-*C
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M1H Y;X6?\DUT+_KU3^0KLJXWX6?\DUT+_KU3^0KLJ "D.<<4M% $<>_RP9
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M<EI!;-#/' D3.3GY)%<Y_(U07PAXEL/$TVNVL5I)(ESYL<4C'#!H4C;\MI-
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M$#)$!.>?IN- 'H5EXSMC+JLE_+##9VLRQPR@_?!SC\>.E:7_  EFA8)&IVQ
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M*WEP"1$R.S%#T^?.5 '& ?:G2:5J,OC&QGN+6_!"6GV+;"2 JJ@=2W\/(;-
M'N=%9NEZE'JEH;B.&:(!V0K*FTY!Q^5:5 !28!ZBEHH **** "BBB@ I, =!
MTI:* *%[I=GJ(C^UP)*(W#J&&1D=*HZEX:LM5UK3]3N'F\RQ),4:N0ASCJ.A
MZ5NT4 %,6-4SM4+DY.!UI]% $9BC;&Y%..F13%MH%^[#&.=W"CKZU/10! (8
MM[/Y:[G&&..3]:8EI;QE62"-67.TJH&,^E6J* *QM+<W(N6@C,ZKM$A4;@/3
M-)#96UN'$-M%'O\ O;$ W?6K5% &<-)TU2NVPMAMSC$2\9Z]O:K7V>#;M\E,
M8VXVCIZ5/10!DQ:#81:])K C)O'B$(8GA4&. .W05.^EV$L\D\EE;O-(NUW:
M,%F'H35^B@"M;6MO9P"&U@C@C'1(U"@?@*LT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1
MH P/AS_R3;PY_P!@^'_T$5U%<O\ #G_DFWAS_L'P_P#H(KJ* "BBB@ HHHH
M**** "BBB@!#G!QU[4U-VP;R"W? XI]% !1110 4444 %%%% !1110 4444
M%%%% !1110 QD5\;E#8.1D=*?110 444T@D<''- "+NQ\Y!.>PI]%% !1110
M 4444 %%%% !6,OAS1EU-]273H1>.VYI<<D^OI6S10 4444 %%%% !1110 4
MW:O]T?E3J* &[5R#M''3BDVKNW%1D=\4^B@!GEIG.Q?RH,:$Y**3ZD4^B@!A
M12#E0<]>.M&U<@[1D=#CI3Z* $ "C  'TI:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_ %R;^1JS5:\_X\;C_KDW
M\C0!@?#G_DFWAS_L'P_^@BNHKE_AS_R3;PY_V#X?_01744 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->*?$DWAQM/*61N(KN
M<0,^<"-CTS]>?RKI:Y[QEI#:UX6O;2)2UQLWP8ZB0=#0!@Q?$*Y?1[N[;2'6
MXM[T6?V;=\S/SG^5:%OXWMDA;^T8A9W#SR0V\;,#YNW.#QZXKD_"_@S4X/$4
M%YJOFO:O"M[/&X_Y>P#S^1/%8\&AO#=PWP\/7?V>/5[EQ"EK\RQMNV8'I0!Z
MAX8\3P>(='6\<);S9;S(2W*;3@FM8:G8-&D@NX2CML4[QR?2O#X]$U!!&^FZ
M)J%M<W-I.DSFW*ESYRMAC[J"!]:M7?AR2XMFN],\/7%M8VLEK*;3R-KM*I3<
MRKW(&[F@#URZ\2:39W=K:S7L2RW,ACC7=U8=JHZMXH72_$%EI1L9YGNX9)4D
M3&W* G;UZ\?K7E\6@^9XLM-2G\*7:VAU=I-IM/F"F+AB/3><_6NN\:RD^+M)
M L+R6&&TN1*T<.Y0'C90/K0!U&@:M]MT>&YO6\B60L=DS*I R1V/M4NMZ[%I
M&DSWL4?VMHO^643KDG\37ASZ3#)I%G;W6BWK31:3,H_<\!]\A3\>145SI3'2
M=5MH])U'RY]/MV7="2?M(:3+?EM_*@#VN]\7V-I#+Y(-S<0NB2P1D;E+9]3[
M5O+=6[/Y8GB+_P!T.,_E7AFJ:%;[-:N%T*X-[)>Q302QV_S;.>_]*66Q@M]8
MEUJUTV^@O1K+L9#%MQ ROG]=M 'N"7EM)(8X[B)G!P5#C.:YW7_&^G:''<A5
M>ZN+9D$\4."8PQ #')''(KS;X?1V'_":6=]>PF"2=9%M'9,&ZD)R)"?7:&_.
MK/B[3;:S\0^+&.BW$DM[';_9YXK?<,?(7Y[<@T >NP:A:RV4=UY\:QNH;)<8
M&1G%6?-C\KS/,7RR,[L\?G7SLVCSR(^G2Z;?+H"WBRR1Q0DD!H0,[?3><FO0
M=6M+J+X/):6]I>M(-L8C;/F!/,QN(] O./3B@#T;[5;X!\^+!Z'>*4W$ ZS1
MCORPKYYL+6*UN-'L]8COH;474Z,/*\LNGEJ< 9Z9)_.II[ ?;([;4A?"9](_
MT>)2=Y8,^S(_O>E 'K9\<6/VO6+46EVTNENB2@*OS[LX*\\CY372">(MM\Q-
MV,E=PR*\*F6ZCM?$7VAK@W;/:J6QR67?G^8JXRNMSJ5TUOJKZW%--N:+(5X2
M1@Y]..!0![%<ZI8VD2R7%U#&C-L5BW!/I5?3=:@U%;ED1X5MYFA8RX )!(R.
M>G%>"Z=IS2:6$O(YIK>+4K>3]Y%@*A1]Q ^NWFM@/.KI#=S7(\/'5;@3D$C:
M#YACS_L_=Q[XH ]U,L8ZNH[]:4L NXD >IKP%_MLD8^W7^H(R6%P8P)BI8B5
MO)SZ_)M-=OXFO+L^"O#\IN9X[.0P+J,T3$,$PH;)],YS^- '8Z[XAL?#]DES
M=LS>8VV..,99SZ"EE\0Z=#81W<LP19(FE1&X8A1D\5X^K^<VA#4=0F^Q?VNR
MV,C2X+0X7;SW^;=BM_XB0:9;^+M)O+V62*,6<P1RV%9@ORC- 'I>FZA!JFG0
M7MOGRIEW+NZX]ZLM(B1M(S *HR3[5\_KK%SIFGR66F>(+C9<:?%,Y\XN8AN?
M<R>F.*] \(.9/ >HQW>LW&H0KYF+R48&W'16R<@?UH Z71/%6E>()95T^8R>
M6 0Q7 =3T(/I6_7SWH-P]EH&CPKKMW:6K:3YT6R8J&N1L^3\,D8J_P#VGKUY
M!K,Z^(K^._L;>VE-K',=H+JHEX[;2Q^F* /=:*^?KOQ)=:9HL)7Q=?:A;O=L
MK7$4I#?ZEBJA\G(#8SZ8-3OKFJ"WMS=>);I6CTPW%G+%<DBYN-Q^4G^+TQ[4
M >S6FLVE[JEYIT+,;BS($H*D 9 (P>_6M/..M>$S^*]4,M_#-KUS;W)N[%!%
MYQ!C5_+$F!V')/XTS6/%DUGI'V>3Q#>O'#?3Q&5)CYK@1HR<]P&8T >]5EW^
MNZ;IAC6[NDC9Y!$HZ_,>@K"\(>(+%['3]*FUA;W59;;[0=TFYG7GG]*\[U.*
MV37-:LWU:XCN9-9BVJTYW!</\P']: /=:SK_ %BQTR6VBNYQ&]S)Y<0(^\V"
M<?H:\.G\4ZK<B"Q?Q/-8VL-Q=*;\RG+E641JQSW&[COBNX\7R?:_"7AB:[U%
MXP]S$TMXA\LC,;?-[9_K0!Z517A4?B+4I9);2]\27L&EPI=/:WJS%'G='(12
M_P#$,=N^*AE\7:XFI::UUJLL#&&-)(C.5#!D&&V_Q'!#9]: /=)I8[>"265M
ML<:EV/H!R35?3-5LM7L4O;"=9[=\A9%Z'!Q7CFG:IJ#:?I<^I>++N*SOY+A)
M9C,5\LHS[%W9XSA?SK2T+5[C3?@E/=Z7,TD\,DJM*IR8P7.7S[ YH ]6OK^U
MTRSDN[R98;>,9>1N@%5M,UK3]:M6N=.NEGA5BK.H(P1UZBO%->U&YO++4M,?
M6[F\T^,VTL5PTQ)W,6W*6[XP/IFN_P#$=P^DZ'HEE!J,MM:W<RI<7ZOAL$?W
MO4^OM0!TUMXCT>\>%+>]CD:=V2, 'YF7&1T[9%;->(:5JSV\UK;66N$1LU\T
MDQ;[S QX;K]?SJF=>\22:+H3_P#"3K&-1M/M+W$LQB$;KM&S/.2=QXXZ4 >]
MTQ75QE&##U!S7C%CXJU34[MVO?$7V:5&$(M8O^6Z>4QWJ,]R V?2F:/>W%GH
MS6UCXBEA^SVD][R^[?.)&^0\\@^E 'MM%>+)XC\57::E?'6DMOL]M$_V5X\9
M:1%P <\$ELCCTK>T3Q/?S?#36]0:\D;4+"*7F=,-&XCW 'GGJ#GWH ]+HKQ.
M?Q-XLM+.YN!X@MY/LUE#?D-;X#%RPV?>Z?)^M3R>+O$5]XUFTRSU%(H+DRP0
MLR<+(JH1CGG[U 'LM%>??#[7=8U]I)[V8B&TMTAF5E^]/SO^F,#\ZX^Z^)&N
M6GB/5D%Q%)9!9A!E,!2DJ(,<]@Q^M 'LT-W;SSSP13*\L! E4=5)Y&:MUXO%
MJFIZ3KU_8VNL0S7&HWMI"U\4^4*8';.,_P"R!U[TZ/Q;XPOKE[2#4[.$6RW)
M:8V^?,\EV4=^^WGZT >Q[E+%01D=1FGUYE\.M2U+6?$.LWU]<##QPXAV]#Y:
M9(] 3VKTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T 8'PY_P"2;>'/^P?#_P"@BNHKE_AS
M_P DV\.?]@^'_P!!%=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!SNG>)[6]UK5=,E MY;"41DO(/GR@?(_!OTJ75O$=EINCW-_'+#=
M>3&\@CCF4%]HR0/PKS;5='EN/B'JZK9W"W4^H6T\5S\PC$"K'YF3TY"L*C73
M"DGBH*XN=/L(IHK)80SYDECY7CK]Z@#U+3-?L]0LK2=I8X);F,2+ \@WX^E6
M1JNGO]V]MSP3Q(.@ZUX2B:B-9\/W:Z7J"+;R6Y950XE0.<YST^G'O5W5_"GB
M.TN9GLE*P171M[< $EHI<9)^FW]: /:XM1LII!%#=022$;@JR DCUKG-<\<6
MNC:U'I:6CW<Q7?)Y3#,8R!TQSUKC?#UA)IOQ+2UMK"YEAB,B,\X<>4H(^=6X
M4@^AR>*D\6FP'BK7C+:7;.UB@5XH)#ELCHRCK0!ZB;VR5D4W, 9R50%QR>X%
M2&YMD?RVFB5NZEAGUKQB>QL;%(X#8WVVZTY39,%F8K.2I;/]TYSUQ6??6T<U
MS,]W!J+WGVFQ@+(DV.(D$V,<8W!N: />?,B\HR[U\L#);/  ]ZQ8?$]A>W-B
MEI%)<PW9D5;A$RB;,YR>W2N9\'*'TCQ/8PPW2VJS21V\<X<?+LYP6YQG-<'I
MHMM.M-%6&UU.&X@AO8[P"*;'(?;VQW'(H ]\S;X)S'@<$\4O[G<$^3<1P.*^
M=ELX/[.<$:H9)-'DFVD3?-.&DV_CPO%:&CQS7'B73[F^N=?6^+Q&VCAC(B9,
M_P 188'.<YH ]QDO+**]CM))X%N)02D3, S >@[]:E:.WN8Y(BJ.I!5P,5YC
MXZM?(\=Z9>PVLQNI+"X2"5 [?OODVYQP/XO:H/AMYO\ ;UC]C^VBV_LO_B8+
M<!^+C*[?O=\;^G% '10Z7X2\+RRWNGV/G75I(L16'+M#N., #H*[<^4Q&=I)
M]:\.UNUTZTU37VEM[M=2?4XY(VC$WS*7SSCY<4V^L[2744N2^HB276I$?;YP
MQ$=Y(QTP>.10![F5B7[P09XY YIS%  &P > #7SS?>=<6VGVMY<ZO!IT!NXU
M:%)&82>=)Y8/!)^3;@FO1O$VDSW_ ,/;*:#[6;S3ECNH_G(D8)AF! ZDJ,8/
MK0!T&N:/IL]S!K-U$\D^GJTD2Q\DXY( QR361-)X>L[^;QA,9_MT=GO>V/+)
M%S_!C/8UYS;Z/K4D.I1:A'=16UM!+J46UY"Q:1-JIUYP4SCWINH"VC;4;AXK
ML23>'46W<QRG,I:7(],].M 'N]N8+JW2=(UVRJ&&5J<)'DD*N>A.*\T^&CR6
M^K:]IRW%Q-9110O$90W#-OW $_05Q-W97/\ 8GVZ/4K\6\FI-#<L2Y"1\[>G
M..O(]J /H#R8L8\I,>FT4AAB(VF)""<XVBOGN[DOXM1M774;^ZAMUBB0;9$D
M"E3\RC !''.[)IZSZG;06\VCZG?7%U)-<17B9+".(%L']!0!]!&&(]8D/;[H
MJ$RVK3?8RT1EV;_).,[<XSCTS7A5M/=Q6=EI\^M7CZ3-/FYFACD_=9A) R1N
MSOQGWXKI/!T,/_"S&F:>\D5M- MY)PP,F&(/Z#- 'J*_9)',2B%GBZH "4_#
MM1=>0D+2SHK)&I8Y3=@5XC>>?IGC'Q#%!<W4,;:C;PS2;B2L+[-Q&>,?,PSV
MQ7;>%+V]D\)Z\+N^GEBMKB5+:[<*"8@BD$<8."3S0!U^F7%CJNGP7]K$I@F3
M*%HMIQZ$'I2:CJ6GZ+##]K(BCGE$2!4X+'H/TKQJ/4M3FTJU1->>V$.CB?:A
M0>9*&;&1C^52:]?2ZHUQ?7>I3?:K?44CM[7C:8\-AL8YSZB@#VYK2V90K01%
M5Z#8.*06MN)'D$$8=QACM'(]Z\%M=<\22:=/=3>)/+GN;;<;9(R&BE\Q 02P
MP" 3Q6Q]KU.SUF99/%=T\=M?"V7>8AN#(Q)/'8B@#O/$_A>QO8(;];F33I+
M-()8%' P=W&#G@FJ-K>>$_#&@:;YL[31REIH))DW2,6))8@#CJ>U<#;:[K,*
M*TWB>699_M\6R41[=L1D"'ISG:/SJ6XC74M9T>[;6F!.AM*0/*PCA#D $8'3
M/XT >PV<.E:K:)?6\$,D4Y#A]GWL'@_I63XC\(6^L/:W4%V]A/:%RKQJNW#
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MR- &+X!_Y$#0.G_'C%T&/X171US_ (&_Y$70_P#KRB_]!%=!0 4444 %%%%
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MY[X!_.NF\%:]JOB.UU34_M'^A@"*U$BX^<*"S?3)(_"@#H!X2T >9_Q*K?\
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M[[2ID(%N@B<1L!_#D;>1ZTNBW5SJT%K%::[J;WD6ERSQ)%<MMDE$LI7</XN
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MU;K;W%C;2P)]V.2)65?H",5XY?\ BS5+/3IVM-<>;?9QSRR,2?)E+,"HYXZ
M8JUJVLZQIU_J4#>)61+;2H;V#>.9)&+\=>1\HH ]4_L#1MP;^R;#<#N!^S)D
M'UZ4U_#>A2?>T;3SQC_CV3_"O+%\5:W/;"^;49(]2&K"S:P'3RL9SCU]ZIW/
MB778?"NG7T>O//<7S$[,; FP<@MDGOZ4 >JW.C^'+6"66YT[3TC0B20F!>O9
MCQUYZU(F@:!/&LRZ58NKDR*WD+SN[].^:\A75KBZ.I:I/JY,KZ9:RB)SE'+;
M=PV].#6N_BS5_(N[J+4DMGLIK>&"Q,?^N1L D<^AS^% 'H[>%/#[,&.C6.0
M 1 O;IVJQ;:+IMFDZ6ME#"L^?-"( 'R,<^M>:Z!XMUJ36M-EO=6C>WN=0N[:
M2W:(+LCC\PAMV?\ 8':NP\9Z_-IOA=;W3)%/GSPPB8<A%=U4M^ - &A_PB6@
M;=O]E6N-AC'[L<*<Y'ZFH?\ A'?#&F7EO*UC:132-Y<6Y!\S>WO7GMSXF\3C
M6%T*#68>+];=;TP [D9$.,9ZC<3UKI/',UW9:AX7(FM9&%X%8SP@\_+\P/\
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M9NDB#S(;-KR0R_QA2!M'IG/6N?AMV\:^+;&YO546JV"S>4!S&X<' /KN[^E
M&RGPZ\*V9C=H)5VE\>9=O@E\AN"<'.3^=:N@^%].T R26?G.\B[=TLK.57.0
MHR3@<]J\V\<WFKSGQ! 9E>.QNK,6R$XVDO'W_&II/B9K]K/+H46CBYU2W<IF
M [P5$2N#C _O8- '777PVT.Z6X#27J_:)7EDVW+@,6 !R,\C %:U]X4TN\T2
MUTLQR1PVA!MWC<AXB.A!'-6]!U&?5-#L[ZYMVMIIH]SQ-U4YQBM6@#D;3P!I
M.G:O9ZG:O<I<6N[DRLWF;L;MV3SG _*M?5M!T_6FM#?P++]EF$T>?[P!'/J.
M>E:]% ''7_P[T"^@CB$,L"I<27&8I64EGSNY!Z?,:2R^'6C6.IV=ZC7#FS"^
M0CRL0A"[<CGT[5V5% '&ZG\/M(U?77U>>2Z6X:2.4A)F"[TQ@X!QT %=>HVJ
M%]!CFGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K
MS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H R/ __(C:'_UY1?\ H(KH*Y_P/_R(
MVA_]>47_ *"*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBD[>E '+W_B_0K"[N89R[&W(6XE2'<D9('#-T'4=:Z"#R)(DFA5-CJ&5E Y!
MYKS+0M4T6PT+6M*\0\W3W<RS0.AWS!F)7&.3\I7I6=#K>HV^J0RPZE.DRZC%
M;?8"H"QVNU,G!&> 2<T >Q>5'@KY:8/4;1S2^5'Q\B\# XKR.VN+Z2UT*1_&
M-]%#?RS1W!S$ FT\ $KQP>]9A\4:^=+O)[S5KBVGL[!9]/RJC[6Y9@0<CD\+
MP,=: /:VM+9T"M!&5!R!M'6H+UK(PM!>>6R.I/EO_$!UP*\FU;Q#KD&FZI?O
MXBGCG2X2W2UA\LK$S9/H2/N]SZUGZ9K5Y?Z[I<^I^()S,+:]B69 JKO5DVC!
M'<9_*@#V/3'T[4K.VOK.%?+"XA8IM*BK=S86EZ4-S;QR[#E=XS@UY/;>);Z?
M3;<_\)$ULR::;A"@0+/(&7CIUY(P*2\\4ZM&&U+^W'B9)+!6L24VYE2,R \;
MN"S=^,4 >I2Z3IT]P;B6SA>8KM+E><=,41Z+ID)B,=C"ODY\O"_=SUQ7G_Q/
M\3:II4UG#I6HM;,UN\_RL@#[03U;KTZ#FLZ'QAK,_B/12=3;['=-%&XB9"F\
MA20RXW<YZCB@#T?4_P"P]#T>>>]AAAL0=TOR\9]ZKZ3+X;O=28::ENUU:1*<
MHO*(V<?R-<'\1M5ENW\2:7/J7V*WM=*,T5O\H^TL=X/WAST'3FLX>)+S3C=-
M8:G"A#6:*1LP0^X$$^V* /9+W3++40GVRVCF\LY7>,X--73+"&[^V+:Q)/C'
MF@<XKRE_$?B.Q\1W44NOP^7:3)&MO,HW3J0WS #DYQVJC=Z_J>L^#)KN3Q0R
M3S6GVF6SB"[H2'0%<X^4#=T//'UH ]AN-&TZ[N#<7%G#+,0%+LN20*;_ &!I
M.R1/L$&V0Y<;>M>93^*M1M(KZXMM=,ITZXAMX;9BA%RAX+G R21SQQ72^"=0
MU/5IM3O[G5#<P13S0I;?*=A$AV]!Z#% ';1PQQ0K%&BK&HP% X JK:Z/IUC/
M)-:V<,4DAR[*O)KS2+Q1J_G6MXVM9>[N;NWDL2%Q L8DVMTR#\H.2<5O^'=2
MU1?!-_K5QJ(U&<0S2Q(,878#@<>N/UH Z";P[H7V*>&;3K;[-(WF2JR_*3UR
M:X4/X-3Q*_B&ZU6RDA*K;102 ?NO+)((YZ#=R:RK[Q-J<NC7\$NJR7$-WHTE
MXSJ5S XW_("!T.T#GFJ]IH]FWB[2H)M3:2-M+,SEQ'@YSE>F,'&/6@#U2TTO
MP[K$D>NVUK:W#S)\ERHSN7ZU,GAG14@2!=,MQ%&YD5=O 8]37E&B^+-2ETI;
M:#5;?3!8Z=%-%&0-L[,7W?4#:.GK4J^,O$\OVG4/M]M%:LSQ"%G7=&01@A>H
MQSG/K0!Z7)X0\.S0)#)I%JT:1B)5*\!!C ^G IMWX=\-P-'J-W86B&TC"K,X
MQY:@;1S].*Q8M<U?2_AQ-KMY/#>731++'L4X4,0,'Z9_2N9UW5M3GT+5]-N=
M429%AMIUN% _B>/*'_OK(^E '7:?X9\%ZK:->:19V,FX2(MQ;G)4MD-@YZ\F
MMJR\/6%GH":)Y?FV:H4*R'.X'.?YURFOWK>#/"=C_9(BBEN9%#84YD8KDD=@
M?TK,G\8>('MUE@NK5-FEO>NC#/S([#&1QSMH [!? GAA8K:%=(MPMM+YL7'*
MOZ_I4^LZ7X?U*_TY-6CMI+F)RUHDK8;/'0=^U<)_PGVO7,,^J1&UCMK:\M[-
MK4@[V$BH2_7_ &SCZ5S:WNJ75OX5U47JR7DEQ=R R#.P +C@4 >R:/X9T?0#
M<'2[**W\\YDV]_0?3D_G54>"?#@N+B?^RX/,N PD..H;K^>!7"CQ[XHOKBW_
M +/M+1TBM(9[CS)EC +,X/WB,CY1C'O74>$M;\1:O%?:AJ'V%;*%I(TBB5A)
MN7UR<8H ZJPTRRTS3TL+.W2&UC7:L2] /2J:>&M&3R-FGPCR"QCPOW2V=WYY
M-<+8^.M=GT6/5773O*O8/-@CWX:)BR@!AG)&&/Z4^\\8^*+759-'1--:ZANT
MA,K*^UU=&8=#UXH Z$?#;PJN\QZ8B,P(W*>1\V[^=:D?AC28M!?14M0+)\ED
M]23DGZYKAI/&_BRPM;G4KRWTZ2SM)WAE6(,&?:#RN3ZC%17/Q"\06FEV]Z\6
MGN+ZU>Y@ 5_W>W)P>?0?G0!ULW@'PU-I\-E)IL;0Q2>:OKNX&2?< "K=EX=T
M+P_J4VH6\,=O<7>V)F+8W'H *XF[\=^(]-NM-ANX].<W,<$K+"CYQ(^W'7CC
MU[U7TS4M3NI6N=0DANHI-?C2-'# Q?<P5P1^M '?7'A'19].MK#[+Y=O;2>;
M$L9QM?KGZUCZA\-='FTR2"Q0V]R-[0S-\P1VQDD<9Z5AGQUKL.DQ:RT5D]O>
M13M#%M;,;)C&>>0<\XK:\)^+=7U/5#8ZS!9QM):I<Q&W##:&S\K9)YX[4 4_
M!'P]N?"VL?VA-=6VT0-#Y-O$4#9(.X\GT_6MJ3X=^&)=0GOI-.5[F:5Y6D)Y
MW-G=CZY-.\3Z[J%AJ&GZ9I:0?:[W>P>?.U57&>AZ\BN:TGQKXHU?7+.QMM/T
M]8S$SW!8MD%&"OCYL8R>/:@#L8/"&C6_AI_#\5KC3G&&CSUYS_.L^'X>>';<
M;8[5PI=)"N[@LF,$\>PK'\4>.]3T3Q=#IMO! ]J F_<K%CN('4'"]>]3>$/%
M^K:WXFU#3+Z"VB2W5R%"LKC#[5ZG# K@Y'K0!N:-X0T#1=1GO]/ME6X=CEMV
M=I/7'IG/ZTV;P1HES-J4EQ \O]HD-.KMD9'0CC@UP5OK.O07L\6G-9VK2ZYY
M<Q&\^:H53_$3CC@UTOA'QAJ>NZW=V.H06L/D@G8@974@D?Q'YN #D<<T 2ZM
M\/=(?0'MM.LQ]JB5V@+/C<S #YCZ' J#2_AW977AO3[37K51>6]O]G<PN,,H
MZ5GW?C[Q%;6UU/\ V7:&-+W[%$XW-E^.2H.2.1P*C3Q_XGFM8VAT6U,Q29G1
M]R']WMR0"<\[OTH Z:3X<>');B6=[1RTOWQOX)_O?6HU^''AU I$4WF+*DHD
MWC<"H('..F":Y>;XK:F+"?5+?2(7L8H()22WS R@X'7_ &33F^)FN0V;M=:7
M#!(LRQK+)%(J$$$]"<CIU/% '<ZOX7L=8EAFDEN8)(8S$'MY I9#U4\'(-+9
M>&K/3]674+>6Y5U@6W6+S!Y810 !C'MGKUKA[+XIZC>Z@D46B[K=5*RR+DA9
M A)PV=N,C%37'CW7YO#LU['86UM(T220%FSG=*L?//J: .EU7P)I&LZA+=W#
MW:-,T;2QQ2!4D*$%21CL0/RJK<?#;0KBYENF>]6ZEE\TSI, X.T+@''3"@5D
M7/Q!U&QUR'2)[*!Y60(75LYD,8<'KP,D#UK-T/Q!KU_=:7?74/VB]DM[EX$1
MMJOM+C:1GVH ]1TVPM]*T^&QM5*P0KM0$Y/K5ZO+I?BH8=.BG?32\KPQMLB!
M;$CNZ!..I^7I[UK0^*;G7_A_JNH3:;=V<\4;KY6-CM@=5W=/QH [NBO)K7XC
MW.CZ9;6\6CSW%K;6<$TUQ)*NY5?/7GD\5U7C#Q>_AB"W:&T%P\V6Y< !1U^I
MH Z^BLS0]5CUO0K'5(D9$NH5E"-U7(SBM.@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?\ 7)OY&K-5KS_CQN/^N3?R
M- &1X'_Y$;0_^O*+_P!!%=!7/^!_^1&T/_KRB_\ 01704 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445&ZEHV4-M)! /I0!4ETK3Y[I;J:QM
MY+A#E96B4L#]<9I6TZQ:=IVM(#,P(,AB7<0>,9QFO'(O%>OQ1K<2:R\BRM>0
M.HB#&((9 C8SW( S46@^*M>U.XBTJ37A;M)?-!YJCS"4,2$8)QSEC]#0!Z=?
M^$[/4=2L)TDBA@L9"YM$MXRCDXSNX[@"MF;2=.N?*\^QMI/).8]T2G9]..*\
M?TF[U*RU>XL5\0SBYN-:-M(TB[CY>V/#8)XZG\JA;QKXAN(+8)K%O;"VB+^;
M,<><P//'?'''O0![)_8^F'SLZ?:MYS;Y,PJ=[>IXY-58[;0);][%+.Q:Y@&]
MH_(7*9[].]><WVOZ^;+4)X=>1Y%O_LL=N(PI9<$G:<]>.*SQK%Z+2?7['5V,
M\5C!(YEA"O,25 ##)[$^M 'JB:9X?NYC;QV-D[V3 %%A4>43SZ58F\.Z/<NS
MS:;:LS,&8F(<D=#7FM_XEU6TN;QK._M;=YM2@B>46Z_<>-C@^I''-=7X.\1-
M=FXTW4=0AN+R.XDC@D"[3,JD\@>V,?A0!M75GHFHWL=E=6]K<7-O%O2*2,,5
M0_+GD=*@N-%\/Z?+!J$UG:VY@8+&^P  D\=.^37,>)-=O](\7:DUJEM\FGQ,
MLIA&]-TH4DGJ0,YQ6;J&OZ@3=Z;>7=M?PP36DPEE@4JP=URN/4=0: /0[_P_
MI&LRI/?6$%PX0JKN@)VGMFJLW@[P]<JZOI<&URI8*N.1TZ>E<N?$6MC6& U"
MW2T&JK8I"(%R498SG.>Q8UI^"Y-2O/!#.=2\V^E:0I.Z!O+/09&><8H Z"7P
MWH\^I0ZA+I\#W<*[4E9 2!3%\,:(BW:IIELHNQB8+&!O'I7F=UX^\46VAS7!
M>W^TV02WN2T0"&=L]^VW;R/]JKD7BGQ7--!83:EI]O=EY1(T<0DP!RO!QZ&@
M#N1X4T+[;!<C3H!-"@1/E&, 8''?'K5_3='L-'$PL+9(1/(9) O\3'O7DL/B
M37;NY75CK"0W":2'6$0!HW)*;N,]:FO_ !UXA$YAL[^T#,MF03"IP944L#_W
MT30!Z5_PC6C_ &NXNC80F>=2LC;>N1@_3-6M-TBRTC3_ +%:PJEN,Y7''->8
MMXT\5P^*);62YTT6=G=16\XF^1G#[?F& <?>XKT#Q/<.?".K7%G=>4T=I*ZR
MH-V,*3Q[\4 1KX/T 6MU;KI\8ANFW2@$\^WL/;I0?!?A_?$YL?FBC$2'>W"C
M)QU]S7!Z;KWB@6\MG;ZO R66EI>O*]NK,V2V1UYX6I[OQOX@%_-;V30SD6$%
MPBB,;MSLX( [GY!Q0!V?_"$^'<V9.F0DVG^IRN<>Q]1[&G3>"O#T[W<KZ='O
MN_\ 6E21GZ8Z?A7$^&?$.LZYXYTUIM7S:M9R,UN(@H)R.HSU_E6CKGC#6+27
M7;FV>WCM](DC7R"H9I]Q(//\/3WH [>VT:PMM'&E1P#[$$\ORF)8;?3FL5?
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M,^T:7&\.F&34)+AX%@1\H=O4[L=/PJ-?BM 8].F;2;F.&Z/S,XP5!Q@CUZT
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M444 %%%% !1110 5#+$DT3Q2+N1U*L#W!ZU-5.^E>#3[F6-@KQQ,P+= 0,T
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M=U*Q31XI;?3S$9I1,<['V\@8ZC=T]JCA^(,\L%I>G3HUT^^DEAM)/-.]G3(
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M?M:E&E)A7. O&<#'/YUV:^,U'@:7Q++9.L:J62(<EQV/XT 9=A\-X;*5+?\
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MWX922 P)'4 ]*<2 ,DX KS;4]>U30M6UN2RT^&:YDO((0);I]I5D)#8QP>G
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M!.<N",C'X4 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.EWXU#3(;PP2P"1=QCE4AE^N:Y _%#11>W-OY5RRPAMLB1E@^T@'H..O?K0
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M\ZV#XZ\-"W2<ZI$%=BJ@JV2P!)&,=< UKZ9J=GJ]A%>V,ZS6\N=KKWP<']:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *K7G_ !XW'_7)OY&K-5KS_CQN/^N3?R-
M%?0@!H-@!T$"_P JT:S]#_Y 5C_UP7^5:% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C
M_KDW\C5FJUY_QXW'_7)OY&@"#0_^0%8_]<%_E6A6?H?_ " K'_K@O\JT* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ-F
M"(6() &< 9-/!R ?6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BH/+_?"3>W"[=F?E^OUJ>@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_
M %R;^1JS5:\_X\;C_KDW\C0!!H?_ " K'_K@O\JT*S]#_P"0%8_]<%_E6A0
M4444 %%%% !1110 4444 %%%% !1110 4444 %-4DYR,<TZB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *802RG<0!U'K3Z* "
MBBB@ HHHH **** "BBB@ HHHH **** "BFD'(P<8Z^].H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD.>
MU+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_ *Y-
M_(U9JM>?\>-Q_P!<F_D: (-#_P"0%8_]<%_E6A6?H?\ R K'_K@O\JT* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!!H@QH=B#_ ,\5
M_E6A533EV:9;+Z1@?I5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M% T4TKF9W$AR%;&%^
ME6:** "BBB@ HHHH **** "BBB@ HHHH **** "BD;./EQGWI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **C3?@[]O7
MC;Z5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: "Q_X\(/]P59J
MM8_\>$'^X*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5KS_CQN/\ KDW\C5FJUY_QXW'_ %R;
M^1H +'_CP@_W!5FJUC_QX0?[@JS0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444A('4@4 +1110 4444 %%%% !1110 4444 %%%% "#.3G\*6B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G
M_'C<?]<F_D:LU6O/^/&X_P"N3?R- !8_\>$'^X*LU6L?^/"#_<%6: "BBB@
MHHHH **** "BBB@ HHHH **** "FA0"3D\^].HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HY)$BC9Y&"HO4GH*DKRKXI:[<H7T>);J&W2#[1//"A(;D83Z'G/T%
M'JM%5+.[2^LH;J-75)4#J'7! /J*MT %%%% !1110 4444 %%%% !1110 4Q
ME5L;@#@Y&?6GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O/\ CQN/^N3?
MR-6:K7G_ !XW'_7)OY&@ L?^/"#_ '!5FJUC_P >$'^X*LT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U#3;74[
M.:UNHE>*5=K\<D5=HH :  ,   = *=110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\
M'C<?]<F_D: "Q_X\(/\ <%6:K6/_ !X0?[@JS0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O/^
M/&X_ZY-_(U9JM>?\>-Q_UR;^1H ?;9^S1YQ]T=*FI  !@# I: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JUY_QXW'_ %R;^1JS5:\_X\;C_KDW\C0!9HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "F,&*,%.&QP3ZT^B@") P10Y!8 ;B.YJ
M6BB@ I!G'-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1
MH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "#(&"<GUI:** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 ?>7]KZ9_T$;3_O^O\ C1_:^F?]!&T_[_K_ (U\&T4 ?>7]KZ9_T$;3_O\
MK_C1_:^F?]!&T_[_ *_XU\&T4 ?>7]KZ9_T$;3_O^O\ C1_:^F?]!&T_[_K_
M (U\&T4 ?>7]KZ9_T$;3_O\ K_C1_:^F?]!&T_[_ *_XU\&T4 ?>7]KZ9_T$
M;3_O^O\ C1_:^F?]!&T_[_K_ (U\&T4 ?>7]KZ9_T$;3_O\ K_C1_:VG?\_]
MKUQ_KE_QKX-J7S),@[VR!N'/>@#[O&IV!Z7UM_W]7_&C^T['_G]MO^_J_P"-
M?"2W=ROW9Y!]&-+]ON_^?F7_ +Z- 'W9_:=C_P _MM_W]7_&C^T['_G]MO\
MOZO^-?"?V^[_ .?F7_OHT?;[O_GYE_[Z- 'W9_:=C_S^VW_?U?\ &C^T['_G
M]MO^_J_XU\)_;[O_ )^9?^^C1]ON_P#GYE_[Z- 'W9_:=C_S^VW_ ']7_&C^
MT['_ )_;;_OZO^-?"?V^[_Y^9?\ OHT?;[O_ )^9?^^C0!]V?VG8_P#/[;?]
M_5_QH_M.Q_Y_;;_OZO\ C7PG]ON_^?F7_OHT?;[O_GYE_P"^C0!]V?VG8_\
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7_P"@E=?]_32?VSJI!!U*ZQ_UU- '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>inmune_ex31img24.jpg
<TEXT>
begin 644 inmune_ex31img24.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9^8H(,B@CGZ$T =(*6J5A?VVH6PN+659(R2,@^AQ5V@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C
M<?\ 7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHIM "Y%)O7^\*C92W!4,0<K[5S
MVI>,M&L+MK5KEY+C&/+A&XB@#ILBC(%8&C>)='UB=DLKN,W*_?B<XD'U%;WW
MJ %W#/6EJ!Y%B#Y.T*-S,?2N5?XB^'%D9/M,C;3C(C+"@#L:*XX?$;P[G_7R
MC_MB13O^%C^'?^?F7_OF@#KZ*XW_ (6+X=_Y[R_]^32CXC>'<?\ 'Q*/^V9%
M '8T5R'_  L?P[_S\R_]\T?\+'\._P#/S+_WS0!U]%<A_P +'\._\_,O_?-'
M_"Q_#O\ S\R_]\T =?17(?\ "Q_#O_/S+_WS1_PL?P[_ ,_,O_?- '7T5R'_
M  L?P[_S\R_]\T?\+'\._P#/S+_WS0!UK.JGE@*7<"!@]>E<_I7BO2M;N6BL
MKK?*%_U3\9K:@ QD)L)^\I[4 3T444 %%%% $$\*SVTL#?=D0H?H1BO(=GC/
MP)//!:6O]HZ2VYXTC7)3)/%>R'[I^E<[%XDM?[7O-,G86\T W+OZ%<?XYH P
M/"GQ!TO7[]K62!K+4W'ED.,9(_\ UUC>*X&TKXHZ/?)/);6]_MAE9&QN.><_
MF*F\2:=;:OXWT"71 /MT%QYMQ-&/D"<=?R-:/COPYJGBBXTM]+BM4>TD,@GN
M.1GCHN1GIZT =%)X?M;B:.YF:4S0.'CD:4L0?4^E<EXST=/%\$U]I8/]HZ7(
M#$R_Q^O\JWAH6NZC:_9]8UB)HSC>MI 8<C\6-:VA>'K3P]:&&SW;6.7+G)-
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M+0HVR;F<L\8ZG&/\37I-M'#%;);Q#:B#8H_V1Q7 W?A'7I/'-GKDMW#=0V[
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M=N_LUN3D6^<._H!B@#K]7^(C&<VFC0_:9&!&0.GN&^[^%<;JLUW(@EU[6EA
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M7=C]_8Q'W7*G\QBL&3P):RZA'<?:[LV\; BW9_EX.1[]0*[+%1LF1G^+ZG%
M#HQA<8Q3Z9&NT<]3[T^@ HHHH *:[!5R3BG4Q@6 ''7G- '+>.M1>P\.N(V8
M27$BVZN.JY/)_+-<?;Z1+>-]EL96MX+;Y6D.QF<^_%=_XET9M9T>>W39YP(D
MAW= XKR#6+WQ7IMZ'L4GM9$XN?W"NC'_ &>M '5OX0U;=SJ3_@B?X4G_  B&
MJ_\ 02D_[X3_  K@CXE^(#DL-4GP>G^A+_\ $T#Q%\0#_P Q2?\ \ U_^)H
M[T^$-5/74I/^^$_PI/\ A#M4_P"@C)_WPG^%<)_PD/Q _P"@I-_X!K_\31_P
MD/Q _P"@I-_X!K_\30!W?_"%ZK_T$I/^^4_PH_X0[55&/[2D_P"^$_PK@_\
MA)/B%_T%)_\ P#7_ .)I/^$D^(&>=3G_ / -?_B: .\'@_5L\ZE)C_<3_"G?
M\(AJO_02D_[X3_"N#/B7Q^1@:E/_ . 2_P#Q-)_PD7Q _P"@G/\ ^ :__$T
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M45ZIX2\20^(M/60D+>1_+(IZF@#J**** "BBB@ HHHH **** "BBB@ HHHH
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MWT\:/ UM*TM^Y^=>PKHK+PUK>H:?';:C<+':Q\JO>NCL/"NG6>UA&KLO0D4
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M,H B^(?_ "-UM_U[R_\ HIJ]<T'_ )%W3/\ KTB_] %>1_$/_D;K;_KWE_\
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M7NE>%_"P_P#%1VO_ %\WO_H,=>Z4 .'2B@=** "BBB@ HHHH **** "BBB@
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M>T'K=7O_ *#'7O&*\&^%_'BBS_Z^KW_T&.O>J "BBB@ HHHH **** "BBB@
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MR^5DGYF8$@?D#4\5F8;JWM;.5S/)SL"\# ZYZ=* )O'$YAM4C\QC+YN]0PY
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M_P#+"7_T6U>MZ%_R+VF_]>D7_H KR;XB?\C1:?\ 7"7_ -%M7K.A?\B]IO\
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M+XAD_P#"56G/_+"7_P!%M7KFA?\ (O:;_P!>D7_H H T1TI:0=*6@ JM>?\
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MILFD_:6\NYFV%<\]<YZ5DZ)JLUY:I)')^]4\AD-=C)J<$\$#AHO.08<;<<T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\ Z1)XBUR?6KQ&2'Y1'&QX 7&U1[8&?PKVM/N#B@!0/FSVQBG4@I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH BF_U$G^X?Y5Y#X7_P"1K_"7_P!#KUZ;_CWD_P!P_P J\A\,?\C9
M^$O_ *'0!7^(G_(T6G_7"7_T6U>L:#_R+^F_]>L7_H KR?XB?\C1:?\ 7"7_
M -%M7K&@_P#(OZ;_ ->L7_H H TZ*** "JUY_P >-Q_UR;^1JS5:\_X\;C_K
MDW\C0!9HHHH *;3J;0!Q_P 2>?#4/M>V_P#Z,6L+P5_R+D^.<[_YFM[XD?\
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ML!2!@G-.HH 04M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 13?\>\G^X?Y5Y#X8_P"1M_"7_P!#
MKUZ;_CWD_P!P_P J\A\+_P#(V_A+_P"AT 5_B+QXHM/^N$O_ *+:O6- _P"1
M?TW_ *]8O_0!7D_Q'_Y&>S_ZX2_^BVKUC0/^1?TS_KUB_P#0!0!IT444 %5K
MS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H LT444 %-IU-H Y#XD?\ (LQ?]?MO
M_P"C%K!\$?\ (O3?5_YFM_XCC_BF8O\ K]M__1BUS_@?GP_./0O_ #- '*^
M/^1TM?\ K\N?Y1U[U7@G@ _\5K:_]?ES_*.O>LT +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10.E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>N:EQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $%S_ *M_]PUY!X7_ .1Q/_;?_P!&
MUZ_<_P"J<_[!KR#PSQXS<>GG_P#HV@"+XB?\C1:?]<)?_1;5ZSH7_(O:;_UZ
M1?\ H KR7XB-_P 51:?]<)?_ $6U>M:%_P B]IG_ %Z1?^@"@#1'2EI!TI:
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M>]UX)X&_Y'V+_K^G_DE>]T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTG\Z .;\%''CV(#O?3?R2O=Z\&\$_P#(^Q?]?TW\DKWF@!PZ44#I10 4444
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MKR/_ *_9_P"25[O7@_@<_P#%>1C_ *?9_P"25[SB@!1THHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (+K_CWE_P!PUY#X4_Y&H_27
M_P!#KUZZ_P"/>7_<->0^%/\ D:C])?\ T.@"K\0_^1JM/^N$O_HMJ]=T+_D7
MM-_Z](O_ $ 5Y%\0_P#D:K0_],)?_1;5Z[H7_(O:9_UZ1?\ H H T1TI:0=*
M6@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T 6:*** "FTZFT <A\1O\ D68_
M^OVW_P#1BU@>"/\ D7I_J_\ ,UT'Q'_Y%B/_ *_;?_T8M<_X&_Y %Q]7_F:
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M.:++J,\;2A"%6-3@LQZ#--Z.S$M3;I*YW2-?N[Z]^Q7^DO83^7YN/.$BX^H
MKHZ!)A1110,**SM/U2SU0W'V27S!!)Y3D=-PK1H **** "BL;Q#K<7A_1Y;^
M6,R;2%2,-@NQZ#-9;>+Y+/PU=:MJNDSV,EO)Y?V=GW;SG VM@9!]<4KCL=92
MURUAXGF=V75],;32ML;DDSB1=H('4 <\UOVMU%>V<-U 28ID$B$CJ",BJL2G
M<M450AU.TGU2?3HI0US @>11_"#T_G5^D,**2N=\/>(7UJ[U.UEL3:36$_DN
M/-#AO?@"CK8#HZ*** "BBB@ HHHH **** "BBB@""Z_X]Y?]PUY#X3_Y&O\
M"7_T.O8)\?9Y<_W#_*O'_"1!\4O["7_T.@"K\0?^1GM?^N$O_HMJ]=T'_D7=
M,_Z](O\ T 5Y%\0_^1JM/^N$O_HMJ]=T+_D7M,_Z](O_ $ 4 :(Z4M(.E+0
M56O/^/&X_P"N3?R-6:K7G_'C<?\ 7)OY&@"S1110 4F*6B@#COB.?^*9B'_3
M];C_ ,B+7/\ @<XT&X^KC]370?$<?\4U&?2_MB?^_BUSW@?_ ) 5R/\ :DH
MY;P&-OCF!?[M[<?J$KWK%>#>!N/'D?\ U_3?R2O>J "FD@*23@#J33J8V-IW
M8VXYSTH \]\+:KIL?B_Q8SZA:JOGQ')F4#[H'KZ\5T'B^ZMX_!>JRR3QI&]H
MX5V< -E3C!]ZDET'1=0M;A+2VL$,ORR2PP1L3SD@\5H'3K-["*QEMXIX(T5
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M4@X&<=Z],@T/2+63S+?2K*&3&-T=NBG\P*DATO3X()((;"VCAD^_&D*A6^H
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M(Q52U6A,='J>7>'+:PE\=V\45C_9%M)IFV2TGC"?;#M'(4<$=\UF:+<+X?\
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M 4444 071Q9S?[A_E7CW@\Y\3-])?_0Z]ANO^/.;_</\J\=\&_\ (S-])?\
MT90!#X_!/BRVYZ6LP_\ (35ZYH QX<TL?].D7_H KR3Q]_R-L'_7O+_Z+:O7
M-!_Y%[3/^O2+_P! % &B.E+2"EH *K7G_'C<?]<F_D:LU6O/^/&X_P"N3?R-
M %FBBB@ HHHH Y#XC_\ (K)_U_6O_HU:Y[P)_P @6^_WY*Z'XC_\BNH]+VV/
M_D5:YWP*<:+>>[.: .7\#_\ (^1_]?L_\DKW>O!O Y/_  GD?_7]/_)*]YH
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M\X25(I1;J&,1?[I;)&!R/SK%\,8/CGQ6,X)>'I_NFN#U/3S%:^,I!?7;$ZA
M@627*\R*<X]1V]J&]5YJX+KY.Q[DC"1%=>C $4^O#M5\1:[H<U_H]IJ%Q<AK
MFWC26>XVM&'1"0'Q\O)('I7?> O^$A@LKRV\03I+(DN8#]H$SA" 0&; R>:M
M*ZN@O:USM:***0PHHHH @N_^/6;_ *YM_*O'?!?_ ",G_?[_ -#KV*ZP+28G
M^X?Y5X]X,V_\),0 >!+_ .AT 0?$'_D9[7_KA+_Z+:O7- _Y%[3/^O2+_P!
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MA(&T.$B7&_+O\V.F?FJ'5M>'@^PT^P6VO-3N3'M4!T#E5'))8@$X';FJ]_\
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M-'A3Q?!XI-XB64]G/:LJR13,K'D9!RI([UU-#07.5A^'GA6WD@DBT>%7M_\
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M\!?\CK;?]?ES_*.O=Z '#I10.E% !1110 4444 %%%% !1110 4444 %%%%
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M'7O%>$>  /\ A,[;_K\N?Y1U[O0 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7
MN_\ CRF_W#_*O'O!_/B=L>DO_H=>Q77_ !YS?[A_E7CO@S_D:&^DO_H= %?X
MB CQ5:?]<)?_ $6U>O:"/^*>TS_KTB_] %>1_$;_ )&FT_ZX2_\ HMJ]=T'_
M )%[3/\ KTB_] % &E12#I2T %5KS_CQN/\ KDW\C5FJUY_QXW'_ %R;^1H
MLT444 %-IU-H X[XD?\ (KI_U_6__HQ:Q?!G_(MS_1_YFMOXD#_BF(QZWUO_
M .C%K#\%'/ANX_X&/U- ')?#O_D<+7_K\N?Y1U[W7@GP\X\8VO\ U^7/\HZ]
M[H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/\ CTF_ZYM_
M*O'/!G_(R?\ ?W_T.O8[H?Z)-_N'^5>/>#5QXE(ST$O_ *'0!#\0O^1KM_\
MKWE_]%M7K>@_\B[IG_7I%_Z *\E^( SXOMUSUMY?_1;5ZWH0QX>TP>EI%_Z
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M:0=*6@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T 6:*** "FTZFT <A\1O\
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M\;C_ *Y-_(U9JM>?\>-Q_P!<F_D: +-%%% !3:=3: .2^(O_ "+47_7[;_\
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MZ<Y__06KV'0?^1=TS_KTB_\ 0!7COCG_ )'.V_Z\Y_\ T%J]BT+_ )%[3/\
MKTB_] % &B.E+2#I2T %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H LT444
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M#4-/_L:YD)NK89C9C]]/\1_44 >ET444 %%%% !1110 4444 %%%% !1110
MVN)U3Q3-HOCB&RU&_LH-(FMC+OE78R,,CEB<=1Z5VU>5>-;B'_A.5,VGW=Q'
M%IDT>Y+.21=Y5\#(!'<5+=F@M=,[VZ\3:'9?9_M6JV</VD P[Y@/,!]/6HG\
M7^'8IV@DURP656"LAG7()Z"O#]2:\U+P]:VD6DWT4T5E_K?L4GF.1(YV<C
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M?^Z1_P !II7!NU['J(((!!R#T-.I.@I:0Q@50VX*,GJ<4^BB@ HHHH ****
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M$@L,]B1T]Z2=QM6/8"0JEB< #))K!M?%^AWMXUK;ZBKS*^PCRW +9Q@$C!_
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MB@!IR00#CWK#T?0VL+JYO;F^EOKRXPIFE15P@SA0%XXR:WJ* "BBB@ HHHH
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M<$$8+'T^E<+K7EW;7407]V5(4 <"MD^*A*BJUOA0,<'U[UBRR)AG4?>/- '
M(]M;W%LT!<S#(EW],@UT=S]J>QE$LD7EE<A _3'H/6L.[^U?9(R1"+87#;<$
M;B>.HZUH&\D9?NJ 5QC'ZT >C?!:\8MJMHQ^51&Z_CNS_2O7*\1^#A*^(;M
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M("LKCENG.>N:\>O]/D\66FM?$36)T-C&SQZ?8W+<LV[ 0@8S@9X')Q[5Z_\
M"33;S2_AQID%ZC+(X:50S9.QCE?IP>G:BP7-W0_#%EX?T1]*M9KJ6U?=_KY=
M[#=G.#CWJC%X#TQ+JWFGNM1NX[9MT-O<W&^)#ZA<5UM%%];ATL<%J'@S3](T
MO4[BR_M*59$D=;")]\?F$'E4 ZYYJGX$\'VAT*TN]1AU-;M(WB^SWI($.XG.
MQ2.,@UZ!+-'!$\LKJD: LSN<!0.I)["DM[B"ZMTGMIHYX7&4DC8,K#V(X-"Z
M@SE5^'6CQP6J0W>I0RVA;R;B.XQ(JG^'=C[OM[U6F^%>BS2W<C:AK -V@CF"
MW> ZCH#\M=[10!P\/PPT..X\Z2ZU.XS;_9BD]SN4Q\<8Q["K,?@#1$LKBVG%
MS=^?&(C+<R[W5!C 4XX P/RKKZ*'J"T.(N/AQI=W:P6]QJ6L2K ZM&SW>6&W
MH,XZ#C\JZ>ZT];G2FL#/.BO'Y9E1\28QC.?6K]5&O+5;N.V:YA6XD7<D1D =
MAZ@=2*'JK,%H[G/6G@;3H+66TFOM3O;:2(Q&&[N/,50<YP,<'FH4\#6NF6US
M+876H2WS0^3#++=8>)><*C8^4<U<M?'/A^[\4-X=M[X2ZDN<HBDKPNX_-TX%
M=/0P,2;1GOO#HTR]N[C<\>R2:&3:Y_&J-MX*L8+*>SGO-2OK>:/RC'>7'F!5
M_P!GCBKGB3Q3I'A73UO=7NO(B9MB@*69C[*.33O#GB73/%6E?VEI,S2VN\Q[
MF0H=PQG@\]Z.K?<%HDNQ5TSPCI^D6MW#;37ADNE"27$DN9=HZ -C@#)IFF>#
M+71]%ETJRU'5(X9'W^9]I_>(>^TXXS7444;@85IX9M+*T:"WN;Q'>022W E_
M>RD?WFQS6[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %:\_X\Y?]QOY&O'? 9QXAE/^P_\ Z%7L=Y_QYS_]<V_D:\:\
M#?\ (P?\!D_]"H B\=.O_"96O_7I-_Z*:O8-!_Y%W3/^O2+_ - %>/>/?^1Q
MM?\ KTF_]%-7L&@?\BYI?_7I%_Z * -(=*6D'2EH *K7G_'C<?\ 7)OY&K-5
MKS_CQN/^N3?R- %FBBB@ HHHH X_XD?\BPI_Z?;8?^15KFO 7_((O?:1A72_
M$?\ Y%9?^OZV_P#1JUS7@+_D$7W_ %U>@#E_!W_)0D_["$W\DKWNO!/!_P O
MQ"4'@C4)<_B$KWN@!PZ44#I10 4444 %%%% !1110 4444 >'?&"(P^*K67_
M )ZP;A^! KG9;A7LBC74/S)]U8N>G3.*[SXRV!:UTZ_5<E7,)]@06_F*\XBN
MX!:0MY"/*!@DGI^% &%!Y$;?-+()UG&$_AV\<UUQMN8+@.ZQ[>"F<9S7-*MR
M]U-;6T41-P.K@?+CG@]JZO1KR75-)MM,B 009$KGIU[4 =?!KMLMK"GG!YL
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M\,Z+K-KJEO)>//;2>8HD=2K'!X(V].:ZV_\ ">@ZE.)[O2K>648PQ!'3ITH
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M!U95<_W<$X' SF@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *]Y_P >DW^XW\C7CW@K_D9&_P!Q_P#T*O8;PXLYO]P_RKQ[P81_PDS
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M&/F;NQ[FJ/A+PE:>%]-$48$ES)S-,1RQ]/I72T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7G_ ,4_%UUX7\.)%I/S:M?/Y5N@0LV/XF '<9'7UKT"O'?&6KW7AGXM
MVFL:AIUY>:0+#R[<11B0+-GDJ">#TR?I0!Y]XC\.WW@F;P;?0-<+XENW>>Z8
M_.Y<E,KW!QD_G7U'7AG@W3O$?CKQTGC'60;73[.0_9;=ARI'15'TZGKTZU[G
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB(41N?E^\=PZ<\57UO6_$5UJ-CH]Q?6ES=K=6L\%S%"%5"Q;AESST]:[/4/
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MD%^+"75K)+PL%$#3J'R>@QG/>@#8HHHH **** "BBB@ HHHH **** "BBB@
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ML+1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&Y_P!1)_NFO'?#?_(ZR?\ ;?\ ]&U[%<_ZB3_=->.^&_\ D=9/^V__
M *-H J?$S_D8-/\ ]V3_ -%M7KGAW_D6]-_Z]X__ $$5Y'\2_P#D9+$=@DG_
M *+:O7/#O_(MZ;_U[Q_^@B@#6'?ZTM(._P!:6@ JM>?\>-Q_UR;^1JS5:\_X
M\;C_ *Y-_(T 6:*** "FTZFT <I\0O\ D57'I<0G_P ?%<I\/N=/O1ZR$UUG
MQ!_Y%>3_ *[P_P#H8KE/A]_QX7G^\: .9\,''Q/G'_42S^87_"O>Z\"\-?\
M)4;C_L(K_2O?: '#I10.E% %#5!(=*O!!D3&!]F/[VTXKS;2)_",?@VW6_1'
MU%9QYL?/VDS;_P#OK&?PQ7JK,%!9B HZDGI68=-T87 OVL; 3L<BX,2;B?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $4_^J?_ '37C?AKCQS-])__
M $;7LDWW&_W37C?AO_D>I?I<?^C: *OQ)_Y&?3_^N,O_ *+:O7_#_P#R+6E_
M]>T7_H(KR#XD_P#(SZ?_ -<9?_1;5Z_X?_Y%K2_^O:+_ -!% &F.]+2#O2T
M%5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: +-%%% !3:=3: .8\??\ (JS?]=8_
M_0A7(^ O^/2\]W/\JZWQ]_R*TW_72,_^/"N1\!'_ $>^'I(0/R% '->&O^2H
M3_\ 807^E>^UX%X:_P"2H3_]A!?Z5[[0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!#/]QO\ <->/>&_^1XE^EQ_Z-KV&YXA<_P"R:\>\-?\
M([R'U%Q_Z-H K_$<#_A)M/X_Y8R_^BVKUO0/^1<TS_KVC_\ 017DGQ%Y\2V!
M](9?_1;5ZYX?_P"1=TT>EK%_Z"* -(=Z6D%+0 56O/\ CQN/^N3?R-6:K7G_
M !XW'_7)OY&@"S1110 4G-+10!RWCY2?"T^.SQ_^A"N1\!*1!J'_ %U/\A78
M>._^15NO]Y/YBN2\"?ZG4?\ KK_[** .6\-_\E1G_P"PBO\ 2O?:\!\.?\E2
MF_["*_TKWZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ* .6\.?\E2F_P"PBO\ 2O?J\!\.\?%*;_L(K_2O?<T +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #)?]6WTKQWP_QX\N/3-Q_P"C:]BDYC->
M.:%QX]N!ZM<?^C: *7Q(&/%&G^GDR_\ HMJ]>\/'_BF],/\ T[1_^@BO(OB:
M=GB/3O\ KE*O_D-J]<\.G_BFM,'I;1C_ ,=% &M129ZTM !5:\_X\;C_ *Y-
M_(U9JM>?\>-Q_P!<F_D: +-%%% !1110!S/CS_D5+SZ+_.N/\!?\>]]_UT_]
ME%=AX[_Y%6\^B_SKC_ /^JO?^NG_ +** .7\/?\ )4IO^PBO]*]\KP/P[_R5
M6X_[""_TKWR@!PZ44#I10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#9/N&O&M#_Y*!/\ [T__ *-KV2;_ %1KQGP_S\09A_MS_P#HV@"K\4/^1CT[
M_=D_]%M7KGAW_D6]-_Z]X_\ T$5Y1\4D_P"*ATS_ 'G_ /1;5ZKX:;?X<TSV
MA'\J -@=_K2TBGBEH *K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ IN
M:=3: .;\=?\ (J7GT7^=<;X$.(;[_>)_\=%=EXZQ_P (I>?1?YUQ_@-08-0P
M>A/_ *"* .5\.'_BZ]S_ -A!*^@*^?\ PX/^+L77_80CKZ H **** "BBB@
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MSP>_6@!OQ//_ !/=*_WW_P#0&KT[PE_R*=C_ -<OZFO+OB?_ ,AS2?\ ??\
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M=8O+>XO+VU2>W=R(+:3S"V5(&1QZU[7X75D\,V <$,(@"/K0!M+WIU-3O3J
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MZ#_A(O!__02MO^_@I?\ A(O!_P#T$;7_ +^"@#GO^%A>(O\ H,:=_P!^6_\
MB*/^$_\ $9Z:QIW_ 'X/_P 170_\)#X-_P"@C:_]_!2?\)%X.'34+;_OX* .
M?_X3_P 2?]!G3O\ OP?_ (BE'C[Q'G_D,:=_WX/_ ,16_P#\)'X._P"@C:_]
M_!2CQ'X.S_R$;7_OX* ,'_A/O$?_ $&-._[\M_\ $4W_ (3[Q)_T&=._[\'_
M .(KH?\ A)?!W_00MO\ OL4[_A)O!O\ T$+;_OL4 <X?'WB0?\QG3O\ OP?_
M (BD_P"$_P#$G_09T[_OP?\ XBNB;Q)X.)XU"V_[^"F_\)'X._Z"-M_W\% '
M/_\ "?\ B3_H,Z=_WX/_ ,13_P#A/O$?_08T[_ORW_Q%;O\ PD?@[_H(VO\
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MO?\ "0^#/^?^S_(4?\)#X,_Y_P"U_P"^A0!@_P#"?>(?^@K;?^ X_P#B:/\
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M"UO_ . P_P#B:W?^$F\$_P#01M/^^A2_\)+X._Z"-M^8H P?^$_U\==8M_\
MP&'_ ,32CQ]KQ./[8M__  &'_P 36Y_PDW@L?>U&TS[D4J^)_!>?EU"T)^HH
M P_^$]U[_H,6_P#X##_XFC_A/]=_Z#%O_P" P_\ B:WO^$G\&_\ /_:_F*3_
M (2CP3_T$;3\Q0!A?\)_KO\ T&+?_P !A_\ $T?\)_KO_07M_P#P&'_Q-;P\
M3>"R,B_M?S%,D\3>"@!F_M/S% &(/'VNYYU>W_\  8?_ !-+_P )]KG_ $&(
M/_ 8?_$UL+XG\$[N+^T'_ A4G_"3>"_^@C:?]]"@##_X3[7/^@Q!_P" P_\
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M&'_+;2O_  %;_P"+I?\ A3S?\]M*_P# 5O\ XNO7** /(_\ A33?\]M*_P#
M5_\ XNC_ (4TW_/;2O\ P%?_ .+KURB@#R/_ (4TW_/;2O\ P%?_ .+H_P"%
M--_SVTK_ ,!7_P#BZ]<HH \C_P"%--_SVTK_ ,!7_P#BZ/\ A33?\]M*_P#
M5_\ XNO7** /(_\ A33?\]M*_P# 5_\ XND_X4XP_P"6VE?^ K?_ !=>NT4
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M74G/G:?_ ,"MF/\ [-7KU% 'D'_"EU'6;3?_  %?_P"*I?\ A3*?\]M-_P#
M5O\ XJO7J* /(O\ A3:?\]['_OR?_BJ/^%-I_P ]['_OR?\ XJO7,#THP/2@
M#R0?!Q/^>UC_ -^3_P#%4I^#D>TYEL2/0V[$'_QZO6L"EH \[T'X?3Z/?6<I
MO[86ULYD6"" ISQZD^E>@1_ZM<YZ?Q=:?@>E0RNJ!WP=RB@"OJ%E;:A%]GNH
M?.C8?ZMA\I^M<I+\.M*65W@N=0MX7/SPP3*$!^A4G]:Z.#46,T*MSOS^%3W=
MSY+$(H)QGGI0!FZ3X=TW0UVV4*B1@=\V/F?ZMTK?7.Q<C!QSS67+J?EQ.2B?
M*B-C_>Q_C6I&=T:MZ@&@!PZ4M%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_
MD: +-%%% !1110!&\:N,'H00?QIBVD"'(C7/7D5/10!#]GA P(T'.?NBG-!&
MZ!64$#I4E% $1MH2V[RUR/:AH(G(+(IQTR,U+10! ;:$N&,:$CH=HXJ;'7GK
M2T4 ':BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "F% 3SR",8I]% $"VD*L"$ (Z4[
MR$+;B 3[BI:* (#;Q%B61#D8(*BI@   .@I:* "BBB@ JM>?\>-Q_P!<F_D:
MLU6O/^/&X_ZY-_(T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_
M (\;C_KDW\C0!9HKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\
MA([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([
MS_GG!_WR?\: .JHKE?\ A([S_GG!_P!\G_&C_A([S_GG!_WR?\: .JJM>?\
H'C<?]<F_D:Y[_A([S_GG!_WR?\:AN_$=Y]BN/W<'^K;^$^GUH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>inmune_ex31img25.jpg
<TEXT>
begin 644 inmune_ex31img25.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JM>?\ 'C<?]<F_D:LU6O/^/&X_ZY-_(T 6:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!9HHHH **** "BBB@
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M_A?/@7_G]N__  %:C_A?/@7_ )_;O_P%:@#TVBO,O^%\^!?^?V[_ / 5J/\
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M*** "JUY_P >-Q_UR;^1JS5:\_X\;C_KDW\C0!9HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F3]H[_ )'C3?\ L'K_
M .C'KK+/]GCP]<V=O.VL:H&EC5R!Y> 2,_W:Y/\ :._Y'C3?^P>O_HQZ^C]*
M_P"0/8_]>\?_ *"* /(O^&;O#O\ T&M4_P#(?_Q-'_#-WAW_ *#6J?\ D/\
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M 4444 ?,G[1O_(\:;_V#U_\ 1CU]':5_R!['_KWC_P#017SC^T;_ ,CQIO\
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M8[G^=>C>,9$E\9?#QT(*E(,$?[U7%:KR?Z$2>C\TSW3^'\*\@^$7_(Y^,_\
MKX3_ -FKU[^#\*^9]'^)$7@#QGXE,FFO>_:K@8VS!-N,^Q]:E-<_R8[-PT[H
M]_\ %L[6OA74YU2-V2!B%D0,I^H/6O*-.^(=YH7P>M-6@LK-+NXNF@C6&$11
M)UYV@8[5?L_BM#X\\.Z_9QZ2]F8;-GW-.'S^@K&\,SV\'P-MS>Z"^L69N7\U
M(WPT0_O]#T_K4M-)_+\RE9\OJ_R-SPSXK^()U*P?4H++5],N_O2:<!F$>K<"
MN4UZ/Q:?CG"+::R&I')M68?((MO\7'7;^M8D']C'Q3I1^',VK_:FE!N8Y0<(
MN>>W2NT\97\?AGXTZ/K>IK(+1H K.B$_-LV\?C6FET]M6OP(=[27DOS/:K7S
MQ:0BY*F<1KYA7H6QSC\:\A\3>,?'MOJ-_+:+I^CZ=:Y\O[>!NG '5>#7KJ3_
M &FP6>#/[V+?'D8ZC(KYBBGTMM;\00>*-/OK[7Y976SBVE@>R\8K-M\S]#2-
MN6_H>B+\3]7O?A%=>([<0PZE;3B%FVAD;ISC\:R+GQ[\2+?PM:>*9(-/32FV
MADV_O)/]KIP/\*YS3)$_X4#KL&-DD>H?-&>J\+7;>)O^3>+7_KW3^M4]+M=+
M?BB5K9/K?\#8\8?$B\TSPQHD^DVJOJFL*# C<A>F?KU%><>/KCQI]LT"W\6Q
M6C,;@/%/;<#J/E(P.:T_$%E?6W@GP+XEMK=YX=,C#3*@R0#CG]#5/X@_$"Q\
M9W7A]=*MKC[+'<J7FEC*C?D?*/7O3LE+3O\ <A7?+KV_$^C4_P!6/I7S!XLM
MM.L?B?J<GC:VOI[&<EH'MV((7MC\.*^GESY0QUQQ7@_BGX@ZIH.N7VF^,?#%
MMJ6G;R+4JGE@KV^8YSQ4/XT_4</@MZ&C\.M#\-Q:K?:EX+\02LSV[!=.G494
MXX+')SSCM7.?#:/Q7_PLO6/LTUF&68?VEN'WEW?P<=:A^&UM+KOQ+AUO0=&?
M2M(B5O,4'<GW2,9P >:V?"FL0>%_BWXBL;]9DN-18):XC)#,<8_#WJ]5)/R>
MA+U37FM31\3^,_'UM?7\]LNGZ/IUKGRQ?@;Y@.Z\&LCQ3XJUGQI\&CJ2+;Q+
M'.T5\/[X !!7CW-<Q;2:6^I^((O$NG7U_P"(I97%I$5+ _W>,<5M>'+=[[X
MZY:P1L9XKIV:(#)&%':IMH[]$G^)=]5;NU^!T7A[Q1K?@SX4)J>K?99XF1(]
M+BBX/.?O\?3UI(?'OC?P]/IM_P"*$L)=)OW";;? DASTW<=:PKV6/QG\$[6R
MTB.XFNM',?VF(1D9ZYQZ]*P].L/ ^JW>G66EZ5KU_J4K#SXC<[%A(ZG)0Y%4
M[N3]5]Q*LHKT?WGH_P"T(ZR?#NS93D-J$9!_X ]:OP(_Y)78?]=Y_P#T,UC_
M !]@6U^'&GP)G:E]&HR<G 1ZV/@3_P DLL/^N\__ *&:':^@*]M3TNBBBD,*
M*** "JUY_P >-Q_UR;^1JS5:\_X\;C_KDW\C0!9HHHH **** "BBB@!#T-?-
M>J12:AXKU1T)WF=F%?2AZ&OFW4(A!XQU2%V*!)F&=Q'3Z4 8ETSVNH%6N&C<
M(2"4))/''->@>!KE%E2%>\>VN#NV U!W6>)5>(@LP+ Y(.!D9SQ6[ILMQ8W%
MA>6S".)AE\C.X^@_#/Y4 >P7D1OM/587*26QWGU*]\55EGL6M$CMFS< @ERP
MS6>WB2SM]C(QE8CYD0'H>#UK!U+2K6-GO;2[EDMRP=E4L&CR>ASQC- '27&J
M2[2LXDVJ=I*IT^O%5)C;LES+%+)O2+S"I7C'/M[5S%Q93W*M&][=@J_\#=]H
M;G\,5-(TVDZ+<2.TKQS*(PTOWF)_PS0!LVVM:=,R%KF54(RP9>#[=*AUJ^AO
M&C:*=#$!G (&*HZ'H=K=6<"S3;IP3O13]WVJ/6]%CL'D^SER@&<$=10!PFKF
M-=4<"5F"RL0N/E )]?PJ;49[9X/]'B2,J^05!Y'/K5:\?S9O+252ID),>WD8
M[YQ[U8U&&)( J(JL3@%226'J<]* /H?PI+YWA/27SD_9(P?KM%'B6RO]2T*Z
ML]+O$L[N9=J3NI(7UZ>V:/"49A\(Z2IZ_9(R?^^13O$>M0>'-"NM5N 62!<[
M1U8DX _,BI=K:C5[JQPEG\,]07PI/HEU=Z<',BSQW,$3AVE5@P9]Q.1QVJ*;
MX::\^B:C##KMM%J&I2JUU,L;;2@50% ZCI^M=%HVO^*9[BQFU#1;8:==QF3S
M;:0EX!@D;PQ],=,]:O'QYX:%S- VJ*LD*-)(CPR+A5ZGE><8/2J?6_\ 5A)]
MAWA?0[S1?#_]FW1L0$!6/['&RKC'4[B237G][\$3=^'+6S&H6Z:C!<O+]H$9
MVLC8^4CKV_6NX'Q(\)&WCG&KJ8Y6VQD02Y<^PVY-7;OQCH%A:6]U=:B(XKCF
M+,3EF_X"!G]*3^+F>^@+161QU]\-=1>75(+/5+>/3]5=7NEDC)D!&?NGH.O>
MK4/PWDM]'\2Z?%?1;=593"Q0YC"D_>]?PK=G\?\ A:U6W:;5X@+A#)%MC=MR
MCJ> ?6M+_A(-.;P^^N6\XGL5B,HD3/S#\:'HG?8$M5;Y'%VWPVU+S+N:\U"R
M:2;3%L%\J)@%V[<-R?\ 9K?@\'(WP_3PO?3"3$ B,J#'(P01GW K+TKQ7XIU
M2&QU1-"MWTN\;@1R'SHTZAV!.W'3IGK5.[^*EGIM]#:SS6=P9+QH'>V64B%5
MS][*\MQCC--Z^Z^HEI[RZ&EIWAKQ;#]FMKKQ%"ME:PM%&MK$0\G!"ERV1QQT
MQTKF8_A-K+ZM]OO-9M)I1%-$9-C[W#@@$Y..,]@.E=_#XT\/3PVDT>IQLMY*
M88,(V7<'!&,9'3O5SQ%J4FC>'K_48HUD>V@>548\,0"<&E)V3;'%7T1R%QX!
MNF\)Z7HR_P!EW$MFK S7,<G!))RNQ@1^-5;;X;ZOIW]F7=EK$+ZG9QO$SW*,
M\;*W8#KQ]:I:3\8_[6L]$:*SMUNKR]%K=1%C^Z!(^9?S[^E=LGCCPY)>R6::
MK&T\>0RA'QD=0#C!/T--K6[$GT.5T;X5S:3J-G=#48I/*@E24%#\SOMY'H.*
MZ/PAX5N?#/@P:&]\KSC>1/$N,9Z8!JX/&?AYH[1UU2-EO 3!M1B7QC/ &1U'
M6F6OCGPY>1W)AU5/]&3?,'C="B^N& -#V:'UN<?:?#'4W\16>J:IJEI*UJK@
M200E))MPP-_8XSV I-*^&6IV5YI?VC4K22VT^\EN$5(F#,K[N"3QG+?I6M9?
M$K3[_P 5S6%LZ2:7%9_:&N1')OSE1C:1G'/I73:-XET?Q 9O[+O5G:$XD78R
M%?J& -&MD)V=TSA+3X2I;:[=7$JV%W9W%RUP#.)?.C)Y^4JP7KZBGZ#\*4TC
M4WDF73KFW$KR12LLOGH3T_BV\'VJ'5OBO>:=XDN+*/2X7M+>Z6W92Q\]L@'<
MJ],<U)H_Q/N]2U6UMYK2RCBO99(8%#MYL;+G'F#L"1VHAJE;L-Z-\QU'@CP[
M?^&-*FT^[NK>XC\YI(FB1@0&.<-FNLKS1_'>O6?B2]TZ]L],DMK"V:YNIK1Y
M"8P 2%^8#DX_6F:+\3KF>[\O6-.BACFLC>6QMMSLR@L,$>O';UHYN;4+6/3J
M*XWP#XPG\9:9=WDUF+7R;AHE0$YP/7WJEXY^(">%=1TVQM[=+F[NY0K!B<1K
MZG'?T_&BVJ7<.C?8] HKS3Q%X[UWPY?F6\T>WBTLW0MX]\A,\PP?G4 XQQW]
M:BTKXHW-YK=JESI\,6E7MQ+!;S(Q,F4W<L.G.T]*%KL#TW/3Z*X7PSX\?Q'X
MRU71DL3!;V48=)'R'?D#IZ<UW/:CHF'6Q\S?M'?\CQIO_8/7_P!&/7T3I\,4
M^AV231I(AMX\JZ@C[HKYV_:-_P"1XTW_ +!Z_P#HQZ^C]*_Y ]C_ ->\?_H(
MH <UG;.B(UO$RI]Q2@POT]*?+;P3!?.ACDV]-Z@X_.I37BWB[XRZYX?\6WFB
M:?H5O>+;GALN6(^@I7UL.VA[$;:!IEF:&,RKT<H-P_&D>TMI91+)!$\@Z.R
MD?C7D'A3XUWNJ>(K?2]>T06'VEML4BAAS[[OZ5Z_]KMA<" W$0F/(C+C<?PZ
MU5FDF3=7L*EM!'(TB01J[_>94 )^IIHL+-79Q:P!FX8B,9/UIQNK=;@0&XB$
MQY$9<;C^'6HYM1LK=_+GO;>*3^Z\JJ?R)I#'&RM3$(C;0F,'(3RQ@?A5@  8
M   Z 5C>(M4O;#P_<7VE6\5Y<HNZ.-Y JM_P+('ZTFB:S+=:'9WFL+;V-U.N
M7B\Y2H.>@.>:%K<'I8TI;"SG?S);2"1SU+Q@G]:$TZRC8/%9VZ,.C+$H/\J1
M=1LGE\E+NW:7_GF)5+?EFI9[F"V3?/-'$G]Z1PH_6@!L5M!!N\J&./=][8@&
M?K3!I]D'\P6=N).NX1+G\\5+#<07,?F031RI_>C8,/S%0MJ=A&_E/>VRR9QL
M:50?RS0!--##,FV:))%]'4$?K38K2W@;=#!%&Q&"40#BI))8XXS)(ZH@&2S'
M _.H8+^SNF*V]W!,PZB.0,?TH =':V\+L\4,<;M]YE0 GZTZ6&*9-DT22(?X
M74$?K4E</H/CBZU?X@:WX<ELX8X=/"E)58[GR,\]J2U=OZT!Z*YV L[8,C"W
MA#1\(0@ROT]*<T$$DJRO#&TB_=<J"1]#1<R/%;R21J&=5)52< FN?\&ZWJ^M
MZ9-<:QIT%C,DI14AF$@*CH<@FFM6_('HCH%MH$F:9(8UD;[SA "?QIPMX$E:
M988UD;JX4 G\:A74K%Y?)2]MFEZ;!*I;\LU-/<06\?F3S1Q)_>D8*/UH 8UE
M:-+YK6T!D_OF,9_.ECM;>)&2."-%;[RJ@ /UI8;F"XB\R">*5!_$CAA^8J#^
MU-/"%C?6H53M)\Y< ^G6@!PTRQ",@L[<*WWE$2X/Z5*;2W9HV:WB)C^X2@^7
MZ>E+'-%+%YL<J-&1G>K C\ZA34["5_*CO;9Y,XV+*I/Y9H NU2;3+!F+/8VS
M,>I,2DG]*FFFBMXS)-*D:#JSL !^)IL%U;W2EK>>*91U,;AA^E #(["SB#".
MU@3<,-MC R*D2V@CA\E(8UB_N*@"_E4M>7_$CXJ3>"M7M;"RLH;QY$+S[V8&
M,9&.GUI-JZ7<:39Z1%96D#[X;6"-O5(P#^E.GM;>X(,]O%*5Z%T#8_.J>B:O
M#K6BV>I0D".XB63&>F1G%3?VKIP5F-_:A5.TGSEP#Z=:;33LR4[JZ+@
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MZUG?$_6XG\<V&@^(;F]ETFV@5KA+,?-,Q'7&16H/ WQ*N+"S\/W%_9QZ3:R
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MR.#DGY@<\&J=G*_6WXBLU&WF6_#E]=V_@WQOX;FN'GM]/#B L<[5SC%)X?\
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MT=_R/&F_]@]?_1CU);_M$:W;6L,"Z'IY6)%0$N_.!CUH ^EZ*^;/^&DM=_Z
M6G?]]O\ XT?\-):[_P! +3O^^W_QH ^DZ*^;/^&DM=_Z 6G?]]O_ (T?\-):
M[_T M._[[?\ QH ^DZ*^;/\ AI+7?^@%IW_?;_XT?\-):[_T M._[[?_ !H
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MX[5\S:U>Z??:KJEW:P:FBR,7LU,.-A9LOGGCJU?4]U<I:6LEQ(&*1*68*,G
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M")_A1_PAGA?_ *%[2_\ P$3_  K=HH PO^$,\+_]"]I?_@(G^%'_  AGA?\
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M Z?X4?V)I/\ T"[+_P !T_PHZ6*OK<\ M]7\&QZ'=6+ZE:)/)&L:7,.GSA\
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M_M[">]ABN[@9AA9L,_T%.CU2PFU&73X[N)KR)0TD ;YE!Z$B@#S7_A36I?\
M10O$'_?P_P#Q5'_"FM2_Z*%X@_[^'_XJO6:KW%Q#:V\D]Q(L<48W.[' 4>M
M'EW_  IK4O\ HH7B#_OX?_BJ/^%-:E_T4+Q!_P!_#_\ %5Z*/$&D'2/[7&HV
MYT\#/VG>-GYU;M[B&[MX[BWD66&10R.IR&![B@#R_P#X4UJ7_10O$'_?P_\
MQ5'_  IK4O\ HH7B#_OX?_BJ]9HH \F_X4UJ7_10O$'_ '\/_P 51_PIK4O^
MBA>(/^_A_P#BJ]9HH \F_P"%-:E_T4+Q!_W\/_Q5'_"FM2_Z*%X@_P"_A_\
MBJ]9HH \F_X4UJ7_ $4+Q!_W\/\ \51_PIK4O^BA>(/^_A_^*KUFB@#R;_A3
M6I?]%"\0?]_#_P#%4?\ "FM2_P"BA>(/^_A_^*KUFB@#R;_A36I?]%"\0?\
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MU&-V\_P[8VTLH7J<E2V?P-=;X)-[XON/%6NZ=>&TN+S;;V]SMSLPBG('U)K
MM?&^FP76MW#>$/$LS:N-LH>!<(NT+A>/:L^Q\1:=IOAV+1;3PYXLBA2Z%R72
M,*SD$':<#IQBG'9I_P!-[B?2W3\EL?0FG03VVG00W-P;B=$ >8CESZU8EB2:
M)HI%#(XPP/<5SW@[Q./%.B-?#3;S3Q'*8?*O%PYP =WTY_2NEH>NX(\'/A^[
M7Q^W@(2C^P#)_:/EYY"Y^[].:ZB\O-6UOQ5K.F6&J7&EVNCVX,:6^!YC=?FR
M#QQ^M=9_PBEK_P )O_PD_GS?:/LWV?RN-F,]?7-4]9\#0:IJDFH6VIWFFSS1
M^5<&V"XF7T.X']*6MDO7[^C&[7;]/^"</I/CG6=7UKP6&NI(H[KSH[J->%E*
M C)_+-=#\.=;U+5=;\4PWUY+/':W[1P*_1%ST%:&H?#K2[FUTF*SN;C3I-,/
M[B:WP6Y&#G<".<U;\)>";7PD^H26][<W3WTWG2M/MX;OC IW5G\R7Y>1YWJV
MM^(I+SQC/#KUY FE.C6\49&WHN0>.G)J]I'B'5].\3:.M[K$]Q;:AI;W<ZW&
M"D3*&Y4#&!\HKK)?AYI\W]O9N[D?VSCS<!?W> !\O'MWIQ^'^FMJ&GW4EQ</
M]BLFLEC.,.C!@2>.OS'I4QNDEY+_ ()6C;^?_ /.X_%FNR>(-'6UU749;759
M7A\V4A8R2< QKC(Q[DUIZ5XKUS6?[ T.+4)DU)+V1-0<8WF--IR?J&K?MOA=
M:6=UIUU_:NH7 TR4RVMNVP*O.=O3IGUJ+P?X4O(/'&M>)K_3S8?:3MM[=W5F
M'7+?*2.>/RJE:Z^\EWL_Z]27XK:OJNDZ=I0TN_EM))[M8G=.I!K ?QCK/AG6
M?%&GRWT^H)9VZRP/<8+*2<=@..:]!\4^%+7Q7%9QW5Q-$+6<3+Y6.2.QS51_
M 6F3>(-4U6>6:4ZC!Y,L+8V >H[YJ4GK\_\ @#=M/E^>OX'('5/$&B7/A]I=
M9N;T:W"0Z28(B<H6!3 X QWS7,2_$;Q#;W&EQ&_D;^SI9%U0_P!X"0H-WYBO
M4-'^'MII6HVUW<:C>:A]C0I:1W&W; /; &>..<U!/\,-&GDUUS-,IU@ 2@!?
MW?S!LKQZBJ;UN"VLR7P!?ZCK6@7NHWMV\J75S+]F.?\ 5QABHQ^6:\GMC>:/
MH'C35+34KI;F'4EB4L5.<E>3QUYQ7O>BZ1;Z'H]KIMKDPVZ!%+=3[GWKEI?A
MEILND:QIQO[L1ZI<BYD8!<H1C@<=..])_'=;6L$?A5^]SSZZ\1W.@>*-<UB,
M>9=+I$)4D?Q$'D_C70^"O$>MW'B&R@9]9O;&[MMT\M[:,BQ2?[#;0-O3UZ5T
MX^'6DMJ%Y=7$L\ZW5HMI)$^-NT C/'.>:L>'O!2:%?K=-J]_?&./RH$G8!8E
MYX 4#/7J<TXZ/43U,[Q=KE]X;\8:/=O=N-)NE>&:(_<5^-K?SKE+/Q)XCNM-
MT:VEU">*;Q!>,T<XZP0CH%]#SW]*ZKXF:)J7B;2X-'L=.>42S*[77F*%A ]0
M3D]>U:NI^#;"_P!!L=/$DEK)8A3;7$.-\1 QD9X_.DEI=]_P*>^G;\>AP6L^
M)]<T&V\3:*-4N)YK$1RV]X^/,"LPR"<8)Y]*FU[Q/K=MXC\/V\.HSI%<:2\T
MJ C#N(\[C[YKKXO &G?V/J=E>7%Q>W&I?\?%Y*0)&P<CH !CV%9D/PIM%O[2
M\N=;U&ZDM;=K:/S GW"NT#@=A1K:S$][H=\*Y-6U+PQ#K.K:M=WDUQN BD8;
M% 8@$#'7CUKBO$NI7ND>,?'-[I]P]O<QVL.R1.H^[7KOACP_!X8T&WTFVFDF
MB@SAY,;CDD]OK6#JWPXT[5[_ %BZFO;I&U6-(Y50+A N,8X]N].6LFUM8(:+
MWN_ZG)Z=KFNZ;XD\/PW&L75Y%JE@TLT<Q!57PV"O''05@++J.O:?X9GN]6O5
MD?6GA#1LJ[0&7!''49KU-O %@^IZ1>F\N=^F6YMXUPN''/)XZ\U2_P"%9:>N
MA6^FPZC>126UV;N&Z4+O1R0>A&,<#M0FM_,6NWE^)@VOB>]L-8\<+=:LT<-B
MJ""25-_ED[NPP2>*Y^+Q-K3ZKJ>CW5U?SV-QI33H+Y@6!XY& , YZ&O0S\-M
M.?\ MLW-Y=7#:NJB8N%&TKG!&!UYJG;_  JM([]KVXUG4+JX:T:TW2!!\AQC
MH.V*&K[]K#3MKYF%X)D%WI/@NQ)_=VUJU[)STV@*,_\ ?=<EK&KVU_XCU#QE
M'J5M'>:?J"1P0/,H=X1E&PN<GL:]=T7P%9Z'9M;07]R^;06B.X7*+C!(XZG%
M/LOA]H=EX6;0O)69&0JUS)&IE)/?..M-OWKH2^&S_I'*:WKFK:G\0=-L-/UF
MYL]/NM.-R5@(Z[-P(R*Y=_&WB6YT#1XDU:>*=M9-E)."-TB;L<UZ/I?PVLM,
MU*QOCJ=[<2V=LULGF;>5(QS@=A5:/X3:5'!:Q#4+PBWU WZG"\OG.T\=*%9-
M=@UMY_\  .0NO%.OZ6?&FF?VO=3-IT:26]Q(070L 2,XZ5M77BC5K?Q'X/C?
M4I4MKJU\RZ!(PY]372-\/-+FU+7;V::X<ZQ$(IHSC:F!C*\9_.J=K\++*#4;
M"\N=8O[PV*&.*.8)MV'^'@"I5]+E:?U\CC8_&>L1^)-$N8-1OKJQO[QH)#+A
M8'&1]Q",C&>N375?"/FTUX_]1!Z?!\*[&*ZL'.K7[PV%QY]M P3;&2>1TSC@
M=:Z7PQX8MO"\5Y';SS2BZG,S>9C@GL,4]$OD_P!"7=OYG+>!A_Q<3QG_ -?"
M?^S5#KVLZU!\2I+'3I2X_LUY(X,#!?Y<'U[FM=_ $T6NZAJVF^)=2TZ6_??,
MD,<3+GG'WE/K4O\ P@=O+K":I?:G>W=T+4VS,^U=P..?E P>.U+HO)6_ ?5O
MNT<!X4\4ZI=ZPNEZOJ^IVEY/!(LMK>QGYGP3F)L *..^:Z?X/6TD/AR\F>]N
M9MUY,NR5@0,.1D<=3BM33/AW:V>I6U]>:E>:BUJI6V2X"#R@01U4 G@XY)K2
M\,>%(O"TEXMK?W,MM<RM*+>0+MB9CDX(&?S-4FOP):?XGG'CSQCJMK>ZM<Z1
MJUZW]G2QJ4@&R"/[N5?(.XG/8CK3#K_B'6?$>M1IKEY:6]MIBW21P$##[">X
M/&177:S\*M.U>?4F_M.]MK?4&#SVT0387&,-R,]AWJY9_#C3[._O[M+VZ9KR
MS%HZD+A5"XR..M0E[MNI;:N<58^+]:U^V\)Z6-0GM);\M]JNH>'8*0."<BM3
MX4P26OBKQC#+,9G2Z0&1CDM][DULK\,["/2-,LK;4;RWN-.D+V]X@7S!G&1@
MC';TK3\*>";;PI=:C<PWUS=2W[AY6GV\$9Z8'O5)J[9#3LEZ'G'Q&LO$>@>,
MYO$UGIZ:IID\ AFA="X5>_ Z?6JMW>6'B#3?!EUHYN=+MFO3$;:&3B-@#DC(
MZ\5Z9K/@?^T]5FO[76M1T]KA-D\<)5TD'T<''X8JM/\ #?26T+3=*M)KBS^P
MR^=%/%@ONP<DY!'.:4=$K]&6]W;JCB_&?BS5+.ZU*;2=7OYO[-DCC8182%.0
M"'R#N)]B*+:\N;?QWJVN-?7C21:*EWY0<;6+(IVD8^Z"?TKJ-0^%EEJ$EZK:
MO?QPWI5[B) FUY!_&>,Y/Y<UI?\ " 67]K0W\=]=1XLQ9SQ *5N(PH7YLC(Z
M#IBDDTO,3:;\CB?"7BW7;S4M'N0VLWT5\S"\2:T<00@D[2C;<8''<UK_ !<,
MBWGA-HK<7$@U)2L)8+O.5XR>!6_HW@*WT:]AF&JW\]M;;OLUH[ 1Q9)/&T G
MKW)JWXK\)0^*OL.^^N;*6RE\Z*6 *2&XQ]X$=JIVNFNCN)7N[]CAWN[N'XK6
MEQJ.F_V-))8,D$<4JR"5N>I48[UF3^+O$"_"VQU)=4N!>OJGDM-D;BF1QTZ5
MZ)IW@=;?6DU;5-9O=6NHHS'";E441@]<! *PY_A%836IL_[9U%;,7/VF.V 3
M;&W?'&>>.II=5<;U.7UWQ;X@TOQ3<KJE[J6FP><GV658R]JT??< ,D].A%6/
M$WBO6+?6_%1LM3=(X-.CEMVC PK$CD5V&H_#BUU&[F9]6OELIW#RV7R,C$>[
M L/P(IVI?#72]1N=4G-U<PC4+9;9D0+B-5((QD>W>FMD#W^XXNT\4:]HFL^&
M'N=6NKZ+4]/:>>*8@J&";AMP*JZ#XY\17\UCJEN=7O)+B]>.>U^RN;:.+) *
ML!C(XSSZUZ$WP\TY[_0KI[FX8Z/;FWC0A<2+MV_-QZ>E1Z?\.K.PU".2+4[_
M .P13-/%IX8+$C-G/(^8]3P33NK_ 'DV=K>AP3^+_$%AXP,.M7^H:8S7P6(2
M0E[5XB<   9R?7/6G^(O%_B'2_%5W_:5]J.FVOG(;2:.(O:M'QG< ,DGGN*[
MB?X;6=S?^9-JM])8^>+C["^UD# YX8C=C/.,T[4?AM9ZC=3$ZI?1V,[J\MC\
MKQL1CNP+#IV(I1TM?H6]6RWXSE$WPUU:8.) ^GNV\# ;*=:?\/R1\.M((ZBV
M_P :U=3T2WU+PY<:*6>&WF@,&Y.JJ1CC-8.C>"+_ $6*UMH?%NJO9V_"VS10
M[2OH3LS^M)]4NMA=%Y7.!T;Q;KEYHFF:8NH2QW&I:K+ UVH&Z-%QP.,9YK;\
M7:GK_@K0/)DU>>\:\O%B@N!&6FBC.<YQPS=.@K<A^&>F0: NF1WEVLD=TUU#
M=C;YD3GTXQ^8J5OAW9W.EW%G?:E>W=Q/,)S=2L/,1QG!4#Y1U/:F_P#(?7[S
M@M3\6^(K/P[K<=O<:PD4+QM:7]];M%*03@J<J,]?2M*SUSQ'IOBRSTU=2N-1
M-_I7VA8YR,++L!^7 '>NHG^'-M>Z+>6%_K&H74MVZO)=2%=W!R % VC\JGF\
M!6$VMV6J/<W.ZUM/LBQ@@!EV[<DCG/TH7]?=_F)GGWA?QMJUOX@C@UO4-2M[
ML)*9K.^B)CD(#$",@#;P!US3='\;>(+V\MM2MWU>Z>6_\J:T%HYMDAW;<A@.
MH'/6N\L/AS:VVIV]W>:E>:A';%C;P7"IB/.1]X ,>#W)I;7X=VEEJ:SQ:G?B
MQ2<W":>'"Q*YYSD#<>><$XIQ:NFQ2V=CMU.Y V",C.#3Z**0PHHHH **** "
MBBB@ HHHH *K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ HHHH ****
M"BBB@ HHHH @EFB@7=-(D:^KL *8;JV$8D,\01N Q<8/XUYUXS2/4?B%H&DZ
ML VBRQN[12'Y)) #@$=#7FVN;VTJXTZ,EM)@UY([;!X4$C*K[9S23O;S&U8^
M@M2UJSTW2[N_:0316L;22+$P9L 9]:H:7XIAU46+Q6=R+>\@,ZSL4"H 3PWS
M9SQV%>1W-O#I'B+Q?IUC&L%H^D;VB084MY?7'K5>+_C\T+_L7)__ &I2OHV%
MNA[^E[;2.$2YA9CT59 2:4W5NLPA:>(2'HA<9_*OG;3[2WTWPYX)U2TC6._E
MU!D><#YF7*_+GT]O>GD:OJ=QK.HRQ:=!J$-^JKJ-W=^7)!CHJC:>#SWJ[:V)
MOH?1;,JC<QP!U-4KC5K&VLY[N2ZB\F!2SLK@X%<[XVU,Z9X%N;FZB>9FC5&6
M&3;DG_:QTKR"TL_LWB36M-D@LUMI]'\Y[:W0",-\N"1W/O47>MNA2M9/N>_Z
M/K%GKFE0ZC9R!K>5=RDD=/>K7VB#"GSH\,<*=PY/M7'?#6QLE^&^GI;0Q1B>
MW_>^6 -S$<D^]>4Z@VH0WS:?%YH3P]=-=$>J&4D?HU5*RERDQNXW/HC[1"7\
ML31E^FW<,_E2"Y@VEO.CV@X)W# /I7AK+-8^%X/'0$GGR7[3,>^QOD'Z51T&
M"]EU6U\/7/FE-3O%U!@1_ &!_P#9:$M;=0;5K]#Z -Q!M#>='M8X!W#!-2"1
M&<J&!9>H!Y%?.^N)>VMY<^'K3S0NCW$M\I'= JD#\P:]#\ ZG9IIU]XCU*Y6
MV_M.ZV1F9L9  P!^9IZ-70W=.QW[7=L"5:XA# X(,@X-2>;$7*"12P&2 PR!
M7A-[IUI=-\0KR:%9)K>8/"Q&=ARW(]ZM7VH7F@6&B>(UW2?VCI@M9F]9"%VD
M_D:E;7]/Q&UK8]G-Y; !C<PA3P"9!S52[U7[+<V\0M9YUGS^\B*[4P"><D'M
MVS7C6H>%+NQM-)CMC97\L=H9KC3KEOG!8 LZC!YR>M6$OH[]O!DD<,T(22:,
MI-(7(*AQU].*JWYV)Z7\CU70O%%CXAAGDM@\?DSM 5EP"S*><<UL>?""X\V,
M;/O#</E^OI7A5A;RP>&;C7;=29=,UEY6QU*%\-^A-,O#?R^$[CQ$B$MK6H*)
M-S;08054*3V!P<T/_+\1_P#!_ ]U%S 8O-$\1C'5]XQ^=8FO>+].\/Q6[2EK
MJ6XD\N*&W92S'\2!7D6M6MY9^'?$,&-/MK0I$WV&TN?,\IO7&T8SQ6YXC\,:
M-:)X-6/3K;-Q<J)V\L9ESM^]ZTK7:]5^(=/D_P #T'1/%UGK-Y?6J0S6\ED5
M67[1M R<]P3Z5N?:(58*TR!B,@%AG%>%ZS"L:^.4B0*B7,. HX ^>K7B*>*;
MQEI_E2*^-);.#[+3>UT"6MCVH7UJ>ES">,_ZP4JW$#QF59HS&.KAA@?C7@5C
MI%B-.\%2"!1)=N4G8#F1<$X/J.*;<W%[8:5K.G:<@%C_ &V(6@#;4$>3\OL"
M<4FK.P+57/H".:*9=T4B2+ZHP(HDN(82!)*D9/0,P&:\W\'R_P!@:KJ[WTNE
MZ=IB1HQM;>ZWK QVC)^48S_6J.I)::WX^U8:MLELX=.\VQ+G*@%2=R^_6E)V
M".IZM]H@\KS?.C\L?Q[AC\Z:+FW,?F">(IG&[>,9^M>&Z*QD\,>';"9O^)3<
MZDZ7&3\KC(P&]JT;G1VN[GQ7HNCJ!86T:3VR)]V.8;N%].@INRW!:_UYV/8_
M-C\P1^8N\C(7<,X^E3UY9\/YI/%?B6Z\27"D"V@2UA!Z9YW?TKU*FU82=Q:*
M**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_P!<F_D:LU6O/^/&X_ZY-_(T
M 6:*** "BBB@ HHHH **** "BBB@#,U;0],UV!8-3LHKJ-3D+(.AJJ_A30I-
M/@L'TRW-K;N)(HBO"L#G/UK=HH QI?#.B375Q<RZ9;M-<Q>3,Y'+IC&T^V*8
M/"F@AX6&EV^Z&$V\9V_=C.<J/;D_G6Y10!A#PGH M;2U&EV_D6;^9;IMXC;U
M'Y43^$M!N=474YM+MWO5((F*\Y'2MVBCS JWMC:ZC9R6EY DUO(,/&XX(K(L
M?!WAS3)C+9Z1;0R&,Q%E!SL/4?3BNAHH QK+1++0M-N(=#LX;9F5F2-/NE\'
M&?QKS633/B5+<7=Q)X>\.-+=IY=PY/,B^A^?VKV.BAZ[AL>.R6'Q-ET@:5)H
M'AUK #:("WRXZ_WZ6.P^)D5]#>QZ!X=6Y@B\J*0-RJ>@^?IS7L-%'6X=+'CL
MNF?$R:\GNY/#_AUKBXC\J60MRZ>A^?W-,;2/B2^G0:>WAWPX;2!@T46[Y5([
MCYZ]EHH \:_L;XD;+U?^$<\.;;XYN1N_UOU^>EFTSXEW&G6^GS>'O#KVEN5,
M,1;Y4(Z8^?M7LE% 'C6IZ1\2M:,9U'P]X=N#'PA=NGY/0VD?$EFM"?#OAP_9
M/]1S_J^,<?/[U[+10!XY!IGQ,MK*XLH?#_AU+:Y+--&&X<GKGYZD^P?%#^RA
MI?\ 8/A[["%VB#=\H'_?5>OT4 >*)X=^(<>G2Z>GAGPV+24YDBW<,??YZMW%
ME\4+O[+]HT+P])]D;=!N;_5GU'S^U>P44 >.?V9\2RUZ3X>\.$WO_'S\W^M^
MOS^]4X/"OCVVD62'PMX:1U0H"&Z*>H^_7M]% 'C*Z+\2$CLXU\.>' EF<VXW
M?ZL^WSTHT?XE+#=Q#P[X<$=X^^X7/^L;U/SU[+11N!XM%H/Q$ATV73X_#7AM
M;28@R1;N&(Z9^>J=]X5^)&I7RW5WI6CR".'R8H3*-D8QCY1NZ_C7NE+0]0V/
M$+'PY\2;'01HO]B:%/9!BQ69P223GLPK1TVS^*.D6IMM/T/P];PDY*(W7_Q^
MO7:*'J%CS'PK9_$'2]1M[:?1]#L]*>??<_9C\V#U(^8\UZ?110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAGE+M*1ZDBC2Z^5_U'K9_.WZ'0^(/'VO>&/$&I6$EVMZEO:IY1>%4S*Q(#'
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MHC7)SM(QNP.F,5PFLZK\0[K7O[;TCP5?:9?/%Y,SC,@D7MD8'(P.?:JUS/\
M$"YL+'=X1U5M5LI3+%?R3,[9.<C:1]WDC&:E;*_S&]W^'W'4>+/&GBCPBVIZ
M5+J"7=TL"3VEV8$4X+8(90,=C7/7'Q@\12Z?H$=K<JEZ[@:@QA0@Y; XQQQZ
M5DWUMX^UA+^75/!]_<ZC=JJ?:<%1&JD'"IC^O>LX>&_%ZW-U.G@J_5KB2%QP
M?DV8XZ=\4*Z:N#U6AVO_  L+Q),=6,6NG[;;3A+73TL583# X+;>/SKO?"'B
M35]5\6:WI^HLHBM(XC'$$ *%MV>1UZ"O//"NJ^._"[:@Z> ;RX^V3>:<N5V\
M 8Z'/2J!U'XI6WB?4M7TKPK<VC7^WS(G@\T#;G&"<>IJKI)+R_$6][=_P.RN
M/%]\_C36M/N_%+Z3;VCJMNB6"S;@<YR=I]!4GB?5?$NF7NA+8>*FE@U.41[F
ML8A@8)W#(]JX2UOOBQIVL7^IV/ARXBFORK3AK4."1GD>G4U?UG5OB'KLFBSW
M?@>[^T:;*)6=00)C@CICY>OO22LEZJ_ZCZOYV-OQ?XV\3^'-5UFP@U,3?8]/
MCFCD>W0$N60$XQ_M'BJND?%O4]3U'1(RP0BWF;4(#&,NR(S CTS@'BN<\2Q>
M./$.LZCJ#>";Z WELEN4!+;-K*V<XY^[^M0_V9XL7Q98Z['\/[U#!;>1-""<
M3?N]F<XXXI1O;4';H=]'XOUQM$M_$-WXEL]/BNI28;*:VW1^6&(PSJA8'@UO
M>/\ Q/?Z/X0L]2TV]2W>>:)6G6,2 *Q&2 P]#Z5Y#<6WQ'?1Y=$@\,:C#HDD
MN\VNTLP!.2H?KC/M6_K^J>.-;T.QTL> ;V".SEBD5]Y8ML(..G?%-V:T[K[N
MH=?D_P#@'5WGBV^T_P ,O>6/B(ZQ=7,L=O$9K-85A=N_"C/44:WK_B;P;>6$
M=_JB:C%J,;*C&!$,,@ Z8'(Y[^E<_P"(?$7C7Q)H?]F7/PXODV[6CE28AD8=
M&'RUSSO\1=1NH[C7/"-]?O;Q&.U 4QK$3_%CG)X'Y4I7=[?TAQLK7-W1OB#K
MU[::3)!XB%_JES.%ETLV:( G<AMO;ZTRX^+&NZ;XA\3V=Y.IAMQ*MAB)1AE<
M #ISP>]<\EEXWM]*T>&U\$7T&H:8^8[U<Y93U4C'3@=ZH:CX>\8ZG?O=W'@F
M^,CWC71P#_$22O3Z<^U/>7EJ):+7R_#_ #/;_A7XAU7Q+X3^VZS*)+L3.C$1
MA,8)&,"N\KY_\*:E\1?#\]O9P^$+I+&6[:6X#QYR'8GKCC&?TKZ [4Y6;NB5
M=;BT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>
M?\>-Q_UR;^1JS5:\_P"/&X_ZY-_(T 6:*** "BBB@ HHHH **** "BBFDA02
M2 !R2: '45D_\))H08J=9TX,#@@W29S^=3+JVFM:M=+J%J;=3@RB9=@/IG.*
M -"BLQO$.B+)Y;:QIX?^Z;E,_EFB?7=(M7\NXU6QA?&=LEPBG'T)H TZ*KP3
MQ7,2S02I+$PRKHP93]"*L4 %%122)#&TDCJB*,EF. *HP:]H]S)Y=OJUC+)C
M.U+A&/Y T :=%92^(-%DE$2:O8-(3@(MRA)/IC-22:QID9*2:C:(RMM(:=00
M?3KUH T:*SY]6TZU8K<:A:1,%#$23*N >AY/2DMM;TF[E$-KJEE/*>B17",Q
M_ &@#1HJG-?VEMO\ZZ@B\L;GWR!=H]3GH*L*ZN@=&#*1D$'(- $E%%4_[1LO
MM?V/[9;_ &K&?)\U=_\ WSG- %RBJUQ=6]I'YEQ/%"F<;I'"C/U--M[VVNRX
MMKF&8H</Y<@;:?0XZ4 6Z**@EEC@A:65U2-1EG<X 'N: )Z*@AFBN(EEAD22
M-AE71@0?H14] !15>>>&VA::>5(HE&6>1@JCZDTZ*2.:-9(G5T895E.01[&@
M":BJ1U&R6[%FUY;BZ;I"95WG_@.<U=H **** "BHG=8T9W8*JC)9C@ 5 E_9
MRW @CNX6F*[Q&L@+%?7'7% %RBBB@ HHHH **BDECA0O*ZH@ZLQP*BAN[::1
MXH9XI)(\;T1P2N?4#I0!:HHJK-=V]LT:37$432MMC#N%+GT&>IH M44F>,U2
MCU*RE4-%>6[J6*@K*I!([=>M %ZBJMO=V]Y'YEM<13QYQNB<,,^F11]KMA="
MV-Q$+@C<(BXWD>N.M %JBJPNK?[2;<3Q&=5W&(.-P'KCKBD6[MFN6MEN(FG0
M9:(."RCU(ZT 6J*@EFB@3?+(D:YQN=@!4P((R#D&@!:*** "BJL=W;R^:L=Q
M$YB.) K@[#Z'T_&J@\0:*\HB35[!I"<!!<H23Z8S0!JT444 %%58+NVNMXM[
MB&;RVVOY;AMI]#CH:>\T4;(LDB*SG"AF +'VH GHHHH **0D 9)P!5:WN;>[
MC,EM/',@."T;AAD=N* +5%45U.Q>Z:T2]MFN5ZPK*I<?\!SFKU !1110 45!
M'-%-N\N5'"G:Q5@<'T-45U_1I)Q"FJV#2D[1&MRA8GTQF@#5HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q
M_P!<F_D:LU6O/^/&X_ZY-_(T 6:*** "BBB@ HHHH **** "F$!@00"#P0:?
M10!Y+<:-I?\ PNR&W.FV?DM8EC&8%VD\<XQC-95_X15/B;#X>AG,>B7C?VA)
M:@<;E[?3(SBO8#869U$7QM(3>!=@GV#?CTSUQ0VGVC7R7S6L1ND78LQ0;P/3
M/I273RO_ , 'K?SL>&Z;X9O=?U_Q=IVGVVE+$;E4,]RI\R$;5_U> :N6NG3V
M?Q'U2R2/1;MH+.%&;6#P<9Y7@\U[-;:;964TTUK:0PR3MNE>- "Y]3ZU2OO"
MOA_4[EKF_P!%L+F=NLDL"LQ_$BA:)+L@?7S,7Q+K5YX<^'LNH6-O:-<Q1X5;
M09A0\\KQT%<1=^.?$NFKJEM%K$>H[--%U'=K"@\E^?EP!@_CZ5Z]'IUC!IXL
M(K2%+,+M$"H F/3'2JL'AG0K6VFMK?2+**"<8EC2!0K_ %&.:-VQK9',Q'4Y
M?AE=76JZDU[<7-GYA8Q*@3(Z#:!FN$\(>#M1U?PKHNILNFVEK:0M*);<,+B;
MY",/QCOZU[=]CMOLGV3R(_L^W9Y6T;=OICTI+:PM+2S6SMK:**V5=HB1 % ]
M,4.S;:ZVM\B5>R3\[_,^:]+$Z^&=)AN=/L8-.NM2<'544^?$P<G!..^,5!XN
MM6N=5U6UMY<M)J4,<<F>Y50#FOI+_A'](_L_^S_[-M/L>[?Y'DC9NSG..F<U
M'_PC>A&3=_8]CN#*^?(7[PZ'IU&*?VKE-GC7P]DNM5^(\^GZ_:I+/9V7V>19
MD#!PN=IP?;%=+\(;"R63Q#,MK LL6IR)&XC&Y%VKP#C@5Z0FEZ?'J#ZA'90+
M>2+M><1@.P]">M.LM-LK#S?L=I#;^:V^3RD"[F]3CJ:=[?=^)+VMYK\$>">-
M5N_[>\;"74W*K:)MA95^<?-@#OQ[>M:<?C;Q-X62[TV2Z_M Q:6ES!F%5\L_
M-Z#GH.M>OW?AO1+ZY>YO-(LIYW78TDD*LQ'H21TJ8Z'I1G:8Z=:F5HO)9_*&
M2G]W/I[5*NE8IM.5SAOAWX@\3ZQ<S#5XI9;)H0\=S+Y((;N,1GI]?2N(NK[4
MM#\7>+=6MI_/N(KE(5:2!&\L,3\V<9&,=O6O;M-T+2M'+_V;IUK9^9]_R(@F
M[ZXIW]BZ8QN&:PMRUU_KR8Q^]_WO6F_B378E;-/N>'^+]?U:YM;[1;S4DU:V
MB-O.EXL:KABR_+\H [_I5?P]XBU'0(-773F$+WFK) ]RRAA"I'WL'C\Z]PA\
M+Z#!:M:PZ/8QV[L&:)8%"DCH<8J3_A']%%O/;C2K/R;AMTR>2N)#ZD=Z%HV-
MZJQY#?\ Q!\4:0E_*+Y-0L]-N DETL*@3*RC X&."W;TK,LOB)XPU>"^LKF1
M(Y+:WFN9B]NC!H_++("",5[C'X>T:+36T^/2K-+)SEK=85"$_3I2_P!@Z0'G
M<:;:AIX_*E/E#YTQC:?48[4M;-!UN>/0>+?%%Q%;Q6.J1V4<6C&]98[6/!<%
M^ ,8 .T4B_$;Q)J<2NNJPZ8(=+^U9:%6^T2988Y'^R.GK7L*^'](B^YIEHO[
MKR>(1_J^?E^G)X]ZY+Q'\+;'7;R.>UNTL8T@\A8/LJRH@YY0$C:>>HHU;&K6
MU(+GQ!J-Q\%/[<GDBEOGLQ(S/$K*Q_W2,?I7'1>-/%K:7J5W;ZM';P:;:P2"
M!+:/#%NHZ<#Z5[#IGAVPT_PY;Z$T2W%G#$(BLJ@AQ[BGKX?T98981I5F(YE"
MR*(5PX'0'UQ3=KR:Z[$J]DF>%Q:SJEOXHUOQ'',)KI;2&50\"L(]^WH<9 &>
MU=#<>-_$>FV^JP1ZO'J!CT^*ZCNQ"@\EV*94@#!^\>M>K1Z#I4)E\K3K5/-0
M1R;8@-RCH#ZBH[?PUH5I;36MOI%E%!/_ *V-(%"O]1CFCI9#6]V>2W?B/QK:
MZA;VH\3%O,THW[,;2+AMF[:/EZ58T/QYK<5[IS:UJN^TU#3);IBL" P,F\9&
M!S]W//K7JSZ'I4DBR/IULSK%Y(8Q#(3&-OTQVIG_  CVC 1_\2JS_=1F)/W*
M_*ASE1[')X]Z&"\SP[4O&VN:S::_IG]JW,EG]@:>&62&)'( ;(&SL<8]:7_A
M,=9\.7$:6DL%\8]'619#;Q[U)+?Q 9P,=*]KA\)^';82"#0]/C\Q"C[;=1N4
M]0>.E26_AC0K4DV^CV,1*>6=D"CY?[O3I0M!W[GD6K>/O%&D+>6MOK,6H?Z&
MEPMVL"#R6.?EP!@_CZ5U7A#Q#KK^-;K0=7OQ>H+-+E9/*5-I/4< 9%=C#X7T
M"WMY;:'1K&."8YDC6!0K_48YJW'I6GPWIO8K*!+HIY9E6,!BOIGTIW2W(:;/
M,/$7C'78M5U]K?5(]/32F00VC1*QNLG&<D9_*LF?QSXOFMM8U5-2%K#8"!Q:
M>0ASOVY4DC/<UZ]>>']&O[Q+R\TJSN+E/NRRPJS#Z$TZ30=*E2X633K5A<D&
M8&('S,=-WK4Q321;:;.%^)MQ=W?PZL;R*[>U,LEO))L P=Q7K[ G/X5P/V[7
M-#U;Q1K&G:QC[*EMYG[E&$^5C!!XXX/:O?;G2["]L#8W5I#-:$!?)D0%,#H,
M55'AO0TAF@72+(13 "5! N'QTR,<XP*:T;:ZAT2?0\DM?B%XPU7Q ZV,,C1Q
M/$/LP6%4=2%+$EB&SR>E=/\ $DL=:\%,Z[6.I*2/0Y2NT?PSH<EW'=OH]BUQ
M'C9*8%W+CI@X[5;N-.LKUX'N;6&9K=M\)D0$QMZCT-+HO)DZZ^AXW:^-O%<=
MM9ZI<:JLUM-J;69M?(0#:,=\9[U@6.JZKJNL:!<RZDEHOVRY51%;QHB[=O)
M !)SWKWO^P-'\E(?[+M/*23S53R5P'_O?7WJ-O"V@/$D3:-8&-'+JI@7"L>I
M''6A;W'N>2Z=X[NXO!<;C47M-2EN9O*CL[2$"0*>X8!1_.H/ ?B&]\2_$#1]
M2U!@UTUC(CL% R05&<"O7Y/"OA^6W2"31+!X48LJ-;J0">I Q4MGX?T:QF2:
MRTJSMY$!"O%"JD ]<$5479W?]:!+5-(XQ+FWM?C7J#7$\4*G34 ,CA0>5]:R
M]2U_6V\8^)+;0I;(R0V<;V\ACC!).W/SXY[X!.*]&U#PSH6JS^?J&CV5W-C'
MF30*S8^I%-7PMX?CBDC31;!4D4(ZB!<,OH>.E19Z>0[ZM][?@>):YXFU76?#
MWV.\UB_CO;6^@%PLL,*J-S+T,>00,YYKU;Q'K2Z#X.@N)=5EAD941+F*)'9F
M/L?EK43PGX>CLY+--$T];:0AGB%NNUB.A(Q5NXT?3;S3UL+FQMY;-<;8'C!0
M8]NE-_"TNXE\2?D>)Z9\1/%NJ7EGI<>IF&674#;M/)!$7V';C( *YY/2M*'Q
MYXCDL8["745CG.IFTDU$PK\J#N5QMKU*#PMH%F\<EMHUC"\;;T9(%!5O4<=:
M?)X=T66UFMI-)LW@F?S)(S"I5V]2.YIB///APSN?&IDNUNW^U-F=0 ).'YP.
M*\YTP3KX7T^*XT^QATZZU-E;554^?$0Q."<=#BOHRPT73-*B>'3]/MK6.7[Z
M0Q!0WUQ3?["T?^SSI_\ 9MK]C+;S!Y0V;NN<=,T;._DE]PT]&O-_B>3GQOXM
MG\4W%GID<DMM9SI"L($(22/H6+.0V2.>*KZAX_\ $Y%]?+J\5D8=22T73C"A
M;86 )R1FO7'\-:$]W'=/I%BUQ$ $E,"[E X&#CM7&:A\);34-=FU"34CY<UR
MMP\;VP:3*X.T2$Y"\=*6MTF-VL['':?XK\7SV6H3Z;+!&D6HE)S;P0)(4VJ>
M V%8\]3S4^I:_>:OJ?A35(=8N\ R@K/#&I+KUR!\N3P.*]9;PAX<DA\J70["
M1"V\A[=3EL8R>.M3MX<T1X;>%M)LC%;'= A@7$9]5&.*?;R%O?S/)?#WCOQG
MJ,S731R2VI\P2;EA5(<="N#O/OD56D\;>-+?1]#N3JDUPVK.V?*MH08@N. 6
M 7)SW/:O8(O"^@V]R]S#H]C'.X(>18%#,#UR<5)-X>T:XT^.QFTJSDLXSE(&
MA4HOT'2E_P  #RU_%WBRX71],U&<:/)<QS--=,L;^8%VXZ949R>E;'PIO5M?
MAM=7LTJL([B=V?H#R:[B;PSH-Q9164VD64EK#_JX6@4JGT&.*FAT;2[;3GT^
M'3[:.R?.Z!8@$.>N1TIO9VW8=K]#YRTNYU+3_$%CXXDTV\2.ZOW+W+E?*>-]
MVT#G/<=NU=/<?$#Q*V+^/6HHU?5A:"P\E"1'NQG)&>0/UKV:31=-ET]+![&W
M:S3&V QC8N.F!7!M\'[%M;%\=1)A%T+GRC;+OR#D+YF<[1Z41T:71 ]4WU9S
M-GX_\:W^KWDEM;RR007+Q-!MA5$0#[V20Y/?IBI=.\7^*F?0;B[U@20ZM<RV
MQB%N@\L D!LXZBO5SX:T-KXWS:19&[/6<P+O/&.N,]*>N@Z2BVX73K4"W<O"
M!$/W;'DE?0T:628G=['"?"'[0="U1KB_>X8WL@\MP,J>.<]>??TK%^'%GJ":
M%/J$>DZ+<6T5U*WG2(3<Y&.GRX_6O6;'1M,TV2:2RL+>V><YE:*,*7/OCK4M
MG86>G0&"SM8K>,L6*1(%&3U.!0[W;79+[A_YW/(--\>>(I)=(O7U&*X_M":2
M.331"H-N !@Y SQ[UGCQ?XUDT+3M3'B+:U[J#6OE?98L(HSSG;G/%>R0>'-%
MM;][Z#2;.*Z?.Z9(5#G/7)I1H.CBWB@&EV@AB?S(T\E<*WJ!V-'5!T9X[#XZ
M\66D_FW.K+<0V^L?V>\9MT7S5.[YB0.#\O:O9=-24/<F35/MH:3*KM0>2/[O
MR]?QJ)O#NBMN!TJS(:7SSF%>9/[WUY/-7+33[*Q:9K2UA@:9]\IC0+O;U..I
MH6UF#WNB[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 56O/\ CQN/^N3?R-6:K7G_ !XW'_7)OY&@"S1110 4444 %%%% !1110 4
M444 -I:\^A\>75U\1X_#<5B8K/8^Z:9&5W9?[N>WX5Z#WHZ)]Q=6@HJ";S/*
M?RBHDVG:6'&>V?:O.H/%/C&3QI<^'F.B?Z-$)VE$,OS+SP/FZ\4KJY5M+GIM
M%>;>#_BC9:ZL5IJ9^SZE+</"@2%Q$V,='/&>>F:Z"R\<Z!J&L?V7;7;M<%BB
ML8F$;L.H5R-K'GL:JVMB;G4=Z*\]^(?CVY\'W>D0VUK'<?;)")%8$D*,9(P?
M>GZ?X_-[XAUR-E@&CZ;;B03C.YF/;.<5*=U?U_ IJUO,[ZEKQ_3/C!=7FA^(
M[^:QAA:P"O9QLK R(Q 4MD^XZ5ACXYZM)8:6L5A8M?W,VRX3:^V-=Y4=^#TZ
MT+5V$]%<]]HKR[_A/-8N_%&H:7!?^']/BLTC._4"P+LRJ2!\XZ$UVO\ :C:=
MX?2_U21+A@N7>PA>16YXVJ,DBGTN'6QN45Q)^*/A46Z3F[G >4PB,VLF_>,<
M;<9[CM5L?$3PVVB_VJ+R0V_F^2%\A_,+^FS&[]* .IQ17%^#?&<GBN\UL")$
MM;*<) VQD=E.?O!NAX]JQK7QQK.IZWJ]K;:GX<L(+*Z,$:WQ822 $C/WQZ>E
M+K;RN'2YZ7CFEQS7E<'Q1NX/%FI:-?QVC16MN2EQ"&"O,%R1R>G!JK/\0O%(
M\&Z3KT4&E*U_<>1Y+QR$Y+D*1AO2GNDUUM^(=;?UH>OXH[UYI%XH\61^.+7P
MW=#2)'GM6G,L,4@$9VD@'+>H%0Z!XI\;^(6U06HT-1ITS0_-#+^]8 'CYN.M
M'G_6]@_X'XGJ5%>5Z%\1]4\1W=AIFG6, U,.W]HET;RH5!QQSU./6KGB3XC3
M^'O'NF:";>)[6X16N)<'='DXSUQC@T6U2[AW\CTB@5Y+%\3]5N;PQ6]I:&.7
M4Q9V[$-RG<GGKTJ'QY\5M4\*^([K3;*SLYDBB0J90Q8NW;@].#2OMYA;5^1[
M!17B-E\9M2U+7M#TVTL[-Q>(GVI]K?(Y7)"\_7K6A=?$O6//UZ2UN-#A@TN<
MQ);W);SI\'!V@,/Y4/3\?P#_ ('XGKN*,5Y8GQ#UB_U\:=;W&BZ6JV<=Q(VI
ME@=S ':/F'K3K_QOKEKXBL=%&I>'$::V:>2]DWB'@M@+\_MZTP/4<<4N*XGP
M5XON?$.DW]WJ26\8LYFC^T0@K%(H .X;CT_&F3_%+P\+:[>VGGDF@B:1$:W=
M1+C^Z2/F_"D] 2N=S17GOAOQ]=W_ (!O/$VHP(1"&98K>WD4\=N<Y^HXK"L?
MC*&O]'^VVICLKNU:28I;2,ZN-OW0.J\GG%.VM@Z7/7Z*Y&Y^(?AJVL;.[:]>
M2.\7?"(87=BOJ5 R!]:V3KVG+HO]L&Z3[#Y?F>;GC'^/M2>BNP6IK45Q0^)G
MA<6$EZUY,D4;*&5[9U?YL8(4C)!R.:SM9^*VC6OAZ[U'3/.N9K>18C%);NA4
ML1@D$ XY_&F!Z-17DVJ?%N/3K>ZG0QSNL<12V%I*KQEL9+D\8],5TEM\2_#D
MND3W\EU+&+;8LZ/;NKJS#@!2,FG8#M**Y'QOXIE\-^$6UBS2)Y&95C$X(7YO
M7H:S8==\3SV-S<6VJ>&+Z6. R+;VN]FS[_.>*F^_D';S/0**\J\)_$K6?&5_
M:Q:?IT$5M!%NU*>96VHWHG/U]:L:)\3VUKXA7&B);(NF*C^3<$'=(R'#8/0C
MK1;6PKZ7/3<48KSFV\6^)O$$VHS^&[.Q:QLIC"!=!M\[*<-M.X =#UIGB3Q7
MXKTG6-&LK6WTQ7U,A/*G5W:)L<DE6P1P>E-:V\QOKY'I)HKA?#7B;6;[QAJ>
M@:D+!_L$*L\MJCKECV^8GMBJ/B7XB77A/Q--8ZA:)):2V_F631(Q>23GY#^0
M_.E?;S"SU\CTFBN9TS6;^V\++JGB& 1S$;VALX7<JO8;1DD_2J/_  L_PL+-
MKDWDX"R^28C;2>;O]-F-WZ4WH[ M5<[.BLBWUJWOM%?4K7S8X@A8&X@>,C'J
MI -<-9_%-);[0[+"W8U MYEQ;VLJJ .FT'GTH2N[=0Z7/4:2N2UOQ?;:%XBM
M;*[O[:"%X&E>-X7,A [AA\H^AJ[X?\5Z7XE#-IINV11G?-:R1*P]BP /X4+4
M'H=!17)7'Q \/6VLW6DR7,PNK49GQ;N4C&,\MC X]Z+/X@^&[VUNIXKUDCM8
MS+)YT+1DKSRH8#<.#TI75KA;6QUM+7GM[\5/#[V-S]@U#R;J*+S@;NSEVA>>
M<8!(X[5?L_B)H4]W'IZW$]S>[5\S[-9RNBD^I ./Q-,#LJ*\[T_XI:7+J&MQ
MZ@LMK;Z?*(XV,+Y?KGMUZ8'7K6I-\2?#-OI:ZC+=S+"9O(V&V?S _/!3&X=#
MVI=+AUL=A17&Q?$KPS+>1VHNKA)'(7+VLBJA/0,2,*?8UE^+/B?8:.KVVF,+
MJ^CN(X7#0N8AN8 C>.,X/3- 'H]%8-]XET_28[ ZE,86O%^0["5SMR>>WXUA
M7?Q.\-G2Y+BSU)?,/F+&7MW8!D&26 &<"F] 6IW5 KR>Z^+7DW"6L$*W#G3V
MN?/6VD"._., \A>.2:W/!?Q'TWQ3!:6TC-%JLL1D>+R'1#CKM9N#^!IK78'H
MKG>TE>9^)?B<VB^(M0TB"S9GM;,S!WA<AGR,#CHO7FK'A_XG:9K>AAS.+?5%
ML_M$J2V\@C'3)7^\,GL:E.ZNAVUL>BT5P=A\3-$>&SAN+M[J^GB$A%C92LN#
MCG&"5'/>NGU/6['1]+.HWTWDVX .2IW'/0!>I/M3>FXEKL:M%>9>)/BSIMCX
M=DO='W3W8E6+RKBWD4IDCEEP#C!X]:YR#XP:G/?W,4AL+2&UB5I)YK"X()//
M0'*CGOUH6KL![A17&K\0O#L=Y#8SWQ-PX0,Z0/Y2LW0%L87Z$U8A\=^'I]:_
MLJ*\=K@OY8<1-Y1;^Z),;<\],T["OI<ZJBBBD,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_ (\;C_KDW\C0!9HHHH ****
M"BBB@ HHHH **** .,U#PQ>S^/K3Q'!/;B*WMFB\I]VXL>G0=*Z/3OMWV1?[
M1%N+G)W?9RQ3';[W/2K]%);6![W&D5QT7A.[C\?WWB$W$!M[BU$"Q\[P>>3Q
MC'-=EFES2:07TL>5P?#&_AL-$M_MEJ&L-1>[E9=WSJQ7@<=?EH\,?"R30M:A
MGN5L[J"WG::&;[3.)5)Q_!]RO5:2K3L[H35U8X?7_!,VO^--/U:>: V-G Z>
M2V=Q9L<],8XKDM,^#^K64%WILFJ6YTV\NEDN-K/YK1+G"9Q[COVKV6BI22*;
MN>-ZO\%YVUHMH5[!:Z3*L:S6\\DCN0I!X)SZ>M4[/X(WMI?-<B]LCNU$7&/G
MXA#;@O3KG%>X44XZ:H3U/+[/P+KMAK>JWRVWAV^2^G\Q3>H[-&H   ^7':NG
M\3:-K&J>'$L='O(+"Z!4L1E8R!U48&0/I74T5/1+L'6YXWHOPCU>PUJTOKF_
ML7CBOENG0-(Y(&,C+#D\=ZO?\*PU6%Y+FWOK/[4FI?;8%?=Y>..&XSV[5ZM1
M57%8XCP=X5U709];N=2N+22?4IO. M@VU#SZ@>M8VB^"=>T>2X\RT\-7OVBY
M:=IKF.1I!DYP/E[5ZA12ZW\K#Z6\[GDM[\)[N^TC7HI+RU6_O[S[3;RIN B&
M3P>,]#CBM6\\ WEQHGA?3(;JW2/29DEGSN_>%1SMX]?6O1:*:TV\OP!Z[^?X
MG$VWA*\C^(5_XDEN86ADMA#;QC.Y#C!)XQCKTJ?P1X6N?"]A?174\4TUU=O<
M%HLX /0<BNO[T4G>UEVL!Q?@WPI+X;N-6GN7@>:^NFF#1 \)@8!R/8UFZI\/
M9M9\3ZMJMY<0F&[LOLMNHW;XS\W)X]^U>B"G46O;R5A+J^[N>2:7\*M5TC1=
M)2"_LY-2T^\>Y#2%_*DW8X/&>U5K_P"$FKZSXB_MG4]0L7FED9YXTW[1P0H7
MCISWKV2BF]=QK0\9\+?!N_\ #^H:3=27ME(UK)))-MW_ #D@A<9'8&IU^&.O
M?8=4L9#H3IJ%TT[7;*YGC!?=A3MX->ODT T-W \LLOA_KFFZU=WL::#J4<T4
M<2_VBKLRA%5>RD?PU;D^'#:GKFH7NJIIQM[BQ^S000H<0M@Y(R.!D]J](HS2
M:NK,%IL<=I'A*>V\!R^&KV:'+Q20B6W7 VMG!/ YYKF4^&6M7$5E;W]]8"#3
MK>2*U, ;<Y;N^1_*O5Z*'JVWU!:*R.-TCPE<Z?\ #P>&Y;B%I_(:(RIG;D_A
MFN;TCX;:S:W>FS7UWI[+8V$EFHBWG.=NUN1['->JD\TM#U;?<%HK'BD7P;U&
M&TTH-=V=Q-:(\<L;S2QHRL1T* -VKM[_ ,%0W?P\D\,P>7:!HP!Y;LR*V0>"
MW.,BNTHH>JLP6CN>/CX279TY(V&G1WBO#NG6XGD\Q$9200^<?=[5:U3X7ZE>
MS>(7BO;1!J7D&%3N^0Q[/O<=]O:O5J*8(\?O_A;KE_)JDTM_IZ37D=NJ!2^U
M3&1UXS@XK-O_  W+K'Q3TN$$%8HHVU18HW$):,DCE@,Y%>Y447LT^P/5-=SC
MO'OAB^\4:+;6%A):)Y4Z2LMSNV,%[< UG7?AKQ1/I5Q9VD/AS2Y)@$:XLHW#
M[._\/6O0:*5M'YCOL>3Z;\,->\.6NI:;H6KVJZ??H@=I]WFJ1U(P,<Y-68/A
M+;:1KFBW^B2"%;0,MV)I'8S!E()4<@')SVKU&BG<FQYMI7A'Q5H:7&GZ5JEA
M#ITUTTXF96,\89BQ4 KM/7O6OJ7A6]O_ !EH>LO=Q-:Z="RR(P.^1R"-PP,=
MZ[&BB^WD-ZW\SSNT\+^*=)\7:UK.GRZ--'J3J=MRTH9  !CY1CM6EKOA.XUO
MQ-H6J3/:B'3B7EC()+-QTXZ<=Z[*BDNGD'?S.=\5Z3JNKZ#)::-?)9718$2/
MG&.XX&1^%>>6'PGU6T34?M TF[>[E65/,N+@&(C.2' W9Y]:]FHH2W\QW..\
M,^&=1TGPC/I-_?K<W$F_:^YG5 >@RWS$#WKF=&^&NLZ++X;GCO;"232C()0Q
M?#AS_#QU^M>K9HS3O[UR;:6.#\4>"+O7O%EGJ\;V;V\%L\+V]QN^<M]!TIO@
MOP5JOAW6+FZN+FWCLY(@D=G;3RRHI]?WG3\*[ZBDM-AO7<\[D^'\]S=>*Y)[
MJ(1ZTH6(H#NCPH'S<>H[5R]Y\,9=+\'ZFUS:PSW4=J4BEL[B:21P,\%9#M ]
MA7ME':E;2R[6"^MWWN?.-GH&L^.=9NH5^SQXTM;?SA#(D:'YL Y4$GZ UVUQ
M\,]7-[;364NGV,D93S;JWN)UDD"^J?</XUZQ157LA6T/(]9^%NK:H^LH+ZR$
M%[>+>1$LX<,N[Y6P.GS'IS5@?"^?[):!%L;:X2_2ZG*3S2K(%##J^3GYJ]4H
MI+38;UW/)Y_A5))XJO-186=W97=P)V2>XFC=#G/ 3Y3SZU#>_"_6_+O+"POM
M/&FW%^MYF;>95P02O3'ZUZ]11M9+H-N[;[G%^.O"$WBKPI'I<%S'#>1;#',^
M< C&>G/(!KB].^"\^G3:H4O[=H[BS:&W5MQV2,FUF/'3->T4M%M_,+Z)=CR9
MOAGK<1M3;WVGG;I3:?+YF_N6^9<#_:[UH:3\/K[3-6\.71N[79I=NT4RINS(
M21R./YUZ/0*=];BZ6/.?$O@35]8\27^I65U8I!>V/V1UG+[EYZC Q5!OA?J7
MF:<4O;15M=+-DX&[YF^7GIT^6O5J2ETL.^MSR%OA9JZ:796UL^F17EO"L1OX
M[B>.3C'91@].]==XH\)3Z]X8LM.%VHO+1HI%EDSM=TQ]['8XKL,T>]#N_ON)
M:;'DFH_"_6=8_M"\O+^P34+N2#Y80WE*D94^F<G;2ZI\+M3OY/$#)>VB_P!I
MQP)'NW?)L"@YX]J];HI[#3L[GE=G\._$&EW-S'8:AIPM+MXI)FGA\R1"H .T
M%2O;O4>C_"B73-<\^X-G>6HN?M".]Q,DB'CHBX3/%>L44)V=R;*UBAIW]H_9
MV&I"V$H8[?LQ8KM[9W<YK0HHH&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@"S1110 4444 %%%% !1110 4Q
MCM4G!.!G I],8D*2HR<<#UH X&7XA75GKEK9W^@W%I9W5T;:"XEDP[D9YV8Z
M''7-=]VKRFWT;Q1=^/9-:UO0/M<,#,M@D=[$$B7H&*DYR1_.O2=/GNKBS62]
MLC9S$G,)D63'/'*\4+X5W!_$^Q/*76-C&@>3:2JDXR>PSVK@X?'FN2^*9M /
MAF);B!!+(W]H @)SR/DY/'2O0N^:X6#PUJ:?$S4-;:%/L,]F(4?S!DMSVZ]Z
MEWO\F/2Q8\*?$72/$T0C-Q;6FHF5H_L33AI#COCBMVW\1Z-=ZG)IEOJ=I+?1
MYWVZ2@NN/45Y?9?#O7+.ST'R[2**YMM4DN+EUE7(C8K@YSST/%+X1^'>KZ7K
MUM)JB7K+:W+31W$5W#Y1SCJF-YSCUJU9Z$NZ1W/BOQ=-X?U#2].L]-%]>ZC(
M4BC,WE@8[DX-8VJ_$+4O#^HV-CJ_AY(9KPL8Q%?"3Y5!))^6I/%7A"Y\3>.=
M%N;JU271[.*3S29=I+$K@8!SV-<_XG^&]_+XEMY]!TZ*.QMK601@S]9&Q_>.
M?6H5]_4JRV.WT7Q<FK^#'\2-:F"-4D<1%\Y"YQSCO7+6?QCM9KG0HKG3'@75
M=WS>=N\K#%1VYR0/SIMOIGBN'X;MX8C\->3<"V$0G^W1%2V1DXSGUK+L?AAJ
M;W)%[ D<5OI:Q6KK*I(N, _AAL\U3LI-K8E7<5W.@7XJVLD]_;Q:;)+/#=_9
M+:-),FX? SVX S[]*Z/1=<UB\U5K/5/#\MA^[WI,DOFQGV+;1@^U>9^'_AQX
MFT&+3]4>TCN]1@NWDGMC.@\Q6!&0V< X-=;X*\+:GIWB?5M7OK);"WNE"PV@
MN/-V'N2<D<TTD#;UM_6I<U3QW>V_B:\T73=%CO&L[<3SS278B50<\?=/I6=8
M?%"ZUF[L+/2- ^T75U TS))=B,( ?7:<TZU^'Z:EXVU[5?$6G1S6MP46TS,?
MNCKD*?YUF:QX)NSXZ:_3PLFHZ5':+!;Q1WJP[2"<]2#W%3'I?J4[:V-S4?'&
MM:;J.FZ5-X;B.I7[/Y<*WX*@+CDMM]ZS[KXL+I]M?_;='"7MG=);/!'<AU);
M/\>W_9]*J7'P\FUOQ+I[W6C"PTBWLW B%V':.5MO<')Z=:R#\-=>.A:?HOV"
M$1PZ@9I[GSU+2H,A6/.<\]*:\_ZU!V_KT.QD^(5W<M>R:/H#WUK8#_2IC<;
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M:M/:Z^[J-.Z3\G_P#HM+\7W4FOPZ)K6DG3+RXB\VWQ/YJR =1G P>#Q4.O\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\
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M-X!UW6?%4_\ 9,,G]GW\2R7#KT$J$X_/-4K'P3XAAL-.U74]*N+V1[QI;^P
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M44 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: +-%%% !1110 4444
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M 'N.M9^@_$+7/">A:;'J26UU9R6#SP"-&$@V] S$G/7TJ5)-7*<6CWJBO,?
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MG%8;A=LL9GD*D9SC!; Y]*\TG\>^++6*[U/^T86M;?5OL2VHMD^9"6_BQG/
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MC<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ HHHH **** "BBB@ HHHH ****
M&]ZPXO"WAN&[^U1Z1IZ7'F>;Y@B7=O\ 7/K6VW0_2O#? FD_;_MMS+X3BU+;
MJ,@^VR7H0H,C^$]<=:2U=@>BN>L3^$_#]S#+#/HUE)',_F2*T((=O4^]7;;2
M=/LM/%A;6<$-F!CR$0!,?2O+IOB+X@L_'4GAIO[,VP$R-(JGF( ?(!N^_P!?
MTXJII?Q1\37L4UZ=-,EFT<A1TL9%2$C&-TF<,.O3%&Z\AV=[=3TF'P1X8MF8
MP^'].CW*5;; HR#U'Z"K%YX6T'4;6WM;S2;.>"W&V&.2(%8QZ =J\FL_B3XV
MN7L4+:2&O;-KI#]G;Y ,<'Y^>M6[?XE^)M9GTN'36TVW:XL&N93<1%AN4#('
MS#UIBN>E77A'PW>^3]KT2PE\E-D?F0J=B^@]JK^(?"EKK_A<Z%$Z6=ME-OEQ
M@JH5@< <>F*\EB\6Z_XCURTU!I;5(AILS/;-&S(Q7ANC=ST]JT?#OCS7+K28
M+'1H=,L#:V3W<WFQ,4< GY4&X8_,T-::_P!6!/70]-L?"&@6.F-81Z39"&0+
MYRB$ 2D8Y([G(JUJ/AO1-62%=1TJTNEA&(A-$&"#VSTKS5OB+XEU62Q728[&
MV$NFR7DOVB(O\T>[(&&'!V_K72Q^,+V?X4OXHCCB6\6V>3:5)3<I(Z9Z<4-V
M3;Z E=I+J=7<Z-IEY;P07-A;RPVY#0H\8(0CH1Z4R30='EGN)I--M6EN4\N9
MS&,R+Z'U'->0?\+'\;#S$9M)+C33J*D6S8"C=E?O]?EZU?M_BIJUUI^LW216
MB?9=/CN8%9#RYW9SSR/E%'J'H>BV_@SPQ:+*MOH.GQ+*FR0) HW+Z'VJ2#PG
MX>MM.FT^#1[*.SG.98%A 5_J*\YN_'_BJ!K"ZGA@LM+FM4E>[^P23J6/495A
MM'UK0\ WNKZAXY\327&HPW%FKH %C(SG.W:<\#&?THL]5_6@FTE?T_$[&'P9
MX8@39#H.GHNX/A8% W#H?J*W7160HR@J1@@],5Y5XT^(VH^'=;"6%W9W5LDZ
MQ36XM'+1YZYD#8!]L4:9\0=>O99-4_XE2:0EU);FVE<1S?+NY#%L$DCH!23Y
MD4URL] C\,Z'$8?+TJS7R)#+%B(?(YZL/0\U/JNBZ7K<*PZII]O>1J<JL\88
M _C7G>E^/]=E@.LW;:6VER>?LM@XCG7R]V.K?,3M["L^7XF>(K'3[74[E-/F
MM]1@FDMH8HR'A*!L;SN.X<>@H>VHNNAZ6_A;0G$8?2+-A'$84S$/E0]5'MR:
M@B\$>%X4D2+P_IR+(NUPL"@,/0UY?;?$;QM.;1-^DAKRQ>\C/V9OD"EL@_/S
M]VKD/Q)\3ZQ>:;:Z8VF6[W%@;F1KB(D;@2"!\P]*;=MP/23X4T'RIHO['LO+
MF</(ODC#L.A/TR:=-X8T.Y:9IM*LY&F</(6B!WL,X)]QDUYA>?%?5/\ A&+?
M4K2[L4O5B+3V9M'E+8_B!##:ON<TZX^)7BBZ>XFTY=/BMK?3HKUQ-"S,=V,J
M,,/6G^@+H>G/X:T5X7A;2;0QO+Y[+Y0P9/[WUY/-</=?"*VN?$+:E+J8,+70
MN2C6P,N0<A?,SG;GMCM65-\5]8MXUADMK87=_!#-IWR'!WXW!N><9]JZ?X@Z
MC<:;X,M9[BVM;FX,T*RI(A*;B1D@ ^OO4OW?>\[ G?W?*YU^I:-INLVJVVI6
M,%Y #D1S(&'ZU33PMX?01!-(L0(4,<>(5^13G('L<G\Z\NB^)/BB.*6],>FC
M3K:_CLS$(6WE20.#NXZ^E<^=?U?4M5MET\V5A$^N^65CB;]XV%(9_FY[=,4T
MKNRZB;LKOH>VOX+\+SQ0Q/H.G/'"?W:F!2$^E32>&=!E:</I-DWVA DN8A^\
M4= ?4<FO,M$\875OH6J/#-IFG7HU)XE"6CR^>0JYP@?)8Y[5F^'O%U]XJ\:^
M&;V\"I,C30N(U**V-O.TGCK1U277_*XWHF^QZ5XB\#Z3KNEW-I%#;6,\T8C-
MPD(+;!T';CFK]AX0T"RTV6RCTFS\F=0)U$( EQ_>'>O+?B3?O8?$*ZF$<<RQ
MZ,[>3-DHW/< BKK>-_$FF1:8WV>WT[16LXW^T"PDG3)[95AM'UH3O&_<&O>M
MV1Z3!X3\/VRR)!H]E&)(Q$X6$#<G]T^W%.M_"F@6EA+8V^D645K*0TD*0@*Q
M!R,BN(\ WNKZAXU\32W.H0W%HLBA0L9&>NW:<\#&:]0HZ)L5]6ET.8USPEI6
ML6LT:V]K!<2B-&G$0+;$8$+_ ..@>U:EWHFFZEIL6GZA9PWEO&J@1S(&''0X
M/TKR+1-+_M3Q;XD:3PM'K0COL"66]$7E<= #UJ[K7CWQ/I5[K:646G0Z?HWD
MJ87B+.58+E0VX=,]<4DU9>>I33YFETT/4--T32-'CECTVPMK-)#F184"ANW.
M*I0^"_"]K>"\AT+3HKE6WB58%# ^N:\7U#Q%K;3>*M1NGLKNW2.W)MIXF*X8
M @###&":ANM<UJWA\47EVUA>00^0IMI86V#(R OS< 9JHW;N*R>BZGNTGA?0
M9M4&IR:39O? @BX,0+Y^M+_PB^@G5#J?]D6?VX\FX\H;S^->8:=\3_$-YK)B
MLM*::P@E2%X(;*1VQCEO,!P/H16OIGC?Q!_PF"Z?KJQ:=;37!CMX7L)#Y@[8
MFW;<_A0E>R0KZ-LZ^3P7X8FC2.30=/>.,ED4P+A2>I'UJU:^'-#L9%:UTRTA
M=8S&"D8!"'J/I7,>+O$^K6'B33M"T8VD,]S$\S37:EDPN..HYYZYKCI/$=P_
MCRSU.[O;*VE73&WRQR": /E1GY3SSVS2CK^(WI^'XGI]OX-\,64_VB#0]/AE
M.?G6%0>00>?<$T^U\(^'K&=9K71;&&1<[72$ C/!_/)KQ_4?B3JEZ+S3M0@L
M;X6\L#Q2-:20JP9E&=I;/?(.:M3_ !-\61-=26RZ8+2VNX[18V@;<=VT#G=_
MM4+4&>L6OA;P_ISSO:Z190-<J4E*1!3(#U!]:GCT#287M7BTVU1K0$6Y6, Q
M ]=OI7CMWX_U2\U6STW5K/3KFYM]6BB$@B8*%8(00-WWAN_2M"#XC^*%=+ZX
M73SIO]I_83$D+"0C*\YW?[7I3[,5['J&J>'-%UN2.35-+M+QX_N-/$&*_3-2
MKH^FK>Q7JV, N84\N.4(-RKZ ^E>4I\2/$UPEKJ<?]FIIUSJ7V-+=HR95 QD
MD[N>OI73?$'QKJ/ANYTFPTR$&YOV/[PV[3;0,<!%()//K4[)>H]VT=1JGA70
M-;N%N-4T>RO)E&T//"&('XU%'X/\-1)&D>A6"K&&" 0+A0W7'UKS'6/B?XIT
MC2]-O+FRM;=KLM T%S"T;B0$?/@G.WK^G-6=7^(OB:SUM-)L[>&ZN(+5)IS;
MV3S"<MCA=I^4<GDYII=$#.B\4?#"TUVYMI+2X@LHH(3"L#VHEC4'NHR-I]ZU
M]*\!:!I^D06$NG6UV8XO*:6:(%G&<\^V>U>?:K\3/%D=SJDMI#8V]M8102/!
M<0,9/GV@J3N&""WIVJ.^^*'BC3VN[*5=.:\7[.\4@A8($EV<$;NHW=<]J(NZ
MLNH-:^AZG;>$O#ME;3P6VBV,,-P,3(D*@./?UI#X2\-OO!T6P.\+O'DKSM^[
MGZ5Y+XF\8^)YM$UK2;JZLDN;.2W8SVL9 =)"ORXW''WORH3QSJ/AW6=4A-I8
M27_DVT2W21LNYGX!?+'@9'I0M6'0])U_P+9:G87L&FI::;<WR>7<W*VH=G3&
M,=16SH.BVV@Z%:Z5; >3 FP'&-WO7EFI_$OQ/I37NF2)IT^I030A9XXR(F63
M/!7=D'CUKK?!'BC5]5UG6M(UG[,]QIS)B6WC**P;/8D^E"6CM_5A-]_ZN=&?
M#&A/826+:3:&TE?S'A,0VLWJ1ZTL7AK1(K2"UCTJT6W@?S(HQ$-J-Z@=C7#Q
M^.->NM9OIX9-*ATFSO?LCQ7+".0]?F#EL=NF*RM5^*&J:=XFCM;:[L;^QF:1
M5:.T==A4$@;]Q#=.<5*M9,JSU\CUVZM+>^M9+:ZA2:&08>-QD,/<5F6?A30-
M.M9[6ST:RA@N!B:..$!7'N.]>9Z/\2?%#3:/)J::>T&J03/&D,15HV1202=Q
MR#BH[#XH^)8(],U#5(K&6QOC.!%!$5<>6'QSN/7;Z535MQ7/1V\#>%'6-6\/
M::5C4J@-NOR@]A^=3?\ ")^'3,\O]BV)=X_+9O)7)7&,?3%>;R?$+Q,UA:7<
MCV'V;5HYA;)%&?,@*AL%CNYZ>@KH/A]-J\GPR\^YO89+AUF:"3RS\G+?>YYY
MR>W%#TBV^@=4EU.RTK1='T2-XM*L;6S5SEE@0+D_A6?+X&\*75RUU+X>TV29
MVW-(T"DD^N:\'T2>YL;73KFX@L;F74+R:,SM&_FIC'(.['?TK2\-_$77=-TF
MQT31[8S3)"T[DVKW#29/"@*1MZ'DYH6K\PZ'MVH^$_#^JRQS:AHUE<R1KM1I
M80Q4>@J%O!'A=I(9&\/Z<7A4+&Q@7*@= *R]<\7W6E?#^+7VL7BO)50>1,I'
MENW]X>U<M>_$+Q)HR:M8WO\ 9]S?VUHES#/!&1'R0-K+N/KZT;-KL"U2\ST6
M7PSH4L[3RZ59M(SAV<Q#)8=#]13I/#NBS_:A)IEH_P!JQ]H!C!\S'3=ZUXYX
MF\8:_=:+JNC:PUJ7:QAO(Y+6,IMW.GRG).?O=:+#QMJ6CV=^^FV=@ERGV6$2
M-&Q+[E09;YN>OM26]A]+H]9/@GPLUFMF?#^G&W5MPB\A=H/KBG3^#?#5U:PV
ML^A6$D$ Q%&T"E4^@[5YCJ'Q5\0Z+)?Z9>PVDVHQS1)%-!"VQ0X4\IDEB-W8
M\UW?@77]7UVPN/[8L9;>>&3:LK6S0+,N <A6Y'7'7M5)75T2W:QT9TC36TO^
MRS8P&Q*[/L^P;-OICTK+@\">%+8R&#P]IL?F(4?;;J-RGJ#[5TM%(9@S>$?#
MUQ)!)-HMC(]NH6%FA!* = /2I9_"V@W6IKJ,^D64EZO(G:$%Q^-;-% &-)X;
MT66*2*32;1HY)O/=3$,-)_>/OR>:A@\'^'+;4?M\&BV,=YDMYRP@/D]3FM^B
MC8#&M?"^A6.I-J-KI-G#>L26G2(!R3UYK9HHH **** "BBB@ HHHH **** "
MBBB@ JM>?\>-Q_UR;^1JS5:\_P"/&X_ZY-_(T 6:*** "BBB@ HHHH ****
M"BBB@ HHHH 3M7*)\//#"3--'I91W<R-LN95!8]\!L5UE%'6X=+'+#P#X7#K
M)_9$7F))YH?>Y;=QSG.3T%/A\"^'K3SC!IP03*5D432;2#U^7=BNFHH YN/P
M1X<A:W:/3(E-O"8(CO;Y4.,CK["N=F^%>DR^([2Y6")=)M[9H5LP[@Y)'.0<
MXX]:]%)HS2ZW#I8YN;P+X;G^S;])B_T:,Q1;7==J'J.#S^-1-X \+RVT%M)I
M$?E0 K&%D=< \D9#9(^M=513 PAX5T43),+&(2);FU4@D8B((*]?<U(GAO1T
MT'^Q$LD&FE2AM]S8P<Y&<Y[GO6Q2T/4-CG#X(\.%B3ID63;&U/S-_JCGY>O3
MDU3F^''A&XV++HL;*D8B $L@^4= <-SU/6NOHH Y>X\!>&KE8EGTT.D2!$3S
MY H Z#&[%7;+PQH^GZK+J=I8K#>2KL>17;YA],X_2MNBB[ Y:]\ ^&-1U"2^
MN](CDN96#N_F.-Q'0D XIZ>!?#4>HB_7281<!MP;<Q&<8SMSC/X5TU%"TV!Z
M[G-6W@GPY;:@U]#I,2W#%B6+,1\W7"DX&<GM3(? OAB"XFDCTF,-*C(^9'(V
MMG( )P,Y/2NHHH YR/P5X>B:!DTZ,&"!K>+YF^6-LY7K[FN=G^%VES^)[6\\
MF%=(@M# +,.X;.2<[@>G/K7HE%+K<.ECE+GX>>%+HQ&;183Y4?E)AW7"^G!Y
M_&K,?@GP[#%+''I<:I+ +=QO;YHQT7K71T4P//;CX?+<^+M(U!Q9Q:5I$>RU
MMHP^_I@;B>,"NNU/2-/URT%KJ5LMQ"&#A&)'(Y!X-:E%'2P=;G-_\(1X;^S2
M6O\ 947DR3"=TW-S(.C=?:H3\/\ PN8RATF/:9_M&!(X_>8 W9W>PKJJ* .3
M?X>^%W@^S-I$?E>:9\"1P=^ -V=V<\"IM/\  OAK2KF&YL=*CAFA8M&X=R5)
MQD\GV%=-11L#UW,#4_"&A:S>/>:AIT<]P\)@9V9@2A[<&JUQX#\,W0B$^F!U
MB4(B&>3: .@QNQ7444+0#FF\#^'6NI;K^S0LTP D9)I%W8Z<!L5T"(L<:H@P
MJC &>U2T4>0'*S^ O#%Q>37DFF8GG;?(Z7$J;CZD!@*F?P7X>DANX7TV-DO
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MF,QF^T#>6((/.WODU*OJ-VT.2N/BAJ]_=^'M1L;5(K.0S-/ +@_/L#Y&<<C
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M44 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H LT444 %%%% !1110 4444
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M;H6QU:,3$ [?+?N,@$[< X[=: .H- K@?#GQ/T?6'N$N9UM&%Y]EMU9'S)T
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M3W$6+[P@M[X,A\.IJ,\"Q1J@N(U^8X]1G]*YJ'X.VT=G>P-J[_Z7+'*Y2U5
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M4G/M7144+160/5W84444 %%%% !1110 56O/^/&X_P"N3?R-6:K7G_'C<?\
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M6,-K-+>Z+?VC+;K<Q1R%"9D) &W!]^].N?BO#9QVOVG0[V*XN8C.D#S1*?*
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MP3U'K6WX3\8ZCKOC/5[*6QDCL(40PMN7"@@$$\YYSG\:2U=^^H]E;MH;&O\
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MJ&1[J#RPX/0KSS3W3OUW#JO(Y>S^%]I9'2BNIS-_9]O- N8A\XDW9)YXQO\
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ME10!RWA7PDGAN-E\^WN&*A%DCL8X& 'J4Y/XUU5)2TVV]Q));!1112&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H LT444 %%%% !1110 4444
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MA_&K;6!:Q=]S>/Q,\."&"027;-/*85A6V8R!QG(*]0>*TM;\9:3H5O;27[7
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M6KIGA#1=)N;.:SB9);166/\ >9SNZEO4GUJ?4?"^F:KJL>HW2RFXCA:%2LA
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M&3%<%3(K$DAC_$.3796EK#8VD5M;H$AB4*BCL*>EA:W+-%%%(84444 %%%%
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M.^VV=E<R17TA$CP,GR1J&W!=V5.0>I/2O3;OX=^%-0G\^ZT:*27"KN\QQPH
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M(.V=HZBGI^0*_P!]SV]=?L'UZ/1U=S>/!]H "_+LX[_B*37_ !'8>&=/6\U
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M'4[?S9X?/C7=RR8SN^E 'G__  I!O^AX\0_]_O\ Z]'_  I!O^AX\0_]_O\
MZ]=K9^/?"]]-Y5KK5K*^TMA2>@&2>E,A^(/A.X?;#KEJYP3QGH!D]J .-_X4
M@W_0\>(?^_W_ ->C_A2#?]#QXA_[_?\ UZ[O2O&/A_7+C[-IFK6]S-C=L0G)
M'XBKFKZ]I>@PK-JE[%:QN<*9#U-&VX;GG'_"D&_Z'CQ#_P!_O_KT?\*0;_H>
M/$/_ '^_^O7?R>+-"ATJ/5)-4MUL9#A)MW#&HI/&?AV'38]2DU>V6SE?8DN3
MAF]* .5T3X3MHNMV>IGQ9K=W]FD#^1/+E']CSTKTJN=A\<>&IX8Y8M7MF223
MRD.3RWITID?C[PK+<?9X];MFEW;=HSU].E'6P>9TU9^J:9:ZQI\EC>*[6\HP
MX21D)'U!!JA:^+] OM3.FVVJV\MX"5\I2<Y'45O4-76H7LRIIVG6NE6$-C9Q
M"*WA7:B#L*N5RTGC_P *PWILI-:MEN0VPQG.<YQCI72(ZR(KJ<JPR#ZBC5ZA
M:VA+1110 4450.I6:ZDNG&=1>,AD$7.2HQD_J* +]%%% !1110 456N+B&UM
MY+BXD6.*-2SNW10.IK#B\=>%YX)IXM:MFBA7=(^3A1Z]/:CR Z6BHD=98UD1
M@RL,@CN*EH **K1WEO+<RV\<R--#CS$!Y7/3-6: "BBB@ HIK,%4LQP ,DU2
MT_5+'5[8W-A<QW$(8H70\9'44 7Z*** "BBB@ HJ-W6-&=SA5&23V%5=/U&S
MU2U%U97"3P%BH=#QD'!_4&@"]1110 4444 9VK:59:UI\EA?PB:WD^\N2/U'
M2JNA^&=*\.12QZ9;M'YS;I&>1I&8^Y8DUMU1U'4K+2;1KJ^N$MX%(!D<\ G@
M4;!N7J*A25)(ED1@489#=B*SEU_2GN+>W6_A,UPS)$@/+E<[@/I@_E1UL'2Y
MKT444 8VL>'],UUK8ZE TPMG\R-?,95S[@'!Z=ZUE4*H4# ' I]%'2P!1110
M 5A:]X9TGQ$D2:G;M)Y1RC)(R,O;JI![UNU2M=2M+V:XAMYTDDMVV2J/X#Z&
M@+V(]+TRST?3XK&QA$5O$,*H.??J>M:%53>6ZW:VK3*)W7<L>>2/6K5%[ZA:
MPM%0S31P0O+*X2-!N9CT J*QOK74[..\LITGMY!E)$Z,* +=%%9TNKV$6J1:
M8]W&M[,I>.$GYF48R1^8H T:*H:CJMAI$"37]U';QNXC5G/!8]!5X$$ CH:
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M-4N;G4)KR6.^TYY,I!$#P0O;CG-=%I7Q".M>*]6M;326FL],B??<*1YFY>H
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MNBV/+$L8<D^V<YIO65R5\-CPL^+/%MRVGPG63;?NF\F:>]%NLSB5E^8D'?P
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MJS5:\_X\;C_KDW\C0!9HHHH **** "BBB@ HHHH *AE9UA=D7<X4E5]34U%
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M"T@2"WA2&%!A8XU"JOT JQ3>K!>9\^6/@?Q0DSWUUH,LP6_CN%MW\D,R\[L
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M(!%#*'^S,2I7)=LYP".,U[E12TM8J[N>'W/@WQ#%!Y+:1)>O=:=;V\<F]/\
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MEC4_[;L?L)?RQ/YPV;O3/K7&1^"];;X2P^'Y%5-2A8-Y?F@AP/X2W3FL75O
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MA!;P$!#)EVG0%1UP21GJ.E*=%^#(L#?-:QB 2+'N/V@'<02/EZ\X/:L#P_\
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MS^]ESCY3GC'':I+?Q]8P>#UT7[#<&5M1%W))E<,H_A^M=1<Z8EMH?B*"[LK
MW3ZHEL\L=N@$:L!G9Q\OX8JC_9&G3WT/AAK6!;".]F'V@1J)&"A, OU[GO1>
MWX/[@:N[/S(M=^+L5[XQAUVRT:&:.*U,"P7X# 9QD\'VK1UCXV6.K^"KC1VT
M1K6ZG4*QM]HA'()P,Y[5BI#:ZM:+<W%I;1/IFGQR0B.%5$K$@$M@?-^.:](\
M?Z3I5QIF@6::38VB:A*//DAMD1@-C' ( (Y%$E:/S!/WK^7Y(X'7_B?HNH>&
M;'3-+T'[//;M$9))$3;($QP=O/) JCK/Q5DU?3H[5M"TVU:.=)<6\>U9 I!P
MW//(JREE9:K;BUGM;>*/3+>:2&1(E4RE)0J[B!EN/7-=_P"-M*M)?ACI5S::
M+I<<UV+83N(%C;YMO0JN>2?RH?\ -W:!;V[)HY*R^.QCB\N?POI:JTB[U@CP
M"@QZGKZ5[EHNJQ>,/!D6HVD36T=]"X1),93DKSCZ5Y=;:]I6EV&?^$.T5],L
MITLYI7C#RF0@<C<O(RW4G-=U\//$-_XATB6X&EV&GZ=&[1VL=NQ!X)ZK@ #Z
M4Y+F3702=FF0V_P]-O\ #VZ\/AK/[?/#)']K$7][/4XSWK(E^%6H27K3C4;4
M M;G&UO^6>[/Y[JE\/ZMJ5AX]\3/X@U >3!;QR!8V9HXER_08Z\>E9>N>-+^
M#QTVI:"Z7]C%IAE>*:5XX\ G)"X^]^%*^J\]?N'RZ-=OU-%?AG=VVGZ<DEW#
M+]ADGED6-2#(' P![\5RG@&TU>;Q;H*36CI!I=O)&VZ!T*#Y0 Q(PQX_AKJC
M\5;N>&:^L],A;3[-8S=M)(1("^?NCH<8[FK5[\39K:TU*XAT^%UM;];6/=(1
MO4ACN/O\OZTU=2N)OF5A-<^&][JVJZM=QWULBWLL+HK*V5"$9S]<5G7/PQUT
MR7WV/6;6.&[N/,D@8.%9=A7!*\YSSP>U=/X-\6ZMXET^\U"XT^UAMHWD2$12
M,SNRDCD$8'3UKG;3XKW(M]3GU*TLK5K0.4M/,D\]L-M&05VX^AJ+*.GD4VW]
M]OF<WJ'@&XM;SPOX>61I[B*5C=R0QN(S#O9\%B,>W6O2?&OA.[\0:=IEOI=Q
M;VTEA<),GG*2IVD8''TKBU^,>HR6JB+2;5[J2:*./#R"(A]H')4'(+<\=JTC
M\3=5BU5]"N]'MEUG[2L0BCE8H8R%)<'&> 3^54V[>=[_ #)5KW\BC+\'KZ>]
M_M2XNK&XOY)VDFB<RI 05 P-N&[>M=;K/@B/4/A__P (Y (;4J 4$9<QAA]<
MMBN6TOQ]J"V%K8:/I*7%]+YTS1W-V[#:I/1FR<G!XZ4^X^+\\6N_8CI**D7E
MK<(S,906)SM"@J0,=SWIVNDAWL^9]"6Y^%MW=:"VE(VFV*W$RO=R6YE=I H.
M,>83@\FN?_X0_P 3P^,K/2DGM&DBTIH#=-"_E%,H,<#[U>[(P=%<=",TM+KJ
M"VT_K6YY#!\&39WEO(KV5]"+>.*9+MY5Y7'*["/3O27WPEU=]]E8ZA81:8;[
M[8JR*YD!Y^7/3'->P9HHZ@M#R*;X4:DUC9P1ZE:;XEN$D+*V"LC.>/<;OTI8
MOA%*ND>2!ID.H1/$T-S$\S;]C!@'#$CMV%>NT4>8'#^"O"6J:#J6K7^J75K-
M-J#JVVV5@JX '?Z5E)\.M1M1;W5K?6AO[;4)+N+S5;RRKA1M;'.?E[5Z92TN
MWD'2QYAX6^&MSX?\3V^LRWT,V(Y/.14/+OC[OMQ4_CSP/K7BN^Q;:G#'8-#L
M:WF+C:V1\PV]3UZ\<UZ/13>MO(=]6^YY5#\+M032KRU;4+0R3O;L'"M@>6.?
MSK<\<^%=8\216D.GZC%!;HI2>"8L%D!!&<KSQ]:[JBB7O;B6CNCQJ'X2ZW8Z
M9);6.IZ>7N;0VUPTRN1C=D%<>P'6GWGPGUG['=6EAJ5@L5[#"EP9E<D-'MY7
M'8[>]>PT4-W=P6AY1:?##5+&*%X=1LS<PZ@MXF]6V$!$4@]_X#^=):_#'5]-
MF^WV>H61OV:4.)5<Q[' Z <Y'->L$T \T/4%H>5P?"N>U5DBOX2K::UGET.=
MY)^;Z5FW7PF\07BVT$NLVDL%N4,6_P P&/;G( '&#D=>>*]FHHOK<.ECCM!\
M,7VD^&[_ $\7RK<W,\LL<T:Y";CD<,*YCP!\/-5T.;6[O5KI#=7RRPJJ !6!
M/WR!Z_UKUBBEW]+ ]?ON>4W_ ,./$$WAK2M$M]5LA;6LK2W$<@<+.2Q(!QSC
MFK^L>#_$VK6"Z=_:MA!ITL:1S6J1';%M8',9QGD#^(UZ/11OOWN&QYWKW@G7
M-6BLGM[VQ@N;!3#;L5<AHBFT[_\ :Z]..E9=_P#":]:TM8M.U*")OL36=T95
M)#*Q8DK@=?F/6O6:*8'':WX3DU+2M%L;:>.)=/N(Y6+@_,%Z@>]<K;?"!8YK
MN&X%C-;RL[17!>;SXRV.V=G;TKUDF@&CJV^H+1)+H<#X$\"GPO(9;FWL3<+"
M(5N+=YB[K_M!SCL.@JE<?#>^-Q<7MO?VPO/[2:^M]ZML .[Y6_[Z[5Z910]7
M<%HCRW2_AE>67B#3=7EO[9Y8;N6ZN456PQ?=PGL-W?TK8\?>$M:\5/8Q6-]:
M16,#B2:WN ^)B#P#M[5W5+0^GD'5ON>3:W\++_5Y8KR/6!:76Z+?#%&#!&J$
M$;,@MVSR>M;.J_#NUN)-.GLW*7,%U%/<23RN_FA""<*20"<=@*[^BA.VW>X/
M7[K'F(^'.H6LZ7UI?6GVZ#4'NX1*K>658(-K <Y^7MZUGCX5:M9B.?3]4M!>
M2),MP95;9^\VYV8';;WKU[O12TV"^MSSKPAX O/#FNVVH7%[#,L6G)9E44Y+
M#'//:G^+_ U[XAU5+NR-C:N H-WNE6< $9'RG:>G<5Z%13;NTWT$E:]NIY+!
M\)&@U&\DD^PW<4[R2)-.\PFC=@>0%(3J?2IM0^%<][X$TS0Q>PQWUC*6%RH8
M JQ.X>O0FO5:*.EO3\!];GE6K_"N:^NQ-;7MO"(K>".!2IQOC8-EO8XJ/4/A
MCK&JRV][?W^GW-U%(2;<H\<&TJ!C*8<GZFO6:* .4\/V>I:-<)I"Z;:6^D06
MX*2PNQS(2<@;B3CIU]:X_P 1?#K7->^(5KJ<FI@:;$WFHRHHDB(_AR!S^.:]
M:HH^TI=4'1KN>6ZE\,]:\13J-=UN&YBMXY$MY$CQ(=Q7&_C'&WM55?A/JDUC
M)+=:G:G54:$V\J*WE@1@CY@1GG/:O7:*%IL#UW//;/P+J4'AJ[T::YLG74'D
MEO)0'R'9MPV>P/K6(/A3J5Q;R3W>I6IU*,0+:O&K;%6(*!NR,\A>U>M4M'6X
M'(>&?"5QHGAO4+&XN8I;V_:6261 =@9\],\X&:YB/X8ZK96JI8ZC9>;-9R6=
MT9E8C:S.<ICOAN_I7J]%)ZO4%HK'!^#_  +)X6U^[O?M<<UO+;1PHN#O!4DD
MG\ZJZKX,\0ZAXZ37FN]-N+. 8MK6Y$G[O_:^7C->C44[ZI]A6T:[G!ZM\/;6
MYU33[S3RL#P7(GG$LLCA\=@"2!UK%@^&&J:?=?VC8ZA9_;"\X(F5C'Y<A![<
MY&*]6HI613=SR5_A3J=E:P1:1J=JK&Q:TG:X5CU*DE<?[O>MWP-X)NO"EY<S
MW%U!/YUO#$!&"""BJIZ_2N^I*J[N2U=6/._%/@6]U[7DOK-[&R^=-]RC2K.R
M@C(P#L/3'(K'M/A$]L]^DAL+A)Q*8;F1YO.C9U(S@'9U/ITKUR@5*22&W<\M
MUKX72ZMX3T325O8HKO3\J\ZA@'0GY@/P--U/X7W5SJ\VHV=[:Q,HMS;(ZMM#
M1DGYL=CD=*]4HIW?XW#I;RL>2ZA\+M5U.ZMM0OKW3[NZ0OYD#J\4&UL<#R\-
MV[FO1]%T^+2='M;&&&.%(4"B.(L57Z;N<?6M2BA:*R!ZN["BBB@ HHHH ***
M* "JUY_QXW'_ %R;^1JS5:\_X\;C_KDW\C0!9HHHH **** "BBB@ HHHH *8
MRAU*L,J1@BGT4 <$/A5X:6\-R%O=V^1U3[0=BEP=V!V^\:N3?#OP_/#%%+#,
MRQ6WV9,R]$SD?CGO78T4=+!UN<OX>\$:3X9O;F]LWO);BY18Y'N9S(2HZ#FL
M[2?AAH>D>+Y_$,",97^:.(_=C8]2*[FBB^MPZ6.8N? VBW=MJ=O-%*R:C+YT
M_P"\Y#XQE?2J3_#3P])I<5B4N0(I3,LXG/F[CC/S]><"NTHH"YQ5S\,_#5RU
MF3;S1BUB$*B.7:'08P'_ +W2KVK>#M,UFUDM[Z2\D1I?-0^><PG!'R'^$8)X
M%=-2T/7<-CB;CX:>&[BUL[<PSQK:C:C1R[6<$Y(8_P 63S6WJ?AS3M7TF#3+
ME'%K T;(L;;<;""O\A6W10!QUQ\._#\]\UX\4_SN)&@$N(F<  ,5Z9X'-;.A
M:#8^'-.^PZ>KK!O9\.VXY)R:V*2A:*R!ZF/:Z#8VFO7>LQK)]LNT6.4E\KA<
MD8'XFJNI^$=*U;49[^Y64SSVQM7*R8&P^WK71T4K(=W>YQ1^&?AXO'B.Z6-5
M57B6<A)=O3>/XNIZTFH_#+P]J=_-=S+>(9I1*\44Y6,N,X;;Z\G\Z[:BGUN(
MQM#\/V'A_3&T^P$BPL[R'<^6RQR>?QK)E^'FBW5[+=W\E[?2.C1C[7<&01J?
M[N>E=?10!R'_  K_ $E[.WM)[K4KF&VF2:%9[HOL*XP!GH.!Q5Z?PGI-QXEB
M\020L=0BA,*L&XVG/;UYKH**3U XN?X:^'YK2*W5;R(1%\/%.5<A_O GN/:I
M[3X?Z+I]^EWISWMBRJJLEK<&-) N<;@.O4UUU)36@/7<I6-BME'(@N+B;>Y?
M,\I<C/89Z#VJ]110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@"S1110 4444 %%%% !111
M0 4Q_N-]#3A2$ @@]#2>J!'AGA6(W5YX@N[K0[O4/(O;DK>F^*I$ 7P"F\$C
MC' JC:^(V+7U^;-#"-/4BT\Z7RP?/ SG=N]^M>S:=X<TO2K2^@LX"D5Z[R3@
MN3N9L[NO3J:S5^'?AE()(5LG"21B)AYS\J&W8Z^M/HEVM_P0>K;[LXNS^)NN
M"9"=.L!IL=Y#9':7,GSJG(RV.-WZ5:@^)>N7&I:>RV.GC3;W439+G?YR@$ D
M\X[^E=:G@+P]'$8A9N%-REUCSF_UB!0IZ_[(XKC;3X5ZC'XOAU*>[MC:0WOV
MM2DK[CTPOEXV#IU'---75Q2V=B]XW^(&M^'_ !#<:?IMG82PV]A]M=KC?N.-
MV0,$>E5]-^)FIW'VR&_32[*=((YX'82%"'W?*0#DGY>U=IJ?@[1-:OY[R^M6
MDGGMC:R,)67,9SQ@'W/-4+KX:^%[S=YUC(2R)'D3N" F=N"#QU-2KI693MT.
M,M/B_J MXKN_LK06OFR022QI(OSC&S 8Y&>>M:?BK6-5U#X0#5;J-+.]G6.3
M9"S*%!(QWS4VN?#*&XT^WTC2(H(;![M;F[DN)G>4D9^[G/7)ZFNTU70=.UO1
MFTF^A+V;  HK%>!TY%#5X^=T"=FOF>5WGQ8U?0-FD7=C9RWVV'R98ED>/:R
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MO$GCFV\,7\-O=Z?=/#(P7[1&\>U2?4%MWZ4M4U]P/WK_ 'BQ>#D3QO?:]/\
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MQ^*NH7MYIT,EMIEDEU$DC2W$DA4EL?*NT'!Y_BQTK?\ 'NI7JOHVC6L[6_\
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M5/\ XBC^VO&'_0H0?^#5/_B*$[;#>NY6O/".I'Q3<Z[IOB#[%+<1+$8VLEE
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MX-4_^(HN%CSOP/X%^(/A?Q(U[))I MKRX5K\H=SLF>0OR\=Z]NKE?[:\8?\
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M8_V,%$L33S;(0!Q\I.#T]Z=U?R_0/Z^9P^C^+=;T*2_#+:W.EWFJ7, 63<9
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>'O^1Q\7_\
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MM)C^Q*Z&V,[O%)NQ^\)*YW<>G>NW_L?QM_T-=C_X*A_\71_8_C;_ *&NQ_\
M!4/_ (NAZW\P6EK=#A9_A/KWFVH6\L[E5MX8FFG=M]N4VY\O@]=OM5W_ (5G
MK(\81ZA]KMGMQ=K<F[=S]H "XV#CI^-=;_8_C;_H:[#_ ,%0_P#BZ/['\;?]
M#78_^"H?_%TT[.XFKJQUU%<C_8_C;_H:[#_P5#_XNC^Q_&W_ $-=A_X*A_\
M%TAG745R/]C^-O\ H:[#_P %0_\ BZ/['\;?]#78?^"H?_%T ==17(_V/XV_
MZ&NP_P#!4/\ XNC^Q_&W_0UV'_@J'_Q= '745R/]C^-O^AKL/_!4/_BZ/['\
M;?\ 0UV'_@J'_P 70 _PY_R-WC#_ *^X/_2=*ZNN;\-Z!?:1=:I=ZCJ$=]=:
MA,DKO'!Y2KM0(!C)["NDH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR
M;^1JS5:\_P"/&X_ZY-_(T 6:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %4I=/LIA();2"3S""^^('=CIGCFKM% &:FB:4DDKIIEFK2KMD86Z@N/
M0\<BFG0M(:=)VTNR,R ;)#;IN7'H<9%:E% &0?#FA[&0Z-IVQCEE^RI@GU/%
M2SZ-IEQ:1VDVGVKV\>-D1A7:F/08P*TJ* ,O^P])W1R?V99>9&NU&^SIE1C&
M <<"E@T32;8N;?3+*(R AS';HNX'J#@<UIT4 9(\/:*(Q$-(L!&"2$^S)C)Z
MG&*8?#NDBWFM[?3[>U652K-;1B)L$8.&7!!Q6S10]0,FRT73K/1TTJ*V1[)%
M*^5*-X(//.>O7O5FWT^RLU46UI! %&U1%$JX'H,"KM%'6X&6/#^C!YG_ +*L
MMTW$A,"_-]>*8OAW0T9V71].#.,,1:IEA[\<UKT4 <%XPU>T\%_99M/TK28I
M;V0Q2331F, 8)Y**2>E<[8^/O"]N+1;KPW +R[+Y>PLU9",D!LD X;W'>O2]
M0T>SU&>VFND9FMF+(,\<@@Y'?@FL:V\ Z58WT=U9W.HV[HQ^6*Z*J03G:1W7
MVH7F#\CG_P#A,_#-G?6G]FZ%$ /-:1XK9%:(JK9 Q_$<?D:9=?$KPK:0VL]Q
MH=P'OC\R_98V=5S]Y\'I72KX$T2*6>6%)X9)YGF=XY=IW,I4D?@35>V^'.BV
M7EM:SZE#*ARTJ71#R#T8]Q[4 8>D^(-$U7519V7A*,V<\:RB0VL0,OS$;@.X
M!'?GBNB\56L=AI)O[/2-'GDM4S_IL8 11SA2%)]>*33_  +IFFWOVNVN-167
M "YNCA1DG '8$DY'O6]J.G6^I6PMKG>8PP8A6QG'K[4/5)(%NVSBQJ>C0Z(^
M[0-/;6(HO/EL8;<;4/KN*@?CUJ>WUO0IM+EN[/2;.75OLXGEMXK8 _BQ S^=
M=E<VD5W9O:R@^7(FQ@#@XJ*'3;>#2UTY WV=8_+ )YV_6CH[?(%TN>?:=XFM
MK_Q%I:_V-HMO+<PQSM+,A$NYUW'8P0@GZD5ZA7,Q>#M/B>QVW%^8;)%6*V-R
M3%\HP"5Z$UTU-VMH+6XM%%%(84444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D
M: +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: +
M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)OY&@"S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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9 +Y/^-0W?B.\^Q7'[N#_ %;?PGT^M '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>inmune_ex31img26.jpg
<TEXT>
begin 644 inmune_ex31img26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/I^J3W"M%JCQ(BN%D).'4[CP,<UI?$+3=5TGQ#=:O<:;#KFDR6RQSKYGSVP
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M[]JW/[9L?^>W_CIJW]EM_P#GA%_WP*/LMO\ \\(O^^!2Z6#K<J?VU8_\]O\
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MV3)Z+Y'M=%%%!04444 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H LT444
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M0: -JBLG^Q#_ ,_UQ^=']B'_ )_KC\Z -:BLG^Q#_P _UQ^=']B'_G^N/SH
MUJ*R?[$/_/\ 7'YT?V(?^?ZX_.@#6HK)_L0_\_UQ^=']B'_G^N/SH UJ*R?[
M$/\ S_7'YT?V(?\ G^N/SH UJ*R?[%/_ #_7'YT?V(?^?ZX_.@#6HK)_L0_\
M_P!<?G1_8A_Y_KC\Z -:BLG^Q#_S_7'YT?V(?^?ZX_.@#6HK)_L0_P#/]<?G
M1_8A_P"?ZX_.@#6HK)_L0_\ /]<?G1_8A_Y_KC\Z -:BLG^Q#_S_ %Q^=']B
M'_G^N/SH UJ*R?[$/_/]<?G1_8A_Y_KC\Z -:BLG^Q#_ ,_UQ^=']B'_ )_K
MC\Z -:BLG^Q#_P _UQ^=']B'_G^N/SH UJ*R?[%/_/\ 7'YT?V(?^?ZX_.@#
M6HK)_L0_\_UQ^=']B'_G^N/SH UJ*R?[%/\ S_7'YT?V(?\ G^N/SH UJ*R?
M[%/_ #_7'YT?V(?^?ZX_.@#6HK)_L0_\_P!<?G1_8A_Y_KC\Z -:BLG^Q#_S
M_7'YT?V(?^?ZX_.@#6HK)_L0_P#/]<?G1_8A_P"?ZX_.@#6K,U[_ )!;_P"\
MO\Z9_8A_Y_KC\Z:VA!UVO>3L/0G- &I%_JD_W14E-4;5"^@Q3J "BBB@ HHH
MH **** "BBB@ HHHH Y/Q3X>U'5KW3[S3GT_S+1B3'?1,Z-D$=!]:Q;[P=XB
MOI&=;S2+8W, @NE@A<*%#@Y09X.!CFO1:*5M+#N>:Z?\,[O2;\W%EXCNV3[,
M\2I.B-ACG_9Y7)^M6(_!.IRP3"[O;)))IX6E6UB9(VC0@D8_O'!S]:]#HJKZ
MW$8#:-(_B>#4VE3[/;VWE10X.58YR?RQ^5<?<?#[6!J=UJ.F7>FZ==LK)"\*
MRD -U+!B1GITQ7IV:,U([GF/_"">(D@A^SW>DP3>2\$Q2.4AU;;\W)SNX-;U
MQX2G;4-+GM[M8UL+*2V&5RQ+%<'T_AKL*2F+K<X/3_ ;3SM/XA-I<2*BI&+,
M/""1_&P!&6_2K&D^%=1L]=BO+R[M'@MB_DF"(I*X8G D/0X!_2NUHH3LQ6N+
M1110,**** "BBB@ HHHH **** "BBB@ JM>?\>-Q_P!<F_D:LU6O/^/&X_ZY
M-_(T 6:*** "BBB@!IZ5Y1JGPZUK^T9=6TJ6V2\?4%N'C>0A)8UVE<G'!!![
M5ZS6&OBK0'U"2P76;%KN/.^$3+O7'7(I=;CZ6/.;[X4WZE3I\R2_;\'5!<3G
MD@\%>#ZGCBJU[\-/%,TT-[YEM->(ZEB+MHB57. '"DCJ:],'B_PXUK+=+KFG
MFWB8+)()UVJ3T!.:GB\2:+/I<FI1ZK:/8Q\/<+*"B_4]*>PMSGH_#NKW?@N7
M3+U5BO!)OC#WKW0;!X#.R@X_"LNY\&:[XAU6WU+6!!I\B2*K1Z?=-G8%(R'V
M@YSC\":[+3O%/A_59O*T_6;&ZD_NPS*Q_2H[CQAX=M)Q#<:YI\4I;:$>=02<
MXQUI];ATL4M?T"YGT>S@TV0SW-C*LL2WDI82D<8=CD]#UP:Q/[%\6)?IKJVF
MD/J.60V?F%8U4@C/F;<D_A[5U^H^(M%T@0_VCJEI:><-T?G2A=X]1GK4MEK.
MF:B56RO[>X9EW@12!LKG&>.V:7=AT1YK_P *QU61;R<Z@UO<30Y$5O<,L;.7
M+%& ZJ0<9_2M#2OAKYMG>G6)IHYII-T<,%TS0I\B@';P,@BNY77-*:4Q)J%L
MTBHSE1(,A5SD_08/Y5#-XDT*WN8;>;5[*.:?!BC:907SP,#O1Y(.MS@M4\$^
M)=<TZ+3;N'3[6*SB>.WE@G.Z7=_>^4;>G;-3'X>ZIYUYITETUQI5\8Q/<373
M-<"-<YC&1TYXYKN=2\2Z)H\L<6I:K:6DD@RBS2A2P]LU$WC#PVMY]C;7=/%S
MG'E&==V?IFBX6.9TWP;J6F:?:Z5$\3V-CJ2W%LSRDMY.&&#QU&15=?"OB'2=
M0GU'3H;"ZFGDG5HKB8HJI(P((.T\\=,5UUKXO\.7OF?9=<L)O+&7V3J=H]^:
MD;Q+HB:BVGMJEF+Q02T!F&\ >U'FPT/-7^%6I1K=7,%W#'?.\3*0QVLO&]#Z
M+GI]!7K-G$T%G!$^-R1JIQZ@8JCIGB31-:FDBTW5;2\DC&76"4,5'OBE?Q'H
ML>I'3GU2T6] R8#*-XXST^E.^EA6UN:]8TESJ,VH7$%JT06+'WQ3M.\2:)JU
MU);:=JMI=3Q??CAE#,OU IUE_P AR_\ HM(8FW6_[]O_ )_"C;K?]^W_ ,_A
M6M10!D[=;_OV_P#G\*3;K8&?,M_\_A6O44NWR7W_ '=ISCTH8')KXIB:YGMU
MUG3S- 2)4!Y4CKV]JJVOCW3KV98;;Q#IDLC9PJD\X&3V]C7,VNIZ=H6NPVMG
M=VM[8SS2R>3*N)[,D,2Y.?N]NG<5F>#-<M(Y+<W.NZ5-9+?7+I91H//7+/AB
M=W(YSTZ4+5!+0]!TSQ=!K-Y]CT[6].N;CG]VC<\=>U:6H:A?:59O=W]Y:6]N
MGWI'Z#]*\Q\*12ZS=)>JUC!I6E:C<3R7JSJ6P2QP1V'/Y5Z=KNKZ'::(NJ:C
M-;/:+\\3NPVL>V#1+2*8?::,^7Q1%!I<6IRZSIRV4IPDQ;Y6/Y58FUV2">S@
MEU.Q26].+92?];].*\[AFT>PGTW4);NVFTAC<F5T8-$DK*,+GITQ^-7VNHM,
M\->"TU.XB@E^WHZB4[2$W>]'^:_$3T7R?X':7.O26>J0Z9<:E91WLV/+A/WF
MS^%:>W6_[]O_ )_"N5O9;>V\<6UQI&K_ &FZN9UBO;$N) J#/S #[N,_K7H'
M:CHF-[V,K;K?]^W_ ,_A1MUO^_;_ .?PK6HH R=NM_W[?_/X4NG75V][/;W3
M(6C4'Y16K63:_P#(>OO]U?Z4 :U%<WKOBZQ\/7,,%W::C*9L!&MK5I%))P%R
M._M4 \=:1]L6V,=\H+B-IFMB(HW/\+-T!]J%KL#TW.J8X4GVK'B?6)XEE1X-
MKC(R*UB08R1T(J#3O^0=;_[@H R;Z\U#3+.2[O;NT@MXQEY'X _2L:;QQ8V]
MO'/-K^F)%(<(Q)P?TK1\:V^GW7AYX=0G>")G79*HSM8<@GVXKRS6?$D,VG"V
M?4=)%S#J$>S4HU'E3#:?F*YYQT/-2GK8;6E_4]!/CS3A9_:SX@TP6^_R_,).
M-V,XZ5K:9J=WK-H+K3;ZSN8"<!XSD?RKS+7-?M/^$4E+ZIINHZC_ &C"QG@(
MCBE(=2 #DXPO\J[;P5:/I%Q>2:G+:6UYJ\WVB&SBF# *% ^7UX&>*M*]R7I8
MT+O76L=3BTZZU2PBO)L>7"Q^9L\#M1'K[RZL^E1ZI8-?H,M #\P_2L7Q?>^&
MI-2@TF>[LK>]>XCN9F=P'^4@@#U8XQ7.Z,RMJ^FZ>C+_ &O%JS33KCYQ%A/F
M/L0/TJ8ZC>AWVG:O/J\$LVGZA97$<+%)&0\*PZ@\4[3=7N-7,PT_4+*Y\AML
MGE\[3Z=*X&YU&*[T'QI%IMXC?Z>3,8&RRQ$<D8^A_*MSX<7EK90WMA#J0N-*
M6=8M/FE<$R$YRH/\6,"J7Z('I][.FU&_OM*LI+R_O+2WMH_OR/T'Z5G:7XNM
M]:N1;Z;K>G7,Q&0B-R1^5:WBVYM[7PMJ,MU+'%$(2"TAP*\HOKW3==T'PE8^
M'YEGURWCC+RVA!:!1&0VXCISCK4IZOY#MI]YZYMUO^_;_P"?PJ.XFU.UMY+B
MXGM8X8U+.[=% ZGI7BG_  FNL6@ABBURYN+U5N(Y899L\K(P&?0A1G]:[WP'
M?ZEJOA[5/M5]'?1E#Y.+Q;F124&58@#!SGBF]FUT$NE^]CJK&ZO]1LX[NSNK
M2>WE&4D3HPZ>E6MNM_W[?_/X5XWIQUBZLX=/T#Q#J"S16\\ES!'+Q ZLY5?]
MG.!Q[UZ%X4?4M2\.WFIRW=VTEVI%O%,^1'A<<<=2P-#V;70.J3+!\5Q#5/[,
M.M:<+W=M\G=SGTZ5LXUK&?,M\?Y]J\C:[TD?#";P^R+_ ,)(79?LN/WYF)X?
M'7'3FM73[^6\.J66M>([VSU:W#1PV,=P(U= .&"D98^]'1OM^/H'5+N>@7=W
MJ-C9R7=U=6D5O&-S2'H!^59R^*8VTD:HNL:>;$OY?GY^7=Z=*H>#[^SL_AA8
M74FKQA/(&ZYNY RQOCH>G ]*YZSO1#\//$4NH7-G)&]R3'>Q#9'<9?.5Y/\
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M_P"/G_N+-_)J$O>:\P?PIGTSK/Q)T+1-.BOKQ;OR98_,7RX@3C=M]?6I]/\
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MB:*2.(*R,,%>:=M_D*^WS-RBBB@84444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_ (\;C_KDW\C0!9HHHH ****
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M[^W-(.?^)I9<=?\ 2$_QH T:*B1UD0.C*RL,AE.0:EH **** "BBB@ HHHH
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MHLUL_#QN22/*")NR.O'X4)6_K[P;_K\B2P7['XFU6_N8UEMH;*.UMT5T)E4
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MX]P7<T@ R5W ?ES2TT\@OJ[=3RR\\'W^FW<GD>'9KK3454%K"J_O'\@#>1D
MX?N?2NG'A6YF\&^']#EL6$(G$MU&<8C ??@_RK??QSX9C5)6UBV%L\7FK<%Q
MY9&[;][US4\?B_PY+-%"FM6323(9(U$HRRC.2/;@T^EO3\!?Y'EEMX)U5(M5
M#V-YYR13K'&MG$L<P<$ !P=S8&, BK%MHNMPQFSM/#=W;QQW1N]VQ%5MJKL4
M8/7(:O2$\<>%I!&4UVP;S)/*3$H^9_[H]^:L^(O$>G>&=&?5-3E*6RD#Y!DL
M3T '>D]M=MBEJ]#R^Z^'D\<%WY&C;YH[&..!]BY:5BQ9OJ,+S[U')X,U6ZM[
MR[N](=[A;=WA60 XED923]1MKT:#QYX4N+,W8URS2)2JOOD *$] ?0\5>O?%
M&@V%S#;7>JVL4\Z[HHFD :0>P[TWN*_Z?@>2^$;>*[\::9:O:R27=I-//-?$
MY$P!V@>O\7>MG4O"]SJ7B*[>716,3WAEDE*+B5!&X4 YR06V]>]==H%WX88Z
MCJ^F6D-HV=UW<&(1EL\Y)[UG:K\7/!VDM"IU+[7YP.TV8$@&/7GBBZTOO;\P
M2M=(X5_"FM"VD6Z\.W%PF\>0(\$QG&X90G:5#<8-=MX@\/7^KZ+H=D;*$R1*
M7E_=KMB<)E>.WS8'%;%CX]\-7EC;7#:E%;?:0QBBNB(W(!(/'X&ICX[\*" 3
MG7]/$1?RP_G#&[T^M#[/O^(+OY6/-XO".IZA=6-N/#TUC:H\:7KN #/B0DMP
M>1@]ZDF^'KEFE700"7N)2JHO/R*(UQZ$@\>]>G6GB?1+[3I]0M=4M9K.WR)9
MDD!5,#)R:J_\)WX5\J*3^W[#9,Q6-O.&&/H*&KZ G;7^M"3PI%<6V@6]E<6T
M\$EJOEDR@?/[C!Z5T%8,7B[1;C74T6WOHY[YE9FCB.[8%QG=Z=:IS>/_  Y%
MJ?\ 9ZWZS3@D/Y7S+&1V8]J&];]Q)65NQU=%<U#X]\)W$D<</B'3W>4D(JS#
M+8ZXJ&3XA^%8[J& :S;2-*YCW1N"JD D[CVZ&@9U=%<R?B#X1"*Y\1:>%8D*
M?.'..M:^F:OIVM6@NM,O(;NW)P)(FW#- %^BL+7?$NE^'GLDU&8QF\F$,6!G
MYCZ^W-;08,H8'((R#1TN ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!9HHHH **** $K
MG[G1+O\ X2*75[.Y@CD>V6$+)&6&06.3@CUKH:*.MP.2U/P78:YXA34M5BBN
MHD@$0A8$8;G)X/O6+??#)+FUN((+FWB$LTLG^J/W7VX'7MM_6H?&M]XF/BJ+
M3]"GOPHMA(8[3R1SD\MY@Z<=JR;GX@>,[$*JZ5I4\AN7M@9)3'RF,EF+!<G<
M,?C25K*PW>_]=CJ-*\"3Z5XLFU:*\M_L\PE5H1"0P#D$8.>,8K+/PQN9K])+
MC4;9[:&0F%! 0Q4L&PYS\QXJC)\1M:DDO+:Y@LK.:)?,2.!_,DP".I!*]ZR[
MWXI>)(=7@^QVNGW'VF+]U:^9M6,\']XQ(PP''7%/JOP%;1G9>,?"VHZC=3W>
MFQP2^=;"V\HX1D^92'#'CC'2L,?#34;B^GA>X@@T^2.,.VW=*[A%R00?E^8'
MM39_B#XG_?(VGZ?;(%$9(<NZR&$R9!!*D9%=98:S<S^ ?MTM];-?BTWO+%\P
M5BO!('>E:R;[?\./=I=S-T+X=-I&AZMIV=.1KZ)HA-;P.K$$=7RQR?IBLS6O
MA5=ZA:RV]MJ5G'%(V3'+;EE'[M5R,$<@KFL>+Q_XBT>W:&#&J7LS*4%[+&(U
M!QD[D( 'H&.:V9_B#XA%M=2I::1;S6R@-;3RDO(Y'5"K8*TVKZB3L6K7X7>1
MH_V-KN!IO+F0R^4>2ZJ >O;%47^$LRRWKPR:.TDQ+1W$UK(TJGW(< _E5&_^
M(?C-XM7MUT[38!:0/_I,4WSJX7.0C-DCD=JCG^+.NV5TUM]DTN[41,$EB=LF
M1<=1G..>M&]@V5CKM1\%:C?>![/0O[2MVG@8&226$M'( ",;00<<^M8>D?""
M73]'CLI-3@>59Q*94A(R K #K_M#\JZ#2_%NK-XBCT75K>RBG6,S3S1%A&J<
M;<%CU.:;XRCUB/4M)DT_7[RQCNKD6[PQ1QLN-K-GYE)S\OZT/OW!;>@W0_!N
MHZ;IFKP7&H6KW%[&D:/! 45 J[1D$G/3FN5LO@[JEH]W+'J^G"2Z 211:ML"
M]R!NX8D9S4L_Q"\76;P00:9IMVK3R0K)-+Y;,L;%2Q)8+N.,X%1Q_%77)+N\
MA73],.R(O$?.(P0^U@_S=N?KCBC=W^06LK>9;_X5/?F2TB?5;1K.U=65?L[;
MVYR0QSSWJ:?X3G[??7$!T@_:.8I)[5VDC.T#J' QQZ57O?BO<V.@O>>3I\EP
M(4>-07"NQDV$#)R0!35^(WBX7\$#Z+I;QM")I&6<H0ISC 9AN_#-#_X T6+C
MX5ZI=16D4FL6BB.+RYI([=A(PR3A3G '/I0OPHNX='6TM9M&MKA9-WGQ6DF2
M/Q<\^]=CX:UJ^U+1$O-32V2YD!D6WMF.0F<#()SG@^U<5;_$?Q!=ZWI^G6MI
MI3O?,"K;G/DKDC#X/WJ+>];J3?W;]#J-2\.:CKWA*ZT?4Y8!,9"L4FTE60?=
M+ 'OWZ5S\WPKN6TR.WM[G3+25%("P6SB+)[[2Q/ZU>U[QQKVG>,1I5CI5K<6
MD4:O/)),$?G/W 6&>GH:R;/XH:BUQ +N'3!#*4)>-V_=JR,V&R>&& *%W[C>
MBMV);[X3/<VMG&+NR<VT<2F.:!C%(RIM)8!@??K71Z%X*71K/58E:U5[Z)8U
M\F(JL>(]O&23C//6N4M_B;J:W4MQ);0RVUP8H[=%!^61AG'T(R?PJI=_%36_
M[8EL3;V:QQLQ22V)+,4;#*P8\=".E&^G?]0??L;%W\*4DO+2=/[+F$4 B=;J
MV=N1_$NUAC\<U77X5ZBULD<FKVH,-RT\*1V["-3@8!&<D9'/-0VOQ(\6W<*D
M:+I<332LL+&?>-@!/S!6)!P*TM#\9:Q.NO7UW]FDBM;?S8;:,'(('/OMR*-M
M0ZV,^+X2W)O8KR[N=+NY?,W2+-:OL X^X PP??FKS?#"5+6W6VO[:.: 9!,)
M*L^>,C/(]JKV7B?Q)KWB32[%+NQMH%G+3O: LLR *VS+9YYQ5;5/BGK5EX@N
M].MK#3IXE#BWDWMN++CAQG(ZCM0NB7R#HV;-E\/;R/Q7#KM_)I%Q*-I<K:.K
M*1G_ %9WX7KW!IFM?#F\U;4+IO[2MTLYIS<*AA)D#DYP6SRO7C%8^K?$37UL
M;JV5-.M+N NLDPW8;:5_U>3R>>]:OC'XA:CX<U2UM+6"SGA9%\XR,1*NX<%1
MD T;V^Y!?5_UL:WB/P9=:K;Z8FG75I;&R4KB6 NI!4@X (]:YV[^%>I2M###
MJUD;*(I((IK=F+.L93)(8<<YJ]8^(]6G\.:W<27[":"& Q2;5_=E@,GIC\ZQ
M9?%.M:-=0QP:ZVLPM!Y[R2*GRMLSY9* #'Z\4NMWU_4$M++I^AKVOPQO0EF+
MW5+>?[. "H@(7B3?P,\56M/A,UIJKW;2:;=!RY/VBW<LA)) 4A@ .1^M5X_B
M)XL748X)=$TV6$6XGE,<VQL,FX;0S9;@C.,]Z+[QYXAM[C3[W[1HK6TR2$VT
M+,2" <!^>"/:F!-'\+M80Q$:Q8(R3F0%+5AL4XX7YN#[G-=A>:)?ZYX<ETW4
MGAC<R *ZKD% !@]>O6N/C^(?B2ZNI;6SLM(EE@1Y))=[B)P$#84[NO..:V+'
MQIJ=]X,?4XH;"34!<BW"(7\H$X[YR>O8T/6-N@;.Y1T[X8W4%]837NH6LT5C
M)&8HXX"NY%SPV3R>>M6?&GP^O?%.L0W4.H6L,$87"2P%F0C^Z01C-4(_B'K5
MM<V:ZG9Z;%#<3",NC.-@_B))/TJJ_P 3M8NI(XX8]-@AN(\Q2%F9RV.P!X'U
M%#Z>6H7U?W'36/@:6U\/ZEIKWJ,UWLVR*A 4KZCO6;:_#6[$US<WM_9R7-Q&
MJ-Y5N50;75@0"3V7'XU1N?&.N65EX;N1>V$CW-B9;@2G"2-\O3'.[DU>\+^/
M=<\0>(FMWT>VATT)_K#.!,K8SRA;./H*=M7Y?H*^B??7[P'P]U""2X%IJ5F(
MKI)8YA-;EB%=BPV'(P1D5'HWPN737MVE&DGR?,&(;9U$FZ,J"^6.3SDXQ563
MXCZ[!'=2SV>FHF9!:Y+\E9O+&\YXSBH;+XF>(]1M(9(--TY9  )PSL5W-*8Q
MM(/3H:2U&^QO:7X(U.P\.:KIC:I;^9=L3$8H"L<0QTP3D_G6#IGPAGL[2\CF
MU&S:2=)%3RK=E6,NH&0"3Z9HC^)OB5]62T71+*5(ES=,)MC?>(_=AF&[@>];
M'@_Q9J&M^)+N/4;FR2W^RQ-## W"LSN,'/.[@<?2G'5W0/16?<GT/P#?:5X@
MAO)-1MI+.!)%CC6$B0[PH.YLX/W?2LQ?A=?_ &U7?5;4P0J4B58"'VG^\<\F
MNA\?G4X-#:]TS5[G3Y+<$D0HC"3/KN!Z>WK7-/XG\1^&-4NH;BZ75K&)X8MU
MPH6;<X<\; %Q\M3I;7H.W3N+-\(T=[##Z;*(+5;>0SV[$Y48W)AA@_7-3S_#
MO5KK2K&QFU/3@MBP$3QVC E I W?-R>1S638_$[QA>"/=H>E1[X6G!$Y?*#'
M96)!Y'6ND\+^+M=U?PO?ZIJ6G6EO-"F^!8)Q(K@CC=AB0?RJG>SOZB6Z,^Q^
M&=U'JEQJ&H7EA<7$EI]F15MF$:X  ;&>N!SS71>$O#VK>';-;6?4+6XA+%F6
M.$KCC@+SP.G7-<O)\0_$EFL4E[I^F"-G1&\LOD%DW@\GH!UJ&_\ BAJ2LQLH
MM+%MY@B\^1V))*@\ ').3Z4KV^X+7.J\2>";;Q3>33Z@Z,%M_+LQM.8).3O]
MSS^E='I=M/::9;V]S,LTT:!6D48#8]J\[E\6:Y'X+T?4EO[+[7<79C>1^(RO
MF8P_IQZ4S3/B-X@U7Q!8V,.CV9M9 OVB4SA&Y8KF,,WS#CT-"C:Z7<3=TF^Q
MZO25Y-XN^(NL:7K]SI-C#8F(AHTFW'S8Y,=USR.?2O0_#EU<WOAVQN;N6*6X
MDB#.\7W2?:A:JXWH[&O1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY1LEW9P1GCGC-<Q:?"C4HGU*<66GV]V\[-:SQR98*6Z].#C-'42U1ZG%8:!
MLT\%GIR!,O*\<2<<<DX'I5;3+WPWJ$#W6G-I[QR*8V=$5=P!.0<@9'6N6\$^
M Y]!L=8M[NR1'O4=6;[89EF)_B*E1M_6N:U+X3ZO)!+:65KIZ+(,I<B7:\([
MQJ,?=/.>?XC1UL,]8MH]!LP/LBZ= %)8>4(UP3U/%/&AZ,\S70TRQ:9QDS"W
M0LWXXYKSM?A):K+D:;8A-P! (Y7: 1T]<UWGAZVO[#38K&\@B18$"HZ2;MW)
M[8X[4P,[4=3\(1:J--U!+ WH;<(Y+7>03WSM(!./TH.L>#-6OF1VTVZNK=22
MTEN&*@=<,5_E5+_A"I[O4-6O[G4KVWGNI3Y4=O<D1F,?=W+WZFL7_A#O$EUI
MEM936VGV:V$!AMS!+DRDD98G V\ \<U*O;S'I?R.BA\7>"I[:58KVR\AE7S5
M,!567( R"O(Y%:$*^%[>>73X+;3HY$B^T20);J,)C[Q &.A_6N!U'X9:L[/!
M%<O>6L900/=7)9XXP,E ".FX+^5;_AKPEJ=NVKWNIM&;N^M!!&=V2HV 8/I@
MBGT;%V-N6[\*O<H\HTYIXK<2HS0J62+H"#C@>U,L?^$0OVQ96NF2L4:8[;51
M\N2"WW?8BN+L_AIK*7EG<W-Q"[>45N0'^]M),8'MPF:L6OAGQ?HYOH['3M/G
M6YMG@25[TH8]Q+=-ISRQH>P+<[NUM=!?3!/:V=B+-E;E(%"E>0W&.G6L2U\6
M>"X[&9+:XM([>W(=HTM]J@\@$#'7C]*6QLO$?_"%7FF7&G6EK=K;-%;^5=&0
M.Q!Y)VC')K@S\/?$QB1A9J$4Q!HFOV9F"L2=K;?E'-'VFN@+X4^IZ1'J'A;5
M-'GOW@LY+&WR9&FMAM7\"*S4\0> %C-Y&-,/E,L0=;0!ER#@#Y<]C0_A_4[_
M ,$'2)$>"6>3;*)+LRLL?<AR <^V*Y;4?A_X@BU#?&9=1A2Y$D<TM^RS;!D*
MN[:<8R:'H[ MCJY_$_@'R+5+DZ>L8.+>.2SR%_W1MX_"M"+5?":Q#68FL$#,
M8OM0@ 8D Y7.,]C^558M"U&Y.AF=/+CL]TDBR7!E<28P.2!GJ:YV7P9XCO(#
M830VD=K!<37$4JW!+3-(6!)&/EX<^M#Z@CHH_$?@:^CE59M.EC09</;\89O=
M><L?SJ2[UGP9H6V!Q8PDD 1Q0#_?' 'OFN5_X5GJ$ES]DFNI+O32D4:M<W)=
MHE4*6501TW U1D\ >);;55N"@O(TE9XS%>&%U7;L49"G^$"@#L6\1>!FNK9Y
M#IXN7 :(O:_,,D@<[>.<UHWC>%M!'GSPZ=9EU,V];=02%YW<#MUKE$\,>*9K
MC4+6:TM5LM0**]P]X9)8XP "N"O)Z\Y[U>\3^#=1UN_ABCD5+%(8H2XE*N%R
M1)CCKMQBCM8.]SI(O$.@ZKI%Q>+=0SV$(S,\D9VCZAA4=UJ7AN&Z6*[ELA-*
M48"2,98G.T]/KC\:J:KX6G_X0Z[TFPN[JZDD''VVY+D_[.X]!7.3^"=7\07W
MVO6H;6#S&4M%#-OV! =F#@9^\?RH=KAT.AFU/P1H<[1N-.M9BS1$1VP!)[CY
M5J;^V/"FD6LPB:RMX25\Q(80 Q89&0!SQ7'1>#?%MI%"P^R7-TSR-)<?:#$\
M99@3S@[@<=..U32>#O$5K.FI01VT]Z'==@F,85>0KJ<'! XQ[T= ZG6Q:GX6
MU&.-5:QD$L;2*CPCE5&"<$=AD5E_VSX 2Y6T2WTUI$8$!+(80GD'[O'6N=7X
M=Z]<6LMS=740U18V6"429QO;+ GZ%AFH]*\&^);"6]4VA\R:,JLR:@R)D1[1
ME-O/0=Z.H=#MM/U3PAKK-I=B+"Y"DL;?[/\ +G/)P5P:V1HVEB:*4:99^9",
M1/Y"Y0>QQQ^%<9I&B^)+>;3[B]L;&#^SU\J-([HMO#$[W)VC'!)Q^M>B?6AB
M7F9LNB:3-=&YFTNSDN#UE>W0N?QQFK=O!#;0K#;Q)%$@PJ1J%4#V JQ10,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1J
MS5:\_P"/&X_ZY-_(T 6:*** "BBB@!*P8?$]C+KS:,8[N*ZYVF:W9$DP,G:Q
MX;\*WJXR/2/$X\1RZE-=:3/" 5MU=)-T0/I@XYI+<'L7_$/C31O#+;=4N'B.
MS> $)R/;U/M4%_X^\.Z9?V]I?7ZV\TZJR+*-N V<$YZ=*B\0>$)==U:&\:6W
M"1QA2CH3S5'Q)X&GUSQ18ZDDED+:'9YL<L9+MMSP.V.>])7LK]_P&^MNWXG3
M?\))H?FQ1_VO8[YEWQKYZY=?4<\BF0^*?#]U-'%!K6GRRRG$:)<*2Q]AGFN"
MA^$TJ:B+B4:9=#RPBO-YH>' (^3:0._?/2K%K\+4MM6TVZ\C3;@6T$<;F42J
MRLH +)M('..^:M6=KB>FQW<NOZ/;7OV2XU.TBN@-QA>90V,9SC/I45OXHT"\
MGCAMM9L)II?N)'<*2WT&>:XGQ;\-M2\1^)FU*.[L4B_@+H_FJ/+*E<CC!)S4
MUI\,H[7Q#9ZB+?3IDABB4F02*\;*H!*;2!R1GG/6E'7<'IL=M/KVDVUY]CN-
M3M(KG;N\EYE#8]<9S6:?'?AH1W4IU>V\JV.'?>-K'&<*?XC]*Y'QK\,M2\4Z
M\]['J%I#$6!1F5O-08 *@CC!YZ^M5V^%NLL\\_VO2O.E5H_+\I_*"E N<?WN
M,Y]:2NT/2YUT'Q(\,W-]]BCO6^T%@H0QD$Y]*TF\6^'$5B^NZ<H1MK9N5&T^
MAYZUPMO\+-0@OO.^WV15W!<^6V\  ?=/YTEM\*KTZI97-[=:>\-FNQ$CC;]X
M/[SYZM38COG\3Z'&XC_M:S>4IO6)9U+LOJ!G)ITGB/2(+:UN+G4+>VCNE#0^
M?($+@^@->;GX4:J;_3YFO[!EM%0"38XDP 05&.,'(Z^E=!K'@>^OH]/6WN;,
M^1:"UE^T(S#&5.Y,=#\O?UH8=17^+?A%=7;3!>S/<++Y1V0,RYSCJ.,>]=)_
MPE7A\1O(=;T\)&^QV-PN%;T//6N-D^&#&PGMX[FU5I(W02^7\PW2AP<XZX&*
MAO?AOJ-_I-G87:Z--'9S%T4QRJ)EP1^\*D$GG/'I1T#J=M-XM\.6\ACFUW3H
MW !*M<H" >G>M&2]M8K-KR2XC6W"[S*S +M]<^E><7'PPE.FW<5K'I:7,\Z2
M1NZ2,L*A%7 R<GH>N:Z(:3K=WX5O]'NGMXI@/)MY\961=HY8?7(^@H?PNVX+
M==AUY\1O"5C.L<NLVS%@"&C<,IR<=1]*UH_%.@2I,Z:U8%81NE(N%^0>_/%>
M6V'P?U2S,SK=:.6D?>$,4A5,= ,\XSG-6(OA-K"ZF]^]]I?F[1PL;@2D=/,'
M3'TH70&>A6/C#0-2U(Z?::K;27( *H)!^\!SC;_>Z=JO'6M+74AIIU"U%Z>E
MN91YG_?/6N3M?!%[_:::E<OIL=R+F&8BUB95"H'!49YYW#\JAO\ P+?WGQ!M
MO$7VJS\B"82#*L)@N""N1QCD=?2CJD)[-G2MXNT9+N:WEO%@:$,7>;Y$&U@I
M^8\=33]-\4:/JMU=6]E?PS/:J'E*,"H4@'(/<<]:Y?5_ -Y?37TR3V3FX60(
MLZOM4M('!./3%2>'O NH:59ZO;W5[:R_;X @DBC*LC!0N/\ =X^M)7W?;\2G
M:]D;%WX\\.6;VL?]IPW#W,XMXUM6$IWGL=O2F#X@>&?[2:PDU2&*=93$?-(4
M!@ <9/UK&T7P#=6.L6FHWL]@S6[\)!$0I4)M!Y_B[DU%<_#>YNM6U*Y>>Q\F
MX\YHAY1WJSQ; 3VX//%/K]__  !?\#_@G9GQ#HBRRQ-JUD)(5WR*9UR@ZY//
M HL_$&C:C+Y5EJMG<R;=^R&=6.WUP#TKSZU^%#0S7C2C396N$V_:F\WSN5 P
M>=N/PKIM'\%+I.JQ7D;6ZA'F)"(02KJ@ _#:?SH$S1L/&'A[4(XC!JUKNE<Q
MHCRA69AU !.:@U#QOX>TG4GL+[4(X+A&16#\ ;@2"3Z<'GZ5R,7PTU&*XDQ=
MZ<(9F 8B)MZ*#P4/0,<\_A6OK?@:?5O$S:AYMF;5WB=TDC)<E%9<9Z8.[/X4
M+H-[NWR.@'BS0?.:%M4M48;-K-( K[AE=I_BX]*CU7QCH>CZO:Z7?7@BN+E2
MZY'RJH&<L>BCZUQ,GPOU/?&T-WIY=&CQ)(CED51C"CI^8KHO$W@Z77989UGM
MQ/%;+&&E3.YPZMDX['&/QHZ)AUL;3>,/#2!2VO:: XRI-RG(_.K-CKFE:E*T
M5CJ5K=2*-S+#*KD#UXK@+#X621RWUQ?3V$DUW)&^U(SLC"R*Q"@] 0,?C6YI
M/A&XT*Z2YL'LA(%9'!1L,#(S=O0''X4UYB?D=O12#.!G&>^*6D,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ9RS^&9XYEN('@N8K-8UBC5\L" ?D..PS5[Q'HU_JWB26[@T"^^U2R0O!=O
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M2F;08KG56L[9)KB&[M&,8D8IE4.#_>SQ[U:?3/&BV]U=I<:PUU+YZ+$9FVJ
MB;"!G@Y+<T:!UL>R5$9X@-QE0+G&=PZ^E>&ZU)X^O[R6:TM?$=L@?, 3.&Z<
M.N> ?QKL+G1]4E\*VL)LYC<#4C*Z;>0N#S]*3;2N"U:1Z$94"ARZA3T8G@TA
MFB658FE02,.%+#)_"O$+S1O$\LJVIMM?FM4CC)7<4C3!'"+G!Q^%;OCGPOJE
M]JR:MI7]HK<1V:JDT1+21G<H.T9^]C.>?6FW;[[ M?N/6:C#J6*A@67J >17
MC^C:9XO3Q)8-=ZUXC:SCQL\RSPL@[B4;^#UYYJYXMLO$">)Y;O38M7,;W"';
M995) %7[S ],CT-'5>8=_(]5WKYFS<-^,[<\XIW:O+O&=CKDOB"SO=/M=4\[
M["B+):,0JRY8XD(ZKR,UR]O;>/"+_P ]O$RH\:-L4$D."V5C.[H1CFDF![U4
M8=&9E5@67J >17BEC9>/I+R2XEN]>MIA!B"V:,R0G_?<L,-^!K8T/3]=M]"\
M330V^KQW<RQFW:Z)\YR-V<'.>]/N&[2[GJU+VKPR]OO%=[XF9!%XAMQ*LLEM
M;HS*1AUVEQG[N":DNK#QU=7L</F:Y%*\S"\E21EA\O=\OE<\<8H6M@OH>UO(
MD:[G=5'JQQ0CK(NY&#*>X.17FNJ:-K-Y\/$M+F/4KB[@OF*@.3,T8E.TD]_E
MP:Y6?P_XQL+*VM].N-?M[2</)<F',DD1\UL!%R,$C!//<T=6O.P=CWFBO/M8
MM]97PSHT?FZS<JC?Z8UJICNF7MP#P?7FN7U!?&-PW]GV-OK\48EE87+LP.PH
MH49SR00:=M;"OI<]H[5&[K&A9V"J.I8X KQ?4/#/BV"T+0ZSXF53=LC&*1II
M!&%7:0I8<9+9.>U1W/AWQ?<:5<BXN-<O#.)T:.1F4%04V?)D@$_-^5(?4]PH
MK/TA=ND6J;9UQ$HQ<?ZP<?Q>]:%-Z.PD[JXM%%%(84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H LT444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD32KV:&VC@\P,;,?.PZCYE]Z[RZ^(OA:U1V.K02&.18Y$C.60G.,C\*U-/\
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MQZ5M_P#"(6(\/:?HTCE[6QE24;T4A]I)PPZ8YKSZ]\#ZC:^)I=1TZPN6GDU
M2&>1MWR@+@DGMG-;O@G1=;73=6@UB]UF62X3&R[38$//^K<,3CIV%)/W;^5Q
MM:_,W+WP9HVL&66VECAB> P 6JIM7IR,=^*HO\-;:XBF^V:E<W%Q.CK),T:
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M]CD5_. A0-(6()& , <=JOM\+;;[4\T>J2KO,F5>UBD 5SG W XQZ]:]%HH
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MD\]* .[O]2LM,M6N;ZZBMH%(!DE8*N2<#GZU6N_$>C6$]O!=ZG;0RW !B5Y
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M<YPH8 94[>HJ4?"_59YX8KJ/3OL\4BF217)>Z7OYGR]1VY/6JMK8F^ESU/\
MM;3OEQ?VI+#*@3*2WTYYJA?^*]$TS2[?4KN_6.TN2!#)L8[\], #->8S_"O7
M3K%O-"FFK!!*'AD65D>)><J %YSQWXQ70>*O".MW/P]TW2K%;>6\M517'?CN
MC8R*GI?S*ZV.H;QGH"3/$]^4=(_-(>&1?EXY&5YZC@4^'Q?H=QI,^JQ7V;*$
MA9)/*<%23@#:1G]*XS4/!/B;5);<W,EIOMK98A,UT[F4C!Y4KA<D=1S5D^&/
M$\FC7D3PZ8MU=3QS%5N'*+L(P,[>^/2F)=#H1\0/#)%N1J@_T@XC_<2==VWG
MY>.>.<5O-J%HDRQ/=0+(PRJ-( Q_"O,4\#>)EN'G*:9NO#BZ7[0^(AYN_*?+
MSP.^*EU[P3J^L>+9'@M[>.W$<(%[(Q$B;2"=F!WQCJ*.P=ST;^UM-SC^T+3(
M.W_7+U].M7@0PR#UKQ[P]\));'7;6ZO;&S:**9I)6-V\OG>A*,N :]?50J@
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M8?-P.V?<5L:=XZ\7:Q9075M<Z?$IQ&X,&_+8Z@YZ5Z]]AM2,&V@QZ>6*>MO
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M,:X)W8[]*.P=6NQUM%>7)\9-'B9([JUNGDDEE5#:IO7:KE5))(QD ?G6E?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML'6YQ5C\+M)MC=B>XO)XIW=EA\W"1A@ <#^]QUJ\_P /]*>*:$7>II;ROO\
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MPG'S\E@V[D]QFM*WNK>YC+V\\<J@X+1L&&?PI9)XH54S2+&&8*I8XR3T'UH
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M8A?)56PQ;!ZC!Z4)\NOG^8G:5UY'.>)/"OB6Z\27=U;Z9-<MYCO%<FZ"H4*
M! NX8.0><=ZP(/ ?B_[+G[%?"17G\@RWBEXBRJ <ANF0>*[0?&G0?[,>[:PU
M/<LGEB$0C<_NO/(K=T?Q_I^MZU'IMM97JEX_,$TB!4^G7.?PH2LK#<M;LP-#
M\,:K:> [O3G74FN9)-RQWTT;L/4AE.,?4TGASP_KMI;^(();.ZB6X7$,D]R'
M>0\],-A?TK0O/BCH\%])8)!<M>*O"$#&[TZ]:FT'QO-J^HQV\MFD2/#+*65R
M2-A7C_QZC>[[H-K+S_(Y ^"O$-C;K#':7EW: 1%H%O,,TFPAFW%N@)Z9KJ?
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MS@MURNWCTX%8EI\/="LY9Y1]LEEGB:%Y)IRS;",8S].E=C12V YR3PCI<BN
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M4Q+<G9)C.-Z_Q'DU%J/P\T/5;^6[N#>;I',C1I.1'N/5@OK[UV-%#UW!:;'
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M3C&<\5TU% $,42PPI$F=J*%&?05-110 56O/^/&X_P"N3?R-6:K7G_'C<?\
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MC9V$G<**XO6]>M]#\;6<FH74L-F]BXX5V4OO7'"@\XS7++=ZUJ'BHZE?//\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "JUY_P >-Q_UR;^1JS5:\_X\;C_KDW\C0!9HHHH **** *MU;K-:RP,\
MB"1"A>-MK+D8R#V/O7._\(';?]!WQ%_X-)*ZIJ\(D\4Z[_:.H16NIWDLP6X
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MNO*:U/E6XE$,<+[/O'(.X=\\8IO1V$M4V=Q_P@=M_P!!WQ%_X-)*/^$#MO\
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M#,68 MSSC'M7)P:_XHL7NA<Z_=7#26AN%YP$.2  /PI+5V!]?(]]HKQL^/\
MQ1;*\EQ+IYAF67R&\@CR0A7YG.[D?-[5L6WB[5+SP@NHR7UO)+'J+P>?:(1'
M*BAL$#)X.!WI]+@>ETM> #XE^);R6,G4-.18KD,'@0[70QLP1QNZYQQZUTWA
MOQEXDU6"WO-1FT\_Z4JK%8S!LJP^[(H)((SG\*:5P>AZS1112 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7G_'C<?]<F_D:LU6O/\
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MF-PP_2@#R;^T[3=N_P"$T\8[L8S_ &1SC_OQ5;?H^6/_  E'BG+=3_88Y_\
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M%E:!_P \]6_\%=Q_\177T4 <A_PLK0/^>>K?^"NX_P#B*/\ A96@?\\]6_\
M!7<?_$5U]% '(?\ "RM _P">>K?^"NX_^(H_X65H'_//5O\ P5W'_P 177T4
M <A_PLK0/^>>K?\ @KN/_B*/^%E:!_SSU;_P5W'_ ,177T4 <A_PLK0/^>>K
M?^"NX_\ B*/^%E:!_P \]6_\%=Q_\177T4 <A_PLK0/^>>K?^"NX_P#B*/\
MA96@?\\]6_\ !7<?_$5U]% '(?\ "RM _P">>K?^"NX_^(H_X65H'_//5O\
MP5W'_P 177T4 <A_PLK0/^>>K?\ @KN/_B*/^%E:!_SSU;_P5W'_ ,177T4
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MX>PO-=0L"W^K=91S]" *]0_X4'X-^[YFJ;?3[2/_ (FG#X!^#?\ GIJO7/\
MQ]#_ .)IQ=FWYW!ZQ2\C(^)W]E7'C&S74-4L;.'^S6"R7$"S MEL  ]#[US^
MB7.CQ>2?&2K]@.F[=/\ ..Y=VY\D9Z,1MQ^%=P?@#X,;[TFJM];H'_V6D/P
M\&$ %]4('3-R/_B:E*RL.^QYSK;O-I6C0M#/+?06[/?E9,$VN>%8]^AKT#X@
MW.C77@S03;W=K!IK7<6'= Z(FUN2IX(J?_A0/@W_ )Z:KTQ_Q]#_ .)H/P"\
M&E=K2:H0.QNA_P#$TWJK>=Q+>_E8\U TH2QPMJ5B-+&JDK>M;*;=@0W(BZ =
M.*ZRSUOPQHGC;0KA-;TUM/2TF4W,$*P1%BPXVKP#6[_PS_X+Z;]4QZ?:1_\
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MSWB_[[%?)GP[^&]UX_AU"2/6/L7V-D4AHR^[=N]QC[M=Q_PSA?\ _0V+_P"
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M.YK1U2Z\,6<&H2Z;?V@FBNRML8Y@2(S&V<>Q)IO01]#7^K66G6;W5S<(L*$
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MM;_@-=-#X=L1X>MM'GB$EO"JC:"0"1S_ #J#1_".B:#=2W6G6K1RR+M):5G
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M+7L-O$MO;I$@"JB@ #M1HU<6M[$]%%% SE_^:I+_ -@5O_1XKJ*Y?_FJ2_\
M8%;_ -'BNHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!9HHHH ***
M* ,#QG_R(VO_ /8/G_\ 19K/O/&.C>$]#TEM8GDA6XAC5&6)G&=HZD#C\:T/
M&?\ R(VO_P#8/G_]%FN<U[P#;>,](TII[^YM?*M%0K&JL&!4=F[^]+6Z&K=3
M,MOB[:7.M1V?V.X6%[IXO,^SR'" *0>G7D_3CUK8C^+/A"6#S4OIB-Y0K]F?
M<I'4E<9 ]ZIR_">U<D)KE]&GF-(%5$XW!0W.,\A16?#\$M-B=Y!K5\97&UW\
MM 67N.G?CFFMK,7F=)I'Q$T;5_$-QHJ>=%=1RM'&2A*2[>X;&/PS6/<?%RPT
M_6KRSO+"[\F&[^S"2.%B1@,2V,<_=[5J:=\.=.TW5H+^"[GS#<-<+&0,9;MG
MKBH[SX;6=[KDVI-J=TJR3F<P!5VABK+UQG^(T=5Z!T9;M_B/X8O-8M-*BU'=
M=W:!XEV'!!&X9/0''8U2O?B-'9:K>03:5,+&SN$MY[WSEPK.!CY>N/F%5]+^
M$FD:7KEGJ27=Q(;;:1&ZKAF"[02>O3MTJSJ'PUMM2U2]N)]6N_L=[,LT]D$3
M8S* !SC=V'>CJ@Z/Y?\ !)(OBKX0N(KJ2+47?[*X1U6!BQ).!M&,MSZ56_X6
MUX;074TQN$LX I$ZQ,^[)Q]T#(Q[U4A^#.CP0SK%?W*RM('AE")F'#;@!QSS
MZYJ)_@KI9A9(]5OHRYRQ"J=W.3D$8YH#J;$OQ7\)Q&;_ $F[=84#R/'9R,J@
M],D#%94_QCTO^TL6=O-<V9@2191&R9W$]R,#IWI\/PBT^WTVYLX]6O%,[1L9
M-B9&PDCC&".>]-C^#FGQ1+$NL7OEB-8W78GS@9QVXZGI35N;R$[\OF;$_P 4
MO"ML\RR7LP\HD$BV<A\==AQ\WX9K33QAHDWAM]<6XD%BC%6+1,'# XQL(SG/
M;%<Q)\(-,EG5GU&[,43$V\6U<1 D$@'&3T'7TK:;P+8MX<N]'-S-LN+EKH2X
M&Z-RV[@=./>I^SYE:<WD4D^*&EW6MZ9IFFV=Y=M?,RES&T?D[<YW!AGM3/\
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MXZGK7-O\9?#LVKV=O9R3/;/O^T3/ Z^5MQV(]^M;.I?#ZRU/0],TM[ZYCCL
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MC=\_WN_/%-+WDA-^ZV>W'4K+[;)9FYC%Q&@=XR<$*>_ZT76IV-E:M<W-W#'
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MG-?3H2Q& ?\ Z]6O[(E_Z"-Q^?\ ]>GZ'_R#!_OM6I2&9']D2_\ 01N/S_\
MKT?V1+_T$;C\_P#Z]:]% &1_9$O_ $$;C\__ *]']D2_]!&X_/\ ^O6O10!D
M?V1+_P!!&X_/_P"O1_9$O_01N/S_ /KUKT4 9']D2_\ 01N/S_\ KT?V1+_T
M$;C\_P#Z]:]% &1_9$O_ $$;C\__ *]']D2_]!&X_/\ ^O6O10!D?V1+_P!!
M&X_/_P"O1_9$O_01N/S_ /KUKT4 <]?V<]E:&9;Z=R"!@G']:WU^XOT%9VO_
M /(+;_>%:*_<7Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '+_P#-4E_[ K?^CQ745R__ #5)?^P*W_H\5U% !1110 56O/\
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M%%% !1110 4444 <O_S5)?\ L"M_Z/%=17+_ /-4E_[ K?\ H\5U% !1110
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M._K783:M\*+FZ:ZFNO#\D[KM:1BI)&,8S].*=!K/PJM;5K:"\T".%WWM&I4
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M[WNH:%.UL,0F1E/ECV]*:T:!]2K\0/%E[H<2'3[^6&\2$226JVT<@(/=F8Y
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M  LGP7_T,VF_]_Q0!U-%<M_PLGP7_P!#-IO_ '_%'_"R?!?_ $,VF_\ ?\4
M=317+?\ "R?!?_0S:;_W_%'_  LGP7_T,VF_]_Q0!U-%<M_PLGP7_P!#-IO_
M '_%'_"R?!?_ $,VF_\ ?\4 =317+?\ "R?!?_0S:;_W_%'_  LGP7_T,VF_
M]_Q0!U-%<M_PLGP7_P!#-IO_ '_%'_"R?!?_ $,VF_\ ?\4 =317+?\ "R?!
M?_0S:;_W_%'_  LGP7_T,VF_]_Q0!U-%<M_PLGP7_P!#-IO_ '_%'_"R?!?_
M $,VF_\ ?\4 =317+?\ "R?!?_0S:;_W_%'_  LGP7_T,VF_]_Q0 O\ S5)?
M^P*W_H\5U%<'I.OZ3K_Q*:;2=0M[R.+1RKM"^X*?.!P:[R@ HHHH *K7G_'C
M<?\ 7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH Y#XA -H5BK $'5K($$=?WZ
M5NW(TRSB#W26D,98*&D55&3T'-8GQ _Y FG_ /87L?\ T>E+XZT*7Q'H,.G1
MHSJ]W$TNUMI5 WS'/L*3&O,U9)M%A21Y7L$6,@.6V *3TSZ4XS:*!.2]@!;C
M,Q^3]W_O>E>5I\/O$VKB[T759I(+)I3(;V)U)EV@;..OKVJG;>"O&4D%Y%<6
MI'V\^5=-YJ_.B_=8<]\FAL2/5?[7\+FZ6U%]I1N'X6+S(]Q^@K7^PVO_ #[0
M?]^Q7D>@^&?$6E>((I9M-OS!O4GROLICQSU+9?\ (U[)5-)(2;*_V&T_Y]H/
M^_8H^PVG_/M!_P!^Q5FBD,K?8;3_ )]H/^_8H^PVG_/M!_W[%6:* *WV&T_Y
M]H/^_8H^PVG_ #[0?]^Q5FB@"M]AM/\ GV@_[]BC[#:?\^T'_?L59HH K?8;
M3_GV@_[]BC[#:?\ /M!_W[%6:* *WV&T_P"?:#_OV*/L-I_S[0?]^Q5FB@"M
M]AM/^?:#_OV*/L-I_P ^T'_?L59HH K?8;3_ )]H/^_8H^PVG_/M!_W[%6:*
M *WV&T_Y]H/^_8H^PVG_ #[0?]^Q5FB@"M]AM/\ GV@_[]BC[#:?\^T'_?L5
M9HH K?8;3_GV@_[]BC[#:?\ /M!_W[%6:* *WV&T_P"?:#_OV*/L-I_S[0?]
M^Q5FB@"M]AM/^?:#_OV*/L-I_P ^T'_?L59HH K?8;3_ )]H/^_8H^PVG_/M
M!_W[%6:* *WV&T_Y]H/^_8H^PVG_ #[0?]^Q5FB@"M]AM/\ GV@_[]BC[#:?
M\^T'_?L59HH K?8;3_GV@_[]BC[#:?\ /M!_W[%6:* *WV&T_P"?:#_OV*/L
M-I_S[0?]^Q5FB@"M]AM/^?:#_OV*/L-I_P ^T'_?L59HH K?8;3_ )]H/^_8
MH^PVG_/M!_W[%6:* *WV&T_Y]H/^_8H^PVG_ #[0?]^Q5FB@#$O[[P_I;HE_
M<:=:,XRHG9$)'MFJ\NM^%+<*9M1TB,,,C=+&,]ZA\8:&=9L;=(K**XFCN(V)
M=5R%# GD^U8&L^$+F\N=5:+3(726\M7@X3[BF/?CT& W%):_>.R.O@NM"N[6
M6YMY;":WB&9)8RC*G&>2.G%16FI^&KT/]DO-+GV8W^4\;;<],XKD+C3M<L6\
M4Z;:>'99;;4PQMYXI8E1<PJN-I.>H/:LO1=%UVPAMEOK#4$BCN("_GK;[2 W
M./*&XCZT]Q/1'HR:CX=DDDCCNM,9XQEU5T)4>_I6D+*T(R+: @_],Q7DMKH6
MK6-W=R3Z5-':+!*'4A&3+=/+V_.<_P"UFO4M%BG@T:TBN23.L0#D^M'2X/1V
M+'V&T_Y]H/\ OV*/L-I_S[0?]^Q5FB@"M]AM/^?:#_OV*/L-I_S[0?\ ?L59
MHH K?8;3_GV@_P"_8H^PVG_/M!_W[%6:* *WV&T_Y]H/^_8H^PVG_/M!_P!^
MQ5FB@"M]AM/^?:#_ +]BC[#:?\^T'_?L59HH K?8;3_GV@_[]BC[#:?\^T'_
M '[%6:* *WV&T_Y]H/\ OV*/L-I_S[0?]^Q5FB@"M]AM/^?:#_OV*/L-I_S[
M0?\ ?L59HH K?8;3_GV@_P"_8H^PVG_/M!_W[%6:* *WV&T_Y]H/^_8H^PVG
M_/M!_P!^Q5FB@"M]AM/^?:#_ +]BC[#:?\^T'_?L59HH K?8;3_GV@_[]BC[
M#:?\^T'_ '[%6:* *WV&T_Y]H/\ OV*/L-I_S[0?]^Q5FB@"M]AM/^?:#_OV
M*/L-I_S[0?\ ?L59HH K?8;3_GV@_P"_8H^PVG_/M!_W[%6:* *WV&T_Y]H/
M^_8H^PVG_/M!_P!^Q5FB@"M]AM/^?:#_ +]BC[#:?\^T'_?L59HH K?8;3_G
MV@_[]BC[#:?\^T'_ '[%6:* .22&*'XH*(HT0'13D*H'_+85UM<O_P U27_L
M"M_Z/%=10 4444 %5KS_ (\;C_KDW\C5FJUY_P >-Q_UR;^1H LT444 %%%%
M ')?$'_D!Z?_ -A>Q_\ 1Z5O:M<RVE@TL) <,!DC-8/Q!_Y >G_]A>Q_]'I6
MUKW_ ""V_P!X4 ,$>LLH(N(.1G[O_P!:E\K6O^?B#_OG_P"M6E'_ *I/]T4^
M@#*\K6O^?B#_ +Y_^M1Y6M?\_$'_ 'S_ /6K5HH RO*UK_GX@_[Y_P#K4>5K
M7_/Q!_WS_P#6K5HH RO*UK_GX@_[Y_\ K4>5K7_/Q!_WS_\ 6K5HH RO*UK_
M )^(/^^?_K4>5K7_ #\0?]\__6K5HH RO*UK_GX@_P"^?_K4>5K7_/Q!_P!\
M_P#UJU:* ,KRM:_Y^(/^^?\ ZU'E:U_S\0?]\_\ UJU:* ,KRM:_Y^(/^^?_
M *U'E:U_S\0?]\__ %JU:* ,KRM:_P"?B#_OG_ZU'E:U_P _$'_?/_UJU:*
M,KRM:_Y^(/\ OG_ZU'E:U_S\0?\ ?/\ ]:M6B@#*\K6O^?B#_OG_ .M1Y6M?
M\_$'_?/_ -:M6B@#*\K6O^?B#_OG_P"M1Y6M?\_$'_?/_P!:M6B@#*\K6O\
MGX@_[Y_^M1Y6M?\ /Q!_WS_]:M6B@#*\K6O^?B#_ +Y_^M1Y6M?\_$'_ 'S_
M /6K5HH RO*UK_GX@_[Y_P#K4>5K7_/Q!_WS_P#6K5HH RO*UK_GX@_[Y_\
MK4>5K7_/Q!_WS_\ 6K5HH RO*UK_ )^(/^^?_K4>5K7_ #\0?]\__6K5HH R
MO*UK_GX@_P"^?_K4>5K7_/Q!_P!\_P#UJU:* ,KRM:_Y^(/^^?\ ZU'E:U_S
M\0?]\_\ UJU:* ,KRM:_Y^(/^^?_ *U'E:U_S\0?]\__ %JU:* ,KRM:_P"?
MB#_OG_ZU'E:U_P _$'_?/_UJU:* ,KRM:_Y^(/\ OG_ZU'E:U_S\0?\ ?/\
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M= RP(RD9!#'!_6@"S]MM/^?F+_OL4?;;3_GYB_[[%0_V38_\^R_F:/[)L?\
MGV7\S0!-]MM/^?F+_OL4?;;3_GYB_P"^Q4/]DV/_ #[+^9H_LFQ_Y]E_,T 3
M?;;3_GYB_P"^Q1]MM/\ GYB_[[%0_P!DV/\ S[+^9H_LFQ_Y]E_,T 3?;;3_
M )^8O^^Q1]MM/^?F+_OL5#_9-C_S[+^9H_LFQ_Y]E_,T 3?;;3_GYB_[[%'V
MVT_Y^8O^^Q4/]DV/_/LOYFC^R;'_ )]E_,T 3?;;3_GYB_[[%'VVT_Y^8O\
MOL5#_9-C_P ^R_F:/[)L?^?9?S- $WVVT_Y^8O\ OL4?;;3_ )^8O^^Q4/\
M9-C_ ,^R_F:/[)L?^?9?S- $WVVT_P"?F+_OL4?;;3_GYB_[[%0_V38_\^R_
MF:/[)L?^?9?S- $WVVT_Y^8O^^Q1]MM/^?F+_OL5#_9-C_S[+^9H_LFQ_P"?
M9?S- $WVVT_Y^8O^^Q1]MM/^?F+_ +[%0_V38_\ /LOYFC^R;'_GV7\S0!-]
MMM/^?F+_ +[%'VVT_P"?F+_OL5#_ &38_P#/LOYFC^R;'_GV7\S0!-]MM/\
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MC?[KFX0!OH<\T :=%9KZWI4;HDFI6B,X!56G4%L],<UH @@$'(/0B@!U%%%
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MO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"<W^?QH_LVZ_Z"<W^?QH
MU:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"<W^?QH_LVZ_Z"<W^
M?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"<W^?QH_LVZ_Z
M"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"<W^?QH_L
MVZ_Z"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"<W^?
MQH_LVZ_Z"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LVZ_Z"
M<W^?QH_LVZ_Z"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK*_LV
MZ_Z"<W^?QH_LVZ_Z"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@#5HK
M*_LVZ_Z"<W^?QH_LVZ_Z"<W^?QH U:*RO[-NO^@G-_G\:/[-NO\ H)S?Y_&@
M#5HK*_LVZ_Z"<W^?QJ 1W%KJMK$UW+*LF20Q]J ,3QEI]S)J6GWPT>36;2)6
M1[- I(8@X?#$ ^E8<_A:]U"*X>YT&)<Z:8X(FQ)Y;^82%!;H<?A7>:EYTFIV
MUO'.\0=3DJ:=_9MU_P!!.;_/XTK:6'?6YQNH^!8+F[\/O;6'V>-55;]+<"-6
M"@$!P,9^;/K7H2(L:*B !5& !V%9_P#9MU_T$YO\_C1_9MU_T$YO\_C57TL3
M8U:*RO[-NO\ H)S?Y_&C^S;K_H)S?Y_&D,U:*RO[-NO^@G-_G\:/[-NO^@G-
M_G\: -6BLK^S;K_H)S?Y_&C^S;K_ *"<W^?QH U:*RO[-NO^@G-_G\:/[-NO
M^@G-_G\: -6BLK^S;K_H)S?Y_&C^S;K_ *"<W^?QH U:*RO[-NO^@G-_G\:/
M[-NO^@G-_G\: -6BLK^S;K_H)S?Y_&C^S;K_ *"<W^?QH U:*RO[-NO^@G-_
MG\:/[-NO^@G-_G\: -6BLK^S;K_H)S?Y_&C^S;K_ *"<W^?QH U:*RO[-NO^
M@G-_G\:AM_/M]3FMWN9)56$L"Q[T <7XUT?4KGQ$MQ::7-<!T55D2-)%.",A
MMY^3IU7GBK$WARXM+W5+NST6!;B:VBCADBB3*NP578'KD98Y[UT]A;75[:+.
M=0F3)(QU_K5K^R[K_H)S_P"?QI6TL.^MSSS3_!.HZ5HVLZ!<VQU6W=/M%I<3
M1H<2,/F49Z'.3574_#6H6/B*UFL]!G:U^QQ(PM;"VE4.#\P/F$;3[BO3O[+N
MO^@G/_G\:3^R[K_H)S_Y_&GU3%TL7;?/V:/*E#M&5(&1Q[<5SGCG[<WA]H]/
MT<:I,[A?+,:/L']X!^"15^6"YM+RTS>RRK)( 035F:XN6U5;6)U1#'OR4SS2
MDK@G8\A?P1J%[+I,&GZ%=Z;:Q2J)6NHHG*GNY7)4CVKO)/"<^G>"K_2K*Y,U
MS.3)N$:Q!B3D@*O"CZ5U7E7G_/XO_?H?XT>5>?\ /XO_ 'Z'^--[6!:.YYA)
MI&H7<<5Q;>$'LK.WD1Y[$E0]UA2,!0=I&3GDU3;0M0CUTZH_@RXFTZ;<(]."
M1$P'!&2"VT9//'K7K?E7G_/XO_?H?XT>5>?\_B_]^A_C0'2QXQ9>&-?TS68Y
M)M(O)HF(8>7:6]P$!;(4F4Y7 X^7TKVN'/D)E2IVCY3QCCIQ3/*O/^?Q?^_0
M_P :3RKS_G\7_OT/\:=]+"MK<N454\J\_P"?Q?\ OT/\:/*O/^?Q?^_0_P :
M0RW153RKS_G\7_OT/\:/*O/^?Q?^_0_QH MT54\J\_Y_%_[]#_&F21WB1L_V
MM3M!/^J'^- &+_S5)?\ L"M_Z/%=17%Z;/)<_$.&:4@N=%?.!C_EN*[2@ HH
MHH *K7G_ !XW'_7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH Y+X@_P#(#T__
M +"]C_Z/2MK7O^06W^\*Q?B#_P @/3_^PO8_^CTK:UQ&?365%+'<. ,T :$?
M^J3_ '13ZQUUEE11]AN.!CI3O[;/_/C<?E0!K45D_P!MG_GQN/RH_ML_\^-Q
M^5 &M163_;9_Y\;C\J/[;/\ SXW'Y4 :U%9/]MG_ )\;C\J/[;/_ #XW'Y4
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M9QSC-6?,\??\^WAS_O\ 3_\ Q--^(/\ R ]/_P"PO8_^CTK3\0^(+#PQI?\
M:.H&1;<2+&2BY().!^% &=O\>_\ /OX<_P"_T_\ \31O\??\^_AS_O\ 3_\
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MA10!Q_E>-O\ GP\,?]_)O_B:/*\;?\^'AC_OY-_\37844 <?Y7C;_GP\,?\
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MQZ-O&/RKTW[?9_\ /S%_WT*C_LFQ_P"?9/S-']DV/_/LGYFFVV))(E^WV?\
MS\Q?]]"C[?9_\_,7_?0J+^R;'_GV3\S1_9-C_P ^R?F:0R7[?9_\_,7_ 'T*
M/M]G_P _,7_?0J+^R;'_ )]D_,T?V38_\^R?F: )?M]G_P _,7_?0H^WV?\
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M?_/S%_WT*/M]G_S\Q?\ ?0J+^R;'_GV3\S1_9-C_ ,^R?F: )?M]G_S\Q?\
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M ,];?\O_ *U &M163LUO_GK;_E_]:C9K?_/6W_+_ .M0!K45D[-;_P">MO\
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MTJVPB3S'NYHF1,*!(%0@'C#'(KVB/PMICV%G;:C9VM^UH@2.2>!20 ,#KFM
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M14'VJW_Y^(O^^Q1]JM_^?B+_ +[% $]%0?:K?_GXB_[[%'VJW_Y^(O\ OL4
M3T5!]JM_^?B+_OL4?:K?_GXB_P"^Q0!/14'VJW_Y^(O^^Q1]JM_^?B+_ +[%
M $]%0?:K?_GXB_[[%'VJW_Y^(O\ OL4 3T5!]JM_^?B+_OL4?:K?_GXB_P"^
MQ0!/14'VJW_Y^(O^^Q1]JM_^?B+_ +[% $]%0?:K?_GXB_[[%'VJW_Y^(O\
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M_(EPUSJB333V1MV=DQABY;/';G%+6P]+D@^(FAJO^DQW]H[(KQ1W-L8WE#'
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MN/\ OJC^PQ_S^W'_ 'U6M10!D_V&/^?VX_[ZH_L,?\_MQ_WU6M10!D_V&/\
MG]N/^^J/[#'_ #^W'_?5:U% &3_88_Y_;C_OJC^PQ_S^W'_?5:U% &3_ &&/
M^?VX_P"^J/[#'_/[<?\ ?5:U% &3_88_Y_;C_OJC^PQ_S^W'_?5:U% &3_88
M_P"?VX_[ZH_L,?\ /[<?]]5K44 9/]AC_G]N/^^J/[#'_/[<?]]5K44 9/\
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M^@9+^?\ ]:LK_A7?A+_H#1?]_7_^*H_X5WX2_P"@-%_W]?\ ^*H U?[3O?\
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MOY__ %J/[3O?^@9+^?\ ]:LK_A7?A+_H#1?]_7_^*H_X5WX2_P"@-%_W]?\
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MJ@#5_M.]_P"@9+^?_P!:H0UU=:K:RO9R1+'D$GITJA_PKOPE_P! :+_OZ_\
M\51_PKOPE_T!HO\ OZ__ ,50!IZD)TU"VN(;=YA&IR%%._M.]_Z!DOY__6KF
M;_PI\/M,=$O[?3[1G'RB>Z*%A[9:HY=!^&<&/-;28\C(W7V,C_ON@#JO[3O?
M^@9+^?\ ]:C^T[W_ *!DOY__ %JYN'PCX"N+=YX;2QDAC7<\B73%5'J3NX%1
MVWACX=7N_P"R1Z;/LQO\J\+;<],X>@#J/[3O?^@9+^?_ -:C^T[W_H&2_G_]
M:N93PK\/9))(TBTYGC&747A)7Z_-Q6@/AUX1(R-&B(/_ $U?_P"*H UO[3O?
M^@9+^?\ ]:C^T[W_ *!DOY__ %JRO^%=^$O^@-%_W]?_ .*H_P"%=^$O^@-%
M_P!_7_\ BJ -7^T[W_H&2_G_ /6H_M.]_P"@9+^?_P!:LK_A7?A+_H#1?]_7
M_P#BJ/\ A7?A+_H#1?\ ?U__ (J@#5_M.]_Z!DOY_P#UJ/[3O?\ H&2_G_\
M6K*_X5WX2_Z T7_?U_\ XJC_ (5WX2_Z T7_ ']?_P"*H U?[3O?^@9+^?\
M]:C^T[W_ *!DOY__ %JRO^%=^$O^@-%_W]?_ .*H_P"%=^$O^@-%_P!_7_\
MBJ -7^T[W_H&2_G_ /6H_M.]_P"@9+^?_P!:LK_A7?A+_H#1?]_7_P#BJ/\
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MHO\ OZ__ ,51_P *[\)?] :+_OZ__P 50!;L)[VRM5@_L^5\$G/2K7]IWO\
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MHK,_MZP_YZ/_ -\&C^WK#_GH_P#WP: -.BLS^WK#_GH__?!H_MZP_P">C_\
M?!H TZ*S/[>L/^>C_P#?!H_MZP_YZ/\ ]\&@#3HK,_MZP_YZ/_WP:/[>L/\
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MY$/_ #R3_OD4>1#_ ,\D_P"^14M% $7D0_\ /)/^^11Y$/\ SR3_ +Y%2T4
M1>1#_P \D_[Y%'D0_P#/)/\ OD5+10!%Y$/_ #R3_OD4>1#_ ,\D_P"^14M%
M $7D0_\ /)/^^11Y$/\ SR3_ +Y%2T4 1>1#_P \D_[Y%'D0_P#/)/\ OD5+
M10!%Y$/_ #R3_OD4>1#_ ,\D_P"^14M% $7D0_\ /)/^^11Y$/\ SR3_ +Y%
M2T4 1>1#_P \D_[Y%'D0_P#/)/\ OD5+10!%Y$/_ #R3_OD4>1#_ ,\D_P"^
M14M% $7D0_\ /)/^^11Y$/\ SR3_ +Y%2T4 1>1#_P \D_[Y%'D0_P#/)/\
MOD5+10!%Y$/_ #R3_OD4>1#_ ,\D_P"^14M% $7D0_\ /)/^^11Y$/\ SR3_
M +Y%2T4 1>1#_P \D_[Y%.6-$Y5%!]ABGT4 5+F\M;) ]U<PP(3@-+(%!/XU
M'+JVFP*#-J-I&&&07F49_,UROC*QN)=1T^];1I-9LXE9'M$"L0Q!PV&(!]*P
MT\+WM[9:H;O0(T\RUQ;0OB38V> "W0X_*E?2X[:V/18M7TV6-I(KZUD12 S)
M,I SZG-7000"#D'H17G<_@.W;6M!EAL3!:B)?MT4 "1ED&Y2RC@G=7HB@*H
M& !@ 4[:$WU'T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA0 G]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\
MT$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F
M_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT
M4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\
MT$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F
M_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT
M4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\
MT$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F
M_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT
M4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\
MT$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F
M_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT
M4 97]EW?_03F_+_Z]']EW?\ T$YOR_\ KUJT4 97]EW?_03F_+_Z]']EW?\
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MF@CE_M*8;U#8],_C4O\ 9=W_ -!.;\O_ *]7;'_CQM_^N:_RJQ0!E?V7=_\
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M  E-[_T(&M?]\0?_ !='_"4WO_0@:U_WQ!_\70!TG]M6/_/;_P =-']M6/\
MSV_\=-<W_P )3>_]"!K7_?$'_P 71_PE-[_T(&M?]\0?_%T =)_;5C_SV_\
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MR[ 8&T^M8O\ PE-[_P!"!K7_ 'Q!_P#%T?\ "4WO_0@:U_WQ!_\ %T 6+?\
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MO,>VO[H2"-T@69@T<.[K@  _K74V5I'864-K%_JXE"K1T![Z%NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .7_ .:I+_V!6_\ 1XKJ*Y?_ )JDO_8%;_T>
M*ZB@ HHHH *K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ HHHH Y+X@_
M\@/3_P#L+V/_ */2MK7O^06W^\*Q?B#_ ,@/3_\ L+V/_H]*VM>_Y!;?[PH
MT(_]4G^Z*?3(_P#5)_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX_Z"4_\ G\:U:* ,K^RKC_H)3_Y_&C^RKC_H)3_Y_&M6B@#*_LJX_P"@E/\
MY_&C^RKC_H)3_P"?QK5HH RO[*N/^@E/_G\:/[*N/^@E/_G\:U:* ,K^RKC_
M *"4_P#G\:/[*N/^@E/_ )_&M6B@#*_LJX_Z"4_^?QH_LJX_Z"4_^?QK5HH
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M7_L"M_Z/%=17+_\ -4E_[ K?^CQ744 %%%% !5:\_P"/&X_ZY-_(U9JM>?\
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M_P#I0*[F@ HHHH *K7G_ !XW'_7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH
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M -!.3\O_ *] &M163_9U_P#]!.3\O_KT?V=?_P#03D_+_P"O0!K45D_V=?\
M_03D_+_Z]']G7_\ T$Y/R_\ KT :U%9/]G7_ /T$Y/R_^O1_9U__ -!.3\O_
M *] &M163_9U_P#]!.3\O_KT?V=?_P#03D_+_P"O0!K45D_V=?\ _03D_+_Z
M]']G7_\ T$Y/R_\ KT :U%9/]G7_ /T$Y/R_^O1_9U__ -!.3\O_ *] &M16
M3_9U_P#]!.3\O_KT?V=?_P#03D_+_P"O0!K45D_V=?\ _03D_+_Z]']G7_\
MT$Y/R_\ KT :U%9/]G7_ /T$Y/R_^O1_9U__ -!.3\O_ *] &M163_9U_P#]
M!.3\O_KT?V=?_P#03D_+_P"O0!K45D_V=?\ _03D_+_Z]']G7_\ T$Y/R_\
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M+C>NBOG!S_RW%=I0 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D: +-%%%
M!1110!SOB[1KO7-&2VL;B&"YBNH;F-YD+)F-P^"!SSBJGV;Q_P#]!+P]_P"
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MQS7/BVU^XT\6L6H:NH\E$DV1LNTF1\@<>F#GWHL[V"ZM<]M^S>/?^@EX?_\
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M(\15G6?<925Q@KCC']*YW3_ASXEO?MTT=E'IV]I0V^3:UV"3A6&.!SUYHO\
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MR?";Q)+:"-;2QMU)F_<I<950Y3 !Q_LFKK_"/6+?Q->7FGR1VMJ\;+"T<V,
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ME'X?LK2R^TM<%YXR^%=?,)&&[';CM25[78[:V/3C=6XQFXB&>1\XYIRS1/\
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M.M^"I+V)["TG6YF1C<+<;65-J@C&.<$'O7J5#2TL*^K%HHHH&%%%% !1110
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MGD\N>*:)7G! .<-W[  _C3K'P1X]@M;\W)OYXWEC+VYNE!F W;MAW?*.G<4
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M*U^'OBFU^T7LFF7<LLCJLD<=V%DE7RP!\VX=&YZ]J4=4F^PVK-I'T+17@R^
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MF6RR^1 B ,65@ ,XSGGG-5[/XW:C=0#?X?AAF0;Y0\QV[-P'RG')Y'%>I?\
M",:$=0GOSI-H;N=2LLWE#<X/4$]ZA'@KPR((8!H5AY4#;XD\D81O44HW228W
M9NZ/,;KXT:S#"+J+P[;R0R7+PQ 3MN(4G)(Q@' -11_%/7=.?5+Z6SM9VEEC
M,-K).RLBF)6X&/3FO5I?"?AZ> 02Z-9-$)C.$:(8\P\EOKR:CN_!7AB_F::\
MT.PFD;&YGA!)P,#]!3$<!'\7=4GBNK]=$MAIEH\2W$AF;S%WA<D#&.-WKVKH
MM0\<:A:>&M*OTTVW%YJ4A6..64K&HSP6;&1D8/2M>Z\#:!<Z?+8Q6@LX)F5I
M5M#Y?F8Q@-CJ.!6G>Z#I>HZ8FG7UC!<VD8 6*9 R\=.*'MIY?\$%NKG!^$O&
M6O\ BCQD(W^SVVE)9"9X%7<Q8LP!#$9_AKE=0^(/BB1/$$ OK1XXU)MRB["J
M@\X(&3VZU[/:Z)IEC-YMI86\,GEB+=&@!V#.%^G)_.JW_"(^'@]TXT:RW78Q
M<'RAF4?[7K0]U8=SR#Q)\6M=1)M(M[.S1@NW[9#<,>5(##I[BNL\*_$Z\UKQ
M6^B7FE1P0QJP%TDNX%E(!Z]N>M=4/ /A(.S#P[IH9AAC]G7D5-%X/\.PF4Q:
M-8H9E"2;80-R@@@'\A33[D-:)(WP01D'(-+42(L4:HBA4484#H!4M(H****
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M163_ &X/^?*X_P"^:/[<'_/E<?\ ?- &M163_;@_Y\KC_OFC^W!_SY7'_?-
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MN6_X61X,_P"ADT__ +^T?\+(\&?]#)I__?V@#J:*Y;_A9'@S_H9-/_[^T?\
M"R/!G_0R:?\ ]_: .IHJK:7=O?V<-W:3+-;S('CD0Y#*>A%6J ,FZ_Y#]E_N
MM_6M:LFZ_P"0_9?[K?UK6H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:+_O@4?8[;_GVB_[X%3T4 0?8[;_ )]HO^^!1]CMO^?:+_O@5/10!!]CMO\
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M:5>122-#?>6KN6("T[^SM2_Z"9_[YK7HH R/[.U+_H)G_OFC^SM2_P"@F?\
MOFM>B@#(_L[4O^@F?^^:/[.U+_H)G_OFM>B@#(_L[4O^@F?^^:/[.U+_ *"9
M_P"^:U@01D'(I: ,C^SM2_Z"9_[YH_L[4O\ H)G_ +YK7HH R/[.U+_H)G_O
MFC^SM2_Z"9_[YK7HH R/[.U+_H)G_OFC^SM2_P"@F?\ OFM>B@#(_L[4O^@F
M?^^:/[.U+_H)G_OFM>B@#&ETF^FC,<FH%D/4%:U(D\N)$SG:H&:EHH ****
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MR>V+B4"-/E&0=ISD=J[!-6NX?A_H^HWLUQ&WV^%[AOF)";N<@<X]JMW'Q?\
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M =517*_\)'>?\\X/^^3_ (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\
MC1_PD=Y_SS@_[Y/^- '545RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =51
M7*_\)'>?\\X/^^3_ (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_P
MD=Y_SS@_[Y/^- '545RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\
M)'>?\\X/^^3_ (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_
MSS@_[Y/^- '545RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?
M\\X/^^3_ (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_
M[Y/^- '545RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/
M^^3_ (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_[Y/^
M- '545RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/^^3_
M (T?\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_[Y/^- '5
M45RO_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/^^3_ (T?
M\)'>?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_[Y/^- '545RO
M_"1WG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/^^3_ (T?\)'>
M?\\X/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_[Y/^- '545RO_"1W
MG_/.#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/^^3_ (T?\)'>?\\X
M/^^3_C0!U5%<K_PD=Y_SS@_[Y/\ C1_PD=Y_SS@_[Y/^- '545RO_"1WG_/.
M#_OD_P"-'_"1WG_/.#_OD_XT =517*_\)'>?\\X/^^3_ (T?\)'>?\\X/^^3
M_C0!U55KS_CQN/\ KDW\C7/?\)'>?\\X/^^3_C4-WXCO/L5Q^[@_U;?PGT^M
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>inmune_ex31img27.jpg
<TEXT>
begin 644 inmune_ex31img27.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1, R # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JM>?\ 'C<?]<F_D:LU6O/^/&X_ZY-_(T 6:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!9HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+J-F"@XRAQVR#^=>@:#:ZE;6SIJ,6F1MNRHT^-D7\0W>MJBA/2PVKNXM%%%
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M6O\ A>UUOP]%I1D,"P&-H)%&=C(05.._05SL7PP0WL>H76K/-?\ VN.YEF$
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MGV],>U=33:L["3NKBT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3O&OA;0[31FT?2IH8G.Z?^T&#8+9)V^7[^M=-%XUT29-4;[2R)IDGE7+2+M
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MG^)=-&H::[O;EBF70J<@X/'X4+4'IN;-%%% !5:\_P"/&X_ZY-_(U9JM>?\
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M!S0!PGB(Q3VT8$LC.)0P,1P:Q=)OUM;:2)X<G=C+@$BM?6+>"&XC@E=X[=G
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M7]N=9HFB=9KZ612K @\,Q'0TGJFN]P6C3[6/GK2C<6^FVWAQ(V\K7?+FW#H
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MA>XE&7E!XRO [=:U7U%]1@=(LPX0[F ^8\=!]:BTZWT9+AK:[M()7W',BC&
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M"T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,;C@@KSGZ5Z/\)O#<TEQ)KUY;CR0-ML6ZGU;'Y5F>#O EQXDF_M/5&:.Q#Y
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M_KO=?^C6KQ=_^20Q_P#84;_T!:]H@_Y(UX@_Z[W7_HUJ\7?_ ))#'_V%&_\
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M.#CUISUO;J*.EK]&?+OQ$_Y'*+_KRA_]%"MWX??\BO:?]AE/_1;5[%JWP?\
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M<8ZC)R/:D[Z^B7W FK+U;^\X/PC_ ,@#_N)6G_LE>C:3_P DV\7_ /72Y_\
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M_P"@G<?^ DG^%'_"]O 7_03N/_ 23_"NW_X1[1/^@/I__@,G^%'_  CVB?\
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M^%'_  CVB?\ 0'T__P !D_PH XC_ (7MX"_Z"=Q_X"2?X4?\+V\!?]!.X_\
M 23_  KM_P#A'M$_Z ^G_P#@,G^%'_"/:)_T!]/_ / 9/\* .(_X7MX"_P"@
MG<?^ DG^%'_"]O 7_03N/_ 23_"NW_X1[1/^@/I__@,G^%'_  CVB?\ 0'T_
M_P !D_PH XC_ (7MX"_Z"=Q_X"2?X4?\+V\!?]!.X_\  23_  KM_P#A'M$_
MZ ^G_P#@,G^%'_"/:)_T!]/_ / 9/\* .(_X7MX"_P"@G<?^ DG^%'_"]O 7
M_03N/_ 23_"NW_X1[1/^@/I__@,G^%'_  CVB?\ 0'T__P !D_PH XC_ (7M
MX"_Z"=Q_X"2?X4?\+V\!?]!.X_\  23_  KM_P#A'M$_Z ^G_P#@,G^%'_"/
M:)_T!]/_ / 9/\* .(_X7MX"_P"@G<?^ DG^%'_"]O 7_03N/_ 23_"NW_X1
M[1/^@/I__@,G^%'_  CVB?\ 0'T__P !D_PH XC_ (7MX"_Z"=Q_X"2?X4?\
M+V\!?]!.X_\  23_  KM_P#A'M$_Z ^G_P#@,G^%'_"/:)_T!]/_ / 9/\*
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MGAVQ/8R;87!R,E,<Y]<T^76W];7$WI=?UK8]"\/^(YUN_$$VLZ[IT]E8OE1
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M !1110 4444 %%%% !1110 4444 %5KS_CQN/^N3?R-6:K7G_'C<?]<F_D:
M+-%%% !1110!Y3X,_P"2[>//^N4'_H*UZM7E/@S_ )+MX\_ZY0?^@K7JU !1
M110 4444 %%%% !1110!SNLZY)I^H6%A:P+/=WLF K-@*@QN8_3-<[<^)?&=
MMXEM=%.EZ(9[F-Y8W^U2[0JXSGY>O(JQ?J\?Q:TN64_N9+*1(LC^(=?YBG:F
M#_PM;1#CC[%/_-*2UMYW_ ;T3\DB.W^(-O8ZS>:;XD>TL)K9(R&B9W5RV<XX
MZ# _.MEO$UI'J4B27ED+-+83[][>9@XYQC&.?7-<HUE!-XH\;RR0J[BTB56*
M]B'R/T%<?IMK:W=C#'J'VE;?^P(2SP)N9,>7SCCI36MO0EJU_4]FTCQ'I&N"
M3^R[Y+DQ??"J01^! KF[[QX(/':^';<6@2./S+B2X9U([X7 (SCGG%9?P_U*
M2Y\37<,=Y:ZQ;):KC4XH0C_PXC8Y.3CW[52\7VEW>>,M?ALU8RMI"X"CJ ZD
MC\LT2T:&MG\CO++Q?X?U">:*SU.*22)6=UPPP!U/(YZ=JJCXA^%-I;^VH=H.
MW.Q\9]!QS7GU_?:;KBZ#!H*A[G3[*479C&/)41,"K>ASGCWJW]CB;PIX'B:(
M%#J 8J1_TUH2O]Z0O\FSNAX[\+F..4:S!LD?RU.UOO>AXXZ]ZV+_ %.STS3I
M+^]N$AM8UW-*W0#UXKR'6["!=+^(TBVZAS)@$+Z(,5V/CL;OA5<KC.;91C\*
M'LFO(:W5_,U%\?>%GBEE7682D1 ?Y6R,].,9[5HVOB+1[VYAM[:_BEFFA^T1
MJI/S1\?-].17"_V;:K\0TQ;( FB,J_+TZ5RGA.\MO#MYX?U347\BTETJ6%9&
M&%WY3"_C@T]!*[5UY?B>M7'C/P_;6@NIM4A6$R-$&PQ^=20PP!GC!K,OOB#I
M5MKFBV5O-'/#J3$><-WRC!QCCU 'XUYKI[Z>^CVFK3:G/I%U]MNS!<O#NAP7
M8[7Y'6M'2-5(O_"=_J%O;V=N+V>-9HH_+CE)$@# =MQ(/XT15VKA)V3MYGI'
MB;Q./#]SI:.D?DWDYCDD<D; %)R,=>E68O%6AS:=+J*:E";2%MLDG(VGTQC-
M<U\1I;2'4?#$][%YMLE\6;C(7Y3\Q]AU_"N U^WFU6_U36]*4QZ(=0A=I_*W
MH=NS+[>A Q^E2M5\QM:_+[SVO2?$&EZ]&\FF7L=PJ'#;001^! -5=2\8:!HU
MZUEJ&IQ07*H',95B0IS@\#V-<EX'2"\\5:AJ=OKJZF7@2.5[>R$,)QG'(8Y8
M9_E3EM(;CXR:F\L0?;I2!21TR7S1+1KT;!;-]K?C8ZZZ\6:#96$%]<:G"EM<
M#,+X)W_0 9K'U7XB:387NCQ6\\4T.HR[?-&["KCKT^E>=^%+BVT*_P!%U36B
M(]+^RRPPRR#Y8WR./;/]*=:21V%QIVL/"UOH\NLR2V^\84(P;'T!XH[ TU=?
MUM<]5?QKX<BU+^SWU:$76_R]F&^]Z9QC/XU7U'QQH=J]Q:PZG:_;H3AHY0X5
M3GG<0IQ7D?B/Q"-1T]K2%+*Q1-3#/8PP@R A_OL>-N?7WKI;>-?^$9\<2JOS
M/=+\V.HR*+^[<&M4N[.T/Q"\-6\<:7>K0QS,J[@(Y-NX@=#MZ<U<N?&?AZTO
M([2XU2&.>0*50AOXNF3C Z]ZX.W\6^'M9N+"PU35K:UT[3H8<P3/@SRA1CCT
M!_45SLR)%=>)+*_UN"P6_F#QPM8":2X0JNTQL6&>V/<4^H+8]9U_QCH^@0RB
MYO81=B$R1PG<=W''('&:I:5XNDNI=%-U:I%!JT):)T8G$@/W3[=,5P7GV/AQ
M/$UKKI9IKVS46;3QX:=-F  /7.>*U4&_PWX"CB!$YNT=1T(4,-WZ8HM^:_$7
M3Y/\#UVBD'2EH&%%%% !1110 4444 %<A\4O^28>(?\ KT;^8KKZY#XI?\DP
M\0_]>C?S% $_PY_Y)MX<_P"P?#_Z"*ZBN7^'/_)-O#G_ &#X?_01744 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: +-%%% !1110!YAKGPA36/%%_K
MMOXEU+3IKUE,B6ORCA0,9!!/2J?_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *
M3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0
M_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\
MQ5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.
MZ_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_
M -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%
M5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)
M_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^
MA^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?
MT_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_
M  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'
M[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3
M_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW1
M0!Y)_P *3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *
M3NO^A^\0_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0
M_P#?T_\ Q5'_  I.Z_Z'[Q#_ -_3_P#%5ZW10!Y)_P *3NO^A^\0_P#?T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML_G-<%N%;R_,V8QUVU2F^)EQ;:6^IS>&[E;%HS)!/YX*R ,1\QV_)T[U//\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY5DFN;J161"J_P#+098#KTKL_ MQJ\GA6Z=[NVO65V^RM'</-@8&%9W4$_\
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ME&H2)\Y7'6M_M67H7_'@W_75J $_LV]_Z"<OY?\ UZ/[-O?^@G+^7_UZU:*
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MNM9M0TRR6T>]>RD,)??O7NN3C'3K5KP_\4]0US6XK5-.B^SW$KPQE(I2T1'
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M\BC[/#_SQC_[Y%2T4 1?9X?^>,?_ 'R*/L\/_/&/_OD5+10!%]GA_P">,?\
MWR*/L\/_ #QC_P"^14M% $7V>'_GC'_WR*/L\/\ SQC_ .^14M% $7V>'_GC
M'_WR*/L\/_/&/_OD5+10!%]GA_YXQ_\ ?(K-M%"Z[>!0  B\ ?2M>LJV_P"0
M_>?[B_TH U:*** "JUY_QXW'_7)OY&K-5KS_ (\;C_KDW\C0!9HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH .U9>A?\>#?]=6K4[5EZ%_QX-_UU:@#4HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(+S_ (\I_P#KFW\JKZ1_R"[?_=_J:L7G_'E/_P!<V_E5?2/^07;_ .[_ %-
M%3Q-HW_"0>'+_2?.\G[5$T?F;=VW(ZXKE-2^'NH:EX6C\.R:]&MG"L8B(M/F
M!7/).[G.?TKT2BD.YP]GX*U%=;36=3UM+R^MX##:%;78D6<9.W<<G@5KZKH-
MUK7A*XT>^OD:XN(MCW*0[1G(.=N?;UKH:*;U5F):.Z/,9_A!92:MHNHQW_ES
M:? L,I$/^OPNT'KQQ]:JS?""ZE$5N?$6+&&ZDN8H?LO*ER21NW<_>/:O6**
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M@#)_L)?^?RX_[ZH_L)?^?RX_[ZK6HH R?["7_G\N/^^J/["7_G\N/^^JUJ*
M,G^PE_Y_+C_OJC^PE_Y_+C_OJM:B@#)_L)?^?RX_[ZH_L)?^?RX_[ZK6HH R
M?["7_G\N/^^J/["7_G\N/^^JUJ* ,G^PE_Y_+C_OJC^PE_Y_+C_OJM:B@#)_
ML)?^?RX_[ZH_L)?^?RX_[ZK6HH R?["7_G\N/^^J/["7_G\N/^^JUJ* ,G^P
ME_Y_+C_OJC^PE_Y_+C_OJM:B@#)_L)?^?RX_[ZH_L)?^?RX_[ZK6HH R?["7
M_G\N/^^J/["7_G\N/^^JUJ* ,G^PE_Y_+C_OJC^PE_Y_+C_OJM:B@#)_L)?^
M?RX_[ZH_L)?^?RX_[ZK6HH R?["7_G\N/^^J/["7_G\N/^^JUJ* ,G^PE_Y_
M+C_OJC^PE_Y_+C_OJM:B@#)_L)?^?RX_[ZH_L)?^?RX_[ZK6HH R?["7_G\N
M/^^J/["7_G\N/^^JUJ* ,G^PE_Y_+C_OJC^PE_Y_+C_OJM:B@#(.A(1@W=P0
M?]JM&V@6UMTA4DJ@P":FHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM>?\
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MX@:S!=MI$VF6?]M&6-(T25O)(?."6Z]O2HT^(&OR:['H*:58C4A(R3,9F\H
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M:KX#T75]0FN[C[4CS@">.&<HDP']]1][KWK5TS0K#2;BYFLXV1KD@N-W''3
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M5/#\ILH)EAEN/M0X)SC"[>>E1Z7X^O[;4;R+6]/$5H;^6WBN1< A"N2%(QZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@?2NLC<2QK(%9=RAMK#!&?4>M>>Z7X,DU+5/$3ZA=:K:V]Q>Y6"*;RXIT\M
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M444 %%%% !1110 4444 %%%% !1110!6CMX87D>*%$>0[G95 +'U/K5FBB@
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M)P'3UK1KC/A_X:O/#UEJ$FH>4MU?W3W#Q0G*QY)X![UV=4R4%%%%(856O/\
MCQN/^N3?R-6:K7G_ !XW'_7)OY&@"S1110 4444 %%%% !1110 AZ45R/Q E
MEB\-!H9&1_M$8RI([UD>$H-3F\5>)=1N7@D>.5H8</)Q@G VYVXX],U*UOY
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MYIV+,0QZ9/I6'#\-?#<+2-]GN9-Z&/$UU(X52<X4$_+[8Z5VE%'F!R-K\/\
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MM9DV2AB66@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JM>?\>-Q_UR;^1JS5:\_X\;C_ *Y-_(T
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MS/N^:V,U=M+RWO[6.ZM)DF@D&4D0Y!% %FBBB@ HHHH **** "BBB@ HHHH
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MD:2"UAB;[Y9%53]:&]6PZ6/ 5:/Q#HFO>(+2:UC$B111Z=;2 M%;I(G+ <]
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M@ HJ)F6-"[L%51DDG  J*&\MKAML-S#*P&[".&./7B@"U1110 4444 %%%%
M!1110 45&\B1C+NJC.,L<52EU?3(%!FU"UC!;8"\ZCYO3KUH T:*@BECGA66
M)UD1AE61L@_0U/0 45&CI(NY&5E]5.:DH **@FFBMXFEFE2*-1EG=@ /J320
M3PW,*RP2QRQ-]UXV#*?H10!8HHJ!YHHSAY$7C/S,!Q0!/14,<L<T:R12*\;=
M&4Y!_&IJ "BJOVJW^T-#Y\?F+C<F\9&>G'X5:H **** "BBHFD1,;W5<G R<
M9- $M%%5WGACD2-Y45Y/N*S %OH.] %BBJ_VB$SF 2H9@,F/<-P'KBK% !14
M3RQQ8\R1$STW,!38I8YXQ)#(DB-T9&!!_&@">BBLVXUK2[.8PW6IV<$HZI+.
MJM^1- &E155;NW=T1;B)FD7<BAP2P]1ZBG//%$R+)(B,YVH&8 L?0>M %BBH
M)IHK>(RS2I'&O5W8 #\34P((R#D&@!:*** "BJDM[:P7$=O)=0I/)]R-Y &;
MZ#J:>L\+3-"LJ&51ED##<![B@"Q1110 4444 %%%% !1110 4444 %5KS_CQ
MN/\ KDW\C5FJUY_QXW'_ %R;^1H LT444 %%%% !1110 4444 <EX]U2;2_#
M,PM(WEO;EA!!''C<S'TS[ UYWH^KZGX1T#5-$AMKO2[A/+FLQ>!';#. YX+
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M RP&[Y<COFM^7PKX?GC:.71;!T=_,96MU(+>O3K5U-/M(K'[#':Q+:A=ODA
M$QZ8]*6O+;J5IS7Z'D'B+4M9NM.O=(D\1+J,#V\%PUQ' @VDRQC8<#&/FSZ\
M5V^LWK>%_!]K%#>B&=@D4<J0H"2<=%QM!^O%;=OX;T2SMY+>UTFRAAE8&1(X
M5 8@Y&1CU JW?:98ZG:_9;ZSAN;?C]U*@9>/8U+V:75B6Z;/+/#_ (]UF>6&
M+4+PK''J9MI9)XXU9DV*1NV_*.3VJE-K&HZWXF%Q)K1%JC7,,:*BA658P<9[
MYSBO4_\ A%M ^R/:_P!BV'V=V#-%Y"[21T)&/84X>&-"6..-=&L0D3;XU$"X
M5O4<=>!5- G9GE,?B'Q)X2\.Z6\6HK<P7=I,T<+0J! 5/!R!D]>]7M1\7>(M
M+,]I;Z_%J+/;K*MR(4'DL<\8 P?Q]*]1.D::\<49L("D2LD:F,853U ]C5>W
M\,:%:0R0VVD644<I!=$@4!B/7BG>[NQ6LM#RS7FUM=?^Q3Z^V8+RTS<BVB1B
M663EB!R!CH?6MVQ\5Z]<>,8O"YE+7,%T\MQ<>4N&MN=OMSE>E=W=:'I=\TAN
MM/MIC(5+F2(-N*YVY^F3^=9^E^%X['Q!?:U+<_:+JY41I^Z""*,=%&#SVY]J
M2T>H/K8YOQ7X@U:'6[^UM-:32X[*S\] T2-Y[<<?,#Z]JHV7B77;DW5W<:W]
MFL[2Q@F9!;H=[O&I.3C(Y;-;OBOX?Q^)=1%V]\L0,?E-'):K-@<<J21L/'45
MT5GH&F6FGK9BUAD3R5A<N@)D50 -WKP!22?+YC^UY'D1\>>)_/N;"+49=[M;
M^3<3PPY DE53@)D$8/?FK6N:AX@>8Z?>ZZ[FQU6W47"PHA8-L/(P!P2:].A\
M*Z#;8\C1;"/!!&R!1@@Y';L>:L7.AZ5>+*MSIUK,)F#2;X@=Y'0GUZ"GM8.Y
MY;I'C;Q==ZHDRVMU<0><8W@(@6,(.-P.[>3WZ5+IFHZAJOB?PQ>WVLQW;3F5
MC:K&J_9^5XX&3^->E)X9T.*_%_'I-DEVO2=85#C\<4EMX;T6TOFO;;2;.*Z)
MR9DA4/GZT+1W!ZIG ^)+B[M?B!J$UIK2::\>GH^616\S!/R_,#^G-59/'OB*
M-K.Q=6%]K$4,EE^Z7]T2,R ^N/>O2;_P]HVI7 N+_2K.YF7&))H59ACIR:SY
M_"J7?BVTUJXN=Z6492VMA$ (R<9.<\]/2B.EDP>MVCF_B.MVE_H!35'MX]TB
M285<,?*?DY^F,>]8.CZWXA\-Z/I;B]^VV]U;2M':")1Y94,1@XR>G>O6M0TK
M3]6C2/4;*WND1MRK-&& /J,TW^R;!1"%LK<"#(BQ&/D!&#CTZFA7LUW#JC@?
M GB;Q-JNJQ#4(KF6RFA+L\P@7RFZ@*$.XCMR,U82#0YO'?B7^V8[)D$28-PJ
MD@;1G&>?RKL;#P_H^F7+W-AI=I;3R??DBA56;ZD5'>^%M U*Y-U?:-8W-P>L
MLL"LWYD4/6P+2YY18ZMKMA86RZ9)A8HIYX/-A5W>-<G:"02 >16Q#XKU76=0
ML]0MYH3ITU\MM;I)"O! !9@2,C.X?E7I@TVR5XW%K"&B0QH=@RJGL/:HET73
M(X(X4L+98HFWQH(AA6]0/6@#R2;QEK]KI^J6^KW4TEZ(&DBC>"W> X(Z%<GO
M_$*O?\)CKPM&U8:S$&6]-N-)\E<[>><XW9X^E>BP>%O#]MYWD:+81^<,2;+=
M1O'OQS4G_"/:)_:/V_\ LFS^V?\ /?R5W_GUH[ ]3@-'U_Q*;_2KR[U83VM]
MJ,MH;7R$4*H#$'<!G/RUJ^*=9U1/$;Z=;:S'I,,-FUP)&C5O.88^7Y@?7MS7
M8+I.GJL2K9VX$,AEC C'R.<Y8>AY-,U'0]*UAHSJ.G6MV8^4\^(/M^F:3V2#
MJV>:>%#?>(/'-OJU_= LFG[A$8%(.&VY!(R,_>R/6G>*-1U'3/%.IOI=R+>Z
MF^RP"4H&VAY54\'V->GQ:?9V\HEAMHHY!&(PRH 0@Z+]*CGTG3[F=I9K*WDE
M8J2[Q@DE3E?R(S3=KKL@76_6WX'E]]K_ (RM'OK"'4C<M:7066=(H5E*%5.%
M5L+U)JWI_CZX=Y&EU!U@733*K742(QE!;/W>#T' KOKOPYH>H,[7NDV5P7;<
MQEA5LGU.1[4V?POH-S%!%/HUC)' ,1*\"D)]..*5GL-63. TWQ1KU]+/=W&M
M_9[.ST^*YD46Z'S&8OG/&0/E'2L1O'_B9+F[L8M1D9FB5X;B:&'C)Q\H3((Y
M[\U["NB:9%#)''86RI)&(G41 !D&<*?;D_G4$'A3P];?ZC1;"/']RW4?TJKK
MFOT)UY;=3@[SQ)XCTFZO='GU7SI%NH8AJ#0(ODJZLQ)4#'\('/K6=J?C+Q-9
MWL.DVNIG4<,Y-[9Q1!C@G"MYFU,_3TKU>XTC3;L7 N+&WE%Q@3!XP?,QTSZX
MJJ_A709+%+%]&L6M4;<L)@78I]0,5.O4?4@\)WNI:CX>MKG5K<P7AR&4E3D
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M["U=KD]%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$7:5SVBBBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU_\ 7H U:*RO-UK_ )]X/^^O_KT>;K7_ #[P?]]?_7H U:*R3-K(!)MX./\
M:_\ KU9TRZ>\LQ-(%#%B.* +M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 56O/^/&X_ZY-_(U9JM>?\>-Q_UR;^1H LT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7%>-->U'1;_3!8[G67S-\
M2A<OA21R:[6N>UWP['K=Y9W#W+Q&VW8"KG=N4C^M3*]M!JW4Y_PGXAU7_A!'
MU[6([R>0_O1&RQ@["?X=O;!SSSQ4E_\ $O2+)F58I9SY,<BE&4!F?&$R3P<-
MGFMR#2UT7PFNEHDMXL%OY055&Z3C'3-<3X;^&<<_A*:#4XC;W=Q=FX3S4$AB
M ;Y%(/!PN!CI5/63MMH):)7WU-)_BQIZVJ;-,NGO&F\EK598LH<9Y?=LZ>]=
MMI]Z=0L(;HPM#YBY\MF5BOXJ2#^!KDC\.V.EFR6]TY=S;F8:+!@_\!Z9]ZU?
M#^A7^@-:V$%VDNDPP$%63#F0LQ)'H.1Q3T%J9NL_$&'2=8NK'^R+ZY6S027-
MQ$4V1H<\G)SV/2H;KXFVD$]VL>D7T]O;,$:X0IM+'[J@$YR?I5.[\(:GK'B[
M7'>]GL=,NX8XG"Q!A.N6R <Y7KU'K6Q)X LSI^H6B7<L8NI5FC95YA91QCGF
MDMM2GOH0Q?$BW63R+_2+ZQN%E1)(YBA**V<.2I(QQ56_^(5C:ZTX;[;';6QE
MC;:J&.=E8#@]>I_6K9\ +=V^I#5=5FO;J^B6(W'E"/RU&<84'&>:K/\ #&SE
MTVQLY=0F?[+$Z-(4&Z1F*DN>>N5H$BC!\1)HM;OIM3LKJPLH+)94MI]FYF9E
M (()'.>YKIO#'C"W\2R7$*VTEI=0 ,\,DB.=IZ'*$CN.]8LGPV%_]I;5M8DU
M"2:W6!6>W50@4J0< \_=_&MSPQX67P\)LS6DSR<;X+".W('H=G7\:.C%J<K:
M>.'M+DOJUY<,BSW"JB(FU@N[:#QG/ QBM"3XF6MM;.U[HU_:7!*B"WF* S!L
M8*MG:.O<BB?X:6=TV9[N1E\R60#8!@ODCOV)_2FWGPY;4K=5U37);V6+;]F,
MMNOEQ!>G[O.UO<FEK9?+_@E:7?J_^ 2?\+-LWM;=K;2KRYO)K@VYLXGC+HX
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M(?&"^'VL(AI=Y>W-Z2L<,!4," 2<[B!V-<S>>#[O4?'NBRW$,LUOIL.;B]=
MB7#<!0%!ZCFNTU#08]0U?3M1:=D:R9BJ 9#9!']:'JKKO^ E=:/M^)F:5X[L
M=5>W1+2ZCDECE=E?;E#&Q5E//7(/2LF;XK6:;FBT;4)XXT,DSH4Q&H;;DY/K
MZ5*WPZ:(QO9:W-:SJ\Y,GD*VY969BN">V[K[4ZS^&L%IIEY9_P!IS2?:;?R&
M<Q#(^;=GK0_(:WLS+UGXCW#Z>#9Z=>V=W'<6[>5)L9IXG<#Y<$@9&1SBM9_B
M79V]E(UUIMU;WZ2B(6,KH)&)Q@@YVXY]:-5^'D>HNLB:G+!(D4$:,L0.#$P8
M'KW(J&Y^&=O?PR2W^HF[U)YA*+J:V5@,8POED[2.*.C]0[$J_$NSFMK0VNE7
MES>7$S0?9(GC+HZA3@G=M_B'0UV\#L\*N\;1LPR4;&5]N*Y73O \5C<:?.;B
M#S+.1Y,V]FD DW;>H7C^']:["GI86IE7_P#R&-/^K5K5C:G(D6J6$DC!54L2
M3VJ[_:MC_P _*4AERBJ?]JV/_/RE']JV/_/RE %RBJ?]JV/_ #\I1_:MC_S\
MI0!<HJG_ &K8_P#/RE']JV/_ #\I0!<HJG_:MC_S\I1_:MC_ ,_*4 7**I_V
MK8_\_*4?VK8_\_*4 7**I_VK8_\ /RE']JV/_/RE %RBJ?\ :MC_ ,_*4?VK
M8_\ /RE %ION-]#6;H/_ "#%_P!\U,^J611@+E.E0Z#_ ,@Q?]\T :E%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O/^/&
MX_ZY-_(U9JM>?\>-Q_UR;^1H LT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$$UM!<8,T2/MZ;AG%1_V;9?\^L7_ 'S5NB@"I_9ME_SZQ?\ ?-']FV7_ #ZQ
M?]\U;HH J?V;9?\ /K%_WS1_9ME_SZQ?]\U;HH J?V;9?\^L7_?-']FV7_/K
M%_WS5NB@"I_9ME_SZQ?]\T?V;9?\^L7_ 'S5NB@"I_9ME_SZQ?\ ?-']FV7_
M #ZQ?]\U;HH J?V;9?\ /K%_WS1_9ME_SZQ?]\U;HH J?V;9?\^L7_?-']FV
M7_/K%_WS5NB@"I_9ME_SZQ?]\U-%#' FR) B]< 5+10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_ *Y-_(U9
MJM>?\>-Q_P!<F_D: +-%%% !1110 VEKSGQ;?7<'Q'\+6\-S-'#*S^9&CD*_
M7J.]-\9>,-3MKZ]T/2;*.2:*Q:XGFDE*%%^;[F!R>/:I<K*_K^ )>];T_$](
MHKPO3?BO=:-X?TC3Q"EW>&S-Q-)=ROEADX"D DMP>M=);_$[4]8N9/[#T-+B
MWMXXWN!-*4D&[/"CH>G<BJMV%?N>G]Z3O7D.D^*=0L=<\8W/VF$B*[011:A<
M,L: [^!M#8Z=A1:_%O4K^TL18:1:2WMS>-:[3.PC&,\@XSCY?2E8;T/8**\C
ME^+L\&NOI\NFVVVWF6WN DCM)O/!*#;@J#ZD<5U_B/Q9)H5[H<,-LDR:G.(B
MSL04!&<TUJDUU!Z73Z'6T5Y"?BQJDU^;*ST6UDF;4FL4W3, < $,>/>K%I\5
M=1U!;:RM=(MO[7EO'M6C>9A$I4 D[L9[^E"U5T'5KL>K=Z*\)T/XCWV@Z-+]
ML"SWUYJLL2?:IG,<0 3/S $XY["M_3_BEJVMZCIFGZ5HUJUS=!_-,\KHJ;<9
M(^7)'/I0E?8'I>_0]7I:XOQIXMU#PS'I<=E80W5U?3"$+)(553CU KD[OXR7
M-@9-/NM,MX=6BNFMY TK&  9YW ;NWI2NAV9Z_17D_\ PM?4;L:3#INC0275
M[YJNLTC(JE,\@XR0<>E2'XHWDGA4:M';:9%/&\B307%PXR4)'R84YSCOBF]%
M=B6IZI17@.L^.-9U+4++5=*E:#SM'FE-N9F$:D;P3CN1CC\*W;+XF:GH&C01
M:[8P&1[#[1:2I,S>>WS?*V1P>* ]#V&CO7&ZOXPFT+P+#KM]8@7<BJ!;(V5#
MMT&?3I7 ^-OB#KYT74M(EM(;#442.3S;:=B/+;/1L @\4:WL"Z/N>X45P$VL
MWG@SX80:BT NKJ)%RDMR\@)/^VW-85[\7[W1/M%OK.CP17@B26W6&4LC!O[Q
MQD?@#0]&UV$G=)]SUREKR)OB]>'2&EBTJVEOA=);A5D<1.&S@ABH/Z5)/XSU
M'0[_ %R>]TV'[=:QP;XTO)'B.\H. 1A<!NPI=1GK&* *\JU[XJWFDWM_;0:3
M;S-;06\J;I2-QD*C!X[;J???$O5?#[O'X@TFS@>6R^TV9MYV=96P<(<@8/%%
M]!V/4J*S-%O;F_T:UN[RW6WN)8P[Q*V0N?>N)\2?$B?P]XBAL6ATVXMI9Q$1
M'.YF7/<KMV_K3:L[=24[J_0])HKS;1OB->ZEXI;2[JTL;"/SC&B3RN)Y!Z@;
M=OZUL^-_%ESX6M$GMQIS_*69+J9T8@?W0JG-)M))OJ4DV['845Q,7C=Y_AJ?
M%<5HID$(D\@L<9R!C/XUR^H?%35]+M]+%[IEC%=:A%]HC'GR%!'MSR0N=W3C
M&*;T;3Z"6J374]>HKR2/XKZMJ4ZQZ3H=O)MLVNI?M$S(5VYW <>QQ4X^)^I7
MESIZ:9I%L\<]B]Y,T\S*8PA8,!@'/W#BAZ;@>JT5Y%HOQ?N-4G96TJ)P\,CP
MI;,[/N7/RMD #..Q-3Z?\697TB_O]1M[")[:$R"TAE<S#&?O!E '3L30] ZV
M/5J2O&O^%TW8TZXF_LFWEN%V&(12/Y;!LY!8J.1@?G2^(/B#X@?0]=L_L5M8
MZG9&,EHIF8;&SD@XZ\"AW0*S/9**\EO_ (DZKX;M--CO(-)G:01HZ1W,C2@D
M=<;<?K6#=>+M;\WQ'/?1K/:17L4<20WDD3)D@*!M'3'6D]';^MP6JN>\T5Y)
M#\5;M&CTUM(C&IBY$/D>:Q_=;=WF9QD_+4FA_%MM5\116+V$2VLUPUNK1L[2
MJ1QEAC !/O5)7=D)NRNSU:D KBO'7C&Z\)V@N+==.DVQEVCN9G1VQ_="J<_C
MBL:U^*4MV9#'I\01=*.H F0Y+#=\OT^7K475F^P[.Z7<]/HKP"[\=>)]=OI[
MB,16ML^C-<"**=AL!)&X''+<5J^'/B=J&C:/I]MK]DCQMIYN(;A)F>27&!\V
M>YSZU734/0]JQ0*\NA^)^I0^4-3T>WB-W9&[M/)F+;@,</D#'7MFLJ'QKK6I
M:WX8N;[2K>W.H*[VWDZA*J@;2?WB@ '\<T6=["OI<]GHKR(?%;5H&U>6[T>R
MDLM-&U[FUG=T:0D *,J.YY^AJ&#XR3/:R(VFV[WTCQ+;^4[^2V\J.6(!R,\X
M':A:[#>FY[#2UY;X$U75[_QQXHCU1BDD8CQ;I,SQQ_*OW<_X5@V'C?6] O/$
M%W-"+W2X=2$<CRW#&2,$+PB],?B*2W2[JXNE_.Q[C17EUK\4;B[O+72TTN(:
MM+>^0UN9#A(\*=^<>_Z5M>.?&%]X56P-KI\4PN7*R33LRQ1=.I4$_I3>B3[C
M6KL=M17C[>,==U+QQH(M9]->RFMI)&$-P_E,1MR22H/&>..]%[\3]3>^OM'B
M@TUKC[*\D$]M.[*",=<J.<9Z9I7TOZ_@-*[MZ?B>P45Y)X2\>:O#;:38:C;0
MS-<V,ET)_.8L=H) .1WK(A^).OZGX@TC4/LUO#8BWN)GMUF;Y@A<$GCKA>!3
M:L[,E.ZN>Y45YCX-^)S^*-:@L9+*"..Y1WA>!G8KMSP^0 #@=B>M5=:\7:QH
MOQ%U!K@1/I5E8>=Y2R')7YN<8QNR#^0I/1I/J-:WMT/6**\]T#QYJ-_KUEIN
MJZ7!;+J$!GM9()2_ [-D#!Z=,UQWCW4]8/Q%N+=GD-A9Z>;D007TL&X ]24[
M^U#T:3\_P&E?8]THKYVT[XB3Z'JYU)VN7MFTJ(Q6DMT\B!V[DGD].O6O5/ W
MC=_%?VR*>WBBGMB/F@+-&X/<%@#^E58FYVA%%>8W_P 3+^&ZU"XM-)AETC3K
MH6UQ*\I$N[.W*KC!&?>L\?%K5&>>Z71;;^S(;U+5I3,WF?,1@@8QW]:E:[%-
M6W/7:6O-?BEJ>H6EGX=GTN5TEFOX\()2@DSC"L1VK)N_C'<:>9-/O-+@AU9+
MH6Y!E8P 8!W%@-W0^E-"['L'6BO$M1\=ZQKVH>%KK28?*NFO)(9;9I72&0C;
MU.,E>?2MU/B?>2^%/[56WTR"YBFDAF@N+AP,KC[F%)/7OBE?34-W9'J'>D[U
M\^ZUX\UC6;_3=5TV1[9I=.E9K<3,(PP*\^_7TKL_!&KW&A?"D:_J;S7+F(3$
MM</*SYZ?>^[UZ#BA;-OH#W2[GJ%%>377Q"UPV$UI<Z;;VUU>:>;JRDBF9AMP
M/O<<'![=Z;X6N=:M/@W>:N)C+?RQ-,DD]T\G'K\WW3CL.*;V;?0%JTEU/6Z*
M\!L/%/BVWUK0[E!%<N=*DGDADNG$;J-QW'C[V!Z5MW'QJ/DV9M+"W,LEN9YE
MF=QR&8;4V@Y/R]\=:&)/J>QT5@+KWVCPNFLP"*(R0^8HNF**#Z,0"17D7B/X
MGZGK%E<6,"PP7=G>0XDLKA]DH8GC) ../2E]KEZC^SS=#WVBO+'^*5WIUKJ-
MMJ>EQ+JEG)'$D<,I:.0OG!W'!'W3VIEY\3]5TF6ZMM2T6W6YLY(S<>3,S(L3
M9^8$@'(XX]Z8'JU)7DM_\8'M[>>X@T^%K=KPVUI/)(P23&<LV 2!QVSUKJ?#
M'C%M?\,WFIM:B*>T\P.@)V,5S@J2 <''I1T;[!U2[G94E>3Z/\4M4O+C3#?Z
M1:6UGJ+2I#*L[$@INZ@CI\M-F^+-U::M>6$UGI\[16LEQ&]K.[*=H)VME1Z=
MLT/3?S_ $KNQZT:*\;7XL>(B-IT"P#M8F_0?:7QY:[LY^7K\IILGQP#SK]DT
MV)HTB2297=O,)).0@ (.,=R.M%M;!TN>S45XOXR\?:MJFCZY#HUJL-G9*BRW
M7G,DRLV?N@=N/6O4]!D>30K-Y&9G:%268Y)XH2=KB;5TNYK4444#"BBB@ HH
MHH *K7G_ !XW'_7)OY&K-5KS_CQN/^N3?R- %FBBB@ HHHH Q-1\-Z?J6LV&
MJW(E-U8Y\DJ^!SZCO6?KW@72/$5]]KNFNX9VB,,C6TWE^8AS\K<<CDU5\7^/
M[3PG>VMD]L)[FX1I KSK"H49YW-QG@\5@GXOV\[J--T6>]'V,W;E;A5"*I;(
MY'7Y?QJ=&OO_ ."/5,W8OAMH=L+,V<M_9S6D7DQSVUR4D*9SAF YZT[4OAUH
M.JWCW5RUYYDJJLX2? G Z;QCYNM<I=?$/4[_ ,2:6;&UE72KG3WN&5)E5_<\
MCMCT[UFZ3\1M;EUO3Q:6-Y>V'V*2=HIKI#+)@CDD #CTQWJKZZBM9:';7/PM
M\,W,MQ)Y=S$\\RSEHIMI1ER!MXX'S&IK#X:>']/N()XOM;20W!N5,D^[+D$$
MGCG[QJ'0/B/9^)-8L=/L+*1C<6OVF63S!B#I\IXY//Z5?\?:S?Z%X.OM0TV,
M-<1J,,6 V9(&?>AWBK@E=V'CP7IT.MS:I:7%_:33OYDT=M<%(Y&]64=:M>(_
M"NG>)HK=+[SU:VD\R&2"38Z-Z@UYE:_$+Q#I_B.62\L)[NUCTJ&>6V%RH$>0
MF9,XY)ST]ZZW6_B-%H^AVFL+IZ3V=Q$LI)O4C=<]@AY;'M0TDEY FV_4FT[X
M8>'M,GAGA^V-+%<FZ#23[B9" "3QSTH/PS\/A&,1O(9C<M=":*?;(KD '#8X
M' K+\'>,M5\2>.-5MY+4IIL<,;1+YH/EY4,"1W)S6#XL\;>);;6?%-I;![>"
MQM%:*2.5<QGD[L=R>GX4F[)7[7&E>]CLH?AAX?M[&.V@:^C:*X-S'<+<8F20
MXR0V./NBM6W\(V$.JV>J//>W%Y:1M''+<3ER0<9SZ]*XBQ^+L6G:8T>N:9-;
MW4-FEPI,P?S\Y Z#Y?N]ZZCP?X\L_%D]U:I MO<VP5F19UF4J<X(9>.W2G9W
MTZ$75KOJ0^/O"EWXHGT=;=@L-M<^9.PDV,%Q_"?6E'PR\/B-2OVQ;I9C/]M6
M?$Y<YR=^,]S7,>-OB'J!TV^71K2X@AL[U+>2_64?>R<C;C...M:$7Q@TDZK]
MC>WQ;B8VYN#<+NW#//EXW8XZTHV:TZERNGKV.H?P9ITUYI]Y<3WMS<V*NL4L
MTY9B&!!W'OUK&;X3>&\HT9OXG4R'?'<;6(<DL"<=#N/%11_$:74H[@VFAWHL
MF\Z**_C.\!T#<E0,J,CJ:Q?#WQ#U#3?A_;ZIJ<0U!C)+YDLM['$^!(P  /+<
M#M3Z7?\ 5PUV.FA^%_AZ!(45+@K%;26JAIL_(^[/;K\QK%USX<3:EJ.@6$,6
M[1],D\QI[BYWRD9^YC'3\>]:%I\2GU/5;:PTO0Y;IIK87+.URL:HIZYR.U4-
M3^*$R2:GI<6EQQZE#9R3QE+U)E&T$\[>A&,XI-V=^VHDM+=SN]7T'3]=T=M+
MOX=]JP P#@C'0@^M<]_PK+P])9W5O/\ ;+@W6T2333[I,+G #8Z<FN0TOXCR
M63:7<:_]NC=M/>Y?9.K12 $\E0N<\8Z]JVIOBQ'90R/J&AW%LQM#=VZ^<&\Y
M![@?*?KZT]FP5W8WO'/AJYUWP3+HNFA/,.T+YCX&![U1@^%_A\V<B7B7%Q<2
MQJC32S;GCV] C8X K-7XO1()1=Z#=02"S%Y#&)0YD3\!\OXUTOA+Q8/%5HUP
M+:"W  (6.]2=N?4+]T_6G9ZBNM!)_ UA=:=#9WEWJ5Y'!,L\9N+HNP9>@R1T
MK%A\&7.LZUXAN/$-M%%::@$CBC@GW-M3;ALX&#\H-9^H?$>+0->U2(VVHWKQ
MW"0+"UPNP%NFT;<C\2:M'XLP1K/!/H\\>I1W*VR6GG [V;D?-C XJ59V:ZE-
M-:=BXOPH\.YG:6349GG6-7>6Y+-A""HSCMM%5_&?@B[\4:[H47V:%=+T]U>2
M=IOWC ?P[<>W7/>N13Q]JBZ_>)J4FI0(=3B@BMH+A!Y60N025.5Y[>M=M8_$
M0ZAJ#1VFA7DUBMR;4WB-N < =5 R!SUZ4UK9KU$]+KY&YIFFZC;>(=1N)KF1
MM.D1$MH#*6"8ZD#^'Z>U8]U\+?#UYJ,UZ[7RM-,)WC2XPF\=]N*S=1^)TL&H
MWFD+I<:WZVTDL)2]2525!^]M^Z>.AK)TOXM2V&@:8-5LA-J-Q$TQ+W:1JR \
M-DC&3R,=>*2?7L-KIW.W?P-IT^JV^H7=[J=T]M)YD,5Q=%XT;V4BE\1>!]'\
M27\%[>FZ2XA1HU>WF\LE3C(/KTKD]3^*@U/2;H>'K">:1;+[1).LH7[.#TX(
M^8\=JZ?PGJUY+\.]-U2X/VJ[:T21S)($WG'=CP*=M'?I^HKZJW4N0>#]*MO"
M;>&D6;^SV7:09/GQG/7\*@O_  /I-\NGG?=VT^G1B*WN+:;RY%4#&-V/2N&\
M0_%&YO=$U"'3HFL=1LIHPWDW*3!P3R RC%;(^*L%B+BTU72KBVU*%(REOYH?
MSM^,88# ^\*+WU"UK(+WX=R:EXS:]NKN[_L_[%Y'FI=$3.>X8XY!&:Z*T\$:
M'97<%Q!;,ODVIM%3=\AC.<Y'<G<:YVX^*J64\EMJ&AW%M<P21K.GG!A&CX ?
M<!@_>'%,N?C#IT,4LD>GN\?VH6MO(\ZHDS8!)W$84#/?TH6UOZU#K<Z72_!=
MEHZR1V%_J<5NP(6 71\N//\ =7''6JI^&^ASW-Q<7\E]J$T\)@9[VX,I5#GA
M<CCK5SPMXNM/%6E27]HFQHI#')'Y@8!A_M#@CD<USTWQ3AM-7NM-N],59H;=
MYU\F]24,%[':/E/UH>CL^WX#5WJC7;X?:7+I/]EW%[J=Q9AE98YKLL$VYQMX
MX'-27O@#0K^;4I9TN-^HHJ3E9<<#ICC@US<GQ:6#3-/O+K0VMSJ/-HLMXBAU
M'4EB,+C(ZUT%GXQ76_ USKVE0;Y4C;$)D'#CJ-W2ANR;?025VDNIG'X0^&BS
MEIM4;S&5Y UV2'9>A/')JW<?#+0;F:Z=VO0MTZO+&MQA"RD$'&.O%<OX<^)^
MK_V9HEK<Z'+?ZAJ$32K(+I5!5<9)R..M:P^+%NNDV5_+I4T?VF^:R,?G ^65
MW9;..1\M#6HD]+G0KX(T-?$B:_\ 9V-\L(A!+?+M"[>GKBETGP9I^AWKW.GW
M5_#&[M(UJ+@^1N/4[.E<W8_%O2[_ %^/3A:[(9+AK9)S.I8N,]8\;@,CK71>
M+/%+^%K+[7]BBN8E4L^^\2$@#T#?>/THO9)]!VNVAOB#P)H_B;4$O[UKJ.X6
M$P%K>;9N0YRIXY')K-F^%7AR6."-6OH1#;FVS%<;2\9).UN.1R:R?^%Q13(T
MEEH5Q<QI:?:Y&%PJ[4&<]1_LFI-8^)?VBP>'1-/GGN'L#=M*L@7R%.>>1\Q^
M4\"IT28U=M&L/A;X>40B-KV,1VWV3Y+C&^/GAN.>M3O\.O#TGV/S89I%M+8V
ML:O)D%#CJ,<G@57\.^*GL_A9:>(=7EDG=+?S)6/WF-5)/B?]CL&N-1T"]M6<
M(;==V]9BV<#>!@'CI56LVNQ*=TF:%G\-M M"_P#Q]SDP&W0SS[_*CXX3CY>@
MJ2?X=Z%/%I<;"Z TR(Q6Y6;!"D;3GCGBLN[^*2:=;:@M]HD\.H613=:><&W!
MNA#XQ38OB3?MJ[Z;+X6FCEBMA=RDWJ$)%@'/3KR.*-Q[%RS^%VA6.G2Z='<Z
MH]C+DO;271:,DG.=N.N>:N/X#TJ?2_[,NKO4KJ!65HC/=%VA*XQL./EQ@5S5
MG\:]&N'8SVIAB9'>%EN%=GVD\%0,KG'>EUSXAZO_ ,(K?75MX?NK.86ZS03O
M(&0HV.=P& <'.*&[*[&E=V.L\.>#-+\-WMY>6<EW+<7>/.DN9O,+8Z?RK+E^
M%_AV;4)[N3[8WVB83RP&?]T[#IE<<]*Z#PS>7=_X<T^YO8C%<RP*SJ7#9..N
M1Z]:V<TFFI>A*::]3SG1?!%VOQ)O/%&H6EO;1B(16T<4N_/7+'@8/2NPUC1$
MUA%1[_4+15SG['<&+=GUQUK7I:?1+L/JWW.%7X6>'(TLUB%Y%]E1T5DGP7#8
MW;N.<X%)8_"CPWI\T<D1OW\N-HD62XW*JMU &*[NB@#@S\+/#_DVL0N-34VJ
M-'$ZW9#!#U7..G/2GP?"_P .VZV:0_;46T1XTQ/]Y7)+!N.0=QKN:* .<T#P
MI9^'6VV-YJ!MP"$MI;DM$F3GY5[=:BU3P1HVKZS)J=TMP9I8/L\J++A)$YX9
M>_4UT]+0]=P6AR>B>!-'T'4EO[<W4UQ''Y41N9O,\I.>%XX'-2ZGX(T;5M7N
M-3NEF-S<6IM'VR8'EGV]?>NGHH>NX+38X,?"?PN%VF&Y8?9UMP6FSM5>A''7
MWKIM(T9-'@:%+V_NE/0W<YE*^P)Z5K4478K(XRZ^'6A7FHRW;BZ432B:6WCF
MQ#(X[LN.30_PY\/O9W-H8[@0W%T+IU$N,.#D8XX''2NRHH6FPWJ<[XB\(Z7X
MEL;2TOS<!;1Q)"T,NQE8=#G\*RU^%WAQ8 JB\%P)A.+SS_WX?CG?C/85V]%
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MMX81$L4R1@<=#\J@YQ@?A714E+3;N))+8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQN/\ KDW\C0!9
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *K7G_'C<?\ 7)OY&K-5KS_CQN/^N3?R- %FBBB@
M HHHH **@EFBA3=-*D:?WG8 ?K0)HFA\Y94,>,[PPQCZT 3T57AN(;A"T$T<
MJ@X)1@P_2K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: +-%%% !1110!@
M>*_#UMXG\.W>E7.-LJ?(W]UNQ_.OG1O%/B?1M%NOAR(G:\:?R(GR<A&_A'US
M^M?1_B37K7PUH%UJEVP$<*$@?WF[#\37S9/H_B?5=/NOB8K%98[GS8DV\[!C
MYOH/Z5*^)WVTO]^@W?ETWZ'T'X#\+0^$O"UKIZ*/.(WSOW9SUKJJYOP3XF@\
M6>%[34X6&]EVRJ#]UQU%=)5ROS.Y$=A:***104444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !5:\_X\;C_KDW\C5FJUY_QXW'_7)O
MY&@"S1110 4444 <-XIBGUEY--O/!<VKV$; I)]MCC5^ <XW ]?7THBO=6AT
MH:9'X!G6S">6(?MT&W;Z?>J'XHIJK^&4&E.Q<3JTL4<WEO*@(RJG(/3/0UQ>
MD^,[2Q\/:-*3?W?E7SI(MU,RR0D!21\I^<<_Q9I)IIIC=TU8Z_0X[SPU%*FC
M_#NXM%E.YU748B"?Q8UL?\)'XE_Z$F[_ / Z#_XJN+7XIZVA@DGTFP$%S9R7
M4)25RV%Z!JTM%^(VJ7LKPZE9Z=9/)8B\@D,C[ #V?C/Y4]6+8Z+_ (23Q+_T
M)-W_ .!T'_Q5'_"2>)?^A)N__ Z#_P"*KSK4/B/KNLE+6T^P126VI1PO)"\@
M24$.?X@#CY?2MZX^)VH6MDTKZ?:F5=1DLRH=L84.=W_COZTKZ7#J=/\ \)'X
ME_Z$F[_\#H/_ (JC_A(_$O\ T)-W_P"!T'_Q5<0WQ8UF'P_I^I3Z;81MJ$S1
MP*'D8*%SDM@9YQVSUKT#PGKS>)- @U*2W-O*Y97C*D8()'&><'&:=GKY";L5
M_P#A)/$O_0DW?_@=!_\ %4?\))XE_P"A)N__  .@_P#BJZNB@9RG_"2>)?\
MH2;O_P #H/\ XJC_ (23Q+_T)-W_ .!T'_Q5=710!RG_  DGB7_H2;O_ ,#H
M/_BJ/^$D\2_]"3=_^!T'_P 575T4 <I_PDGB7_H2;O\ \#H/_BJ/^$D\2_\
M0DW?_@=!_P#%5U=% '*?\))XE_Z$F[_\#H/_ (JC_A)/$O\ T)-W_P"!T'_Q
M5=710!RG_"2>)?\ H2;O_P #H/\ XJC_ (23Q+_T)-W_ .!T'_Q5=710!RG_
M  DGB7_H2;O_ ,#H/_BJ/^$D\2_]"3=_^!T'_P 575T4 <I_PDGB7_H2;O\
M\#H/_BJ/^$D\2_\ 0DW?_@=!_P#%5U=% '*?\))XE_Z$F[_\#H/_ (JC_A)/
M$O\ T)-W_P"!T'_Q5=710!RG_"2>)?\ H2;O_P #H/\ XJC_ (23Q+_T)-W_
M .!T'_Q5=710!RG_  DGB7_H2;O_ ,#H/_BJ/^$D\2_]"3=_^!T'_P 575T4
M <I_PDGB7_H2;O\ \#H/_BJ/^$D\2_\ 0DW?_@=!_P#%5U=% '*?\))XE_Z$
MF[_\#H/_ (JC_A)/$O\ T)-W_P"!T'_Q5=710!RG_"2>)?\ H2;O_P #H/\
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M '*?\))XE_Z$F[_\#H/_ (JC_A)/$O\ T)-W_P"!T'_Q5=710!RG_"2>)?\
MH2;O_P #H/\ XJC_ (23Q+_T)-W_ .!T'_Q5=710!RG_  DGB7_H2;O_ ,#H
M/_BJ/^$D\2_]"3=_^!T'_P 575T4 <I_PDGB7_H2;O\ \#H/_BJ/^$D\2_\
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M2_\ 0DW?_@=!_P#%4?\ "2>)?^A)N_\ P.@_^*KJZ* .4_X23Q+_ -"3=_\
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M9JM>?\>-Q_UR;^1H LT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJM%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&!K/ABTUK3;:R:2:V^RLK030$!XBN,8R".U5=)\&V&C7%O=Q37$MU&SN\LK
MF5F&"6P.N/3TKJ:6B]G<.ECF-0\,7U[?37,7BK6;1)#D00-'L3V&4)_6H/\
MA#-1_P"ATU__ +[B_P#B*ZZB@#D?^$,U'_H=-?\ ^^XO_B*/^$,U'_H=-?\
M^^XO_B*ZZB@#D?\ A#-1_P"ATU__ +[B_P#B*/\ A#-1_P"ATU__ +[B_P#B
M*ZZB@#D?^$,U'_H=-?\ ^^XO_B*/^$,U'_H=-?\ ^^XO_B*ZZB@#D?\ A#-1
M_P"ATU__ +[B_P#B*/\ A#-1_P"ATU__ +[B_P#B*ZZB@#D?^$,U'_H=-?\
M^^XO_B*/^$,U'_H=-?\ ^^XO_B*ZZB@#D?\ A#-1_P"ATU__ +[B_P#B*/\
MA#-1_P"ATU__ +[B_P#B*ZZB@#D?^$,U'_H=-?\ ^^XO_B*/^$,U'_H=-?\
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MMM'<VTJ30R#<DB'(8>U6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (&1_P"-'_"7>&O^AATO_P #(_\ &K/]@:-_T";#_P !D_PH_L#1O^@38?\
M@,G^%(9!;^)="N[A+>UUK3YYY#A(X[E&9C[ 'FMBLZ'2-+@E66'3;2.13E72
M!01]"!6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5:\_P"/&X_ZY-_(U9JM>?\ 'C<?]<F_D: +-%%% !1110 4
M53GO;6VGA@GGCCEG)$2,<%R.3BKE !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^!T_P#\70!U5%<K_P *Y\,?\^5Q_P"!T_\ \71_PKGPQ_SY7'_@=/\ _%T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JUY_QXW'_7)OY&K-5KS_CQ
MN/\ KDW\C0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?,%/)&?3@5:IMW"VHM%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUV-% ''?\*TT'_GXUG_P;7'_ ,71_P *TT'_ )^-9_\ !M<?_%UV-% ''?\
M"M-!_P"?C6?_  ;7'_Q='_"M-!_Y^-9_\&UQ_P#%UV-% ''?\*TT'_GXUG_P
M;7'_ ,71_P *TT'_ )^-9_\ !M<?_%UV-% ''?\ "M-!_P"?C6?_  ;7'_Q=
M'_"M-!_Y^-9_\&UQ_P#%UV-% ''?\*TT'_GXUG_P;7'_ ,71_P *TT'_ )^-
M9_\ !M<?_%UV-% ''?\ "M-!_P"?C6?_  ;7'_Q='_"M-!_Y^-9_\&UQ_P#%
MUV-% ''?\*TT'_GXUG_P;7'_ ,71_P *TT'_ )^-9_\ !M<?_%UV-% ''?\
M"M-!_P"?C6?_  ;7'_Q='_"M-!_Y^-9_\&UQ_P#%UV-% ''?\*TT'_GXUG_P
M;7'_ ,71_P *TT'_ )^-9_\ !M<?_%UV-% ''?\ "M-!_P"?C6?_  ;7'_Q=
M'_"M-!_Y^-9_\&UQ_P#%UV-% ''?\*TT'_GXUG_P;7'_ ,71_P *TT'_ )^-
M9_\ !M<?_%UV-% ''?\ "M-!_P"?C6?_  ;7'_Q='_"M-!_Y^-9_\&UQ_P#%
MUV-% ''?\*TT'_GXUG_P;7'_ ,71_P *TT'_ )^-9_\ !M<?_%UV-% ''?\
M"M-!_P"?C6?_  ;7'_Q='_"M-!_Y^-9_\&UQ_P#%UV-% '*V'@32--U"&]MY
MM3:6%MRB749I%S[JS$'\:ZJBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#QF_\ B1KVE75W#=*&C-YBUD6,?,BMAHSQUP#S5FT^*.N_
M96N=2\.QVMO*S);R+-NWMCY <'().!7I,FB:9,@273K9U$GF -&" W][ZU!!
MX7T*V5E@T>RC5I!*P6%1EP<AOKFB.BLP>KNCSNX^+&IVNKRV4NEVS(8V,,J2
MM]\#)#CJ ,BJ<?Q7URSO)H;FTL+L)>>7*(I2/*0@8V\#=WKTUO"GAY[N:Z;1
M;$W$RE9)# NYP1@@GO42^"?"ZE"OA_304.Y<6Z_*?4<41T:O\Q/5.QS/C/Q#
MJVG:K"MC>M% D(EDCBC1FYQRV_''TR:RA\4]<>[NA#H$+V".8HKQIMH+9QEE
MSD+^%>DZCX?TC5I(I-0TZWN7B^XTL88K5>3PGX?FGFGDT6Q>69=LKM I+CT/
MK1'3<;U.)UGQ_P")=):Y1-)TR[-LB;F@N&*LS8P 2.G/>LO_ (69XJMVNY+O
M3+"%Q&OE64LW.[ )PRYR,9ZFO3D\,Z'%926<>E6:VTH"R1"$;6 Z BJ[>#/"
M[Q"-M TYD"[0IMUQCKCI2 X?3OB=K-_:3:E_8]HFG6H7[2?-8R G&=HZ$ FM
MS5O&.HV6D:?/!:6@N+Q))2+B1EC1%!(Y'.2!^9K:NO!VC3:<UA':BTMF96=+
M0^5OQC@XZCCI5Z\T+2M1LXK6]L+>Z@AQY:31A@N.F,TWY NESB]#\1>(M0L/
M$.K7=U:P6T"$6L.S(B8+DECC)'/O6##XX\0V=Q# ]Y')F:,R?:T1<JQ/0IG@
MX[\UZS'I]E!'+#':PI'+_K%5  W&.?P%9T?A#PY%"\2:+8B-W#LODK@D=#0]
M]/(.FIY6/B[X@EU3RSI]C%%;@O(J2%A.IZ;3V/!]*[#3/%VNZIX&U/5;W2UT
MZ\@3,.QUD5@>XY/ZUT47@SPQ <PZ!IR'.[Y;=1SZ]*MVGA_1[&PEL;73;6&U
MF_UD*1 *_P!1WH>S2"^J9YE#X^U[2=!_M2]\^\W.B&.Z2"/[P/*>423SCKBI
MK#XG>)+R6Y)\.0&WB4!9EGXWY Y&<XSW KNH_ _A:$?N_#VFISGY;=1_2IX_
M"^@Q7'GQZ-8K-M"[Q"N<#H,^V!1U8ELCS^[^)?B"PBC-SH^G*TLJP+^^? 8G
M'/'3%4]0^)/B"*=IA':100Q(TL<?S;SYI4["1SD#%>@Z_P"'=$O](G^UZ;!)
M'"#/M"A=Q7G&??&#7G>G>-O#C_-J'A[1H[2SB8H;-Q-)" 20"I5=N3[]323[
M]"K?F:#_ !*UWSHK2#2]-EN95,JE9WV!,=SC.[VK>U77=1N[#0'M=1326U!F
M\V7RT<+C' W\5DZ;XN\"?V<;O3])2(.2ZI]D5"[MP1UZG'Y8J23QAX0U2Q%G
MJVBEH;2!IV26V5X8@.H!)Z\>E-_Y"73YF8GQ+\16UXNGQ:2FK^2[":[#K'O0
M8PRC(!/7I5^Z\?ZU'H5IK+1Z9%%.P*0K*S'!!XDX^4_2J,WCKP'>Z2MSIWAX
M7LUDI,,+6:CR ,<G^Z/<>E=S8^'O#EY9RD>';:%96_>));*/,([^XYZT6?*%
MU<X:Q^*>OWV^-=&T^&:W25[GS9VVKM8*,$9SDM5'_A:7B.](=+:RLO(++.@;
M?OPW!4D<\5U5E>>$].GU:UO-%L-(M;9UMPTD07S@^3C&.AVUCZ'K?@V>_N8;
MK2?#MA8V]PR6[*P,C.&P"4V#&1GN:%KMV#;?N.'Q/UHQP)%I=A+-<@& "9N!
MOV_O..#WXKO_  SJTVMZ'#>W$*13,SHZ1DE058J<$_2N(U/6M%T&;59+;PQ8
M1M#Y<B2RJ(Q,691N) .!SG/M7:^&ITN]!M[E8+. 2[FV6DF^/)8YP<#.?I35
MG%L3332-ZBBBD,*K7G_'C<?]<F_D:LU6O/\ CQN/^N3?R- %FBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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5QJ&[\1WGV*X_=P?ZMOX3Z?6@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>inmune_ex106img1.jpg
<TEXT>
begin 644 inmune_ex106img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #9 4\# 2(  A$! Q$!_\0
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MHL=[%A)E^2>'/^K<=?P[CVKIJXY1<79GKQDI*Z%HHHI%!1110 4444 %%%%
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M/XUO7M4IQJ]=F94+TYNGTW1UM% Z45RG8%%%% !1110 4444 %%%% !1110
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MZ%"#^5>4_!53_P 3EA]W]R/_ $.NFGK1DO0Y*FE:+1Z\.E+0.E%<QUA1110
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M8@*!U-=6&IZ\[/)S"NU:E'J7-.TZ;4KQ8(_E'5WQPB^M=;;Z]IFDWT>E0(!
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MB3_77'_/1Q]WZ#M70 8KBH8:7M'6J?$_P%"F^;GEN I:**]$V"BBB@ HHHH
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M8HH0K._&T9_.JOQ=_P"1W7_KSC_]">N<\*:,FO\ B2STV9F6"1BTI4\[5!)
M^N,?C5TJ%'V"G-="*E:JJSC%]34U/XE^)M1G9HKT641/RQ6Z 8_X$1DG\OI2
M:;\1_%&GSJ[Z@;N,'YHKE00WX@9%>O3^ _#<VG-9_P!DVT:E<!T3#K[ANN:^
M>+B+[/<S0$Y,<C(3ZX.*>'>'KIQ4+6"O[:BU)RW/I7PWX@M_$NBPZC;J4#Y5
MXR>8W'533M?U^Q\.:9)?7TFV,?*JK]YV[*H]:XKX+R,="U-"?E6[! ],HO\
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M_"HQ^%A"/M*96%Q$I2Y)LP=8_P"0U??]=W_G6UX'_P"0S./^F!_]"%8NL?\
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MCJ>5-=Q\(O\ D<I?^O*3_P!"2M:^'5*$Y1V9C2K.I."?0E^,/_(WVW_7DO\
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MLX&<C!_&N59?6C3<8R]S8CE:_=J1A:%X<N+^=)KN,Q6JG)#<&3V'M7I"*%4
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M_+Z5HDJMIK=;_P"9#;I7@]GL>[>E<'J&GQ^*_&E]9S'=9:98&#/I<3#DCW"
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$*"C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
